[{"acceptsHealthySubjects":"Yes","brandName":"mRNA-1273","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"clinicaltrials@modernatx.com","name":null,"notes":"ADOLESCENTS ONLY (Ages 12 to <18)","phone":"8556636762","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"SKIPPED"},{"category":"pre-clinical","date":"Mon, 13 Jan 2020 00:00:00 GMT","milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":"Fri, 07 Feb 2020 00:00:00 GMT","milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Wed, 04 Mar 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 16 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 29 May 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 27 Jul 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":"Sat, 11 Jan 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"mRNA-based vaccine","numSites":"7","otherPartners":"CEPI,Lonza,BARDA","phase":"2/3","preferredName":"mRNA-1273","primaryCompletionDate":"","productId":1,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04649151?","repurposed":"New","siteLocations":[{"city":"Meridian","country":"USA","lat":43.6001608,"lng":-116.3586239,"locationId":"ef04bd8e940cc8b5901f3cfd1a30186b3163da0a","name":"Advanced Clinical Research","state":"ID"},{"city":"Minneapolis","country":"USA","lat":44.9749718,"lng":-93.27345509999999,"locationId":"e73ae34b20719bacb6395dd1ca4aa612e2af676a","name":"Clinical Research Institute","state":"MN"},{"city":"Liverpool","country":"USA","lat":43.1636374,"lng":-76.2344584,"locationId":"0c8643bbdbba62afc460e8209336971b8f0314b0","name":"Child Healthcare Associates","state":"NY"},{"city":"Oklahoma City","country":"USA","lat":35.5305938,"lng":-97.58305449999999,"locationId":"1cdae2e27469c3d5b8e0ee86821c41705e744b8a","name":"Lynn Health Sciences Institute","state":"OK"},{"city":"Houston","country":"USA","lat":29.9311422,"lng":-95.5843338,"locationId":"82f4a3c0aaccdff53de319e1c0a11f3b3036579c","name":"Kool Kids Pediatrics","state":"TX"},{"city":"Austin","country":"USA","lat":30.230871,"lng":-97.802988,"locationId":"79329c799327b39979c937b6b4342a41c60c1a67","name":"Tekton Research","state":"TX"},{"city":"West Jordan","country":"USA","lat":40.5899928,"lng":-111.9762061,"locationId":"2c6e990c5fe17198560ba09d8b036a1c4ba79206","name":"Advanced Clinical Research","state":"UT"}],"sources":["https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins","https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19","https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427&draw=2&rank=1"],"sponsors":[{"sponsorId":"375ad6c4b12a03acefcf5e9b052423279351910a","sponsorName":"Moderna"},{"sponsorId":"69301ed353817a1eb80b77b32f82e5809965a871","sponsorName":"National Institute of Allergy and Infectious Diseases"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"NVX-CoV2373","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"Kristin.Ciccarelli@iconplc.com        ","name":null,"notes":"$1200 Compensation","phone":"215-616-6815","website":"https://www.novavax.com/PREVENT-19"}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Tue, 10 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 25 May 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 17 Aug 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 28 Sep 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Subunit Vaccines","notes":"not totally clear that it is prophylactic vaccine. P1 expected late spring,Trial is technically Phase I/II but they have only started phase 1 work","numSites":"114","otherPartners":"CEPI","phase":"3","preferredName":"NVX-CoV2373","primaryCompletionDate":"Wed, 31 Mar 2021 00:00:00 GMT","productId":2,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04611802","repurposed":"New","siteLocations":[{"city":"DeLand","country":"USA","lat":29.0446615,"lng":-81.31497069999999,"locationId":"cd5db10f9d0a3dc0da9ed77dfd8936556a1def17","name":"Accel Research Sites","state":"FL"},{"city":"Chinle","country":"USA","lat":36.1575812,"lng":-109.6076963,"locationId":"98b2ae56454875a6780fa41801f68f5fc6366fc1","name":"Centers For American Indian Health","state":"AZ"},{"city":"Glendale","country":"USA","lat":33.6123712,"lng":-112.1822241,"locationId":"fb5d1de7a9c38c53275b49f82410b216d56559aa","name":"Synexus Clinical Research Us","state":"AZ"},{"city":"Phoenix","country":"USA","lat":33.5108568,"lng":-111.9975147,"locationId":"7880091f25e8ccda02ac846c5ef6d2d5d82d3e87","name":"Hope Research Institute","state":"AZ"},{"city":"Tempe","country":"USA","lat":33.3769849,"lng":-111.9774285,"locationId":"9af34a56f588bd76b295d8a0fb2abaffe100cf9c","name":"Amr Tempe Clinical Research Consortium","state":"AZ"},{"city":"Little Rock","country":"USA","lat":34.7410376,"lng":-92.3442824,"locationId":"cc427400f88d187c47a0bb97916ff9678a67247d","name":"Lynn Institute Of The Ozarks","state":"AR"},{"city":"Little Rock","country":"USA","lat":34.7463098,"lng":-92.39897909999999,"locationId":"9bbce45ea51ef1d1e0b193b94dc45a24f7bd38e7","name":"Preferred Research Partners","state":"AR"},{"city":"Anaheim","country":"USA","lat":33.848296,"lng":-117.9699,"locationId":"6f270582b82d4664767e0f213bbc5f35dc5fcd33","name":"Anaheim Clinical Trials","state":"CA"},{"city":"Banning","country":"USA","lat":33.9305885,"lng":-116.9454506,"locationId":"5be2898b22503887bfe4cec1c092a48fb66f9ad9","name":"Advanced Clinical Research","state":"CA"},{"city":"Chula Vista","country":"USA","lat":32.6172649,"lng":-117.024154,"locationId":"f6fdba3806684e6e3b0ccedd12dfbaca4dae2183","name":"Estudy Site","state":"CA"},{"city":"San Diego","country":"USA","lat":32.77637170000001,"lng":-117.0612977,"locationId":"09805e76364ac653f27af4342622a6cecaeefc25","name":"Estudysite","state":"CA"},{"city":"Los Alamitos","country":"USA","lat":33.8038138,"lng":-118.0583222,"locationId":"19e48a6bf9e6a7d3dfe23d8bd98afbac15c54ef4","name":"Wr","state":"CA"},{"city":"Los Angeles","country":"USA","lat":34.0572759,"lng":-118.2751596,"locationId":"04c9f165de4355b8b1270c84e409f233be1e05a2","name":"National Research Institute","state":"CA"},{"city":"Pomona","country":"USA","lat":34.0952181,"lng":-117.7477368,"locationId":"088f31378ca2c7c7fc6128f2d8ed8c6a7675a598","name":"Empire Clinical Research","state":"CA"},{"city":"Sacramento","country":"USA","lat":38.5523913,"lng":-121.4517779,"locationId":"ce0e259736fb8a85f99067c5c60ae3afe2be7bec","name":"University Of California Davis Medical Center","state":"CA"},{"city":"Sacramento","country":"USA","lat":38.5964009,"lng":-121.3629124,"locationId":"f485f9ce65d6d5c3c12d8a388b6894615302f28c","name":"Benchmark Research","state":"CA"},{"city":"Vista","country":"USA","lat":33.1862915,"lng":-117.2875428,"locationId":"b53bfbd568fc9a8ec616971672df31bd439abe0b","name":"Synexus Clinical Research Us","state":"CA"},{"city":"Woodland","country":"USA","lat":38.663975,"lng":-121.7947206,"locationId":"035b124861c19f580c92d6a15ec88dc6e6b5e7d2","name":"Woodland Clinic Medical Group","state":"CA"},{"city":"Aurora","country":"USA","lat":39.7418846,"lng":-104.8411885,"locationId":"01b99dfad69077f75a3ec042c973c8285e6e2e59","name":"University Of Colorado Hospital Crs","state":"CO"},{"city":"Colorado Springs","country":"USA","lat":38.9255448,"lng":-104.7729877,"locationId":"060cc3014b0670f348859bf7fd415d79bb21d364","name":"Lynn Institute Of The Rockies","state":"CO"},{"city":"Washington","country":"USA","lat":38.9190264,"lng":-77.0200981,"locationId":"7a647534fb364b8951d63a6d95e7021ce5f9f173","name":"Howard University Hospital Howard/ University College Of Medicine","state":"DC"},{"city":"DeLand","country":"USA","lat":29.0446615,"lng":-81.31497069999999,"locationId":"542c74c4413a90bc94508ac1b002b23fb74f036b","name":"University Clinical Research","state":"FL"},{"city":"Gainesville","country":"USA","lat":29.6546021,"lng":-82.3890026,"locationId":"167520f174278b7c1d99a5424e606089e0904853","name":"Simed Health","state":"FL"},{"city":"Hallandale Beach","country":"USA","lat":25.9864583,"lng":-80.13901609999999,"locationId":"fcb871735f2cdd2614fb83566124ef52c402f747","name":"M D Clinical","state":"FL"},{"city":"Hollywood","country":"USA","lat":26.03195,"lng":-80.23431,"locationId":"8412dc6db407f62ee1efcbe31b2815ace5601e12","name":"Research Centers Of America","state":"FL"},{"city":"Jacksonville","country":"USA","lat":30.282953,"lng":-81.601697,"locationId":"695ab823941ef83a7cd4c0d7ccc65bcaf9be088b","name":"Jacksonville Center For Clinical Research","state":"FL"},{"city":"Lakeland","country":"USA","lat":28.01717,"lng":-81.97534209999999,"locationId":"1aa3f1916f71751a2c061e7ac5294df1cca8c4d3","name":"Meridien Research/accel Research","state":"FL"},{"city":"Miami","country":"USA","lat":25.7914998,"lng":-80.2162924,"locationId":"1f2b7e4cadce58eed7beca37316219983426e2c2","name":"Miami Veterans Affairs Medical Center","state":"FL"},{"city":"Miami","country":"USA","lat":25.7725061,"lng":-80.2298857,"locationId":"931ed4f053be4ffae311153cde8c27dc6b82f060","name":"Suncoast Research Associates","state":"FL"},{"city":"Orlando","country":"USA","lat":28.4639511,"lng":-81.47531889999999,"locationId":"0717f04fa0e2b6501cc4ee870c0b79e1da775421","name":"Clinical Neuroscience Solutions Inc","state":"FL"},{"city":"Pinellas Park","country":"USA","lat":27.838734,"lng":-82.71583199999999,"locationId":"bcc6871613179a78138d1435c697efb4911b3248","name":"Synexus Clinical Research Us","state":"FL"},{"city":"Tampa","country":"USA","lat":28.0587031,"lng":-82.41385389999999,"locationId":"06ad9b938e8a2faa13fb636a0da72ff8b5e8e1f4","name":"University Of South Florida","state":"FL"},{"city":"Tampa","country":"USA","lat":28.0524488,"lng":-82.3963666,"locationId":"e4a9d560704c168354e08c40de536177f30d13a5","name":"Jedidiah Clinical Research","state":"FL"},{"city":"The Villages","country":"USA","lat":28.9288774,"lng":-82.0083897,"locationId":"8b2d0de093363e22ab5953140d90e21b7cad3d29","name":"Synexus Clinical Research Us","state":"FL"},{"city":"West Palm Beach","country":"USA","lat":26.713249,"lng":-80.0989365,"locationId":"77329ba24e5ae0ab9d55bfcdfbaecf5ea9ebba47","name":"Comprehensive Clinical Trials","state":"FL"},{"city":"Atlanta","country":"USA","lat":33.77185300000001,"lng":-84.3761076,"locationId":"e67b7cd2c045564099a9f0a257e78bbcb88d36dd","name":"Ponce De Leon Center","state":"GA"},{"city":"Atlanta","country":"USA","lat":33.7427835,"lng":-84.41195809999999,"locationId":"99710bf69c4b595ad1c860ad1d36c0cd678e7dce","name":"Morehouse School Of Medicine","state":"GA"},{"city":"Atlanta","country":"USA","lat":33.9200858,"lng":-84.3780831,"locationId":"17a40ffcd92903acdb5c4bf375d4f60f0e023194","name":"Synexus Clinical Research Us","state":"GA"},{"city":"Atlanta","country":"USA","lat":33.739876,"lng":-84.51258159999999,"locationId":"b2fd488260f74f4c4f5b97662b850544be8cbc32","name":"Atlanta Center For Medical Research","state":"GA"},{"city":"Stockbridge","country":"USA","lat":33.5055533,"lng":-84.2252365,"locationId":"217c1d601225c0d067dfd921dbea44a3f098ba29","name":"Clinical Research Atlanta","state":"GA"},{"city":"Meridian","country":"USA","lat":43.6001608,"lng":-116.3586239,"locationId":"47e3b9d237314b193f28fa847ee17fb935e66d09","name":"Advanced Clinical Research","state":"ID"},{"city":"Chicago","country":"USA","lat":41.8830299,"lng":-87.6291732,"locationId":"aaf9a8241df27c4e4719852d83c40ea0379c1273","name":"Synexus","state":"IL"},{"city":"Chicago","country":"USA","lat":41.871519,"lng":-87.63435,"locationId":"02a7ff9401c5937a9b28710e57b9075e41ce23f1","name":"Cedar Crosse Research Center","state":"IL"},{"city":"Mokena","country":"USA","lat":41.5434948,"lng":-87.8677879,"locationId":"0b525505e1d5cb8087ec1322eb7a590edb1c4218","name":"Providea Health Partners Llc","state":"IL"},{"city":"Evansville","country":"USA","lat":37.9635495,"lng":-87.4963483,"locationId":"30afd53e4a8d6307b9841eba78c2a6e0282a8f06","name":"Synexus Usa","state":"IN"},{"city":"Valparaiso","country":"USA","lat":41.46726719999999,"lng":-87.0426882,"locationId":"03e910d79cdcba126145c707538b7ad37c7fcf1f","name":"Buynak Clinical Research","state":"IN"},{"city":"Iowa City","country":"USA","lat":41.66270780000001,"lng":-91.5549771,"locationId":"fe5d9eb356d21f87d4acb0b62eeab2fb950bbadb","name":"University Of Iowa Medical Center","state":"IA"},{"city":"Sioux City","country":"USA","lat":42.4550777,"lng":-96.3450005,"locationId":"bbb346ae7ae5e4dd1c922737e01039f550738a9b","name":"Meridian Clinical Research","state":"IA"},{"city":"Lenexa","country":"USA","lat":38.9278708,"lng":-94.7750937,"locationId":"24460b16f4e2763fbc138911a10a2194eebed81a","name":"Johnson County Clin","state":"KS"},{"city":"Baton Rouge","country":"USA","lat":30.4028557,"lng":-91.11409370000001,"locationId":"adf07f8b77a411026f4fb3526288a3a64fc34c29","name":"Meridian Clinical Research","state":"LA"},{"city":"Metairie","country":"USA","lat":30.01050529999999,"lng":-90.18101709999999,"locationId":"5ad4b30d5ce5caac774d415c4463131e8c1c79f3","name":"Med Pharmics","state":"LA"},{"city":"Shreveport","country":"USA","lat":32.5007512,"lng":-93.74560810000001,"locationId":"6bd1be32b3c6e0281cda3c33934ff793ed7ea46a","name":"Willis","state":"LA"},{"city":"Baltimore","country":"USA","lat":39.2889604,"lng":-76.625715,"locationId":"a77ae6b2f378879ed504b0f3c1af98d77a8e70d4","name":"University Of Maryland School Of Medicine","state":"MD"},{"city":"Boston","country":"USA","lat":42.3396063,"lng":-71.10498199999999,"locationId":"c190b86e7ac2c9b313744179c18b2c4d603607b5","name":"Beth Israel Deaconess Medical Center","state":"MA"},{"city":"Ann Arbor","country":"USA","lat":42.2864311,"lng":-83.71364439999999,"locationId":"34fb471141c2449df6a0ca4617849fdcfa35255c","name":"Va Medical Center","state":"MI"},{"city":"Detroit","country":"USA","lat":42.3509891,"lng":-83.05434489999999,"locationId":"5da7aac9f80591d5241b1f47a009b3bab7345b5e","name":"Wayne State University/ Children's Hospital Of Michigan","state":"MI"},{"city":"Minneapolis","country":"USA","lat":44.97399,"lng":-93.2277285,"locationId":"4ba841696bb740926724f999e7534aa925edec68","name":"University Of Minnesota","state":"MN"},{"city":"Minneapolis","country":"USA","lat":44.8829662,"lng":-93.2861769,"locationId":"f28c82fd33b22537705b58bd477f5582694d11a3","name":"Synexus Clinical Research Us","state":"MN"},{"city":"Gulfport","country":"USA","lat":30.4439769,"lng":-89.0928144,"locationId":"0fe61ede5a7893c3fd822eb190533cb7ca96971d","name":"Medpharmics","state":"MS"},{"city":"Columbia","country":"USA","lat":38.9403808,"lng":-92.32773750000001,"locationId":"1ce0fdf391684ca1e474e9c36e1f3c7fceea62ef","name":"The Curators Of University Of Missouri","state":"MO"},{"city":"St. Louis","country":"USA","lat":38.6686897,"lng":-90.43885039999999,"locationId":"851b5408effee2ae7d3022e5386cf3e76c6ce45a","name":"Sundance Clinical Research","state":"MO"},{"city":"Norfolk","country":"USA","lat":42.0488645,"lng":-97.4258863,"locationId":"71b179ac5aa4f1328caa0fea6bd063d908661698","name":"Meridian Clinical Research","state":"NE"},{"city":"Omaha","country":"USA","lat":41.289367,"lng":-96.079509,"locationId":"8afa91bc405626498d1b76344b76f8e02d491d71","name":"Meridian Clinical Research Associates","state":"NE"},{"city":"Omaha","country":"USA","lat":41.2548549,"lng":-95.9759165,"locationId":"c4efa40cf05f8f6e9d449a8ad76fa91d2fea3ecd","name":"University Of Nebraska Medical Center","state":"NE"},{"city":"Henderson","country":"USA","lat":36.0005714,"lng":-115.1121134,"locationId":"7726e43906013fd0563e4729e9678ac76f052e0b","name":"Synexus Clinical Research Us","state":"NV"},{"city":"Commack","country":"USA","lat":40.823162,"lng":-73.291653,"locationId":"b726eaa34913e41b1116813930b9849d23a9c9b8","name":"Stony Brook Responder Vaccine Program","state":"NY"},{"city":"New York","country":"USA","lat":40.7441606,"lng":-73.9932413,"locationId":"9b6a0e7e2b0b0defdabb3f2b207fd65885dc0ba0","name":"Weill Cornell Chelsea Crs","state":"NY"},{"city":null,"country":"USA","lat":35.9049122,"lng":-79.0469134,"locationId":"739a239a4eaa9bd96b6e7f458617e961464bfb91","name":"University Of North Carolina","state":"NC"},{"city":"Charlotte","country":"USA","lat":35.2034162,"lng":-80.8385574,"locationId":"5ccef834ce5012197e33b2d5bdb24a5811a39be8","name":"The Charlotte","state":"NC"},{"city":"Fayetteville","country":"USA","lat":35.0423538,"lng":-78.9230338,"locationId":"cf5225f5b248f9a41b1f70b09ec91bf2a51a9d1a","name":"Carolina Institute For Clinical Research","state":"NC"},{"city":"Fort Bragg","country":"USA","lat":35.14615,"lng":-79.00209269999999,"locationId":"ced388abc09d9f51acee44312f87ab45502d34a0","name":"Womack Army Medical Center","state":"NC"},{"city":"Raleigh","country":"USA","lat":35.8238254,"lng":-78.70605359999999,"locationId":"655a14316785d088d7ebbab9aa4d529b138ab3ff","name":"M3 Wake Research","state":"NC"},{"city":"Rocky Mount","country":"USA","lat":35.9790625,"lng":-77.8428923,"locationId":"51a22e9396fcbbb7f938d67a40dd220bf523562d","name":"Pmg Research Of Rocky Mount","state":"NC"},{"city":"Akron","country":"USA","lat":41.07120279999999,"lng":-81.5262233,"locationId":"0c10b7a66d688953545a0d641b0282d287048e7b","name":"Synexus Clinical Research","state":"OH"},{"city":"Cincinnati","country":"USA","lat":39.1228674,"lng":-84.50795099999999,"locationId":"bd635e1b1f995ba6e089f7bfadb866de804fd6a7","name":"Sterling Research Group","state":"OH"},{"city":"Cincinnati","country":"USA","lat":39.20803069999999,"lng":-84.38412819999999,"locationId":"97c4da0bb514463d00b8b0b3c3e9f25a81fdb4e2","name":"Synexus Clinical Research Us","state":"OH"},{"city":"Cincinnati","country":"USA","lat":39.1228674,"lng":-84.50795099999999,"locationId":"bd635e1b1f995ba6e089f7bfadb866de804fd6a7","name":"Sterling Research Group","state":"OH"},{"city":"Beachwood","country":"USA","lat":41.4618221,"lng":-81.49290169999999,"locationId":"01cb738ed1736e772d0c6e804983da83ec728e4e","name":"Rapid Medical Research","state":"OH"},{"city":"Oklahoma City","country":"USA","lat":35.4928141,"lng":-97.4815126,"locationId":"958741d8b0063237df9f6836380c85c1715428f5","name":"Synexus Clinical Research Us","state":"OK"},{"city":"Oklahoma City","country":"USA","lat":35.5305938,"lng":-97.58305449999999,"locationId":"cda6023d08c15586f7f8f0a1b649ce721883594b","name":"Lynn Health Science Institute","state":"OK"},{"city":"Medford","country":"USA","lat":42.3722953,"lng":-122.854721,"locationId":"2f260685bb318cf03c9e805905f2c168bc103ac6","name":"Crisor","state":"OR"},{"city":"Warwick","country":"USA","lat":41.7267967,"lng":-71.47917190000001,"locationId":"38978c02bfc7b80609518550667624b1952ff276","name":"Velocity Clinical Research","state":"RI"},{"city":"Anderson","country":"USA","lat":34.5345225,"lng":-82.6321133,"locationId":"4a1b6fe7b3bb0b3308ea48f5b8ed8096058cf35c","name":"Synexus Clinical Research Us","state":"SC"},{"city":"Charleston","country":"USA","lat":32.7850493,"lng":-79.9478413,"locationId":"f80840b18679bf7f29378394fe3c876f9c8b130c","name":"Medical University Of South Carolina","state":"SC"},{"city":"Eagle Butte","country":"USA","lat":44.9923228,"lng":-101.2435495,"locationId":"05fcbdf96ba5d86b32a46b4c5ba2dc47e0dba020","name":"American Indian Clinical Trials Research Network","state":"SD"},{"city":"Bristol","country":"USA","lat":36.59453999999999,"lng":-82.2046249,"locationId":"97dff9977fa4ef3454b337132cbb2bee77578742","name":"Pmg Research Of Bristol","state":"TN"},{"city":"Chattanooga","country":"USA","lat":35.0534759,"lng":-85.1822423,"locationId":"6ae68b95f848b03fa1952ae6305955fe387719f7","name":"Wr Clinsearch","state":"TN"},{"city":"Knoxville","country":"USA","lat":36.0022871,"lng":-83.9836662,"locationId":"00ef5e2fe76cd52f7cc262580431710ad1802732","name":"Pmg Research","state":"TN"},{"city":"Memphis","country":"USA","lat":35.0996189,"lng":-89.849203,"locationId":"3627520216c59052a2972ea44f80293c188ca107","name":"Clinical Neurosciecne Solutions","state":"TN"},{"city":"Nashville","country":"USA","lat":36.1668749,"lng":-86.8077028,"locationId":"af9ce0fe9e8698c0c5dda40f996fd4de543e26bb","name":"Meharry Medical College","state":"TN"},{"city":"Austin","country":"USA","lat":30.290713,"lng":-97.72794139999999,"locationId":"9a43d2bf9f1666956dd12e4f4261331ad70417f6","name":"Benchmark Research","state":"TX"},{"city":"Fort Worth","country":"USA","lat":32.8222237,"lng":-97.4190954,"locationId":"313850b8666dca7e7b34ea20de3601ac72f03992","name":"Benchmark Research","state":"TX"},{"city":"Houston","country":"USA","lat":29.71052959999999,"lng":-95.39649899999999,"locationId":"b96385a097621e3b764f1b4fe6ffba60e683e751","name":"Baylor College Of Medicine","state":"TX"},{"city":"Houston","country":"USA","lat":29.7098598,"lng":-95.4746682,"locationId":"539e98c88b80ce442e934a0e4d39da9e938482d0","name":"Texas Center For Drug Development","state":"TX"},{"city":"McAllen","country":"USA","lat":26.2506973,"lng":-98.22294169999999,"locationId":"0368e24a8d770c1e5bc50700a682110e28a43cde","name":"Centex Studies","state":"TX"},{"city":"Plano","country":"USA","lat":33.0439926,"lng":-96.83191760000001,"locationId":"6c203b14f30f4a7b7365d2d28611310773f00224","name":"Research Your Health","state":"TX"},{"city":"San Antonio","country":"USA","lat":29.5153168,"lng":-98.568596,"locationId":"c8f56a5039f6e7ec467b82ce56e03b050a5cf952","name":"Synexus","state":"TX"},{"city":"San Antonio","country":"USA","lat":29.5074654,"lng":-98.57535209999999,"locationId":"22646e7c9545a8ad18071d7db5ea05b2d86fe1e2","name":"University Of Texas Health Science Center San Antonio","state":"TX"},{"city":"West Jordan","country":"USA","lat":40.5899928,"lng":-111.9762061,"locationId":"1d53f9bf67230eee43638fddfeeb80953006d77d","name":"Advanced Clinical Research","state":"UT"},{"city":"Cheney","country":"USA","lat":47.4930979,"lng":-117.5777047,"locationId":"5ea7a11db44fcebfc9c604cc6e5d40ba685bdfed","name":"Multicare Institute For Research & Innovation","state":"WA"},{"city":"Seattle","country":"USA","lat":47.6145005,"lng":-122.3420369,"locationId":"e7054287963526337c069275d0aaf6da82729a04","name":"University Of Washington Vteu","state":"WA"},{"city":"Guadalajara","country":"MEX","lat":20.6771497,"lng":-103.3903547,"locationId":"33d64bdfabfea22f4184c4baf102317383facd3b","name":"Panamerican Clinical Research Mexico S.a De C.v","state":"Jal."},{"city":"M\u00e9xico D.F.","country":"MEX","lat":19.2879435,"lng":-99.1563518,"locationId":"e0cb0aff5889fa978f0090d98741e1188b57de18","name":"Instituto Nacional De Ciencias Medicas Y Nutricion Salvador Zubiran","state":"CDMX"},{"city":"El Salitre","country":"MEX","lat":20.6836586,"lng":-100.4341151,"locationId":"cd27722351a03c4a6bdae872d1d5cba126c91117","name":"Panamerican Clinical Research Mexico","state":"Qro."},{"city":"M\u00e9rida","country":"MEX","lat":20.9870063,"lng":-89.6254835,"locationId":"cb66da44c56c857043c441c269d695b63ac13a02","name":"Unidad De Atencion Medica E Investigacion En Salud (unamis)","state":"Yuc."},{"city":"Cuernavaca","country":"MEX","lat":18.9774645,"lng":-99.2459329,"locationId":"9403f5d276415deeab583ff436e1a4e27fd1bc02","name":"Instituto Nacional De Salud Publica (insp)","state":"Mor."},{"city":"M\u00e9xico D.F.","country":"MEX","lat":19.4071886,"lng":-99.16494589999999,"locationId":"09f54bf37731c84f1409140229979f0234be8e96","name":"Caimed Investigacion En Salud S.a De C.v","state":"CDMX"}],"sources":["http://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-12-clinical-trial-covid-19-vaccine","https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-novavax-manufacture?field_nir_news_date_value[min]=","https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development","https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&recrs=ab&draw=2&rank=1"],"sponsors":[{"sponsorId":"605f6647f1bdd3849bac0626225a6effc774a373","sponsorName":"Novavax Inc"},{"sponsorId":"f4d20a236175ba7e1926d1e68974b9e499bd94ed","sponsorName":"Emergent BioSolutions Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 30 Nov 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"BNT-162,BNT162b2","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Germany"],"countryCodes":["DEU"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Mon, 16 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 23 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 23 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 27 Jul 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"Expect clinical testing in late april. Note this drug is also being developed in china with fosun pharma. Assumed this is in discovery as no explicit statements aboit preclinical found","numSites":"","otherPartners":"Polymun","phase":"","preferredName":"BNT-162,BNT162b2","primaryCompletionDate":"","productId":3,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine","https://biontech.de/","https://www.fiercebiotech.com/biotech/weeks-to-go-to-covid-19-vaccine-trial-biontech-lands-135m-deal-and-advances-pfizer-talks","https://clinicaltrials.gov/ct2/show/NCT04380701","https://biontech.de/node/159","https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-against"],"sponsors":[{"sponsorId":"531d5b28f1f18f219741627c0f2a1e09d355e46a","sponsorName":"Pfizer"},{"sponsorId":"6154f72a3188d3cf7f9c626a195615fb8858c842","sponsorName":"BioNTech"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"LNP-nCoVsaRNA","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"covactrials@imperial.ac.uk","name":null,"notes":"Compensation: $120-150 per visit","phone":"","website":"https://www.imperial.ac.uk/covid-19-vaccine-trial/participants-info/"}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Mon, 10 Feb 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 23 Jun 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"Expect clinical testing in summer","numSites":"1","otherPartners":"Maravai Lifesciences Inc.,Trilink Biotechnologies Inc.","phase":"1","preferredName":"LNP-nCoVsaRNA","primaryCompletionDate":"Sat, 31 Jul 2021 00:00:00 GMT","productId":4,"registryLink":"http://www.isrctn.com/ISRCTN17072692","repurposed":"New","siteLocations":[{"city":null,"country":"GBR","lat":51.516825,"lng":-0.2343059,"locationId":"aac1481bde055691869231ea510c214770e7cdfa","name":"Nihr Imperial Clinical Research Facility","state":"England"},{"city":null,"country":"GBR","lat":51.239237,"lng":-0.605954,"locationId":"f992722f1c1a346d69a4bad38f6c65fa2519bc94","name":"Surrey Clinical Research Facility","state":"England"},{"city":null,"country":"GBR","lat":50.93365619999999,"lng":-1.4346812,"locationId":"5dd4ef6ccc742186098260154b0af991aee71e55","name":"University Hospital Southampton","state":"England"},{"city":null,"country":"GBR","lat":51.42656299999999,"lng":-0.1752284,"locationId":"f8f92fe10d8398e5f1e37102e2de667394639c79","name":"St George's Hospital","state":"England"}],"sources":["https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/","https://www.imperial.ac.uk/news/198533/first-volunteers-receive-imperial-covid-19-vaccine/","https://www.imperial.ac.uk/covid-19-vaccine-trial/"],"sponsors":[{"sponsorId":"1a693dd5acf9f3ae07a65241da0b2f2102ed1377","sponsorName":"Imperial College London"}],"status":"Ongoing","studyCompletionDate":"Sat, 31 Jul 2021 00:00:00 GMT","studyStartDate":"Thu, 23 Jul 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"INO-4800,CELLECTRA\u00ae 20000","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"clinical.trials@inovio.com","name":null,"notes":"","phone":"267-440-4237","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":"Tue, 24 Mar 2020 00:00:00 GMT","milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 03 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 22 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":"Thu, 23 Jan 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"30","otherPartners":"US DoD,Bill and Melinda Gates Foundation,Coalition for Epidemic Prepardness Innovations Funding","phase":"2/3","preferredName":"INO-4800,CELLECTRA\u00ae 20000","primaryCompletionDate":"Thu, 01 Sep 2022 00:00:00 GMT","productId":5,"registryLink":["https://clinicaltrials.gov/ct2/show/NCT04642638","https://clinicaltrials.gov/ct2/show/NCT04447781","https://clinicaltrials.gov/ct2/show/NCT04336410"],"repurposed":"New","siteLocations":[{"city":"Chandler","country":"USA","lat":33.2976201,"lng":-111.8776367,"locationId":"8daf8902f2f0714df1d3049144db357c51a90d5f","name":"Synexus Clinical Research Us","state":"AZ"},{"city":"Phoenix","country":"USA","lat":33.5477327,"lng":-112.0512584,"locationId":"0cec49352963e3a23609ba67d1591b79e24fbccb","name":"Central Phoenix Synexus Clinical Research","state":"AZ"},{"city":"Mesa","country":"USA","lat":33.4142761,"lng":-111.8446578,"locationId":"33bd7d26eba443bf4d64d7a97bb25a5a96ccd999","name":"Amr Tempe","state":"AZ"},{"city":"San Diego","country":"USA","lat":32.766251,"lng":-117.186366,"locationId":"b0ea8a88dab5bec60dba1370054605ae779c1d3b","name":"Optimal Research","state":"CA"},{"city":"Medley","country":"USA","lat":25.8871662,"lng":-80.3729685,"locationId":"fabe96552dd7557f65b1eab3f75d113187f67e5e","name":"Amr South Florida","state":"FL"},{"city":"Tampa","country":"USA","lat":27.9805709,"lng":-82.48761429999999,"locationId":"ffc4a45bebc07a6be7b4ed353d6e1e461a32b9c9","name":"Clinical Research Trials Of Florida","state":"FL"},{"city":"Lexington","country":"USA","lat":38.0877072,"lng":-84.4915726,"locationId":"397adf3cef6e9cb1715983d8f8aa5032143b0fe2","name":"Amr Lexington","state":"KY"},{"city":"Silver Spring","country":"USA","lat":39.0056247,"lng":-77.0531111,"locationId":"e3467de6818aab7f59b5e9ba50d4c6528322b5ca","name":"Walter Reed Army Institute Of Research","state":"MD"},{"city":"Detroit","country":"USA","lat":42.4198303,"lng":-82.91485190000002,"locationId":"c0d6a111fdd0693d84387d10e851ff8d2f4e4f5b","name":"Ascension St John Hospital","state":"MI"},{"city":"Kansas City","country":"USA","lat":39.045324,"lng":-94.65008639999999,"locationId":"a2b1f769ac00a90461ac2ad2526f2f2a6ccb7e68","name":"Amr Kansas City","state":"KS"},{"city":"Las Vegas","country":"USA","lat":36.1153911,"lng":-115.1230425,"locationId":"fe1da589286827d142c6a34d11e97ad894e38517","name":"Amr Clinical Research Consortium","state":"NV"},{"city":"Philadelphia","country":"USA","lat":39.9522188,"lng":-75.1932137,"locationId":"611f1592349342d302fd7bc9e702a2960238e234","name":"University Of Pennsylvania","state":"PA"},{"city":"Philadelphia","country":"USA","lat":39.9489108,"lng":-75.15596169999999,"locationId":"4504bfbbf1ad56b6ecff421731fa97ec15d9c3ee","name":"Thomas Jefferson University","state":"PA"},{"city":"Austin","country":"USA","lat":30.230871,"lng":-97.802988,"locationId":"9383ab3d7322bd53e19b37e7d1a1962a600358ef","name":"Tekton Research","state":"TX"},{"city":"Tomball","country":"USA","lat":30.0849793,"lng":-95.6235351,"locationId":"376f67c97c8b545b08761c0f5dc8825c9bc4cc7a","name":"Dm Clinical Research","state":"TX"},{"city":"West Jordan","country":"USA","lat":40.5899928,"lng":-111.9762061,"locationId":"1c78a9e8c5152fd43eaa40645ba20f19009baf7a","name":"Advanced Clinical Research","state":"UT"}],"sources":["https://www.precisionvaccinations.com/vaccines/ino-4800-dna-coronavirus-vaccine","https://clinicaltrials.gov/ct2/show/NCT04336410"],"sponsors":[{"sponsorId":"a28cb988e230163b5e185750856269de4f3cd2eb","sponsorName":"Inovio Pharmaceuticals Inc"},{"sponsorId":"2534fc505ec4a7e9f4871746ebd7fe5a84b18af8","sponsorName":"Beijing Advaccine Biotechnology"},{"sponsorId":"09820e27323251c097da890722d6b1060e453555","sponsorName":"US Department of Defense"},{"sponsorId":"8b02e4cb59e0603882788f6b09eece49a6f530e2","sponsorName":"Ology Bioservices Inc"}],"status":"Ongoing","studyCompletionDate":"Thu, 01 Sep 2022 00:00:00 GMT","studyStartDate":"Mon, 30 Nov 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"Ad26.COV2-S,Ad26 SARS-CoV-2","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"JNJ.CT@sylogent.com","name":null,"notes":"Compensation: $140 per visit (No compensation for UK Trial)","phone":"844-434-4210","website":"https://www.ensemblestudy.com/ "}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Tue, 31 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 15 Jul 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 15 Jul 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 23 Sep 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Gene therapies","notes":"Expect clinical testing no later than fall 2020","numSites":"110","otherPartners":"BARDA","phase":"3","preferredName":"Ad26.COV2-S,Ad26 SARS-CoV-2","primaryCompletionDate":"Tue, 10 May 2022 00:00:00 GMT","productId":6,"registryLink":["https://www.clinicaltrials.gov/ct2/show/NCT04614948","https://clinicaltrials.gov/ct2/show/NCT04505722","https://www.clinicaltrials.gov/ct2/show/NCT04436276","https://clinicaltrials.gov/ct2/show/NCT04509947"],"repurposed":"New","siteLocations":[],"sources":["https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html","https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609467/","https://www.sciencemag.org/news/2020/03/1-billion-bet-pharma-giant-and-us-government-team-all-out-coronavirus-vaccine-push"],"sponsors":[{"sponsorId":"79c2245b2e99e2ee02f6cc48aaefe048e67e29e0","sponsorName":"Johnson  Johnson"},{"sponsorId":"519b2a07c1422487cad73d5610c9f1e043dd7462","sponsorName":"Janssen Pharmaceutical"}],"status":"Ongoing","studyCompletionDate":"Thu, 11 May 2023 00:00:00 GMT","studyStartDate":"Sun, 15 Nov 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Sanofi recombinant vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Tue, 18 Feb 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Subunit Vaccines","notes":"they are repurposing vaccines that have been preclinically tested for SARS - hence I have put the current status as preclinical,No plans for a phase I trial until July at the earliest","numSites":"","otherPartners":"BARDA","phase":"","preferredName":"Sanofi recombinant vaccine","primaryCompletionDate":"","productId":7,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine","https://www.google.com/search?q=sanofi+pasteur+headquarters&rlz=1C5CHFA_enGB854GB854&oq=sanofi+pastuer+head&aqs=chrome.1.69i57j0l7.7080j1j9&sourceid=chrome&ie=UTF-8","https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00"],"sponsors":[{"sponsorId":"551135a9f6ade78853bbd5fdbd66283c70e2f776","sponsorName":"Sanofi"},{"sponsorId":"b0667c7bd3f77f09b501f5439a15d5af327ec17f","sponsorName":"GSK"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"REGN-COV2,REGN10933+REGN10987","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"COVID19SiteInterest@regeneron.com","name":null,"notes":"","phone":"844-734-6643","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 16 Jun 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 16 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 16 Jun 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":"Tue, 04 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"141","otherPartners":"","phase":"3","preferredName":"REGN-COV2,REGN10933+REGN10987","primaryCompletionDate":"Wed, 25 Nov 2020 00:00:00 GMT","productId":8,"registryLink":["https://clinicaltrials.gov/ct2/show/NCT04425629","https://clinicaltrials.gov/ct2/show/NCT04452318","https://clinicaltrials.gov/ct2/show/NCT04519437?term=REGN10933&draw=2&rank=1","https://clinicaltrials.gov/ct2/show/NCT04426695?term=REGN10933%2BREGN10987+placebo&recrs=a&draw=2"],"repurposed":"New","siteLocations":[{"city":"Birmingham","country":"USA","lat":33.5185892,"lng":-86.8103567,"locationId":"dbdbbd00ebc7ba8ecfad1e684cca19cde1d657cb","name":"Birmingham","state":"AL"},{"city":"Chandler","country":"USA","lat":33.3061605,"lng":-111.8412502,"locationId":"bef6ab4d3ed538375d0760212fc99a7b572654ef","name":"Chandler","state":"AZ"},{"city":"Mesa","country":"USA","lat":33.4151843,"lng":-111.8314724,"locationId":"4a4affd79dd63cbac6c0bd03745d467abcda8545","name":"Mesa","state":"AZ"},{"city":"Tempe","country":"USA","lat":33.4255104,"lng":-111.9400054,"locationId":"89c8db620cd22f0f3f538bd8d2f8a09c0586ae85","name":"Tempe","state":"AZ"},{"city":"Tucson","country":"USA","lat":32.2226066,"lng":-110.9747108,"locationId":"007709a71990db2befb2006df983e687be9b2f38","name":"Tucson","state":"AZ"},{"city":"Rogers","country":"USA","lat":36.3320196,"lng":-94.1185366,"locationId":"210d0b6462f68b302e84167e7810203a02e64b5c","name":"Rogers","state":"AR"},{"city":"Los Angeles","country":"USA","lat":34.208254,"lng":-118.6058609,"locationId":"f7678d382d38da3031c2ae39ba8a817ff0a0337e","name":"Canoga Park","state":"CA"},{"city":"La Mesa","country":"USA","lat":32.7678287,"lng":-117.0230839,"locationId":"1fe995f8bd0e98ddeb242227c484b6583865db52","name":"La Mesa","state":"CA"},{"city":"La Palma","country":"USA","lat":33.8463218,"lng":-118.0461393,"locationId":"d987a517b20ba46cbb823b29d99b36c4e231b3ed","name":"La Palma","state":"CA"},{"city":"Long Beach","country":"USA","lat":33.7700504,"lng":-118.1937395,"locationId":"e938da3981121c60b09cdcc3f4105ffeb2bda89f","name":"Long Beach","state":"CA"},{"city":"Los Angeles","country":"USA","lat":34.0522342,"lng":-118.2436849,"locationId":"3bb9323268f0c02d55401f727fdd28d52cdf4fe8","name":"Los Angeles","state":"CA"},{"city":"Los Angeles","country":"USA","lat":34.2722582,"lng":-118.4688776,"locationId":"700adf06979cafa74db786c5683d81bf10a9765e","name":"Mission Hills","state":"CA"},{"city":"Montclair","country":"USA","lat":34.0775104,"lng":-117.6897776,"locationId":"559ed8a0cf0f571a3728e7d7f77e0db787b451f1","name":"Montclair","state":"CA"},{"city":"Los Angeles","country":"USA","lat":34.2381251,"lng":-118.530123,"locationId":"172732e5def91c1b5eea735019e54fc08a126c4b","name":"Northridge","state":"CA"},{"city":"Oxnard","country":"USA","lat":34.1975048,"lng":-119.1770516,"locationId":"1481022a856c0be3bfdc49d2c8cb9db6327ce230","name":"Oxnard","state":"CA"},{"city":"Sacramento","country":"USA","lat":38.5815719,"lng":-121.4943996,"locationId":"f96254f2ecf0459337a95a8126cd7f4d45c68699","name":"Sacramento","state":"CA"},{"city":"SF","country":"USA","lat":37.7749295,"lng":-122.4194155,"locationId":"8bf4997bc6c363c8d61692d2fffd5c9a2297acd5","name":"San Francisco","state":"CA"},{"city":"Santa Monica","country":"USA","lat":34.0194543,"lng":-118.4911912,"locationId":"db84a661b43445fd8968450bfac3786f5a87e3f6","name":"Santa Monica","state":"CA"},{"city":"Stanford","country":"USA","lat":37.42410599999999,"lng":-122.1660756,"locationId":"49121a8c031eab67e5b7ed29cd453868ab0d086a","name":"Stanford","state":"CA"},{"city":"Torrance","country":"USA","lat":33.8358492,"lng":-118.3406288,"locationId":"31b7a231affbd8a284f45f335bd57b50f6852e5c","name":"Torrance","state":"CA"},{"city":"Aurora","country":"USA","lat":39.7294319,"lng":-104.8319195,"locationId":"44bf2625f83c438a88832f58abe6b384adc61533","name":"Aurora","state":"CO"},{"city":"Colorado Springs","country":"USA","lat":38.8338816,"lng":-104.8213634,"locationId":"b160c49e10261dfd4a2001034ee1d9dcc7fb0ae9","name":"Colorado Springs","state":"CO"},{"city":"Washington","country":"USA","lat":38.9071923,"lng":-77.0368707,"locationId":"202f42fdd9a9350f555f4e4ccf105ec153405ec2","name":"Washington","state":"DC"},{"city":"Boca Raton","country":"USA","lat":26.3683064,"lng":-80.1289321,"locationId":"6f8f5927b4b023f652bf67a18ee540032d2482cd","name":"Boca Raton","state":"FL"},{"city":"Clearwater","country":"USA","lat":27.9658533,"lng":-82.8001026,"locationId":"dc1dc68367b7e9a204b7ac3b1a9b697f0a0e0d72","name":"Clearwater","state":"FL"},{"city":"DeLand","country":"USA","lat":29.028318,"lng":-81.3031179,"locationId":"ed5778430f0ef1c7285cd58244be5748380b2dfa","name":"Deland","state":"FL"},{"city":"Fort Pierce","country":"USA","lat":27.4467056,"lng":-80.3256056,"locationId":"7c9289323cbd396507969efca3843be716a69139","name":"Fort Pierce","state":"FL"},{"city":"Gainesville","country":"USA","lat":29.6516344,"lng":-82.32482619999999,"locationId":"39876660c5d8b347c5b06eaa46ef8b2818cff8ea","name":"Gainesville","state":"FL"},{"city":"Hialeah","country":"USA","lat":25.8575963,"lng":-80.2781057,"locationId":"25a6e6507faabd103047c62ddaffe60bcd848464","name":"Hialeah","state":"FL"},{"city":"Jacksonville","country":"USA","lat":30.3321838,"lng":-81.65565099999999,"locationId":"658c005ceb788382e40e8d0a6c4d029077c7a19a","name":"Jacksonville","state":"FL"},{"city":"Lakeland","country":"USA","lat":28.0394654,"lng":-81.9498042,"locationId":"999744f349eef0759b6be9075929a40c96d77f6e","name":"Lakeland","state":"FL"},{"city":"Loxahatchee Groves","country":"USA","lat":26.7064797,"lng":-80.2657478,"locationId":"86f4ea7a25d68b21b5b2693aa2289aa9be114275","name":"Loxahatchee Groves","state":"FL"},{"city":"Maitland","country":"USA","lat":28.6277767,"lng":-81.36312439999999,"locationId":"3a8812a00df5ac872fa0fce2b0d1560d568e1c9b","name":"Maitland","state":"FL"},{"city":"Miami","country":"USA","lat":25.7616798,"lng":-80.1917902,"locationId":"8f248209db7155b10aeb0d4298aeae510a1f533f","name":"Miami","state":"FL"},{"city":"Orlando","country":"USA","lat":28.5383355,"lng":-81.3792365,"locationId":"50b14bc1e9a9062adacb9733d5114f6d92355860","name":"Orlando","state":"FL"},{"city":"Pensacola","country":"USA","lat":30.42130899999999,"lng":-87.2169149,"locationId":"29d4c590b65a1424c963bba0e8d085012a18df23","name":"Pensacola","state":"FL"},{"city":"St. Petersburg","country":"USA","lat":27.7676008,"lng":-82.64029149999999,"locationId":"f615b329dec93e145de0e5114acdbe63bdb6d917","name":"Saint Petersburg","state":"FL"},{"city":"Sarasota","country":"USA","lat":27.3364347,"lng":-82.53065269999999,"locationId":"c75bd42c3753f2f47c9a214af4c4dba1ca2f6d06","name":"Sarasota","state":"FL"},{"city":"Tampa","country":"USA","lat":27.950575,"lng":-82.4571776,"locationId":"efe094aaf8da037295c3c218531db0acd4b30f5a","name":"Tampa","state":"FL"},{"city":"West Palm Beach","country":"USA","lat":26.7153424,"lng":-80.0533746,"locationId":"2935e428bd1bd4765c79158419fdd34b51a5f74b","name":"West Palm Beach","state":"FL"},{"city":"Winter Haven","country":"USA","lat":28.0222435,"lng":-81.7328567,"locationId":"a36a4730dcea29fb8dd56ac8be039b6164f6dfcf","name":"Winter Haven","state":"FL"},{"city":"Winter Park","country":"USA","lat":28.5999998,"lng":-81.33923519999999,"locationId":"4f01348f20234cc5db70aadcc97f0fede85d94ec","name":"Winter Park","state":"FL"},{"city":"Atlanta","country":"USA","lat":33.7489954,"lng":-84.3879824,"locationId":"6b1de99138d2c4fcc15ce789cecfc6a4978dec6a","name":"Atlanta","state":"GA"},{"city":"Augusta","country":"USA","lat":33.4734978,"lng":-82.0105148,"locationId":"c597674e96f2e1f108c39848f2aaab29c1e3524c","name":"Augusta","state":"GA"},{"city":"Columbus","country":"USA","lat":32.4609764,"lng":-84.9877094,"locationId":"6f90ad5fda4f3241b496edc7b0fe7040e5171e4e","name":"Columbus","state":"GA"},{"city":"Decatur","country":"USA","lat":33.7748275,"lng":-84.2963123,"locationId":"fa9a5dab42b26d0cd4af8920ffe3f65921757318","name":"Decatur","state":"GA"},{"city":"Eatonton","country":"USA","lat":33.3267997,"lng":-83.3884961,"locationId":"35007f3a0a36e15f479777f7797427d38bfb9729","name":"Eatonton","state":"GA"},{"city":"Marietta","country":"USA","lat":33.95260200000001,"lng":-84.5499327,"locationId":"549182e530f7b629e20d421d9ed80f7f329f5ff8","name":"Marietta","state":"GA"},{"city":"Sandy Springs","country":"USA","lat":33.9304352,"lng":-84.3733147,"locationId":"9a846573fdd4672920c079ae14168916433c2269","name":"Sandy Springs","state":"GA"},{"city":"Chicago","country":"USA","lat":41.8781136,"lng":-87.6297982,"locationId":"03fc410b3b3bf049cfd7bf1f46c7447d107f035e","name":"Chicago","state":"IL"},{"city":"Downers Grove","country":"USA","lat":41.8089191,"lng":-88.01117459999999,"locationId":"cbf58f780130c27505572ceb42f6414c8c2d3c60","name":"Downers Grove","state":"IL"},{"city":"Urbana","country":"USA","lat":40.1105875,"lng":-88.2072697,"locationId":"a6a0eed9ed412a426ccc54fa5d75e3fa8160ba3d","name":"Urbana","state":"IL"},{"city":"Indianapolis","country":"USA","lat":39.768403,"lng":-86.158068,"locationId":"d9725da690f1c5a133f38ae1f16849f3f84d4845","name":"Indianapolis","state":"IN"},{"city":"Ames","country":"USA","lat":42.0307812,"lng":-93.63191309999999,"locationId":"67136c4704607462a5fa6bd1402f0b7510eb9a93","name":"Ames","state":"IA"},{"city":"Iowa City","country":"USA","lat":41.6611277,"lng":-91.5301683,"locationId":"d15d5d9582a0137dcebc9cfcba08132002e51102","name":"Iowa City","state":"IA"},{"city":"Louisville","country":"USA","lat":38.2526647,"lng":-85.7584557,"locationId":"6b72a204c3fd2250310e60df154dec18ae91aefe","name":"Louisville","state":"KY"},{"city":"Lake Charles","country":"USA","lat":30.2265949,"lng":-93.2173758,"locationId":"90cdd793aef5e24c5f3442f5b29736eacca916fe","name":"Lake Charles","state":"LA"},{"city":"Marrero","country":"USA","lat":29.8993723,"lng":-90.1003506,"locationId":"59d42e33849f05e8fcd6f60ecc900f4bf11c33dc","name":"Marrero","state":"LA"},{"city":"Metairie","country":"USA","lat":29.9840922,"lng":-90.1528519,"locationId":"2c528d51b25f09ff27cee0a3a723a6e77a04f0f7","name":"Metairie","state":"LA"},{"city":"New Orleans","country":"USA","lat":29.95106579999999,"lng":-90.0715323,"locationId":"c6a18874480ba660d6b13f301d769ec4b43f1de7","name":"New Orleans","state":"LA"},{"city":"Shreveport","country":"USA","lat":32.5251516,"lng":-93.7501789,"locationId":"9997ecf9b2c8ca4a82f8229f12ff2e34ee071880","name":"Shreveport","state":"LA"},{"city":"Baltimore","country":"USA","lat":39.2903848,"lng":-76.6121893,"locationId":"a3743fe00f46091738186d800b77dd15e001593f","name":"Baltimore","state":"MD"},{"city":"Boston","country":"USA","lat":42.3600825,"lng":-71.0588801,"locationId":"007bf575e256999b11da2c39a6e2605fe33c88ce","name":"Boston","state":"MA"},{"city":"Detroit","country":"USA","lat":42.331427,"lng":-83.0457538,"locationId":"d61f8c03bc2306e94012c3f8caee6868fc246ebc","name":"Detroit","state":"MI"},{"city":"Grand Rapids","country":"USA","lat":42.9633599,"lng":-85.6680863,"locationId":"6d0adbe2ab5ccbd4ff6d235e58f29c1547c8746c","name":"Grand Rapids","state":"MI"},{"city":"Royal Oak","country":"USA","lat":42.4894801,"lng":-83.1446485,"locationId":"79d759d84ebd1401d6655a39331057798942713e","name":"Royal Oak","state":"MI"},{"city":"Minneapolis","country":"USA","lat":44.977753,"lng":-93.2650108,"locationId":"14e78f9d3d8074cc96aadb9c6882257010e4eb3d","name":"Minneapolis","state":"MN"},{"city":"Rochester","country":"USA","lat":44.0121221,"lng":-92.4801989,"locationId":"a7fc67a36caff5be56f948b0df9f7f7a0b2aae06","name":"Rochester","state":"MN"},{"city":"Gulfport","country":"USA","lat":30.3674198,"lng":-89.0928155,"locationId":"3ee64a202cc1da1a9c72fd0cff9c2dc071624911","name":"Gulfport","state":"MS"},{"city":"Jackson","country":"USA","lat":32.2987573,"lng":-90.1848103,"locationId":"2b0ee5023ee5cb4c49be6c292781d7c188667b09","name":"Jackson","state":"MS"},{"city":"Chesterfield","country":"USA","lat":38.6631083,"lng":-90.5770675,"locationId":"93356491112024bad024fcb1d39f93559446f7cd","name":"Chesterfield","state":"MO"},{"city":"Hazelwood","country":"USA","lat":38.7714396,"lng":-90.3709489,"locationId":"5552a3e0b8f8dbcc36abb71f663b67a39f777116","name":"Hazelwood","state":"MO"},{"city":"St. Louis","country":"USA","lat":38.6270025,"lng":-90.19940419999999,"locationId":"35c4f9bdf029ad1efa0c1f4b3b4e469bc92cd699","name":"Saint Louis","state":"MO"},{"city":"Lincoln","country":"USA","lat":40.813616,"lng":-96.7025955,"locationId":"053ad731f594e3c8cb9a9de3744f0255e136ad37","name":"Lincoln","state":"NE"},{"city":"Omaha","country":"USA","lat":41.2565369,"lng":-95.9345034,"locationId":"80c1e1d6f47b6127ef3462905089d72ae5d1d919","name":"Omaha","state":"NE"},{"city":"Las Vegas","country":"USA","lat":36.1699412,"lng":-115.1398296,"locationId":"a8fdb0bbdca76fc8f2e636fb94cf95f084fd9ecf","name":"Las Vegas","state":"NV"},{"city":"Englewood","country":"USA","lat":40.8928771,"lng":-73.9726381,"locationId":"616195797aef9c4fc545ed3b38190ed22dae1928","name":"Englewood","state":"NJ"},{"city":"Hackensack","country":"USA","lat":40.8859325,"lng":-74.0434736,"locationId":"cf68caeb1a30641826c9331549a2854eb7b96c20","name":"Hackensack","state":"NJ"},{"city":"Morristown","country":"USA","lat":40.79676670000001,"lng":-74.4815438,"locationId":"3eef63fdbdd4ae34be18f18b114b6678628085c2","name":"Morristown","state":"NJ"},{"city":"Neptune City","country":"USA","lat":40.2005472,"lng":-74.03141649999999,"locationId":"c52bcb434f23f05c268056bd1ee9ac6fba577fe7","name":"Neptune","state":"NJ"},{"city":"Newark","country":"USA","lat":40.735657,"lng":-74.1723667,"locationId":"449edc3a98fd18aab945e6770f5f95d0a3c15e02","name":"Newark","state":"NJ"},{"city":"Pennington","country":"USA","lat":40.3284402,"lng":-74.790718,"locationId":"da4c690536f7b5ad46ad09b44549205a0caba85b","name":"Pennington","state":"NJ"},{"city":"Ridgewood","country":"USA","lat":40.9792645,"lng":-74.11653129999999,"locationId":"ceb09aac7e6f284c62a3feb18ba805513599c3b0","name":"Ridgewood","state":"NJ"},{"city":"Summit","country":"USA","lat":40.7146376,"lng":-74.3646122,"locationId":"43ea3288d2af4006186875b04eb482a0412adf25","name":"Summit","state":"NJ"},{"city":"Teaneck","country":"USA","lat":40.8932469,"lng":-74.0116536,"locationId":"2662b08b3e95491d63d2ec596900374882860376","name":"Teaneck","state":"NJ"},{"city":"Albuquerque","country":"USA","lat":35.0843859,"lng":-106.650422,"locationId":"3ffc9d7682593800644d5e2c29880585e5028eb9","name":"Albuquerque","state":"NM"},{"city":null,"country":"USA","lat":40.8447819,"lng":-73.8648268,"locationId":"f1b2e6d668f7f0408ba133626f6eb469d263f51b","name":"Bronx","state":"NY"},{"city":null,"country":"USA","lat":40.6781784,"lng":-73.9441579,"locationId":"004fc0050fd633f90832961a2fcda9dc63caab0c","name":"Brooklyn","state":"NY"},{"city":"Buffalo","country":"USA","lat":42.88644679999999,"lng":-78.8783689,"locationId":"af21f94384767ca1edfb7316138397f32f51d906","name":"Buffalo","state":"NY"},{"city":null,"country":"USA","lat":40.702677,"lng":-73.7889689,"locationId":"592d080a4e913bf017efd0718c6323dab4c7ffa1","name":"Jamaica","state":"NY"},{"city":"New York","country":"USA","lat":40.7127753,"lng":-74.0059728,"locationId":"d57698d63a3739516007774f6d0d303e39f0c52b","name":"New York","state":"NY"},{"city":"Rochester","country":"USA","lat":43.15657789999999,"lng":-77.6088465,"locationId":"9df9f48e9b6dd27aa340a5db66042c1316d45ba7","name":"Rochester","state":"NY"},{"city":"Syracuse","country":"USA","lat":43.0481221,"lng":-76.14742439999999,"locationId":"7e6d440c717e8effd7019a45da8902b05bc1f48c","name":"Syracuse","state":"NY"},{"city":"West Islip","country":"USA","lat":40.7062104,"lng":-73.3062302,"locationId":"fdfa4b15106db51b0b80147fa10b99e4359f256c","name":"West Islip","state":"NY"},{"city":"White Plains","country":"USA","lat":41.03398620000001,"lng":-73.7629097,"locationId":"882adb3011e9f6a8716104a4bb3a0188ac6d4ade","name":"White Plains","state":"NY"},{"city":"Chapel Hill","country":"USA","lat":35.9131996,"lng":-79.0558445,"locationId":"f041d437268ee8da846b61f49e600f31f97fb32e","name":"Chapel Hill","state":"NC"},{"city":"Charlotte","country":"USA","lat":35.2270869,"lng":-80.8431267,"locationId":"09484a5282ef5be8bd7d9f54a8993afa8f5cfa3a","name":"Charlotte","state":"NC"},{"city":"Concord","country":"USA","lat":35.4087517,"lng":-80.579511,"locationId":"9764dd6d3006ef15103c4b645faa81b9f77f9387","name":"Concord","state":"NC"},{"city":"Durham","country":"USA","lat":35.9940329,"lng":-78.898619,"locationId":"66bfb65aa0159b51fb6fed3efef867747253ec7b","name":"Durham","state":"NC"},{"city":"Fayetteville","country":"USA","lat":35.0526641,"lng":-78.87835849999999,"locationId":"bccc69deddeecdf0cc51d30f52e55bd5c930b8ca","name":"Fayetteville","state":"NC"},{"city":"Greensboro","country":"USA","lat":36.0726354,"lng":-79.7919754,"locationId":"36f7522bf74043465166dd1f5713457b6422ecbc","name":"Greensboro","state":"NC"},{"city":"Raleigh","country":"USA","lat":35.7795897,"lng":-78.6381787,"locationId":"3a663869d8fe5cee7f8d33d707a1cdbc8c8f6b68","name":"Raleigh","state":"NC"},{"city":"Wilmington","country":"USA","lat":34.2103894,"lng":-77.8868117,"locationId":"df5a897f995788f4ebef6b5c56ccbb9d0ea79578","name":"Wilmington","state":"NC"},{"city":"Winston-Salem","country":"USA","lat":36.09985959999999,"lng":-80.244216,"locationId":"cf03b73d1e64e6d089d7b73a66ee6882908c2f56","name":"Winston","state":"NC"},{"city":"Cincinnati","country":"USA","lat":39.1031182,"lng":-84.5120196,"locationId":"69c3c0fcc614411f4567918dcbb3bb35329626a1","name":"Cincinnati","state":"OH"},{"city":"Columbus","country":"USA","lat":39.9611755,"lng":-82.99879419999999,"locationId":"e9a3ed9a861c4a5056c81e940ea8d394bf9c04c2","name":"Columbus","state":"OH"},{"city":"Dayton","country":"USA","lat":39.7589478,"lng":-84.1916069,"locationId":"3208d93722df8151fff37416acd48af2abd1a7b5","name":"Dayton","state":"OH"},{"city":"Portland","country":"USA","lat":45.5051064,"lng":-122.6750261,"locationId":"d5eee441445cbd646c374705dce52d6bd7c72112","name":"Portland","state":"OR"},{"city":"Danville","country":"USA","lat":40.96342,"lng":-76.6127329,"locationId":"fd8da9b9bd04c9de1a474ed352a05fb44fa49b57","name":"Danville","state":"PA"},{"city":"Philadelphia","country":"USA","lat":39.9525839,"lng":-75.1652215,"locationId":"f21bbf56ade9d901998767c4fd5a15d1ee6ab404","name":"Philadelphia","state":"PA"},{"city":"Wilkes-Barre","country":"USA","lat":41.2459149,"lng":-75.88130749999999,"locationId":"eedb1948d96d3863a85e43d8125d1032414fa20a","name":"Wilkes","state":"PA"},{"city":"Providence","country":"USA","lat":41.8239891,"lng":-71.4128343,"locationId":"0fdd91291182eb4a3c1df680a91aa55746c08dc5","name":"Providence","state":"RI"},{"city":"Charleston","country":"USA","lat":32.7764749,"lng":-79.93105120000001,"locationId":"331cdbb9f35c12af5a2c13de4cea4b51b95a7323","name":"Charleston","state":"SC"},{"city":"Clinton","country":"USA","lat":34.4726276,"lng":-81.88065619999999,"locationId":"0bc3d8b2fb703c12687e117ce8f9970b375be2b5","name":"Clinton","state":"SC"},{"city":"Gaffney","country":"USA","lat":35.0717945,"lng":-81.64981949999999,"locationId":"a382706d308a17b85b7173ea79f92e30f3b97eac","name":"Gaffney","state":"SC"},{"city":"Sioux Falls","country":"USA","lat":43.5460223,"lng":-96.731265,"locationId":"fe6d334c6db67ceb6104aaed9466d566a4315502","name":"Sioux Falls","state":"SD"},{"city":"Chattanooga","country":"USA","lat":35.0456297,"lng":-85.3096801,"locationId":"a282316272c66dccd6deda797e9cb0000a837e2f","name":"Chattanooga","state":"TN"},{"city":"Knoxville","country":"USA","lat":35.9606384,"lng":-83.9207392,"locationId":"aa536b3905c3334788d555e3e18e39189780ff58","name":"Knoxville","state":"TN"},{"city":"Memphis","country":"USA","lat":35.1495343,"lng":-90.0489801,"locationId":"2336d66934f991b3f35fcd6bf356774231559615","name":"Memphis","state":"TN"},{"city":"Nashville","country":"USA","lat":36.1626638,"lng":-86.7816016,"locationId":"7488a4cf43b5ae19d10588fa4d3849dd08437fcc","name":"Nashville","state":"TN"},{"city":"Amarillo","country":"USA","lat":35.2219971,"lng":-101.8312969,"locationId":"8769e1d9cb4b84551c781132fd5d82351b534be1","name":"Amarillo","state":"TX"},{"city":"Austin","country":"USA","lat":30.267153,"lng":-97.7430608,"locationId":"088b10dadb14fd3734feab0678e61bb1e742dc5a","name":"Austin","state":"TX"},{"city":"Bellaire","country":"USA","lat":29.7057858,"lng":-95.4588299,"locationId":"622695062a77fac1380aa8ff5caeaead66e01f7c","name":"Bellaire","state":"TX"},{"city":"Corpus Christi","country":"USA","lat":27.8005828,"lng":-97.39638099999999,"locationId":"9ed8fd3d4d7f64ad3bb4405e7fd2c7f4b7c8b0f7","name":"Corpus Christi","state":"TX"},{"city":"Dallas","country":"USA","lat":32.7766642,"lng":-96.79698789999999,"locationId":"1e8fa3b8a8681e5f6d68a350729c12360e0165c0","name":"Dallas","state":"TX"},{"city":"Houston","country":"USA","lat":29.7604267,"lng":-95.3698028,"locationId":"7d0ec08712c88a254426f4749ca400f0a3b466ac","name":"Houston","state":"TX"},{"city":"Pearland","country":"USA","lat":29.5635666,"lng":-95.2860474,"locationId":"0fecaccc99a990fbf62eee7f10f2b3d24f0b29a0","name":"Pearland","state":"TX"},{"city":"Red Oak","country":"USA","lat":32.5332101,"lng":-96.8153,"locationId":"609406ada56391b5352ce8e3ef726560f40e3ce4","name":"Red Oak","state":"TX"},{"city":"San Antonio","country":"USA","lat":29.4241219,"lng":-98.49362819999999,"locationId":"b6663fdded13e6c649c4aeb336c7eb5f50b4c88a","name":"San Antonio","state":"TX"},{"city":"Sugar Land","country":"USA","lat":29.5984434,"lng":-95.6225521,"locationId":"891e11ef17d90f3a346bad0b83c894ee36069a5f","name":"Sugar Land","state":"TX"},{"city":"Tyler","country":"USA","lat":32.3512601,"lng":-95.30106239999999,"locationId":"693fc97a03d72595a22a189e9d565dbd9c00e3bf","name":"Tyler","state":"TX"},{"city":"Murray","country":"USA","lat":40.6668916,"lng":-111.8879909,"locationId":"79b4b905635867514f01a313fc72ca2320729f9d","name":"Murray","state":"UT"},{"city":"Salt Lake City","country":"USA","lat":40.7607793,"lng":-111.8910474,"locationId":"f011723c12990a2e9658da469bae1406599c74d2","name":"Salt Lake City","state":"UT"},{"city":"Charlottesville","country":"USA","lat":38.0293059,"lng":-78.47667810000002,"locationId":"43baf30dbb8701268cf6489e0e39d71ee3f97cc2","name":"Charlottesville","state":"VA"},{"city":"Falls Church","country":"USA","lat":38.88233400000001,"lng":-77.1710914,"locationId":"c2c5b7f03b330d90e2c840be6db9ab87f5b3c4fd","name":"Falls Church","state":"VA"},{"city":"Richmond","country":"USA","lat":37.5407246,"lng":-77.4360481,"locationId":"c6baed2ecaf79f7a8c0fbc387014907ee3befbf5","name":"Richmond","state":"VA"},{"city":"Everett","country":"USA","lat":47.9789848,"lng":-122.2020795,"locationId":"ac16728cb42f1040323fe0d09b52087d7cc8fc94","name":"Everett","state":"WA"},{"city":"Seattle","country":"USA","lat":47.6062095,"lng":-122.3320708,"locationId":"e3ccfa8e03337b7d791140252de71d078f4bbb66","name":"Seattle","state":"WA"},{"city":"Yakima","country":"USA","lat":46.6020711,"lng":-120.5058987,"locationId":"7db7191992c317fec7f48f1c41e65c3b36d3b63d","name":"Yakima","state":"WA"},{"city":"Madison","country":"USA","lat":43.0730517,"lng":-89.4012302,"locationId":"2586bdfef0f2d9e53b876cbb8160950abea6f568","name":"Madison","state":"WI"},{"city":"Chi\u0219in\u0103u","country":"MDA","lat":47.0104529,"lng":28.8638102,"locationId":"43d6f5fd40bcf824abb48000f725a4f616591f78","name":"Chisinau","state":"Chisinau"},{"city":"Bucharest","country":"ROU","lat":44.4267674,"lng":26.1025384,"locationId":"e28767aac8d717797e9f362374115a6c7793b3b3","name":"Bucuresti","state":"Bucharest"},{"city":null,"country":"ROU","lat":45.943161,"lng":24.96676,"locationId":"67a350d5d919d7a34779b98b243efc729abae6a4","name":"Romania","state":null}],"sources":["https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody","https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody","https://www.regeneron.com/covid19"],"sponsors":[{"sponsorId":"a7cbf979a98fdc448b32b211e3d5e8264875995e","sponsorName":"Regeneron"},{"sponsorId":"fc75c1a3f384fb950104d48eeee9665cc126614f","sponsorName":"HHS"}],"status":"Ongoing","studyCompletionDate":"Wed, 25 Nov 2020 00:00:00 GMT","studyStartDate":"Tue, 16 Jun 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Vaxart Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Wed, 18 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Subunit Vaccines","notes":"Oral tablet. Recombinant vaccine. Plan to initiate Phase I trial in second half of 2020.","numSites":"","otherPartners":"Emergent","phase":"","preferredName":"Vaxart Vaccine","primaryCompletionDate":"","productId":9,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions"],"sponsors":[{"sponsorId":"80a6767f041a7aef5269023e2f54d91aa27066da","sponsorName":"Vaxart"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"University of Queensland Vaccine","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"p.griffin@nucleusnetwork.com.au","name":null,"notes":"","phone":"61 402077302","website":""}],"countries":["Australia"],"countryCodes":["AUS"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 14 Jul 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":"Fri, 24 Jan 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Subunit Vaccines","notes":"Plans for clinical trials in July in Queensland.","numSites":"1","otherPartners":"CEPI,The Queensland Government,Paul Ramsay Foundation,a2 Milk Company","phase":"1","preferredName":"University of Queensland Vaccine","primaryCompletionDate":"","productId":10,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04495933?term=University+of+Queensland&recrs=a&cond=covid&draw=2&rank=3","repurposed":"New","siteLocations":[{"city":"Herston","country":"AUS","lat":-27.4451489,"lng":153.0206887,"locationId":"82eef0d30668a237c8146a2f003f237bfe812ed4","name":"Herston","state":"QLD"}],"sources":["https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine","https://stories.uq.edu.au/news/2020/17m-shot-in-the-arm-for-uq-covid-19-vaccine-research/index.html","https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true"],"sponsors":[{"sponsorId":"83489a1277ddc5cf37050ab7342ac914748abdc2","sponsorName":"University of Queensland"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 13 Jul 2020 00:00:00 GMT","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"VIDO-InterVac Vaccine Candidate","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Sat, 01 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"Canadian Federal Government","phase":"","preferredName":"VIDO-InterVac Vaccine Candidate","primaryCompletionDate":"","productId":11,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.technologynetworks.com/tn/news/12m-awarded-for-new-covid-19-vaccine-manufacturing-efforts-332506","https://www.cbc.ca/news/health/coronavirus-covid-19-vido-intervac-saskatchewan-vaccine-1.5508114?__vfz=medium%3Dsharebar"],"sponsors":[{"sponsorId":"52a54b2f0746508531714d16ee2993cb5ff764a5","sponsorName":"International Vaccine Centre"},{"sponsorId":"7ffe768f0f9cf49a08e526fad894319b1b874d64","sponsorName":"University of Saskatchewan"},{"sponsorId":"00779c5db9466de70c91f79cb8ce78836132058d","sponsorName":"VIDOInterVac"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"","brandName":"Monoclonal Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"IIBR will use the manufacturing platform of Dyadic to produce their monoclonal antibody candidate","numSites":"","otherPartners":"IIBR,Dyadic","phase":"","preferredName":"Monoclonal Antibodies","primaryCompletionDate":"","productId":105,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://apnews.com/4e3931bb97391362be6cd5da36e8ef28"],"sponsors":[{"sponsorId":"bc5f1b8a05634976386ebb4a0eb43f430166cf2f","sponsorName":"Israel Institute for Biological Research IIBR"},{"sponsorId":"4aa813a58d95ae6daf00386144326869f4a7e3ee","sponsorName":"Dyadic International Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"ChAdOx1 nCoV-19,AZD1222","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"vaccinetrials@ndm.ox.ac.uk","name":null,"notes":"For United States: https://www.coronaviruspreventionnetwork.org/;  For Brazil: 01865 611424 vaccinetrials@ndm.ox.ac.uk; Compensation: $100-$140 per visit, 7 total visits     ","phone":"","website":"https://www.coronaviruspreventionnetwork.org/"}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 20 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 23 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 28 May 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"90","otherPartners":"University of Oxford","phase":"3","preferredName":"ChAdOx1 nCoV-19,AZD1222","primaryCompletionDate":"Sun, 01 Aug 2021 00:00:00 GMT","productId":12,"registryLink":["https://clinicaltrials.gov/ct2/show/NCT04324606","https://clinicaltrials.gov/ct2/show/NCT04444674","https://clinicaltrials.gov/ct2/show/NCT04400838","https://www.clinicaltrials.gov/ct2/show/NCT04536051","https://www.clinicaltrials.gov/ct2/show/NCT04444674","https://www.clinicaltrials.gov/ct2/show/NCT04568031","https://www.clinicaltrials.gov/ct2/show/NCT04516746"],"repurposed":"New","siteLocations":[],"sources":["https://economictimes.indiatimes.com/news/international/world-news/oxford-university-begins-enrolling-over-500-volunteers-for-coronavirus-vaccine-trial/articleshow/74864754.cms","https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development","https://www.clinicaltrials.gov/ct2/show/NCT04324606","https://www.jackfm.co.uk/news/oxfordshire-news/oxford-uni-clinical-trials-for-covid-19-vaccine-could-begin-next-month/","https://www.gov.br/pt-br/noticias/saude-e-vigilancia-sanitaria/2020/08/brasil-possui-quatro-estudos-clinicos-de-vacinas-contra-o-coronavirus"],"sponsors":[{"sponsorId":"bb9ed07e215d6bebb274790c7ee0711a0da9f41e","sponsorName":"AstraZeneca"},{"sponsorId":"b91bf90d7d04e343ba36d6ff216e09bcbdf60f8f","sponsorName":"Jenner Institute"},{"sponsorId":"d1cf38e4f7d70b602814433c015565b664ba5fa5","sponsorName":"Oxford Vaccine Group"}],"status":"Ongoing","studyCompletionDate":"Sun, 01 Aug 2021 00:00:00 GMT","studyStartDate":"Thu, 28 May 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"NIV Pune Vaccine Candidate","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["India"],"countryCodes":["IND"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"NIV Pune Vaccine Candidate","primaryCompletionDate":"","productId":13,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.livemint.com/news/india/covid-19-india-becomes-5th-country-globally-to-isolate-virus-strain-11584102221498.html"],"sponsors":[{"sponsorId":"db62a75311d8473967f358928e8460e901771f76","sponsorName":"National Institute of VirologyPune"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"","brandName":"Chinese CDC Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Mon, 10 Feb 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":"Fri, 24 Jan 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"Animal Testing","numSites":"","otherPartners":"Stermirna Therapeutics Co. Ltd","phase":"","preferredName":"Chinese CDC Vaccine","primaryCompletionDate":"","productId":14,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm"],"sponsors":[{"sponsorId":"52d02c14b6240aabfbdc4ded5640e554e55e2ca1","sponsorName":"Chinese Center for Disease Control and Prevention"},{"sponsorId":"5f73dfa644e6480f6632298372551fe30f6bfc70","sponsorName":"Tongji University School of Medicine"},{"sponsorId":"3020404bf63cebc77d8c10a2cc920657b5249ee2","sponsorName":"Stermirna Therapeutics Co Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"","brandName":"DelNS1-SARS-CoV2-RBD LAIV","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Whole-pathogen vaccines","notes":"Live-attenuated vaccine. Plans for clinical trials in July. Proof of concept testing done using MeRS-CoV and various animal models.","numSites":"","otherPartners":"CEPI,Xiamen University,Changchun-Baike,Hualan-Bio,Beijing Wantai,Sinovac,CNBG","phase":"","preferredName":"DelNS1-SARS-CoV2-RBD LAIV","primaryCompletionDate":"","productId":15,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://fightcovid19.hku.hk/hku-state-key-laboratory-for-emerging-infectious-diseases-joins-global-effort-to-develop-covid-19-vaccine/","https://www.hku.hk/press/news_detail_20788.html"],"sponsors":[{"sponsorId":"6b014b07406a291e8e325b2a212ac65562a16644","sponsorName":"University of Hong Kong"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"CureVac Vaccine,CVnCoV","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"clinicaltrials@curevac.com","name":null,"notes":"","phone":"(+49) 69 76805870","website":""}],"countries":["Germany"],"countryCodes":["DEU"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 15 Jun 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 17 Aug 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"Not named yet,2 products currently undergoing animal studies,plan to start a clinical trial in early summer","numSites":"5","otherPartners":"CEPI","phase":"3","preferredName":"CureVac Vaccine,CVnCoV","primaryCompletionDate":"Fri, 05 Mar 2021 00:00:00 GMT","productId":16,"registryLink":["https://clinicaltrials.gov/ct2/show/NCT04652102","https://www.clinicaltrials.gov/ct2/show/NCT04449276","https://www.clinicaltrials.gov/ct2/show/NCT04515147"],"repurposed":"New","siteLocations":[{"city":"T\u00fcbingen","country":"DEU","lat":48.5274189,"lng":9.0621355,"locationId":"a3a269a2cc45c80e711490ff4eefb678862ab745","name":"University Hospital T\u00fcbingen Institut F\u00fcr Tropenmedizin","state":"BW"},{"city":"Panama City","country":"PAN","lat":8.9823792,"lng":-79.51986959999999,"locationId":"6d1d30aa09a92ebe6e802ce282a4ee58925808e3","name":"Panama City","state":"Panama"},{"city":"Munich","country":"DEU","lat":48.1351253,"lng":11.5819805,"locationId":"0d0e1f601aa69198bfb2ddf80546a87ef0066429","name":"M\u00fcnchen","state":"BY"},{"city":"Hanover","country":"DEU","lat":52.3758916,"lng":9.732010400000002,"locationId":"003458b463b4e59230b7dfabfc2ad3f1c65c15a7","name":"Hannover","state":"NDS"},{"city":"Ghent","country":"BEL","lat":51.0543422,"lng":3.7174243,"locationId":"85c7ef251ac4c68f3583e31051e7d493d84092b6","name":"Ghent","state":"Flanders"}],"sources":["https://www.curevac.com/news/curevac-focuses-on-the-development-of-mrna-based-coronavirus-vaccine-to-protect-people-worldwide","https://www.curevac.com/our-pipeline","https://www.youtube.com/watch?v=1ZMWJJyoK7A"],"sponsors":[{"sponsorId":"40795cb229b892237d8be44830cd652481d40676","sponsorName":"CureVac AG"}],"status":"Ongoing","studyCompletionDate":"Sat, 04 Mar 2023 00:00:00 GMT","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"Ad5-nCoV","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"jinbo.gou@cansinotech.com\t","name":null,"notes":"We suggest going to the contact website, scroll down to site location and call/email the site location closest to you directly","phone":"86-022-58213600-6051","website":"https://clinicaltrials.gov/ct2/show/NCT04526990"}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Mon, 16 Mar 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 16 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 12 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"clinical_development","date":null,"milestoneId":43,"name":"phase_3","status":"ESTIMATED"},{"category":"pre-clinical","date":"Wed, 01 Jan 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Gene therapies","notes":"Vaccine candidate is genetically engineered with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein,Immunogenic action,Current study is assessing evaluate the safety reactogenicity and immunogenicity,Active but not recruiting","numSites":"44","otherPartners":"Institute of Biotechnology-Academy of Military Medical Sciences-PLA of China,Jiangsu Province Centers for Disease Control and Prevention,Hubei Provincial Center for Disease Control and Prevention,Tongji Hospital","phase":"3","preferredName":"Ad5-nCoV","primaryCompletionDate":"","productId":17,"registryLink":["https://clinicaltrials.gov/ct2/show/NCT04526990","https://www.clinicaltrials.gov/ct2/show/NCT04540419","https://www.clinicaltrialsarena.com/news/cansino-vaccine-saudi-trial/","https://www.clinicaltrials.gov/ct2/show/NCT04566770","https://www.clinicaltrials.gov/ct2/show/NCT04341389","https://clinicaltrials.gov/ct2/show/NCT04398147","https://www.clinicaltrials.gov/ct2/show/NCT04313127"],"repurposed":"New","siteLocations":[{"city":"AAO","country":"ARG","lat":-34.5991877,"lng":-58.3932257,"locationId":"32ebfc75dd4b5b7310885bd4577408ac233c8618","name":"Fundaci\u00f3n Socolinsky Centro De Vacunaci\u00f3n Proteger","state":"CABA"},{"city":null,"country":"ARG","lat":-34.5649008,"lng":-58.47106529999999,"locationId":"1612074ae100ed163e65dd81c42a7818f4654ee9","name":"Hospital Pirovano","state":"CABA"},{"city":"Ca\u00f1uelas","country":"ARG","lat":-35.0252825,"lng":-58.7304007,"locationId":"991bb9aa56de3a4931e92e45542e43332c264ab2","name":"Htal De Alta Complejidad Cuenca Alta N\u00e9stor Kirchner","state":"Provincia de Buenos Aires"},{"city":"La Plata","country":"ARG","lat":-34.9489515,"lng":-57.95069280000001,"locationId":"0e46079cc02c493d7a1957a8a1b3d08774f1233f","name":"Hospital Interzonal De Agudos \"san Juan De Dios\" De La Plata","state":"Provincia de Buenos Aires"},{"city":"AAE","country":"ARG","lat":-34.6037061,"lng":-58.3921411,"locationId":"f065107256e41ed44035e5560a243dca33a02541","name":"Hospital Rossi","state":"CABA"},{"city":"AVG","country":"ARG","lat":-34.909665,"lng":-57.94375350000001,"locationId":"ed18a3b2f34a065de1b60b5dc3b3b1e6bfa35854","name":"Inst. M\u00e9dico Platense","state":"Provincia de Buenos Aires"},{"city":"Z\ufffdrate","country":"ARG","lat":-34.6037132,"lng":-58.38161789999999,"locationId":"b98ae4b1b6cef8a67b6745b16052928b61bcee0a","name":"Instituto De Investigaciones Cl\u00ednicas","state":"CABA"},{"city":"Moreno","country":"ARG","lat":-34.6423338,"lng":-58.7888432,"locationId":"7a10f9ab5be089a36db3a94e9fda8bbef727433c","name":"Htal Mariano Y Luciano De La Vega","state":"\u0544\u0565\u056e \u0532\u0578\u0582\u0565\u0576\u0578\u057d \u0531\u0575\u0580\u0565\u057d"},{"city":"Florida","country":"ARG","lat":-34.5224275,"lng":-58.4898131,"locationId":"5c28950c7e9e602bb69d1f60934bbf384a5f27da","name":"Hospital Houssay","state":"Provincia de Buenos Aires"},{"city":"Florida","country":"ARG","lat":-34.5218231,"lng":-58.4898913,"locationId":"f251aea30b2dbbb918d53c39caa3267c94933df7","name":"Hospital Zonal General De Agudos \"cetrangolo\"","state":"Provincia de Buenos Aires"},{"city":"Quilmes","country":"ARG","lat":-34.727306,"lng":-58.262632,"locationId":"75e9b87a5f8fe86e42861ba34af9cf125186f64c","name":"Instituto Cer","state":"Provincia de Buenos Aires"},{"city":"BBD","country":"ARG","lat":-34.5862595,"lng":-58.4419716,"locationId":"02c84efa8442c65833d3e9c07373c13364bb6557","name":"Previvax Centro De Vacunaci\u00f3n","state":"CABA"},{"city":"Temuco","country":"CHL","lat":-38.7370008,"lng":-72.59966399999999,"locationId":"ac9318fcaa31acb761a85ce23b1faf24f3b0910d","name":"Hospital Dr. Hernan Henriquez Aravena Temuco","state":"Araucan\u00eda"},{"city":"Providencia","country":"CHL","lat":-33.4314474,"lng":-70.6093325,"locationId":"530327e03e3f518edd16d68c9185291f50f0f7db","name":"Cimer Centro De Investigaciones Medicas Respiratorias Santiago","state":"Santiago Metropolitan Region"},{"city":"Santiago","country":"CHL","lat":-33.4611969,"lng":-70.64174419999999,"locationId":"caed84eccd1112f3513eaf37ae99c4db8e297517","name":"Hospital San Borja Arriar\u00e1n Santiago","state":"Regi\u00f3n Metropolitana"},{"city":"Hualp\u00e9n","country":"CHL","lat":-36.8004114,"lng":-73.071997,"locationId":"68d3be443f366c98cb7c83d1f78a8899d3bc3523","name":"Cl\u00ednica Andes Salud Concepci\u00f3n","state":"B\u00edo B\u00edo"},{"city":"Puerto Montt","country":"CHL","lat":-41.4491766,"lng":-72.9572697,"locationId":"37d1105a7aeb093bddb9667f20a44377b67250ba","name":"Hospital De Puerto Montt Dr. Eduardo Sch\u00fctz Schoroeder Puerto Montt","state":"Los Lagos"},{"city":"Osorno","country":"CHL","lat":-40.587566,"lng":-73.1283199,"locationId":"f4955062ea1d1186738ae873b66c7b3d7f6bd51b","name":"Hospital Base De Osorno","state":"Los Lagos"},{"city":"Valdivia","country":"CHL","lat":-39.818554,"lng":-73.2395179,"locationId":"6e5440bcd8326bd0e9a61fa05a62cea99455e3a0","name":"Clinica Alemana De Valdivia Valdivia","state":"Los R\u00edos"},{"city":"Aguascalientes","country":"MEX","lat":21.9325436,"lng":-102.2982291,"locationId":"2ebad6d932d56f106b6abd2f0f4b8eb461d5542c","name":"Centro De Investigaci\u00f3n M\u00e9dica Aguascalientes (cima)","state":"Ags."},{"city":"M\u00e9xico D.F.","country":"MEX","lat":19.4819488,"lng":-99.1368813,"locationId":"d72f8e47966073a6557bec9feec55b69cba90d49","name":"Hospital Ju\u00e1rez De M\u00e9xico (hjm)","state":"CDMX"},{"city":"M\u00e9xico D.F.","country":"MEX","lat":19.2879435,"lng":-99.1563518,"locationId":"d17fbe91ef69d86df7ccec53fd9451a0de325358","name":"Instuto De Ciencias M\u00e9dicas Y De La Nutrici\u00f3n Salvador Subir\u00e1n (incmnsz)","state":"CDMX"},{"city":"Chihuahua","country":"MEX","lat":28.6538722,"lng":-106.0986822,"locationId":"ac2402ec332e1a0c16f9640e3af697349f486609","name":"Centro De Investigacion Integral Medivest Sc","state":"Chih."},{"city":null,"country":"MEX","lat":20.0910963,"lng":-98.7623874,"locationId":"ee6206aa0b557460fbdd83f646a6dbdb547dc8e9","name":"Hidalgo","state":"Hgo."},{"city":"Guadalajara","country":"MEX","lat":20.6849733,"lng":-103.3855182,"locationId":"87027379eafab8b0113bd8fcd01ada2ec2e13e24","name":"Instituto Jaliscience De Metabolismo","state":"Jal."},{"city":"Morelia","country":"MEX","lat":19.6843901,"lng":-101.1900969,"locationId":"9c48d79310ee3aa5c9d9bc9ae29e14c64563bdfb","name":"Asociaci\u00f3n De Investigaci\u00f3n Pedi\u00e1trica Y Adultos (ainpad)","state":"Mich."},{"city":"Cuernavaca","country":"MEX","lat":18.9327534,"lng":-99.2211596,"locationId":"8664128bb22ff75f7b073620fb747515f8c7621b","name":"Jm Research","state":"Mor."},{"city":"San Nicol\u00e1s de los Garza","country":"MEX","lat":25.7140788,"lng":-100.274372,"locationId":"bb7fcdfb095427c8825d5cae151e8ab64179cd94","name":"Hospital Metropolitano \"dr. Bernardo Sep\u00falveda\"","state":"N.L."},{"city":"M\u00e9xico","country":"MEX","lat":17.0680246,"lng":-96.72113019999999,"locationId":"466b52bd7e81ab2112811f90251efcc4bae54606","name":"Oaxaca Site Management Organization (osmo)","state":"Oax."},{"city":"Canc\u00fan","country":"MEX","lat":21.1516008,"lng":-86.84195319999999,"locationId":"2b73e92ee7e1719dcca8f0174d70902e86e54135","name":"Centro De Investigaci\u00f3n Y Avances M\u00e9dicos Especializados (ciame)","state":"Q.R."},{"city":"Veracruz","country":"MEX","lat":19.1927791,"lng":-96.1290069,"locationId":"3b528182956844127636340a0f579a12cb9eb908","name":"Faicic","state":"Ver."},{"city":"M\u00e9rida","country":"MEX","lat":20.987738,"lng":-89.6303365,"locationId":"19e715a12279a8fc9f6e459deab39aabb173cebe","name":"Kohler & Milstein Research","state":"Yuc."},{"city":"Chihuahua","country":"MEX","lat":28.680421,"lng":-106.0897929,"locationId":"757ea8ae5d403a87705a120fd3cc6a094ba8e7af","name":"Miro (medical Invetigation Research Organisation Sc)","state":"Chih."},{"city":"M\u00e9xico D.F.","country":"MEX","lat":19.306596,"lng":-99.1853235,"locationId":"84dd3f34c683d8ac6ff55b9d2a0a3565c0eb4f9a","name":"Instituto Nacional De Pediatr\u00eda (inp)","state":"CDMX"},{"city":"Durango","country":"MEX","lat":24.0288174,"lng":-104.6683902,"locationId":"b5ba869726800678d36ee0bb85e1a07b4f475b24","name":"Instituto De Investigaciones Aplicada A Las Neurociencias (iian)","state":"Dgo."},{"city":"Puebla","country":"MEX","lat":19.0519679,"lng":-98.2227928,"locationId":"3c8efcd44cd4b5b48d965cdc11befc14e29f61b9","name":"Administraci\u00f3n De Especialistas De Puebla S.c. (udep)","state":"Pue."},{"city":"Islamabad","country":"PAK","lat":33.6755497,"lng":73.0671876,"locationId":"6f652eaf6871d88bd108679ef29115d804d33582","name":"Shifa International Hospital","state":"Islamabad Capital Territory"},{"city":"Lahore","country":"PAK","lat":31.4487693,"lng":74.2717158,"locationId":"d14baa2652fa2401048d7bd17c093462ae2762e6","name":"Shaukat Khanum Memorial Cancer Hospital And Research Centre","state":"Punjab"},{"city":"Lahore","country":"PAK","lat":31.506564,"lng":74.3097031,"locationId":"c9cb8d41b19f83deaa647d89bebc1d078ec8daea","name":"University Of Health Scinces","state":"Punjab"},{"city":"Karachi","country":"PAK","lat":24.8927887,"lng":67.075502,"locationId":"4f0179773702d3c8d9f4bd75351bcd759ec9c2d0","name":"Aga Khan University Hospital","state":"Sindh"},{"city":"Karachi","country":"PAK","lat":24.8169442,"lng":67.1118,"locationId":"b734b91f6f38538f5e8e0abd4083aedc1f81dcd4","name":"The Indus Hospital","state":"Sindh"},{"city":"Ryazan'","country":"RUS","lat":54.6224048,"lng":39.7101378,"locationId":"b837c6d4ee8a9eafd496f61423278afbcf9e6ff6","name":"Ryazan State Medical University","state":"Ryazanskaya oblast'"},{"city":"\u0421\u041f\u0411","country":"RUS","lat":59.9310584,"lng":30.3609096,"locationId":"da6384ec3ddf258a1b70c2b40f491e2b8bbf675a","name":"Ooo \"kurator\"","state":null},{"city":"\u0421\u041f\u0411","country":"RUS","lat":59.9310584,"lng":30.3609096,"locationId":"356a5f6bf8e0c7a873ba647f2f37c02ef8dae3b6","name":"Research Center Eco","state":null},{"city":"\u0421\u041f\u0411","country":"RUS","lat":59.9310584,"lng":30.3609096,"locationId":"11f7de774bc73131f6ee52a92719f59031320be5","name":"Ooo \"baltijskaya Meditsina\"","state":null},{"city":"\u0421\u041f\u0411","country":"RUS","lat":59.9310584,"lng":30.3609096,"locationId":"356a5f6bf8e0c7a873ba647f2f37c02ef8dae3b6","name":"Research Center Eco","state":null},{"city":"\u0421\u041f\u0411","country":"RUS","lat":59.9310584,"lng":30.3609096,"locationId":"47bf9c86ad84536f2c1d4474cf3e3d1bff92b09d","name":"Federal State Budgetary Institution \"scientific Research Institute Of Influenza Named After A. A. Smorodintsev\" Of The Ministry Of Healthcare Of The Russian Federation Named After A. A. Smorodintsev\" Of The Ministry Of Healthcare Of The Russian Federation","state":null},{"city":"\u0421\u041f\u0411","country":"RUS","lat":59.8510434,"lng":30.192288,"locationId":"1939c8e7b465e1aee2b626048d17149143a64e3a","name":"Saint Petersburg State Budgetary Healthcare Institution \"city Polyclinic #106\"","state":null},{"city":"Aramil","country":"RUS","lat":56.6968024,"lng":60.8088537,"locationId":"cc1793ec5a17460345f6fcf8d5628ba4bd8e1e15","name":"State Budgetary Healthcare Institution Of Sverdlovsk Region \"aramil City Hospital\"","state":"Sverdlovskaya oblast'"},{"city":"Chelyabinsk","country":"RUS","lat":55.1644419,"lng":61.4368432,"locationId":"0a8730d382c8037254135da9b1b9ddffcd9e395d","name":"Non","state":"Chelyabinsk Oblast"},{"city":"Yekaterinburg","country":"RUS","lat":56.8430993,"lng":60.64540859999999,"locationId":"4632a27e1405fb3f47d5664f3b78dfb9d87488c7","name":"Municipal Budgetary Institution \"central City Clinical Hospital # 6\"","state":"Sverdlovsk Oblast"},{"city":"Moskva","country":"RUS","lat":55.70393490000001,"lng":37.5286696,"locationId":"df3c194288b9f4ed2bf64983d40c24370589de84","name":"Moscow State Budgetary Healthcare Institution \"city Polyclinic #2 Of The Moscow City Healthcare Department\"","state":null},{"city":"Moskva","country":"RUS","lat":55.7301734,"lng":37.56690330000001,"locationId":"cc2bc8fdbe767485881f311a12c3ae782f6f8dea","name":"Federal State Autonomous Educational Institution Of Higher Education I.m. Sechenov First Moscow State Medical University Of Ministry Of Healthcare Of The Russian Federation (sechenovsky University)","state":null},{"city":"Nizhny Novgorod","country":"RUS","lat":56.3268684,"lng":44.0058793,"locationId":"b3912e233ea0ae060e077755f2b6e92438ead15d","name":"Private Healthcare Institution \"clinical Hospital \"rzhd","state":"Nizhny Novgorod Oblast"},{"city":"Novosibirsk","country":"RUS","lat":55.03425300000001,"lng":82.92184209999999,"locationId":"cf312c5cf7c5b274bcf45108708590a9bd600027","name":"\"life Benefits Service","state":"Novosibirskaya oblast'"},{"city":"Omsk","country":"RUS","lat":54.9913545,"lng":73.3645204,"locationId":"af433424081a2d1b97fd10a28c9798cd87424694","name":"Ooo \"clinical And Diagnostic Center \"ul'tramed\"","state":"Omsk Oblast"},{"city":"Omsk","country":"RUS","lat":54.9913545,"lng":73.3645204,"locationId":"debb99a31e4cf4f65c3d6534822db0cf84f1dcb0","name":"Budgetary Institution Of Heathcare Of Omsk Region \"city Clinical Hospital #1 N.a. Kabanova A.n.\"","state":"Omsk Oblast"},{"city":"\u0421\u041f\u0411","country":"RUS","lat":59.8331665,"lng":30.3378742,"locationId":"80946fe68b22c8fbdfdb41d2fb50bca62569d294","name":"Ooo Zvyezdnaya Klinika","state":null},{"city":"\u0421\u041f\u0411","country":"RUS","lat":59.9310584,"lng":30.3609096,"locationId":"0ba26bf3b9fe8007647056e3b3b472a13a0ca528","name":"Federal State Budgetary Institution \"children Scientific And Clinical Centre Of Infectional Diseases Of Federal Medical And Biological Agency \"","state":null},{"city":"Saratov","country":"RUS","lat":51.531565,"lng":45.98338039999999,"locationId":"37178bcba91d3c1fe31e4632f423dc42c59e4544","name":"Federal State Budgetary Educational Institution Of Higher Education \"saratov State Medical University Named After V.i. Razumovsky\" The Ministry Of Health Of The Russian Federation","state":"Saratovskaya oblast'"},{"city":"Smolensk","country":"RUS","lat":54.7604401,"lng":32.0942887,"locationId":"fba7b7f0b79a51cb0cbcf55b9fe730ed8e161302","name":"Ooo \"uromed\"","state":"\u0421\u043c\u043e\u043b\u0435\u043d\u0441\u043a"},{"city":"Tomsk","country":"RUS","lat":56.4923955,"lng":84.948675,"locationId":"17cc7ad530b3f91d2cb301593bcff5d3e5d413be","name":"Ooo \"medical Scientific And Practical Center\"","state":"Tomskaya oblast'"},{"city":"Tomsk","country":"RUS","lat":56.4728589,"lng":84.9491219,"locationId":"dbd6fd613e65952d9ea9a1601c2aae4934f9cfde","name":"Federal State Budgetary Educational Institution Of Higher Education \"siberia State Medical University\" Of The Ministry Of Healthcare Of The Russian Federation","state":"Tomskaya oblast'"},{"city":"Yaroslavl","country":"RUS","lat":57.62607440000001,"lng":39.8844709,"locationId":"4f021a0f6c7c6f2caeae2b9733d412506d09445a","name":"State Autonomous Healthcare Institution Of Yaroslavl Region \"clinical Emergency Hospital Named After N.v. Solovyev\"","state":"Yaroslavl Oblast"},{"city":"Yaroslavl","country":"RUS","lat":57.62607440000001,"lng":39.8844709,"locationId":"456f6d1bd91b941205a9f8fc96a2179956c48cea","name":"Federal State Budgetary Institution \"scientific Research Institute Of Influenza Named After A. A. Smorodintsev\" Of The Ministry Of Healthcare Of The Russian Federation","state":"Yaroslavl Oblast"},{"city":"Yaroslavl","country":"RUS","lat":57.62607440000001,"lng":39.8844709,"locationId":"40a210bb695185518e7ee0c85d6a97b88fb4f52a","name":"State Budgetary Healthcare Institution Of Yaroslavl Region \" Clinical Hospital #2\"","state":"Yaroslavl Oblast"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1","https://www.bioworld.com/articles/433791-china-approves-first-homegrown-covid-19-vaccine-to-enter-clinical-trials  https://www.youtube.com/watch?v=1ZMWJJyoK7A","http://www.cansinotech.com/homes/article/show/56/153.html"],"sponsors":[{"sponsorId":"ae6d6a42f1f04b04f866b7d03b344389efca16ee","sponsorName":"CanSino Biologics Inc"}],"status":"Ongoing","studyCompletionDate":"Sun, 30 Jan 2022 00:00:00 GMT","studyStartDate":"Tue, 15 Sep 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"GeoVax Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Unknown","notes":"Using existing vaccine platform called GV-MVA-VLP,3 candidates have been identified,animal trials soon to begin","numSites":"","otherPartners":"BravoVax","phase":"","preferredName":"GeoVax Vaccine","primaryCompletionDate":"","productId":18,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.geovax.com/news/geovax-progresses-in-coronavirus-covid-19-vaccine-development-program","https://www.geovax.com/technology-pipeline/pipeline-summary"],"sponsors":[{"sponsorId":"f5413cebc2f1a8871f47600364147dc47dbb9ad1","sponsorName":"GeoVax Labs Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"CoVLP","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"mary.hardison@syneoshealth.com        ","name":null,"notes":"Active, not recruiting","phone":"1(919)666 0737","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Thu, 12 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 10 Jul 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":"Fri, 21 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Other","notes":"Company developed a virus-derived plant-like particle of SARS-COV-2 that mimics the structure but lacks genetic material","numSites":"","otherPartners":"","phase":"3","preferredName":"CoVLP","primaryCompletionDate":"Sat, 12 Sep 2020 00:00:00 GMT","productId":19,"registryLink":["https://www.clinicaltrials.gov/ct2/show/NCT04636697","https://www.clinicaltrials.gov/ct2/show/NCT04662697","https://www.clinicaltrials.gov/ct2/show/NCT04450004"],"repurposed":"New","siteLocations":[{"city":"Mirabel","country":"CAN","lat":45.7033352,"lng":-73.9273209,"locationId":"197dfab8d673a93e46dad9ca98e4c9ba602b0ad9","name":"Manna Research (mirabel)","state":"QC"},{"city":"Quebec City","country":"CAN","lat":46.8093961,"lng":-71.2445056,"locationId":"b2cf56714aabe6103e4c513aa65e6714699c861a","name":"Diex Research Quebec Inc.","state":"QC"},{"city":null,"country":"CAN","lat":46.0744567,"lng":-73.4950004,"locationId":"41ae7355dfdba6df684f526c1f55a35149a49249","name":"Diex Recherche Joliette","state":"QC"},{"city":"Sherbrooke","country":"CAN","lat":45.3984494,"lng":-71.9266659,"locationId":"0f22b0c5fcbe2c10b5ef2c933814949ad3b05421","name":"Q&t Research Sherbrooke Inc.","state":"QC"}],"sources":["https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/","https://www.biospace.com/employer/541504/medicago-inc-/","https://www.medicago.com/en/pipeline/","https://clinicaltrials.gov/ct2/show/NCT04450004","Date calculated from: https://www.businesswire.com/news/home/20200312005345/en/.","https://www.businesswire.com/news/home/20200312005345/en/"],"sponsors":[{"sponsorId":"e59212c9eed9f476dcb441a9645267e5e6b915c2","sponsorName":"Medicago"}],"status":"Ongoing","studyCompletionDate":"Fri, 30 Apr 2021 00:00:00 GMT","studyStartDate":"Fri, 10 Jul 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"AdCOVID (based on NasoVax)","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Gene therapies","notes":"This is a repurposing of the NasoVax technology (recombinant intranasal) for a COVID-19 vaccine,It should be noted that the provided source on Atimmune's Nasovax-based COVID-19 vaccine was published on February 28. Since then there has been no news on the vaccine until March 30 which is when a new article was published stating that Altimmune will collaborate with UAB to develop AdCOVID. Because AdCOVID possesses the same characteristics as the NasoVax analog (recombinant vaccine - single-dose - and intranasal) I believe that this entry should be reclassified as AdCOVID. NasoVax is still currently in a Phase 2a trial so I have opted to classify AdCOVID as a repurposed-not approved product. Currently working on preclinical animal studies and characterization of vaccine immunogenicity,aims to receive IND approval and enable phase 1 by Q3 2020","numSites":"","otherPartners":"University of Alabama at Birmingham (UAB)","phase":"","preferredName":"AdCOVID (based on NasoVax)","primaryCompletionDate":"","productId":20,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.precisionvaccinations.com/vaccines/nasovax-influenza-vaccine","https://ir.altimmune.com/news-releases/news-release-details/altimmune-and-university-alabama-birmingham-collaborate","https://ir.altimmune.com/news-releases/news-release-details/altimmune-completes-first-development-milestone-toward-single","https://altimmune.com/nasovax/ https://ir.altimmune.com/news-releases/news-release-details/altimmune-completes-first-development-milestone-toward-single https://ir.altimmune.com/news-releases/news-release-details/altimmune-and-university-alabama-birmingham-collaborate"],"sponsors":[{"sponsorId":"e97fb449c577795bfb9ae1692146c17455a06ef8","sponsorName":"Altimmune"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Galidesivir","chemicalName":"BCX4430","conditionOrDisease":"COVID-19","contact":[{"email":"clinicaltrials@biocryst.com","name":null,"notes":"","phone":"919-859-1302","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"Other","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 09 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Neucleoside analogue for Yellow Fever broad spectrum.","numSites":"1","otherPartners":"NIAID,BARDA-NIH","phase":"1","preferredName":"BCX4430","primaryCompletionDate":"Mon, 31 May 2021 00:00:00 GMT","productId":42,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT03891420","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"S\u00e3o Paulo","country":"BRA","lat":-23.5505199,"lng":-46.63330939999999,"locationId":"d9e34e3facfb87ae04b7f80818a7c681fe946856","name":"Sao Paulo","state":"SP"}],"sources":["http://ir.biocryst.com/news-releases/news-release-details/biocryst-completes-phase-1-clinical-trial-galidesivir","https://www.drugbank.ca/drugs/DB11676","https://www.clinicaltrials.gov/ct2/show/NCT03891420?term=Galidesivir&cond=COVID&draw=2&rank=1"],"sponsors":[{"sponsorId":"ec79288164e657a6770558c7e361bf039abbc3c1","sponsorName":"Biocryst Pharmaceuticals"}],"status":"Ongoing","studyCompletionDate":"Sun, 31 May 2020 00:00:00 GMT","studyStartDate":"Thu, 09 Apr 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"IBV,Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Israel"],"countryCodes":["ISR"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Thu, 27 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Subunit Vaccines","notes":"Adaption of Avian CoronaVirus Infectious Bronchitis Virus Vaccine for Human Use. This is an adaptation of the IBV vaccine (against poultry coronavirus) for use in humans against COVID-19,IBV vaccine was based on a protein expression vector and the COVID vaccine will likely work in a similar manner,the Israeli ministries plan to accelerate the approval process to bring the vaccine to the market ASAP,MIGAL believes the vaccine could enter Phase 1 by June 1,it is still in the final stages of development due to delays in receiving the genetic construct,MIGAL has begun trials in mice","numSites":"","otherPartners":"Israel Innovation Authority,Health Ministry and the Headquarters of the National Digital Israel Initiative","phase":"","preferredName":"IBV,Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine","primaryCompletionDate":"","productId":21,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.trialsitenews.com/israel-government-announces-13m-covid-19-research-funds-while-migals-claims-a-covid-19-breakthrough/","https://migal.org.il/en/node/7010","https://www.jpost.com/health-science/israeli-scientists-active-component-of-coronavirus-vaccine-days-away-623228"],"sponsors":[{"sponsorId":"83dd887c3fd8789867722d2edd6b259ee645f1a3","sponsorName":"MIGAL Research Institute"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"TNX-1800","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Wed, 26 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Other","notes":"Modified horsepox virus designed to express the SARS-CoV-2 spike protein,currently in the pre-clinical stage of development and Tonix expects preliminary data from animal experiments in Q3 2020","numSites":"","otherPartners":"","phase":"","preferredName":"TNX-1800","primaryCompletionDate":"","productId":22,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.tonixpharma.com/","https://www.tonixpharma.com/news-events/press-releases/detail/1199/tonix-pharmaceuticals-reports-first-quarter-2020-financial","https://www.tonixpharma.com/contact","https://www.tonixpharma.com/news-events/press-releases/detail/1195/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year","https://www.tonixpharma.com/news-events/press-releases/detail/1191/tonix-pharmaceuticals-announces-research-collaboration-with"],"sponsors":[{"sponsorId":"40e82256fff7abb570316aa4f46cf693fc0c6c98","sponsorName":"Tonix Pharmaceuticals"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"Clover Recombinant subunit vaccine","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"min.dong@cloverbiopharma.com","name":null,"notes":"","phone":"86 010 82022300","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 19 Jun 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"1","otherPartners":"Glaxosmithkline,Dynavax","phase":"1","preferredName":"Clover Recombinant subunit vaccine","primaryCompletionDate":"Tue, 20 Oct 2020 00:00:00 GMT","productId":23,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04405908","repurposed":"New","siteLocations":[{"city":"Nedlands","country":"AUS","lat":-31.96652,"lng":115.815571,"locationId":"4113b776921dbea7a03f69b4c3c988629ebc5952","name":"Linear Clinical Research","state":"WA"}],"sources":["https://www.bioworld.com/articles/433055-clover-produces-subunit-vaccine-candidate-s-trimer-for-coronavirus","https://www.clinicaltrialsarena.com/comment/clover-biopharmaceuticals-covid-19-vaccine/","http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=42","http://www.cloverbiopharma.com/index.php?m=content&c=index&a=lists&catid=51","https://clinicaltrials.gov/ct2/show/NCT04405908","https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1"],"sponsors":[{"sponsorId":"2ad3e27aa56a9275005c084d1c2ca3c71cc945a1","sponsorName":"Clover Biopharmaceuticals"}],"status":"Ongoing","studyCompletionDate":"Tue, 30 Mar 2021 00:00:00 GMT","studyStartDate":"Fri, 19 Jun 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Linear DNA Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Italy"],"countryCodes":["ITA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Wed, 18 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"PCR produced linear DNA vaccine","numSites":"","otherPartners":"Applied DNA Sciences,Takis Biotech","phase":"","preferredName":"Linear DNA Vaccine","primaryCompletionDate":"","productId":24,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://adnas.com/coronavirus-preclinical-trials-italy-ministry-health/","https://adnas.com/coronoavirus-applied-dna-linearx-takis-biotech-vaccine/","https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1"],"sponsors":[{"sponsorId":"35a1314de34e0181bb072a8ab28865c9f1cdecc1","sponsorName":"Applied DNA Sciences"},{"sponsorId":"3d80bed6c0a0fd89072a0112ae97d02303dc1b5e","sponsorName":"Takis Biotech"},{"sponsorId":"ea1f0842312281e699947cd442445fd782ddde1c","sponsorName":"Linearx Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Predictive Oncology Vaccine AI Platform","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Thu, 12 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Other","notes":"Vaccine will be based on a new self-assembling nanoparticle technology called Non Specific Protein (NSP)-10","numSites":"","otherPartners":"Soluble Therapeutics","phase":"","preferredName":"Predictive Oncology Vaccine AI Platform","primaryCompletionDate":"","productId":25,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug","https://www.pharmaceutical-technology.com/news/predictive-oncology-covid-19-vaccine/","https://www.globenewswire.com/news-release/2020/05/06/2028420/0/en/Predictive-Oncology-and-Dr-Daniel-Carter-Collaborating-to-Develop-a-Potential-COVID-19-Vaccine-Utilizing-Novel-Nanoparticle-Vaccine-Platform-Based-on-NSP-10.html"],"sponsors":[{"sponsorId":"5e5fd3a94173dbc6792d6963099af3d35fffc59a","sponsorName":"Predictive Oncology"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"AJ Vaccines,S protein Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Denmark"],"countryCodes":["DNK"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"the vaccine being developed is an S protein vaccine","numSites":"","otherPartners":"","phase":"","preferredName":"AJ Vaccines,S protein Vaccine","primaryCompletionDate":"","productId":26,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1","https://ajvaccines.com/news/"],"sponsors":[{"sponsorId":"f3d84a99a68fdd7ad327bbc8ce41458fc29dec50","sponsorName":"AJ Vaccines"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"GS-5734","chemicalName":"remdesivir","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"On Market","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 15 Mar 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Other trials undertaken by NIAD-USA,INSERM-France,China Japanese friendship hospital,No of study is increasing rapidly","numSites":"","otherPartners":"Gilead Sciences","phase":"","preferredName":"remdesivir","primaryCompletionDate":"","productId":27,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w","https://www.gilead.com/purpose/advancing-global-health/covid-19","https://www.drugbank.ca/drugs/DB14761","https://www.gilead.com/utility/contact","https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials#","https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials","https://clinicaltrials.gov/ct2/show/NCT04292730","https://clinicaltrials.gov/ct2/show/record/NCT04292730"],"sponsors":[{"sponsorId":"cbb34f9aed92e21ff89501b842a385faabf9c8c6","sponsorName":"Gilead Sciences Inc"}],"status":"On Market","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Kaletra,Aluvia","chemicalName":"lopinavir,ritonavir","conditionOrDisease":"COVID-19","contact":[{"email":"qning@vip.sina.com","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 4","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Unclear what to do with this one - abbvie is not the sponsor but is the manufacturer of the drug. Some studies are published: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true,https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1.full.pdf. Note that for the highest study there were multiple phase 4 so I picked the largest one that had already started recruiting","numSites":"1","otherPartners":"AbbVie","phase":"4","preferredName":"lopinavir,ritonavir","primaryCompletionDate":"Mon, 01 Jun 2020 00:00:00 GMT","productId":28,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04255017","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Wuhan","country":"CHN","lat":30.592849,"lng":114.305539,"locationId":"5da8cff769d22a3a3607bf12687fa25a88d812b4","name":"Wuhan","state":"Hubei"}],"sources":["https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf","https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/factsheet-coronavirus-030420.pdf","https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true","https://www.drugbank.ca/drugs/DB01601; https://www.drugbank.ca/drugs/DB01601","https://www.kaletra.com/","https://www.clinicaltrials.gov/ct2/show/NCT04255017?term=lopinavir+ritonavir&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2","https://www.clinicaltrials.gov/ct2/show/record/NCT04255017?term=lopinavir+ritonavir&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2"],"sponsors":[{"sponsorId":"69e116d4f9df799550df0e74438d37589994fb45","sponsorName":"AbbVie"}],"status":"Ongoing","studyCompletionDate":"Wed, 01 Jul 2020 00:00:00 GMT","studyStartDate":"Sat, 01 Feb 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"","brandName":"siRNA against  SARS-CoV-2","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"150 candidates under in vitro test","numSites":"","otherPartners":"","phase":"","preferredName":"siRNA against  SARS-CoV-2","primaryCompletionDate":"","productId":56,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/","https://sirnaomics.com/contact-us/","https://www.npr.org/sections/health-shots/2020/02/19/807338329/hunt-for-new-coronavirus-treatments-includes-gene-silencing-and-monoclonal-antib"],"sponsors":[{"sponsorId":"d4d4713f1054b2bc9d367a86155cb363519d5ad5","sponsorName":"Sirnaomics"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"","brandName":"LY3819253,LY-CoV555","chemicalName":"UPDATE1","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Thu, 05 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Monoclonal antibodies,500 antibody sequences isolated 03/12/2020","numSites":"","otherPartners":"Vaccine Research Centre - NIAID","phase":"","preferredName":"UPDATE1","primaryCompletionDate":"","productId":57,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.genengnews.com/news/to-develop-coronavirus-treatment-lilly-taps-abcellera-antibody-platform/"],"sponsors":[{"sponsorId":"c3e548eb19a8c76ea5f8eeabdbc8086a91e469af","sponsorName":"AbCellera Biologics"},{"sponsorId":"3415f73b4bae4701d6612a2aa318423dc3c571b2","sponsorName":"Eli Lilly and Company"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Kevzara","chemicalName":"Sarilumab","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"COMPLETED","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 16 Mar 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Sarilumab","primaryCompletionDate":"","productId":29,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.drugbank.ca/drugs/DB11767","http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19","https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-begin-global-kevzarar-sarilumab-clinical","https://www.google.com/search?rlz=1C5CHFA_enGB854GB854&sxsrf=ALeKk022og2HFqxgB2OGNk6Vdmns2VRRhQ%3A1585861871624&ei=71SGXuTZJYKvggfAjrv4BA&q=regeneron+&oq=regeneron+&gs_lcp=CgZwc3ktYWIQAzIICAAQgwEQkQIyBAgAEEMyBQgAEIMBMgUIABCDATIFCAAQgwEyBQgAEIMBMgIIADICCAAyBQgAEIMBMgUIABCDAToECAAQRzoECCMQJzoFCAAQkQI6BwgAEBQQhwJQ2U1Y2ltgp1xoAHABeACAAYYBiAGSB5IBAzYuM5gBAKABAaoBB2d3cy13aXo&sclient=psy-ab&ved=0ahUKEwikjZXs08roAhWCl-AKHUDHDk8Q4dUDCAs&uact=5","https://clinicaltrials.gov/ct2/show/NCT04315298?term=kevzara&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2","https://clinicaltrials.gov/ct2/show/NCT04315298?term=kevzara&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1","https://www.clinicaltrials.gov/ct2/show/NCT04315298"],"sponsors":[{"sponsorId":"a7cbf979a98fdc448b32b211e3d5e8264875995e","sponsorName":"Regeneron"},{"sponsorId":"551135a9f6ade78853bbd5fdbd66283c70e2f776","sponsorName":"Sanofi"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Plaquenil,Hydroquin,Axemal,Dolquine,Quensyl,Quinoric","chemicalName":"hydroxychloroquine","conditionOrDisease":"COVID 19","contact":[{"email":"javiercrespo1991@gmail.com","name":null,"notes":"","phone":"","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"Phase 4","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla","phase":"4","preferredName":"hydroxychloroquine","primaryCompletionDate":"Fri, 06 Nov 2020 00:00:00 GMT","productId":30,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf","https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html; https://www.npr.org/sections/coronavirus-live-updates/2020/03/31/824572119/clinical-trials-set-to-determine-if-anti-malaria-drug-effective-against-covid-19","https://www.drugbank.ca/drugs/DB01611","https://www.drugbank.ca/drugs/DB01612","https://www.drugbank.ca/drugs/DB01613","https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2","https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=3","https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=4","https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=5","https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=6","https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=7","https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=8","https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=9","https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=10","https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=11"],"sponsors":[{"sponsorId":"a5091ee00972baec20a88b0bfc29cf8df11fc10e","sponsorName":"Sanofi SA"},{"sponsorId":"11f8e68d5ce8289f7c1254157f73a6429006ed8c","sponsorName":"Amneal Pharmaceuticals INc"},{"sponsorId":"a951d8e8824303ff34be3adad3b714181ce40092","sponsorName":"Rising Pharma Holdings Inc"},{"sponsorId":"d49e1350f4c21eef623eb4e22b9709b13ac08f82","sponsorName":"University of Minnesota"},{"sponsorId":"38652628acf1b84b92cad2bea1a82015a920b0c3","sponsorName":"University of Oxford"},{"sponsorId":"c6596b3fee7a992d790e288b27e50edfb07b5974","sponsorName":"IHUM\u00e9diterran\u00e9e Infection"},{"sponsorId":"de07adc682970664b17a2475d74c5691cd707ef6","sponsorName":"Sandoz Inc"},{"sponsorId":"67da3aa3718d35ed721af558ab42d840a58dfdbe","sponsorName":"Bayer AG"},{"sponsorId":"00a23d14d5c43daa469abd0a9c6a20c98de6e086","sponsorName":"University of Washington"},{"sponsorId":"d0b12c5f18dc027ada9bc28c72459c2e0d798809","sponsorName":"PatientCenterede Outcomes Research Institute"},{"sponsorId":"03fdeb1f847122b01435c2cc44a82112b2f1e5c9","sponsorName":"World Health Organization"},{"sponsorId":"f87860860d12518378b68c8b4c2d0d61407eac5a","sponsorName":"New York State Department of Health"}],"status":"Ongoing","studyCompletionDate":"Fri, 06 Nov 2020 00:00:00 GMT","studyStartDate":"Mon, 06 Apr 2020 00:00:00 GMT","therapeuticApproach":"Antimalarial drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"TJM2","chemicalName":"TJ003234","conditionOrDisease":"COVID-19","contact":[{"email":"US.Info@I-MabBiopharma.com","name":null,"notes":"","phone":"240-767-6981","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 11 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"AntiBody against GM-CSF. Previously passed a phase 1 trial. INDs submitted for phase II clinical trials in China USA and South Korea.","numSites":"8","otherPartners":"","phase":"2","preferredName":"TJ003234","primaryCompletionDate":"Tue, 01 Sep 2020 00:00:00 GMT","productId":31,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04341116","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Washington","country":"USA","lat":38.9001083,"lng":-77.04905459999999,"locationId":"d4cda226586ebf8ddeb607182f535bdc2d20d6df","name":"Gw Medical Faculty Associates","state":"DC"},{"city":"Peoria","country":"USA","lat":40.7031614,"lng":-89.5904178,"locationId":"31e17a568dabb1f048d3fbb2bf89d57a890d33a7","name":"Osf Healthcare Saint Francis Medical Center","state":"IL"},{"city":"Indianapolis","country":"USA","lat":39.7756075,"lng":-86.1761174,"locationId":"1fc2da031c408a6707b8abef316d8f4f1ee88148","name":"Indiana University Health","state":"IN"},{"city":"Metairie","country":"USA","lat":30.01050529999999,"lng":-90.18101709999999,"locationId":"48dab1173ced35a33086185a2c7f869202185a87","name":"Medpharmics","state":"LA"},{"city":"New Orleans","country":"USA","lat":29.9376843,"lng":-90.10432109999999,"locationId":"64ecf855d2039e1de285035d4324f01d01d95ecb","name":"Ochsner Medical Center","state":"LA"},{"city":"Jackson","country":"USA","lat":32.3282527,"lng":-90.17365459999999,"locationId":"b65e2a34f054daa49d7a9e31bd2dc7252ace91d3","name":"University Of Mississippi Medical Center","state":"MS"},{"city":"Portland","country":"USA","lat":45.4992017,"lng":-122.6867232,"locationId":"376d88cfedfa948030870e40a4519d535342877a","name":"Oregon Health And Science University","state":"OR"},{"city":"Philadelphia","country":"USA","lat":40.0067149,"lng":-75.1511702,"locationId":"8e7033da21be47ccb36b70520a03e9e201ca0517","name":"Temple University Hospital","state":"PA"}],"sources":["http://www.i-mabbiopharma.com/en/article-491.aspx","https://clinicaltrials.gov/ct2/show/NCT03794180","https://apnews.com/Globe%20Newswire/bd107410eacfaa7143eb9ec954e11c70"],"sponsors":[{"sponsorId":"4d5fc82efed329adf6897a54f395828e900a3a4d","sponsorName":"IMab Biopharma"}],"status":"Ongoing","studyCompletionDate":"Tue, 01 Sep 2020 00:00:00 GMT","studyStartDate":"Sat, 11 Apr 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"AT-100","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Recombinant surfactant protein developed to treat bronchopulmonary dysplatia. No timeline for clinical trials.","numSites":"","otherPartners":"","phase":"","preferredName":"AT-100","primaryCompletionDate":"","productId":32,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.airwaytherapeutics.com/at-100/","https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/"],"sponsors":[{"sponsorId":"cce5891ec7c3582e4abbb8a5a1675065288b051b","sponsorName":"Airway Therapeutics"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"TZLS-501","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Tiziana Life Sciences,Novimmune","phase":"","preferredName":"TZLS-501","primaryCompletionDate":"","productId":33,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.marketwatch.com/story/uk-biotech-tiziana-life-sciences-says-its-tzls-501-may-be-of-use-in-treating-coronavirus-2020-03-11"],"sponsors":[{"sponsorId":"2a18b405cfddff30dc89c827294ce141e1078ed6","sponsorName":"Tiziana Life Sciences"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"OYA1","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"OyaGen","phase":"","preferredName":"OYA1","primaryCompletionDate":"","productId":34,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":[""],"sponsors":[{"sponsorId":"09c1011fb00f7f2c97e9b4ebc1373e23f10f3703","sponsorName":"OyaGen"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"BPI-002","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Fri, 13 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Also being considered as a vaccine adjuvant to stimulate long term immunity,Very little information is available on development stages - A patent has been filed for it by the company but it is not clear what that translates to,Information in column T was seen on just one website","numSites":"","otherPartners":"BeyondSpring Inc","phase":"","preferredName":"BPI-002","primaryCompletionDate":"","productId":35,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.biospace.com/article/releases/beyondspring-files-for-patent-protection-on-bpi-002-for-the-treatment-of-viral-infections-including-covid-19/","https://www.beyondspringpharma.com/otherpipeline/index.aspx","https://adisinsight.springer.com/drugs/800049541","https://www.beyondspringpharma.com/pipelineoverview/index.aspx"],"sponsors":[{"sponsorId":"bdc58d6b3c51adacec8fd2e5f71d1d5d71046d8d","sponsorName":"BeyondSpring Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"No","brandName":"NP-120","chemicalName":"Ifenprodil","conditionOrDisease":"COVID-19","contact":[{"email":"nstewart@gvicds.com","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Therapeutic approach - receptor antagonist,Drug originally evaluated for treatment of Idiopathic Pulmonary Fibrosis","numSites":"5","otherPartners":"Cascade chemistry","phase":"2","preferredName":"Ifenprodil","primaryCompletionDate":"Wed, 10 Mar 2021 00:00:00 GMT","productId":36,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04318704","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Brookvale","country":"AUS","lat":-33.7661083,"lng":151.2683365,"locationId":"13613ae635bfa8ac1691bd759f935043185daf0d","name":"Vale Medical Practice","state":"NSW"},{"city":"Concord","country":"AUS","lat":-33.8374705,"lng":151.0925689,"locationId":"e5892fd7cf996ac878dcecb26296494fecddb582","name":"Concord Repatriation General Hospital","state":"NSW"},{"city":"Cairns City","country":"AUS","lat":-16.91244,"lng":145.768365,"locationId":"78e5aab6757078f235c75e2d65e7591bee4e3937","name":"Cairns Hospital","state":"QLD"},{"city":"Christchurch","country":"NZL","lat":-43.5340873,"lng":172.6258673,"locationId":"0ce3b9b2eb3fcb1750d78f8924cbe53cc286a500","name":"University Of Otago","state":"Canterbury"},{"city":"Hamilton","country":"NZL","lat":-37.8044818,"lng":175.2830896,"locationId":"49a5ea5303f83d03cacbf3942447949e145ccca2","name":"Waikato Hospital","state":"Waikato"}],"sources":["https://algernonpharmaceuticals.com/ipf-np-120/","https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2"],"sponsors":[{"sponsorId":"4ec6ff9fa7840783f9d6a9a99ce82cc52a732239","sponsorName":"Algernon Pharmaceuticals"}],"status":"Ongoing","studyCompletionDate":"Thu, 10 Jun 2021 00:00:00 GMT","studyStartDate":"Wed, 10 Jun 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"APN01","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"sonja.hoeller@apeiron-biologics.com","name":null,"notes":"","phone":"","website":""}],"countries":["Austria"],"countryCodes":["AUT"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 06 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"9","otherPartners":"Austrian government","phase":"2","preferredName":"APN01","primaryCompletionDate":"","productId":37,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04335136","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Innsbruck","country":"AUT","lat":47.2692124,"lng":11.4041024,"locationId":"59ffb0c89bc67d08e2e2fdb5532904c6566da277","name":"Insbruck","state":"Tyrol"},{"city":"Vienna","country":"AUT","lat":48.2081743,"lng":16.3738189,"locationId":"0006043cc59a01f0186b6bc82dfe4900a37a9bdd","name":"Wien","state":"Vienna"},{"city":"Vienna","country":"AUT","lat":48.2081743,"lng":16.3738189,"locationId":"0006043cc59a01f0186b6bc82dfe4900a37a9bdd","name":"Wien","state":"Vienna"},{"city":"Copenhagen","country":"CNK","lat":55.6760968,"lng":12.5683372,"locationId":"d939fee507a04410d47e45774277234e3da25686","name":"Copenhagen","state":null},{"city":null,"country":"CNK","lat":55.736943,"lng":12.4215514,"locationId":"ff56abeae6f9b3ced98fd704c280c0a875ea2723","name":"Herlev","state":null},{"city":"Hiller\u00f8d","country":"CNK","lat":55.927909,"lng":12.300806,"locationId":"d45ef9f524c6b54b0e006bb95aa3f6f23baa0263","name":"Hiller\u00f8d","state":null},{"city":"Hvidovre","country":"CNK","lat":55.64252200000001,"lng":12.4753859,"locationId":"0ef49b59a09a442c937b9e81a972ce8451a2ccc6","name":"Hvidovre","state":null},{"city":"Hamburg","country":"DEU","lat":53.5510846,"lng":9.9936819,"locationId":"2781a40516d7469698d40938533d3a71edae6006","name":"Hamburg","state":"HH"},{"city":"Munich","country":"DEU","lat":48.1351253,"lng":11.5819805,"locationId":"eefdfc335be5ec69d98766c264f6aac0628b2eaf","name":"M\u00fcnchen","state":"BY"}],"sources":["https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf","https://clinicaltrials.gov/ct2/show/NCT00886353","https://www.google.com/search?q=apeiron+biologics&rlz=1C5CHFA_enGB854GB854&oq=apeir&aqs=chrome.0.69i59j69i57j0l2j46j69i60l3.1226j0j7&sourceid=chrome&ie=UTF-8","https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1"],"sponsors":[{"sponsorId":"6f60b15593583caa5a157b68e379e898ed540bfe","sponsorName":"University of British Columbia"},{"sponsorId":"135275cdf7dd39808bf7b9ddb4115db4750d3cdc","sponsorName":"APEIRON Biologics"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Fri, 10 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Brilacidin","chemicalName":"Brilacidin Tetrahydrochloride","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Sun, 01 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"Innovation Pharamaceuticals","phase":"","preferredName":"Brilacidin Tetrahydrochloride","primaryCompletionDate":"","productId":38,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://static1.squarespace.com/static/5715352e20c647639137f992/t/5e5c0bbea72c2f71ab0978ee/1583090668780/IPIX+Brilacidin+Defensin+Mimetics+-+COVID-19+Overview+March+1+2020+update.pdf"],"sponsors":[{"sponsorId":"d74b3bc88aff79062ddc7572f048d10a2f1b7254","sponsorName":"Innovation Pharmaceuticals"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antibiotics and antiparasitics","trialId":""},{"acceptsHealthySubjects":"No","brandName":"PRO-140","chemicalName":"leronlimab","conditionOrDisease":"COVID-19","contact":[{"email":"kushd@amarexcro.com","name":null,"notes":"","phone":"301-956-2536","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Patient treatment underway via Emergency IND,Phase 2 trial protocol filed","numSites":"11","otherPartners":"RedChip companies","phase":"2","preferredName":"leronlimab","primaryCompletionDate":"","productId":39,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04347239","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Los Angeles","country":"USA","lat":34.068921,"lng":-118.4451811,"locationId":"660ebd4e03f175514f76e2706bdcc5285ac06779","name":"Ucla","state":"CA"},{"city":"Rancho Mirage","country":"USA","lat":33.7634956,"lng":-116.4054165,"locationId":"f3b3d41e249ea5f55041ff3ef3974534a74972f1","name":"Esienhower Health","state":"CA"},{"city":"New Haven","country":"USA","lat":41.302073,"lng":-72.9352096,"locationId":"f13885c8ea69014854aac010e41f17b7149a13c0","name":"Yale","state":"CT"},{"city":"Boston","country":"USA","lat":42.3396063,"lng":-71.10498199999999,"locationId":"f57fc1f805a6509a2e5be6a0e67614abf2e0fa31","name":"Beth Israel Harvard","state":"MA"},{"city":"Livingston","country":"USA","lat":40.7727608,"lng":-74.35437890000001,"locationId":"df329e9389ce1ec5c8eb8db79dba48bc1507a66c","name":"St Barnabas","state":"NJ"},{"city":"Morristown","country":"USA","lat":40.7888312,"lng":-74.4662803,"locationId":"2625306797cba09cca5afaa37f2965f13f6be46d","name":"Altantic Health System Hospital","state":"NJ"},{"city":null,"country":"USA","lat":40.88042,"lng":-73.88005489999999,"locationId":"7e6da988c80dd04e9a2d0aa063449a2dfbf03012","name":"Montefiore Medical Center","state":"NY"},{"city":"Winston-Salem","country":"USA","lat":36.0765703,"lng":-80.2962649,"locationId":"24a4c34b71f7e10bc4cb0a2c502d0ad075336bdc","name":"Novant Health","state":"NC"},{"city":"Columbus","country":"USA","lat":40.0063879,"lng":-83.045577,"locationId":"48c61f1ed1825da24e5003f929628a5d32b07c7e","name":"Ohio Health","state":"OH"},{"city":"Portland","country":"USA","lat":45.4992017,"lng":-122.6867232,"locationId":"b1b4fb52cab861835838563c63790e9612ac9a07","name":"Oregon Health And Sciences University","state":"OR"},{"city":"Houston","country":"USA","lat":29.7031663,"lng":-95.4032312,"locationId":"c30758b0af3ff573149b6b941c90916a351889e5","name":"University Of Texas","state":"TX"}],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"a5c509d28e5944d0d7121691e82a49f47e20f7ef","sponsorName":"CytoDyn"}],"status":"Ongoing","studyCompletionDate":"Thu, 01 Apr 2021 00:00:00 GMT","studyStartDate":"Wed, 15 Apr 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"BTX-025","chemicalName":"Novel Viral Inhibitor","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Tue, 24 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Novel galectin inhibitor for use in COVID-19. Currently pre-clinical.","numSites":"","otherPartners":"Bioxytran","phase":"","preferredName":"Novel Viral Inhibitor","primaryCompletionDate":"","productId":40,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.globenewswire.com/news-release/2020/03/24/2005534/0/en/Bioxytran-Licenses-Novel-Viral-Inhibitor-for-COVID-19-Patients.html"],"sponsors":[{"sponsorId":"6e5983b2fe019c343dfaeb0ad2e7419f3dfaa118","sponsorName":"BIOXYTRAN"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Actemra","chemicalName":"tocilizumab","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"COMPLETED","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 19 Mar 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"first approved anti-IL-6 receptor biologic available in both intravenous (IV) and subcutaneous (SC) formulations for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA).","numSites":"67","otherPartners":"Roche","phase":"3","preferredName":"tocilizumab","primaryCompletionDate":"Wed, 24 Jun 2020 00:00:00 GMT","productId":41,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04320615","repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.roche.com/media/releases/med-cor-2020-03-19.htm"],"sponsors":[{"sponsorId":"7acdde062bf6d75cd4f60fb9c8d60bb3caa89d9a","sponsorName":"Roche"}],"status":"Ongoing","studyCompletionDate":"Tue, 28 Jul 2020 00:00:00 GMT","studyStartDate":"Fri, 03 Apr 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Monoclonal Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"","milestones":[],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Monoclonal Antibodies","primaryCompletionDate":"","productId":103,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://www.astrazeneca.com/media-centre/articles/2020/researching-antibodies-to-target-covid-19.html"],"sponsors":[{"sponsorId":"156a9d5b5c0452de6985da63b61ee8521a939741","sponsorName":"AstraZeneca PLC"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"REGN10933+REGN10987,REGN-COV2","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"COVID19SiteInterest@regeneron.com","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"There is conflicting information. I found a trial that used these drugs for MERS suggesting it is reporpused-not approved but here it says they are starting a first in human trial: https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/ -- The combination of neutralising monoclonal antibodies REGN3048 and REGN3051 is being studied against coronavirus infection in a first-in-human clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).","numSites":"107","otherPartners":"","phase":"3","preferredName":"REGN10933+REGN10987,REGN-COV2","primaryCompletionDate":"Sun, 11 Apr 2021 00:00:00 GMT","productId":43,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04452318","repurposed":"New","siteLocations":[],"sources":["https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/","https://clinicaltrials.gov/ct2/show/NCT03301090?term=REGN3048&draw=2&rank=1","https://www.google.com/search?q=regeneron&rlz=1C5CHFA_enGB854GB854&oq=regeneron&aqs=chrome..69i57j0l3j69i60l4.1356j0j7&sourceid=chrome&ie=UTF-8","https://clinicaltrials.gov/ct2/show/NCT03301090?term=REGN3048&draw=2&rank=1; https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/","Implied P1 from first in human here: https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/"],"sponsors":[{"sponsorId":"a7cbf979a98fdc448b32b211e3d5e8264875995e","sponsorName":"Regeneron"}],"status":"Ongoing","studyCompletionDate":"Sun, 11 Apr 2021 00:00:00 GMT","studyStartDate":"Tue, 30 Jun 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"SNG001","chemicalName":"Interferon beta","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 16 Mar 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Other","notes":"inhaled forumation of beta-1a interferon","numSites":"","otherPartners":"Public funding through shares","phase":"","preferredName":"Interferon beta","primaryCompletionDate":"","productId":44,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.synairgen.com/covid-19/","https://www.morningstar.co.uk/uk/news/AN_1585205934091906300/synairgen-raises-cash-to-go-towards-covid-19-drug-trial.aspx","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB","https://www.clinicaltrialsarena.com/news/cansino-synairgen-covid-19-trials/"],"sponsors":[{"sponsorId":"844645398c47a20691e7b88009bf4a28ca9e0a56","sponsorName":"Synairgen Research"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"AmnioBoost","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 17 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Other","notes":"","numSites":"1","otherPartners":"Lattice Biologics","phase":"1","preferredName":"AmnioBoost","primaryCompletionDate":"","productId":45,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":"Seattle","country":"USA","lat":47.6062095,"lng":-122.3320708,"locationId":"210eebcd06052d1af3861b6ffbe936a109bcaa58","name":"Seattle","state":"WA"}],"sources":["https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/","https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients"],"sponsors":[{"sponsorId":"3269ba5b3b1fa17511555e6336cff3ddd90b84b2","sponsorName":"Lattice Biologics"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Tue, 17 Mar 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Enanta Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Fri, 13 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Unknown","notes":"direct acting antiviral,Starting phase II study for RSV patients","numSites":"","otherPartners":"Enanta Pharmaceuticals","phase":"","preferredName":"Enanta Therapeutic","primaryCompletionDate":"","productId":46,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx","https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx; https://www.pharmaceutical-technology.com/news/enanta-pharmaceuticals-covid-19-drugs/"],"sponsors":[{"sponsorId":"7bf6d2f389a2e6a86e1d696dcc1c2052ef9a9eae","sponsorName":"Enanta Pharmaceuticals"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"COVID-HIG","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Thu, 02 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Unknown","notes":"Manufactured using plasma donations from people who have recovered from COVID19 with antibodies,human hyperimmune product,NIAID has agreed to include COVID-HIG product candidate in one of its clinical studies of treatment of COVID-19 upon availability of clinicla material.","numSites":"","otherPartners":"US Government,BARDA,ASPR","phase":"","preferredName":"COVID-HIG","primaryCompletionDate":"","productId":47,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.biospace.com/article/releases/emergent-biosolutions-partners-with-u-s-government-for-comprehensive-response-to-expedite-development-of-plasma-derived-therapy-for-covid-19/","https://www.biospace.com/article/releases/emergent-biosolutions-partners-with-u-s-government-for-comprehensive-response-to-expedite-development-of-plasma-derived-therapy-for-covid-19/; https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive?field_nir_news_date_value[min]="],"sponsors":[{"sponsorId":"cd5be69c518689ef12547e8559a4ff1c7ebed1d1","sponsorName":"Emergent BioSolutions"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"LEAPS COVID-19","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Mon, 23 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":"Fri, 03 Jan 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"immunotherapy","numSites":"","otherPartners":"CEL-SCI,University of Georgia\u2019s (UGA\u2019s) Center for Vaccines","phase":"1","preferredName":"LEAPS COVID-19","primaryCompletionDate":"","productId":48,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":[""],"sponsors":[{"sponsorId":"7146a8671f847f80a0c4c99c0466916089840d58","sponsorName":"CELSCI"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"TAK-888","chemicalName":"Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG)","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Japan"],"countryCodes":["JPN"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Fri, 06 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"a plasma-derived therapy","numSites":"","otherPartners":"Takeda Pharmaceutical Company","phase":"1","preferredName":"Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG)","primaryCompletionDate":"","productId":49,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":[""],"sponsors":[{"sponsorId":"ab95e09c1c41756dc8b947ebd1fa0e087a23da6c","sponsorName":"Takeda Pharmaceutical Company"}],"status":"On Hold","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"Azithromycin,Hydroxychloroquine","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"","numSites":"","otherPartners":"Pfizer","phase":"","preferredName":"Azithromycin,Hydroxychloroquine","primaryCompletionDate":"","productId":50,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://pfe-pfizercom-prod.s3.amazonaws.com/news/ZithroComboStatement.pdf"],"sponsors":[{"sponsorId":"531d5b28f1f18f219741627c0f2a1e09d355e46a","sponsorName":"Pfizer"},{"sponsorId":"fd203d1438cfd911102049306e6081fba3f89b87","sponsorName":"Intermountain Healthcare"},{"sponsorId":"e8c2d02eac49d122b3733cdbc1e0009caae5b4c7","sponsorName":"University of Utah Health"},{"sponsorId":"f504a9b418cd0c0f06bc0337180c16761e95b8b1","sponsorName":"Fondation Mediterranee Infection"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antibiotics and antiparasitics","trialId":""},{"acceptsHealthySubjects":"","brandName":"OT-101","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 18 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"Appears to still be in vitro testing","numSites":"","otherPartners":"","phase":"","preferredName":"OT-101","primaryCompletionDate":"","productId":51,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["http://investor.mateon.com/news-releases/news-release-details/mateon-achieves-milestone-its-development-ot-101-phase-3","http://investor.mateon.com/news-releases/news-release-details/mateon-develop-its-ot-101-phase-3-clinical-drug-candidate","http://investor.mateon.com/"],"sponsors":[{"sponsorId":"839146f1d67c1b00a841adde72a3555186ed2ee2","sponsorName":"Mateon Therapeutics"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Southwest Research Institute Screening Platform","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 19 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Unknown","notes":"Developed Rhodium a novel-structure based virtual screening tool that can help screen millions of drug compounds and speed up preliminary efficacy and safety evaluations","numSites":"","otherPartners":"Texas Biomedical Research Institute","phase":"","preferredName":"Southwest Research Institute Screening Platform","primaryCompletionDate":"","productId":52,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.swri.org/swri-covid-19-response-resources","Assumed given large number of compounds investigated: https://www.swri.org/press-release/virtual-screening-software-rhodium-coronavirus-research","https://www.swri.org/press-release/virtual-screening-software-rhodium-coronavirus-research","https://www.swri.org/sites/default/files/rhodium-covid19-infographic.pdf"],"sponsors":[{"sponsorId":"24d9d6c7cef2fb07a9bf63de1e32e0d49e73466f","sponsorName":"Southwest Research Institute"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"NanoViricides Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Mon, 16 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Other","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"NanoViricides Therapeutic","primaryCompletionDate":"","productId":53,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["http://www.nanoviricides.com/"],"sponsors":[{"sponsorId":"ce9215688edb9650cbc3b3d92876af43dd53d52b","sponsorName":"NanoViricides"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"VIR-7831","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"2 different modifications of one single clone of antibody originally developed against SARS-CoV-1,shown to act as both vaccine and therapeutic","numSites":"","otherPartners":"Wuxi Biologics,Biogen","phase":"","preferredName":"VIR-7831","primaryCompletionDate":"","productId":54,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/","https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer; https://www.biospace.com/article/vir-biotechnology-ids-2-monoclonal-antibodies-against-the-covid-19-coronavirus/","https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer","https://www.vir.bio/contact/"],"sponsors":[{"sponsorId":"6c32fa743ed510db10e7c97fd975d2a2a5700a4a","sponsorName":"Vir Biotechnology Inc"},{"sponsorId":"b0667c7bd3f77f09b501f5439a15d5af327ec17f","sponsorName":"GSK"},{"sponsorId":"7b6f419a075a9d4cfc1742367fdc3d11cc35f994","sponsorName":"Biogen Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"VIR-2703,ALN-COV","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"350 candidates undergoing in vitro test","numSites":"","otherPartners":"","phase":"","preferredName":"VIR-2703,ALN-COV","primaryCompletionDate":"","productId":55,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://investors.alnylam.com/press-release?id=24656","https://www.vir.bio/contact/"],"sponsors":[{"sponsorId":"2a0f6fec0d49bd2ca117ccbc0cfd8c816f776165","sponsorName":"Alnylam"},{"sponsorId":"ec6e5f3e381b52ffa801d3826f90ffc80615c431","sponsorName":"Vir Biotechnology"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"No","brandName":"BDB-001","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"SKIPPED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"SKIPPED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"SKIPPED"},{"category":"regulatory","date":"Fri, 07 Feb 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"ONGOING"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"SKIPPED"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Anti-C5a Antibody,Phase 2 trial number 2020L0003","numSites":"","otherPartners":"Staidson (Beijing) Biopharmaceuticals Co. Ltd,InflaRx","phase":"2","preferredName":"BDB-001","primaryCompletionDate":"","productId":58,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/","https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v1.full.pdf","https://www.bioworld.com/articles/433447-increasing-number-of-biopharma-drugs-target-covid-19-as-virus-spreads","https://www.staidson.com/article/147.html","https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v1"],"sponsors":[{"sponsorId":"0086ba154cc66744d6566f5674dc67a137770778","sponsorName":"Beijing Defengrei Biotechnology  Staidson"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Sylvant","chemicalName":"siltuximab","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"SKIPPED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"SKIPPED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"SKIPPED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Clinical trial NCT04322188 started but phase UNKNOWN","numSites":"1","otherPartners":"Ergomed,Papa Giovanni XXIII Hospital","phase":"","preferredName":"siltuximab","primaryCompletionDate":"Tue, 19 May 2020 00:00:00 GMT","productId":59,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":"Bergamo","country":"ITA","lat":45.686107,"lng":9.638066,"locationId":"8681a4023e3dc784d104dd55e72d0c935d281c35","name":"Papa Giovanni Xxiii Hospital","state":"Lombardia"}],"sources":["https://www.clinicaltrialsarena.com/news/eusa-pharma-siltuximab-study-covid-19/","https://www.clinicaltrials.gov/ct2/show/record/NCT04322188"],"sponsors":[{"sponsorId":"887084fb166ace787dba446286c132705fbea1b3","sponsorName":"EUSA Pharma"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Thu, 19 Mar 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"47D11","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Thu, 12 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":"Thu, 12 Mar 2020 00:00:00 GMT","milestoneId":13,"name":"lead_selection","status":"ONGOING"},{"category":"pre-clinical","date":"Thu, 12 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Monoclonal antibodies created in lab that target COVID-19 infected cells as well as similar proteins of molecules that cause SARS","numSites":"","otherPartners":"Mount Sinai,Utrecht University,Eurasmus MC","phase":"","preferredName":"47D11","primaryCompletionDate":"","productId":60,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.biorxiv.org/content/10.1101/2020.03.11.987958v1.full.pdf+html","https://www.nature.com/articles/s41467-020-16256-y#change-history","https://www.bloomberg.com/news/articles/2020-05-04/scientists-create-antibody-that-defeats-coronavirus-in-lab"],"sponsors":[{"sponsorId":"4e2f58ce0e723737336ad8f95d829829f4eca5cd","sponsorName":"Harbour Biomed"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"PolyTope mAb Therapy","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Mon, 30 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":"Thu, 12 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Monoclonal antibodies candidates created using AI - computations - and statistics that will target multiple epitopes. 1200 ideal candidates will be chosen and validated in vitro.","numSites":"","otherPartners":"","phase":"","preferredName":"PolyTope mAb Therapy","primaryCompletionDate":"","productId":61,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.proactiveinvestors.com/companies/news/916160/immunoprecise-antibodies-and-its-ai-collaborator-team-up-on-research-program-to-help-fight-coronavirus-916160.html","https://www.thepharmaletter.com/article/immunoprecise-debuts-polytope-mab-therapy-to-tackle-coronavirus-pandemic","https://www.proactiveinvestors.com/companies/news/916160/immunoprecise-antibodies-and-its-ai-collaborator-team-up-on-research-program-to-help-fight-coronavirus-916160.html ; https://www.genengnews.com/covid-19-candidates/immunoprecise-antibodies-ipa-and-evqlv/","https://www.immunoprecise.com/immunoprecises-artificial-intelligence-partner-evqlv-submits-first-panel-of-optimized-antibody-sequences-to-coronavirus-for-polytope-mab-therapy-program/","https://www.immunoprecise.com/immunoprecise-announces-the-launch-of-polytope-mab-therapy-tm-to-tackle-coronavirus-pandemic/"],"sponsors":[{"sponsorId":"7670240cc18d7cdc6c4cdc1e43d130218caa45c4","sponsorName":"ImmunoPrecise Antibodies Ltd"},{"sponsorId":"6eab2ef2c61e3007604b07fb544709610e671afa","sponsorName":"EVQLV"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"IFX-1","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"korinna.pilz@inflarx.de\t","name":null,"notes":"","phone":"","website":""}],"countries":["Germany"],"countryCodes":["DEU"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Sun, 01 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Sat, 01 Feb 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 01 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 31 Mar 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 31 Mar 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":"Sat, 01 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Monoclonal antibodies","numSites":"3","otherPartners":"","phase":"2","preferredName":"IFX-1","primaryCompletionDate":"Mon, 31 May 2021 00:00:00 GMT","productId":62,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04333420","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Amsterdam","country":"NLD","lat":52.35581819999999,"lng":4.955726299999999,"locationId":"02641f09ed9ae1c4069d01e6184dba00cef7a8e8","name":"University Amsterdam","state":"NH"},{"city":"Maastricht","country":"NLD","lat":50.83929680000001,"lng":5.708785900000001,"locationId":"2ae946b12458416c6c82351b1bd79080fb3bcd22","name":"University Maastricht","state":"LI"}],"sources":["https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html","https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/","https://www.nature.com/articles/d41587-020-00005-z","https://www.inflarx.de/Home/Research---Development/Pipeline.html","https://www.inflarx.de/Home/Investors/Press-Releases/02-2020-InflaRx-Announces-Positive-Initial-Data-from-Ongoing-Phase-IIa-Open-Label-Study-with-IFX-1-in-Patients-Suffering-from-Pyoderma-Gangraenosum-.html","https://www.genengnews.com/virology/coronavirus/catching-up-to-coronavirus-top-60-treatments-in-development/","https://clinicaltrials.gov/ct2/show/NCT04333420?term=InflaRx&draw=2&rank=5"],"sponsors":[{"sponsorId":"8b37254ccb340a35bc492a85125002e78f979b1e","sponsorName":"InflaRx"}],"status":"Ongoing","studyCompletionDate":"Tue, 31 Aug 2021 00:00:00 GMT","studyStartDate":"Tue, 31 Mar 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Aplidin","chemicalName":"Plitidepsin","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Spain"],"countryCodes":["ESP"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Fri, 13 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 01 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":"Sat, 01 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Anti-melanoma agent,Currenlt approved in Australia for the treatment of multiple myeloma and demonstrated antiviral activity in vitro,Protcol for Phase 2 clinical trial for COVID-19 treatment was submitted on 04/02/2020 and is being evaluated.","numSites":"","otherPartners":"CSIC","phase":"2","preferredName":"Plitidepsin","primaryCompletionDate":"","productId":63,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":"Walsenburg","country":"USA","lat":37.60034419999999,"lng":-104.8317586,"locationId":"36ae865c0fededd9586cba4484c6e1da04250ee3","name":"Spanish Hospitals","state":"CO"}],"sources":["https://www.thepharmaletter.com/article/in-vitro-promise-of-aplidin-plitidepsin-for-covid-19-sends-pharmamar-upwards","https://www.drugbank.ca/drugs/DB04977","https://www.researchgate.net/publication/26280244_The_mechanism_of_action_of_plitidepsin","https://www.pharmamar.com/wp-content/uploads/2018/12/PR_Approval-APLIDIN-Australia.pdf","https://www.oncozine.com/plitidepsin-a-novel-anti-cancer-agent-possibly-active-against-covid18/","http://pharmamar.com/?lang=en","https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505631/ ; http://pharmamar.com/wp-content/uploads/2020/04/PR_clinical_trial_plitidepsin_covid19_DEF.pdf","https://www.thepharmaletter.com/article/pharmamar-says-its-drug-aplidin-could-treat-covid-19","https://www.contractpharma.com/contents/view_breaking-news/2020-03-13/pharmamar-reports-positive-results-for-aplidin-against-coronavirus/"],"sponsors":[{"sponsorId":"ec5f02cd738afe63b04534d0cc394af54573dc39","sponsorName":"Pharmamar"},{"sponsorId":"880c99550c8a42deeaff83ad0902af0b020c8848","sponsorName":"Centro Nacional Biotecnologia"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-immunosupressive","trialId":""},{"acceptsHealthySubjects":"","brandName":"Ganovo","chemicalName":"Danoprevir,Ritonavir","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 4","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Sat, 25 Jan 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 27 Feb 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 10 Mar 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Danoprevir has been approved in China for treatment of Hepititis C,Ritonavir is found in a combination FDA-approved product for treamtent of Hepititis C virus,A Phase 4 clinical trial was completed by no results have been posted,2nd Phase 4 clinical trial is currently underway.","numSites":"","otherPartners":"Shaoxing Government","phase":"","preferredName":"Danoprevir,Ritonavir","primaryCompletionDate":"","productId":64,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.clinicaltrialsarena.com/news/ascletis-pharma-coronavirus-pneumonia-study/","https://pubmed.ncbi.nlm.nih.gov/30117020/ ; https://clinicaltrials.gov/ct2/show/NCT04291729?term=Ganovo&draw=1&rank=1 ; https://clinicaltrials.gov/ct2/show/NCT04345276?term=Ganovo&draw=1&rank=2","https://clinicaltrials.gov/ct2/show/NCT04345276?term=Ganovo&draw=1&rank=2"],"sponsors":[{"sponsorId":"3799735fca71d687b33e157b0589e09999052c4f","sponsorName":"Ascletis Pharma"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Protease Inhibitor","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"LUNAR-COV19","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"steveh@arcturusrx.com","name":null,"notes":"","phone":"858-900-2660","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Fri, 08 May 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 11 Aug 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 11 Aug 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":"Fri, 27 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"mRNA vaccine. They color code where in the pipeline their drugs are. Someone who can tell shades of blue apart better than me should double check their current status. On 05/08/2020 preclinical data was reported to have strong support for human vaccine clinical trials to begin this summer.","numSites":"1","otherPartners":"Duke-National University of Singapore","phase":"1/2","preferredName":"LUNAR-COV19","primaryCompletionDate":"","productId":65,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04480957","repurposed":"New","siteLocations":[{"city":"Singapore","country":"SGP","lat":1.2809842,"lng":103.8388793,"locationId":"d040b56b930dda3d1d9f1486714827df30682332","name":"Singhealth Investigational Medicine Unit Singapore General Hospital","state":null}],"sources":["https://arcturusrx.com/pipeline/#lunarcovid19","https://www.globenewswire.com/news-release/2020/03/27/2007544/0/en/Arcturus-COVID-19-Vaccine-to-Benefit-from-Duke-NUS-Genetic-Correlation-System.html","https://arcturusrx.com/pipeline/#lunarcovid19 ;  https://www.genengnews.com/covid-19-candidates/arcturus-therapeutics-and-duke-nus/","https://arcturusrx.com/pipeline/#lunarcovid19 ; https://www.genengnews.com/covid-19-candidates/arcturus-therapeutics-and-duke-nus/ ; https://www.globenewswire.com/news-release/2020/05/08/2030402/0/en/Arcturus-Reports-Additional-Supportive-Preclinical-Data-for-its-COVID-19-Vaccine-Candidate-LUNAR-COV19.html","https://www.globenewswire.com/news-release/2020/05/08/2030402/0/en/Arcturus-Reports-Additional-Supportive-Preclinical-Data-for-its-COVID-19-Vaccine-Candidate-LUNAR-COV19.html"],"sponsors":[{"sponsorId":"20dfe597bbef86e0b9719260a7c300a5b0df15ae","sponsorName":"Arcturus"}],"status":"Ongoing","studyCompletionDate":"Sun, 10 Jan 2021 00:00:00 GMT","studyStartDate":"Tue, 04 Aug 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Avigan,favilavir,T-705","chemicalName":"Favipiravir","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Japan"],"countryCodes":["JPN"],"currentStage":"Phase 4","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 31 Mar 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Japan has stockpile of 2 million,Interim clinical test reports no clear efficiency so Japan has given up fasttracking approval. Clinical studies will still continue to show efficacy.","numSites":"11","otherPartners":"","phase":"","preferredName":"Favipiravir","primaryCompletionDate":"Sun, 31 May 2020 00:00:00 GMT","productId":66,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":"Hefei Shi","country":"CHN","lat":31.84583099999999,"lng":117.268745,"locationId":"628f4edb85c909e0ddc062a00765cb36ae846382","name":"Anhui Medical University Affiliated First Hospital","state":"Anhui Sheng"},{"city":null,"country":"CHN","lat":39.9619537,"lng":116.3662615,"locationId":"19ce316ca5e6465932837b6bf97026bdea2b37dc","name":"Guiqiang Wang","state":"Beijing Shi"},{"city":null,"country":"CHN","lat":39.931765,"lng":116.380416,"locationId":"eb9829c51252ecab9885ddf9f3baf3f490e832d7","name":"Peking University First Hospital","state":"Beijing Shi"},{"city":"Wuhan Shi","country":"CHN","lat":30.599041,"lng":114.301165,"locationId":"0542d5f3bc75f05312b4048a958206ac1cc3650f","name":"Cancer Hospital Union Hospital Tongji Medical College Huazhong University Of Science And Technology","state":"Hubei Sheng"},{"city":"Ezhou Shi","country":"CHN","lat":30.3987825,"lng":114.8819099,"locationId":"52723488fce4b3ed650a371ae3778dab533c727b","name":"Ezhou Central Hospital","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.6668794,"lng":114.2868443,"locationId":"6cdef09a787c0b581f9de2fc8bf0c7b706a000b7","name":"Huoshenshan Hospital Of Wuhan","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.6668794,"lng":114.2868443,"locationId":"68a311a4eddb131280560e88063fb5b2c19e3ccc","name":"Jinyintan Hospital Of Wuhan","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.5130043,"lng":114.4202756,"locationId":"1a7ffc54160f41376fac579704d3acbe4e74702f","name":"Tongji Hospital Of Huazhong University Of Science And Technology","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.4917469,"lng":114.1732702,"locationId":"3028149fdc42299ce8147ad0a856a05d2079fbb4","name":"West Hospital Union Hospital Huazhong University Of Science And Technology","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.552985,"lng":114.353743,"locationId":"59e4e5686719a45876bc79f8a3ad87bdbd5a9da4","name":"Wuhan Pulmonary Hospital","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.552985,"lng":114.353743,"locationId":"c65becbec1d9396ae7c2bde7c5a35a088cfca1e9","name":"Zhongnan Hospital Of Wuhan University","state":"Hubei Sheng"}],"sources":["https://www.fujifilm.com/jp/en/news/hq/3211","https://www.fujifilm.com/jp/en/news/hq/3211 ; https://english.kyodonews.net/news/2020/05/10107f9396b1-breaking-news-japan-gives-up-on-approving-avigan-in-may-minister.html","https://clinicaltrials.gov/ct2/show/NCT04359615?term=Avigan&phase=3&draw=2&rank=1","https://clinicaltrials.gov/ct2/show/NCT04310228"],"sponsors":[{"sponsorId":"d3f2295022832956ff09046194ed9b4ab9077636","sponsorName":"Fujifilm"},{"sponsorId":"e3b26f3f63704a702040cad0b3d5f4ff56f7360a","sponsorName":"Peking University First Hospital"}],"status":"Ongoing","studyCompletionDate":"Sun, 31 May 2020 00:00:00 GMT","studyStartDate":"Sun, 08 Mar 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"Zydus Cadila DNA plasmid Vaccine","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"r.mittal@zyduscadila.com;         makova@hacettepe.edu.tr        ","name":null,"notes":"","phone":"For India: 07948040000","website":""}],"countries":["India"],"countryCodes":["IND"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Sun, 05 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Fri, 03 Jul 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 15 Jul 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 06 Aug 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":"Sat, 15 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"Uses a measles vector. They also are working on a DNA vaccine.","numSites":"9","otherPartners":"","phase":"2","preferredName":"Zydus Cadila DNA plasmid Vaccine","primaryCompletionDate":"","productId":67,"registryLink":"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306","repurposed":"New","siteLocations":[],"sources":["https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf","https://www.indiatoday.in/mail-today/story/zydus-cadila-serum-institute-too-in-the-hunt-for-coronavirus-vaccine-1663434-2020-04-05","https://zyduscadila.com/public/pdf/pressrelease/Zydus_vaccine_for_COVID-19_ZyCoV-D)_successfully_completes_preclinical_development_and_receives_permission_to_initiate_human_clinical_trials.pdf","https://www.hindustantimes.com/india-news/zydus-cadilla-begins-human-dosing-in-trials/story-WI0sdKieiVMbnWdoAhJ8ZK.html"],"sponsors":[{"sponsorId":"9e1c8045b7fdc2fe2d635960c9b93dbbdd1a14a7","sponsorName":"Zydus Cadila"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 13 Jul 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"CoronaVac","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"ricardo.palacios@butantan.gov.br; makova@hacettepe.edu.tr; katia@med.puc.cl","name":null,"notes":"For Indonesian Sites: +6222-2033755 ext 14101 novilia@biofarma.co.id For Turkey Sites: +90 (312) 305 12 96 makova@hacettepe.edu.tr For Brazil: 55 11 37232121 Ricardo.palacios@butantan.gov.br For Chile: Katia Abarca +56996797787 katia@med.puc.cl or Alvaro Rojas +56934056808 arojasgo@uc.cl","phone":"For Brazil: 551137232121; For Turkey: +90 (312) 305 12 96","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 16 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 20 May 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 21 Jul 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Whole-pathogen vaccines","notes":"Dynaxax is contributing an adjuvant to boost immune responses in vaccinated patients and Sinovac is contributing an inactivated coronavirus vaccine candidate. Based on a SARS platform. Very little direct information. \"many months\" before its current stage of research is complete. Promise of efficacy has been shown in primates.","numSites":"12","otherPartners":"","phase":"3","preferredName":"CoronaVac","primaryCompletionDate":"Wed, 01 Sep 2021 00:00:00 GMT","productId":68,"registryLink":["https://clinicaltrials.gov/ct2/show/NCT04352608","https://clinicaltrials.gov/ct2/show/NCT04383574","https://www.clinicaltrials.gov/ct2/show/NCT04551547","https://clinicaltrials.gov/ct2/show/NCT04456595","https://www.clinicaltrials.gov/ct2/show/NCT04508075","https://www.clinicaltrials.gov/ct2/show/NCT04582344","https://clinicaltrials.gov/ct2/show/NCT04617483"],"repurposed":"New","siteLocations":[{"city":null,"country":"BRA","lat":-15.7631573,"lng":-47.8706311,"locationId":"568e88bb79fd81f212299843ba8b84acd66bd2ce","name":"Universidade De Brasilia","state":"DF"},{"city":null,"country":"BRA","lat":-19.870682,"lng":-43.9677359,"locationId":"0401eb4172aebd293853d2b0d93bb5f8416e79e6","name":"Universidade Federal De Minas Gerais","state":"MG"},{"city":null,"country":"BRA","lat":-25.4241606,"lng":-49.26194779999999,"locationId":"bd919134cb2dde39d661af4d47d2e255d7a0d266","name":"Hospital Das Clinicas Da Universidade Federal Do Parana","state":"PR"},{"city":null,"country":"BRA","lat":-30.0552693,"lng":-51.1733967,"locationId":"2df6a88a738321d4c881840b9a50580ab2295fba","name":"Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul","state":"RS"},{"city":null,"country":"BRA","lat":-22.8269585,"lng":-47.064116,"locationId":"af7ac189b747ba457be772c916ec3ccadd04b0cb","name":"Hospital Da Clinicas Da Unicamp","state":"SP"},{"city":null,"country":"BRA","lat":-21.1624332,"lng":-47.8528816,"locationId":"a80407d80cdabc629894ef57a9f835020b36ba22","name":"Hospital Das Clinicas Da Faculdade De Medicina De Ribeirao Preto Da Universidade De Sao Paulo","state":"SP"},{"city":null,"country":"BRA","lat":-23.5558033,"lng":-46.6675382,"locationId":"330b652c0466a2062c46f0e9dec80d393dfd278f","name":"Instituto De Infectologia Emilio Ribas","state":"SP"},{"city":null,"country":"BRA","lat":-23.5571357,"lng":-46.6698263,"locationId":"6a106e36a0b1f5f9019d4fe30c167c498047ae99","name":"Centro De Pesquisa Clinicas Do Instituto Central Do Hospital Das Clinicas Da Faculdade De Medicina Da Universidade De Sao Paulo","state":"SP"},{"city":null,"country":"BRA","lat":-23.558394,"lng":-46.659163,"locationId":"409ad10e3d8d6e4db68552054e9a086756b44d9d","name":"Instituto Israelita De Ensino E Pesquisa Albert Einstein","state":"SP"},{"city":null,"country":"BRA","lat":-23.6093188,"lng":-46.5736873,"locationId":"2fd04e21d0f87a9de4ed169472127d160dc01607","name":"Universidade Municipal De Sao Caetano Do Sul","state":"SP"},{"city":null,"country":"BRA","lat":-20.8275796,"lng":-49.3962249,"locationId":"9b14ae3571b387697c3bd9babfab85f517e5e605","name":"Faculdade De Medicina De Sao Jose Do Rio Preto","state":"SP"},{"city":null,"country":"BRA","lat":-22.8786221,"lng":-43.2432405,"locationId":"4c0893e3bfa392b09a1e31a5417cddad948c629f","name":"Instituto De Infectologia Evandro Chagas","state":"RJ"},{"city":null,"country":"IDN","lat":-6.8964253,"lng":107.5989129,"locationId":"66149038488aedb54ec3c77dcd8b54194cd06abd","name":"Hasan Dikidin Hospital","state":"Jawa Barat"},{"city":null,"country":"TUR","lat":39.9015954,"lng":32.7570771,"locationId":"275665c7bf06bd2dbdba1c98af6effc9ba8e1984","name":"Tr Ministry Of Health Ankara City Hospital","state":"Ankara"},{"city":null,"country":"TUR","lat":39.9375377,"lng":32.8773179,"locationId":"620654876886e18bb92f2bc237414dd1e2fc82da","name":"Tr Ministry Of Health Provincia Heath Directorate Ankara Training And Research Hospital","state":"Ankara"},{"city":null,"country":"TUR","lat":39.9334621,"lng":32.8833852,"locationId":"d93e69f723a34159fe5180a19929d7aa33e41992","name":"Ankara University Faculty Od Medicine","state":"Ankara"},{"city":null,"country":"TUR","lat":37.055548,"lng":35.3640783,"locationId":"ced1bcc49c358882bed72484f09a2aee5caa4b84","name":"Cukurova University Faculty Of Medicine","state":"Adana"},{"city":null,"country":"TUR","lat":39.9303672,"lng":32.8631625,"locationId":"89774936bb1c328daba0c664b2af3de4cbb62a2e","name":"Hacettepe Univercity Faculty Of Medicine Department Of Infectious Diseases And Clinical Microbiology","state":"Ankara"},{"city":"Ankara","country":"TUR","lat":39.9333635,"lng":32.8597419,"locationId":"2318b0d638208f59347276d302a674d03ad43e79","name":"Tc Ministry Of Health Ankara Provicnial Health Directorate Health Sciences University Ankara Ataturk Chest Disease And Thoracic Surgery Training And Research Hospital","state":"Ankara"},{"city":null,"country":"TUR","lat":40.2251434,"lng":28.877503,"locationId":"a8f37f7d5f57a01f605400174d0dc5582d247221","name":"Bursa Uludag University Faculty Of Medicine","state":"Bursa"},{"city":null,"country":"TUR","lat":37.9202945,"lng":40.2661165,"locationId":"290e42e467c3f5d373aa4b11da3f7bebf4026c7b","name":"Dicle University Faculty Of Medicine","state":"Diyarbak\u0131r"},{"city":null,"country":"TUR","lat":37.0349074,"lng":37.317347,"locationId":"37873e5b110a0e6c07bc94f32ded393cbdbdce45","name":"Gaziantep University Faculty Of Medicine","state":"Gaziantep"},{"city":null,"country":"TUR","lat":41.0351124,"lng":28.7789098,"locationId":"ee550da919b1dfe6762da8493da1e68a2ce5516f","name":"Acibadem Atakent Hospital","state":"\u0130stanbul"},{"city":null,"country":"TUR","lat":40.9954578,"lng":28.86239149999999,"locationId":"208d670fc90e3b73e36c1877bd9368a50ca4e132","name":"Altinbas University Medical Park Bahcelievler Infectious Disease And Microbiology","state":"\u0130stanbul"},{"city":null,"country":"TUR","lat":41.003979,"lng":28.939803,"locationId":"6cf0d5911a3028c750e11eaa38bbafeb393aba24","name":"Cerrahpasa Faculty Of Medicine","state":"\u0130stanbul"},{"city":null,"country":"TUR","lat":41.0910974,"lng":29.0915489,"locationId":"60b1e87224cac0d6625a4b574724f7df54be9dad","name":"Istanbul Medipol University Faculty Of Medicine","state":"\u0130stanbul"},{"city":null,"country":"TUR","lat":41.0164319,"lng":28.9332156,"locationId":"ee51642f803b4bd608f67a28b648df340594509e","name":"Istanbul University Istanbul Faculty Of Medicine","state":"\u0130stanbul"},{"city":null,"country":"TUR","lat":40.88641399999999,"lng":29.26260289999999,"locationId":"6340ef1c85849ace2dac9cc98ea6ef6f3eda2eba","name":"Tr Ministry Of Health Instanbul Provincial Health Directorate Marmara University Istanbul Pendik Education And Research Hospital","state":"\u0130stanbul"},{"city":null,"country":"TUR","lat":41.0651521,"lng":28.97395169999999,"locationId":"44ddaee805d7e3b6488ae0cd78446d056ac5767e","name":"Tr Ministry Of Health Istanbul Provincial Helath Directorate Prof Dr Cemil Tascioglu City Hospital","state":"\u0130stanbul"},{"city":null,"country":"TUR","lat":41.0033012,"lng":28.915593,"locationId":"130de8fabc2d31c6e407f742ca3902463129c67b","name":"Tr Ministry Of Health Yedikule Chest Diseases And Thoracic Surgery Training And Research Hospital","state":"\u0130stanbul"},{"city":null,"country":"TUR","lat":38.4569938,"lng":27.2113593,"locationId":"ddb79fc5ad80b9e830307b5ea7ba85c3a3a2bbb7","name":"Ege University Faculty Of Medicine Hospital","state":"\u0130zmir"},{"city":null,"country":"TUR","lat":38.4241657,"lng":27.1627201,"locationId":"231fe6b330c2dc2a8e07790dd35f042281152a3f","name":"Republic Of Turkey Ministry Of Health Izmir Provincial Health Directorate Health Sciences University Dr Suat Seren Chest Diseases And Chest Srugery Training And Research Hospital","state":"\u0130zmir"},{"city":null,"country":"TUR","lat":38.4228265,"lng":27.1658776,"locationId":"3c6b32fd2aecd2c1d044719f5630ddbb5e676933","name":"Tr Ministry Of Health Izmir Provincial Helath Directorate Izmir Health Sciences University Tepecik Training And Research Hospital","state":"\u0130zmir"},{"city":null,"country":"TUR","lat":38.71554649999999,"lng":35.4994583,"locationId":"9b1d1400a3f2df41088ed104add7c08d4bb4f46a","name":"Tr Minsitry Of Health Kayseri City Training And Research Hospital","state":"Kayseri"},{"city":null,"country":"TUR","lat":40.8223347,"lng":29.9217153,"locationId":"6ba35c13557d355d76fd1cdf930e4add7d07a4b8","name":"Kocaeli University Faculty Of Medicine","state":"Kocaeli"},{"city":null,"country":"TUR","lat":38.3302973,"lng":38.4399655,"locationId":"2a9626f7f7039e60030d2bd6505bc319269752c7","name":"Malatya Inonu University Of Medicine","state":"Malatya"},{"city":null,"country":"TUR","lat":40.9976782,"lng":39.7712184,"locationId":"e4360c1f1ee976d0aad1cc9f1de74b23fb986991","name":"Karadeniz Technical University Medical Faculty Hospital","state":"Trabzon"},{"city":"Heroica Matamoros","country":"MEX","lat":25.8884264,"lng":-97.50171069999999,"locationId":"f98ed0107d53a6fef0ea74aa0b602c0caa348df6","name":"Centro De Especialidades Medicas","state":"Tamps."},{"city":"Santiago","country":"CHL","lat":-33.4488897,"lng":-70.6692655,"locationId":"423ca6b9705e9288dc9d36881e8fc7f7f52711e2","name":"Santiago","state":"Santiago Metropolitan Region"},{"city":null,"country":"CHL","lat":-35.675147,"lng":-71.542969,"locationId":"afeaca5c8bc9bb1fb530fa6fad7179af7db0b68b","name":"Chile","state":null}],"sources":["http://www.sinovac.com/?optionid=748","https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1","https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1 ; https://www.fool.com/investing/2020/05/29/dynavax-stock-soars-264-today-on-covid-19-vaccine.aspx"],"sponsors":[{"sponsorId":"8cc7224f8b0bf621aabeff6011656a8d75f8d1ef","sponsorName":"Sinovac Biotech Ltd"}],"status":"Ongoing","studyCompletionDate":"Fri, 01 Oct 2021 00:00:00 GMT","studyStartDate":"Wed, 01 Jul 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Wuhan Institute Inactivated Vaccine","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 12 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 25 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 15 Jul 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Whole-pathogen vaccines","notes":"Currently entered in Phase 2 Clinical Trial and will take about a year to complete a Phase 3 trial.","numSites":"","otherPartners":"","phase":"3","preferredName":"Wuhan Institute Inactivated Vaccine","primaryCompletionDate":"","productId":69,"registryLink":"https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving","repurposed":"New","siteLocations":[],"sources":["http://www.xinhuanet.com/english/2020-04/25/c_139005855.htm","https://www.reuters.com/article/us-health-coronavirus-emirates-vaccine/chinas-sinopharm-begins-late-stage-trial-of-covid-19-vaccine-in-abu-dhabi-idUSKCN24H14T","https://www.firstpost.com/health/first-phase-3-human-trials-of-sinopharms-covid-19-vaccine-with-inactivated-virus-begins-in-abu-dhabi-8618421.html; https://www.thenational.ae/world/mena/coronavirus-saudi-arabia-and-bahrain-to-start-vaccine-trials-1.1061883; https://www.reuters.com/article/us-health-coronavirus-vaccine-sinopharm/peru-to-test-china-sinopharms-covid-19-vaccine-in-phase-3-trial-idUSKCN25G0G9"],"sponsors":[{"sponsorId":"3bd129a36a22b99edf40b395c2fad7b78193bda9","sponsorName":"Sinopharm"},{"sponsorId":"ad6a16130480e1a77d5ffb88a5752fdae6685597","sponsorName":"Wuhan Institute of Biological Products"}],"status":"Ongoing","studyCompletionDate":"Sun, 13 Sep 2020 00:00:00 GMT","studyStartDate":"Wed, 15 Jul 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Codagenix Live-Attenuated Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Thu, 28 May 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":"Thu, 13 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Whole-pathogen vaccines","notes":"Live-Attenuated vaccine. Country might need to be switched to India later. Targeting September for human trials and 2022 for release.","numSites":"","otherPartners":"","phase":"","preferredName":"Codagenix Live-Attenuated Vaccine","primaryCompletionDate":"","productId":70,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html","https://www.fortuneindia.com/technology/covid-19-vaccine-possible-by-q2-of-2022-adar-poonawalla/104401","https://www.hindustantimes.com/cities/serum-institute-confident-of-manufacturing-covid-vaccine-s-100-million-doses-if-trials-establish-efficacy/story-MrVAw982iSC2IdxAqWt9II.html"],"sponsors":[{"sponsorId":"4f658739e6abe56363d5f2d9559538ae578e3aad","sponsorName":"Codagenix"},{"sponsorId":"adee3b214297c2f83d459d75e4e295cde4fd187c","sponsorName":"Serum Institute of India"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"MVA-S encoded","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Germany"],"countryCodes":["DEU"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Unknown","notes":"The MVA vaccine for MERS acts as a basis for developing a vaccine for COVID-19. The first-human trial for MVA was completed 04/22/2020 and demonstrated safety and triggered the development of antibodies and T cell immunity.","numSites":"","otherPartners":"","phase":"","preferredName":"MVA-S encoded","primaryCompletionDate":"","productId":71,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.sciencedaily.com/releases/2020/04/200422132600.htm"],"sponsors":[{"sponsorId":"42dc4894fcc96aa20e701b0f9bbb2fb79c1f0279","sponsorName":"DZIF  German Center for Infection Research"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Greffex Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Wed, 11 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"They lack funding to start animal trials.","numSites":"","otherPartners":"","phase":"","preferredName":"Greffex Vaccine","primaryCompletionDate":"","productId":72,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/","https://markets.businessinsider.com/news/stocks/greffex-inc-completes-covid-19-vaccine-and-prepares-for-testing-1028986183"],"sponsors":[{"sponsorId":"6c01129b833a3f153fc0408879e5a2bb4bf21b9b","sponsorName":"Greffex"}],"status":"On Hold","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"AdaptVac Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Denmark"],"countryCodes":["DNK"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Mon, 09 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Subunit Vaccines","notes":"Consortium of Danish companies and universities. One of the universities will likely be the sponsor when they go to clinical trials.","numSites":"","otherPartners":"PREVENT-nCOV Consortium,Bavarian Nordic,AGC Biologics","phase":"","preferredName":"AdaptVac Vaccine","primaryCompletionDate":"","productId":73,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf","https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_8a2ffeae006e4e64981c2275ce894c89.pdf; https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_643c666ae7d84b0fb2189e635332a363.pdf","https://www.adaptvac.com/","https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_8a2ffeae006e4e64981c2275ce894c89.pdf"],"sponsors":[{"sponsorId":"b3dd9ec1147ddf57383d3eda6cd2d861e37911df","sponsorName":"AdaptVac"},{"sponsorId":"af0e9043938d3ffd18d4aa4f263c303abe7a87c1","sponsorName":"PREVENTnCoV consortium"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Denmark"],"countryCodes":["DNK"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"Being utilized in various COVID-19 therapeutic developments","numSites":"","otherPartners":"","phase":"","preferredName":"Vaccine","primaryCompletionDate":"","productId":74,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-supporting-an-advantageous-covid-19-diagnostic-antibody-development-project","c3102671","https://news.cision.com/expres2ion-biotechnologies"],"sponsors":[{"sponsorId":"433f99ff8c5ca5efa43e610e5d05b69e4f37d5ef","sponsorName":"ExpreS2ion Biotechnologies ApS"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Combination","trialId":""},{"acceptsHealthySubjects":"","brandName":"USAMRIID Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"USAMRIID Vaccine","primaryCompletionDate":"","productId":75,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/"],"sponsors":[{"sponsorId":"455288f646569f2165f9af95d690d300bbd182a8","sponsorName":"WRAIR"},{"sponsorId":"301d4da21e654a4dac3ab28cf3feba940a10bc5f","sponsorName":"USAMRIID"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Monoclonal Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"they have 300 candidates now will narrow down to fewer candidates","numSites":"","otherPartners":"Celltrion","phase":"","preferredName":"Monoclonal Antibodies","primaryCompletionDate":"","productId":104,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/","https://www.centerforbiosimilars.com/news/celltrion-amgen-join-race-to-develop-antisarscov2-antibodies"],"sponsors":[{"sponsorId":"625c2965f7108c1ad1edf37eef366aad6b28fbd8","sponsorName":"Celltrion"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"VaxHit","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Israel"],"countryCodes":["ISR"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Thu, 13 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Other","notes":"Utilized single peptide technology","numSites":"","otherPartners":"","phase":"","preferredName":"VaxHit","primaryCompletionDate":"","productId":76,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://vaxil-bio.com/wp-content/uploads/2020/04/Vaxil-Overview-Exec-Sum-public-v4.1.pdf","https://vaxil-bio.com/","https://vaxil-bio.com/vaxil-provides-update-on-preclinical-experiment/","https://www.bioworld.com/COVID19products","https://vaxil-bio.com/vaxil-announces-the-identification-of-a-potential-corona-virus-vaccine-and-provides-an-update-in-the-previously-announced-debt-financing/","https://www.globenewswire.com/news-release/2020/03/27/2007667/0/en/VAXIL-COMMENCES-PRECLINICAL-COVID-19-VACCINE-TRIAL-AND-FILES-AN-ADDITIONAL-COVID-19-PATENT.html"],"sponsors":[{"sponsorId":"6326cfa8bba7bb5f22c4c0c558835079ac7fc122","sponsorName":"Vaxil Bio Therapeutics"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"FlowVax COVID 19","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Other","notes":"Approach - Biodegradable microsphere peptide vaccine targeting SARS-CoV-2 nucleocapsid,T-cell vaccine,Expected to be used for pre- and post-exposure prophylaxis,Currently being tested on nonhuman primates","numSites":"","otherPartners":"University of Texas Medical Branch at Galveston","phase":"","preferredName":"FlowVax COVID 19","primaryCompletionDate":"","productId":77,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.flowpharma.com/","https://www.accesswire.com/584325/Flow-Pharma-Announces-Start-of-Pre-Clinical-Efficacy-Study-for-FlowVax-COVID-19-Vaccine"],"sponsors":[{"sponsorId":"306b4a5ca7bafa2c8cb1637d2068fec4dcf4c872","sponsorName":"Flow Pharma"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"EPV-CoV19","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Other","notes":"Peptide-based epitope driven vaccine candidate,Expected to stimulate protective T-cell response,Expected to protect against severe disease rather than protect against infection,Specifically targeted at healthcare workers,Availability of no-cost licenses for the vaccine recipe for developing world countries who have GMP facilities for production of the vaccine,Phase 1 trial expected to begin in 3 months","numSites":"","otherPartners":"Generex Biotechnology,GAIA Vaccine Foundation,Entos Pharmaceuticals","phase":"","preferredName":"EPV-CoV19","primaryCompletionDate":"","productId":78,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://epivax.com/home/vaccine-services/covid-19","https://www.generex.com/covid-19; https://epivax.com/home/vaccine-services/covid-19","https://epivax.com/pipeline/epv-cov19"],"sponsors":[{"sponsorId":"bd27e9eeb1bca08ea29864fa4bd2121d5abb6345","sponsorName":"EpiVax Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"EpiVax Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Unknown","notes":"This seems to be separate from the partnership between Epivax and Generex,Also seems to be in pre-discovery phase as no specific mechanism has been identified","numSites":"","otherPartners":"","phase":"","preferredName":"EpiVax Vaccine","primaryCompletionDate":"","productId":79,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://epivax.com/news/press-release-epivax-accelerates-covid-19-vaccine-development-with-ugas-center-for-vaccines-and-immunology","https://epivax.com/home/vaccine-services/covid-19","https://news.uga.edu/uga-researchers-developing-coronavirus-vaccine/"],"sponsors":[{"sponsorId":"2b2068ecd13962f5098c0b0cd04aaf01f7c38c14","sponsorName":"EpiVax"},{"sponsorId":"e4bf2c53813e4971a809acf75b015ef7d10cbebc","sponsorName":"University of Georgia"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"","brandName":"COVID 19 Vaccine","chemicalName":"gp96-mediated vaccine","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Cell therapies","notes":"Mechanism of action - gp96 + Viral Antigens","numSites":"","otherPartners":"University of Miami","phase":"","preferredName":"gp96-mediated vaccine","primaryCompletionDate":"","productId":80,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.forbes.com/sites/nathanvardi/2020/04/08/handicapping-the-most-promising-of-267-potential-coronavirus-cures/#4efa3587f23b","https://www.heatbio.com/product-pipeline/covid-19-vaccine","https://physician-news.umiamihealth.org/miller-school-and-heat-biologics-to-collaborate-on-covid-19-vaccine/"],"sponsors":[{"sponsorId":"69a6b23cf97fddaef2d35262b69a690f029417f4","sponsorName":"Heat Biologics Inc"},{"sponsorId":"0fc2d17219cc99046bce21a2c41bc8215617c73d","sponsorName":"University of Miami"},{"sponsorId":"9166254a6d2692220fda9b8f507259e0813000b3","sponsorName":"Zolovax Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"T-cell therapies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Cell therapies","notes":"T-cell therapy,Baylor college of medicine is also pushing for testing of a vaccine developed against SARS-Cov-1 in 2016 - not much information about this","numSites":"","otherPartners":"","phase":"","preferredName":"T-cell therapies","primaryCompletionDate":"","productId":81,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.allovir.com/news-blog/allovir-expands-its-research-collaboration-with-baylor-college-of-medicine-to-discover-and-develop-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-for-covid-19"],"sponsors":[{"sponsorId":"41801411fe7d66b24eae2e0411ee409f9ad29507","sponsorName":"Baylor College of Medicine"},{"sponsorId":"e6c4cbd24fa49f8c604388e030a0790d277ad9a6","sponsorName":"AlloVir"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"IBIO-200","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Small molecule","notes":"Virus-like particle,Developed using FastPharming technology,Patent filed in March 2020","numSites":"","otherPartners":"Texas A&M University System Laboratories","phase":"","preferredName":"IBIO-200","primaryCompletionDate":"","productId":82,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.ibioinc.com/pipeline","https://www.ibioinc.com/news/ibio-announces-development-of-proprietary-covid-19-vaccine-candidates","https://www.ibioinc.com/news/ibio-announces-advancement-of-covid-19-vaccine-program","https://www.ibioinc.com/therapeutics-and-vaccines"],"sponsors":[{"sponsorId":"505b07d6981f93ee187513e197589f4c16f04b35","sponsorName":"iBio Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"OncoGen Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Romania"],"countryCodes":["ROU"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Other","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"OncoGen Vaccine","primaryCompletionDate":"","productId":83,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf","https://oncogen.ro/recognition-by-who/"],"sponsors":[{"sponsorId":"102fe9bb3724bbad454162ce2f31318baff6facb","sponsorName":"OncoGen"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Measles Vector Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"Molecule type - DNA based vaccine,Based on the use of measles vaccine as a vector","numSites":"","otherPartners":"Themis Bioscience GmbH,University of Pittsburg - Center for Vaccine Research,CEPI - MSD","phase":"","preferredName":"Measles Vector Vaccine","primaryCompletionDate":"","productId":84,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.pasteur.fr/fr/espace-presse/documents-presse/covid-19-cepi-finance-developpement-vaccin-contre-sars-cov-2-projet-porte-consortium-institut","https://www.pasteur.fr/en/press-area/coronavirus-mobilisation/coronavirus-covid-19-research-projects","https://www.pasteur.fr/en/press-area/press-documents/cepi-collaborates-institut-pasteur-consortium-develop-covid-19-vaccine","http://pasteur.fr/en/press-area/coronavirus-mobilisation/coronavirus-covid-19-research-projects#p1 https://www.pasteur.fr/fr/espace-presse/documents-presse/covid-19-cepi-finance-developpement-vaccin-contre-sars-cov-2-projet-porte-consortium-institut"],"sponsors":[{"sponsorId":"4504468bad51eef6a2ac6172fa89a91614df3c56","sponsorName":"Merck"},{"sponsorId":"613e550610f0a7b4bbfd4fa0ab61e13afc1f9b01","sponsorName":"Themis"},{"sponsorId":"a2a15d79e1f0b774dbc631aeed3b73af7f225cfe","sponsorName":"Institute Pasteur"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"RNACure 2019-nCoV Vaccine Candidate VLP","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"","otherPartners":"RNACure Biopharma","phase":"","preferredName":"RNACure 2019-nCoV Vaccine Candidate VLP","primaryCompletionDate":"","productId":85,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1","https://www.fudan.edu.cn/en/2020/0307/c344a104281/page.htm","http://rnacure.com/pipeline"],"sponsors":[{"sponsorId":"4567098e44fc907783878b149c6d70d1f14aec40","sponsorName":"Fudan University"},{"sponsorId":"aa6799f660cd49b264d3e155560878bb15e8b804","sponsorName":"Shanghai JiatTong University"},{"sponsorId":"f8f4d45187fd48b7b35c26e73dc0b1c09938f8e0","sponsorName":"RNACure Biopharma"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Stermina 2019-nCoV Vaccine Candidate","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"","otherPartners":"Stermina Therapeutics","phase":"","preferredName":"Stermina 2019-nCoV Vaccine Candidate","primaryCompletionDate":"","productId":86,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1","https://www.wired.com/story/everything-you-need-to-know-about-coronavirus-vaccines/"],"sponsors":[{"sponsorId":"20e19a20e9874c07beba2c307650020c6a63535b","sponsorName":"China CDC"},{"sponsorId":"0a82122244646304c943aa942a96ad3ace268562","sponsorName":"Tongji University"},{"sponsorId":"30508a3774a3fd8aeb4cf75885e2ee9011d8514f","sponsorName":"Stermina"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"OpenCorona 2019-nCoV Vaccine Candidate","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Sweden"],"countryCodes":["SWE"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"","otherPartners":"Horizon 2020","phase":"","preferredName":"OpenCorona 2019-nCoV Vaccine Candidate","primaryCompletionDate":"","productId":87,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine"],"sponsors":[{"sponsorId":"a26c2ef25366b153b9c8bb0d553426bbab80d427","sponsorName":"Karolinska Institute"},{"sponsorId":"4b38f0c3421f6f67e79a27c6fd64a3930c0c2627","sponsorName":"CobraBiologics"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"ReiThera 2019-nCoV Vaccine Candidate","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"dirsan@inmi.it","name":null,"notes":"","phone":"","website":"https://www.inmi.it/vaccino-covid"}],"countries":["Italy"],"countryCodes":["ITA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 29 Jul 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Other","notes":"expected to enter clinical trials summer 2020","numSites":"","otherPartners":"","phase":"1","preferredName":"ReiThera 2019-nCoV Vaccine Candidate","primaryCompletionDate":"","productId":88,"registryLink":"https://www.aifa.gov.it/sperimentazioni-cliniche-covid-19","repurposed":"New","siteLocations":[],"sources":["https://born2invest.com/articles/italian-biotech-companies-entered-the-race-to-find-a-vaccine-against-covid-19/","https://www.genengnews.com/topics/bioprocessing/single-dose-adenovirus-based-covid-19-vaccine-planned/"],"sponsors":[{"sponsorId":"6887e6de5a46033245e0bcb4f49450dcbadd7441","sponsorName":"ReiThera"},{"sponsorId":"47a629349220fd43fa70123dac8ceb26e2dffba6","sponsorName":"Leukocare"},{"sponsorId":"83f1710949070fb1e8f686c8dc72ac16dd164641","sponsorName":"and Univercell"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Wed, 29 Jul 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"COVIGEN,BioNet 2019-nCoV Vaccine Candidate","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Gene therapies","notes":"phase 1/2 trial is planned for Q3 2020","numSites":"","otherPartners":"","phase":"","preferredName":"COVIGEN,BioNet 2019-nCoV Vaccine Candidate","primaryCompletionDate":"","productId":89,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["http://www.bionet-asia.com/media/news-events/","https://www.nationthailand.com/news/30383030"],"sponsors":[{"sponsorId":"6a4be0a2fbeb04dd3db2a97fc2f68a2388bb723b","sponsorName":"BioNet Asia"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Ivomec","chemicalName":"Ivermectin","conditionOrDisease":"COVID-19","contact":[{"email":"chm@jhmi.edu","name":null,"notes":"","phone":"410-955-0231","website":""}],"countries":["Australia"],"countryCodes":["AUS"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"Ivermectin","primaryCompletionDate":"Wed, 10 Nov 2021 00:00:00 GMT","productId":90,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04374279","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Baltimore","country":"USA","lat":39.2967385,"lng":-76.59273619999999,"locationId":"fb433e0b67ba376c72dff6fa360b0d11a3a4c799","name":"Johns Hopkins Hospital","state":"MD"}],"sources":["https://www.thejakartapost.com/news/2020/04/06/covid-19-antiparasitic-drug-can-kill-coronavirus-within-two-days-study-finds.html","https://www.doherty.edu.au/news-events/news/possible-coronavirus-drug-identified-by-melbourne-scientists","https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=2","https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=3","https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=4","https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=5","https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=6","https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=7"],"sponsors":[{"sponsorId":"e8af2a52a069a3c9d2e7076dbd1450dcac577b76","sponsorName":"Doherty Institute"},{"sponsorId":"5f1bf89bc842335651ec9768cc0377edaff0185e","sponsorName":"Monash University"}],"status":"Ongoing","studyCompletionDate":"Wed, 10 Nov 2021 00:00:00 GMT","studyStartDate":"Mon, 01 Jun 2020 00:00:00 GMT","therapeuticApproach":"Antibiotics and antiparasitics","trialId":""},{"acceptsHealthySubjects":"","brandName":"Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"NIH","phase":"","preferredName":"Vaccine","primaryCompletionDate":"","productId":91,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.newswise.com/articles/tulane-university-awarded-10-3-million-to-test-therapeutics-vaccines-for-novel-coronavirus"],"sponsors":[{"sponsorId":"b4a99af9eec1a8f807ede0e67dd5e8d77867b245","sponsorName":"Tulane University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"","brandName":"Vaxcelerate vaccine,Hoth Voltron 2019-nCoV Vaccine Candidate,HaloVax","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Combination","notes":"","numSites":"","otherPartners":"Hoth,Voltron,MGH","phase":"","preferredName":"Vaxcelerate vaccine,Hoth Voltron 2019-nCoV Vaccine Candidate,HaloVax","primaryCompletionDate":"","productId":92,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://finance.yahoo.com/news/hoth-surges-collaboration-voltron-covid-134601408.html","https://www.globenewswire.com/news-release/2020/03/24/2005714/0/en/Emerging-Markets-Report-Hoth-Therapeutics-is-Working-on-a-Potential-Coronavirus-Vaccine-COVID-19.html","https://www.sec.gov/Archives/edgar/data/1711786/000121390020007153/ea119888ex99-1_hoththerap.htm"],"sponsors":[{"sponsorId":"a0e1dd25259a873fb5bbf352459b984c718be493","sponsorName":"Hoth Therapeutics"},{"sponsorId":"465edc414eb3f341233a89dca1b03de024926e45","sponsorName":"Voltron Therapeutics"},{"sponsorId":"d515d87719a8a1e6a5874fe40dfaa22d5f577854","sponsorName":"Vaccine and Immunotherapy Center"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"STI-6991","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"STI-6991","primaryCompletionDate":"","productId":93,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine","https://www.sciencedirect.com/science/article/pii/S2590098620300130?via%3Dihub","https://sorrentotherapeutics.com/contact-us/"],"sponsors":[{"sponsorId":"d4f038c1fd0e4c52d93147fc334849bc67394496","sponsorName":"Sorrento Therapeutics"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"VTP-500","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Phase 1","indication":"Other","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 14 Mar 2018 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"MERS","numSites":"","otherPartners":"UNIVERSITY OF OXFORD,JANSSEN,CEPI","phase":"","preferredName":"VTP-500","primaryCompletionDate":"","productId":94,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.vaccitech.co.uk/pipeline/","https://clinicaltrials.gov/ct2/show/study/NCT03399578"],"sponsors":[{"sponsorId":"3539cc93ae38ac97613e91267777269795073379","sponsorName":"Vaccitech"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"mRNA vaccines","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"","otherPartners":"Sanofi Pasteur","phase":"","preferredName":"mRNA vaccines","primaryCompletionDate":"","productId":95,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00","https://translate.bio/pipeline/"],"sponsors":[{"sponsorId":"551135a9f6ade78853bbd5fdbd66283c70e2f776","sponsorName":"Sanofi"},{"sponsorId":"1ddb247542fcbc349fe829611d29e6ded2b999e7","sponsorName":"Translate Bio"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"nebulized Ampion","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"In Phase 3 Trials for Osteoarthritis of the Knee","numSites":"","otherPartners":"","phase":"","preferredName":"nebulized Ampion","primaryCompletionDate":"","productId":96,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://ampiopharma.com/news/ampio-reports-acceptance-of-publication-on-the-potential-benefits-of-nebulized-ampion-for-covid-19-patients/","https://www.drugbank.ca/drugs/DB14940","https://ampiopharma.com/pipeline/","https://ampiopharma.com/wp-content/uploads/2020/04/01-Apr-2020-Ampion-SARS-COV-2-and-ARDS-Flyer_v4.pdf"],"sponsors":[{"sponsorId":"02881a510323f0cd43a11e035e7be1138b026116","sponsorName":"Ampio Pharmaceuticals"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"Piclidenoson","conditionOrDisease":"COVID-19","contact":[{"email":"Zivit@canfite.co.il","name":null,"notes":"","phone":"","website":""}],"countries":["Israel"],"countryCodes":["ISR"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Mon, 13 Apr 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 06 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"In Phase 3 Trials for Rhumetoid Arthritis","numSites":"1","otherPartners":"","phase":"2","preferredName":"Piclidenoson","primaryCompletionDate":"Sat, 06 Mar 2021 00:00:00 GMT","productId":97,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04333472","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"\u05e4\"\u05ea","country":"ISR","lat":32.0891567,"lng":34.8668668,"locationId":"5ab47c40b5e04d266d5dca9b61fe4501928e2bc9","name":"Rabin Medical Center","state":"Center District"}],"sources":["http://www.canfite.com/?KPageId=19","https://ir.canfite.com/press-releases/detail/894/can-fite-to-explore-the-anti-coronavirus-effects-of-piclidenoson-in-collaboration-with-lewis-katz-school-of-medicine-at-temple-university","http://www.canfite.com/?KPageId=18","https://ir.canfite.com/press-releases/detail/897/can-fite-piclidenoson-is-submitted-for-compassionate-use-treatment-for-coronavirus-patients-in-israel","https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1"],"sponsors":[{"sponsorId":"2ea7e102c17c41b12f5ea330cafbdf8e967c6742","sponsorName":"CanFite BioPharma Ltd"}],"status":"Ongoing","studyCompletionDate":"Tue, 06 Jul 2021 00:00:00 GMT","studyStartDate":"Tue, 06 Oct 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"IFX-1","chemicalName":"BDB-1","conditionOrDisease":"COVID-19","contact":[{"email":"korinna.pilz@inflarx.de","name":null,"notes":"","phone":"","website":""}],"countries":["Netherlands"],"countryCodes":["NLD"],"currentStage":"Phase 2","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 31 Mar 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 31 Mar 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"2","otherPartners":"","phase":"2","preferredName":"BDB-1","primaryCompletionDate":"Mon, 31 May 2021 00:00:00 GMT","productId":98,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04333420","repurposed":"New","siteLocations":[{"city":"Amsterdam","country":"NLD","lat":52.35581819999999,"lng":4.955726299999999,"locationId":"88eb1ab73aaaaae11cb5a7999b3b0db3b540e47c","name":"University Of Amsterdam","state":"NH"},{"city":"Maastricht","country":"NLD","lat":50.83929680000001,"lng":5.708785900000001,"locationId":"87daeb2b657b958c8faf2c4eda2e6cd42186fdf0","name":"University Of Maastricht","state":"LI"}],"sources":["https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html","https://www.inflarx.de/Home/Research---Development/Pipeline.html","https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5","https://www.clinicaltrials.gov/ct2/show/study/NCT04333420?term=Inflarx&draw=1&rank=5#contacts"],"sponsors":[{"sponsorId":"ecc0feedb452374f3f35ae9224fd597c82fca6a1","sponsorName":"InflaRx NV"}],"status":"Ongoing","studyCompletionDate":"Tue, 31 Aug 2021 00:00:00 GMT","studyStartDate":"Tue, 31 Mar 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Ryoncil","chemicalName":"remestemcel-L","conditionOrDisease":"COVID-19","contact":[{"email":"mary.marks@mountsinai.org","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Mon, 06 Apr 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 30 Apr 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":"Tue, 10 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"15","otherPartners":"","phase":"3","preferredName":"remestemcel-L","primaryCompletionDate":"Thu, 01 Apr 2021 00:00:00 GMT","productId":99,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04371393","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Los Angeles","country":"USA","lat":34.0223519,"lng":-118.285117,"locationId":"f7e9678e72fcf19f11556fea6b7b5ca667ffb63a","name":"University Of Southern California","state":"CA"},{"city":"Atlanta","country":"USA","lat":33.7971368,"lng":-84.32224,"locationId":"55884df185cc43acae944cf17489a894f48772f6","name":"Emory University","state":"GA"},{"city":"Fort Wayne","country":"USA","lat":41.0405029,"lng":-85.24895819999999,"locationId":"562a206b40042c310cc1fd7efa21f06975947275","name":"Lutheran Hospital","state":"IN"},{"city":"New Orleans","country":"USA","lat":29.9631002,"lng":-90.1436859,"locationId":"10b5265055e3e8f267ab3165bf9d769dd956b147","name":"Ochsner Clinic","state":"LA"},{"city":"Baltimore","country":"USA","lat":39.2892017,"lng":-76.6257057,"locationId":"9048d45e811cababfcfb78ad044bc8ca8310bfbb","name":"University Of Maryland","state":"MD"},{"city":"Boston","country":"USA","lat":42.3355661,"lng":-71.1062852,"locationId":"1d88dc78615f794df483bf218ceecd38a6275fd2","name":"Brigham And Women's Hospital","state":"MA"},{"city":"Ann Arbor","country":"USA","lat":42.2780436,"lng":-83.7382241,"locationId":"6585a68d680b6da9cc01f05a23331c58630d5e85","name":"University Of Michigan","state":"MI"},{"city":"Lebanon","country":"USA","lat":43.6754932,"lng":-72.2729588,"locationId":"d10f0b26f596b620eca3b8f4a6be5c0a68e4b0a6","name":"Dartmouth","state":"NH"},{"city":"New York","country":"USA","lat":40.7901099,"lng":-73.95295740000002,"locationId":"8fbdf62643b6ef4c4195882604156188a29b12a9","name":"Mount Sinai Health","state":"NY"},{"city":"Asheville","country":"USA","lat":35.5811784,"lng":-82.5502539,"locationId":"4fd67f7405e587b7b9f6bcecf33a163e3b787d8f","name":"Mission Hospital","state":"NC"},{"city":"Durham","country":"USA","lat":36.0075052,"lng":-78.938442,"locationId":"53b316c68a4c558952307ce0b6a10e702e4765ce","name":"Duke University Medical Center","state":"NC"},{"city":"Cleveland","country":"USA","lat":41.502527,"lng":-81.620983,"locationId":"1903412e3d4179aa26147a7fd5cebee112e10cd0","name":"Cleveland Clinic Foundation","state":"OH"},{"city":"Philadelphia","country":"USA","lat":39.9478831,"lng":-75.15453470000001,"locationId":"62ed4c1b58ff106e174e6034f0fccb4f38573691","name":"University Of Pennsylvania Health System","state":"PA"},{"city":"Plano","country":"USA","lat":33.0148185,"lng":-96.78957299999999,"locationId":"a9f0d3b78e4dc6a4502bfe77289b3be78f141875","name":"Baylor Smith & White","state":"TX"},{"city":"Charlottesville","country":"USA","lat":38.0335529,"lng":-78.5079772,"locationId":"06d25e7fa24460af9268e83322b7167f0baf2c8f","name":"University Of Virginia","state":"VA"}],"sources":["https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14","http://investorsmedia.mesoblast.com/static-files/336699fe-c5ab-41f2-801e-404c3739275c","http://investorsmedia.mesoblast.com/static-files/c1428818-0b9f-44f9-bb4f-79ad518002cc","http://investorsmedia.mesoblast.com/static-files/f9eb8ecd-9c72-4207-8a51-0187607948b6","https://clinicaltrials.gov/ct2/show/study/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14#contacts"],"sponsors":[{"sponsorId":"d4959407d4633b3c9180469947d99a947263aeb9","sponsorName":"Mesoblast Limited"}],"status":"Ongoing","studyCompletionDate":"Fri, 01 Apr 2022 00:00:00 GMT","studyStartDate":"Thu, 30 Apr 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Actemra","chemicalName":"tocilizumab","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"888-662-6728","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 03 Apr 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"69","otherPartners":"Biomedical Advanced Research and Development Authority,U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response","phase":"3","preferredName":"tocilizumab","primaryCompletionDate":"Wed, 24 Jun 2020 00:00:00 GMT","productId":100,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04320615","repurposed":"Repurposed-Approved","siteLocations":[{"city":"La Jolla","country":"USA","lat":32.8800604,"lng":-117.2340135,"locationId":"8cb039582b6f6e47c40283f07b3af9c98d678eda","name":"University Of California San Diego","state":"CA"},{"city":"La Mesa","country":"USA","lat":32.7804422,"lng":-117.0094774,"locationId":"b71de2610f5389101d9393bba4734400758be379","name":"Estudysite","state":"CA"},{"city":"Los Angeles","country":"USA","lat":34.06428289999999,"lng":-118.4423562,"locationId":"c3df2a6174b219434730376818c72e30eaa2eaa1","name":"David Geffen School Of Medicine Ucla","state":"CA"},{"city":"Stanford","country":"USA","lat":37.4274745,"lng":-122.169719,"locationId":"f295c5048923b024a3298727b669a2dd70fceb5e","name":"Stanford University","state":"CA"},{"city":"Denver","country":"USA","lat":39.7279895,"lng":-104.9913193,"locationId":"68259fd3a310eaa470ade5c9a4689d49a09a2f8b","name":"Denver Health Medical Center","state":"CO"},{"city":"Miami","country":"USA","lat":25.788898,"lng":-80.2140723,"locationId":"4d3f5de12e80e65d0c79b5991aa9b317c91273b9","name":"University Of Miami Miller School Of Medicine","state":"FL"},{"city":"Chicago","country":"USA","lat":41.8747917,"lng":-87.6674637,"locationId":"c37ee33104bba6b7200b7b5fcab138b8be8cd3f5","name":"Rush University Medical Center","state":"IL"},{"city":"Baton Rouge","country":"USA","lat":30.3927983,"lng":-91.0919304,"locationId":"3cae94aaf9792ee43272b5a26a677d24da9f59ba","name":"Ochsner Clinic Foundation","state":"LA"},{"city":"Springfield","country":"USA","lat":42.1216158,"lng":-72.6037013,"locationId":"06b598a0497ed459bc452abf97a2d8b2cf9b722b","name":"Baystate Health System","state":"MA"},{"city":"Rochester","country":"USA","lat":44.0226255,"lng":-92.46688329999999,"locationId":"453565686a61619d2f42ce8a0c647b1fa504b325","name":"Mayo Clinic Ppds","state":"MN"},{"city":"Hackensack","country":"USA","lat":40.8840335,"lng":-74.0565417,"locationId":"f3af84d919a82f3e2c0c43f42e3c0d0ebac7be6b","name":"Hackensack University Medical Center","state":"NJ"},{"city":"New Brunswick","country":"USA","lat":40.4952121,"lng":-74.450131,"locationId":"12eb0ecb75b146878c148f96be9f72a1ed281415","name":"Robert Wood Johnson University Hospital/rutgers","state":"NJ"},{"city":null,"country":"USA","lat":40.8674032,"lng":-73.9064045,"locationId":"92403d2a7b2686ccf86a33adf3caff73bca4bc89","name":"James J Peters Veterans Administration Medical Center \u2013 Navref","state":"NY"},{"city":"Cleveland","country":"USA","lat":41.4620067,"lng":-81.69753519999999,"locationId":"a8b704cd917dbe6c9cd78e8a5ca985a3250de8a4","name":"Cleveland Clinic Foundation","state":"OH"},{"city":"Cleveland","country":"USA","lat":41.4613462,"lng":-81.6974151,"locationId":"ae19f477efd259f2a4cb424cb3eec9d759545134","name":"Pulmonary Allergy & Critical Care Medicine","state":"OH"},{"city":"Philadelphia","country":"USA","lat":39.9489108,"lng":-75.15596169999999,"locationId":"932e63990cce2a30fe40fe7290ddec75386af8d2","name":"Thomas Jefferson University","state":"PA"},{"city":"Houston","country":"USA","lat":29.7077057,"lng":-95.40062239999999,"locationId":"ff4c2354111927ba418171396bfe5f08059e7cb3","name":"Baylor St. Luke's Medical Center","state":"TX"},{"city":"Houston","country":"USA","lat":29.7110567,"lng":-95.3945559,"locationId":"c3175f9b47a0a723049b05aa52459b08cd0d096c","name":"Ben Taub General Hospital \u2013 Hchd","state":"TX"},{"city":"St. George","country":"USA","lat":37.0968017,"lng":-113.5539707,"locationId":"c369d9fd9ebed0a69a295c01df9fdc862a5abde5","name":"Intermountain Medical Group","state":"UT"},{"city":"Salt Lake City","country":"USA","lat":40.7607793,"lng":-111.8910474,"locationId":"e77fedcb3b35440bac3caaad57ff72d0b09f75ac","name":"Salt Lake City","state":"UT"},{"city":"Kirkland","country":"USA","lat":47.715878,"lng":-122.1786164,"locationId":"c2ef6dc2dd5f06bb137ae4f8af10e3601f35ad23","name":"Evergreen Health Infectious Disease","state":"WA"},{"city":"Seattle","country":"USA","lat":47.6073059,"lng":-122.3102867,"locationId":"fde6b80130ba0f167df7f53d872aff3fe0c31945","name":"Swedish Hospital Medical Center","state":"WA"},{"city":"Hamilton","country":"CAN","lat":43.2624646,"lng":-79.85409159999999,"locationId":"98f0f94c57cad68ae6bb34726aa2db04e2d5d968","name":"Hamilton General Hospital Pharmacy","state":"ON"},{"city":"Hamilton","country":"CAN","lat":43.2491399,"lng":-79.8702177,"locationId":"8e2f83687f2d68c44977c8462c6e3439220e1d72","name":"St. Joseph's Healthcare Hamilton","state":"ON"},{"city":"Toronto","country":"CAN","lat":43.6598777,"lng":-79.38761810000001,"locationId":"2522822400ba47f1b2c790984320565dfb5d736c","name":"University Health Network","state":"ON"},{"city":"Toronto","country":"CAN","lat":43.6533546,"lng":-79.4055865,"locationId":"53a868e1c228f098e4d40b53af9c34fef64bfbd9","name":"Toronto Western Hospital","state":"ON"},{"city":"Montr\u00e9al","country":"CAN","lat":45.513589,"lng":-73.5761859,"locationId":"2cffd3a051209220e4972b6d48d3cc844a87121a","name":"Clinical Research Institute Of Montreal","state":"QC"},{"city":"K\u00f8benhavn","country":"CNK","lat":55.6960841,"lng":12.5667877,"locationId":"962fdbfb53544fe3f73ec3fd54f0390afe0ef1e9","name":"Rigshospitalet Copenhagen University Hospital","state":null},{"city":"Hvidovre","country":"CNK","lat":55.648779,"lng":12.470292,"locationId":"8bbd760fbae45c1c84344e71ee4e0ed2060f7b9e","name":"Hvidovre Hospital","state":null},{"city":"Odense","country":"CNK","lat":55.3850091,"lng":10.3675736,"locationId":"a7a41faa41d69b3a373cf92cf7cd1afb59f6a12c","name":"Odense Universitets Hospital","state":null},{"city":"Roskilde","country":"CNK","lat":55.6361646,"lng":12.0903485,"locationId":"d0c2c73442e288364749873f954cbfe390978149","name":"Sj\u00e6llands Universitetshospital","state":null},{"city":"La Roche-sur-Yon","country":"FRA","lat":46.6677714,"lng":-1.4118805,"locationId":"9ee74a539590d77b7a0623f8e09f31570b723bb6","name":"Centre Hospitalier Departemental De Vendee","state":"Pays de la Loire"},{"city":"Limoges","country":"FRA","lat":45.812311,"lng":1.2357132,"locationId":"469a144987d89604d7b98156614a148a8dc4e128","name":"Centre Hospitalier Et Universitaire De Limoges","state":"Nouvelle-Aquitaine"},{"city":"Lyon","country":"FRA","lat":45.7818414,"lng":4.8308236,"locationId":"75bb5e58dde800c797646c78b942af9768cc6536","name":"H\u00f4pital De La Croix Rousse","state":"Auvergne-Rh\u00f4ne-Alpes"},{"city":"Nantes","country":"FRA","lat":47.2123597,"lng":-1.5530454,"locationId":"1dd25216eb54501c923887a4acf358fd24bd2b9a","name":"Hotel Dieu","state":"Pays de la Loire"},{"city":"Paris","country":"FRA","lat":48.8370792,"lng":2.3650429,"locationId":"128fcf4cbc7b5ef017fea1117a771598dc8cb304","name":"Hopital De La Pitie Salpetriere","state":"IDF"},{"city":"Paris","country":"FRA","lat":48.8368937,"lng":2.3402667,"locationId":"3236ac19f48845ca88fa0cbad992f574bcdf4f8e","name":"Hopital Cochin University Hospital","state":"IDF"},{"city":"Tours","country":"FRA","lat":47.3868449,"lng":0.6682328,"locationId":"0fd8a511d4b7b63badcbf88a2d74642a74a5db6b","name":"Chru De Tours Pharmacie","state":"Centre-Val de Loire"},{"city":"D\u00fcsseldorf","country":"DEU","lat":51.1964742,"lng":6.7904089,"locationId":"6c53f5d2bdb6313e1f720f9e5da84d33aaf8e8b5","name":"Universitatsklinikum Dusseldorf","state":"NRW"},{"city":"Hannover","country":"DEU","lat":52.383675,"lng":9.804955399999999,"locationId":"da80c79f1f8911011154b600f7ea8fce694e1a0e","name":"Medizinische Hochschule","state":"NDS"},{"city":"KI","country":"DEU","lat":54.3298132,"lng":10.1406978,"locationId":"636d2588407903c28adae89a75d85c3f382d8c74","name":"Universitatsklinikum Schleswig Holstein","state":"SH"},{"city":"K\u00f6ln","country":"DEU","lat":50.9238042,"lng":6.9172177,"locationId":"7a7530149ef2052afd5d98d59d3c8a2c7a40a89c","name":"Uniklinik K\u00f6ln","state":"NRW"},{"city":"Munich","country":"DEU","lat":48.1099251,"lng":11.467721,"locationId":"4149de41d2c76a655f9a3ae724285923a85ffeba","name":"Lmu Klinikum Der Universitat Munchen","state":"BY"},{"city":"Napoli","country":"ITA","lat":40.8701948,"lng":14.2100284,"locationId":"de35520b7c1c0a79c917ee93f6cd684f0874566f","name":"Azienda Ospedaliera Dei Colli","state":"Campania"},{"city":"Roma","country":"ITA","lat":41.866501,"lng":12.4564793,"locationId":"e1ad68fa4bb65b13cc855f749f4aa3e744df7279","name":"Istituto Nazionale Malattie Infettive Lazzaro Spallanzani Irccs","state":"Lazio"},{"city":"Bergamo","country":"ITA","lat":45.686107,"lng":9.638066,"locationId":"6aab733abb1083117dbc232fe97d69484b44ea9c","name":"Asst Papa Giovanni Xxiii","state":"Lombardia"},{"city":"Bergamo","country":"ITA","lat":45.686107,"lng":9.638066,"locationId":"5ed67cdb6e9f5f6945143772fc1791503b2c9975","name":"Dipartimento Interaziendale Di Farmacia Clinica","state":"Lombardia"},{"city":"Milano","country":"ITA","lat":45.4847912,"lng":9.2190716,"locationId":"4dfb9e1e0481cd90d614dc0c45e3f5bed097179c","name":"Asst Fatebenefratelli Sacco","state":"Lombardia"},{"city":"Monza","country":"ITA","lat":45.6018705,"lng":9.2597899,"locationId":"77d21467cd1f2773621a7f50e687bf8b51e1a6fd","name":"Azienda Ospedaliera San Gerardo Di Monza","state":"Lombardia"},{"city":"Pavia","country":"ITA","lat":45.19622,"lng":9.1488409,"locationId":"060557332c4410393d3baaa84577199bb97a15bb","name":"Fondazione Irccs Policlinico San Matteo Di Pavia","state":"Lombardia"},{"city":"Pavia","country":"ITA","lat":45.19622,"lng":9.1488409,"locationId":"1db851e905f157ab91082809ede4f58cb67c3886","name":"S.s. Fisiopatologia Respiratoria","state":"Lombardia"},{"city":"Breda","country":"NLD","lat":51.57417,"lng":4.7628566,"locationId":"1906cf443b75d04ecf7ee18cad06535e42e4d688","name":"Amphia Ziekenhuis","state":"NB"},{"city":"Nieuwegein","country":"NLD","lat":52.0252656,"lng":5.081456,"locationId":"6867ead656a99377dc7eb497287361b8c8cf0367","name":"St. Antonius Ziekenhuis Nieuwegein","state":"UT"},{"city":"Rotterdam","country":"NLD","lat":51.9108848,"lng":4.467854099999999,"locationId":"3d6105eab61e0c3718106852045bc32e84498aa7","name":"Erasmus Mc","state":"ZH"},{"city":"Utrecht","country":"NLD","lat":52.0865646,"lng":5.179913099999999,"locationId":"4ad558b05dc982ce83a3d0fa2eeb0cb0fc340aec","name":"Universitair Medisch Centrum Utrecht","state":"UT"},{"city":"L'Hospitalet de Llobregat","country":"ESP","lat":41.3448959,"lng":2.1042573,"locationId":"a70229bb456a869ae8d158e04c076e8dc16bc077","name":"Hospital Universitario De Bellvitge","state":"CT"},{"city":"L'Hospitalet de Llobregat","country":"ESP","lat":41.3661865,"lng":2.1164942,"locationId":"b67d3decbbe25d4e8f7191dcdfc9e0f60737b4ba","name":"Hospitalet De Llobregat","state":"CT"},{"city":"Barcelona","country":"ESP","lat":41.4282326,"lng":2.1409889,"locationId":"a3565b7d720c6fdd7f1c80e0c3faea3960c9f433","name":"Hospital Universitari Vall D'hebron","state":"CT"},{"city":"Barcelona","country":"ESP","lat":41.3894436,"lng":2.1523119,"locationId":"0185a3b01cabec6f496b6bf3e77d0b655b70e7e3","name":"Hospital Clinic De Barcelona","state":"CT"},{"city":"Madrid","country":"ESP","lat":40.4811633,"lng":-3.6873977,"locationId":"c7b8f75d94050fa2f486afb0df20699c22fa342e","name":"Hospital Universitario La Paz","state":"Comunidad de Madrid"},{"city":"Madrid","country":"ESP","lat":40.48760430000001,"lng":-3.6951156,"locationId":"59dcc31746fdc8642ea76ab714239d0fb0d4a0f5","name":"Hospital Universitario Ramon Y Cajal","state":"Comunidad de Madrid"},{"city":"Madrid","country":"ESP","lat":40.4191053,"lng":-3.6703866,"locationId":"0b84abd6bab3552d1a8767edfeca9f26221be961","name":"Hospital General Universitario Gregorio Maranon","state":"Comunidad de Madrid"},{"city":"Madrid","country":"ESP","lat":40.49026920000001,"lng":-3.6667845,"locationId":"8df770eb6b58e2c17a84098e60cbf4c189abf4b6","name":"Hospital Universitario Hm Sanchinarro","state":"Comunidad de Madrid"},{"city":null,"country":"GBR","lat":55.883619,"lng":-4.321016,"locationId":"c03b4b0a6e4ab5906e2f3b8c375a1f6db6814fb4","name":"Greater Glasgow And Clyde Health Board","state":"Scotland"},{"city":null,"country":"GBR","lat":53.80254309999999,"lng":-1.5528919,"locationId":"952419eed7c9160e780d3d7dd6b7eef69cc007d5","name":"Leeds Teaching Hospitals Nhs Trust","state":"England"},{"city":null,"country":"GBR","lat":51.5251538,"lng":-0.1361126,"locationId":"9f771f12c0020e21826311bca9f4d11d5fa169d9","name":"University College Hospital","state":"England"},{"city":null,"country":"GBR","lat":51.5530368,"lng":-0.1653391,"locationId":"b5fd83876046eb6716ef89844694287fed61584d","name":"Royal Free Hospital","state":"England"},{"city":null,"country":"GBR","lat":51.4272585,"lng":-0.1745699,"locationId":"e0a6ea549d149e0b7a72a830ab83098da10736c3","name":"St George's Clinical Research Facility","state":"England"},{"city":null,"country":"GBR","lat":51.49882220000001,"lng":-0.1748735,"locationId":"7e6e4526c21e1cc52601447088fd3b23706ed739","name":"Imperial College London","state":"England"},{"city":"Crumpsall","country":"GBR","lat":53.517431,"lng":-2.2287604,"locationId":"b33390251c8011e19828f758cc975209795cae03","name":"North Manchester General Hospital","state":"England"},{"city":null,"country":"GBR","lat":53.487482,"lng":-2.3238955,"locationId":"84d40210d216ef7b99d0f3c9137ef4f8db4defe2","name":"Salford Royal Hospital","state":"England"}],"sources":["https://www.gene.com/media/press-releases/14855/2020-05-27/genentech-initiates-phase-iii-clinical-t","https://www.drugbank.ca/drugs/DB06273","https://www.drugbank.ca/drugs/DB06274","https://www.drugbank.ca/drugs/DB06275","https://clinicaltrials.gov/ct2/show/NCT04320615?term=COVACTA&draw=2&rank=1#contacts"],"sponsors":[{"sponsorId":"5a5027c645a5720c448e627baafac159a26508b8","sponsorName":"Genetech"}],"status":"Ongoing","studyCompletionDate":"Tue, 28 Jul 2020 00:00:00 GMT","studyStartDate":"Fri, 03 Apr 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"Diammonium glycyrrhizinate","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"Unclear if any clincial trials are occuring","numSites":"","otherPartners":"","phase":"","preferredName":"Diammonium glycyrrhizinate","primaryCompletionDate":"","productId":101,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.cancer.gov/publications/dictionaries/cancer-drug/def/diammonium-glycyrrhizinate","https://pubchem.ncbi.nlm.nih.gov/compound/Diammonium-glycyrrhizinate"],"sponsors":[{"sponsorId":"828d3ce717e4188e36142a37dde46c7150e54532","sponsorName":"Sino Biopharmaceuticals"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Dantonic","chemicalName":"T89","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 26 Feb 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Other","notes":"T89 is an industrialized botanical drug formula developed from traditional Chinese Medicine. It is a mixture of multiple plant extracts and other excipients. It is to be tested for increasing blood O2 saturation in the ongoing clinical trial registered in US. The trial was approved but not yet recruiting.","numSites":"","otherPartners":"Tasly Pharmaceuticals","phase":"","preferredName":"T89","primaryCompletionDate":"","productId":102,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://clinicaltrials.gov/ct2/show/NCT04285190","https://www.taslyus.com/pipeline/t89/","https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts"],"sponsors":[{"sponsorId":"0dda51f9c95a47c39d878234d93d16d7902c83f1","sponsorName":"Tasly Pharmaceuticals"},{"sponsorId":"3a0d49eb534018ed04f1ba984529ab2611135695","sponsorName":"Arbor Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"KPL-301","chemicalName":"mavrilimumab","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 2","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 20 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"The drug had up to phase-2 trial for other indications. Successfully used in Covid-19 pts in Italy (did not find the exact trial description).","numSites":"1","otherPartners":"Kiniksa Pharmaceuticals,Virginia Commonwealth University","phase":"2","preferredName":"mavrilimumab","primaryCompletionDate":"","productId":106,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Richmond","country":"USA","lat":37.5407246,"lng":-77.4360481,"locationId":"60018afdd403508f4c88478496c2f10f6f1d6cf6","name":"Richmond","state":"VA"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2","https://www.kiniksa.com/our-pipeline/mavrilimumab/","https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-early-evidence-treatment-response-mavrilimumab; https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2","https://clinicaltrials.gov/ct2/results?term=Mavrilimumab; https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-early-evidence-treatment-response-mavrilimumab"],"sponsors":[{"sponsorId":"f0b7d34b0d2bf183e3127d2f2ae6859f2e0c2303","sponsorName":"Kiniksa Pharmaceuticals"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Plasma-derived hyperimmune globulin therapy","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":"https://www.donatingplasma.org/donation/find-a-donor-center"}],"countries":["Japan"],"countryCodes":["JPN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Fri, 06 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Takeda started development as TAK-888. Several groups working on immunoglobulin strategies are now working together. They need plasma donors.","numSites":"","otherPartners":"Biotest,Bio Products Laboratory,Octa Pharma,LFB,CSL Behrig","phase":"","preferredName":"Plasma-derived hyperimmune globulin therapy","primaryCompletionDate":"","productId":107,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.takeda.com/newsroom/newsreleases/2020/covig-19-plasma-alliance-builds-strong-momentum-through-expanded-membership-and-clinical-trial-collaboration/","https://www.takeda.com/newsroom/featured-topics/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda/","https://www.fiercebiotech.com/biotech/takeda-csl-led-plasma-players-band-together-covid-19","https://www.donatingplasma.org/donation/find-a-donor-center"],"sponsors":[{"sponsorId":"43916cc52a3993e63c8a49430c524b6ee70b288e","sponsorName":"CoVIg19 Plasma Alliance"},{"sponsorId":"33b00f7cf4a1544653db151375b5993b9a65892b","sponsorName":"Biotest"},{"sponsorId":"117e9d7e0ecaab7bb098d842d06eeb5b61264077","sponsorName":"BPL"},{"sponsorId":"55f0aa800f25c9093f14e24ae7f37b8f48615a59","sponsorName":"CSL Behring"},{"sponsorId":"1a10f3633823419c6252ef6740cd1775636313a8","sponsorName":"LFB"},{"sponsorId":"0a79402e1456155833c273467179eed61b8a15b2","sponsorName":"Octapharma"},{"sponsorId":"31759effba9dd9037b4a5b2a4e1bf87cb0e4042b","sponsorName":"Takeda"},{"sponsorId":"33f0ad8645fb9f5cb965a79f41b7d258aeb45002","sponsorName":"ADMA Biologics"},{"sponsorId":"8602f1675de8eabf55cab947fb769a020c61501b","sponsorName":"BioPharma Plasma"},{"sponsorId":"fb88543fd60aa16c3c184e6208739bc678ea7909","sponsorName":"GC Pharma"},{"sponsorId":"fdcec5fc0acc497097b5595f555306625de122b3","sponsorName":"Sanquin"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Plasma Immunoglobulins","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Thu, 26 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Other","notes":"Convalescent Plasma","numSites":"","otherPartners":"Cerus Corporation,California Department of Public Health,University of California,Irvine\u2019s Vaccine Development Research Laboratory,Vitalant Research Institute,California National Primate Research Center,Enable Biosciences","phase":"Discovery","preferredName":"Plasma Immunoglobulins","primaryCompletionDate":"","productId":108,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19"],"sponsors":[{"sponsorId":"fe619f6a989eee7d5e22b0c5a964b30deeb615db","sponsorName":"CERS actually spelt Cerus Corporation"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Plasma Immunoglobulins","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 25 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Other","notes":"Convalescent Plasma","numSites":"","otherPartners":"Grifols,BARDA,FDA","phase":"Discovery","preferredName":"Plasma Immunoglobulins","primaryCompletionDate":"","productId":109,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19"],"sponsors":[{"sponsorId":"893c4bdb7386d6aa83dda414cb161d199a4e191f","sponsorName":"Grifols"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Plasma Immunoglobulins","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"Convalescent Plasma Program. Ongoing. No dates given.","numSites":"","otherPartners":"Mayo Clinic","phase":"","preferredName":"Plasma Immunoglobulins","primaryCompletionDate":"","productId":110,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.mountsinai.org/about/covid19/convalescent-plasma-program"],"sponsors":[{"sponsorId":"67cc1b58cfec53c29d2af191d961276e32239c1b","sponsorName":"Mount Sinai Health System"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Plasma Immunoglobulins","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 20 Feb 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Other","notes":"Convalescent Plasma Program. Ongoing. No dates given.","numSites":"3","otherPartners":"China National Biotec Group","phase":"2","preferredName":"Plasma Immunoglobulins","primaryCompletionDate":"","productId":111,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Wuhan Shi","country":"CHN","lat":30.6668794,"lng":114.2868443,"locationId":"b3140e07f166a3b84bb5a33ff2a9b2bd0009bbe2","name":"Wuhan Jinyintan Hospital","state":"Hubei Sheng"},{"city":"Wuhan","country":"CHN","lat":30.375552,"lng":114.320726,"locationId":"bb10ef8c8639547fd87dd10a35105eb5d87c6685","name":"Jiangxia District Hospital Of Integrative Traditional Chinese And Western Medicine","state":"Hubei"},{"city":"Wuhan Shi","country":"CHN","lat":30.3488361,"lng":114.3162141,"locationId":"8d91234ff95472b5f24dfdcc930674386b1b5f89","name":"First People\u2019s Hospital Of Jiangxia District","state":"Hubei Sheng"}],"sources":["http://www.xinhuanet.com/english/2020-02/14/c_138783268.htm","https://www.pnas.org/content/early/2020/04/02/2004168117"],"sponsors":[{"sponsorId":"de649c1e3ec322020be03d52590a6461de6d1a6a","sponsorName":"China National Biotec"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Aviptadil","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"rbesthof@neurorxpharma.com","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"COMPLETED"},{"category":"regulatory","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":51,"name":"nda","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Vasoactive Intestinal Polypeptide which inhibits inflammatory cytokines causing ARDS","numSites":"4","otherPartners":"NeuroRx","phase":"3","preferredName":"Aviptadil","primaryCompletionDate":"Sat, 01 Aug 2020 00:00:00 GMT","productId":112,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04311697","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Miami","country":"USA","lat":25.7904064,"lng":-80.21199279999999,"locationId":"a8a9722cf13540129186fcb5c5aa690072eadc51","name":"Miller School Of Medicine","state":"FL"},{"city":"New York","country":"USA","lat":40.7420166,"lng":-73.9736534,"locationId":"85df56ccd3112fbaf71c8e2ad7e07c35df373283","name":"Robert I Grossman School Of Medicine","state":"NY"},{"city":"Philadelphia","country":"USA","lat":39.9488442,"lng":-75.1572272,"locationId":"c50085a261ae3beb5de9217022cad38c6a93ae73","name":"Thomas Jefferson University Hospital","state":"PA"},{"city":"Haifa","country":"ISR","lat":32.8329875,"lng":34.9857066,"locationId":"cd00296ab88ba90456baa07ebbd85902c81ffc05","name":"Rambam Health Care Campus","state":"Haifa District"}],"sources":["https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/","https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2"],"sponsors":[{"sponsorId":"b5a0fa2b0ae4008c8789c58eee3a5db3b93fdc0e","sponsorName":"NeuroRx"},{"sponsorId":"a30d64bea24fb02aa2230fa1359a99643a0fc3a3","sponsorName":"Relief Therapeutics"}],"status":"Ongoing","studyCompletionDate":"Tue, 01 Sep 2020 00:00:00 GMT","studyStartDate":"Fri, 15 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"STI-4398,COVIDTRAP","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Fri, 20 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Designed to block the SARS-CoV-2 virus from binding and infecting respiratory epithelial cells - which is expected to effectively interrupt the viral life cycle","numSites":"","otherPartners":"Sorrento Theraputics","phase":"","preferredName":"STI-4398,COVIDTRAP","primaryCompletionDate":"","productId":113,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential","https://sorrentotherapeutics.com/"],"sponsors":[{"sponsorId":"dd736e19d9cf47b8b0d9049c8729f5f8c706b691","sponsorName":"Sorrento Therapeutics inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"INOpulse","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"Other","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Inhaled Nitric Oxide at Phase 2 for  for COPD - ILD - Sarcoidosis","numSites":"","otherPartners":"Bellerophon Therapeutics","phase":"2","preferredName":"INOpulse","primaryCompletionDate":"","productId":114,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug","http://www.bellerophon.com/","http://www.bellerophon.com/pipeline/","http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-receives-approval-commence-phase-2-trial-ph-copd","http://www.bellerophon.com/ ; http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug"],"sponsors":[{"sponsorId":"e5750b2be1ef356fc53942e9fba92281f2fa8b6f","sponsorName":"Bellerophon Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"SNX-5542","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"","milestones":[],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"SNX-5542","primaryCompletionDate":"","productId":115,"registryLink":null,"repurposed":"","siteLocations":[],"sources":[""],"sponsors":[{"sponsorId":"282eaef03c22bad7cc8a8fd8da311711425b1a20","sponsorName":"Esanex"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"Mytesi","chemicalName":"crofelemer","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"antidiarrheal for those on anti-retroviral therapy - used in HIV patients - permission sought from FDA for use in COVID patients","numSites":"","otherPartners":"Jaguar Health","phase":"","preferredName":"crofelemer","primaryCompletionDate":"","productId":116,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support","https://www.marketscreener.com/JAGUAR-HEALTH-INC-59550999/news/JAGUAR-HEALTH-INC-Other-Events-form-8-K-30397142/","https://www.reuters.com/article/brief-jaguar-health-says-declined-to-iss/brief-jaguar-health-says-declined-to-issue-an-eua-for-crofelemer-at-this-time-idINFWN2BY04H"],"sponsors":[{"sponsorId":"c7563c3b7fe4829bad22fa8782140bff9d34561f","sponsorName":"Jaguar Health"}],"status":"Failed","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Leibniz Instutute Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"","milestones":[],"moleculeType":"","notes":"could not find therapeutic use,only antibody test for covid?","numSites":"","otherPartners":"","phase":"","preferredName":"Leibniz Instutute Therapeutic","primaryCompletionDate":"","productId":117,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://www.wbur.org/commonhealth/2020/04/10/covid-19-coronavirus-antibody-testing"],"sponsors":[{"sponsorId":"8e15d495d6fb7018df95d75779b82dcd926be20f","sponsorName":"Leibniz Institute"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"Allergan Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"","milestones":[],"moleculeType":"","notes":"could not find any therapeutic drug/vaccine","numSites":"","otherPartners":"","phase":"","preferredName":"Allergan Therapeutic","primaryCompletionDate":"","productId":118,"registryLink":null,"repurposed":"","siteLocations":[],"sources":[""],"sponsors":[{"sponsorId":"81ce487fc0d3a5b4c58a218b8adceb96a044468f","sponsorName":"Allergan"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"No","brandName":"CD24Fc","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 08 Apr 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"first-in-class recombinant fusion protein (biologic)","numSites":"1","otherPartners":"OncoImmune","phase":"3","preferredName":"CD24Fc","primaryCompletionDate":"Mon, 10 May 2021 00:00:00 GMT","productId":119,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":"Baltimore","country":"USA","lat":39.2892017,"lng":-76.6257057,"locationId":"2732c8ef872d2ab6b2a3ddd0fd8b96d8503c0935","name":"University Of Maryland","state":"MD"}],"sources":["https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/","http://www.oncoimmune.com/product-development/","https://www.clinicaltrials.gov/ct2/show/NCT04317040"],"sponsors":[{"sponsorId":"01bbc68194bde084f23cb9df2a7ae7d59d15b54f","sponsorName":"OncoImmune"}],"status":"Ongoing","studyCompletionDate":"Tue, 10 May 2022 00:00:00 GMT","studyStartDate":"Wed, 08 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"PUL-042 Inhalation Solution","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Other","notes":"2 Clinical Trials: one for short term immunisation,also one for reducing severity (link below for latter)","numSites":"","otherPartners":"Pulmotect","phase":"2","preferredName":"PUL-042 Inhalation Solution","primaryCompletionDate":"Thu, 10 Sep 2020 00:00:00 GMT","productId":120,"registryLink":null,"repurposed":"New","siteLocations":[{"city":"Houston","country":"USA","lat":29.71072,"lng":-95.3995173,"locationId":"02019857a6b7739620fbae4ddb6a2af225a741e4","name":"Houston Methodist Hospital","state":"TX"}],"sources":["https://pulmotect.com/covid19-update/","https://www.clinicaltrials.gov/ct2/show/NCT04312997","https://clinicaltrials.gov/ct2/show/NCT04313023"],"sponsors":[{"sponsorId":"1eab813cb618e383ce0ca0e7f81c6684b50fdddc","sponsorName":"Pulmotect"}],"status":"Ongoing","studyCompletionDate":"Sat, 10 Oct 2020 00:00:00 GMT","studyStartDate":"Fri, 10 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"DDRI Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"","milestones":[],"moleculeType":"","notes":"could not find therapeutic drug/vaccine","numSites":"","otherPartners":"","phase":"","preferredName":"DDRI Therapeutic","primaryCompletionDate":"","productId":121,"registryLink":null,"repurposed":"","siteLocations":[],"sources":[""],"sponsors":[{"sponsorId":"4df36b5a59c84e2083f2bc2c1d75bda25e29f290","sponsorName":"Digestive Disease Research Institute"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"Gene MAb\u2122","chemicalName":"antibody","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Mon, 23 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"uses Gene MAb\u2122 platform for ab delivery","numSites":"","otherPartners":"Sorrento Therapeutics Inc.","phase":"","preferredName":"antibody","primaryCompletionDate":"","productId":157,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus"],"sponsors":[{"sponsorId":"99401ebed0fa84553f3dab49ec5651d6e16ebb72","sponsorName":"SmartPharm Therapeutics Inc"},{"sponsorId":"5fc64f72797f9967b8f89cf58d0d24a43168cffc","sponsorName":"Sorrento Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"INSERM Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"Clinical Trials - stage unknown - to test 4 therapes: Remdesevir,Hydroxychloroquine,Lopinavir and Rotinavir,plus IFN-beta","numSites":"","otherPartners":"National Insitute for Health and Medical Research","phase":"","preferredName":"INSERM Therapeutic","primaryCompletionDate":"","productId":122,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial","https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments#"],"sponsors":[{"sponsorId":"0e1ea407af0902261db76719a57a5c127ea53bfe","sponsorName":"INSERM"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"Nitric Oxide","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 23 Mar 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Other","notes":"4 Current/upcoming trials - to assess use of Nitric Oxide for treating COVID patients - and also potentially preventing the disease","numSites":"2","otherPartners":"Massachusetts General Hospital","phase":"2","preferredName":"Nitric Oxide","primaryCompletionDate":"Mon, 01 Mar 2021 00:00:00 GMT","productId":123,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":"Boston","country":"USA","lat":42.3626109,"lng":-71.067566,"locationId":"1e101870bb667ac90b45650f5430dc5856553e91","name":"Massachusetts General Hospital","state":"MA"},{"city":"Xi'an","country":"CHN","lat":34.2706897,"lng":108.9880179,"locationId":"104d350cb950f391e6f9af2d3fd77c01fcb88940","name":"Xijing Hospital","state":"Shaanxi"}],"sources":["https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests","https://clinicaltrials.gov/ct2/show/NCT04290871"],"sponsors":[{"sponsorId":"8a365c9b40d6477fb64fadbb35d6bac33dafb436","sponsorName":"Massachusetts General Hospital"},{"sponsorId":"df85596f7d7dbeb2a2e8c43c35f6f8fa02b44690","sponsorName":"Mallincrodt plc"}],"status":"Ongoing","studyCompletionDate":"Tue, 01 Mar 2022 00:00:00 GMT","studyStartDate":"Mon, 23 Mar 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"RoActerma","chemicalName":"Tocilizumab","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Phase 3 approved","numSites":"","otherPartners":"Roche and BARDA","phase":"2","preferredName":"Tocilizumab","primaryCompletionDate":"","productId":124,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":[""],"sponsors":[{"sponsorId":"2ca60c923f9bd40c651529c4a7b5a6972829d31d","sponsorName":"National Cancer Institute"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Tamiflu","chemicalName":"oseltamivir","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Thailand"],"countryCodes":["THA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 15 Apr 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"Rajavithi Hospital","phase":"3","preferredName":"oseltamivir","primaryCompletionDate":"Sat, 31 Oct 2020 00:00:00 GMT","productId":125,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://clinicaltrials.gov/ct2/show/NCT04303299","https://www.drugbank.ca/drugs/DB00198"],"sponsors":[{"sponsorId":"6929a0f7701affd68fc35e0bb16ed03f8cfbfee6","sponsorName":"Rajavithi Hospital"},{"sponsorId":"ef7f40a7a4970541f7271499b9755b383671309d","sponsorName":"Roche AG"}],"status":"Ongoing","studyCompletionDate":"Mon, 30 Nov 2020 00:00:00 GMT","studyStartDate":"Wed, 15 Apr 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"Hydroxychloroquine,Lopinavir,Ritonavir,Interferon-\u03b2 1a","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"","milestones":[],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Hydroxychloroquine,Lopinavir,Ritonavir,Interferon-\u03b2 1a","primaryCompletionDate":"","productId":126,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://www.smartpatients.com/trials/NCT04343768"],"sponsors":[{"sponsorId":"eb058ec8d1b15050f17777e54392b41479ffda20","sponsorName":"Shahid Beheshti Univeristy of Medical Sciences"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"sofosbuvir,ledipasvir","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Iran","Islamic Republic of"],"countryCodes":["IRN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"sofosbuvir,ledipasvir","primaryCompletionDate":"","productId":127,"registryLink":null,"repurposed":"","siteLocations":[],"sources":[""],"sponsors":[{"sponsorId":"3d91d8a2763ff7a2305e9571ce331344f8db21d8","sponsorName":"Tehran University of Medical Sciences"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"Beijing Chaoyang Hospital Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"","milestones":[],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Beijing Chaoyang Hospital Therapeutic","primaryCompletionDate":"","productId":128,"registryLink":null,"repurposed":"","siteLocations":[],"sources":[""],"sponsors":[{"sponsorId":"2edadb0a368326e19a38c17e17aa31d37ca94581","sponsorName":"Beijing Chaoyang Hospital"},{"sponsorId":"ffd8a5577b16ce486d568c58bbd8c4ecc8d5b073","sponsorName":"Capital Medical University"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"Beijing You'an Hospital Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"","milestones":[],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Beijing You'an Hospital Therapeutic","primaryCompletionDate":"","productId":129,"registryLink":null,"repurposed":"","siteLocations":[],"sources":[""],"sponsors":[{"sponsorId":"321cfa99e2d96ffd805132b7d743b6bce706e380","sponsorName":"Beijing Youan Hospital"},{"sponsorId":"ffd8a5577b16ce486d568c58bbd8c4ecc8d5b073","sponsorName":"Capital Medical University"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"Carrimycin","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 4","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"","notes":"","numSites":"11","otherPartners":"Beijing YouAn Hospital","phase":"4","preferredName":"Carrimycin","primaryCompletionDate":"Sun, 28 Feb 2021 00:00:00 GMT","productId":130,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://clinicaltrials.gov/ct2/show/record/NCT04286503"],"sponsors":[{"sponsorId":"ffd8a5577b16ce486d568c58bbd8c4ecc8d5b073","sponsorName":"Capital Medical University"},{"sponsorId":"47b3533192dd0db49fc64ee3adb03d999199d9d4","sponsorName":"Shenyang Tonglian Group Co Ltd"}],"status":"Ongoing","studyCompletionDate":"Sun, 28 Feb 2021 00:00:00 GMT","studyStartDate":"Thu, 27 Feb 2020 00:00:00 GMT","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"No","brandName":"CMAB806","chemicalName":"Interleukin-6 monoclonal antibody","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 20 Feb 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"","notes":"Study goes to May 31st","numSites":"1","otherPartners":"","phase":"2","preferredName":"Interleukin-6 monoclonal antibody","primaryCompletionDate":"Sun, 31 May 2020 00:00:00 GMT","productId":131,"registryLink":"http://www.chictr.org.cn/showprojen.aspx?proj=49883","repurposed":"","siteLocations":[{"city":"Wuhan","country":"CHN","lat":30.592849,"lng":114.305539,"locationId":"e2259674b43e12ae75129a83ef411e1e79eaa0be","name":"Wuhan","state":"Hubei"}],"sources":["http://www.chictr.org.cn/showprojen.aspx?proj=49883"],"sponsors":[{"sponsorId":"6c1d2cca1e1c545b115cedcb4a88a86dfc5cc4c0","sponsorName":"JinYu BioTechnology"}],"status":"Ongoing","studyCompletionDate":"Sun, 31 May 2020 00:00:00 GMT","studyStartDate":"Thu, 20 Feb 2020 00:00:00 GMT","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"No","brandName":"CAStem","chemicalName":"Mesenchymal Stem Cells","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 05 Mar 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"","numSites":"2","otherPartners":"","phase":"2","preferredName":"Mesenchymal Stem Cells","primaryCompletionDate":"Tue, 12 May 2020 00:00:00 GMT","productId":132,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04288102","repurposed":"New","siteLocations":[{"city":"Wuhan Shi","country":"CHN","lat":30.606345,"lng":114.264701,"locationId":"e7477e0887462192ca31afb300b120692af8ab72","name":"Maternal And Child Hospital Of Hubei Province","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.6668794,"lng":114.2868443,"locationId":"9d000b96124333bf70c82d7e028aef30f8e3b71c","name":"Wuhan Huoshenshan Hospital","state":"Hubei Sheng"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04288102","http://www.xinhuanet.com/english/2020-03/05/c_138846353.htm"],"sponsors":[{"sponsorId":"e13a47c3805a5ea782acbdd30bf4d9672426da11","sponsorName":"Beijing 302 Hospital"}],"status":"Ongoing","studyCompletionDate":"Thu, 09 Jul 2020 00:00:00 GMT","studyStartDate":"Thu, 05 Mar 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"NKG2D-ACE2 CAR-NK Cells","conditionOrDisease":"COVID-19","contact":[{"email":"gwzxliumin@foxmail.com","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 21 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 21 Mar 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"Phase I/II Trial","numSites":"1","otherPartners":"Chongqing Sidemu Biotechnology","phase":"2","preferredName":"NKG2D-ACE2 CAR-NK Cells","primaryCompletionDate":"Sun, 31 May 2020 00:00:00 GMT","productId":133,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04324996","repurposed":"New","siteLocations":[{"city":null,"country":"CHN","lat":29.5749191,"lng":106.4218862,"locationId":"b50d39564c232047bdd9354067e839281f0f72e6","name":"Chongqing Public Health Medical Center","state":"Chongqing Shi"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04324996"],"sponsors":[{"sponsorId":"45c8692c794fd50c930fb0b97c607465d7d554b9","sponsorName":"Chongqing Public Health Medical Center"}],"status":"Ongoing","studyCompletionDate":"Wed, 30 Sep 2020 00:00:00 GMT","studyStartDate":"Sat, 21 Mar 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"Long-acting interferon alpha-2a,ribavirin","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 26 Feb 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"5","otherPartners":"","phase":"2","preferredName":"Long-acting interferon alpha-2a,ribavirin","primaryCompletionDate":"Wed, 26 Aug 2020 00:00:00 GMT","productId":134,"registryLink":"http://www.chictr.org.cn/showprojen.aspx?proj=51141","repurposed":"New","siteLocations":[{"city":"Foshan Shi","country":"CHN","lat":22.8500072,"lng":113.2578008,"locationId":"84293ae1f4bf44361228c33c938272d36fbdb65d","name":"Foshan First People's Hospital","state":"Guangdong Sheng"},{"city":"Zhuhai Shi","country":"CHN","lat":22.274973,"lng":113.576144,"locationId":"14b0be89c1b46d4e91cf1b0329534c8f37a8bfc0","name":"Zhongshan Second People's Hospital","state":"Guangdong Sheng"},{"city":"Dongguan Shi","country":"CHN","lat":23.114826,"lng":113.883764,"locationId":"2af8708ea63168b60a707a49da127f48abed57e9","name":"The Ninth People's Hospital Of Dongguan","state":"Guangdong Sheng"},{"city":"Jiangmen Shi","country":"CHN","lat":22.605688,"lng":113.115602,"locationId":"0a1f7df427f7c9492121b2c0110387560e740f01","name":"Jiangmen Central Hospital","state":"Guangdong Sheng"},{"city":"Foshan Shi","country":"CHN","lat":22.960003,"lng":112.978451,"locationId":"c13d7a7cc0232322ea4aa5452aa339ead49b1311","name":"Foshan Fourth People's Hospital","state":"Guangdong Sheng"}],"sources":["http://www.chictr.org.cn/showprojen.aspx?proj=51141"],"sponsors":[{"sponsorId":"0aa5baf3a5bfcd9bd34bc49ddd68b3369a8bd29f","sponsorName":"Foshan First Peoples Hospital"}],"status":"Ongoing","studyCompletionDate":"Wed, 26 Aug 2020 00:00:00 GMT","studyStartDate":"Wed, 26 Feb 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"Triazavirin","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 15 Feb 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Originally developed in Russia for Influenza.","numSites":"4","otherPartners":"","phase":"3","preferredName":"Triazavirin","primaryCompletionDate":"Thu, 28 May 2020 00:00:00 GMT","productId":135,"registryLink":"http://www.chictr.org.cn/showprojen.aspx?proj=49723","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Haerbin Shi","country":"CHN","lat":45.76524999999999,"lng":126.650714,"locationId":"3a6cc1b4d4ee826d5bad1c38be5eeb0504d1f944","name":"The First Affiliated Hospital Of Harbin Medical University","state":"Heilongjiang Sheng"},{"city":"Haerbin Shi","country":"CHN","lat":45.696577,"lng":126.616301,"locationId":"c9be1ce302facd9d6315067b335ab99ecc32152e","name":"The Second Affiliated Hospital Of Harbin Medical University","state":"Heilongjiang Sheng"},{"city":"Haerbin Shi","country":"CHN","lat":45.696577,"lng":126.616301,"locationId":"4e91b30b3353e519e41ed3f99946b4e4cb4160d6","name":"The Fourth Affiliated Hospital Of Harbin Medical University","state":"Heilongjiang Sheng"},{"city":"Haerbin Shi","country":"CHN","lat":45.7289211,"lng":126.6869291,"locationId":"0f790db338870018a139cf3fb0afaa90d613ff86","name":"Heilongijiang Provincial Hospital","state":"Heilongjiang Sheng"}],"sources":["http://www.chictr.org.cn/showprojen.aspx?proj=49723","https://www.drugbank.ca/drugs/DB15622"],"sponsors":[{"sponsorId":"74eb28bb89c6d76ecbdcbb4b00449a43dd0efd98","sponsorName":"Health commission of Heilongjiang province"}],"status":"Ongoing","studyCompletionDate":"Thu, 28 May 2020 00:00:00 GMT","studyStartDate":"Sat, 15 Feb 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"azvudine","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"http://www.chictr.org.cn/showprojen.aspx?proj=50507","numSites":"","otherPartners":"","phase":"","preferredName":"azvudine","primaryCompletionDate":"","productId":136,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.digitaltrends.com/health-fitness/coronavirus-covid-19-vaccines-treatments-list/","https://en.wikipedia.org/wiki/Azvudine","http://www.ecns.cn/news/sci-tech/2020-04-15/detail-ifzviiqq6926898.shtml","http://www.chictr.org.cn/showprojen.aspx?proj=49532"],"sponsors":[{"sponsorId":"590809afc11f993a1d02526632882469be2ae713","sponsorName":"Henan Provincial Peoples Hospital"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"","brandName":"Esbriet","chemicalName":"Pirfenidone","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 3","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Pirfenidone","primaryCompletionDate":"","productId":137,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://en.wikipedia.org/wiki/Pirfenidone","https://clinicaltrials.gov/ct2/show/NCT04282902?term=Pirfenidone&cond=Coronavirus&draw=2&rank=1"],"sponsors":[{"sponsorId":"abf659ef96c4f7cef8ec83e1e16ec37d171098bb","sponsorName":"Huilan Zhang"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"Chloroquine","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"3","preferredName":"Chloroquine","primaryCompletionDate":"Thu, 30 Apr 2020 00:00:00 GMT","productId":138,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":"Wuhan Shi","country":"CHN","lat":30.5130043,"lng":114.4202756,"locationId":"50977af8dd7ad88a4526eb24a85fea551a53cc10","name":"Tongji Hospital Affiliated To Huazhong University Of Science And Technology","state":"Hubei Sheng"}],"sources":["https://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029935","https://en.wikipedia.org/wiki/Chloroquine#Medical_uses"],"sponsors":[{"sponsorId":"617b848747bc14a2a9fc203852ab5529565cab2a","sponsorName":"Hwa Mei Hospital"},{"sponsorId":"ac1ac20ca0b9ec951428fe364c421040f1f4829b","sponsorName":"University of Chinese Academy of Sciences"}],"status":"Ongoing","studyCompletionDate":"Mon, 01 Jun 2020 00:00:00 GMT","studyStartDate":"Tue, 04 Feb 2020 00:00:00 GMT","therapeuticApproach":"Antimalarial drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"XueBiJing","chemicalName":"XueBiJing","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 1","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"SKIPPED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"SKIPPED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"SKIPPED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 18 Feb 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Other","notes":"Traditional Chinese Medicine,5-herb combination","numSites":"1","otherPartners":"N/A","phase":"1","preferredName":"XueBiJing","primaryCompletionDate":"","productId":139,"registryLink":"http://www.chictr.org.cn/showprojen.aspx?proj=50306","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Jingzhou Shi","country":"CHN","lat":30.30907899999999,"lng":112.259189,"locationId":"602977d03fc479b8a057902def940adb39c20bc2","name":"Jingzhou First People's Hospital","state":"Hubei Sheng"}],"sources":["http://www.chictr.org.cn/showprojen.aspx?proj=50306","https://reader.elsevier.com/reader/sd/pii/S0254627211600113?token=59E71863CD81881AD517D44BB2CFB5E0524ACEE75F7729C3AEEE19F30F987FC7F744F2B5CEC187F763578C32AA680098","https://clinicaltrials.gov/ct2/show/study/NCT03475732","https://clinicaltrials.gov/ct2/show/NCT03475732"],"sponsors":[{"sponsorId":"de88121edbf4cca2b6df882b71a3a79995714b11","sponsorName":"Jingzhou First Peoples Hospital"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Tue, 18 Feb 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"Methylprednisolone","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"SKIPPED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"SKIPPED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"SKIPPED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 26 Jan 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"Zhongda Hospital,Renmin Hospital of Wuhan University","phase":"","preferredName":"Methylprednisolone","primaryCompletionDate":"","productId":140,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts","https://www.drugbank.ca/drugs/DB00959"],"sponsors":[{"sponsorId":"10172e384c8eaa0f469f305f6d2b50b0eabb14f5","sponsorName":"Peking Union Medical College Hospital"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"Favipiravir,Tocilizumab","conditionOrDisease":"COVID-19","contact":[{"email":"john131212@sina.com","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"SKIPPED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"SKIPPED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"SKIPPED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 08 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Other","notes":"Favipiravir - Small molecule,Tocilizumab - protein based,Anti-viral and monoclonal antibody combination","numSites":"9","otherPartners":"N/A","phase":"0","preferredName":"Favipiravir,Tocilizumab","primaryCompletionDate":"Fri, 01 May 2020 00:00:00 GMT","productId":141,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04310228","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Hefei Shi","country":"CHN","lat":31.84583099999999,"lng":117.268745,"locationId":"6b00ace8aaf4ec15bf4a4cfe810bc46e37e8204d","name":"Anhui Medical University Affiliated First Hospital","state":"Anhui Sheng"},{"city":null,"country":"CHN","lat":39.931765,"lng":116.380416,"locationId":"30e1fce9ea5f62906ce192292ef85c3abd8eba57","name":"Peking University First Hospital","state":"Beijing Shi"},{"city":"Wuhan Shi","country":"CHN","lat":30.599041,"lng":114.301165,"locationId":"fc8e1369ac51d626dd722f639602ebe23743c6cf","name":"Cancer Hospital Union Hospital Tongji Medical College Huazhong University Of Science And Technology","state":"Hubei Sheng"},{"city":"Ezhou Shi","country":"CHN","lat":30.3987825,"lng":114.8819099,"locationId":"781545c3ef297963c068b569838ebe72fbfa9e95","name":"Ezhou Central Hospital","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.552985,"lng":114.353743,"locationId":"88da3493c98e88b151b07b78a2fa750efa9240d2","name":"Huoshenshan Hospital Of Wuhan","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.6668794,"lng":114.2868443,"locationId":"a20793e0cc82c32ca763dd1a58bd3bf455177c44","name":"Jinyintan Hospital Of Wuhan","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.5130043,"lng":114.4202756,"locationId":"2dd2f2f1308a8891dc6962e636d21f6f54f601e2","name":"Tongji Hospital Of Huazhong University Of Science And Technology","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.4917469,"lng":114.1732702,"locationId":"68444ff2891c2f85f5a4b3e82268df65202c82e4","name":"West Hospital Union Hospital Huazhong University Of Science And Technology","state":"Hubei Sheng"},{"city":"Boston","country":"USA","lat":42.3159679,"lng":-71.1119168,"locationId":"871718f4767ad43ce823b49c422273e58d761018","name":"Wuhan Pulmonary Hospital","state":"MA"},{"city":"Wuhan Shi","country":"CHN","lat":30.552985,"lng":114.353743,"locationId":"5b149e6031cabfb9a2fcad42f9e8a8b994e61fde","name":"Zhongnan Hospital Of Wuhan University","state":"Hubei Sheng"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1","https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts","https://www.drugbank.ca/drugs/DB12466; https://www.drugbank.ca/drugs/DB06273","https://www.drugbank.ca/drugs/DB06273 ; https://www.drugbank.ca/unearth/q?utf8=%E2%9C%93&query=favipravir&searcher=drugs"],"sponsors":[{"sponsorId":"e3b26f3f63704a702040cad0b3d5f4ff56f7360a","sponsorName":"Peking University First Hospital"}],"status":"Ongoing","studyCompletionDate":"Fri, 01 May 2020 00:00:00 GMT","studyStartDate":"Sun, 08 Mar 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Azvudine","chemicalName":"RO-0622","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 0","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"SKIPPED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"SKIPPED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"SKIPPED"}],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"N/A","phase":"0","preferredName":"RO-0622","primaryCompletionDate":"Thu, 16 Apr 2020 00:00:00 GMT","productId":142,"registryLink":"http://www.chictr.org.cn/showprojen.aspx?proj=49532","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Xinyang","country":"CHN","lat":32.014808,"lng":114.906546,"locationId":"20addd0b5ed3005bfab434bca8f55c09145ee325","name":"People's Hospital Of Guangshan County","state":null}],"sources":["https://en.wikipedia.org/wiki/Azvudine","http://www.chictr.org.cn/showprojen.aspx?proj=49532","https://pubchem.ncbi.nlm.nih.gov/compound/Azvudine#section=Structures","https://www.ncbi.nlm.nih.gov/pubmed/25144636"],"sponsors":[{"sponsorId":"9b38a8623a43ac6813f56ef17b83f2ca2a213237","sponsorName":"Peoples Hospital of Guangshan County"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Sun, 16 Feb 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Noscovid","chemicalName":"Noscapine","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Iran","Islamic Republic of"],"countryCodes":["IRN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"SKIPPED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"SKIPPED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"SKIPPED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 17 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"N/A","phase":"2","preferredName":"Noscapine","primaryCompletionDate":"","productId":143,"registryLink":"https://en.irct.ir/trial/46576","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Qazvin","country":"IRN","lat":36.3236215,"lng":49.9975763,"locationId":"d5874ccbd2b33860e24c980c235f8ffefa55b4f0","name":"Velayat Hospital","state":null}],"sources":["http://ethics.research.ac.ir/ProposalViewEn.php?id=125991","https://www.irct.ir/trial/46576","https://www.drugbank.ca/drugs/DB06174","https://pubchem.ncbi.nlm.nih.gov/compound/Noscapine","http://en.qums.ac.ir/Portal/home/?124884/Velayat-Hospital"],"sponsors":[{"sponsorId":"2c3dce78e2656e4bdf014ec95f1f244efcb85b05","sponsorName":"Qazvin University of Medical Sciences"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Fri, 17 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Avastin","chemicalName":"Bevacizumab","conditionOrDisease":"COVID-19","contact":[{"email":"jiaojiaopang@126.com","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"SKIPPED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"SKIPPED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"SKIPPED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"1","otherPartners":"Renmin Hospital of Wuhan University,Ialy Moriggia Pelascini Gravedona Hospital S.p.A,Wuhan University,Jiangbei Union Hospital of Huazhong University of Science and Technology,Shandong Provincial Chest Hospital","phase":"","preferredName":"Bevacizumab","primaryCompletionDate":"Tue, 30 Jun 2020 00:00:00 GMT","productId":144,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04305106","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Jinan Shi","country":"CHN","lat":36.655439,"lng":117.018034,"locationId":"7ad1f7f1605c75ee2323c035109b14dea67ea8a2","name":"Qilu Hospital Of Shandong University","state":"Shandong Sheng"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04305106","https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/bevacizumab","https://www.drugbank.ca/drugs/DB00112","https://www.drugs.com/history/avastin.html"],"sponsors":[{"sponsorId":"5097a8114e431ac8ebcbd82cdf94884e315a5cba","sponsorName":"Qilu Hospital of Shandong University"},{"sponsorId":"1cc9d3179b66670e4a36a366afbbe7179bae5329","sponsorName":"Genentech Inc"},{"sponsorId":"7acdde062bf6d75cd4f60fb9c8d60bb3caa89d9a","sponsorName":"Roche"}],"status":"Ongoing","studyCompletionDate":"Fri, 31 Jul 2020 00:00:00 GMT","studyStartDate":"Tue, 17 Mar 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"Leflunomide","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"","milestones":[],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Leflunomide","primaryCompletionDate":"","productId":145,"registryLink":null,"repurposed":"","siteLocations":[],"sources":[""],"sponsors":[{"sponsorId":"14a2146233138c07a64e0baef6cc949f64c7af25","sponsorName":"Renmin Hospital of Wuhan University"},{"sponsorId":"b28e8b218d5a198cef37e9f446f38a9e8846175b","sponsorName":"University of Chicago"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Bisolvon","chemicalName":"Bromhexine Hydrochloride","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"SKIPPED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"SKIPPED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"SKIPPED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"SKIPPED"}],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"WanBangDe Pharmaceutical Group Co. Ltd.","phase":"","preferredName":"Bromhexine Hydrochloride","primaryCompletionDate":"Sun, 10 May 2020 00:00:00 GMT","productId":146,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04273763","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Wenzhou Shi","country":"CHN","lat":28.006211,"lng":120.67225,"locationId":"d9ad82775c579e5d84b4e187b0165121be0ac668","name":"The Second Affiliated Hospital Of Wenzhou Medical University","state":"Zhejiang Sheng"}],"sources":["https://www.clinicaltrials.gov/ct2/results?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=","https://www.drugbank.ca/drugs/DB09019","https://www.drugsbanks.com/bisolvon/","https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1"],"sponsors":[{"sponsorId":"87b385be246abb1a4c3e0d7f6bbe23e811156173","sponsorName":"Second Affiliated Hospital of Wenzhou Medical University"}],"status":"Ongoing","studyCompletionDate":"Mon, 01 Jun 2020 00:00:00 GMT","studyStartDate":"Sun, 16 Feb 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Avigan","chemicalName":"Interferon beta,Favipiravir","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Iran","Islamic Republic of"],"countryCodes":["IRN"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 17 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 27 Mar 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Used to treat Influenza","numSites":"1","otherPartners":"ChemRar,RDIF","phase":"3","preferredName":"Interferon beta,Favipiravir","primaryCompletionDate":"","productId":147,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":null,"country":"JPN","lat":36.204824,"lng":138.252924,"locationId":"7c48e99a2763d3c66e0fb9569fcec406208c28de","name":"Japan","state":null}],"sources":["https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug","https://www.drugbank.ca/drugs/DB12466","https://www.ncbi.nlm.nih.gov/pubmed/25333492","https://www.thepharmaletter.com/article/russia-s-rdif-backs-chemrar-for-the-production-of-favipiravir-against-covid-19","https://www.clinicaltrialsarena.com/news/fujifilm-avigan-covid-19-trial-japan/"],"sponsors":[{"sponsorId":"b58861dc99cd85f531c98907e3577fe93964d0f3","sponsorName":"Shahid Beheshti University of Medical Sciences"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Prezcobix","chemicalName":"Darunavir,cibicistat","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"008602137990333 ext 3222","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Treat pneumonia","numSites":"1","otherPartners":"Johnson and Johnson","phase":"3","preferredName":"Darunavir,cibicistat","primaryCompletionDate":"Mon, 31 Aug 2020 00:00:00 GMT","productId":148,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":"Shanghai","country":"CHN","lat":31.230416,"lng":121.473701,"locationId":"c8d0e4765be05702c7f1714bfa69f99f5cc2519f","name":"Shanghai: China","state":"Shanghai"}],"sources":["https://aidsinfo.nih.gov/drugs/397/darunavir/0/patient","https://www.drugbank.ca/drugs/DB01264","https://www.europeanpharmaceuticalreview.com/news/111977/johnson-johnson-launch-response-to-coronavirus/","https://www.natureindex.com/institution-outputs/china/shanghai-public-health-clinical-center-fudan-university/52cf526a140ba04763000006","https://clinicaltrials.gov/ct2/show/NCT04252274"],"sponsors":[{"sponsorId":"78190ce5e186ac701c260b91aa1008a6c4b862de","sponsorName":"Shanghai Public Health Clinical Center"},{"sponsorId":"0ff0405e4544cd120687a915ea369ae1dac78dca","sponsorName":"Johnsons  Johnson"},{"sponsorId":"667987d4de01dd23efc5563684db4e2117b5d910","sponsorName":"Janssen"},{"sponsorId":"8cd26a383793b281ef40085df75c92792db1b43d","sponsorName":"Gilead"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Thu, 30 Jan 2020 00:00:00 GMT","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"PD1,thymosin,Camrelizumab","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Cancer therapy","numSites":"","otherPartners":"NIHR","phase":"2","preferredName":"PD1,thymosin,Camrelizumab","primaryCompletionDate":"Mon, 20 Apr 2020 00:00:00 GMT","productId":149,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.cebm.net/covid-19/registered-trials-and-analysis/","https://www.frontiersin.org/articles/10.3389/fimmu.2019.02298/full","https://www.frontiersin.org/articles/10.3389/fonc.2019.00873/full","https://jhoonline.biomedcentral.com/articles/10.1186/s13045-019-0779-5","https://www.seu.edu.cn/english/","https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0636-7","https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20032020v3-posting.pdf"],"sponsors":[{"sponsorId":"9ba50a6c509f14bcba0e2116a0a021e05e985ae6","sponsorName":"Southeast University  China"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"Meplazumab","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 03 Feb 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Treat pneumonia","numSites":"1","otherPartners":"National Science and Technology Major Project","phase":"2","preferredName":"Meplazumab","primaryCompletionDate":"Mon, 10 Feb 2020 00:00:00 GMT","productId":150,"registryLink":null,"repurposed":"New","siteLocations":[{"city":"Huizhou","country":"CHN","lat":22.94223,"lng":114.29824,"locationId":"8eb22bb1cc8389f3a6a880540193a2db9adcde38","name":"Tang Du: China","state":"Guangdong Province"}],"sources":["https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf","https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1"],"sponsors":[{"sponsorId":"90580332dd2c5e7458dc3f0dc0ba01024427917e","sponsorName":"TangDu Hospital"},{"sponsorId":"2453464d7d85243db737220519ad6c684bfec004","sponsorName":"Jingsu Pacific Meinuoke Biopharmaceutical Co"},{"sponsorId":"fd9f01621385a9d2c18ef56159f02c2acd10e0e0","sponsorName":"Fourth Military Medical University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 03 Feb 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Gilenya","chemicalName":"Fingolimod","conditionOrDisease":"COVID-19","contact":[{"email":"wanjinchen75@fjmu.edu.cn","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 22 Feb 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Treats MS","numSites":"1","otherPartners":"NIHR","phase":"2","preferredName":"Fingolimod","primaryCompletionDate":"Wed, 01 Jul 2020 00:00:00 GMT","productId":151,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":"Fuzhou","country":"CHN","lat":26.074478,"lng":119.296482,"locationId":"6e82c0bcc6b76f4feca5249787b42d5d6119a135","name":"Fuzhou: China","state":"Fujian"}],"sources":["https://www.drugbank.ca/drugs/DB08868","https://www.ncbi.nlm.nih.gov/pubmed/17785617","http://www.io.nihr.ac.uk/wp-content/uploads/migrated_new/11115-Fingolimod-oral.pdf","https://en.fjmu.edu.cn/","https://clinicaltrials.gov/ct2/show/NCT04280588"],"sponsors":[{"sponsorId":"beea472f9414420dd2ba494bd1b0dbf60d0df7a7","sponsorName":"The First Affiliated Hospital of Fujian Medical University"},{"sponsorId":"a47ed0af8e79c0d5e04834a88fa5c0fa3a019663","sponsorName":"Novartis AG"}],"status":"Ongoing","studyCompletionDate":"Wed, 01 Jul 2020 00:00:00 GMT","studyStartDate":"Sat, 22 Feb 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Avigan","chemicalName":"ASCO9F,ritonavir,favipiravir","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"HIV protease inhibitor","numSites":"1","otherPartners":"Self funding,National Natural Science Foundation of China","phase":"2","preferredName":"ASCO9F,ritonavir,favipiravir","primaryCompletionDate":"","productId":152,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":null,"country":"CHN","lat":35.86166,"lng":104.195397,"locationId":"ae700f64d3786e101873fa8610118478f22997e6","name":"China","state":null}],"sources":["https://www.ncbi.nlm.nih.gov/pubmed/32147628","https://www.europeanpharmaceuticalreview.com/news/116491/positive-results-from-initial-lopinavir-ritonavir-covid-19-clinical-trial/","https://www.drugbank.ca/drugs/DB00503","http://www.chictr.org.cn/sourceofspendsprojen.aspx","https://english.tjh.com.cn/","https://www.sciencedaily.com/releases/2020/04/200406120130.htm"],"sponsors":[{"sponsorId":"5b5b8fac5162ad1d88a07970c29180291cab2655","sponsorName":"Tongji Hospital"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 06 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"Nitric Oxide (g)","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Sun, 01 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 01 Mar 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":"Sat, 01 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"2","otherPartners":"Private","phase":"2","preferredName":"Nitric Oxide (g)","primaryCompletionDate":"Mon, 01 Mar 2021 00:00:00 GMT","productId":153,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":null,"country":"CHN","lat":35.86166,"lng":104.195397,"locationId":"230adf05f544f3ab0b986d79dabb87b379a2b750","name":"China","state":null}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04290858","https://www.marketwatch.com/press-release/nu-med-plus-closely-monitoring-outcomes-on-two-new-human-clinical-trials-using-inhaled-nitric-oxide-in-treatment-of-covid-19-2020-03-25?mod=mw_quote_news","https://aospine.aofoundation.org/education/fellowship/spine-centers-asia-pacific/xijing-hospital","https://www.streetwisereports.com/article/2020/03/26/inhaled-nitric-oxide-being-tested-as-covid-19-treatment.html"],"sponsors":[{"sponsorId":"c8523547da03b9b3e757de3bc960672aa18072e3","sponsorName":"Xijing Hospital"}],"status":"Ongoing","studyCompletionDate":"Tue, 01 Feb 2022 00:00:00 GMT","studyStartDate":"Sun, 01 Mar 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"Vitamin C,Sodium Ascorbate","conditionOrDisease":"COVID-19","contact":[{"email":"pengzy5@hotmail.com","name":null,"notes":"","phone":"8618672396028","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 14 Feb 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":"Sat, 01 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Prevent cytokine induced damage to lungs","numSites":"1","otherPartners":"","phase":"2","preferredName":"Vitamin C,Sodium Ascorbate","primaryCompletionDate":"Wed, 30 Sep 2020 00:00:00 GMT","productId":154,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":"Wuhan Shi","country":"CHN","lat":30.552985,"lng":114.353743,"locationId":"488a995bcbf4738667daa762cc9c91f26b30965a","name":"Zhongnan Hospital Of Wuhan University","state":"Hubei Sheng"},{"city":null,"country":"CHN","lat":35.86166,"lng":104.195397,"locationId":"a878a5210a026b4dc84a3c3944e80eac7baa88da","name":"China","state":null}],"sources":["https://www.drugbank.ca/drugs/DB14482","https://www.medicinenet.com/script/main/art.asp?articlekey=228745","https://lpi.oregonstate.edu/mic/vitamins/vitamin-C","https://www.researchgate.net/scientific-contributions/2136361683_Zhiyong_Peng","https://clinicaltrials.gov/ct2/show/NCT04264533"],"sponsors":[{"sponsorId":"4aa837dcf498f3cc77b727f1990dd1d645311b0b","sponsorName":"ZhiYong Peng"}],"status":"Ongoing","studyCompletionDate":"Wed, 30 Sep 2020 00:00:00 GMT","studyStartDate":"Fri, 14 Feb 2020 00:00:00 GMT","therapeuticApproach":"Antioxidant","trialId":""},{"acceptsHealthySubjects":"No","brandName":"CYNK-001","chemicalName":"antibody","conditionOrDisease":"COVID-19","contact":[{"email":"CYNK-001-COVID-19@idri.org","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Mon, 30 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Thu, 02 Apr 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 02 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":"Wed, 29 Jan 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"","numSites":"2","otherPartners":"Sorrento Therapeutics Inc.","phase":"2","preferredName":"antibody","primaryCompletionDate":"","productId":155,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04365101","repurposed":"New","siteLocations":[{"city":"Hackensack","country":"USA","lat":40.8840335,"lng":-74.0565417,"locationId":"e412f537205f431d630ce1b6ccbb14166351e224","name":"Hackensack University Medical Center","state":"NJ"},{"city":"Tacoma","country":"USA","lat":47.29469539999999,"lng":-122.3812852,"locationId":"e72eecf1f5d8d7794e598de738e881eaea6a3074","name":"Multicare Health System","state":"WA"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04365101"],"sponsors":[{"sponsorId":"4f61c20da897e770e987eca3fb88439618947bee","sponsorName":"Celularity Incorporated"},{"sponsorId":"d4f038c1fd0e4c52d93147fc334849bc67394496","sponsorName":"Sorrento Therapeutics"},{"sponsorId":"766438974fbc280cb2aed1baca9444d8e3a9f66c","sponsorName":"IDRI"},{"sponsorId":"edbbafc744cc960bef0e37292940fec196315898","sponsorName":"Lung Biotechnology PBC"}],"status":"Ongoing","studyCompletionDate":"Wed, 30 Jun 2021 00:00:00 GMT","studyStartDate":"Wed, 13 May 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"ACE-MAB\u2122,STI-4920,CMAB020","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Tue, 24 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"bispecific ACE-MAB fusion protein","numSites":"","otherPartners":"Sorrento Therapeutics Inc.,Mabpharm Limited","phase":"","preferredName":"ACE-MAB\u2122,STI-4920,CMAB020","primaryCompletionDate":"","productId":156,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.biospace.com/article/releases/sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19/"],"sponsors":[{"sponsorId":"5fc64f72797f9967b8f89cf58d0d24a43168cffc","sponsorName":"Sorrento Therapeutics Inc"},{"sponsorId":"c9c165926c1b9b7b8832e8afef24f2834d6e595c","sponsorName":"Mabpharm Limited"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Anti-Corona Immunoglobulin (IgG)","chemicalName":"antibody","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Israel"],"countryCodes":["ISR"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 11 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Other","notes":"plasma of recovered people w ab is used in patients","numSites":"","otherPartners":"Kamada","phase":"","preferredName":"antibody","primaryCompletionDate":"","productId":158,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/"],"sponsors":[{"sponsorId":"5929da2b33c19978e9dd493734a7e92160428081","sponsorName":"Kamada Ltd"},{"sponsorId":"3e412b7cf7607d2c373441c8651e88306e8012b0","sponsorName":"Kedrion Biopharma Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"antibody","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Thu, 19 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Centivax","phase":"","preferredName":"antibody","primaryCompletionDate":"","productId":159,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.distributedbio.com/covid19"],"sponsors":[{"sponsorId":"06e3c85a544975e5dfcec88f45b51e3fdf635c59","sponsorName":"Centivax"},{"sponsorId":"bcb8d1f52e45cce0b2413d1c2485755444633dbb","sponsorName":"Swiftscale Biologics"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Human mAb 47D11","chemicalName":"antibody","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Netherlands"],"countryCodes":["NLD"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Mon, 23 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":"Tue, 10 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Erasmus MC","phase":"","preferredName":"antibody","primaryCompletionDate":"","productId":160,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.nature.com/articles/s41467-020-16256-y"],"sponsors":[{"sponsorId":"fe367a0d5ee946a16335321f006255c41d4c8e7b","sponsorName":"Erasmus MC"},{"sponsorId":"b80905e2bb739693e1253446c2e0849e97ab16dd","sponsorName":"Utrecht University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"darunavir,cobicistat,CYP3A inhibitor","conditionOrDisease":"COVID-19","contact":[{"email":"luhongzhou@fudan.edu.cn","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Thu, 30 Jan 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"1","otherPartners":"Janssen Pharmaceutical Companies,Shanghai Public Health Clinical Center","phase":"3","preferredName":"darunavir,cobicistat,CYP3A inhibitor","primaryCompletionDate":"Mon, 31 Aug 2020 00:00:00 GMT","productId":161,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04252274","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":null,"country":"CHN","lat":30.791749,"lng":121.341627,"locationId":"51b8e7333ddd13838c2f774f7821d355848b743d","name":"Shanghai Public Health Clinical Center","state":"Shanghai Shi"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2"],"sponsors":[{"sponsorId":"78190ce5e186ac701c260b91aa1008a6c4b862de","sponsorName":"Shanghai Public Health Clinical Center"},{"sponsorId":"7745b01b52b6f1cf88a706afd1b056e344c46e24","sponsorName":"Zhongnan Hospital of Wuhan University"},{"sponsorId":"79c2245b2e99e2ee02f6cc48aaefe048e67e29e0","sponsorName":"Johnson  Johnson"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Fri, 10 Jan 2020 00:00:00 GMT","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Arbidol","chemicalName":"Umifenovir","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 4","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Fri, 07 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Small molecule","notes":"Membrane fusion inhibitor","numSites":"1","otherPartners":"China\u2019s Ruijin Hospital","phase":"4","preferredName":"Umifenovir","primaryCompletionDate":"Wed, 22 Apr 2020 00:00:00 GMT","productId":162,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04350684","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Tehran","country":"IRN","lat":35.8001144,"lng":51.3980673,"locationId":"3f06479d2799fe85eb96f818a6dc12d9b2d1fa5a","name":"Loghman Hakim Hospital","state":"Tehran Province"}],"sources":["https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata","https://clinicaltrials.gov/ct2/show/NCT04350684?term=Umifenovir&draw=2&rank=1"],"sponsors":[{"sponsorId":"deef1b7181395ef02ad3b7cd894fb64716ba0215","sponsorName":"Pharmstandard"}],"status":"Ongoing","studyCompletionDate":"Fri, 24 Apr 2020 00:00:00 GMT","studyStartDate":"Wed, 15 Apr 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Xofluza","chemicalName":"baloxavir marboxil","conditionOrDisease":"COVID-19","contact":[{"email":"qiuyq@zju.edu.cn","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 02 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"polymerase acidic endonuclease inhibitor","numSites":"1","otherPartners":"The First Hospital Affiliated to Zhejiang University's Medical School,Roche","phase":"1","preferredName":"baloxavir marboxil","primaryCompletionDate":"Sun, 31 May 2020 00:00:00 GMT","productId":163,"registryLink":"http://www.chictr.org.cn/showprojen.aspx?proj=49013","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Hangzhou","country":"CHN","lat":30.2558917,"lng":120.1780985,"locationId":"848209ff7a5d35d40e699f2bbd5cf4078f80c306","name":"The First Affiliated Hospital Zhejiang University School Of Medicine","state":"Zhejiang"}],"sources":["http://www.chictr.org.cn/showprojen.aspx?proj=49013"],"sponsors":[{"sponsorId":"7acdde062bf6d75cd4f60fb9c8d60bb3caa89d9a","sponsorName":"Roche"},{"sponsorId":"50a9bfad2cbb96596fb34d34cdfbd349c1a4fbbc","sponsorName":"The First Hospital Affiliated to Zhejiang Universitys Medical School"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Thu, 02 Apr 2020 00:00:00 GMT","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"","brandName":"PLX cell product","chemicalName":"placenta-based cells","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Fri, 08 May 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 30 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 08 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":"Fri, 13 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"placenta-based cell therapy","numSites":"","otherPartners":"Pluristem Therapeutics,BIH Center for Regenerative Therapy,Berlin Center for Advanced Therapies","phase":"","preferredName":"placenta-based cells","primaryCompletionDate":"","productId":164,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf","https://www.pluristem.com/wp-content/uploads/2020/05/FDA-Clearance-COVID-19-FINAL.pdf"],"sponsors":[{"sponsorId":"2b9a512817547dd6eca9ae64392478de4df5ea55","sponsorName":"Pluristem Therapeutics"},{"sponsorId":"14df6ecd68ad3a991782c40f386042236234019a","sponsorName":"BIH Center for Regenerative Therapy"},{"sponsorId":"3c023d5d2630d83ff1f51fee219f0e0dec252a08","sponsorName":"Berlin Center for Advanced Therapies"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"Thalidomide","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 20 Feb 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"An approved drug with noted immunosuppressive and anti-angiogenic activity,used for a number of immunological and inflammatory disorders,clinical trials aim to see if these properties of thalidomide can be used to prevent or treat COVID-19 induced lung injury instead of functioning as a direct antiviral,note that there is a second study with the same sponsors and utilizing thalidomide as well - but that includes the use of low does hormones as well and only enrolls 40 participants,discovery start - NDA approval - and on the market are completed with respect to thalidomide itself without taking into account its prospective use in treating COVID-19","numSites":"","otherPartners":"Second Affliated Hospital of Wenzhou Medical University,Wenzou Central Hospital","phase":"2","preferredName":"Thalidomide","primaryCompletionDate":"Sat, 30 May 2020 00:00:00 GMT","productId":165,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04273529,https://clinicaltrials.gov/ct2/show/NCT04273581","repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1","https://www.drugbank.ca/drugs/DB01041 https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04273581?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=2","https://www.drugbank.ca/drugs/DB01041","https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1","https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020785s000_ThalidomideTOC.cfm","https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1 https://clinicaltrials.gov/ct2/show/NCT04273581?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=2","https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts","https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts https://clinicaltrials.gov/ct2/show/NCT04273581?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=2"],"sponsors":[{"sponsorId":"c34399f07cbf1f511eb20748b32ec47045ae18f5","sponsorName":"Celgene Corp"},{"sponsorId":"4337c2a735b1c82b0b730abbf6b584dd7f97e512","sponsorName":"The First Affiliated Hospital of Wenzhou Medical University"}],"status":"Ongoing","studyCompletionDate":"Tue, 30 Jun 2020 00:00:00 GMT","studyStartDate":"Thu, 20 Feb 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"ARB,Cozaar","chemicalName":"Losartan","conditionOrDisease":"COVID-19","contact":[{"email":"Covid19trial@umn.edu","name":null,"notes":"","phone":"612-624-4373","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 02 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Approved drug used to treat hypertension by functioning as an angiotensin II receptor blocker,study intends to track COVID-19 patients' risk status in the ICU using the Sequential Organ Failure Assessment (SOFA) respiratory score following treatment with losartan or a placebo","numSites":"3","otherPartners":"Bill and Melinda Gates Foundation","phase":"2","preferredName":"Losartan","primaryCompletionDate":"Thu, 01 Apr 2021 00:00:00 GMT","productId":166,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04311177,https://clinicaltrials.gov/ct2/show/NCT04312009","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Minneapolis","country":"USA","lat":44.9722301,"lng":-93.2615932,"locationId":"78cdc6a49e85e8d6b469cc449476413ff5717717","name":"Hennepin County Medical Center","state":"MN"},{"city":"Minneapolis","country":"USA","lat":44.9668439,"lng":-93.236916,"locationId":"253e3ba655647d9530fc9d763f43f86eec9f0391","name":"M Health Fairview University Of Minnesota Medical Center","state":"MN"},{"city":"Minneapolis","country":"USA","lat":44.97399,"lng":-93.2277285,"locationId":"154076c54d4d805cdd6d24fea3abbf5e380284fc","name":"University Of Minnesota","state":"MN"},{"city":"Rochester","country":"USA","lat":44.0660148,"lng":-92.5260912,"locationId":"69e823296a159031df2c2f69548faeca2d6b75a4","name":"Mayo Clinic Health System","state":"MN"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts","https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1","https://www.drugbank.ca/drugs/DB00678 https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts","https://www.drugbank.ca/drugs/DB00678","https://clinicaltrials.gov/ct2/show/NCT04311177?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1","https://clinicaltrials.gov/ct2/show/NCT04311177?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts"],"sponsors":[{"sponsorId":"d49e1350f4c21eef623eb4e22b9709b13ac08f82","sponsorName":"University of Minnesota"}],"status":"Ongoing","studyCompletionDate":"Thu, 01 Apr 2021 00:00:00 GMT","studyStartDate":"Thu, 09 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"sildenafil citrate","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 09 Feb 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Approved drug used to treat pulmonary arterial hypertension,angina,and erectile dysfunction,study evaluates rate of disease remission,rate of entering the critical stage,and time of entering the critical stage after treatment with sildenafil citrate","numSites":"1","otherPartners":"","phase":"3","preferredName":"sildenafil citrate","primaryCompletionDate":"Sun, 01 Mar 2020 00:00:00 GMT","productId":167,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04304313","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Wuhan","country":"CHN","lat":30.592849,"lng":114.305539,"locationId":"a5f29052f68003db9f62f30ea64410bd50f741ed","name":"Wuhan","state":"Hubei"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1","https://www.drugbank.ca/drugs/DB00203 https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts","https://www.drugbank.ca/drugs/DB00203","https://www.drugbank.ca/drugs/DB00203#reference-A175732","https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts"],"sponsors":[{"sponsorId":"5b5b8fac5162ad1d88a07970c29180291cab2655","sponsorName":"Tongji Hospital"}],"status":"Ongoing","studyCompletionDate":"Mon, 09 Nov 2020 00:00:00 GMT","studyStartDate":"Sun, 09 Feb 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"a lipic acid","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"","milestones":[],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"a lipic acid","primaryCompletionDate":"","productId":168,"registryLink":null,"repurposed":"","siteLocations":[],"sources":[""],"sponsors":[{"sponsorId":"d8a6fb8782589eff1784a987131a3510fd1991ff","sponsorName":"Zhongshan Hospital"},{"sponsorId":"4567098e44fc907783878b149c6d70d1f14aec40","sponsorName":"Fudan University"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"Chloroquine phosphate","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"","milestones":[],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Chloroquine phosphate","primaryCompletionDate":"","productId":169,"registryLink":null,"repurposed":"","siteLocations":[],"sources":[""],"sponsors":[{"sponsorId":"2d7ffefe148247749f6402c5edc286a5095cc88a","sponsorName":"Jingzhou Central Hospital"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"Ebastine,Lopinavir,Interferon a","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"","milestones":[],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Ebastine,Lopinavir,Interferon a","primaryCompletionDate":"","productId":170,"registryLink":null,"repurposed":"","siteLocations":[],"sources":[""],"sponsors":[{"sponsorId":"6a61efee7bdf9baf309997f1ccf652ee02887c52","sponsorName":"Wuhan Red Cross Hospital"},{"sponsorId":"1be6e3f3520226675b831cc738fab10a9812c4fd","sponsorName":"Minanyang Central Hospital"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"Danoprevir,Ritonavir,Interferon","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 4","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Danoprevir is an oral hepatitis C virus protease inhibitor approved in China in June 2018,used in a phase 4 trial that began 02/17/2020 to observe its effects on the rate of composite adverse outcomes and time to recovery among other measures","numSites":"","otherPartners":"Ascletis Pharmaceutials Co. Ltd.","phase":"","preferredName":"Danoprevir,Ritonavir,Interferon","primaryCompletionDate":"","productId":171,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1"],"sponsors":[{"sponsorId":"bdb545b6c04a880d9d0382f48b816fee837c1330","sponsorName":"The Ninth Hospital of Nanchang"},{"sponsorId":"e1bafffd3c4ccdf8eaf5841a8838a032654edc76","sponsorName":"Ascletis Pharmaceuticals"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Allocetra","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Israel"],"countryCodes":["ISR"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 07 May 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"Undergoing multi-center investigator-initiated phase 2 trial as of May 7 but no entry on clinicaltrials,drug aims to balance immune response and prevent cytokine storm","numSites":"","otherPartners":"Israel Innovation Authority","phase":"","preferredName":"Allocetra","primaryCompletionDate":"","productId":227,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.enlivex.com/investor-relations/#b2iLibScrollTo","https://www.enlivex.com/allocetra/","https://www.enlivex.com/investor-relations/#b2iLibScrollTo https://www.enlivex.com/allocetra/"],"sponsors":[{"sponsorId":"35f03ea5c43e45df3a66c005c91958a6ddad2bc3","sponsorName":"Enlivex Therapeutics Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"Mesenchymal Stem Cells","conditionOrDisease":"COVID-19","contact":[{"email":"447822853@qq.com","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 01 Feb 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"MSCs have been shown to exert antiinflammatory and immunoregulatory functions - promote regeneration of damaged tissues - and inhibit tissue fibrosis,trial aims to explore MSC's potential to treat COVID-19 patients","numSites":"1","otherPartners":"Puren Hospital Affliated to Wuhan University of Science and Technology,Shanghai University,Qingdao Co-orient Watson Biotechnology group co. LTD,Basic Medical Sciences - Chinese Academy of Medical Sciences","phase":"1","preferredName":"Mesenchymal Stem Cells","primaryCompletionDate":"Tue, 30 Jun 2020 00:00:00 GMT","productId":172,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04339660","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Wuhan","country":"CHN","lat":30.592849,"lng":114.305539,"locationId":"3fee0925b121582c3dcb7d08ad9515c111d90daf","name":"Wuhan","state":"Hubei"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2"],"sponsors":[{"sponsorId":"bf5e7b2bebc0928fcae433d07b46f1bb4fc5c3ba","sponsorName":"Chinese Academy of Medical Sciences"}],"status":"Ongoing","studyCompletionDate":"Tue, 30 Jun 2020 00:00:00 GMT","studyStartDate":"Sat, 01 Feb 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"Recombinant ACE2","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Study to investigate if there is efficacy signal that warrants a large Phase 2B trial or harm that suggests trial should not be done,study in question has a not applicable phase,status is withdrawn as of 03/17/2020 (which is why many cells were left blank)","numSites":"","otherPartners":"","phase":"","preferredName":"Recombinant ACE2","primaryCompletionDate":"","productId":173,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1","https://clinicaltrials.gov/ct2/show/NCT04287686"],"sponsors":[{"sponsorId":"ea78fbfadca996d3b3279e672883c8476ffd78cf","sponsorName":"The First Affiliated Hospital of Guangzhou Medical University"}],"status":"On Hold","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"Washed micrbiota transplantation","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Discovery","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 05 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Cell therapies","notes":"Molecule type - microbiota. The recent study on using washed microbiota transplantation (WMT) as rescue therapy in critically ill patients with AAD demonstrated the important clinical benefits and safety of WMT. Additionally the recent animal study provided direct evidence supporting that antibiotics could decrease gut microbiota and the lung stromal interferon signature and facilitate early influenza virus replication in lung epithelia. Importantly the above antibiotics caused negative effects can be reversed by fecal microbiota transplantation (FMT) which suggested that FMT might be able to induce a significant improvement in the respiratory virus infection.","numSites":"","otherPartners":"The Second Hospital of Nanjing Medical University","phase":"","preferredName":"Washed micrbiota transplantation","primaryCompletionDate":"","productId":174,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1","https://www.smartpatients.com/trials/NCT04251767","https://techstartups.com/2020/03/17/clinical-trials-for-covid-19-are-expected-to-complete-by-the-end-of-april/"],"sponsors":[{"sponsorId":"3452304684b286fca6c4db5bb90b92026a7d077b","sponsorName":"The Second Hospital of Nanjing Medical University"}],"status":"On Hold","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Persantine","chemicalName":"Dipyridamole","conditionOrDisease":"COVID-19","contact":[{"email":"zqling68@hotmail.com","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 4","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"Type - vasodilator","numSites":"6","otherPartners":"Major regional immunity cultivation project - 91742109","phase":"4","preferredName":"Dipyridamole","primaryCompletionDate":"Fri, 10 Apr 2020 00:00:00 GMT","productId":175,"registryLink":"http://www.chictr.org.cn/showprojen.aspx?proj=49864","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Guangzhou Shi","country":"CHN","lat":23.096999,"lng":113.23067,"locationId":"6aa1c43f7b28b02817f8fa8abc647db3e7e0da1a","name":"The First Affiliated Hospital Of Guangzhou Medical University","state":"Guangdong Sheng"},{"city":"Wuhan","country":"CHN","lat":30.53535699999999,"lng":114.299525,"locationId":"734e424493637663ded0f1c0420751a18f3ded10","name":"Wuhan University People's Hospital","state":null},{"city":"Wuhan Shi","country":"CHN","lat":30.599041,"lng":114.301165,"locationId":"ef3a459a70afc317bcde50c98712db37efd636fb","name":"Union Hospital Affiliated To Tongji Medical College Of Huazhong University Of Science And Technology","state":"Hubei Sheng"},{"city":"Brattleboro","country":"USA","lat":42.88607529999999,"lng":-72.56599899999999,"locationId":"a7cc3846bd55ed326aa40840afbd0083b1719d83","name":"Wuhan Huangpi District Hospital Of Traditional Chinese Medicine","state":"VT"},{"city":"Middletown","country":"USA","lat":41.5566104,"lng":-72.65690409999999,"locationId":"0f9d1423a3aa7b0e8e9059810c99a93aaed4f614","name":"Dawu County People's Hospital","state":"CT"},{"city":"Wenzhou","country":"CHN","lat":27.939761,"lng":120.695887,"locationId":"4acf032b0704e583bece920c36b4aca7e208b7be","name":"The First Affiliated Hospital Of Wenzhou Medical University","state":null}],"sources":["http://www.chictr.org.cn/showprojen.aspx?proj=49864","https://techstartups.com/2020/03/17/clinical-trials-for-covid-19-are-expected-to-complete-by-the-end-of-april/","https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1.full.pdf"],"sponsors":[{"sponsorId":"ea78fbfadca996d3b3279e672883c8476ffd78cf","sponsorName":"The First Affiliated Hospital of Guangzhou Medical University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 10 Feb 2020 00:00:00 GMT","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"Bromhexine hydrochloride,Arbidol umifenovir,Favipiravir,Interferon a2b","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"","notes":"On going recruitment","numSites":"1","otherPartners":"","phase":"","preferredName":"Bromhexine hydrochloride,Arbidol umifenovir,Favipiravir,Interferon a2b","primaryCompletionDate":"Wed, 15 Apr 2020 00:00:00 GMT","productId":176,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04273763","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Wenzhou Shi","country":"CHN","lat":28.006211,"lng":120.67225,"locationId":"761586104dc49446f2714ea9a6d0c139ed7b89b0","name":"The Second Affiliated Hospital Of Wenzhou Medical University","state":"Zhejiang Sheng"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04273763"],"sponsors":[{"sponsorId":"1a54d298d5b18d923897d81e7dd0a48df5240f94","sponsorName":"The Second Affiliated Hospital of Wenzhou Medical University"},{"sponsorId":"9b98ab2f7f83afd2e87f907a0f64dbc3220477b6","sponsorName":"WanBangDe Pharmaceutical Group"}],"status":"Ongoing","studyCompletionDate":"Thu, 30 Apr 2020 00:00:00 GMT","studyStartDate":"Sun, 16 Feb 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"Dihydroartemisinin,piperaquine,arbidol umifenovir,interferon a","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 4","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[],"moleculeType":"","notes":"Cancelled by investigator","numSites":"","otherPartners":"","phase":"","preferredName":"Dihydroartemisinin,piperaquine,arbidol umifenovir,interferon a","primaryCompletionDate":"","productId":177,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["http://www.chictr.org.cn/showprojen.aspx?proj=49915","https://techstartups.com/2020/03/17/clinical-trials-for-covid-19-are-expected-to-complete-by-the-end-of-april/"],"sponsors":[{"sponsorId":"b2025696e611deea59bde95a78322849a7a75f10","sponsorName":"The First Affiliated Hospital of Nanchang University"}],"status":"Failed","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified,Anti-malarial","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Intravenous Immunoglobulin","chemicalName":"Human Immunoglobulin (pH4)","conditionOrDisease":"Pneumonia","contact":[{"email":"litsh@263.net","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"SKIPPED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"SKIPPED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"SKIPPED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 10 Feb 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"1","otherPartners":"Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology","phase":"2","preferredName":"Human Immunoglobulin (pH4)","primaryCompletionDate":"Thu, 30 Apr 2020 00:00:00 GMT","productId":178,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04261426","repurposed":"Repurposed-Approved","siteLocations":[{"city":null,"country":"CHN","lat":39.911431,"lng":116.41481,"locationId":"f9fa92bc7e13cbc0a7a3cf51cba19991ee9202ae","name":"Peking Union Medical College Hospital","state":"Beijing Shi"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts","https://www.drugbank.ca/drugs/DB00028"],"sponsors":[{"sponsorId":"10172e384c8eaa0f469f305f6d2b50b0eabb14f5","sponsorName":"Peking Union Medical College Hospital"}],"status":"Ongoing","studyCompletionDate":"Tue, 30 Jun 2020 00:00:00 GMT","studyStartDate":"Mon, 10 Feb 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"RoActemra","chemicalName":"Tocilizumab","conditionOrDisease":"Covid-19","contact":[{"email":"john131212@sina.com","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"SKIPPED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"SKIPPED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"SKIPPED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"SKIPPED"},{"category":"clinical_development","date":"Sun, 08 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Being used in above trial","numSites":"9","otherPartners":"N/A","phase":"0","preferredName":"Tocilizumab","primaryCompletionDate":"Fri, 01 May 2020 00:00:00 GMT","productId":179,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04310228","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Hefei Shi","country":"CHN","lat":31.84583099999999,"lng":117.268745,"locationId":"60960b6a1d8f72767182c8c8d9db3ba9e635fd30","name":"Anhui Medical University Affiliated First Hospital","state":"Anhui Sheng"},{"city":null,"country":"CHN","lat":39.931765,"lng":116.380416,"locationId":"a8303c848e5030da27306b91147580d55eb8ded8","name":"Peking University First Hospital","state":"Beijing Shi"},{"city":"Wuhan Shi","country":"CHN","lat":30.599041,"lng":114.301165,"locationId":"12644b640833f1e594d1c62bd13dcfff68fb95ce","name":"Cancer Hospital Union Hospital Tongji Medical College Huazhong University Of Science And Technology","state":"Hubei Sheng"},{"city":"Ezhou Shi","country":"CHN","lat":30.3987825,"lng":114.8819099,"locationId":"61dfaf63e8ebec5368ace7b8b5b3561c624a9d15","name":"Ezhou Central Hospital","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.552985,"lng":114.353743,"locationId":"f15c4a519e2f9f36ad1cabd67f760f4e63545675","name":"Huoshenshan Hospital Of Wuhan","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.6668794,"lng":114.2868443,"locationId":"fe72e86455c79883149ee7df5225bcc6bfd969e6","name":"Jinyintan Hospital Of Wuhan","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.5130043,"lng":114.4202756,"locationId":"cdec532728317fcb14464fcf3d35d0969236f578","name":"Tongji Hospital Of Huazhong University Of Science And Technology","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.4917469,"lng":114.1732702,"locationId":"0a38d0cdfd2e0c0ea8c847cc2371de2c5bf78206","name":"West Hospital Union Hospital Huazhong University Of Science And Technology","state":"Hubei Sheng"},{"city":"Boston","country":"USA","lat":42.3159679,"lng":-71.1119168,"locationId":"41533106ba677bfdbae31e17665b11a03eb6f7b0","name":"Wuhan Pulmonary Hospital","state":"MA"},{"city":"Wuhan Shi","country":"CHN","lat":30.552985,"lng":114.353743,"locationId":"a7f66167400fe03e341c1e98d096276e367120ab","name":"Zhongnan Hospital Of Wuhan University","state":"Hubei Sheng"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1","https://www.drugbank.ca/drugs/DB06273"],"sponsors":[{"sponsorId":"e3b26f3f63704a702040cad0b3d5f4ff56f7360a","sponsorName":"Peking University First Hospital"},{"sponsorId":"1cc9d3179b66670e4a36a366afbbe7179bae5329","sponsorName":"Genentech Inc"}],"status":"Ongoing","studyCompletionDate":"Fri, 01 May 2020 00:00:00 GMT","studyStartDate":"Sun, 08 Mar 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Anulohuaxian","chemicalName":"Anulohuaxian","conditionOrDisease":"Covid-19","contact":[{"email":"john131212@sina.com","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"SKIPPED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"SKIPPED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"SKIPPED"}],"moleculeType":"Other","notes":"Traditional Chinese Medicine","numSites":"8","otherPartners":"N/A","phase":"0","preferredName":"Anulohuaxian","primaryCompletionDate":"Mon, 01 Jun 2020 00:00:00 GMT","productId":180,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04334265","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Fuyang Shi","country":"CHN","lat":33.164296,"lng":115.628262,"locationId":"3713b4d4a47994c65b3edbc70594a749b667daf5","name":"The Second People's Hospital Of Fuyang","state":"Anhui Sheng"},{"city":"Ezhou Shi","country":"CHN","lat":30.3987825,"lng":114.8819099,"locationId":"818276556ae00ae768147b24fc2f60d697031057","name":"Ezhou Central Hospital","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.552985,"lng":114.353743,"locationId":"9adb25985ba20a1c3d4d22ea82c5adf8f7422177","name":"Huoshenshan Hospital Of Wuhan","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.6668794,"lng":114.2868443,"locationId":"38ff92ee75c38c5ef4f231871ce62efb5e6b39c5","name":"Jinyintan Hospital Of Wuhan","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.5130043,"lng":114.4202756,"locationId":"f663563e78675765fe65c37f033b37abfd043cc8","name":"Tongji Hospital Of Huazhong University Of Science And Technology","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.4917469,"lng":114.1732702,"locationId":"401fc385f8f248bee55251996ca09f392a1b93f5","name":"West Hospital Union Hospital Huazhong University Of Science And Technology","state":"Hubei Sheng"},{"city":"Boston","country":"USA","lat":42.3159679,"lng":-71.1119168,"locationId":"b2d9768fd31c17a316fb4c2b34d4b4eef3126ecf","name":"Wuhan Pulmonary Hospital","state":"MA"},{"city":"Wuhan Shi","country":"CHN","lat":30.552985,"lng":114.353743,"locationId":"6b6778a4b747c14e52294da4f7ca3f0631ef276f","name":"Zhongnan Hospital Of Wuhan University","state":"Hubei Sheng"},{"city":"Wenzhou","country":"CHN","lat":27.939761,"lng":120.695887,"locationId":"044ea3a2b945df30a0855cb4ab6569e17e6e93b3","name":"Wenzhou Medical University Affiliated First Hospital","state":null}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3","https://journals.lww.com/md-journal/fulltext/2019/05310/the_efficacy_of_chinese_patent_medicine_combined.18.aspx","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708750/"],"sponsors":[{"sponsorId":"e3b26f3f63704a702040cad0b3d5f4ff56f7360a","sponsorName":"Peking University First Hospital"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Wed, 01 Apr 2020 00:00:00 GMT","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"Allogeneic human dental pulp stem cells","conditionOrDisease":"COVID-19","contact":[{"email":"\tqingsongye@foxmail.com","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 1","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 06 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"","numSites":"1","otherPartners":"Beijing SH Bio-Tech Corporation - Beijing - China,Utooth Biological Technology Co. Ltd. - Hubei - China","phase":"1","preferredName":"Allogeneic human dental pulp stem cells","primaryCompletionDate":"","productId":181,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04336254","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Wuhan","country":"CHN","lat":30.53535699999999,"lng":114.299525,"locationId":"c4b8354268b2cf88896c2b31aed538d87f8f67a5","name":"Renmin Hospital Of Wuhan University (east Campus)","state":null}],"sources":["https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429131/"],"sponsors":[{"sponsorId":"14a2146233138c07a64e0baef6cc949f64c7af25","sponsorName":"Renmin Hospital of Wuhan University"}],"status":"Ongoing","studyCompletionDate":"Wed, 31 Mar 2021 00:00:00 GMT","studyStartDate":"Mon, 06 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"IBIO-100","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"Other","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Being repurposed to treat idiopathic pulmonary fibrosis,Previously granted orphan drug designation for treatment of systemic sclerosis investigated to systemic scleroderma","numSites":"","otherPartners":"","phase":"","preferredName":"IBIO-100","primaryCompletionDate":"","productId":182,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.ibioinc.com/pipeline#IBIO100"],"sponsors":[{"sponsorId":"505b07d6981f93ee187513e197589f4c16f04b35","sponsorName":"iBio Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"chloroquine,azithromycin","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"","milestones":[],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"chloroquine,azithromycin","primaryCompletionDate":"","productId":183,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://www.forbes.com/sites/nathanvardi/2020/04/08/handicapping-the-most-promising-of-267-potential-coronavirus-cures/#4efa3587f23b"],"sponsors":[{"sponsorId":"9f993454bdb55447c232ff4e925773960b482c3a","sponsorName":"Population Health Research"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"Favipiravir,Baloxavir marboxil","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"","milestones":[],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Favipiravir,Baloxavir marboxil","primaryCompletionDate":"","productId":184,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://www.forbes.com/sites/nathanvardi/2020/04/08/handicapping-the-most-promising-of-267-potential-coronavirus-cures/#4efa3587f23b"],"sponsors":[{"sponsorId":"a81e304214bfeeb11d72efbec071b026a7bec070","sponsorName":"First Hospital Affiliated"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"Avian paramyxovirus vector vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Combination","notes":"","numSites":"","otherPartners":"Lancaster University","phase":"","preferredName":"Avian paramyxovirus vector vaccine","primaryCompletionDate":"","productId":528,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://dnd.com.pk/pakistani-scientist-dr-muhammad-munir-listed-as-potential-covid-19-vaccine-maker-by-who/189385"],"sponsors":[{"sponsorId":"3f5ef18f6b48973f961a316e793e87f14b04ffff","sponsorName":"Lancaster University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Jakafi,Jakavi","chemicalName":"Ruxolitinib","conditionOrDisease":"COVID 19","contact":[{"email":"medinfo@incyte.com","name":null,"notes":"","phone":"18554633463","website":""}],"countries":["Switzerland"],"countryCodes":["CHE"],"currentStage":"","indication":"Other","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Being evaluated for treatment of COVID 19 associated cytokine storm","numSites":"","otherPartners":"","phase":"Expanded Access ","preferredName":"Ruxolitinib","primaryCompletionDate":"","productId":185,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04355793","repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.janssen.com/lack-evidence-support-use-darunavir-based-treatments-sars-cov-2-0","https://www.globenewswire.com/news-release/2020/04/02/2011153/0/en/Novartis-announces-plan-to-initiate-clinical-study-of-Jakavi-in-severe-COVID-19-patients-and-establish-international-compassionate-use-program.html","https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04355793?term=ruxolitinib&cond=covid+19&draw=1&rank=2"],"sponsors":[{"sponsorId":"5b5b8fac5162ad1d88a07970c29180291cab2655","sponsorName":"Tongji Hospital"},{"sponsorId":"28de4f9051af1771961895dd1ee280ee55497988","sponsorName":"Incyte Corporation"},{"sponsorId":"a47ed0af8e79c0d5e04834a88fa5c0fa3a019663","sponsorName":"Novartis AG"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Peginterferon Lambda-1a","chemicalName":"Peginterferon Lambda-1a","conditionOrDisease":"COVID 19","contact":[{"email":"usingh@stanford.edu","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"Peginterferon Lambda-1a","primaryCompletionDate":"Fri, 14 Aug 2020 00:00:00 GMT","productId":186,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04331899","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Stanford","country":"USA","lat":37.4318102,"lng":-122.175758,"locationId":"70dc84a56cbce5ee3c700640c1595acd7b59dbb3","name":"Stanford University School Of Medicine","state":"CA"}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/study/NCT04331899","https://clinicaltrials.gov/ct2/show/NCT04331896","https://clinicaltrials.gov/ct2/show/NCT04331897","https://clinicaltrials.gov/ct2/show/NCT04331898","https://clinicaltrials.gov/ct2/show/NCT04331899"],"sponsors":[{"sponsorId":"683d20f6c6f23f9c1e0851b35e3f725262584fe3","sponsorName":"Stanford University"},{"sponsorId":"4b56e1109e3c62392ddb122d219ce7bd5514472d","sponsorName":"Eiger Biopharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"Sat, 01 May 2021 00:00:00 GMT","studyStartDate":"Fri, 24 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"LV-SMENP-DC,Synthetic Minigene Vaccine","chemicalName":"","conditionOrDisease":"COVID 19","contact":[{"email":"c@szgimi.org","name":null,"notes":"","phone":"For China: +86(755)8672 5195","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Other","notes":"Vaccine to treat and prevent severe Covid-19 pneumonia,Innovative COVID19 minigenes engineered based on multiple viral genes using an efficient lentiviral vector system to express viral proteins and immune modulatory genes to modify dendritic cells and to activate T cells","numSites":"3","otherPartners":"Shenzhen Third People's Hospital,Shenzhen Second People's Hospital","phase":"2","preferredName":"LV-SMENP-DC,Synthetic Minigene Vaccine","primaryCompletionDate":"Mon, 31 Jul 2023 00:00:00 GMT","productId":187,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04276896","repurposed":"New","siteLocations":[{"city":"Shenzhen","country":"CHN","lat":22.543096,"lng":114.057865,"locationId":"c703ab197caa47ee9a00925cce4074a0e6a7e4c8","name":"Shenzhen Geno","state":"Guangdong Province"},{"city":"Shenzhen","country":"CHN","lat":22.635796,"lng":114.130144,"locationId":"a2759b3711dabb5cd1a6df3ae579ee8034a4c643","name":"Shenzhen Third People's Hospital","state":null},{"city":"Shenzhen Shi","country":"CHN","lat":22.556599,"lng":114.086145,"locationId":"4247297bdc05022aae1be9500f7234c6c05fd303","name":"Shenzhen Second People's Hospital","state":"Guangdong Sheng"}],"sources":["https://www.nature.com/articles/d41573-020-00073-5","https://clinicaltrials.gov/ct2/show/NCT04276896","https://clinicaltrials.gov/ct2/show/NCT04276897"],"sponsors":[{"sponsorId":"36892fb1d881bf4eb83d3e08c9a4f8319cf53660","sponsorName":"Shenzhen GenoImmune Medical Institute"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Tue, 24 Mar 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"No","brandName":"aAPC Vaccine","chemicalName":"","conditionOrDisease":"COVID 19","contact":[{"email":"c@szgimi.org","name":null,"notes":"","phone":"For China: +86(755)8672 5195","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"Covid-19/aAPC vaccine is prepared by applying lentivirus modification including immune modulatory genes and the viral minigenes to the artificial antigen presenting cells","numSites":"3","otherPartners":"Shenzhen Third People's Hospital,Shenzhen Second People's Hospital","phase":"1","preferredName":"aAPC Vaccine","primaryCompletionDate":"Mon, 31 Jul 2023 00:00:00 GMT","productId":188,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04299724","repurposed":"","siteLocations":[{"city":"Shenzhen","country":"CHN","lat":22.543096,"lng":114.057865,"locationId":"9fc5ba5cf386270ba15d3b77d6bc2044045de1b9","name":"Shenzhen","state":"Guangdong Province"}],"sources":["https://www.nature.com/articles/d41573-020-00073-5","https://clinicaltrials.gov/ct2/show/NCT04299724"],"sponsors":[{"sponsorId":"36892fb1d881bf4eb83d3e08c9a4f8319cf53660","sponsorName":"Shenzhen GenoImmune Medical Institute"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Sat, 15 Feb 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Peptide-based therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Fri, 14 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"48Hour Discovery Inc.","phase":"","preferredName":"Peptide-based therapeutic","primaryCompletionDate":"","productId":189,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"970c9dcb0770cc2be64dd33cbfa88ac640f9e606","sponsorName":"48Hour Discovery Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"Pharmetrx therapeutics","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Fri, 14 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"The compounds were identified using PharmetRx\u00ae Afecta's proprietary artificial intelligence platform and demonstrate bioactivity via two key therapeutic mechanisms of action-(1) immunomodulation similar to that of hydroxychloroquine or (2) inhibition of viral replication or attachment to host cells.","numSites":"","otherPartners":"Afecta Pharmaceuticals Inc.","phase":"","preferredName":"Pharmetrx therapeutics","primaryCompletionDate":"","productId":190,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"f3b4e5e84c266ea60771ec2883e82c2204ec2f04","sponsorName":"Afecta Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"Active Agent","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Germany"],"countryCodes":["DEU"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Tue, 04 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Aicuris Anti-infective Cures GmbH","phase":"","preferredName":"Active Agent","primaryCompletionDate":"","productId":191,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"f2b34e7e5c8d41cfa0c7e4ca7543514b6c633fe9","sponsorName":"Aicuris Antiinfective Cures GmbH"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antiviral component","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Fri, 14 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"The compounds seek to inhibit replication of multiple viruses,including Influenza virus,SARS-CoV,MERS-CoV,Ebolavirus and Marburg virus.","numSites":"","otherPartners":"Aikido Pharma Inc.,the University of Maryland -Baltimore","phase":"","preferredName":"Antiviral component","primaryCompletionDate":"","productId":192,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"39b3f1f3677b274c50b99d83330f4862d0b8f6a8","sponsorName":"Aikido Pharma Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"ADX-629,reproxalap","chemicalName":"reproxalap(reactive aldehyde species (RASP) inhibitor)","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 14 Feb 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Aldeyra Therapeutics Inc.","phase":"","preferredName":"reproxalap(reactive aldehyde species (RASP) inhibitor)","primaryCompletionDate":"","productId":193,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"5525922d920320b60e93d8e039b662d088125b7d","sponsorName":"Aldeyra Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Soliris","chemicalName":"Eculizumab","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Tue, 24 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":"Tue, 24 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"replaced by Ultomiris(ravulizumab-cwvz) for further tests.","numSites":"","otherPartners":"Alexion Pharmaceuticals Inc.","phase":"","preferredName":"Eculizumab","primaryCompletionDate":"","productId":194,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"41794d8c7643f99fc7895546d19147d1b41daf20","sponsorName":"Alexion Pharmaceuticals Inc"}],"status":"On Hold","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"DAS-181","chemicalName":"recombinant sialidase","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Thu, 02 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 30 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":"Fri, 06 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Ansun Biopharma Inc.,Renmin Hospital of Wuhan University","phase":"","preferredName":"recombinant sialidase","primaryCompletionDate":"","productId":195,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"5e79a7dfd885e0baf118378ff6d6ac832c4a44f3","sponsorName":"Ansun Biopharma Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"SARS-CoV-2 targeting recombinant methioninase","chemicalName":"Methioninase","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Mon, 03 Feb 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":"Mon, 03 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"Anticancer Inc.,AntiCancer Beijing","phase":"","preferredName":"Methioninase","primaryCompletionDate":"","productId":196,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"84e8fc3396832ade5506a951a3b3ebbaebd87cde","sponsorName":"Anticancer Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"Solnatide","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Austria"],"countryCodes":["AUT"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 28 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 04 May 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Solnatide IMP has been designed for activation of the pulmonary epithelial sodium channel (ENaC) and for the restoration of the injured endothelial-epithelial barrier of pulmonary alveoli.","numSites":"","otherPartners":"Apeptico Forschung und Entwicklung GmbH,The Austrian Research Promotion Agency","phase":"","preferredName":"Solnatide","primaryCompletionDate":"","productId":197,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"f8b9528ccb10701b24f862db161ec27fbc4847fd","sponsorName":"Apeptico Forschung und Entwicklung GmbH"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"Cannabinoid-based therapy","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Tue, 14 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Small molecule","notes":"cannabinoids may act as anti-androgens","numSites":"","otherPartners":"Applied Biology Inc.,Applied Bonanics LLC","phase":"","preferredName":"Cannabinoid-based therapy","primaryCompletionDate":"","productId":198,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"30a0bfe60f04ff11e51d1901a52fbea2c76f2b5d","sponsorName":"Applied Biology Inc"},{"sponsorId":"0112e7fffc5a7da4b036b0306729e2a12720f796","sponsorName":"Applied Bonanics LLC"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"AT-001","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"","indication":"Other","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Aldose Reductase Inhibitor,New York Hospital Investigator Initiated Studies used under an emergency IND","numSites":"","otherPartners":"","phase":"","preferredName":"AT-001","primaryCompletionDate":"","productId":199,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-ind-and-investigator-initiated","https://www.sec.gov/Archives/edgar/data/1697532/000104746919002659/a2238624zs-1a.htm"],"sponsors":[{"sponsorId":"3304021f998972cba57fa873b78bbbcda69f3122","sponsorName":"Applied Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Small molecules","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"3 molecules targeting two viral replication enzymes- 3CL-Protease and RNA dependent RNA Polymerase,Pre-Clinical studies will be taken over by the University of Hong Kong,Covar Pharmaceuticals is another collaborator","numSites":"","otherPartners":"","phase":"","preferredName":"Small molecules","primaryCompletionDate":"","productId":200,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.businesswire.com/news/home/20200330005263/en/Aptorum-Group-Collaborates-Covar-Pharmaceuticals-Investigate-3"],"sponsors":[{"sponsorId":"552bb9ce9d50b56342d0722bdf6a2e671ba4796e","sponsorName":"Aptorum Group Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"IgY-110","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"IgY-110","primaryCompletionDate":"","productId":562,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.pharmaceutical-business-review.com/news/igy-life-sciences-mms-covid-19-antibody/"],"sponsors":[{"sponsorId":"4391ec9967da9a1a57bf2f12cfc8f17f209f34c2","sponsorName":"IGY Life Sciences"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"ALT-100","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"eNAMPTOR is a platform of three products which includes ALT-100","numSites":"","otherPartners":"","phase":"","preferredName":"ALT-100","primaryCompletionDate":"","productId":201,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.aqualungtherapeutics.com/enamptor/","https://www.aqualungtherapeutics.com/contact","https://www.aqualungtherapeutics.com/pipeline/","https://aqualungtherapeutics.reportablenews.com/pr/aqualung-therapeutics-advances-its-investigational-monoclonal-antibody-into-ind-enabling-studies-of-acute-respiratory-distress-syndrome-ards-and-ventilator-induced-lung-injury-vili","https://www.technologynetworks.com/biopharma/blog/antibody-to-treat-lung-inflammation-may-offer-potential-in-covid-19-332369","https://www.aqualungtherapeutics.com/key-activities-and-press/"],"sponsors":[{"sponsorId":"4e3c43064be49069b8902b88fe3a123622091b1f","sponsorName":"Aqualung Therapeutics Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"ASC09F","chemicalName":"TMC-310911,ritonavir","conditionOrDisease":"COVID19","contact":[{"email":"xxw69@126.com","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"HIV-1 Protease Inhibitor,Another clinical trial with oseltamivir retracted due to insufficient patients,ASC09-Ritonavir vs Lopinavir-Ritonavir trial sponsor is First Affiliated Hospital of Zhejiang University and Ascletis is collaborator","numSites":"","otherPartners":"","phase":"","preferredName":"TMC-310911,ritonavir","primaryCompletionDate":"Sun, 31 May 2020 00:00:00 GMT","productId":202,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04261907","repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","http://ascletis.com.cn/single/145.html","https://www.drugbank.ca/drugs/DB15623; https://www.drugbank.ca/drugs/DB00503","http://ascletis.com.cn/single2/139.html","https://www.drugbank.ca/drugs/DB15623; https://www.drugbank.ca/drugs/DB00503; https://clinicaltrials.gov/ct2/show/record/NCT04261907","http://www.chictr.org.cn/showprojen.aspx?proj=49075","http://www.chictr.org.cn/showprojen.aspx?proj=49352","https://clinicaltrials.gov/ct2/show/record/NCT04261907"],"sponsors":[{"sponsorId":"9c77c2ee252590839e7e90f484ab0c46df479dbb","sponsorName":"Ascletis Pharma Inc"}],"status":"Ongoing","studyCompletionDate":"Tue, 30 Jun 2020 00:00:00 GMT","studyStartDate":"Fri, 07 Feb 2020 00:00:00 GMT","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Calquence","chemicalName":"acalabrutinib","conditionOrDisease":"COVID19","contact":[{"email":"information.center@astrazeneca.com","name":null,"notes":"","phone":"1-877-240-9479","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"ESTIMATED"}],"moleculeType":"Small molecule","notes":"Acerta Pharma B.V. discovered acalabrutinib and is a collaborator on the clinical trial","numSites":"1","otherPartners":"","phase":"2","preferredName":"acalabrutinib","primaryCompletionDate":"Thu, 26 Nov 2020 00:00:00 GMT","productId":203,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04346199","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Barcelona","country":"ESP","lat":41.3850639,"lng":2.1734035,"locationId":"0a00c64f1ff6a85e07c8bfbc5f4d10c5ee41db6c","name":"Barcelona","state":"CT"}],"sources":["https://www.bioworld.com/COVID19products","https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html","https://www.drugbank.ca/drugs/DB11703","https://www.astrazeneca.com/our-company/contact-us.html","https://clinicaltrials.gov/ct2/show/record/NCT04346199?view=record","https://www.acerta-pharma.com/about/","https://www.astrazeneca.com/our-therapy-areas/oncology.html#OurOncologypipeline","https://www.astrazeneca.com/our-therapy-areas/oncology.html#OurOncologymedicines","https://clinicaltrials.gov/ct2/show/NCT04346199","https://clinicaltrials.gov/ct2/show/study/NCT04346199"],"sponsors":[{"sponsorId":"2c75b2d91db07786aabe9dcac98ed68f752804f1","sponsorName":"AstraZeneca plc"}],"status":"Ongoing","studyCompletionDate":"Thu, 26 Nov 2020 00:00:00 GMT","studyStartDate":"Fri, 12 Jun 2020 00:00:00 GMT","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Virazole","chemicalName":"ribavirin inhalation solution","conditionOrDisease":"COVID19","contact":[{"email":"Alexandre.Brkovic@bauschhealth.com","name":null,"notes":"","phone":"514-904-4863","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"ESTIMATED"}],"moleculeType":"Small molecule","notes":"Control # 238007 for Canadian Clinical Trial Website - works best with Internet Explorer,first posted on Clinicaltrials.gov 04/22/2020","numSites":"","otherPartners":"Hospira Inc.","phase":"1","preferredName":"ribavirin inhalation solution","primaryCompletionDate":"Sat, 10 Apr 2021 00:00:00 GMT","productId":204,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04356677","repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://ir.bauschhealth.com/news-releases/2020/04-13-2020-120008693","https://www.drugbank.ca/drugs/DB00811","http://www.virazole.com/","https://health-products.canada.ca/ctdb-bdec/search-recherche.do;jsessionid=6E35384F37BD4DFE705B0CEA1440F945","https://clinicaltrials.gov/ct2/show/study/NCT04356677","https://clinicaltrials.gov/ct2/show/record/NCT04356677"],"sponsors":[{"sponsorId":"a88af720747218a96a8aad641b4265d2da310f54","sponsorName":"Bausch Health Cos Inc"}],"status":"Ongoing","studyCompletionDate":"Thu, 01 Apr 2021 00:00:00 GMT","studyStartDate":"Thu, 10 Sep 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"Niclocide","chemicalName":"niclosamide","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Voluntarily withdrawn from market by Bayer in 1996,Another Brand name is Yomesan","numSites":"","otherPartners":"","phase":"","preferredName":"niclosamide","primaryCompletionDate":"","productId":205,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00052","https://www.drugbank.ca/drugs/DB06803","https://www.kxan.com/news/coronavirus/can-an-existing-drug-be-re-purposed-to-treat-covid-19-patients-ut-researchers-working-to-find-out/","https://www.drugbank.ca/drugs/DB06803; https://www.bayer.co.za/static/documents/MSDS/PIs/YOMESAN_EN_PI.pdf"],"sponsors":[{"sponsorId":"67da3aa3718d35ed721af558ab42d840a58dfdbe","sponsorName":"Bayer AG"},{"sponsorId":"541210ab7a6daa7079e19f753dbf3002c81ab5a8","sponsorName":"Union Therapeutics AS"},{"sponsorId":"3f0f11935fb0a109bff465cc279e3b68c954fede","sponsorName":"Ana Therapeutics"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"Nanobody","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"ESTIMATED"},{"category":"pre-clinical","date":"Thu, 20 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Beroni Group submitted Emergency Use Authorization for COVID-19 Rapid Test Detection Kit to FDA in March","numSites":"","otherPartners":"","phase":"","preferredName":"Nanobody","primaryCompletionDate":"","productId":206,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/","https://www.bioworld.com/COVID19products","https://www.beronigroup.com/2020/03/06/beroni-group-collaborates-with-tianjin-university-to-develop-novel-solution-for-coronavirus-covid-19/","https://www.beronigroup.com/2020/04/01/beroni-group-announces-submission-of-emergency-use-authorization-to-us-fda-for-its-covid-19-rapid-test-detection-kit/"],"sponsors":[{"sponsorId":"b738e5214e4eac0d75fea1d6f1cfdd47e57c0e9b","sponsorName":"Beroni Group"},{"sponsorId":"28bd9f926647c0b6e60a19fd1317a5fdb10635eb","sponsorName":"Tianjin University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"rhu-pGSN","chemicalName":"recombinant human plasma gelsolin","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Next step is to move into Phase 2b","numSites":"","otherPartners":"","phase":"","preferredName":"recombinant human plasma gelsolin","primaryCompletionDate":"","productId":207,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.bioaegistherapeutics.com/covid19/plasma-gelsolin-to-protect-tissue-organs-in-severe-coronavirus-infection-without-compromising-pathogen-response/","https://www.bioaegistherapeutics.com/overview-immunotherapy-treatment/","http://www.globenewswire.com/news-release/2020/04/02/2010466/0/en/Small-NJ-Biotech-Firm-BioAegis-Therapeutics-Accelerating-Multiple-Clinical-Trial-Submissions-for-Severe-COVID-19-Pneumonia-Patients.html","https://www.bioaegistherapeutics.com/news/may-17-2011-bioaegis-therapeutics-signs-exclusive-option-human-protein-clinical-development/","https://www.bioaegistherapeutics.com/news/september-2018-bioaegis-therapeutics-enrolls-first-patients-in-phase-1b-2a-community-acquired-pneumonia-study-and-raises-4-mm-in-equity-round/","https://clinicaltrials.gov/ct2/show/study/NCT03466073","https://clinicaltrials.gov/ct2/show/record/NCT03466073"],"sponsors":[{"sponsorId":"a6c2d1473eb80756c87eca409671a57e3947b727","sponsorName":"Bioaegis Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Final product aim is a Nanobody-an antibody but contains only a single very small unit needed for recognition and disruption of the COVID-19 targets","numSites":"","otherPartners":"Wuxi-Jiangsu local government","phase":"","preferredName":"Antibodies","primaryCompletionDate":"","productId":208,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://bioduro.com/article/bioduro-announces-covid19-nanobody/"],"sponsors":[{"sponsorId":"69fd255e06de9b1173c6fdf9c2a593c7a7784d3e","sponsorName":"Bioduro LLC"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Vazegepant,BHV-3500","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"clinicaltrials@biohavenpharma.com","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Wed, 08 Apr 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 25 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 25 Apr 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"CGRP receptor antagonist that is to be administered intranasally,currently in phase 2/3 trial to evaluate efficacy and potential for quick onset","numSites":"2","otherPartners":"","phase":"2","preferredName":"Vazegepant,BHV-3500","primaryCompletionDate":"Sat, 10 Apr 2021 00:00:00 GMT","productId":209,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04346615","repurposed":"New","siteLocations":[{"city":"Washington","country":"USA","lat":38.911464,"lng":-77.0751693,"locationId":"4994a6d8b266a45ed446d60f141d93ccb16a3803","name":"Georgetown University Medical Center","state":"DC"},{"city":"Philadelphia","country":"USA","lat":39.9488442,"lng":-75.1572272,"locationId":"1e335e3dc99fb2bad069eea2303f8b8abb054106","name":"Thomas Jefferson University Hospital","state":"PA"}],"sources":["https://www.bioworld.com/COVID19products","https://www.biohavenpharma.com/index.php/contact-us","https://www.biohavenpharma.com/science-pipeline/cgrp/bhv-3500","https://www.biohavenpharma.com/investors/news-events/press-releases/04-09-2020","https://clinicaltrials.gov/ct2/show/NCT04346615?intr=vazegepant&draw=2&rank=1"],"sponsors":[{"sponsorId":"9416a898d6c70803634f7f9d56ed68eda301ff71","sponsorName":"Biohaven Pharmaceutical Holding Co Ltd"}],"status":"Ongoing","studyCompletionDate":"Sat, 10 Apr 2021 00:00:00 GMT","studyStartDate":"Sat, 25 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"anti-viroporin therapeutics","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Australia"],"countryCodes":["AUS"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Biotron is currently testing whether their small molecules that target viroporins (virus-encoded proteins) will be effective against SARS CoV-2,the E protein of SARS CoV-2 was shown to be a viroporin and can potentially be a good target","numSites":"","otherPartners":"","phase":"","preferredName":"anti-viroporin therapeutics","primaryCompletionDate":"","productId":210,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.ausbiotech.org/news/australian-biotech-at-the-forefront-of-global-health-responses"],"sponsors":[{"sponsorId":"b9c81254affc60230c18ca7f16da8eb9fd4cc3e6","sponsorName":"Biotron Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"BOLD-100","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Small molecule that downregulates GRP78 with the intention to treat cancer,completed phase 1 that involved 41 cancer patients with tolerable safety profile,currently under investigation for potential therapeutic effects among COVID-19 patients: downregulating GRP78 shows promise because SARS CoV-2 can bind to GRP78,note that there are no details on the phase 1 trial aside from the number of subjects","numSites":"","otherPartners":"University of Ottawa","phase":"","preferredName":"BOLD-100","primaryCompletionDate":"","productId":211,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.thepharmaletter.com/article/bold-therapeutics-partners-with-academia-to-study-bold-100-as-covid-19-therapy","https://www.bold-therapeutics.com/COVID-19"],"sponsors":[{"sponsorId":"d66e29eb51e46ebb67035da91e045d8c5ced9d8d","sponsorName":"Bold Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"monoclonal antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"ESTIMATED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Working on discovering monoclonal antibodies against SARS CoV-2,aims to begin clinical trials within 6 months","numSites":"","otherPartners":"Brii Biosciences","phase":"","preferredName":"monoclonal antibodies","primaryCompletionDate":"","productId":212,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.briibio.com/news/45.html"],"sponsors":[{"sponsorId":"a635c9162245b5b265427b6b347bf36ec00ab510","sponsorName":"Brii Biosciences"},{"sponsorId":"597be3ec42623eb2b339b165717d84c7c3137601","sponsorName":"Columbia University"},{"sponsorId":"bfce396095503d26f651c5dad224c79f44d87649","sponsorName":"Tsinghua University"},{"sponsorId":"8bdecc942a48de24772aedb84f5bd52bc0737054","sponsorName":"3rd Peoples Hospital of Shenzhen"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"CM-4620-IE","chemicalName":"Auxora","conditionOrDisease":"COVID-19","contact":[{"email":"sudarshan@calcimedica.com","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Thu, 09 Apr 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 08 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Originally developed to treat acute pancreatitis,currently undergoing phase 2 to observe efficacy in COVID-19 patients,functions by inhibiting CRAC channels to alleviate inflammation","numSites":"3","otherPartners":"","phase":"2","preferredName":"Auxora","primaryCompletionDate":"Wed, 10 Mar 2021 00:00:00 GMT","productId":213,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04345614","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Detroit","country":"USA","lat":42.3671003,"lng":-83.0851036,"locationId":"5667f36c65397d00e858c11ffdea6d7064649693","name":"Henry Ford Hospital","state":"MI"},{"city":"St Louis Park","country":"USA","lat":44.9300754,"lng":-93.3619384,"locationId":"7d6cb88910e1139dfc41fdc05dd97e98e198f83f","name":"Methodist Hospital","state":"MN"},{"city":"St Paul","country":"USA","lat":44.9562032,"lng":-93.0943145,"locationId":"dba1abb4f664e79efcb21637c888726247c1d110","name":"Regions Hospitla","state":"MN"}],"sources":["https://www.calcimedica.com/news/calcimedica-announces-positive-topline-data-from-interim-analysis-of-trial-evaluating-auxora-in-patients-with-severe-covid-19-pneumonia","https://www.bioworld.com/COVID19products","https://www.biospace.com/article/releases/fda-grants-calcimedica-permission-to-begin-dosing-cm4620-ie-in-patients-with-severe-covid-19-pneumonia-under-a-newly-opened-ind/","https://clinicaltrials.gov/ct2/show/NCT04345614?intr=CM-4620-IE&draw=2&rank=2"],"sponsors":[{"sponsorId":"878b8442cb543076e452c2d646f57de1f361f6f6","sponsorName":"Calcimedica Inc"}],"status":"Ongoing","studyCompletionDate":"Sat, 10 Apr 2021 00:00:00 GMT","studyStartDate":"Wed, 08 Apr 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"CAP-1002","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Cell therapies","notes":"Currently not approved for clinical investigation but FDA has granted expanded access protocol to treat up to 20 more COVID-19 patients after 6 compassionate care cases were treated successfully,plans to launch a randomized and placebo-controlled trial,drug is a cardiac cell therapy that modifies immune activity to promote cellular regeneration","numSites":"","otherPartners":"","phase":"1","preferredName":"CAP-1002","primaryCompletionDate":"","productId":214,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","http://capricor.com/product-pipeline/cap-1002/","http://capricor.com/contact/","https://www.bioworld.com/articles/434747-capricors-covid-19-success-gets-fda-and-market-attention https://www.biospace.com/article/releases/new-capricor-data-reports-100-percent-survival-in-critical-covid-19-patients-treated-with-cap-1002u-s-fda-approves-company-s-expanded-access-protocol-to-treat-additional-patients/","http://capricor.com/product-pipeline/","https://www.biospace.com/article/releases/new-capricor-data-reports-100-percent-survival-in-critical-covid-19-patients-treated-with-cap-1002u-s-fda-approves-company-s-expanded-access-protocol-to-treat-additional-patients/","https://clinicaltrials.gov/ct2/show/NCT04338347","https://clinicaltrials.gov/ct2/show/record/NCT04338347"],"sponsors":[{"sponsorId":"2488a9c05ed2f222808e0d9c70595368ed86a7a6","sponsorName":"Capricor Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Carterra will use proprietary LSA platform to simultaneously screen and characterize antibodies to quickly determine ones that are effective against SARS CoV 2","numSites":"","otherPartners":"Coronavirus Immunotherapy Consortium (CoVIC)","phase":"","preferredName":"antibodies","primaryCompletionDate":"","productId":215,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://carterra-bio.com/news/carterra-inc-selected-by-the-la-jolla-institute-of-immunology-to-provide-antibody-screening-and-characterization-for-the-coronavirus-immunotherapy-consortium-covic/"],"sponsors":[{"sponsorId":"ef5993e2d91aec68e38a7180d305dc11099e9ba5","sponsorName":"Carterra Inc"},{"sponsorId":"c4a8ae6729d9974f1941051e2956e64de583ec66","sponsorName":"La Jolla Institute for Immunology"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"CK-0802","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Tue, 02 Jun 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"Intends to collaborate with BARDA,the application for a phase-1 randomised double-blind trial has been approved by FDA,CK-0802 is an allogenic cell therapy that consists of TREG cells derived from umbilical cord blood units,hypothesized to improve ARDS by interrupting cytokine storm and resolving inflammation,pre-clinical studies showed favorable results,has been used in clinical trials for other inflammatory disorders","numSites":"","otherPartners":"","phase":"","preferredName":"CK-0802","primaryCompletionDate":"","productId":216,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.prnewswire.co.uk/news-releases/cellenkos-r-inc-announces-fda-clearance-to-initiate-phase-1-double-blinded-randomized-placebo-controlled-trial-of-cryopreserved-cord-blood-derived-t-regulatory-cells-ck0802-for-treatment-of-covid-19-associated-acute-respiratory-distress-syn-891362475.html","https://www.biospace.com/article/releases/cellenkos-inc-focuses-on-the-development-of-cell-therapy-for-treatment-of-covid-19-mediated-acute-respiratory-distress-syndrome-cov-ards-/","https://www.biospace.com/article/releases/cellenkos-inc-focuses-on-the-development-of-cell-therapy-for-treatment-of-covid-19-mediated-acute-respiratory-distress-syndrome-cov-ards-/ ; https://www.prnewswire.co.uk/news-releases/cellenkos-r-inc-announces-fda-clearance-to-initiate-phase-1-double-blinded-randomized-placebo-controlled-trial-of-cryopreserved-cord-blood-derived-t-regulatory-cells-ck0802-for-treatment-of-covid-19-associated-acute-respiratory-distress-syn-891362475.html"],"sponsors":[{"sponsorId":"92d27d31ee16c9150c4ce4a2d09f18d71707dba3","sponsorName":"Cellenkos Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Mesenchymal stem cells","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Cell therapies","notes":"Celltex submitted an emergency expanded access clinical study to the United States Food and Drug Administration (FDA) that would allow patients with COVID-19 to receive infusions of autologous Adipose-tissue derived Mesenchymal Stem Cells (AdMSCs)","numSites":"","otherPartners":"","phase":"","preferredName":"Mesenchymal stem cells","primaryCompletionDate":"","productId":217,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://celltexbank.com/celltex-has-submitted-emergency-expanded-access-clinical-study-for-subjects-with-coronavirus-2019-covid-19-using-multiple-dose-infusions-of-autologous-adipose-tissue-derived-mesenchymal-stem-cells/","https://www.linkedin.com/company/celltex-therapeutics-corporation/"],"sponsors":[{"sponsorId":"9e2adf519c2fb405939c957dd6389845849f22ca","sponsorName":"CellTex Therapeutics Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"anti-LIGHT","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"jwilkins@cerecor.com","name":null,"notes":"","phone":"610-457-5095","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Tue, 26 May 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Thu, 28 May 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":"Thu, 26 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Fully human antibody targetting the cytokine storm in COVID-19 ARDS,antibody to LIGHT which has been shown to play key role in viral pneumonia,FDA has approved a randomised double blind placebo-controlled proof of concept clinical trial,also being developed for Pediatric-onset Crohn\u2019s Disease","numSites":"11","otherPartners":"","phase":"2","preferredName":"anti-LIGHT","primaryCompletionDate":"Sat, 10 Oct 2020 00:00:00 GMT","productId":218,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04412057","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Newport Beach","country":"USA","lat":33.624397,"lng":-117.9296357,"locationId":"2021a99b04ff62e6ce2d9d32dc743851d7a8815d","name":"Hoag Memorial Hospital","state":"CA"},{"city":"Fort Pierce","country":"USA","lat":27.3744279,"lng":-80.3210202,"locationId":"7568da60c054aa3f56ee6642133716b443359e9f","name":"Midway Immunology And Research Center","state":"FL"},{"city":"West Palm Beach","country":"USA","lat":26.758317,"lng":-80.09951199999999,"locationId":"48e69d15bf2234da5cd8443d4c30bdfbeba3c8a1","name":"Triple O Research Institute P.a.","state":"FL"},{"city":"Fort Wayne","country":"USA","lat":41.0923314,"lng":-85.10754159999999,"locationId":"477ec0efa2e8ab687740f272473478f7eefd03d1","name":"Parkview Research Center","state":"IN"},{"city":"Metairie","country":"USA","lat":30.01050529999999,"lng":-90.18101709999999,"locationId":"74c3ceddf14c0656e3dfa903c147574d2b0fdf29","name":"Medpharmics","state":"LA"},{"city":"Shreveport","country":"USA","lat":32.480598,"lng":-93.760668,"locationId":"96405748ddf700bec15f1c68210c800a4d12dc17","name":"Lsuhsc","state":"LA"},{"city":"Fayetteville","country":"USA","lat":35.0317827,"lng":-78.93507029999999,"locationId":"e1d913468cd76fcd08542b2f84dd239543a817ae","name":"Cape Fear Valley Medical Center","state":"NC"},{"city":"Philadelphia","country":"USA","lat":40.0067149,"lng":-75.1511702,"locationId":"8ae9d20b3a7e6990cc6f0fa7b3584253d37fe4c2","name":"Temple University Hospital","state":"PA"},{"city":"Anderson","country":"USA","lat":34.5115601,"lng":-82.6462775,"locationId":"8fbd1b8cfd8970d7b7c67c626c7fd43573141bca","name":"Anmed Health Medical Center","state":"SC"},{"city":"Charleston","country":"USA","lat":32.8163761,"lng":-80.0432792,"locationId":"fc7f4de6890a44bc9df1f78bc81db2662da7c858","name":"Lowcountry Infectious Diseases","state":"SC"},{"city":"Plantation","country":"USA","lat":26.1470945,"lng":-80.26005549999999,"locationId":"4ced9db010bd9a03e134c2286da110d8fe9dabde","name":"Brcr Global Texas","state":"FL"}],"sources":["https://www.bioworld.com/COVID19products","https://www.globenewswire.com/news-release/2020/05/28/2040087/0/en/Cerecor-Announces-FDA-Clearance-of-IND-for-CERC-002-in-COVID-19-Induced-ARDS.html","https://www.cerecor.com/about/contact","https://clinicaltrials.gov/ct2/show/record/NCT04412057","https://ir.cerecor.com/press-releases/detail/90/cerecor-announces-exploration-of-the-role-of-an","https://clinicaltrials.gov/ct2/show/study/NCT04412057"],"sponsors":[{"sponsorId":"96d364e5af844fa0968bbd605a149ba3cfd69ca8","sponsorName":"Cerecor Inc"}],"status":"Ongoing","studyCompletionDate":"Tue, 10 Nov 2020 00:00:00 GMT","studyStartDate":"Wed, 10 Jun 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"HLCM-051","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"t.oe@healios.jp","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 14 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":"Tue, 01 Jan 2019 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"stem cell therapy","numSites":"2","otherPartners":"Healios K.K.,Athersys Inc.","phase":"2","preferredName":"HLCM-051","primaryCompletionDate":"","productId":236,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT03807804","repurposed":"New","siteLocations":[{"city":"\u5f18\u524d\u5e02","country":"JPN","lat":40.5996582,"lng":140.4658188,"locationId":"8a0cffd0b4ccdc39261b78663350861d0c55f411","name":"Hirosaki University Hospital","state":"\u9752\u68ee\u770c"},{"city":"Kumamoto","country":"JPN","lat":32.7649934,"lng":130.7008681,"locationId":"670b4e4ae45baae933c74de545ca3ad0c5828db8","name":"Saiseikai Kumamoto Hospital","state":"Kumamoto"}],"sources":["https://www.bioworld.com/COVID19products","https://www.healios.co.jp/en/development/ssc/","https://www.healios.co.jp/en/","https://www.clinicaltrials.gov/ct2/show/NCT03807804?term=HLCM-051&sort=nwst&draw=2&rank=1"],"sponsors":[{"sponsorId":"7d37b38fc6903794e0d2745bf6a891faddf43237","sponsorName":"Healios KK"}],"status":"Ongoing","studyCompletionDate":"Mon, 31 May 2021 00:00:00 GMT","studyStartDate":"Tue, 01 Jan 2019 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Chromovert","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"NOT a treatment or a vaccine but tecnology. The tecnology is called Chromovert and is used to accelerate drug discovery against hard-to-express biological target.  It has been successfully used to identify a novel non-addictive pain blocker that is in clinical development and it has identified a number of compounds in its pipeline that may help address COVID-19-related disease","numSites":"","otherPartners":"","phase":"","preferredName":"Chromovert","primaryCompletionDate":"","productId":219,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://www.prnewswire.com/news-releases/chromocell-makes-chromovert-technology-and-novel-compounds-available-to-support-covid-19-research-301036544.html","https://www.bioworld.com/COVID19products","https://www.linkedin.com/company/chromocell-corporation/"],"sponsors":[{"sponsorId":"4f6dba72f4ca74bcc6cb4c053fcddbbd0605b4a8","sponsorName":"Chromocell Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"2-DG","chemicalName":"WP1122","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Mon, 13 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"research was done by University of Frankfurt,2-DG inhibits glycolysis which prevents coronavirus replication in Caco-2 cells","numSites":"","otherPartners":"WPD Pharmaceuticals Inc.","phase":"","preferredName":"WP1122","primaryCompletionDate":"","productId":220,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/","https://www.bioworld.com/COVID19products","https://www.bioworld.com/COVID19products; https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/","https://www.drugbank.ca/drugs/DB08831","https://cnspharma.com/","https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/ ; https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/"],"sponsors":[{"sponsorId":"b843740e853ec52aa48f7c4d941b036355d61f11","sponsorName":"CNS Pharmaceuticals"},{"sponsorId":"c06ea1b1f971aa6a31cad5c82904f1d56d6c4a6f","sponsorName":"WPD Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"protase inhibtors","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"the compouds are protase inhibitors with a novel mechanism of action","numSites":"","otherPartners":"Kansas State University Research Foundation","phase":"","preferredName":"protase inhibtors","primaryCompletionDate":"","productId":221,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.cocrystalpharma.com/news/press-releases/detail/91/cocrystal-pharma-expands-exclusive-license-agreement-with","https://www.bioworld.com/COVID19products","https://www.cocrystalpharma.com/development-pipeline/coronavirus/coronavirus-protease-inhibitor","https://www.cocrystalpharma.com/about/overview","https://www.cocrystalpharma.com/contact-us"],"sponsors":[{"sponsorId":"85acfe2552787d1aab27f27a6db39a840956ca36","sponsorName":"Cocrystal Pharma Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"NK immunotherapies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Bifunctional antibodies - NK activating antibodies combined with novel antibodies neutralising or blocking SARS CoV2","numSites":"","otherPartners":"Macromoltek","phase":"","preferredName":"NK immunotherapies","primaryCompletionDate":"","productId":222,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.genengnews.com/a-lists/vanquishing-the-virus-160-covid-19-drug-and-vaccine-candidates-in-development/5/","https://www.globenewswire.com/news-release/2020/04/07/2012885/0/en/CYTOVIA-Therapeutics-and-MACROMOLTEK-to-Develop-Dual-Acting-Natural-Killer-Immunotherapy-Against-SARS-CoV2-COVID-19.html"],"sponsors":[{"sponsorId":"96da9064b2e31d835251dbc8767057c31f3e37cf","sponsorName":"Cytovia Inc"},{"sponsorId":"f9bfea84937e5d2a1fc4c5dd3aa3872a28df26f8","sponsorName":"Macromoltek Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Trans Sodium Crocetinate","chemicalName":"Transcrocetinate UPDATE1","conditionOrDisease":"ARDS","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Fri, 01 May 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Tue, 26 May 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Believed to benefit patients that present with significantly impaired oxygen levels due to COVID-19","numSites":"","otherPartners":"University of Virginia Health,the Integrated Translational Research Institute of Virginia,Romanian National Institute of Infectious Diseases,ARENSIA Exploratory Medicine GmbH","phase":"1","preferredName":"Transcrocetinate UPDATE1","primaryCompletionDate":"","productId":223,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.drugbank.ca/drugs/DB05974","https://www.bioworld.com/COVID19products","https://investors.diffusionpharma.com/News/news-details/2020/Diffusion-Pharmaceuticals-Evaluating-TSC-Against-Acute-Respiratory-Distress-Syndrome-ARDS-in-COVID-19-Patients/default.aspx","https://www.bioworld.com/COVID19products ; https://www.globenewswire.com/news-release/2020/05/20/2036342/0/en/Diffusion-Pharmaceuticals-Expands-Clinical-Trial-Program-of-TSC-for-the-Treatment-of-COVID-19-Patients-to-Include-the-Romanian-National-Institute-of-Infectious-Diseases.html","https://investors.diffusionpharma.com/News/news-details/2020/Diffusion-Pharmaceuticals-Receives-Accelerated-FDA-Response-to-Proposed-TSC-COVID-19-Clinical-Trial-Program/default.aspx","https://www.globenewswire.com/news-release/2020/05/20/2036342/0/en/Diffusion-Pharmaceuticals-Expands-Clinical-Trial-Program-of-TSC-for-the-Treatment-of-COVID-19-Patients-to-Include-the-Romanian-National-Institute-of-Infectious-Diseases.html"],"sponsors":[{"sponsorId":"51372c96cd390e9e8158f561b56bea3bddd3f04d","sponsorName":"Diffusion Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"LY3127804","chemicalName":"UPDATE1","conditionOrDisease":"COVID-19","contact":[{"email":"Clinicaltrials.gov@lilly.com","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 20 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Selective against angiopoietin 2,which is elevated in ARDS patients","numSites":"2","otherPartners":"","phase":"2","preferredName":"UPDATE1","primaryCompletionDate":"Mon, 30 Nov 2020 00:00:00 GMT","productId":224,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04342897","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Evanston","country":"USA","lat":42.0640773,"lng":-87.6848502,"locationId":"b483132f97b348343132019d935043b0ada7eb01","name":"Northshore University Healthsystem","state":"IL"},{"city":"Indianapolis","country":"USA","lat":39.6492587,"lng":-86.0798355,"locationId":"a6f330b653693792b08ff095b14609f982c0b868","name":"Franciscan St. Francis Health","state":"IN"}],"sources":["https://www.bioworld.com/COVID19products","https://www.pharmaceutical-business-review.com/news/lilly-baricitinib-covid-19/","https://www.thestreet.com/latest-news/eli-lilly-studying-two-potential-treatments-for-covid-19","http://www.pharmatimes.com/news/lilly_to_test_olumiant","_ly3127804_against_covid-19_1338253","https://clinicaltrials.gov/ct2/show/NCT04342897"],"sponsors":[{"sponsorId":"c3304b2181ddd0c29d7e4e948394439adc182494","sponsorName":"Eli Lilly and Co"}],"status":"Ongoing","studyCompletionDate":"Mon, 30 Nov 2020 00:00:00 GMT","studyStartDate":"Mon, 20 Apr 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Olumiant","chemicalName":"Baricitinib","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Oral JAK1/JAK2 inhibitor previously approved for treatment of arthritis,Bioworld classifies the trial as a phase 2/3 hybrid but there exists no detailed entry for said trial","numSites":"","otherPartners":"National Institute of Allergy and Infectious Diseases","phase":"","preferredName":"Baricitinib","primaryCompletionDate":"","productId":225,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.biospace.com/article/eli-lilly-to-begin-testing-ra-drug-olumiant-and-an-anti-ang2-drug-in-covid-19-patients/","https://www.drugbank.ca/drugs/DB11817","https://www.biospace.com/article/eli-lilly-to-begin-testing-ra-drug-olumiant-and-an-anti-ang2-drug-in-covid-19-patients/ https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"c3304b2181ddd0c29d7e4e948394439adc182494","sponsorName":"Eli Lilly and Co"},{"sponsorId":"d70d811c8de3a7e0ae950118837789ce8599f09b","sponsorName":"Incyte Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"","brandName":"COVID-HIG,COVID-EIG","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Cell therapies","notes":"No indication that COVID-HIG or EIG (human and horse hyperimmune plasma - respectively) are entering pre-clinical or phase 1 trials any time soon,no projected dates either","numSites":"","otherPartners":"Biomedical Advanced Research and Development Authority,Emergent and the National Institute of Allergy and Infectious Diseases","phase":"","preferredName":"COVID-HIG,COVID-EIG","primaryCompletionDate":"","productId":226,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive?field_nir_news_date_value[min]=","https://www.fool.com/investing/2020/03/25/fda-facilitating-use-of-plasma-from-recovered-pati.aspx","https://www.fool.com/investing/2020/03/25/fda-facilitating-use-of-plasma-from-recovered-pati.aspx https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive?field_nir_news_date_value[min]="],"sponsors":[{"sponsorId":"fb6f2b512443fdfe4d4b85aa2d74466d4ef9bcb4","sponsorName":"Emergent Biosolutions Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"GC376","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Tue, 26 May 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Protease Inhibitor","numSites":"","otherPartners":"","phase":"","preferredName":"GC376","primaryCompletionDate":"","productId":563,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.anivive.com/news/anivive-repurposes-veterinary-drug-gc376-for-covid-19"],"sponsors":[{"sponsorId":"87a69b194f663880aae077ec24d04b741ce55425","sponsorName":"Anivive Lifesciences"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"ENU-200","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Oral drug intended for asymptomatic and mild to moderate cases,Ennaid in discussions with FDA and other agencies to bring ENU200 to market within 6-9 months through phase 3 in-home self-dosing clinical trial","numSites":"","otherPartners":"Catalent Inc.","phase":"","preferredName":"ENU-200","primaryCompletionDate":"","productId":228,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://ennaidthera.com/science/","https://ennaidthera.com/catalent-signs-development-agreement-with-ennaid-therapeutics-on-its-covid-19-lead-program/","https://ennaidthera.com/science/ https://www.prnewswire.com/news-releases/ennaid-therapeutics-announces-development-of-enu200-a-new-antiviral-therapeutic-for-the-treatment-of-covid-19-301034232.html","https://www.dallasweekly.com/articles/black-woman-scientist-files-patent-for-coronavirus-treatment/"],"sponsors":[{"sponsorId":"5d1294f0cbab726f6c4136eaea842857641103a9","sponsorName":"Ennaid Therapeutics LLC"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"","brandName":"Interferon-beta-1a,traumakine","chemicalName":"FP-1201-lyo","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Finland"],"countryCodes":["FIN"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 18 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Tested with ritonavir and lopinavir in the WHO Solidarity Trial,the researchers who completed the first study is currently conducting two more","numSites":"","otherPartners":"","phase":"","preferredName":"FP-1201-lyo","primaryCompletionDate":"","productId":229,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.faron.com/index.php/pipeline/traumakine-fp-1201-lyo","https://www.bioworld.com/COVID19products","https://www.faron.com/news-events/news-and-press-releases?rnsid=1387792&cid=2223","https://www.sciencedirect.com/science/article/pii/S0166354220302059","https://www.faron.com/contact","https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-; https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2&rank=3","https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30894-1/fulltext https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2","https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments","https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2&rank=3","https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2"],"sponsors":[{"sponsorId":"a14a930a99f757de7464f323c64a61c4425eeab9","sponsorName":"Faron Pharmaceuticals Oy"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"No","brandName":"FW-1022","chemicalName":"niclosamide","conditionOrDisease":"COVID-19","contact":[{"email":"karine.faure@chru-lille.fr","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Oral drug targeting GI symptoms,expected to reach clinical trials in mid-2020 in the European Union and United States","numSites":"","otherPartners":"","phase":"3","preferredName":"niclosamide","primaryCompletionDate":"Sat, 01 May 2021 00:00:00 GMT","productId":230,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04372082","repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.firstwavebio.com/pipeline/","https://www.bioworld.com/COVID19products","https://www.firstwavebio.com/firstwave-bio-to-initiate-phase-2a-2b-study-of-fw-1022-a-proprietary-form-of-niclosamide-to-treat-covid-19/","https://www.clinicaltrials.gov/ct2/show/NCT04372082?term=niclosamide&draw=2&rank=10"],"sponsors":[{"sponsorId":"cbb02257499f9c2c7d7271d953b3560d56ea08ab","sponsorName":"Firstwave Bio Inc"}],"status":"Ongoing","studyCompletionDate":"Sat, 01 May 2021 00:00:00 GMT","studyStartDate":"Sat, 01 May 2021 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"FIB Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Germany"],"countryCodes":["DEU"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Mon, 16 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Isolated and characterized antibody that can bind conserved epitope on spike protein and neutralize lab virus as of May 7,moving to enter preclinical testing","numSites":"","otherPartners":"Labs of Jason McLellan (University of Texas at Austin- US),Markus Hoffman and Stefan Pohlmann (German Primate Center - Leibniz Institute for Primate Research - Gottingen - Germany)","phase":"","preferredName":"FIB Therapeutic","primaryCompletionDate":"","productId":231,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","http://www.vib.be/en/news/Pages/VIB-moves-forward-in-the-development-of-a-COVID-19-prophylactic.aspx","https://www.sciencedaily.com/releases/2020/05/200506104425.htm"],"sponsors":[{"sponsorId":"57edd5513cc69010f620c128c8a4cd203199a017","sponsorName":"Flanders Institute for Biotechnology"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"rCIG","chemicalName":"gammaglobulin","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Polyclonal antibodies,will not enter clinical trials until early 2021","numSites":"","otherPartners":"","phase":"","preferredName":"gammaglobulin","primaryCompletionDate":"","productId":232,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.fiercebiotech.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies?mkt_tok=eyJpIjoiT0dFNE16bGhPRFk1WTJNMiIsInQiOiJiUDhYM1ZWdzJLY04zbnc1T3IzVmFUK2NVVzFSeXY3SFhtZnNVWU5wWHFSYUxjcVwva0ZLZUVGRTBVSlBoMFlpY1FHQ0ZGODF0akV6TENzb3pWSmR0bFwvRllHbnQ5amptalwvZTdhN0J5UlJMeXVhSnhYcHNabkNBVXhhZTFSVHNJRHVtVEpqcU02aXN3SWRFSXRuUGNkVlE9PSJ9&mrkid=72869502","https://www.bioworld.com/COVID19products","https://www.fiercebiotech.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies?mkt_tok=eyJpIjoiT0dFNE16bGhPRFk1WTJNMiIsInQiOiJiUDhYM1ZWdzJLY04zbnc1T3IzVmFUK2NVVzFSeXY3SFhtZnNVWU5wWHFSYUxjcVwva0ZLZUVGRTBVSlBoMFlpY1FHQ0ZGODF0akV6TENzb3pWSmR0bFwvRllHbnQ5amptalwvZTdhN0J5UlJMeXVhSnhYcHNabkNBVXhhZTFSVHNJRHVtVEpqcU02aXN3SWRFSXRuUGNkVlE9PSJ9&mrkid=72869502 https://healthadvancesblog.com/2020/05/13/protective-antibody-therapy-preventing-future-covid-19-outbreaks/","https://gigagen.com/#pipeline"],"sponsors":[{"sponsorId":"88873a8fec57e2eafb81051d4b164951b8b32ded","sponsorName":"Gigagen Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"Truvada","chemicalName":"emtricitabine,tenofovir","conditionOrDisease":"COVID-19","contact":[{"email":"jamo@mscbs.es; rpolor@mscbs.es","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 15 Apr 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Previously accepted HIV treatment that combines emtricitabine and tenofovir repurposed to treat COVID 19","numSites":"65","otherPartners":"Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital","phase":"3","preferredName":"emtricitabine,tenofovir","primaryCompletionDate":"","productId":233,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04334928","repurposed":"Repurposed-Approved","siteLocations":[{"city":null,"country":"ESP","lat":40.46366700000001,"lng":-3.74922,"locationId":"b2ebb441256ed8bd5724370ae78746c8c5aa4954","name":"Spain","state":null}],"sources":["https://www.bioworld.com/COVID19products","https://www.gilead.com/science-and-medicine/medicines","https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/edit#gid=2075421071","https://www.gilead.com/","https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2&rank=2","https://www.pharmacytimes.com/ajax/prep-medications-may-be-potential-covid-19-treatments","https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2"],"sponsors":[{"sponsorId":"cbb34f9aed92e21ff89501b842a385faabf9c8c6","sponsorName":"Gilead Sciences Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Wed, 15 Apr 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Trike therapeutic","chemicalName":"GTB-3550 (OXS-3550)","conditionOrDisease":"High-risk myelodysplastic syndromes,acute myelogenous leukemia,systemic mastocytosis,mast cell leukemia","contact":[{"email":"mille011@umn.edu","name":null,"notes":"","phone":"612-625-7409","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 21 Jan 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 31 Mar 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Currently in clinical trial for acute myeloid lukemia,however it has not been cleared for clinical trials in COVID-19 patients - note that the clinical trial information in columns AD to AM is not representative of the COVID-19 pipeline","numSites":"1","otherPartners":"","phase":"2","preferredName":"GTB-3550 (OXS-3550)","primaryCompletionDate":"Thu, 01 Feb 2024 00:00:00 GMT","productId":234,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT03214666","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Minneapolis","country":"USA","lat":44.97399,"lng":-93.2277285,"locationId":"76be534543b0e7ea232045055102e6b4cecafbb2","name":"University Of Minnesota Minneapolis","state":"MN"}],"sources":["https://www.gtbiopharma.com/news-media/press-releases/detail/182/gt-biopharma-and-cytovance-biologics-announce-collaboration","https://www.bioworld.com/COVID19products","https://www.gtbiopharma.com/news-media/press-releases/detail/185/gt-biopharma-announces-commencement-of-retreatment-of","https://www.gtbiopharma.com/news-media/press-releases/detail/159/gt-biopharma-receives-fda-clearance-to-commence","https://www.gtbiopharma.com/news-media/press-releases/detail/180/gt-biopharma-provides-update-concerning-triketm-drug","https://www.clinicaltrials.gov/ct2/show/NCT03214666?term=gtb-3550&draw=2&rank=1"],"sponsors":[{"sponsorId":"19311beed76e39b72841d55b12b1026f4994706e","sponsorName":"GT Biopharma Inc"},{"sponsorId":"66f07a8584ac1fa31540d4786854faf6c4aa3957","sponsorName":"Cytovance Biologics"}],"status":"Ongoing","studyCompletionDate":"Fri, 01 Aug 2025 00:00:00 GMT","studyStartDate":"Wed, 01 Jan 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Harrington Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Unknown","notes":"Aims to accelerate near-term therapies to treat COVID-19,developed a proven model to allow other scientists to accelerate their breakthrough discovers,overall I believe this entry should be deleted - very vague and little promise of anything,if anything this entry is more of a call to action for others to find therapies than a therapy in itself","numSites":"","otherPartners":"","phase":"","preferredName":"Harrington Therapeutic","primaryCompletionDate":"","productId":235,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.uhhospitals.org/harrington-discovery-institute/multimedia/hdi-press-releases/hdi-at-uh-to-aid-in-global-fight-against-coronavirus-pandemic"],"sponsors":[{"sponsorId":"bf94ba6ac350c9a5c8dc12ad79ceb170e893d9a7","sponsorName":"Harrington Discovery Institute"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"HB-adMSCs","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 14 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 24 Apr 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"Clinical study mentioned is one of three,two more are in earlier stages","numSites":"1","otherPartners":"Medrio","phase":"2","preferredName":"HB-adMSCs","primaryCompletionDate":"","productId":237,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04349631","repurposed":"New","siteLocations":[{"city":"Sugar Land","country":"USA","lat":29.6018105,"lng":-95.625022,"locationId":"297e3106e7e8f7d67b1c9897ae1fd06a46abd748","name":"Hope Biosciences","state":"TX"}],"sources":["https://www.bioworld.com/COVID19products","https://www.hope.bio/clinical-trials","https://www.pharmaceutical-business-review.com/news/hope-biosciences-covid-19-stem-cell/","https://www.medindia.net/health-press-release/Medrio-Assisting-Hope-Biosciences-to-Combat-COVID-19-with-New-Stem-Cell-Clinical-Trial-461667-1.htm#","https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/edit#gid=2075421071","https://www.clinicaltrials.gov/ct2/show/NCT04349631?term=HB-adMSCs&sort=nwst&draw=2&rank=3"],"sponsors":[{"sponsorId":"b6a4863d0716a8f9abb22fd5f19ab102949816cc","sponsorName":"Hope Biosciences LLC"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Thu, 07 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Lenzilumab","chemicalName":"humanized monoclonal antibody (class IgG1 kappa)","conditionOrDisease":"COVID 19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"16","otherPartners":"Catalent,Humanigen Inc.","phase":"3","preferredName":"humanized monoclonal antibody (class IgG1 kappa)","primaryCompletionDate":"Tue, 01 Sep 2020 00:00:00 GMT","productId":238,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04351152","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Phoenix","country":"USA","lat":33.65676,"lng":-111.959062,"locationId":"3a826d564fb136e640ea6885fb2f66d797bf7f16","name":"Mayo Clinic","state":"AZ"},{"city":"Los Angeles","country":"USA","lat":34.0223519,"lng":-118.285117,"locationId":"85f8cb53bfd8fb13df433486b332c4ff493c0a70","name":"University Of Southern California","state":"CA"},{"city":"Jacksonville","country":"USA","lat":30.315687,"lng":-81.6637016,"locationId":"422208cff4d2c910298ee0c4f7cfa4ae2a9776ee","name":"Baptist Medical Center","state":"FL"},{"city":"Jacksonville","country":"USA","lat":30.2626481,"lng":-81.44514559999999,"locationId":"6184c3ae79971d3aa00e087ca4fc1c823cd0b701","name":"Mayo Clinic","state":"FL"},{"city":"Orlando","country":"USA","lat":28.5746404,"lng":-81.37075089999999,"locationId":"a968ee3b71dd230874857892d518dda4e7cb6817","name":"Adventhealth Orlando","state":"FL"},{"city":"Atlanta","country":"USA","lat":33.7971368,"lng":-84.32224,"locationId":"6cc290c28a0757817c5750fc34cd81d3b1185757","name":"Emory University","state":"GA"},{"city":"Florence","country":"USA","lat":39.0161895,"lng":-84.63103559999999,"locationId":"74be18b974ed97d98a4b2cecef8e1ace5bb94b8f","name":"St. Elizabeth Healthcare","state":"KY"},{"city":"Minneapolis","country":"USA","lat":44.9722301,"lng":-93.2615932,"locationId":"cedd07a46ae74d01a90ec507978bf36ca47d067a","name":"Hennepin County Medical Center","state":"MN"},{"city":"Lebanon","country":"USA","lat":43.6754932,"lng":-72.2729588,"locationId":"1a22476ff033ef232907ef036618a761b2ba9ca4","name":"Dartmouth","state":"NH"},{"city":"Livingston","country":"USA","lat":40.7631494,"lng":-74.3047629,"locationId":"6eb7e564f33c65f7d806d31229ffbb732269af39","name":"Saint Barnabas Medical Center","state":"NJ"},{"city":"Charlotte","country":"USA","lat":35.2034162,"lng":-80.8385574,"locationId":"970e0392494f356a43981b2eb94cab05ca4c0ed6","name":"Atrium Health","state":"NC"},{"city":"Austin","country":"USA","lat":30.4114435,"lng":-97.70628219999999,"locationId":"cf728023543b5e61400507c56a67971589ad8add","name":"St. David's Healthcare","state":"TX"},{"city":"Austin","country":"USA","lat":30.4114435,"lng":-97.70628219999999,"locationId":"e34f24cec89db491b4f1f375c6fae3e6aa74f33a","name":"St. David's North Austin Medical Center","state":"TX"},{"city":"Dallas","country":"USA","lat":32.8796854,"lng":-96.762135,"locationId":"66000b0aaa27f4252c2ed9b225822d0e85cbc39b","name":"Texas Health","state":"TX"}],"sources":["https://www.bioworld.com/COVID19products","https://www.humanigen.com/press/FDA-Approves-Initiation-of-Humanigen%E2%80%99s-Phase-III-Study-of-Lenzilumab-in-COVID-19-Patients","https://clinicaltrials.gov/ct2/show/NCT04351152?term=lenzilumab&draw=2&rank=3"],"sponsors":[{"sponsorId":"a81896aa5b137b226eae204c475800cdbc8c227f","sponsorName":"Humanigen Inc"}],"status":"Ongoing","studyCompletionDate":"Tue, 01 Sep 2020 00:00:00 GMT","studyStartDate":"Sun, 10 May 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"endonuclease","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Sun, 01 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Small molecule","notes":"Considering the use of endonuclease inhibitors that have been proven useful in blocking the SARS virus","numSites":"","otherPartners":"Iktos SAS","phase":"","preferredName":"endonuclease","primaryCompletionDate":"","productId":239,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.sri.com/iktos-and-sri-international-announce-collaboration-to-combine-artificial-intelligence-and-novel-automated-discovery-platform-for-accelerated-development-of-new-anti-viral-therapies/press-release/","https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"9363c36807614b06638e420a1f2fa93b6641816b","sponsorName":"SRI International"},{"sponsorId":"29880b129c04d0739018086a6448810f55c10ce5","sponsorName":"Iktos"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"Monoclonal Antibody","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Other","notes":"","numSites":"","otherPartners":"ImmuneCyte Life Sciences Inc.,Thermogenesis Holdings Inc.","phase":"","preferredName":"Monoclonal Antibody","primaryCompletionDate":"","productId":240,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://thermogenesis.com/thermogenesis-and-immunecyte-joint-venture-developing-several-convalescent-plasma-and-antibody-therapeutic-approaches-against-covid-19-featured-on-fox40-and-other-local-news-outlets/"],"sponsors":[{"sponsorId":"892eef6b8ee8f7b4199971bb0a2cbe4a6ac874c3","sponsorName":"ImmuneCyte Life Sciences Inc"},{"sponsorId":"2d735c3d9d663fcc08e98c3576299ec02b7f8090","sponsorName":"Thermogenesis Holdings Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Lodonal - CYTO 106,IRT-101","chemicalName":"Low Dose Naltrexone","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Unknown","notes":"Initially developed for use in HIV,Has shown efficacy in decreasing replication of H1N1 influenza","numSites":"","otherPartners":"Immune therapeutics Inc.","phase":"2","preferredName":"Low Dose Naltrexone","primaryCompletionDate":"","productId":241,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"6ea4d83cf95f6a8d357720443be824816569a0f0","sponsorName":"Cytocom Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Avdoralimab","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"nicolas.schleinitz@ap-hm.fr","name":null,"notes":"","phone":"","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 27 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"In phase 1 development for treatment of solid tumors including hepatocellular carcinoma and non-small cell lung cancer","numSites":"1","otherPartners":"Assistance Publique Hopitaux De Marseille","phase":"2","preferredName":"Avdoralimab","primaryCompletionDate":"Sat, 27 Jun 2020 00:00:00 GMT","productId":242,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04371367","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Marseille","country":"FRA","lat":43.296482,"lng":5.36978,"locationId":"1e38bbc557d13f86efd55cb8b6ad1f233798a7f6","name":"Marseille","state":"Provence-Alpes-C\u00f4te d'Azur"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=1","https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/record/NCT04371367","https://www.innate-pharma.com/en/news-events/press-releases/first-patient-dosed-avdoralimab-phase-ii-clinical-trial-covid-19-patients-severe-pneumonia","https://clinicaltrials.gov/ct2/show/study/NCT04371367","https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=2","https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=3","https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=4","https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=5","https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=6","https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=7","https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=8","https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=9"],"sponsors":[{"sponsorId":"b337560632de8abae925da303babdc79ea05dadb","sponsorName":"Innate Pharma SA"},{"sponsorId":"587b66a05b02fcac9b73edf0cbb79d9cd55ecd52","sponsorName":"Marseille Immunopole"}],"status":"Ongoing","studyCompletionDate":"Tue, 27 Oct 2020 00:00:00 GMT","studyStartDate":"Mon, 27 Apr 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"IZN-101","chemicalName":"Namilumab","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"At the Humanitas Research Hospital","numSites":"","otherPartners":"Humanitas Research Group","phase":"2","preferredName":"Namilumab","primaryCompletionDate":"","productId":243,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Milan","country":"ITA","lat":45.4642035,"lng":9.189982,"locationId":"7b9d132ba05c1162beb91535a650ac569c042a7d","name":"Milan","state":"Lombardy"}],"sources":["https://www.bioworld.com/COVID19products","https://izanabio.com/initiation-of-two-centre-compassionate-use-study-involving-namilumab-in-the-treatment-of-individual-patients-with-rapidly-worsening-covid-19-infection-in-italy/","https://www.pharmaceutical-technology.com/news/izana-namilumab-covid-19-study/","http://www.pharmatimes.com/news/izana_intiates_study_assessing_namilumab_for_covid-19_1337405"],"sponsors":[{"sponsorId":"62b5112b8c89d1a47c69aa94e5bc89d7166f157b","sponsorName":"Izana Bioscience Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Airuka","chemicalName":"camrelizumab plus thymosin","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 10 Feb 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Originally intended for the treatment of Hodgkin Lymphoma and hepatocellular carcinoma","numSites":"1","otherPartners":"Southeast University","phase":"2","preferredName":"camrelizumab plus thymosin","primaryCompletionDate":"Thu, 30 Apr 2020 00:00:00 GMT","productId":244,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04268537","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Lakeland","country":"USA","lat":28.0301306,"lng":-81.9179961,"locationId":"20fa223c976b7acd71bd6c1ecc2b18a03d17b5bd","name":"Southeast University","state":"FL"}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04268537"],"sponsors":[{"sponsorId":"44eafbed318ddb4f38d794fb4efd9f98455cbe54","sponsorName":"Jingsu HengRui Medicine Co"}],"status":"Ongoing","studyCompletionDate":"Sat, 31 Oct 2020 00:00:00 GMT","studyStartDate":"Mon, 10 Feb 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Tocilizumab biosimilar","chemicalName":"monoclonal antibody","conditionOrDisease":"COVID-19","contact":[{"email":"Pengzy5@hotmail.com","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 25 Feb 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Originally intended for the treatment of Rheumatoid arthritis and systemic juvenile idiopathic arthritis","numSites":"1","otherPartners":"Central South Hospital of Wuhan University","phase":"2","preferredName":"monoclonal antibody","primaryCompletionDate":"","productId":245,"registryLink":"http://www.chictr.org.cn/showprojen.aspx?proj=49883","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Arkansas City","country":"USA","lat":37.1329945,"lng":-97.0384445,"locationId":"ceadfd4ec10f4a178cb1343fbb944b1e312718b0","name":"Central South Hospital","state":"KS"},{"city":"Wuhan","country":"CHN","lat":30.5360485,"lng":114.3643219,"locationId":"938468403edaff8bc0a3a927c184310b64eed5f2","name":"Wuhan University","state":"Hubei"}],"sources":["https://www.bioworld.com/COVID19products","http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030196","http://www.chictr.org.cn/showprojen.aspx?proj=49883","http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030197","http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030198","http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030199","http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030200","http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030201","http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030202"],"sponsors":[{"sponsorId":"324d178c669e71e0405a90eac0b5a43232854ad4","sponsorName":"Jinyu Biotechnology Co Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Tue, 25 Feb 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"Antibodies","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Antibody treatment for the neutralization of COVID-19 (The drug candidate is designed to prevent the binding of viruses to host cell surface receptor ACE2)","numSites":"","otherPartners":"Junshi Biosciences Ltd,Institute of Microbiology of the Chinese Academy of Sciences -Eli Lilly","phase":"Pre-Clinical","preferredName":"Antibodies","primaryCompletionDate":"","productId":246,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://asia.nikkei.com/Spotlight/Caixin/Eli-Lilly-partners-with-Shanghai-Junshi-for-COVID-19-cure"],"sponsors":[{"sponsorId":"cf093c3c3034066cc4fc396f460d2433806ea0c3","sponsorName":"Junshi Biosciences Ltd"},{"sponsorId":"e494e00fc769e5a7fbfae8fa40eb4e348fb6dd3b","sponsorName":"Institute of Microbiology of the Chinese Academy of Sciences"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"Colchicine","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"priscilla.hsue@ucsf.edu","name":null,"notes":"","phone":"6282068257","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"4","otherPartners":"","phase":"3","preferredName":"Colchicine","primaryCompletionDate":"","productId":261,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04322682","repurposed":"Repurposed-Approved","siteLocations":[{"city":"SF","country":"USA","lat":37.7749295,"lng":-122.4194155,"locationId":"ef4632ea0884b1702fc0900ea41938463140223a","name":null,"state":"CA"},{"city":"New York","country":"USA","lat":40.742133,"lng":-73.97385109999999,"locationId":"44475c99bba066b4049db2cb0b597458fe74002f","name":"New York University School Of Medcine","state":"NY"},{"city":"Montr\u00e9al","country":"CAN","lat":45.5734782,"lng":-73.5785783,"locationId":"d63f77cb6638c9f8be249d5a66b1dfc6fe105454","name":"Montreal Heart Institute","state":"QC"},{"city":"Madrid","country":"ESP","lat":40.4811633,"lng":-3.6873977,"locationId":"c9a82d36c480ddf26cda0240b10365e8532a8312","name":"Hospital Universitario La Paz","state":"Comunidad de Madrid"}],"sources":["https://www.bioworld.com/COVID19products","https://www.icm-mhi.org/en/new-clinical-trial-treatment-covid-19-positive-patients-start-nyu-grossman-school-medicine","https://www.drugbank.ca/drugs/DB01394"],"sponsors":[{"sponsorId":"249179236abc76c285b00f0d0d7abc1e9abfdaa2","sponsorName":"Montreal Heart Institute"},{"sponsorId":"21765278273510ad7dc80a80afe9b1cf27f3e6d5","sponsorName":"NYU Grossman School of Medicine"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 23 Mar 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Xpovio","chemicalName":"selinexor","conditionOrDisease":"COVID-19","contact":[{"email":"jshah@karyopharm.com","name":null,"notes":"","phone":"(617) 658-0600","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 30 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"33","otherPartners":"Karyopharm Therapeutics Inc ","phase":"2","preferredName":"selinexor","primaryCompletionDate":"Mon, 31 Aug 2020 00:00:00 GMT","productId":247,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04349098","repurposed":"Repurposed-Approved","siteLocations":[{"city":null,"country":"USA","lat":37.09024,"lng":-95.712891,"locationId":"82264002e4326c4dae85b074ee94f1f902ae9fa3","name":"United States","state":null},{"city":null,"country":"AUT","lat":47.516231,"lng":14.550072,"locationId":"b0cfc062e0853bd7f7c0ffcaa86c838ad5049046","name":"Austria","state":null},{"city":null,"country":"FRA","lat":46.227638,"lng":2.213749,"locationId":"de2f2cd1054a45794ac96cd3a9236e798d42afb6","name":"France","state":null},{"city":null,"country":"ISR","lat":31.046051,"lng":34.851612,"locationId":"9d123586ec0d1b1cf5d9b8309feecebf2c1632ff","name":"Israel","state":null},{"city":null,"country":"ESP","lat":40.46366700000001,"lng":-3.74922,"locationId":"b75da34389b1fe2e1812d0d859f1f8301a28dcf7","name":"Spain","state":null},{"city":null,"country":"GBR","lat":55.378051,"lng":-3.435973,"locationId":"59c220ad5f3ee79a85b5ca4325c50d770aa1057f","name":"The United Kingdom","state":null}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=1","https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=2","https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=3","https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=4","https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=5","https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=6","https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=7","https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=8","https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=10","https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=12","https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=13","https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=14","https://clinicaltrials.gov/ct2/show/NCT04349098?term=Selinexor&cond=covid&draw=2&rank=2#contactlocation"],"sponsors":[{"sponsorId":"e6cb84b316561809b01b60e49451ae9585f9599e","sponsorName":"Karyopharma Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"Mon, 31 Aug 2020 00:00:00 GMT","studyStartDate":"Fri, 17 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"ARM/NK Therapy","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Combination","notes":"","numSites":"","otherPartners":"Kleo Pharmaceuticals Inc.,Green Cross Labcell","phase":"","preferredName":"ARM/NK Therapy","primaryCompletionDate":"","productId":248,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=605","https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=606","https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=607","https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=608","https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=609","https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=610","https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=611"],"sponsors":[{"sponsorId":"65a4395646171957f48b542bb3f8a88cb60f8744","sponsorName":"Kleo Pharmaceuticals Inc"},{"sponsorId":"5d01024199c1e46eb25ce5e44ac99c1bd0431f67","sponsorName":"Green Cross Labcell"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Panaphix","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"Komipharm International","phase":"","preferredName":"Panaphix","primaryCompletionDate":"","productId":249,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.biospectrumasia.com/news/39/15559/novotech-wins-cro-contract-for-covid-19-clinical-trial-in-south-korea.html"],"sponsors":[{"sponsorId":"80d5660a048cb4f5f9120ad0ee6693d572076feb","sponsorName":"Komipharm International Co Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"","brandName":"Giapreza","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"La Jolla Pharmaceutical Co.","phase":"","preferredName":"Giapreza","primaryCompletionDate":"","productId":250,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.rxlist.com/giapreza-drug.htm","https://www.giapreza.com/about-giapreza/"],"sponsors":[{"sponsorId":"eaeb4d2f6090de798cc599bb33c63aece3ea3e59","sponsorName":"La Jolla Pharmaceutical Co"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Lemellosome","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Discovery","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"Novel treatment based on using lipid vesicles for nucleic acid delivery","numSites":"","otherPartners":"Lamellasome Biomedical","phase":"Discovery","preferredName":"Lemellosome","primaryCompletionDate":"","productId":251,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.lamellar.com/news/9/59/Lamellar-Biomedical-launches-program-designed-to-prevent-the-severe-respiratory-effects-of-COVID-19-using-its-unique-LAMELLASOME-Technology.html","https://www.lamellar.com/","https://www.lamellar.com/lamellasome-and-pulmonary-diseases/"],"sponsors":[{"sponsorId":"a1a954d36a30fd0780c3b830f4faea0c8c2affb2","sponsorName":"Lamellar Biomedical Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"LAU-7b","chemicalName":"fenretinide","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Novel drug for CF,but Phase 2 will include 200 COVID-19 patients","numSites":"","otherPartners":"","phase":"","preferredName":"fenretinide","primaryCompletionDate":"","productId":252,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.bioworld.com/COVID19products","https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/laurent-pharmaceuticals-joins-battle-against-covid-19","https://www.drugbank.ca/drugs/DB05076","https://www.manchestertimes.com/news/business/laurent-pharmaceuticals-receives-health-canada-s-approval-to-initiate-covid-19-clinical-trial/article_a59fbdf1-509a-569f-a9c4-841fa17608ae.html"],"sponsors":[{"sponsorId":"7fccb09ede9fdc5e7fac92574b058cb03352c217","sponsorName":"Laurent Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"LB-1148","chemicalName":"tranexamic acid","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"tranexamic acid","primaryCompletionDate":"","productId":253,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://pipelinereview.com/index.php/2020040774270/Small-Molecules/Leading-BioSciences-Announces-Potential-for-Investigational-Drug-LB1148-to-Treat-Multiple-Organ-Dysfunction-Syndrome-in-COVID-19-Patients.html","https://leadingbiosciences.com/lb1148/","https://leadingbiosciences.com/"],"sponsors":[{"sponsorId":"939a860ac278db9d975ccb0616222eeeef87f0e8","sponsorName":"Leading Biosciences Inc"},{"sponsorId":"910ae71fffb2962bd05519a67ecec935ef621b0d","sponsorName":"University of Alabama"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Sanofi SA,Amneal Pharmaceuticals INc.,Rising Pharma Holdings Inc.,University of Minnesota,University of Oxford,IHU-M\u00e9diterran\u00e9e Infection,Sandoz Inc.,Bayer AG,University of Washington,Patient-Centerede Outcomes Research Institute,World Health Organization,New York State Department of Health,National Institute or Respiratory Diseases - Mexico,","chemicalName":"chloroquine or hydroxychloroquine","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"On March 28th,FDA issued emergency use authorization of chloroquine phosphate and hydroxychloroquine sulfate","numSites":"","otherPartners":"","phase":"","preferredName":"chloroquine or hydroxychloroquine","primaryCompletionDate":"","productId":254,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"86b83695165cca282e4f9c439eda39501ae4f0df","sponsorName":"Lupus Therapeutics"}],"status":"On Hold","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antimalarial drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Thiolanox","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"chris@nitricsolutions.com","name":null,"notes":"","phone":"778-899-0607","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"Inhaled gaseous Nitric Oxide","numSites":"1","otherPartners":"","phase":"2","preferredName":"Thiolanox","primaryCompletionDate":"","productId":255,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT03331445","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Vancouver","country":"CAN","lat":49.2609056,"lng":-123.1259083,"locationId":"56eae1111d76c074e0968e1ad698bb46a042d7ad","name":"Diamond Centre","state":"BC"}],"sources":["https://www.bioworld.com/COVID19products","https://pharmaphorum.com/news/mallinckrodt-novoteris-nitric-oxide-will-start-covid-19-trial/","https://eyewire.news/articles/mallinckrodt-and-novoteris-receive-clearance-from-health-canada-to-start-pilot-trial-of-inhaled-nitric-oxide-therapy-for-covid-19/"],"sponsors":[{"sponsorId":"1bae5c9e81061a3096b953a0c281893f63528dcf","sponsorName":"Mallinckrodt plc"},{"sponsorId":"6911212feb8516a3c67e4d56ab144214fba04e7c","sponsorName":"Novoteris LLC"}],"status":"Ongoing","studyCompletionDate":"Wed, 31 Mar 2021 00:00:00 GMT","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Prototype powders","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"Pulmonary Drug Delievery","numSites":"","otherPartners":"","phase":"","preferredName":"Prototype powders","primaryCompletionDate":"","productId":256,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.ondrugdelivery.com/mannkind-refocuses-pipeline-resources-in-response-to-covid-19-pandemic/"],"sponsors":[{"sponsorId":"98d35ba7fbc9135eb8b0efad1c369b7efd428d50","sponsorName":"Mannkind Corp"},{"sponsorId":"7879cb30e61a74d5398a4ad84131b67c7bdef5e5","sponsorName":"Immix Biopharma Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Cell therapies","notes":"","numSites":"","otherPartners":"Canadian Institutes for Health Research","phase":"","preferredName":"Antibodies","primaryCompletionDate":"","productId":257,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.medicago.com/en/covid-19-programs/","https://www.medicago.com/en/"],"sponsors":[{"sponsorId":"c3b31ebe3bec88be1939ba82b92fd751109ba63c","sponsorName":"Medicago Inc"},{"sponsorId":"89ce3145e138aa498d0b8624253df8d652b51d01","sponsorName":"Laval University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"MN-166","chemicalName":"ibudilast","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"ibudilast","primaryCompletionDate":"","productId":258,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.medicago.com/en/covid-19-programs/","https://www.clinicaltrialsarena.com/news/yale-ibudilast-covid-19-trial/"],"sponsors":[{"sponsorId":"93b330b91c5cf5de4858a317eb4e5d88f5c33274","sponsorName":"Medicinova Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"Ivermectin","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"sbudhiraja@maxhealthcare.com","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"","preferredName":"Ivermectin","primaryCompletionDate":"Sat, 25 Jul 2020 00:00:00 GMT","productId":259,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04373824","repurposed":"Repurposed-Approved","siteLocations":[{"city":"New Delhi","country":"IND","lat":28.6139391,"lng":77.2090212,"locationId":"9a9c5ceebe2cbe49147dcadbc7bb0dce67e30eab","name":null,"state":"DL"}],"sources":["https://www.bioworld.com/COVID19products","https://www.ncbi.nlm.nih.gov/pubmed/28942281","https://www.fda.gov/animal-veterinary/product-safety-information/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment-covid-19-humans"],"sponsors":[{"sponsorId":"62af02d502c3b46af39cf1393ded764d02cf2dd3","sponsorName":"Medincell SA"},{"sponsorId":"4504468bad51eef6a2ac6172fa89a91614df3c56","sponsorName":"Merck"}],"status":"Ongoing","studyCompletionDate":"Sat, 25 Jul 2020 00:00:00 GMT","studyStartDate":"Sat, 25 Apr 2020 00:00:00 GMT","therapeuticApproach":"Antibiotics and antiparasitics","trialId":""},{"acceptsHealthySubjects":"","brandName":"WP-1122","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"WP-1122","primaryCompletionDate":"","productId":260,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.prnewswire.com/news-releases/moleculin-announces-active-compound-in-wp1122-reduces-coronavirus-replication-in-vitro-by-100-301037143.html","https://www.moleculin.com/covid-19/"],"sponsors":[{"sponsorId":"bfc86f4330be66b8207ed43b7e662f038bf16e6e","sponsorName":"Moleculin Biotech Inc"},{"sponsorId":"47b17e1c6508ca65a8f74513d8a91bf7fea67bd1","sponsorName":"University of Texas Medical Branch"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"CD-16,N-803,mesenchymal stem cells","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 15 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":"Wed, 15 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"CD-16 off-the-shelf natural killer cells to enhance antibody killing of infected cells given alone or combined with Convalescent Plasma (CP) in combination with ImmunityBio\u2019s IL-15 superagonist N-803 and Avelumab","numSites":"","otherPartners":"Nantkwest Inc.,Immunitybio Inc.,National Institute of Allergy and Infectious Diseases.","phase":"","preferredName":"CD-16,N-803,mesenchymal stem cells","primaryCompletionDate":"","productId":262,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"13fabd5b14178a13d0539b59d6a9be0b068e4309","sponsorName":"Nantkwest Inc"},{"sponsorId":"8bfec75fcf441b5e6dfde4d8556e152456e80321","sponsorName":"Immunitybio Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Pritumumab","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Thu, 19 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":"Tue, 03 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"a natural human IgG1 kappa antibody that has been derived from a B cell isolated from regional draining lymph node of a cervical carcinoma patient","numSites":"","otherPartners":"Nascent Biotech Inc.","phase":"","preferredName":"Pritumumab","primaryCompletionDate":"","productId":263,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"b3867b6cd9697e882535adad3e08532327c9d976","sponsorName":"Nascent Biotech Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Nitricil therapeutic","chemicalName":"nitric oxide","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":"Fri, 20 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"Wainwright & Co. LLC","phase":"","preferredName":"nitric oxide","primaryCompletionDate":"","productId":264,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"ddee329111caa7d96be4e5aea7fa3ccfaccac422","sponsorName":"Novan Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"ST-266","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Mon, 30 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"Noveome Biotherapeutics Inc.,US government","phase":"","preferredName":"ST-266","primaryCompletionDate":"","productId":265,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"8c4038c7c0eddd116fc3688efef61be78abbacb4","sponsorName":"Noveome Biotherapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"RNAi therapeutic","chemicalName":"small interfering RNAs","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Mon, 23 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"","notes":"The siRNAs would operate within the RNAi pathway where it interferes with the expression of the genes with complementary nucleotide sequences by degrading mRNA after transcription resulting in no translation.","numSites":"","otherPartners":"OliX Pharmaceuticals Inc","phase":"","preferredName":"small interfering RNAs","primaryCompletionDate":"","productId":266,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"96c730a852872cf66c35cb125b2d7d05d8530e76","sponsorName":"Olix Pharmaceuticals"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"","brandName":"KTH-222","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Small molecule","notes":"anticancer drug","numSites":"","otherPartners":"Kalos Therapeutics,Oncology Pharma Inc.","phase":"","preferredName":"KTH-222","primaryCompletionDate":"","productId":267,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"94591eec9484636deee6e0aa9cf402169c390282","sponsorName":"Oncology Pharma Inc"},{"sponsorId":"eb7a2deb781669d168a882d3eb969a94f3b7b5d9","sponsorName":"Kalos Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"","brandName":"VNAR antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Wed, 08 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Lundbeck,Ossianix Inc.","phase":"","preferredName":"VNAR antibodies","primaryCompletionDate":"","productId":268,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"e0168852b1423a84cb2e4cc6a63702915618d555","sponsorName":"Ossianix Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"Ostrich antibodies","chemicalName":"ostrich IgY antibodies","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":"Mon, 30 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Ostrich Pharma USA","phase":"1","preferredName":"ostrich IgY antibodies","primaryCompletionDate":"","productId":269,"registryLink":null,"repurposed":"New","siteLocations":[{"city":"Frisco","country":"USA","lat":33.1021814,"lng":-96.84083869999999,"locationId":"207c6cb4e7ad0208bd3cd01a0134bb39ed136ad5","name":"Rinku Medical Clinic","state":"TX"}],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"81131cc14196ec0102f65dd04174c541d8ed0900","sponsorName":"Ostrich Pharma USA Ostrigen"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Sat, 04 Jan 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Leukine","chemicalName":"Sargramostim","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Belgium"],"countryCodes":["BEL"],"currentStage":"Phase 4","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"SKIPPED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"SKIPPED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"SKIPPED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"1","otherPartners":"University Hospital Ghent,Flanders Institute of Biotechnology","phase":"4","preferredName":"Sargramostim","primaryCompletionDate":"","productId":270,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":"Gent","country":"BEL","lat":51.0243683,"lng":3.7261567,"locationId":"88212547ebf5e374a06771de9364421741ba0f49","name":"University Hospital Ghent","state":"Vlaanderen"}],"sources":["https://www.bioworld.com/COVID19products","https://www.partnertx.com/11508-2/","https://www.drugbank.ca/drugs/DB00020","https://www.oncolink.org/cancer-treatment/oncolink-rx/sargramostim-leukine-r-gm-csf","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE"],"sponsors":[{"sponsorId":"8b5205e0d7efb338bddea3c077306518cd3232bc","sponsorName":"Partner Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Microbiome therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Microbiome therapeutic","primaryCompletionDate":"","productId":271,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.prnewswire.com/news-releases/persephone-biosciences-announces-ai-driven-microbiome-therapeutic-and-diagnostic-programs-for-covid-19-301033668.html","https://www.nbcsandiego.com/news/local/microbiome-targeted-therapeutics-may-have-role-in-covid-19-fight/2306310/"],"sponsors":[{"sponsorId":"8a2aaacc01bd11f71c410206ebedcdc6087bc015","sponsorName":"Persephone Biosciences Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Centhaquine","chemicalName":"PMZ-2010","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["India"],"countryCodes":["IND"],"currentStage":"Phase 3","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"PMZ-2010","primaryCompletionDate":"","productId":272,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.pharmazz.com/pmz-2010-h.php","https://www.bioworld.com/COVID19products","https://www.pharmiweb.com/press-release/2020-04-09/centhaquine-can-provide-hemodynamic-stability-improve-tissue-oxygenation-reduce-pulmonary-edema-a","https://pubchem.ncbi.nlm.nih.gov/compound/Centhaquine#section=Related-Compounds-with-Annotation","https://clinicaltrials.gov/ct2/results?cond=&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=Pharmazz%2C+Inc.&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=","https://clinicaltrials.gov/ct2/show/NCT04045327"],"sponsors":[{"sponsorId":"ccbaab96d082b74ca31a6f4f904d47ead69db5d3","sponsorName":"Pharmazz INc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Neumifil","chemicalName":"Sp2CBMTD","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Carbohydrate bonding module (CBM40) blocks sialic acid receptors in respiratory tract and prevents virus from entering host cells","numSites":"","otherPartners":"","phase":"Pre-clinical","preferredName":"Sp2CBMTD","primaryCompletionDate":"","productId":273,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.pneumagen.com/uploads/images/publications/Antimicrob.%20Agents%20Chemother.-2015-Govorkova-1495-504.pdf","https://www.bioworld.com/COVID19products","https://www.prnewswire.co.uk/news-releases/pneumagen-leverages-its-novel-glycan-approach-to-target-coronavirus-covid-19-infections-840930671.html","https://www.pneumagen.com/science.html","https://www.pneumagen.com/pipeline/respiratory-tract-infection.html","https://www.linkedin.com/company/pneumagen-limited/","https://www.pneumagen.com/pipeline.html"],"sponsors":[{"sponsorId":"983efe23794f5ea689b6644c79f8581943a74fe3","sponsorName":"Pneumagen Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"CoreCyte,Others","chemicalName":"Umbilical Cord Mesenchymal Stem Cells (UC-MSCs)","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Manufacturing","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Cell therapies","notes":"Umbilical Cord Mesenchymal Stem Cells isolated from Wharton's Jelly,Applied for FDA approval for immediate use for Covid-19 on 04/09/2020","numSites":"","otherPartners":"Wuhan Union Hospital- China,Wuhan Hamilton Bio-technology Co. Ltd  - China.,ZhiYong Peng,Tuohua Biological Technology Co. Ltd","phase":"","preferredName":"Umbilical Cord Mesenchymal Stem Cells (UC-MSCs)","primaryCompletionDate":"","productId":274,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.biospace.com/article/releases/predictive-submits-emergency-use-authorization-application-for-treatment-of-acute-respiratory-distress-syndrome-secondary-to-covid-19-with-umbilical-cord-mesenchymal-stem-cells/","https://www.bioworld.com/COVID19products; https://www.predictivebiotech.com/company/","https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04269525","https://clinicaltrials.gov/ct2/show/NCT04273646","https://www.predictivebiotech.com/wp-content/uploads/2019/05/CC_Product_Snapshot_v3_2019.pdf","https://clinicaltrials.gov/ct2/show/NCT04269525 ; https://clinicaltrials.gov/ct2/show/NCT04273646","https://www.predictivebiotech.com/company/","https://www.predictivebiotech.com/products/"],"sponsors":[{"sponsorId":"761c8b0485e032a24d29f63f18726bb53f50bdc1","sponsorName":"Predictive Biotech"},{"sponsorId":"0a520daf69e8730cf20a260e53d5354fd23003aa","sponsorName":"Predictive Technology"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"PRTX-007","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":"Tue, 31 Mar 2020 00:00:00 GMT","milestoneId":13,"name":"lead_selection","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Activates TLR7 to stimulate innate immune system","numSites":"","otherPartners":"","phase":"","preferredName":"PRTX-007","primaryCompletionDate":"","productId":275,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.primmunerx.com/press-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications/","https://www.bioworld.com/COVID19products","https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html","https://www.primmunerx.com/#contact"],"sponsors":[{"sponsorId":"59184ad543e6f439787b2e2ac1527ea53b1e5ac1","sponsorName":"Primmune Therapeutics"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Inhalded mRNA","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Sat, 04 Jan 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"Manufacturing intended to initiate summer 2020,Expected clinical testing in 4th quarter of 2020 pending regulatory approval","numSites":"","otherPartners":"","phase":"","preferredName":"Inhalded mRNA","primaryCompletionDate":"","productId":340,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.neurimmune.com/news/neurimmune-and-ethris-sign-collaboration-agreement-to-rapidly-develop-inhaled-mrna-based-antibody-therapy-for-the-treatment-of-covid-19"],"sponsors":[{"sponsorId":"1d194ed49d10f544c68a1c9d4116020692ba8b5b","sponsorName":"Neurimmune"},{"sponsorId":"c6ddaeaa6ff1e400a4d8f29afd9415df2398bd02","sponsorName":"Ethris"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"SARS-CoV-2 neutralizing antibody","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Singapore"],"countryCodes":["SGP"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 25 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"No candidate yet. Still at discovery stage.","numSites":"","otherPartners":"Heidelberg University Hospital,T\u00fcbingen University Hospital,the German Cancer Research Center (DKFZ),the NMI Natural and Medical Sciences Institute,NUS Enterprise,10x Genomics,NovogeneAIT","phase":"","preferredName":"SARS-CoV-2 neutralizing antibody","primaryCompletionDate":"","productId":276,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://proteona.com/Proteona-leads-international-consortium-to-develop-SARS-CoV-2-neutralizing-antibody-to-help-vulnerable-immunocompromised-individuals.html"],"sponsors":[{"sponsorId":"245b051b6523c597e8560495815affabbbd6151f","sponsorName":"Proteona Pte Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Yeliva","chemicalName":"Opaganib","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Israel"],"countryCodes":["ISR"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Fri, 08 May 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Phase 2 trial IND application made","numSites":"","otherPartners":"","phase":"","preferredName":"Opaganib","primaryCompletionDate":"","productId":277,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.redhillbio.com/yeliva","https://www.bioworld.com/COVID19products","https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/redhill-seeks-us-fda-approval-to-begin-clinical-study-of-yeliva-for-covid-19-58087112","https://pubchem.ncbi.nlm.nih.gov/compound/abc294640#section=Pharmacology-and-Biochemistry","http://apogee-biotech.com/index.php/news/","https://www.globenewswire.com/news-release/2020/05/08/2030275/0/en/RedHill-Biopharma-Receives-FDA-Approval-for-COVID-19-Clinical-Study-with-Opaganib-in-the-U-S.html"],"sponsors":[{"sponsorId":"e8c8185248be3a1b2daf8211acc52922e6293844","sponsorName":"Redhill Biopharma Ltd"},{"sponsorId":"f01ab327db3d24c889ea79c039140f87ed85ab74","sponsorName":"Apogee Biotechnology Group Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Upamostat","chemicalName":"RHB-107","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Israel"],"countryCodes":["ISR"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Passed phase 1 and 2 clinical trials for other diseases currently being tested in-vitro for Covid-19","numSites":"","otherPartners":"NIAID","phase":"Pre-clinical","preferredName":"RHB-107","primaryCompletionDate":"","productId":278,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15260","https://www.bioworld.com/COVID19products","https://www.pharmaceutical-technology.com/news/redhill-biopharma-covid-19-drug-candidate/","https://www.drugbank.ca/drugs/DB13052","https://www.redhillbio.com/rhb-107","https://www.redhillbio.com/contact","https://www.thepharmaletter.com/article/wilex-wx-671-enters-clinic","https://clinicaltrials.gov/ct2/show/NCT00615940?spons=Wilex&draw=2&rank=4"],"sponsors":[{"sponsorId":"e8c8185248be3a1b2daf8211acc52922e6293844","sponsorName":"Redhill Biopharma Ltd"},{"sponsorId":"4f42e3229651f0892787042619eb74da72a1a688","sponsorName":"Link Health Group"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Apabetalone","chemicalName":"2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-1,4-dihydroquinazolin-4-one","conditionOrDisease":"COVID19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Tue, 24 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 15 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 17 Mar 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 23 Mar 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":"Mon, 03 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"Private,NIHR","phase":"3","preferredName":"2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-1,4-dihydroquinazolin-4-one","primaryCompletionDate":"","productId":279,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.drugbank.ca/drugs/DB12000","https://www.bioworld.com/COVID19products","https://adisinsight.springer.com/drugs/800027698","https://www.resverlogix.com/science-and-programs/apabetalone","http://www.io.nihr.ac.uk/wp-content/uploads/2018/11/11198-Apabetalone-for-MACE-V1.0-OCT18-NON-CONF.pdf","https://www.resverlogix.com/science-and-programs/clinical","https://www.resverlogix.com/investors/news.html?article=660","https://www.resverlogix.com/upload/button/3/b9c82f751024/2019-rvx-corp-pres-march-18.pdf","https://www.globenewswire.com/news-release/2020/03/23/2004624/0/en/Resverlogix-Invites-Collaborations-for-use-of-Apabetalone-in-Trials-and-Studies-to-Combat-the-Spread-of-COVID-19-Based-on-New-Research.html","https://www.marketwatch.com/press-release/resverlogix-clinical-candidate-apabetalone-featured-as-a-potential-covid-19-treatment-in-recent-publication-2020-03-24?siteid=bigcharts&dist=bigcharts&tesla=y"],"sponsors":[{"sponsorId":"9e60afe62e3596c8891ede53bfdc0f1c2a71320a","sponsorName":"Resverlogix Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Bucillamine","chemicalName":"N-(mercapto-2-methylpropionyl)-l-cysteine","conditionOrDisease":"COVID19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 09 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Antirheumatic","numSites":"","otherPartners":"","phase":"2","preferredName":"N-(mercapto-2-methylpropionyl)-l-cysteine","primaryCompletionDate":"","productId":280,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":"Boston","country":"USA","lat":42.3584648,"lng":-71.0540018,"locationId":"b874fc2f196de0583c853b7ab086a0447a3d4f50","name":"Novotech: Asia","state":"MA"}],"sources":["https://www.globenewswire.com/news-release/2020/03/20/2003915/0/en/Revive-Therapeutics-Explores-the-Use-of-Bucillamine-as-a-Novel-Treatment-for-Infectious-Diseases-including-COVID-19.html","https://www.bioworld.com/COVID19products","https://www.drugbank.ca/drugs/DB12160","https://www.mdpi.com/1424-8247/12/4/165","https://www.reuters.com/companies/RVV.CD","https://clinicaltrials.gov/ct2/show/NCT02942420","https://novotech-cro.com/news/novotech-selected-new-covid-19-clinical-trial-asia-pacific"],"sponsors":[{"sponsorId":"df3723439d2a920860a172a5dd962f7ec0f7cc36","sponsorName":"Revive Therapeutics Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"EIDD-2801","chemicalName":"","conditionOrDisease":"COVD19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Tue, 07 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 10 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Oral antiviral","numSites":"4","otherPartners":"Wayne and Wendy Holman","phase":"1","preferredName":"EIDD-2801","primaryCompletionDate":"Tue, 16 Jun 2020 00:00:00 GMT","productId":281,"registryLink":null,"repurposed":"New","siteLocations":[{"city":"Daytona Beach","country":"USA","lat":29.213059,"lng":-81.08267699999999,"locationId":"3ea1ee3ee832ca66b55b5c427508a339b254c9a2","name":"Covance Daytona Beach Clinical Research Unit","state":"FL"},{"city":"Dallas","country":"USA","lat":32.8224209,"lng":-96.86509079999999,"locationId":"2e340ea9c2a410d560bdc2ba1057ff919b1e3124","name":"Covance Dallas Clinical Research Unit","state":"TX"},{"city":"Madison","country":"USA","lat":43.1268654,"lng":-89.33176209999999,"locationId":"a33de6b1c912ae05ab5b0d315741abe425993c46","name":"Covance Madison Clinical Research Unit","state":"WI"},{"city":null,"country":"GBR","lat":53.804327,"lng":-1.5563236,"locationId":"43060f6bd96b13b55317228c44befd5bd7f935a1","name":"Covance Leeds Clinical Research Unit","state":"England"}],"sources":["https://www.bioworld.com/COVID19products","https://www.drugbank.ca/drugs/DB15661","https://www.ptcommunity.com/wire/ridgeback-biotherapeutics-announces-mhra-clearance-begin-human-testing-eidd-2801-uk-covid-19","https://www.ridgebackbio.com/","https://clinicaltrials.gov/ct2/show/NCT04392219?term=EIDD-2801&draw=2&rank=1","https://www.drugtargetreview.com/news/59567/eidd-2801-shows-efficacy-against-covid-19-in-human-cells-and-mice/"],"sponsors":[{"sponsorId":"d4086aa4aca201f3493eee784dbab92ad400778f","sponsorName":"Ridgeback Biotherapeutics LP"},{"sponsorId":"4504468bad51eef6a2ac6172fa89a91614df3c56","sponsorName":"Merck"},{"sponsorId":"490f2c2447baa96b61de933f67b94a46fd87a097","sponsorName":"Drug Innovations at Emory LLC"}],"status":"Ongoing","studyCompletionDate":"Tue, 16 Jun 2020 00:00:00 GMT","studyStartDate":"Fri, 10 Apr 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Gimsilumab","chemicalName":"MORAb-022","conditionOrDisease":"COVID19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Switzerland"],"countryCodes":["CHE"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 19 Feb 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 12 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"14","otherPartners":"","phase":"2","preferredName":"MORAb-022","primaryCompletionDate":"Fri, 10 Jul 2020 00:00:00 GMT","productId":282,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.drugbank.ca/drugs/DB15280","https://www.bioworld.com/COVID19products","https://www.technologynetworks.com/drug-discovery/news/first-us-trial-participant-receives-gimsilumab-for-covid-19-and-acute-respiratory-distress-syndrome-333448","https://www.empr.com/home/news/drugs-in-the-pipeline/pipeline-investigational-therapies-for-covid-19/","https://www.clinicaltrialsarena.com/news/roivant-gimsilumab-covid-19-trial/","https://roivant.com/","https://pharmaphorum.com/news/roche-begins-phase-3-trial-of-actemra-in-covid-19-pneumonia/"],"sponsors":[{"sponsorId":"c0cd5a7a71a7a2120e0b79f29aacd606755aff2a","sponsorName":"Roivant Sciences Ltd"},{"sponsorId":"f062e8029186acd42f78d91ab787d4579d4c5484","sponsorName":"Altasciences Co Inc"}],"status":"Ongoing","studyCompletionDate":"Sat, 10 Oct 2020 00:00:00 GMT","studyStartDate":"Sun, 12 Apr 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"SAB-185","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"BARDA","phase":"","preferredName":"SAB-185","primaryCompletionDate":"","productId":283,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.medicalcountermeasures.gov/newsroom/2020/sab-185/","https://www.cslbehring.com/newsroom/2020/sab-covid-19","https://globalbiodefense.com/2020/04/01/jpeo-cbrnd-barda-partner-with-sab-biotherapeutics-to-develop-covid-19-therapeutic/","https://sabbiotherapeutics.com/"],"sponsors":[{"sponsorId":"21fe6f5f8237968ddc20622797f630647c872671","sponsorName":"Sab Biotherapeutics"},{"sponsorId":"586353dc7d3f7de1b8b0aaf247aaacaa7293cc9f","sponsorName":"CSL Behring LLC"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"S-Protein/ACE2 Targeted prohylactic polypeptide","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 01 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Apeiron Biologics","phase":"","preferredName":"S-Protein/ACE2 Targeted prohylactic polypeptide","primaryCompletionDate":"","productId":284,"registryLink":null,"repurposed":"New","siteLocations":[{"city":null,"country":"AUT","lat":47.516231,"lng":14.550072,"locationId":"0d5ae1ff91e5666a11370e496e608d18fcbb1f88","name":"Austria","state":null},{"city":null,"country":"DEU","lat":51.165691,"lng":10.451526,"locationId":"10a792092e80219ae219a444ad33396c999b03fb","name":"Germany","state":null},{"city":null,"country":"CNK","lat":56.26392,"lng":9.501785,"locationId":"5cbb4529066feb3dd8ab51fe043666f8ff39e445","name":"Denmark","state":null}],"sources":["https://www.bioworld.com/COVID19products","https://www.drugtargetreview.com/news/59290/decoy-ace2-receptors-could-be-promising-covid-19-infection-preventing-drug/","https://www.clinicaltrialsarena.com/news/apeiron-biologics-phaseii-covid-19/","https://www.cslbehring.com/","https://www.technologynetworks.com/drug-discovery/news/phase-2-clinical-trial-of-apn01-for-treatment-of-covid-19-inititated-332897"],"sponsors":[{"sponsorId":"8812b6d8e3894f01681250e96efa2ff723ccf680","sponsorName":"Sichuan Kelun Pharmaceutical Co Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Monoclonal antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Tue, 24 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"$14 million contract from US Department of Defense for Ology Bioservices and Vanderbilt to collaborate on antibody discovery against COVID-19,Twist to build a synthetic antibody discovery library based on sequences from a recovered COVID-19 patient from Vandebilt","numSites":"","otherPartners":"Twist Bioscience Corp.,DARPA,NIAID,Ology Bioservices Inc.","phase":"","preferredName":"Monoclonal antibodies","primaryCompletionDate":"","productId":294,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://news.vanderbilt.edu/2020/05/14/the-front-lines-vanderbilt-physicians-researchers-join-worldwide-fight-against-covid-19/","https://investors.twistbioscience.com/news-releases/news-release-details/twist-bioscience-partners-vanderbilt-university-medical-center","https://www.pharmaceutical-technology.com/news/covid-19-allovir-ology-drugs/ https://investors.twistbioscience.com/news-releases/news-release-details/twist-bioscience-partners-vanderbilt-university-medical-center","https://www.pharmaceutical-technology.com/news/covid-19-allovir-ology-drugs/"],"sponsors":[{"sponsorId":"3505691a86b3a9dacf9bb0dd76bfd49b7cd40e83","sponsorName":"Vanderbilt University"},{"sponsorId":"bb9ed07e215d6bebb274790c7ee0711a0da9f41e","sponsorName":"AstraZeneca"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Lipocurc","chemicalName":"Liposomal curcumin","conditionOrDisease":"COVID19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 12 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Other","notes":"Cancer Treatment","numSites":"","otherPartners":"Paracelsus Medical University,Discretionary Research Fund","phase":"2","preferredName":"Liposomal curcumin","primaryCompletionDate":"","productId":285,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":null,"country":"USA","lat":41.2033216,"lng":-77.1945247,"locationId":"9784410c908f0f56e6e27f028c17ce5e55a33a14","name":"Pennysylvania: Usa","state":"PA"}],"sources":["https://www.ncbi.nlm.nih.gov/pubmed/30430227","https://www.bioworld.com/COVID19products","https://www.researchgate.net/publication/258347314_Liposomal-formulated_curcumin_Lipocurc_targeting_HDAC_Histone_Deacetylase_prevents_apoptosis_and_improves_motor_deficits_in_Park_7_DJ-1-knockout_rat_model_of_Parkinson's_disease_implications_for_epige","https://finance.yahoo.com/news/signpath-pharma-focus-coronavirus-disease-132000816.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAMtxCulSHQRqpcWfz5eXklfWPZIxsyEpH3LfUs0lYTGd5XWIzXUfKYIN7lg0efispLMaTlsqNlKlgK0RXT8AEMJCBu_TipsZnVZutbwo1plJidTAfNKK9RxEYjbWGuefhN3x9Q-kMoFP-tPUWbZeHi2005ieCWY6KunPZMA8h7Bx","https://link.springer.com/article/10.1007/s00280-018-3654-0 ;  https://www.researchgate.net/publication/258347314_Liposomal-formulated_curcumin_Lipocurc_targeting_HDAC_Histone_Deacetylase_prevents_apoptosis_and_improves_motor_deficits_in_Park_7_DJ-1-knockout_rat_model_of_Parkinson's_disease_implications_for_epige","http://signpathpharma.com/","http://signpathpharma.com/portfolio/liposomal-curcumin-for-treatment-of-cancer/","https://www.businesswire.com/news/home/20200317005082/en/SignPath-Pharma-Focus-Coronavirus-Disease-COVID-19-Developing","http://signpathpharma.com/pipeline/#details"],"sponsors":[{"sponsorId":"3a23c78238689fa6d8b86e48413a0fbe0d9d35c1","sponsorName":"Signpath Pharma Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antiviral","chemicalName":"Interferon Alpha","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase1/2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 26 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 26 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"NIHR","phase":"","preferredName":"Interferon Alpha","primaryCompletionDate":"","productId":286,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.drugbank.ca/drugs/DB05258","https://www.thenews.com.pk/print/648623-chinese-healthcare-group-invites-nih-for-covid-19-vaccine-test","http://www.sinopharm.com/1156.html"],"sponsors":[{"sponsorId":"74c3cd3bc3fa22bf3900e0d4e84bb19508cb9132","sponsorName":"Sinopharm Group"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antiviral","chemicalName":"Glycosides","conditionOrDisease":"COVID19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"Private","phase":"","preferredName":"Glycosides","primaryCompletionDate":"","productId":287,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":"Val-de-Reuil","country":"FRA","lat":49.258212,"lng":1.187725,"locationId":"2215fe3af7e1c25a27bb66e4da312fb7ddcf9f8c","name":"Tfchem: France","state":"Normandie"}],"sources":["https://www.barrons.com/press-release/PR-CO-20200331-902751?tesla=y","https://www.bioworld.com/COVID19products","https://www.sironabiochem.com/sirona-biochem-initiates-covid-19-and-infectious-diseases-development-program/","https://www.sironabiochem.com/"],"sponsors":[{"sponsorId":"b943d0928f25a94239b30d1f795032375383033f","sponsorName":"Sirona Biotechem Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"Therapeutic","chemicalName":"Compounds that block the activity of the SARS-CoV-2 MPro protease","conditionOrDisease":"COVID19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Japan"],"countryCodes":["JPN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Tue, 14 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Compounds that block the activity of the SARS-CoV-2 MPro protease","primaryCompletionDate":"","productId":288,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://soseiheptares.com/news/599/129/Sosei-Heptares-to-apply-its-Structure-based-Drug-Design-Expertise-in-New-COVID-19-RD-Program.html","https://www.bioworld.com/COVID19products","https://www.sironabiochem.com/sirona-biochem-initiates-covid-19-and-infectious-diseases-development-program/"],"sponsors":[{"sponsorId":"a116938a80ab1812d2085339b93325c5e6a0805b","sponsorName":"Sosei Group Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"Lung airway cells","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Manufacturing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"Neither a treatment nor a prophylactic,mainly used to propagate the SARS-CoV-2 which allowed scientists at China's CDC to isolate the virus and obtain the gene sequence,clinical milestones and studies will not be filled out for this reason,development was finished before 03/25/2020 (which is when article about this breakthrough was published)","numSites":"","otherPartners":"CDC - China","phase":"","preferredName":"Lung airway cells","primaryCompletionDate":"","productId":289,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.stemcell.com/canadian-biotechnology-company-stemcell-technologies-provides-critical-support-to-sequence-the-covid-19-virus-accelerating-vaccine-development.html","https://www.bioworld.com/COVID19products https://www.stemcell.com/canadian-biotechnology-company-stemcell-technologies-provides-critical-support-to-sequence-the-covid-19-virus-accelerating-vaccine-development.html"],"sponsors":[{"sponsorId":"49edcacef773406a08e3a11e32fb4caf84388c84","sponsorName":"Stemcell Technologies Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Epaspire","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Tue, 14 Apr 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 13 Apr 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Purified EPA in a capsule currently in a Phase 3 clinical trial in Europe for treatment of FAP,well established safety profile and observed suppression of inflammatory cytokines that may contribute to COVID-19 progression,this allowed the quick initiation of Phase 3 COVID-19 trials and led to the goal of using EPAspire to reduce the complications of COVID-19","numSites":"Undisclosed","otherPartners":"","phase":"3","preferredName":"Epaspire","primaryCompletionDate":"Mon, 13 Jul 2020 00:00:00 GMT","productId":290,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04335032","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Sussex","country":"USA","lat":41.2136727,"lng":-74.4943643,"locationId":"03d2ed88bba76f1815be7c339d0ea74003b819ee","name":"Undisclosed","state":"NJ"}],"sources":["https://www.bioworld.com/COVID19products","https://www.kdpharmagroup.com/en/news/kd-pharma-group-sla-pharma-initiate-clinical-trial-covid-19","https://clinicaltrials.gov/ct2/show/NCT04335032?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=EPA&draw=2&rank=1"],"sponsors":[{"sponsorId":"06ec5df840715222bbeb972210bfa28ff5aceb2c","sponsorName":"The KD Pharma Group SA"},{"sponsorId":"b47bc7cc175c3bb7640659ad687ac2f480ba8fd6","sponsorName":"SLA Pharma AG"}],"status":"Ongoing","studyCompletionDate":"Fri, 31 Jul 2020 00:00:00 GMT","studyStartDate":"Mon, 13 Apr 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"TD-0903","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"medinfo@theravance.com","name":null,"notes":"COMPLETED","phone":"1-855-633-8479","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Lung-selective inhaled JAK inhibitor that has the potential to block cytokines and chemokines associated with ALI and ARDS,shown to have effective and broad inhibition of JAK-STAT signaling in rodent models,CTA was submitted in the UK on 04/09/2020 - approval pending and phase 1 will begin immediately after","numSites":"1","otherPartners":"","phase":"1","preferredName":"TD-0903","primaryCompletionDate":"Wed, 10 Jun 2020 00:00:00 GMT","productId":291,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04350736","repurposed":"New","siteLocations":[{"city":"Manchester","country":"GBR","lat":53.4807593,"lng":-2.2426305,"locationId":"39aed4b6096b95c2dfc3b91bbcfe2c39e250b24e","name":"Manchester","state":"England"}],"sources":["https://www.bioworld.com/COVID19products","https://www.prnewswire.com/news-releases/theravance-biopharma-responds-to-covid-19-pandemic-by-advancing-td-0903-to-treat-hospitalized-patients-with-acute-lung-injury-301038037.html","https://clinicaltrials.gov/ct2/show/NCT04350736"],"sponsors":[{"sponsorId":"262d9fad81968c24466a839589f81bece22471db","sponsorName":"Theravance"}],"status":"Ongoing","studyCompletionDate":"Wed, 10 Jun 2020 00:00:00 GMT","studyStartDate":"Fri, 10 Apr 2020 00:00:00 GMT","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"ARMS-I","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"ESTIMATED"}],"moleculeType":"Other","notes":"ARMS-I is a microbe-impermeable barrier with anti-viral action designed to prevent upper respiratory infections,currently holds an IND as a potential flu prophylaxis,clinical trial (unspecified phase but characteristics inmply phase 2) to investigate whether ARMS-I will help protect against COVID-19 in frontline health workers,no entry in clinicaltrials.gov yet","numSites":"","otherPartners":"ARMS Pharmaceutical LLC,Cleveland Foundation,Case Western Reserve University","phase":"2","preferredName":"ARMS-I","primaryCompletionDate":"","productId":292,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Cleveland","country":"USA","lat":41.5050672,"lng":-81.605476,"locationId":"c31ff1f3f251c874faf4e52e17a5ec105b78b538","name":"University Hospitals","state":"OH"},{"city":"Warren","country":"USA","lat":41.2221809,"lng":-80.7967887,"locationId":"f6da234fad2aca790cecab509e0c2d29da5d8aeb","name":"Northeast Ohio Health Systems","state":"OH"}],"sources":["https://www.bioworld.com/COVID19products","https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/04/uh-to-launch-clinical-trial-in-the-fight-to-protect-clinicians-against-covid19 https://www.trialsitenews.com/university-hospitals-cleveland-launch-clinical-trial-assessing-arms-i-to-protect-clinicians-from-covid-19/","https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/04/uh-to-launch-clinical-trial-in-the-fight-to-protect-clinicians-against-covid19","https://www.armspharmaceutical.com/arms-i-science https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/04/uh-to-launch-clinical-trial-in-the-fight-to-protect-clinicians-against-covid19"],"sponsors":[{"sponsorId":"081649a78e8f049d5576bf2c9694fd3841668997","sponsorName":"Cleveland University Hospitals"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Fri, 01 May 2020 00:00:00 GMT","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Tradipitant","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 13 Apr 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Tradipitant is currently undergoing clinical trials for other conditions such as gastroparesis,tradipitant is an NK-1R antagonist that is being tested to see if it can treat inflammatory lung injury associated with COVID-19","numSites":"1","otherPartners":"University of Illinois at Chicago","phase":"3","preferredName":"Tradipitant","primaryCompletionDate":"Sat, 01 Aug 2020 00:00:00 GMT","productId":293,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04326426","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"New York","country":"USA","lat":40.7736341,"lng":-73.9608549,"locationId":"78daf8f1826cc32f2806e8065fe01cd867115f58","name":"Lenox Hill Hospital Northwell Health","state":"NY"}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04326426?intr=tradipitant&draw=2&rank=2 https://vandapharmaceuticalsinc.gcs-web.com/node/14066/pdf","https://vandapharmaceuticalsinc.gcs-web.com/node/14066/pdf","https://clinicaltrials.gov/ct2/show/NCT04326426?intr=tradipitant&draw=2&rank=2"],"sponsors":[{"sponsorId":"d2734c3b72bd97da45e8be5b00151cb1c2fe5838","sponsorName":"Vanda Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"Mon, 31 Aug 2020 00:00:00 GMT","studyStartDate":"Mon, 13 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"VIR-7832","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"VIR-7831 and VIR-7832 are leading antibody candidates that have demonstrated high affinity for the SARS-CoV-2 spike protein,companies aim to directly enter phase 2 clinical trial within the next three to five months,currently still in the development phase","numSites":"","otherPartners":"Wuxi Biologics,National Institute of Allergy and Infectious Diseases,Xencor Inc.,Glaxosmithkline plc,Samsung Biologics Co. Ltd.","phase":"","preferredName":"VIR-7832","primaryCompletionDate":"","productId":295,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.vir.bio/contact/","https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-enter-collaboration-to-find-coronavirus-solutions/"],"sponsors":[{"sponsorId":"6c32fa743ed510db10e7c97fd975d2a2a5700a4a","sponsorName":"Vir Biotechnology Inc"},{"sponsorId":"7b6f419a075a9d4cfc1742367fdc3d11cc35f994","sponsorName":"Biogen Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Elpida","chemicalName":"elsafavirine","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 08 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Elpida is a non-nucleoside reverse transcriptase inhibitor that received market approval from the Russian Ministry of Health to treat HIV on 06/30/2017,initated Phase 2 clinical study to evaluate efficacy of Elpida in adults with COVID-19 on 04/08/2020 but currently has no entry on clinicaltrials.gov","numSites":"","otherPartners":"","phase":"2","preferredName":"elsafavirine","primaryCompletionDate":"","productId":296,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[{"city":null,"country":"RUS","lat":61.52401,"lng":105.318756,"locationId":"a9e15451ccc0f66427a41a8c2738ee18ee3f046e","name":"Russia","state":null},{"city":null,"country":null,"lat":52.0055148,"lng":37.95874939999999,"locationId":"d1f6cc6975856aaea33bc8257d615db855728ecd","name":"Eastern Eu Countries","state":null}],"sources":["https://www.bioworld.com/COVID19products","https://www.viriom.com/contact","https://www.viriom.com/news/2020/4/8/viriom-initiates-phase-2-clinical-study-of-elsulfavirine-for-treatment-of-covid-19 https://www.viriom.com/news/2017/11/30/viriom-obtains-first-market-approval-of-elsulfavirine-elpida-for-treatment-of-hiv-1-infection-in-russia","https://www.viriom.com/news/2020/4/8/viriom-initiates-phase-2-clinical-study-of-elsulfavirine-for-treatment-of-covid-19"],"sponsors":[{"sponsorId":"3e65bda0e3a4586a7154c208c474b7fc79f60ab1","sponsorName":"Viriom Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Fri, 01 May 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"","brandName":"Viscient Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"Viscient is using 3D bioprinting tech to create lung tissue to support research efforts on finding and testing COVID-19 therapies - clinical trial in a dish, as of 04/20/2020 - still working on a way to develop infected lung tissue","numSites":"","otherPartners":"","phase":"","preferredName":"Viscient Therapeutic","primaryCompletionDate":"","productId":297,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.10news.com/news/coronavirus/biotechs-3d-models-could-lead-to-coronavirus-treatments","https://www.scienceboard.net/index.aspx?sec=sup&sub=can&pag=dis&ItemID=610 https://www.kusi.com/san-diego-biotech-company-fighting-coronavirus-through-3d-bioprinting/"],"sponsors":[{"sponsorId":"8d59671a4747cb2aa6f2acfa1c51b5de8644ae5b","sponsorName":"Viscient Biosciences Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"CB1 antagonist","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"CB1 antagonist","primaryCompletionDate":"","productId":298,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"96dc8ffb76c357cda9bf1ea512a6b3faedc50ed5","sponsorName":"Viripharm Biopharmaceuticals LLC"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"KL4 surfactant","chemicalName":"Sinapultide","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Sinapultide","primaryCompletionDate":"","productId":299,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"b9d4687e32bd1665b98b110c465c991959943db7","sponsorName":"Windtree Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Mesenchymal stem cells","chemicalName":"UC-MSCs","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Unknown","notes":"","numSites":"1","otherPartners":"","phase":"","preferredName":"UC-MSCs","primaryCompletionDate":"Tue, 30 Jun 2020 00:00:00 GMT","productId":300,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04273646","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Wuhan Shi","country":"CHN","lat":30.599041,"lng":114.301165,"locationId":"cd5909d65fa7ffee855d71199d2af05e6065fbac","name":"Union Hospital","state":"Hubei Sheng"}],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"14038d17d9fa18917792c69af98837142687f2af","sponsorName":"Wuhan Hamilton Biotechnology Co Ltd"}],"status":"Ongoing","studyCompletionDate":"Tue, 15 Feb 2022 00:00:00 GMT","studyStartDate":"Mon, 20 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibody","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Belgium"],"countryCodes":["BEL"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Antibody","primaryCompletionDate":"","productId":301,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"aceff18e5b0594f0ed960779ae931d91cbc7fa9f","sponsorName":"VIBUGent Center for Medical Biotechnology"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Plasma treatment","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Plasma treatment","primaryCompletionDate":"","productId":302,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"d1a873903a92cac9d889e8f9ff8977b7f9e100ce","sponsorName":"Xbiotech Inc"},{"sponsorId":"96240c6492e03d5753e52d4da6fa236a7e4dc6f2","sponsorName":"Biobridge Global"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"XRx-101","chemicalName":"Oxypurinol","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Oxypurinol","primaryCompletionDate":"","productId":303,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"3942d9eba6d7c598d2d7548e1f99237e337f7f56","sponsorName":"Xortx Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antiviral","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Antiviral","primaryCompletionDate":"","productId":304,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"40539840e055053cf646a7a6c2d6f01184a9f4a3","sponsorName":"Xphyto Therapeutics Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Slovakia"],"countryCodes":["SVK"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Cell therapies","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Vaccine","primaryCompletionDate":"","productId":305,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"0fc1c2eb025301d74761cfdaad2e702a05e14ea7","sponsorName":"Axon Neuroscience SE"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Dendritic cell vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Cell therapies","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Dendritic cell vaccine","primaryCompletionDate":"","productId":306,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"08a21a27c82e51464712adac2679fb2dc228d69b","sponsorName":"Betta Pharmaceuticals Co Ltd"},{"sponsorId":"5971cf2c808d095d9d239606be69759cc12a3ff5","sponsorName":"Beijing Dingcheng Taiyuan Biotechnology"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Vaccine","primaryCompletionDate":"","productId":307,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"61c10d4a8a5dee7e9c508ca4cf94e5fb4aedf2a3","sponsorName":"Chongqing Zhifei Biological Products Co Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Fusogenix DNA Vaccine","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"Direct introduction of a plasmid encoding the antigen(s) against which an immune response is sought and relies on the production of the target antigen in the patient\u2019s own cells","numSites":"","otherPartners":"","phase":"Discovery","preferredName":"Fusogenix DNA Vaccine","primaryCompletionDate":"","productId":308,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.entospharma.com/news/entos-pharmaceuticals-is-developing-a-dna-vaccine-against-covid-19-using-its-fusogenix-nanomedicine-platform","https://www.pharmaceutical-business-review.com/news/entos-pharmaceuticals-fusogenix-covid-19/","https://www.entospharma.com/about"],"sponsors":[{"sponsorId":"792d66b4f6751aa1d3eabedb66b4e1a4b26c759b","sponsorName":"Entos Pharmaceuticals"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"ERC\u2019s SARS-Cov-2 Vaccine","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Belgium"],"countryCodes":["BEL"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Thu, 09 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Other","notes":"Vaccine containing virions,viral proteins at different stages of viral replication,whole human cells and cellular fragments,composing all elements of viral replication","numSites":"","otherPartners":"","phase":"Discovery","preferredName":"ERC\u2019s SARS-Cov-2 Vaccine","primaryCompletionDate":"","productId":309,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.globenewswire.com/news-release/2020/04/09/2014261/0/en/ERC-Launches-Development-Program-for-Novel-Cell-Based-Therapeutic-and-Prophylactic-SARS-CoV-2-Vaccine.html","https://www.erc-immunotherapy.com/","https://www.erc-immunotherapy.com/media/news/latest-situation-%E2%80%93-ceo-statement"],"sponsors":[{"sponsorId":"2bae05a8f1ef431f06f3f32e8a5b62ac2088a4e7","sponsorName":"Epitopoietic Research Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"","brandName":"Coroflu","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"Modification of M2SR by adding part of the coding region for the coronavirus spike protein","numSites":"","otherPartners":"Flugen Inc,Bharat Biotech International Ltd - India,University of Wisconsin-Madison","phase":"Discovery","preferredName":"Coroflu","primaryCompletionDate":"","productId":310,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://news.wisc.edu/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/","https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-in-tie-up-to-develop-a-covid-vaccine/articleshow/74977030.cms?from=mdr","http://flugen.com/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/"],"sponsors":[{"sponsorId":"d0615a827003e8423ac0ea3c03f9fbd824fc52b3","sponsorName":"Flugen Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"Ii-Key-SARS 2 peptide vaccine","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Thu, 27 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"China Technology Exchange,Beijing Zhonghua Investment Fund Management Co. LTD,Biology Institute of Shandong Academy of Sciences,Sinotek-Advocates International Industry Development (Shenzhen) Co. LTD","phase":"Discovery","preferredName":"Ii-Key-SARS 2 peptide vaccine","primaryCompletionDate":"","productId":311,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://pipelinereview.com/index.php/2020022973919/Vaccines/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html","https://generex.com/covid-19"],"sponsors":[{"sponsorId":"bd241b032c9ac50523b8215691176cc94b2966b6","sponsorName":"Generex Biotechnology Group"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Z-VacciRNA","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"","otherPartners":"","phase":"Discovery","preferredName":"Z-VacciRNA","primaryCompletionDate":"","productId":312,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"de3c929194d9aac1196f6a1b8c9e5983cfa58911","sponsorName":"Guanhao Biotech Co Ltd"},{"sponsorId":"f12c99eed6736f965feb517d2d827d893d1cd2b0","sponsorName":"Zy Therapeutics Inc"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Vaccine","primaryCompletionDate":"","productId":313,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"344b517c43ad6d6219c6a66b35a3d655b2918e54","sponsorName":"Hualan Biological Engineering"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Vaccine","primaryCompletionDate":"","productId":314,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"07b42758a4b70d9b70f8e828e2488a0d0c69160d","sponsorName":"ID Pharma Co Ltd"},{"sponsorId":"4567098e44fc907783878b149c6d70d1f14aec40","sponsorName":"Fudan University"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"Virus Suppressing Factor","chemicalName":"HzVSFv13","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Korea","Democratic People's Republic of"],"countryCodes":["PRK"],"currentStage":"Phase 1","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 28 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":43,"name":"phase_3","status":"COMPLETED"},{"category":"regulatory","date":"Fri, 21 Feb 2020 00:00:00 GMT","milestoneId":51,"name":"nda","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"HzVSFv13","primaryCompletionDate":"","productId":315,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","http://www.koreabiomed.com/news/articleView.html?idxno=7596","https://www.prnewswire.com/news-releases/immunemeds-hzvsf-used-for-treatment-of-covid-19-pneumonia-patients-301031662.html","http://www.immunemed.co.kr/eng/news/news.asp?look_url=%2Feng%2Fnews%2Fnews.asp&BPart=news&SPart=eng&sno=4328&mode=read&page_no=1&search_field=&search_text="],"sponsors":[{"sponsorId":"1b6935230a67257c55ec98d018cd779af0ce72b1","sponsorName":"Immunemed"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Nucleic Acid Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Nucleic Acid Vaccine","primaryCompletionDate":"","productId":316,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://epivax.com/featured/press-release-immunomic-therapeutics-forms-collaboration-with-epivax-and-pharmajet-to-develop-novel-vaccine-candidate-against-covid-19-using-its-investigational-unite-platform","https://www.hospimedica.com/covid-19/articles/294781719/immunomic-epivax-and-pharmajet-jointly-developing-covid-19-vaccine.html","https://epivax.com/news/press-release-pharmajet-partners-with-immunomic-therapeutics-and-epivax-to-develop-and-deliver-covid-19-vaccine"],"sponsors":[{"sponsorId":"32698ef58730c0db442e4711afe4d8872c1122fa","sponsorName":"Immunomic Therapeutics Inc"},{"sponsorId":"668459853f4364a918946339a776e7b4d8542169","sponsorName":"Epivax Inc"},{"sponsorId":"4a67621b1cdb93f9e5a800f34f028cee1e42d049","sponsorName":"Pharmajet"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"DPX-COVID-19","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Wed, 18 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Subunit Vaccines","notes":"Epitope based vaccine,Design of a Phase 1 clinical study in 48 healthy subjects completed,clinical sites identified in Nova Scotia and Quebec","numSites":"","otherPartners":"","phase":"Discovery","preferredName":"DPX-COVID-19","primaryCompletionDate":"","productId":317,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.ondrugdelivery.com/imv-development-of-dpx-covid-19-vaccine-its-ongoing-business-and-clinical-operations/","https://ir.imv-inc.com/press-releases/detail/635/imv-inc-launches-plans-to-advance-clinical-development-of","https://ir.imv-inc.com/press-releases/detail/638/imv-inc-provides-updates-on-the-development-of"],"sponsors":[{"sponsorId":"48214836aaae1d030dc63fd584ec75a89c69a299","sponsorName":"IMV Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"IPT-001","chemicalName":"peptide vaccine","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"peptide vaccine","primaryCompletionDate":"","productId":318,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://bioinformant.com/covid-19-vaccine-intellistem/","https://www.bioworld.com/COVID19products","https://www.drugbank.ca/unearth/q?utf8=%E2%9C%93&query=IPT-001&searcher=drugs","https://www.intellistemtech.com/contact"],"sponsors":[{"sponsorId":"e307a242cd4a80ef8961828e2bd56978153ba4c4","sponsorName":"Intellistem Technologies Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Polypeptide vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Polypeptide vaccine","primaryCompletionDate":"","productId":319,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.marketwatch.com/press-release/nucleic-acid-vaccine-market-report-covers-top-countries-data-2020-regional-analysis-by-top-key-players-development-size-global-industry-share-forecast-to-2026-2020-04-23"],"sponsors":[{"sponsorId":"e01b4e370f661002ed37476bd661968f309a64db","sponsorName":"Liaoning Chengda Biotechnology"},{"sponsorId":"bfce396095503d26f651c5dad224c79f44d87649","sponsorName":"Tsinghua University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"peptide mini-scaffold","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"High-affinity peptide scaffold that blocks interactions of SARS-CoV-2 to ACE2 receptor","numSites":"","otherPartners":"","phase":"","preferredName":"peptide mini-scaffold","primaryCompletionDate":"","productId":320,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.ligandal.com/"],"sponsors":[{"sponsorId":"4f3b270f3c1a96d8081041d6786e25d3ccc38629","sponsorName":"Ligandal Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Medigen Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Taiwan","Province of China"],"countryCodes":["TWN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"National Institutes of Health","phase":"","preferredName":"Medigen Vaccine","primaryCompletionDate":"","productId":321,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.malaysiakini.com/news/511154","http://www.medigen.com.tw/en/home/"],"sponsors":[{"sponsorId":"c76c86ae23d07fd42bbc979f6877c5fb8af70eb6","sponsorName":"Medigen Biotechnology Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"","brandName":"Mologic Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"UK Government COVID-19 research funding package","phase":"","preferredName":"Mologic Vaccine","primaryCompletionDate":"","productId":322,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://mologic.co.uk/mologic-awarded-c-1-million-by-uk-government-to-develop-rapid-diagnostic-test-for-covid-19/"],"sponsors":[{"sponsorId":"dd2867855c9bba29ec1a2f9db4b0e7896eb33b42","sponsorName":"Mologic Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"","brandName":"NantKwest vaccine","chemicalName":"second-generation AD5 platform","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Unknown","notes":"Clinical trials expected to start this quarter","numSites":"","otherPartners":"","phase":"","preferredName":"second-generation AD5 platform","primaryCompletionDate":"","productId":323,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://immunitybio.com/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/","https://www.bioworld.com/COVID19products","https://nantkwest.com/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/","https://nantkwest.com/contact/"],"sponsors":[{"sponsorId":"13fabd5b14178a13d0539b59d6a9be0b068e4309","sponsorName":"Nantkwest Inc"},{"sponsorId":"8bfec75fcf441b5e6dfde4d8556e152456e80321","sponsorName":"Immunitybio Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"Soligenix Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"University if Hawai'i at Manoa","phase":"","preferredName":"Soligenix Vaccine","primaryCompletionDate":"","productId":324,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","http://ir.soligenix.com/2020-03-23-Soligenix-and-University-of-Hawai-i-at-Manoa-Initiate-Work-on-Novel-Coronavirus-Vaccine-for-COVID-19","Seems implied in this article: http://ir.soligenix.com/2020-03-23-Soligenix-and-University-of-Hawai-i-at-Manoa-Initiate-Work-on-Novel-Coronavirus-Vaccine-for-COVID-19","seems implied in this article: http://ir.soligenix.com/2020-03-23-Soligenix-and-University-of-Hawai-i-at-Manoa-Initiate-Work-on-Novel-Coronavirus-Vaccine-for-COVID-19"],"sponsors":[{"sponsorId":"7795392453455f76046eb84a28aa370b14026e0c","sponsorName":"Soligenix Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"S Protein Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"S Protein Vaccine","primaryCompletionDate":"","productId":325,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.nbcnews.com/news/us-news/walter-reed-researchers-join-global-search-coronavirus-vaccine-n1165806","this source says the initial stages of clinical trials but I am not positive this means pre-clinical trials: https://www.nbcnews.com/news/us-news/walter-reed-researchers-join-global-search-coronavirus-vaccine-n1165806"],"sponsors":[{"sponsorId":"8badc8865679f144a1d2fbf604740245348ebc8e","sponsorName":"US Army Medical Research and Development Command"},{"sponsorId":"5dfde89cd058e25942ead74f974aa75a0b3ed04c","sponsorName":"Walter Reed Army Institute of Research"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"COVID-19 XWG-03","chemicalName":"truncated S-protein","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Originally started being developed to treat HPV","numSites":"","otherPartners":"GlaxoSmithKline","phase":"","preferredName":"truncated S-protein","primaryCompletionDate":"","productId":326,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1","https://www.bioworld.com/COVID19products","https://www.chinadaily.com.cn/a/201909/07/WS5d734d85a310cf3e3556a43c.html","https://www.reuters.com/article/brief-gsk-says-to-collaborate-with-xiame-idUSFWN2BR07C"],"sponsors":[{"sponsorId":"f3e18d1badc8e3e140a4e145313f20f56e471293","sponsorName":"Xiamen Innovax Biotech Co Ltd"},{"sponsorId":"bf45296df9f69d118ce8ad2b5fd20dcd2bb45568","sponsorName":"Xiamen University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"ZIP-1642","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Belgium"],"countryCodes":["BEL"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"ZIP-1642","primaryCompletionDate":"","productId":327,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.bioworld.com/articles/433873-other-news-to-note-for-march-23-2020"],"sponsors":[{"sponsorId":"12f2c56c2a8c8e754b73a3d0736ac5246e1fc2ca","sponsorName":"Ziphius Therapeutics NV"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"AG0302-COVID19,AG0301-COVID19","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"anges-cr@anges.co.jp","name":null,"notes":"","phone":"81-3-5730-2488","website":""}],"countries":["Japan"],"countryCodes":["JPN"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 30 Jun 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"8","otherPartners":"Takara Bio Inc.","phase":"Phase 3","preferredName":"AG0302-COVID19,AG0301-COVID19","primaryCompletionDate":"Sat, 26 Sep 2020 00:00:00 GMT","productId":328,"registryLink":["https://clinicaltrials.gov/ct2/show/NCT04655625","https://www.clinicaltrials.gov/ct2/show/NCT04527081"],"repurposed":"New","siteLocations":[{"city":"Narita","country":"JPN","lat":35.7612397,"lng":140.350504,"locationId":"8ca02ddd60b3222fa627f6ad505e41c6362d46ec","name":"Uhw Narita Hospital","state":"Chiba"},{"city":"Osaka","country":"JPN","lat":34.6987244,"lng":135.4928432,"locationId":"3972514bec5830ca127fe6b4a55d345547360396","name":"Medical Corporation Heishinkai Ocrom Clinic","state":"Osaka"},{"city":"Shibuya City","country":"JPN","lat":35.6874324,"lng":139.6970059,"locationId":"74fa2f84af4f9b468d8ec334266bf970e3404a82","name":"Medical Corporation Tsurukamekai Shinjuku Tsurukame C Linic","state":"Tokyo"},{"city":"Shinjuku City","country":"JPN","lat":35.6881821,"lng":139.7257391,"locationId":"3ebaad5bb736d3141f98d226a400d076b2cdb19d","name":"Medical Corporation Heishinkai Tocrom Clinic","state":"Tokyo"},{"city":"Minato City","country":"JPN","lat":35.6588818,"lng":139.746417,"locationId":"1c5d65c4aac40a6ba1784b4fc5fcbe20914d0c75","name":"Medical Corporation Shinanokai Shinanozaka Clinic","state":"Tokyo"},{"city":"Tokyo","country":"JPN","lat":35.6803997,"lng":139.7690174,"locationId":"5706f8c9a672b7cb02ecb750e542b9f5f44507b4","name":"Sekino Clinical Pharmacology Clinic","state":"Tokyo"},{"city":"Osaka","country":"JPN","lat":34.6994727,"lng":135.4919052,"locationId":"7343e5a7abd233edc931ac7d6193187ea2afff6d","name":"Nishi","state":"Osaka"},{"city":"Osaka","country":"JPN","lat":34.73518,"lng":135.496937,"locationId":"5f8e0639efb99955f2dd450099132f9c0460b693","name":"Medical Corporation Heishinkai Ophac Hospital","state":"Osaka"}],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.anges.co.jp/en/pdf.php?pdf=003Mk7IxCg7spYu6nteDj80QPMCznRi2.pdf","https://ir.takara-bio.co.jp/en/news_all/news_Release/news_Release201889409321505118082820200306.html","https://www.japantimes.co.jp/news/2020/06/30/national/science-health/japan-first-coronavirus-vaccine-clinical-test-starts/#.XxXF5yhKgdU","https://www.reuters.com/article/us-health-coronavirus-japan-anges/pharma-firm-anges-and-osaka-university-to-begin-testing-coronavirus-vaccine-on-animals-idUSKBN21B019","https://japantoday.com/category/national/update-1-pharma-firm-anges-and-osaka-university-to-begin-testing-coronavirus-vaccine-on-animals"],"sponsors":[{"sponsorId":"17be17f24c77c426a72f3b040131c995834c2be1","sponsorName":"AnGes"},{"sponsorId":"51adf29b45adb2321acc929eef1a1764661b4261","sponsorName":"Osaka University"}],"status":"Ongoing","studyCompletionDate":"Sat, 31 Jul 2021 00:00:00 GMT","studyStartDate":"Tue, 30 Jun 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Ilaris","chemicalName":"canakinumab","conditionOrDisease":"COVID-19 Pneumonia","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Switzerland"],"countryCodes":["CHE"],"currentStage":"","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Not yet recruiting for observational study,Very limited information on Novartis website about using Ilaris for COVID,just listed as one of numerous drugs under investigation for people with COVID infection","numSites":"","otherPartners":"","phase":"","preferredName":"canakinumab","primaryCompletionDate":"Fri, 10 Jul 2020 00:00:00 GMT","productId":329,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04348448","repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.clinicaltrials.gov/ct2/show/NCT04348448?term=ilaris&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1","https://www.drugbank.ca/drugs/DB06168","https://www.novartis.com/news/novartis-corporate-fact-sheet/major-facilities","https://www.novartis.com/coronavirus/response","https://www.clinicaltrials.gov/ct2/show/NCT04348448?term=ilaris&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1; https://www.novartis.com/coronavirus/response"],"sponsors":[{"sponsorId":"b08c1310d27c7a8b020bed114122bccabe38726f","sponsorName":"Novartis"}],"status":"Ongoing","studyCompletionDate":"Thu, 10 Sep 2020 00:00:00 GMT","studyStartDate":"Fri, 10 Apr 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Gamifant","chemicalName":"emapalumab","conditionOrDisease":"Hyperinflammation and respiratory distress in COVID-19 patients","contact":[{"email":"sobi.immuno@sobi.com","name":null,"notes":"","phone":"","website":""}],"countries":["Sweden"],"countryCodes":["SWE"],"currentStage":"Phase 2","indication":"Other","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 02 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"4","otherPartners":"","phase":"2","preferredName":"emapalumab","primaryCompletionDate":"Fri, 10 Jul 2020 00:00:00 GMT","productId":330,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04324021","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Brescia","country":"ITA","lat":45.5564352,"lng":10.2310468,"locationId":"99cba8b0054a4299a34c05154fb34aca46e08510","name":"Asst Spedali Civili Di Brescia Dipartimento Di Reumatologia E Immunologia Clinica","state":"Lombardia"},{"city":"Milano","country":"ITA","lat":45.4588156,"lng":9.195013699999999,"locationId":"11d2c6c0b29a18887fe9906073d26a2859d4db25","name":"Ospedale Maggiore Policlinico","state":"Lombardia"},{"city":"Parma","country":"ITA","lat":44.8006724,"lng":10.3084285,"locationId":"559373528983f308d49ec7cf465ae801229d23bd","name":"Azienda Ospedaliero","state":"Emilia-Romagna"},{"city":"Roma","country":"ITA","lat":41.866501,"lng":12.4564793,"locationId":"c2dfd99d8f6b9eeaf63ac30d070c97086fec94dd","name":"Ospedale Lazzaro Spallanzani","state":"Lazio"}],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.sobi.com/index.php/en/press-releases/sobi-initiate-clinical-study-evaluate-whether-anakinra-and-emapalumab-may-relieve","https://www.sobi.com/en/products","https://www.drugbank.ca/drugs/DB14724","https://www.sobi.com/en/about","https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3","https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3#contacts"],"sponsors":[{"sponsorId":"4be4dbabdaa77091d49b0c6b38bd5a8ef5b04a9d","sponsorName":"Swedish Orphan Biovitrum Sobi"}],"status":"Ongoing","studyCompletionDate":"Thu, 10 Sep 2020 00:00:00 GMT","studyStartDate":"Thu, 02 Apr 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibody","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Crowdsourcing","phase":"","preferredName":"Antibody","primaryCompletionDate":"","productId":331,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.distributedbio.com/covid19"],"sponsors":[{"sponsorId":"9ceaf8fbcb1950d5b4df0acbe1671777bd9893a0","sponsorName":"Distributed Bio"},{"sponsorId":"06e3c85a544975e5dfcec88f45b51e3fdf635c59","sponsorName":"Centivax"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"UK Government,University of Kent,Hong Kong University,National Institute for Biological Standards and Control","phase":"","preferredName":"Antibodies","primaryCompletionDate":"","productId":332,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.imperial.ac.uk/news/196413/fighting-coronavirus-imperial-researchers-secure-funds/","https://www.gov.uk/government/news/vaccine-trials-among-recipients-of-20-million-coronavirus-research-investment; https://www.imperial.ac.uk/news/196413/fighting-coronavirus-imperial-researchers-secure-funds/","https://www.gov.uk/government/news/vaccine-trials-among-recipients-of-20-million-coronavirus-research-investment"],"sponsors":[{"sponsorId":"9b2652ee65b8f7ac2fbc009851b6ef7d2faac03a","sponsorName":"Chelsea and Westminster Hospital"},{"sponsorId":"1a693dd5acf9f3ae07a65241da0b2f2102ed1377","sponsorName":"Imperial College London"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibody Therapeutic Innovent Biologics","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Antibody Therapeutic Innovent Biologics","primaryCompletionDate":"","productId":333,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.scmp.com/business/companies/article/3078085/chinese-cancer-drugs-developer-innovent-joins-crowded-field","https://www.btimesonline.com/articles/129691/20200403/chinese-drug-maker-innovent-biologics-developing-antibody-treatment-for-covid-19.htm"],"sponsors":[{"sponsorId":"d6b2121d955a97b23570b0c2284d3d758aca0355","sponsorName":"Innovent Biologics"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"recombinant chimeric monoclonal antibody","chemicalName":"IC14","conditionOrDisease":"COVID-19,ARDS","contact":[{"email":"dagna.lorenzo@unisr.it","name":null,"notes":"","phone":"","website":""}],"countries":["Australia"],"countryCodes":["AUS"],"currentStage":"","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Expanded access available","numSites":"1","otherPartners":"","phase":"Expanded access","preferredName":"IC14","primaryCompletionDate":"","productId":334,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04346277","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Milano","country":"ITA","lat":45.5069106,"lng":9.267293800000001,"locationId":"d2267653c61ddf3fb73d4bd48009544b129723fb","name":"Irccs San Raffaele Scientific Institute","state":"Lombardia"}],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://clinicaltrials.gov/ct2/show/NCT04346277","https://implicitbioscience.com/home/"],"sponsors":[{"sponsorId":"9676cb2db18bbea317e9ea9e591807187950be72","sponsorName":"Implicit Bioscience"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Vicromax","chemicalName":"merimepodib","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Submitted IND to FDA for Phase 2 trial for COVID-19 patients,Three Phase 2 trials completed in other idications,completed animal testing and phase 1 trials for other indications","numSites":"","otherPartners":"","phase":"","preferredName":"merimepodib","primaryCompletionDate":"","productId":335,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.biospace.com/article/releases/mayo-clinic-preparing-to-commence-phase-ii-fda-clinical-trial-for-the-treatment-of-covid-19-with-vicromax-/","https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf; https://www.biosig.com/viralclear","https://www.biosig.com/viralclear","https://www.drugbank.ca/drugs/DB04862","https://www.biosig.com/contact-biosig","https://www.biosig.com/viralclear; https://www.biosig.com/news-media/press-releases/detail/194/biosig-to-host-conference-call-on-recent-developments-of","https://www.biosig.com/news-media/press-releases/detail/194/biosig-to-host-conference-call-on-recent-developments-of"],"sponsors":[{"sponsorId":"7f3751a18145834311154ab95bfefa71b80ad512","sponsorName":"ViralClear Pharmaceuticals"},{"sponsorId":"0d1321a5cc1c5a48c7918152a67c04e65aaf4844","sponsorName":"BioSig Technologies"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"ISR-50","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Sweden"],"countryCodes":["SWE"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"","notes":"Hope to have animal testing done in 2nd quarter and human testing complete in 4th quarter","numSites":"","otherPartners":"","phase":"","preferredName":"ISR-50","primaryCompletionDate":"","productId":336,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf; http://israb.se/pressdetalj/?id=http://publish.ne.cision.com/v2.0/Release/GetDetail/6C15E245715A57C0","http://israb.se/pressdetalj/?id=http://publish.ne.cision.com/v2.0/Release/GetDetail/6C15E245715A57C0"],"sponsors":[{"sponsorId":"987e067b08e440461ef8fc126e195d7d57d749c7","sponsorName":"ISR Immune System Regulation"},{"sponsorId":"5dcd0fc710b300f98746062aff74be3806516be0","sponsorName":"TCER AB"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"antiviral Fc conjugates","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"","notes":"Uses Antiviaral Fc Conjugates (AVCs)","numSites":"","otherPartners":"","phase":"","preferredName":"antiviral Fc conjugates","primaryCompletionDate":"","productId":337,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.cidara.com/cloudbreak/","https://www.cidara.com/pipeline/"],"sponsors":[{"sponsorId":"124c17c54d9555bc7787cea6f6043207f25479ba","sponsorName":"Cidara Therapeutics"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antiviral combination","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Netherlands"],"countryCodes":["NLD"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Unknown","notes":"It is indicted that combinations of FDA-approved drugs will be teste but unknown as to which ones.","numSites":"","otherPartners":"European Union's Horizon 2020 program","phase":"","preferredName":"Antiviral combination","primaryCompletionDate":"","productId":338,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://cordis.europa.eu/project/id/101003627","https://www.lumc.nl/over-het-lumc/nieuws/2020/Maart/lumc-doet-onderzoek-naar-coranavirus-remmers/?setlanguage=English&setcountry=en"],"sponsors":[{"sponsorId":"3ca1363324c98b475983319168e4c05919716630","sponsorName":"SCORE Consortium"},{"sponsorId":"8717ea76eb52afd496f981afcc95aa693b0fbbd9","sponsorName":"Helmholtz Centre for Infection Research"},{"sponsorId":"da5d8fe85f181501e049f3e20e8e1e2e438b9267","sponsorName":"Janssen Pharmaceutica NV"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Multistem","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Cell therapies","notes":"The Multistem cells express a range of therapeutically-relevant proteins that act like drugs,Planning to start Phase 2/3 Clinical Trial by 06/30/2020,Completed Phase 1/2 Clinical Trial on July 2019,Fast-Track Designation by the FDA","numSites":"","otherPartners":"","phase":"","preferredName":"Multistem","primaryCompletionDate":"","productId":339,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.biospace.com/article/barda-says-athersys-cell-therapy-highly-relevant-for-covid-19/","https://www.athersys.com/our-company/contact-us/default.aspx","https://www.athersys.com/clinical-trials/clinical-pipeline/default.aspx","https://www.biospace.com/article/barda-says-athersys-cell-therapy-highly-relevant-for-covid-19/ ; https://www.businesswire.com/news/home/20200413005160/en/FDA-Authorizes-Athersys-Initiate-Pivotal-Clinical-Trial","https://www.businesswire.com/news/home/20200413005160/en/FDA-Authorizes-Athersys-Initiate-Pivotal-Clinical-Trial","https://clinicaltrials.gov/ct2/show/study/NCT02611609?term=MultiStem&draw=2&rank=4"],"sponsors":[{"sponsorId":"6a3a12b6d931e87c4b8d0d2273853f647cf3c65f","sponsorName":"Athersys"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Novaferon","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 4","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Currently licensed in China for treatment of Hepatitis B,Started recruiting for Phase 4 Clinical Trial(Hu'nan) for COVID-19 patients,Also in testing in another Phase 4 Clinical Trail (Zhejiang) for COVID-19 patients","numSites":"2","otherPartners":"","phase":"4","preferredName":"Novaferon","primaryCompletionDate":"","productId":341,"registryLink":"http://www.chictr.org.cn/showprojen.aspx?proj=48809","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Changsha","country":"CHN","lat":28.301619,"lng":113.005226,"locationId":"b3638f91d98ac7495881ee5031a089e6e03fb001","name":"The First Hospital Of Changsha","state":"Hunan"},{"city":"Changsha","country":"CHN","lat":28.1869777,"lng":112.9939852,"locationId":"797527c87404b5e66801deab81aa7b9eed20cb5c","name":"The Second Xiangya Hospital Of Central South University","state":"Hunan"}],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","http://www.chictr.org.cn/showprojen.aspx?proj=48809","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976097/","http://en.people.cn/n3/2018/0529/c90000-9465205.html","https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1 ; http://en.people.cn/n3/2018/0529/c90000-9465205.html","http://www.chictr.org.cn/showprojen.aspx?proj=48809 ;  http://www.chictr.org.cn/showproj.aspx?proj=49065","https://www.medrxiv.org/content/10.1101/2020.03.04.20031401v1.full.pdf"],"sponsors":[{"sponsorId":"818e1de4129b2f52a53d8da808ff6c036588610d","sponsorName":"The First Hospital of Changsha"},{"sponsorId":"815809b19bd18eae88cb00c73fd9f3bbc9764dd3","sponsorName":"The Second Xiangya Hospital of Central South University"},{"sponsorId":"9e8c8e9d300f14660fbd928824d2e2e27fbba9ce","sponsorName":"First Affiliated Hospital of Zhejiang University Medical School"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Wed, 29 Jan 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"BIO-11006","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Currently tested in a pilot Phase 2a clinical trial","numSites":"","otherPartners":"","phase":"","preferredName":"BIO-11006","primaryCompletionDate":"","productId":342,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","http://www.biomarck.com/pipeline/","https://www.ptcommunity.com/wire/biomarck-announces-statistically-significant-results-phase-2-controlled-clinical-study-non","https://clinicaltrials.gov/ct2/show/NCT03202394?term=BIO-11006&draw=2&rank=3"],"sponsors":[{"sponsorId":"ee0168c868efcb79c99cceb1ad9c4b367356e247","sponsorName":"Biomarck Pharmaceuticals"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Nafamostat","chemicalName":"nafamostat mesylate","conditionOrDisease":"COVID-19","contact":[{"email":"gianpaolo.rossi@unipd.it","name":null,"notes":"","phone":"","website":""}],"countries":["Japan"],"countryCodes":["JPN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 20 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 20 Apr 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Currently recruiting for Phase 2/3 clinical trial in Padova-Italy,Set to start a unknown phase clinical trial at National Center for Global Health and Medicine in April 2020,Requested EUA from FDA with planned Phase 1/2 clinical trial in United States at unknown start time","numSites":"","otherPartners":"","phase":"2","preferredName":"nafamostat mesylate","primaryCompletionDate":"","productId":343,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04352400","repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.drugbank.ca/drugs/DB12598","https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.businesswire.com/news/home/20200415005156/en/Ensysce-California-Based-Biotech-Company-Mission-Solve","https://clinicaltrials.gov/ct2/show/NCT04352400?term=Nafamostat&draw=2&rank=1 ; https://www.businesswire.com/news/home/20200415005156/en/Ensysce-California-Based-Biotech-Company-Mission-Solve ; https://www.trialsitenews.com/university-of-tokyo-institute-of-medical-science-considers-nafamostat-for-clinical-trial-assessing-potential-to-treat-covid-19-clinical/","https://clinicaltrials.gov/ct2/show/NCT04352400?term=Nafamostat&draw=2&rank=1"],"sponsors":[{"sponsorId":"ab1e8ad3d379bcd134e4e3f47f828591f21bca7b","sponsorName":"University of Tokyo"},{"sponsorId":"e5fd2e305fd3cf838a58fa49356e6a687de59229","sponsorName":"Ensysce Biosciences"},{"sponsorId":"e22bdba3cbf2ef89fffeee543c2f866f142cd77f","sponsorName":"National Center for Global Health Medicine"},{"sponsorId":"fee8ee418bcb93a56059c6670596e6c18214fd42","sponsorName":"University Hospital Padova"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 20 Apr 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Activase","chemicalName":"alteplase","conditionOrDisease":"ARDS","contact":[{"email":"ernest.moore@dhha.org","name":null,"notes":"","phone":"(303) 602-1820","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 22 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"FDA-approved for treating blood clots but currently in Phase 2 clinical trial for COVID-19 patients,Therapeutic Approach is human tissue plasminogen activator","numSites":"3","otherPartners":"National Institutes of Health,Department of Defense Peer Reviewed Medical Research Program","phase":"2","preferredName":"alteplase","primaryCompletionDate":"Tue, 01 Sep 2020 00:00:00 GMT","productId":344,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04357730","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Aurora","country":"USA","lat":39.742917,"lng":-104.8393041,"locationId":"2ff275aa932062644d3f608dea1efc595e333a67","name":"University Of Colorado Anschultz Medical Campus","state":"CO"},{"city":"Denver","country":"USA","lat":39.7279895,"lng":-104.9913193,"locationId":"58474c00e04da0f1332b58fad53b0d4852722c53","name":"Denver Health","state":"CO"},{"city":"Boston","country":"USA","lat":42.3396063,"lng":-71.10498199999999,"locationId":"b8ebe972d5fdf1f09809e644f0d76fcee4bee962","name":"Beth Israel Deaconess Medical Center","state":"MA"}],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","http://news.mit.edu/2020/covid-19-treat-respiratory-patients-plasminogen-0324","https://www.drugbank.ca/drugs/DB00009","https://clinicaltrials.gov/ct2/show/NCT04357730?term=Alteplase&draw=4&rank=6","https://clinicaltrials.gov/ct2/show/NCT04357730?term=Alteplase&draw=4&rank=6 ; https://www.drugbank.ca/drugs/DB00009"],"sponsors":[{"sponsorId":"b03aa77c14c56ff5b4f5d3426dfb679c28ea44f9","sponsorName":"Beth Israel Deaconess"},{"sponsorId":"4c60ee4e3a2c0a8b5e660916048f460f70033ae3","sponsorName":"University of Colorado Anschultz Medical Campus"},{"sponsorId":"aeb9a00ace7546f0b60499cf3dd4a85be50b4e0d","sponsorName":"Denver Health"},{"sponsorId":"3ef65938333d443798d2043926bf988ac4c3c305","sponsorName":"Genentech"}],"status":"Ongoing","studyCompletionDate":"Sun, 01 Nov 2020 00:00:00 GMT","studyStartDate":"Wed, 22 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Kineret","chemicalName":"anakinra","conditionOrDisease":"COVID-19","contact":[{"email":"info@remapcap.org","name":null,"notes":"","phone":"","website":""}],"countries":["Netherlands"],"countryCodes":["NLD"],"currentStage":"Phase 4","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Currently testing in Phase 4 clinical trial named REMAP-CAP that was updated to include a sub-platform  REMAP-COVID for COVID-19 patients,Also testing in numerous other Phase 2/3 clinical trials","numSites":"89","otherPartners":"","phase":"4","preferredName":"anakinra","primaryCompletionDate":"","productId":345,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT02735707","repurposed":"Repurposed-Approved","siteLocations":[{"city":null,"country":"AUS","lat":-25.274398,"lng":133.775136,"locationId":"271aca543349c66aed17b5f44f07c3dcf811a4de","name":"Australia","state":null},{"city":null,"country":"BEL","lat":50.503887,"lng":4.469936,"locationId":"dc0f876ea2c410f14f463b68ea9477a24c3c9412","name":"Belgium","state":null},{"city":null,"country":"CAN","lat":56.130366,"lng":-106.346771,"locationId":"f8ddccf5c2a767df95acb2e10d9de44a87939453","name":"Canada","state":null},{"city":null,"country":"HRV","lat":45.1,"lng":15.2000001,"locationId":"b090c78808731e01c760afce49d26e0d6553696e","name":"Croatia","state":null},{"city":null,"country":"DEU","lat":51.165691,"lng":10.451526,"locationId":"af6f019d9c0e737387001dc92992d7322bd11943","name":"Germany","state":null},{"city":null,"country":"HUN","lat":47.162494,"lng":19.5033041,"locationId":"ac5c972c765b71f50b322877c7e6d0653168a2a2","name":"Hungary","state":null},{"city":null,"country":null,"lat":53.1423672,"lng":-7.692053599999999,"locationId":"b9f559f3712b7e004c3469fa0fb5c394a90b6cd5","name":"Ireland","state":null},{"city":null,"country":"NLD","lat":52.132633,"lng":5.291265999999999,"locationId":"6bcd25aa8d9f6e0726f98e262aab4c02a8243e04","name":"Netherlands","state":null},{"city":null,"country":"NZL","lat":-40.900557,"lng":174.885971,"locationId":"4bebe7166e6802493721588e537461f66202cf9d","name":"New Zealand","state":null},{"city":null,"country":"PRT","lat":39.39987199999999,"lng":-8.224454,"locationId":"4b75d777991c0b4cc234698f603e2b7e2fd35301","name":"Portugal","state":null},{"city":null,"country":"ROU","lat":45.943161,"lng":24.96676,"locationId":"17c161867f4847019b3ddf2204c58740eea236d9","name":"Romania","state":null},{"city":null,"country":"ESP","lat":40.46366700000001,"lng":-3.74922,"locationId":"d961513407eee030d923825859662422b01a169e","name":"Spain","state":null},{"city":null,"country":"GBR","lat":55.378051,"lng":-3.435973,"locationId":"857fa4862744fc94f02c57d7da387028df4cfa4a","name":"United Kingdom","state":null}],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://clinicaltrials.gov/ct2/show/NCT02735707","https://www.drugbank.ca/drugs/DB00026","https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/interleukin-1-receptor-antagonist","https://clinicaltrials.gov/ct2/show/NCT02735707 ; https://clinicaltrials.gov/ct2/show/NCT04330638 ; https://clinicaltrials.gov/ct2/show/NCT04324021 ; https://clinicaltrials.gov/ct2/show/NCT04341584 ; https://clinicaltrials.gov/ct2/show/NCT04339712 ; https://clinicaltrials.gov/ct2/show/NCT04357366","https://clinicaltrials.gov/ct2/show/NCT02735707?term=anakinra+COVID-19&draw=2&rank=6"],"sponsors":[{"sponsorId":"584eb38a0c9689f77c37d2ae76a472d221834c3c","sponsorName":"Swedish Orphan Biovitrum"},{"sponsorId":"a3251a4d28a25ad747e6996701cdcb53bf96499b","sponsorName":"Fundacion Miguel Servet"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"PP-001","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Austria"],"countryCodes":["AUT"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Drug has just completed a Phase 2 clinical trial for treatment of severe eye disesases,Article states that clinical trials for COVID-19 could begin shortly.","numSites":"","otherPartners":"","phase":"","preferredName":"PP-001","primaryCompletionDate":"","productId":346,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.lisavienna.at/news/the-austrian-biotech-company-panoptes-pharma-gmbh-has-a-promising-candidate-against-covid-19/","https://www.4sc.com/product-pipeline/out-licensed-products/pp-001/"],"sponsors":[{"sponsorId":"d84536309abcf2b1a75abfa06c2300e2a5917cb8","sponsorName":"Panoptes Pharma GmbH"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Xeljanz","chemicalName":"tofacitinib","conditionOrDisease":"Pneumonia","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"FDA approved to treat arthritis and colitis,Currently testing in Phase 2 clinical trial for COVID-19 related pneuomia","numSites":"1","otherPartners":"","phase":"2","preferredName":"tofacitinib","primaryCompletionDate":"Sat, 20 Jun 2020 00:00:00 GMT","productId":347,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04332042","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Ancona","country":"ITA","lat":43.6158299,"lng":13.518915,"locationId":"8549954d30fcf1630e70d784220cfdb6a02a2309","name":"Ospediali Riuniti Di Ancona","state":"Marche"}],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.pfizer.com/news/press-release/press-release-detail/pfizer_advances_battle_against_covid_19_on_multiple_fronts","https://www.drugbank.ca/drugs/DB08895","https://www.pfizer.com/contact","https://clinicaltrials.gov/ct2/show/NCT04332042?term=tofacitinib&cntry=IT&draw=2&rank=1 ; https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://clinicaltrials.gov/ct2/show/NCT04332042?term=tofacitinib&cntry=IT&draw=2&rank=1"],"sponsors":[{"sponsorId":"531d5b28f1f18f219741627c0f2a1e09d355e46a","sponsorName":"Pfizer"}],"status":"Ongoing","studyCompletionDate":"Fri, 10 Jul 2020 00:00:00 GMT","studyStartDate":"Thu, 02 Apr 2020 00:00:00 GMT","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"No","brandName":"BLD-2660","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Caplain (protease) inhibitor,used to be a drug to treat fibrosis","numSites":"","otherPartners":"","phase":"2","preferredName":"BLD-2660","primaryCompletionDate":"Mon, 10 Aug 2020 00:00:00 GMT","productId":348,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04334460","repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://clinicaltrials.gov/ct2/show/record/NCT04334460","https://adisinsight.springer.com/drugs/800052329","https://www.blademed.com/contact/"],"sponsors":[{"sponsorId":"89667736796d6828f9626bcd8b0fbb2b3f0c30ba","sponsorName":"Blade Therapeutics"}],"status":"Ongoing","studyCompletionDate":"Thu, 10 Sep 2020 00:00:00 GMT","studyStartDate":"Sun, 10 May 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"PREVENT","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"","milestones":[],"moleculeType":"","notes":"this consortium includes many different groups that are making different drugs,one main group involved is AdaptVac (line 79)","numSites":"","otherPartners":"","phase":"","preferredName":"PREVENT","primaryCompletionDate":"","productId":349,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf"],"sponsors":[{"sponsorId":"af0e9043938d3ffd18d4aa4f263c303abe7a87c1","sponsorName":"PREVENTnCoV consortium"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"Biological Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["India"],"countryCodes":["IND"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Biological Vaccine","primaryCompletionDate":"","productId":350,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf","https://www.livemint.com/news/india/covid-19-six-indian-companies-working-on-coronavirus-vaccine-11587016987400.html"],"sponsors":[{"sponsorId":"18d359f3a6a2fc44b7f04abc4ab8baad62117955","sponsorName":"Biological E Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"Vaxine Vaccine","chemicalName":"COVAX19","conditionOrDisease":"COVID-19","contact":[{"email":"nikolai.petrovsky@flinders.edu.au;  d.gordon@flinders.edu.au","name":null,"notes":"","phone":"For Australia: +61413131635","website":""}],"countries":["Australia"],"countryCodes":["AUS"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"1","otherPartners":"","phase":"1","preferredName":"COVAX19","primaryCompletionDate":"Thu, 01 Jul 2021 00:00:00 GMT","productId":351,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04453852","repurposed":"New","siteLocations":[{"city":"Adelaide","country":"AUS","lat":-34.9284989,"lng":138.6007456,"locationId":"7a8dc6bffbe7a412fcbad1696c068d8d0210527d","name":"Adelaide","state":"SA"}],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.eurekalert.org/pub_releases/2020-04/fu-cio040220.php","https://news.flinders.edu.au/blog/2020/04/03/flinders-targets-covid-19-vaccine/"],"sponsors":[{"sponsorId":"b103c316060fe38a9bb6cb32740cba7009ff4993","sponsorName":"Vaxine Pty Ltd"},{"sponsorId":"5b15122e16efd5040af4ad925335499c22697ac0","sponsorName":"Flinders University"}],"status":"Ongoing","studyCompletionDate":"Thu, 01 Jul 2021 00:00:00 GMT","studyStartDate":"Sat, 20 Jun 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"University of Cambridge Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"University of Cambridge Vaccine","primaryCompletionDate":"","productId":352,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.cam.ac.uk/research/news/cambridge-research-team-working-towards-vaccine-against-covid-19"],"sponsors":[{"sponsorId":"83c94185cc09e66de46b286461805b6666ee47e1","sponsorName":"University of Cambridge"},{"sponsorId":"7d21b3cf2e2c033e713858c5883640d91677f72e","sponsorName":"DIOSynVax"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"St. Petersburg Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Russian Federation"],"countryCodes":["RUS"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"St. Petersburg Vaccine","primaryCompletionDate":"","productId":353,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://tass.com/society/1136863","https://www.corona24.news/c/2020/04/12/st-petersburg-scientists-will-take-part-in-the-development-of-a-standard-against-covid-19-news-news.html","https://interfax.com/newsroom/top-stories/68233/"],"sponsors":[{"sponsorId":"1c450dbef9738d9b66fe108c2438eedf9206b820","sponsorName":"St Petersburg Scientific Research Institute of Vaccines and Serums"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"VBI Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"in collaboration with the National Research Council of Canada (NRC),advances on VBI's enveloped virus-like particle vaccines (eVLP vaccines)","numSites":"","otherPartners":"","phase":"","preferredName":"VBI Vaccine","primaryCompletionDate":"","productId":354,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.vbivaccines.com/wire/nrc-pan-coronavirus-vaccine-collaboration/"],"sponsors":[{"sponsorId":"ccba56f09bfbe72461df11aa67398b87f33bc6a5","sponsorName":"VBI Vaccines"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"BIOCAD Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Russian Federation"],"countryCodes":["RUS"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"BIOCAD Vaccine","primaryCompletionDate":"","productId":355,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1","https://biocadglobal.com/index.php?posts&post=45","https://gmpnews.net/2020/03/biocad-begins-developing-covid-19-vaccine/"],"sponsors":[{"sponsorId":"7a849d71160735d95f7cfb3ca259e2bb33ed4fb8","sponsorName":"BIOCAD"},{"sponsorId":"05fc10448e3ccf081b100a8e2f7113e804fec492","sponsorName":"IEM"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"IAVI Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"","notes":"intends to help lower the cost for producing vaccines for Covid-19","numSites":"","otherPartners":"","phase":"","preferredName":"IAVI Vaccine","primaryCompletionDate":"","productId":356,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","https://www.bataviabiosciences.com/news/iavi-vsv-vector-epidemic-preparedness-vaccines/","https://www.iavi.org/contact-us","https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1"],"sponsors":[{"sponsorId":"4504468bad51eef6a2ac6172fa89a91614df3c56","sponsorName":"Merck"},{"sponsorId":"44d1bb59e8c48cd0b43da165d6d9606f2583b5fe","sponsorName":"IAVI"},{"sponsorId":"f2e8788350358421b65552cc2679a931104ad1ab","sponsorName":"Batavia"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"Saiba Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Switzerland"],"countryCodes":["CHE"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Other","notes":"Has been able to induce high levels of antibodies within a week in animals","numSites":"","otherPartners":"","phase":"","preferredName":"Saiba Vaccine","primaryCompletionDate":"","productId":357,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","Virus-like particles; https://biorender.com/covid-vaccine-tracker","https://www.saiba-biotech.com/Latest","https://www.saiba-biotech.com/contact"],"sponsors":[{"sponsorId":"a558e81d8b75a91096450dac109735d6cb004a49","sponsorName":"Saiba GmbH"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Imophoron Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Other","notes":"Vaccines require no refrigeration","numSites":"","otherPartners":"University of Bristol's Emergency Research Group","phase":"","preferredName":"Imophoron Vaccine","primaryCompletionDate":"","productId":358,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf","http://www.pharmatimes.com/news/imophoron_develops_covid-19_vaccine_candidates_1337851","https://www.thepharmaletter.com/article/imophoron-to-begin-preclinical-tests-on-covid-19-vaccines","VLP; ADDomerTM multiepitopedisplay; https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf"],"sponsors":[{"sponsorId":"47418e382f699611afcc07ba422a212ac3cd258e","sponsorName":"Imophoron Ltd"},{"sponsorId":"2142575a70dd242d662f1604a63d59f331c865ae","sponsorName":"University of Bristol"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"","brandName":"PRTX-007","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":"Tue, 31 Mar 2020 00:00:00 GMT","milestoneId":13,"name":"lead_selection","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Activates TLR7 to stimulate innate immune system","numSites":"","otherPartners":"","phase":"","preferredName":"PRTX-007","primaryCompletionDate":"","productId":359,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html","https://www.primmunerx.com/#contact"],"sponsors":[{"sponsorId":"59184ad543e6f439787b2e2ac1527ea53b1e5ac1","sponsorName":"Primmune Therapeutics"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"AB00-1","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Acts on ACE-2 to inhibit the entry of the virus into the cell and workds on NSP15 to prevent its replication,Intends to begin human clinical trials this year","numSites":"","otherPartners":"","phase":"Pre-Clinical","preferredName":"AB00-1","primaryCompletionDate":"","productId":360,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.agastiyabiotech.com/covid19/","https://www.agastiyabiotech.com/contact/","https://www.agastiyabiotech.com/covid19/;https://www.manchestertimes.com/news/business/agastiya-biotech-proceeding-with-drug-candidate-for-covid-19/article_52279711-3ec6-5087-a02f-e43158a68929.html"],"sponsors":[{"sponsorId":"939b55ffb6ce9f4b830c8776c83f2f2116fd16d3","sponsorName":"Agastiya Biotech LLC"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Ultomiris","chemicalName":"ravulizumab-cwvz","conditionOrDisease":"COVID 19 Severe Pneumonia,Acute Lung Injury,or Acute Respiratory Distress Syndrome","contact":[{"email":"clinicaltrials@alexion.com","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"A terminal complement inhibitor of C5","numSites":"","otherPartners":"","phase":"3","preferredName":"ravulizumab-cwvz","primaryCompletionDate":"Tue, 10 Nov 2020 00:00:00 GMT","productId":361,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04369469","repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.biospace.com/article/releases/alexion-announces-plans-to-initiate-phase-3-study-of-ultomiris-ravulizumab-cwvz-in-hospitalized-patients-with-severe-covid-19/","https://www.drugbank.ca/drugs/DB11580","https://alexion.com/our-medicines/medicines/ultomiris","https://clinicaltrials.gov/ct2/show/NCT04369469?term=Ravulizumab&draw=2&rank=5","https://alexion.com/our-company/about-us"],"sponsors":[{"sponsorId":"41794d8c7643f99fc7895546d19147d1b41daf20","sponsorName":"Alexion Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"Wed, 10 Feb 2021 00:00:00 GMT","studyStartDate":"Sun, 10 May 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Metablok","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"The primary endpoint is to prevent acute respiratory distress syndrome in patients infected with COVID19,DPEP-1 inhibitor treating inflammation in the lungs liver and kidneys","numSites":"","otherPartners":"","phase":"","preferredName":"Metablok","primaryCompletionDate":"","productId":362,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/157-arch-biopartners-submits-application-to-health-canada-to-conduct-covid19-phase-ii-human-trial-for-metablok-to-prevent-lung-and-kidney-inflammation","https://www.precisionvaccinations.com/vaccines/metablok-lsalt-peptide","https://archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/152-arch-biopartners-safely-completes-expanded-dosing-of-metablok-in-phase-i-human-trial-and-begins-focus-on-phase-ii-trial","https://www.biospace.com/article/releases/arch-biopartners-releases-new-video-showing-metablok-reducing-lung-inflammation-in-an-animal-model-/","https://clinicaltrials.gov/ct2/show/NCT03772678?term=LSALT+peptide&draw=2&rank=1"],"sponsors":[{"sponsorId":"6ae7877eca7b978170ddee9d611fbce51b4868f7","sponsorName":"Arch Biopartners Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"MEDI-3506","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"","notes":"Targeting Interluekin 33","numSites":"","otherPartners":"Medimmune,ACCORd","phase":"","preferredName":"MEDI-3506","primaryCompletionDate":"","productId":363,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html","https://www.astrazeneca.com/media-centre/articles/2020/investigating-an-existing-medicine-as-a-potential-treatment-for-covid-19.html","https://adisinsight.springer.com/drugs/800049222; https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html","https://clinicaltrials.gov/ct2/show/NCT03096795"],"sponsors":[{"sponsorId":"e4db405906dfdb58ac2ee1ccf9877fc1ad52116d","sponsorName":"Aztrazeneca plc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Farxiga","chemicalName":"dapagliflozin","conditionOrDisease":"COVID19","contact":[{"email":"swindsor@saint-lukes.org","name":null,"notes":"","phone":"816-932-9858","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 15 Apr 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"A sodium glucose cotransporter 2 inhibitor indicated for managing diabetes mellitus type 2,currently recruiting,estimated completion date October 2020","numSites":"1","otherPartners":"Saint Luke's Health System,AstraZeneca,George Clinical Pty Ltd","phase":"3","preferredName":"dapagliflozin","primaryCompletionDate":"Sat, 10 Oct 2020 00:00:00 GMT","productId":364,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04350593","repurposed":"Repurposed-Approved","siteLocations":[{"city":"KCMO","country":"USA","lat":39.0477453,"lng":-94.5901791,"locationId":"2ef6f255508b20342c7948c7d002b5a20f9587ca","name":"Saint Luke's Mid America Heart Institute Kansas City","state":"MO"}],"sources":["https://www.bioworld.com/COVID19products","https://www.drugbank.ca/drugs/DB06292","https://clinicaltrials.gov/ct2/show/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1","https://clinicaltrials.gov/ct2/show/record/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1","https://clinicaltrials.gov/ct2/results?cond=&term=Dapagliflozin&cntry=&state=&city=&dist=","https://clinicaltrials.gov/ct2/show/study/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1"],"sponsors":[{"sponsorId":"e4db405906dfdb58ac2ee1ccf9877fc1ad52116d","sponsorName":"Aztrazeneca plc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Wed, 22 Apr 2020 00:00:00 GMT","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"IgM Antibodies,IgA Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Idenitfying the sequeneces of antibodies made by B cells found in blood from acutely infected COVID-19 patients and engineering IgM and IgA antibodies (from the identified sequence) with greater binding power per antibody.","numSites":"","otherPartners":"","phase":"","preferredName":"IgM Antibodies,IgA Antibodies","primaryCompletionDate":"","productId":365,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","http://ir.beigene.com/static-files/e62cb49b-21dd-40d0-b305-60946431c587","https://www.atreca.com/about/; https://www.beigene.com/about/our-story; https://igmbio.com/"],"sponsors":[{"sponsorId":"300c03c87517131e06a725327908570fd8798f8b","sponsorName":"Atreca Inc"},{"sponsorId":"5a19a0834e482d0229a397f62492ab8dfcd271d9","sponsorName":"Beigene Ltd"},{"sponsorId":"4852c490222a54deb2d41b655f588096c92cb6ad","sponsorName":"IGM Biosciences Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Audax Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Audax Therapeutic","primaryCompletionDate":"","productId":366,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.northeastern.edu/cri/news/northeastern-professor-partners-with-audax-medical-inc-to-combat-covid-19/","https://news.northeastern.edu/2020/03/04/heres-how-nanoparticles-could-help-us-get-closer-to-a-treatment-for-covid-19/"],"sponsors":[{"sponsorId":"06fe14bef7ae50a2f1a152d1eba019ce4b0b33bf","sponsorName":"Audax Medical Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Bemcentinib","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Norway"],"countryCodes":["NOR"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"Department of Health and Social Care (DHSC),UK Research and Innovation (UKRI)","phase":"2","preferredName":"Bemcentinib","primaryCompletionDate":"","productId":367,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.bergenbio.com/bergenbios-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative/","https://www.bioworld.com/articles/434740-bergenbios-bemcentinib-joins-fast-tracked-accord-program-targeting-covid-19"],"sponsors":[{"sponsorId":"e99b1e4fd130967b98ec911ffe343851949fc17b","sponsorName":"Bergenbio ASA"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"","brandName":"COVID-19 treatments","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"AI company that helps identify drugs (Project Prodigy AI)","numSites":"","otherPartners":"","phase":"","preferredName":"COVID-19 treatments","primaryCompletionDate":"","productId":368,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.biovista.com/artificial-intelligence-firm-biovista-repositions-four-promising-therapeutics-against-covid-19/","https://www.biovista.com/solutions/project-prodigy-vs-covid-19/"],"sponsors":[{"sponsorId":"8ff2bf908543da634f6c955434fd59ba86816e6d","sponsorName":"Biovista Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"CLBS-119","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Cell therapies","notes":"Repairs lung damage","numSites":"","otherPartners":"","phase":"","preferredName":"CLBS-119","primaryCompletionDate":"","productId":369,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.biospace.com/article/releases/caladrius-biosciences-plans-to-assess-its-clbs119-cell-therapy-for-repair-of-covid-19-induced-lung-damage/"],"sponsors":[{"sponsorId":"28d929d86c67592db08f4897b313d80028476e9e","sponsorName":"Caladrius Biosciences Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Dociparstat sodium","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"","numSites":"","otherPartners":"","phase":"2","preferredName":"Dociparstat sodium","primaryCompletionDate":"","productId":370,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-initiation-phase-23-study-dstat-acute-lung","https://www.globenewswire.com/news-release/2019/12/10/1958467/0/en/Chimerix-Presents-Updated-Results-from-Phase-2-Clinical-Trial-of-DSTAT-in-Refractory-Myelodysplastic-Syndrome-and-Acute-Myeloid-Leukemia-at-American-Society-of-Hematology-Annual-Me.html","https://www.chimerix.com/contact-us/"],"sponsors":[{"sponsorId":"b205baf63638325039ee5a5cb8163c92032c7373","sponsorName":"Chimerix Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Itanapraced","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Itanapraced","primaryCompletionDate":"","productId":371,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.biospace.com/article/releases/cerespir-incorporated-identifies-possible-link-between-covid-19-induced-brain-inflammation-and-acute-respiratory-stress-syndrome-via-breakdown-of-the-blood-brain-barrier/","https://drugs.ncats.io/drug/C35RF1MWQZ","https://www.globenewswire.com/news-release/2020/04/16/2017370/0/en/CERESPIR-INCORPORATED-Identifies-Possible-Link-Between-COVID-19-Induced-Brain-Inflammation-and-Acute-Respiratory-Stress-Syndrome-Via-Breakdown-of-the-Blood-Brain-Barrier.html"],"sponsors":[{"sponsorId":"b3fae6fd4eeae1f99462dfff0a75d2eab3c4253a","sponsorName":"Cerespir Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Niagen","chemicalName":"nicotinamide riboside","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"nicotinamide riboside","primaryCompletionDate":"","productId":372,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.businesswire.com/news/home/20200420005265/en/ChromaDex-Commits-COVID-19-Research-Promising-Initial-Preclinical"],"sponsors":[{"sponsorId":"e44b4742cbdb4c8802c4d11e460311b5195d0a43","sponsorName":"Chromadex Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Pacritinib","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"3","preferredName":"Pacritinib","primaryCompletionDate":"","productId":373,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.biospace.com/article/releases/cti-biopharma-announces-initiation-of-phase-3-pre-vent-study-evaluating-pacritinib-in-hospitalized-patients-with-severe-covid-19/","http://lincs.hms.harvard.edu/db/sm/10381-101/","https://www.ctibiopharma.com/pacritinib/","https://www.ctibiopharma.com/"],"sponsors":[{"sponsorId":"9f40c9583b5968ab1adbdf1d8a099bc79d1c1c88","sponsorName":"CTI Biopharma Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"","brandName":"CYC-065","chemicalName":"Fadraciclib","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"University of Edinburgh,LifeArc","phase":"","preferredName":"Fadraciclib","primaryCompletionDate":"","productId":374,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.globenewswire.com/news-release/2020/04/20/2018510/0/en/Cyclacel-Pharmaceuticals-Announces-Collaboration-With-the-University-of-Edinburgh-to-Study-Its-CDK-Inhibitors-to-Reduce-Runaway-Inflammation-in-COVID-19-Disease.html","https://www.bioworld.com/articles/434562-cyclacel-pharming-repurpose-drugs-to-fight-severe-respiratory-symptoms-of-covid-19"],"sponsors":[{"sponsorId":"083cc5ab8a9ad04ea7d576a9f70799ae43c5aaae","sponsorName":"Cyclacel Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"","brandName":"CYC-202,R-roscovitine","chemicalName":"Seliciclib","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"University of Edinburgh,LifeArc","phase":"","preferredName":"Seliciclib","primaryCompletionDate":"","productId":375,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.globenewswire.com/news-release/2020/04/20/2018510/0/en/Cyclacel-Pharmaceuticals-Announces-Collaboration-With-the-University-of-Edinburgh-to-Study-Its-CDK-Inhibitors-to-Reduce-Runaway-Inflammation-in-COVID-19-Disease.html","https://www.bioworld.com/articles/434562-cyclacel-pharming-repurpose-drugs-to-fight-severe-respiratory-symptoms-of-covid-19"],"sponsors":[{"sponsorId":"083cc5ab8a9ad04ea7d576a9f70799ae43c5aaae","sponsorName":"Cyclacel Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"","brandName":"Ryanodex","chemicalName":"dantrolene sodium","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"ESTIMATED"}],"moleculeType":"Small molecule","notes":"Growth inhibitor by modulating free intracellular calcium levels in host cells","numSites":"","otherPartners":"","phase":"","preferredName":"dantrolene sodium","primaryCompletionDate":"","productId":376,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.eagleus.com/eagle-pharmaceuticals-corporate-website-statement/","https://www.bioworld.com/COVID19products","https://investor.eagleus.com/press-releases/news-details/2020/Eagle-Pharmaceuticals-Announces-Laboratory-Test-Results-Demonstrating-In-Vitro-Antiviral-Activity-of-RYANODEX-dantrolene-sodium-Against-Coronavirus-SARS-CoV-2/default.aspx","https://www.drugbank.ca/drugs/DB01219","https://www.eagleus.com/contact/"],"sponsors":[{"sponsorId":"6bd89fd19b2baf31fb93f1a63de6b53953ee9577","sponsorName":"Eagle Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"mRNA Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Belgium"],"countryCodes":["BEL"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"An intranasal delivery system is being explored with this vaccine.","numSites":"","otherPartners":"","phase":"","preferredName":"mRNA Vaccine","primaryCompletionDate":"","productId":545,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.thepharmaletter.com/article/etherna-launches-consortium-and-starts-development-of-cov-2-mrna-vaccine"],"sponsors":[{"sponsorId":"b41a4d43ef7f7aa0b03c1fa4cb9acc260b974c38","sponsorName":"eTheRNA"},{"sponsorId":"f67f36df3e690591d2422dcdf7a98d9c579d2302","sponsorName":"Epivax"},{"sponsorId":"1705936639243ce00a503a24d65f03b3840a89c2","sponsorName":"Nexelis"},{"sponsorId":"d018b4e85291ddac56b886398d68650a668bc8ba","sponsorName":"Reprocell and the Center for the Evaluation of Vaccination of the University of Antwerp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"EB05 and EB06","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"NI-0101 and NI-0801 programs at lightchain bioscience work as TLR4 and CXCL10 antagonists respectively - being licensed to Edesa Biotech Inc","numSites":"","otherPartners":"","phase":"","preferredName":"EB05 and EB06","primaryCompletionDate":"","productId":377,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.accesswire.com/585646/Edesa-Biotech-and-Light-Chain-Bioscience-Sign-License-Agreement-to-Develop-Treatments-for-COVID-19-Pneumonia-and-Other-Disorders","https://www.bioworld.com/COVID19products","https://www.lightchainbio.com/our-focus/pipeline.html","https://www.edesabiotech.com/about/contact-us/","https://www.edesabiotech.com/clinical-pipeline/"],"sponsors":[{"sponsorId":"df7336e82b3ee964918b55e0124c5c863386b59e","sponsorName":"Edesa Biotech Inc"},{"sponsorId":"9898e6e8a31d2229ba186cbe74951fc0875a5ae1","sponsorName":"Light Chain Bioscience"},{"sponsorId":"18504c03801e154a688184f061e282ba41d0c0e4","sponsorName":"Novimmune SA"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Zotatifin","chemicalName":"eFT226","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Eukaryotic initiation factor 4A inhibitor which is used by the virus for replication","numSites":"","otherPartners":"","phase":"","preferredName":"eFT226","primaryCompletionDate":"","productId":378,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://effector.com/pipeline/#zotatifin","https://www.bioworld.com/COVID19products","https://www.globenewswire.com/news-release/2020/04/30/2025303/0/en/eFFECTOR-s-Zotatifin-Demonstrates-in-vitro-Anti-SARS-CoV-2-Activity-in-Independent-International-Study-Reported-in-Peer-Reviewed-Journal-Nature.html","https://effector.com/contact/"],"sponsors":[{"sponsorId":"d2b4445d416dbf8501b919b961f16cb45cf218d9","sponsorName":"Effector Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Antibodies","primaryCompletionDate":"","productId":379,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.businesswire.com/news/home/20200416005046/en/Leading-Global-Antibody-Discovery-Companies-FairJourney-Biologics"],"sponsors":[{"sponsorId":"09467ddba3462cd3be13db3493e74a1cd13ee832","sponsorName":"Fairjourney Biologics SA"},{"sponsorId":"e461e3fcff3dfbf264418228bb2872ec75a77d64","sponsorName":"Iontas Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Part of the Northern Ireland Coronavirus Antibody Development Alliance (\u201cNICADA\u201d)","numSites":"","otherPartners":"","phase":"","preferredName":"Antibodies","primaryCompletionDate":"","productId":380,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.fusionantibodies.com/news/research-alliance-with-queens-university-belfast/","https://www.bioworld.com/COVID19products","https://www.fusionantibodies.com/contact-us/"],"sponsors":[{"sponsorId":"4c15e115bbf73c231a08f5b902eca1c36dbc7fe1","sponsorName":"Fusion Antibodies plc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Company is using its proprietary humanized mice called Advanced peripheral blood Hematopoietic Chimera","numSites":"","otherPartners":"","phase":"","preferredName":"Antibodies","primaryCompletionDate":"","productId":381,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://hemogenyx.com/investors/investors/announcements/announcement/2020/covid-19-project-initiated/","https://hemogenyx.com/contact/","https://www.thearmchairtrader.com/hemogenyx-stock-price/"],"sponsors":[{"sponsorId":"3f5e70ee0770a61cea95a52724b629ed752e8d50","sponsorName":"Hemogenyx Pharmaceuticals plc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"IMU-838","chemicalName":"vidofludimus calcium","conditionOrDisease":"COVID-19","contact":[{"email":"andreas.muehler@imux.com","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"ESTIMATED"}],"moleculeType":"Small molecule","notes":"Inhibitor of dihydroorotate dehydrogenase- an enzyme of pyrimidine de novo biosynthesis","numSites":"4","otherPartners":"","phase":"2","preferredName":"vidofludimus calcium","primaryCompletionDate":"Thu, 10 Sep 2020 00:00:00 GMT","productId":382,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04379271","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Clearwater","country":"USA","lat":27.9652556,"lng":-82.78555589999999,"locationId":"e55e6ebaa9ef4b1473f94c3f746b712b66e00e0f","name":"Military Medical Academy","state":"FL"},{"city":"Sofia","country":"BGR","lat":42.6563826,"lng":23.3599263,"locationId":"06759a9839f3ea5909f977a953f9b96535dc6c1c","name":"Clinic Of Infectious Diseases","state":"Sofia City Province"},{"city":"Sofia","country":"BGR","lat":42.6900517,"lng":23.3073914,"locationId":"0c83b0efac5ac0bf48c125bf2d3f003f6c443efd","name":"Umhatem N.i.pirogov","state":"Sofia City Province"},{"city":"Frankfurt am Main","country":"DEU","lat":50.0951726,"lng":8.6616969,"locationId":"71bc3c6cd965260f84f028f34d2076157d41120e","name":"University Hospital Frankfurt","state":"HE"},{"city":"Hannover","country":"DEU","lat":52.39043520000001,"lng":9.7971815,"locationId":"71981b44b2d33d073f7a5e0db19d8773c6148372","name":"Clinic Of The Hannover Medical School","state":"NDS"}],"sources":["https://www.immunic-therapeutics.com/imu838/","https://www.bioworld.com/COVID19products","https://www.immunic-therapeutics.com/2020/04/21/immunic-inc-reports-that-imu-838-a-selective-oral-dhodh-inhibitor-has-demonstrated-preclinical-activity-against-sars-cov-2-and-explores-plans-for-a-phase-2-clinical-trial-in-covid-19-patients/","https://www.immunic-therapeutics.com/contact/","https://clinicaltrials.gov/ct2/show/record/NCT04379271?term=imu-838&draw=2&rank=3","https://clinicaltrials.gov/ct2/show/NCT04379271?term=imu-838&draw=2&rank=3"],"sponsors":[{"sponsorId":"8ebeaa89bdf967acb860530de89f2bf521947797","sponsorName":"Immunic Inc"}],"status":"Ongoing","studyCompletionDate":"Thu, 01 Oct 2020 00:00:00 GMT","studyStartDate":"Wed, 10 Jun 2020 00:00:00 GMT","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Xpro-1595 ","chemicalName":"dominant-negative TNF Inhibitor","conditionOrDisease":"COVID-19","contact":[{"email":"trials@inmunebio.com","name":null,"notes":"","phone":"1 (858) 964-3720","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"Other","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Supposed to treat respiratory symptoms without being immunosuppressive-TNF has been linked to cytokine storm in COVID-19 patients","numSites":"","otherPartners":"","phase":"2","preferredName":"dominant-negative TNF Inhibitor","primaryCompletionDate":"Wed, 10 Feb 2021 00:00:00 GMT","productId":383,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04370236","repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.inmunebio.com/index.php/en/news-2/2020/321-muneioncnnouncesnitiationoflinicalrogram20200420","https://www.inmunebio.com/index.php/en/science/xpro1595/overview","https://www.inmunebio.com/index.php/en/contact-2/contact-us","https://clinicaltrials.gov/ct2/show/NCT04370236?term=inmune&draw=2&rank=3","https://clinicaltrials.gov/ct2/show/record/NCT04370236?term=inmune&draw=2&rank=3&view=record"],"sponsors":[{"sponsorId":"dab857f942f999776776bf0b8f3c12093bcdf582","sponsorName":"Inmune Bio Inc"}],"status":"Ongoing","studyCompletionDate":"Mon, 01 Feb 2021 00:00:00 GMT","studyStartDate":"Wed, 10 Jun 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Cannabidiol-loaded exosomes","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Israel"],"countryCodes":["ISR"],"currentStage":"Pre-Clinical Testing","indication":"Other","interventionType":"Therapeutic","milestones":[],"moleculeType":"Cell therapies","notes":"Aim is to use exosome as a targeted delivery sytem to release cannabidiol into the lungs for anti-inflammatory effects","numSites":"","otherPartners":"","phase":"","preferredName":"Cannabidiol-loaded exosomes","primaryCompletionDate":"","productId":384,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.newsfilecorp.com/release/54575/InnoCan-Pharma-Collaborates-with-Tel-Aviv-University-to-Develop-a-New-Revolutionary-Approach-to-Treat-the-COVID19-Corona-Virus-with-ExosomesLoaded-CBD","https://innocanpharma.com/cell-therapy/","https://innocanpharma.com/our-story/","https://www.euroweeklynews.com/2020/04/27/israeli-scientists-begin-trials-into-the-effectiveness-of-cannabis-in-treating-covid-19/"],"sponsors":[{"sponsorId":"f5509fdc8d977098de524cfe1324119bca44d958","sponsorName":"Innocan Pharma Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"INS-1007","chemicalName":"Brensocatib","conditionOrDisease":"COVID-19","contact":[{"email":"j.chalmers@dundee.ac.uk","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Phase 3","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Multi-center Investigator Initiated Trial,Drug is a Dipeptidyl Peptidase 1 inhibitor which ultimately aims to reduce neutrophil-mediated damage via serine proteases in the lungs","numSites":"10","otherPartners":"Insmed Inc.","phase":"3","preferredName":"Brensocatib","primaryCompletionDate":"","productId":385,"registryLink":"https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001643-13/GB","repurposed":"Repurposed-Approved","siteLocations":[{"city":null,"country":"GBR","lat":55.378051,"lng":-3.435973,"locationId":"a7c84522b5993a156e32ca0206148487240ae03b","name":"United Kingdom","state":null}],"sources":["https://www.bioworld.com/COVID19products","https://investor.insmed.com/2020-04-23-Brensocatib-Formerly-INS1007-to-be-Studied-in-Patients-with-Severe-COVID-19-in-Investigator-Initiated-Trial","https://www.drugbank.ca/drugs/DB15638","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001643-13/GB","https://insmed.com/science/pipeline/"],"sponsors":[{"sponsorId":"3705775d63e9f24d20b5c6e4736f7f613881237f","sponsorName":"University of Dundee"},{"sponsorId":"e97f167fe7a9cdf40d469f7fe1f8fc68fcce2030","sponsorName":"Insmed Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Sonlicromanol","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Netherlands"],"countryCodes":["NLD"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Currently in Phase 2b clinical trial for mitochondrial diseases,Sponsor looking for partners to start trial in COVID-19 patients as of April 15th","numSites":"","otherPartners":"","phase":"","preferredName":"Sonlicromanol","primaryCompletionDate":"","productId":386,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.globenewswire.com/news-release/2020/04/15/2016163/0/en/Khondrion-highlights-potential-role-of-inflammatory-lipid-modulator-prostaglandin-E2-in-COVID-19-disease-and-proposes-potential-treatment-pathway-with-sonlicromanol.html","https://mitochondrialdiseasenews.com/2020/01/31/khondrion-doses-first-patient-phase-2b-trial-testing-sonlicromanol-mitochondrial-diseases/","https://clinicaltrials.gov/ct2/show/NCT04165239?term=Sonlicromanol&draw=2&rank=1"],"sponsors":[{"sponsorId":"515553435142eb535852e295f3bd6c501327f36b","sponsorName":"Khondrion BV"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"VAP-1 Inhibitors","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Discovery","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Thu, 16 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Small molecule","notes":"Currently in Discovery Phase,Screening for novel VAP-1 inhibitor compounds for inflammatory conditions","numSites":"","otherPartners":"","phase":"","preferredName":"VAP-1 Inhibitors","primaryCompletionDate":"","productId":387,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases"],"sponsors":[{"sponsorId":"e738bf6a692bdb6a103840a21c304833dc861452","sponsorName":"Kubota Vision Inc"},{"sponsorId":"267bf8e98b940f881544a2ce9ccf3dca31f50926","sponsorName":"Leo Pharma AS"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"XAV-19","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"Manufacturing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":"Wed, 15 Apr 2020 00:00:00 GMT","milestoneId":21,"name":"clinical_batch","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Agreetment signed for first clinical batch of drug as of April 15th","numSites":"","otherPartners":"","phase":"","preferredName":"XAV-19","primaryCompletionDate":"","productId":388,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.thepharmaletter.com/article/lfb-inks-deal-with-xenothera-for-xab-19-for-treatment-of-coronavirus-infections"],"sponsors":[{"sponsorId":"e051009634417c8e337feeb1e73c8c03b2ff106c","sponsorName":"LFB SA"},{"sponsorId":"39f19090c785e55de80ad34b54bc88b1ea610d27","sponsorName":"Kenothera SAS"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Carragelose Inhalation therapy","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Austria"],"countryCodes":["AUT"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"Inhalation solution based on iota-carrageenan polymers derived from red seaweed with physical mode of action,Currently approved OTC in EU/Asia & other markets (non-US),Recieved funding for Phase 1 clinical trial and then a proof-of-concept study on viral pneumonia patients","numSites":"","otherPartners":"Austrian Research Promotion Agency","phase":"","preferredName":"Carragelose Inhalation therapy","primaryCompletionDate":"","productId":389,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.oindpnews.com/2020/04/marinomed-gets-funding-for-development-of-carragelose-inhalation-solution-for-the-treatment-of-covid-19-pneumonia/","https://media.marinomed.com/22/ea/2a/carragelose-teaser-new-072019.pdf","https://media.marinomed.com/22/ea/2a/carragelose-teaser-new-072019.pdf ; https://www.oindpnews.com/2020/04/marinomed-gets-funding-for-development-of-carragelose-inhalation-solution-for-the-treatment-of-covid-19-pneumonia/"],"sponsors":[{"sponsorId":"b76c240d33285d07cee07c91c6542ec704092b3e","sponsorName":"Marinomed Biotech AG"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antiviral","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Switzerland"],"countryCodes":["CHE"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Engineered trispecific antiviral proteins therapeutic that targets epitopes of viral spikeprotein needed for infection,Currently undergoing expedited preclinical testing for lead candidate,Target of manufactured drug product in Q3 2020","numSites":"","otherPartners":"","phase":"","preferredName":"Antiviral","primaryCompletionDate":"","productId":390,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.molecularpartners.com/molecular-partners-initiates-anti-covid-19-therapeutic-program-leveraging-multi-target-binding-of-darpin-proteins-to-neutralize-sars-cov-2-virus/","https://www.molecularpartners.com/contact-us/"],"sponsors":[{"sponsorId":"156f730ad2e8e71aaec7362be122a0c821d51c14","sponsorName":"Molecular Partners AG"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"","brandName":"Veyonda","chemicalName":"idronoxil","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Manufacturing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Currently has IND approval as anti-cancer agent,Currently trying to get FDA approval to pursue clinical study for COVID-19 patients.","numSites":"","otherPartners":"","phase":"","preferredName":"idronoxil","primaryCompletionDate":"","productId":391,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.biospace.com/article/releases/noxopharm-investigating-potential-covid-19-treatment/","https://www.drugbank.ca/drugs/DB04915","https://www.biospace.com/employer/545349/noxopharm/","https://www.pharmashots.com/31369/noxopharm-anticipates-the-us-fdas-approval-for-evaluating-veyonda-in-a-clinical-study-for-covid-19/"],"sponsors":[{"sponsorId":"98fbd4c7c935e48e7246ffa9696377e27973373d","sponsorName":"Noxopharm Co"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Peptides","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Ireland"],"countryCodes":["IRL"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Curently using AI platform screen for peptide candidates (Takes 4-5 months)","numSites":"","otherPartners":"","phase":"","preferredName":"Peptides","primaryCompletionDate":"","productId":392,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.biospace.com/article/using-ai-to-find-peptide-therapeutics-for-covid-19/"],"sponsors":[{"sponsorId":"de93cb0c4a3bc024e5f42b0cf2117729b320a781","sponsorName":"Nuritas Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"2X-121","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Denmark"],"countryCodes":["DNK"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Fri, 24 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Currently in Phase 2 clinical trial for ovarian cancer,Started pre-clinical testing at Northern Arizona University as of 04/24/2020","numSites":"","otherPartners":"","phase":"","preferredName":"2X-121","primaryCompletionDate":"","productId":393,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://oncologyventure.com/pipeline/2x-121/","https://oncologyventure.com/about-us/","https://www.technologynetworks.com/drug-discovery/news/covid-19-testing-service-center-to-evaluate-promising-drugs-333864 ; https://oncologyventure.com/pipeline/2x-121/","https://www.technologynetworks.com/drug-discovery/news/covid-19-testing-service-center-to-evaluate-promising-drugs-333864"],"sponsors":[{"sponsorId":"7c3734e76aa183a3eb2e24a57c0009a112b44055","sponsorName":"Oncology Ventures AS"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Foipan","chemicalName":"Camostat mesylate","conditionOrDisease":"COVID-19","contact":[{"email":"joseph.vinetz@yale.edu","name":null,"notes":"","phone":"(203) 737-9730","website":""}],"countries":["Japan"],"countryCodes":["JPN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Currently approved in Japan to treat pancreatic inflammation,Currently in Phase 2a clinical trial for COVID-19 patients,Anti-inflammatory properties and shown in vitro virus inhibitory ability","numSites":"1","otherPartners":"","phase":"2","preferredName":"Camostat mesylate","primaryCompletionDate":"Mon, 31 May 2021 00:00:00 GMT","productId":394,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04353284","repurposed":"Repurposed-Approved","siteLocations":[{"city":"New Haven","country":"USA","lat":41.3163244,"lng":-72.92234309999999,"locationId":"2d3bada9faa86677b645240b9b09ebd66ffd8bb1","name":"Yale University","state":"CT"}],"sources":["https://www.bioworld.com/COVID19products","https://www.thailandmedical.news/news/coronavirus-drug-research-german-researchers-identify-japanese-drug","-camostat-mesylate-that-could-be-repurposed-to-treat-covid-19","https://clinicaltrials.gov/ct2/show/NCT04353284#contacts","https://www.drugbank.ca/drugs/DB13729","https://clinicaltrials.gov/ct2/show/NCT04353284","https://www.ono.co.jp/eng/about/business_locations.html"],"sponsors":[{"sponsorId":"4c42301126ac99d75b7be429df5e77830bc45d8b","sponsorName":"Ono Pharmaceuticals Inc"},{"sponsorId":"3066c4c7f3115869a60b33c425a7528be9a6e3bf","sponsorName":"Yale University"},{"sponsorId":"7024be22f1d029e9b85014aef3977d4a224b9e27","sponsorName":"Liebniz Institute for Primate Research"}],"status":"Ongoing","studyCompletionDate":"Mon, 31 May 2021 00:00:00 GMT","studyStartDate":"Fri, 19 Jun 2020 00:00:00 GMT","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Vafidemstat","chemicalName":"","conditionOrDisease":"ARDS","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Spain"],"countryCodes":["ESP"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 27 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Currently in a Phase 2 clinical trial","numSites":"3","otherPartners":"","phase":"2","preferredName":"Vafidemstat","primaryCompletionDate":"","productId":395,"registryLink":"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001618-39","repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES","https://www.biospace.com/article/releases/oryzon-to-initiate-escape-a-phase-ii-clinical-trial-to-test-efficacy-of-vafidemstat-in-severely-ill-covid-19-patients/"],"sponsors":[{"sponsorId":"54df2e1eb201b7a6fc15d098af3042d22ffa6dde","sponsorName":"Oryzon Genomics SA"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 27 Apr 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Q Biomed Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"Mannin Research,Cyclica","phase":"","preferredName":"Q Biomed Therapeutic","primaryCompletionDate":"","productId":396,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://qbiomed.com/news-and-media/news-2020/191-q-biomed-initiates-rapid-development-of-novel-covid-19-therapeutics"],"sponsors":[{"sponsorId":"b275b8324ed9b360015738d5c52283b783d3e511","sponsorName":"Q Biomed Inc"},{"sponsorId":"6369487c22ff53cc21139097558058341e98e631","sponsorName":"Mannin Research"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Recursion Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"Therapeutic","milestones":[],"moleculeType":"","notes":"this is a dataset,not a therapy","numSites":"","otherPartners":"","phase":"","preferredName":"Recursion Therapeutic","primaryCompletionDate":"","productId":397,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.recursionpharma.com/news/rxrx19"],"sponsors":[{"sponsorId":"11fe98d508be31415b00d71b9e4504f2beb1ee7a","sponsorName":"Recursion Pharmaceuticals Inc"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"RTB-101","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"candidate is an inhibitor of target of rapamycin complex 1 (TORC-1)","numSites":"","otherPartners":"Restorbio stockholders will receive net proceeds from the commercialization","phase":"","preferredName":"RTB-101","primaryCompletionDate":"","productId":398,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.bioworld.com/articles/434734-other-news-to-note-for-april-29-2020","https://www.restorbio.com/pipeline/","https://www.restorbio.com/contact/"],"sponsors":[{"sponsorId":"2afef1b9b3945cdfc232fc3cd9fc8ed8d184003f","sponsorName":"Restorbio Inc"},{"sponsorId":"b284e0fd16c925a93e4f38c453f4c70e7636b223","sponsorName":"Adicet Bio Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"RT-001","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"RT-001 is a chemically stabilized fatty acid","numSites":"","otherPartners":"","phase":"","preferredName":"RT-001","primaryCompletionDate":"","productId":399,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.retrotope.com/"],"sponsors":[{"sponsorId":"db62040470630e8a5c0d95e03ff88dcb0d440132","sponsorName":"Retrotope Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"NT-300","chemicalName":"Nitazoxanide","conditionOrDisease":"","contact":[{"email":"matthew.bardin@romark.com","name":null,"notes":"","phone":"813-282-8544","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"clinical_development","date":null,"milestoneId":43,"name":"phase_3","status":"ESTIMATED"}],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"3","preferredName":"Nitazoxanide","primaryCompletionDate":"","productId":400,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04343248","repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.romark.com/research-development/clinical-trials-covid/","https://www.drugbank.ca/drugs/DB00507","https://clinicaltrials.gov/ct2/show/study/NCT04343248?recrs=b&cond=nitazoxanide&draw=2&rank=5#contacts"],"sponsors":[{"sponsorId":"1a4907ea590dbc75efbbb16b2e8f00a1c68f3cf6","sponsorName":"Romark Laboratories LC"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Tue, 12 May 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"No","brandName":"olokizumab,RPH-104","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"in phase 2/3","numSites":"","otherPartners":"","phase":"2","preferredName":"olokizumab,RPH-104","primaryCompletionDate":"","productId":401,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.globenewswire.com/news-release/2020/04/28/2022958/0/en/Cromos-Pharma-Supports-R-Pharm-in-Initiation-of-a-Global-Program-to-Test-Two-of-its-Leading-Candidates-in-Patients-with-Severe-COVID-19-Infection-First-Patients-Have-Been-Recruited.html"],"sponsors":[{"sponsorId":"101d14f6d9ef50bd326177b2fd9683e6cfe02662","sponsorName":"RPharm JSC"},{"sponsorId":"1e8c65f7ae6e1857da235f503ee96eecdfc212b5","sponsorName":"Cromos Pharma LLC"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Cocktail","trialId":""},{"acceptsHealthySubjects":"","brandName":"POL-6014","chemicalName":"Ionodelestat","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Switzerland"],"countryCodes":["CHE"],"currentStage":"Pre-Clinical Testing","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Cold Spring Harbor Laboratory (CSHL)","phase":"","preferredName":"Ionodelestat","primaryCompletionDate":"","productId":402,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","http://www.santhera.com/assets/files/press-releases/2020-04-27_CSHL_lono_covid_e_final.pdf","http://www.santhera.com/"],"sponsors":[{"sponsorId":"6e39bc194deb64616e841179d70de0e3e8f6e7ad","sponsorName":"Santhera Pharmaceuticals Holding AG"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antisense oligonucleotides","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"will be using Sarepta\u2019s RNA technology to identify the antisense oligonucleotides","numSites":"","otherPartners":"","phase":"","preferredName":"Antisense oligonucleotides","primaryCompletionDate":"","productId":403,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.biospace.com/article/releases/sarepta-therapeutics-announces-research-agreement-with-u-s-department-of-defense-to-evaluate-multiple-constructs-from-its-proprietary-rna-platform-as-treatments-for-covid-19/"],"sponsors":[{"sponsorId":"318a3819bc03871596e0a772e1caa9643afd627c","sponsorName":"Sarepta Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Shionogi Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Japan"],"countryCodes":["JPN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"Hokkaido University Research Center for Zoonosis Control","phase":"","preferredName":"Shionogi Therapeutic","primaryCompletionDate":"","productId":404,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.americanpharmaceuticalreview.com/1315-News/563823-Shionogi-Accelerates-Development-of-Potential-COVID-19-Treatments-Vaccine/?catid=6262","http://www.shionogi.co.jp/en/"],"sponsors":[{"sponsorId":"49af49978e8b9f02c1384c21ddd1c7526817f753","sponsorName":"Shionogi  Co Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"","brandName":"Cynarine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Spain"],"countryCodes":["ESP"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"The company\u2019s artificial intelligence (AI)-based screening technology,SOMAIPRO,was used to discover the inhibitors of 3CL proteases","numSites":"","otherPartners":"","phase":"","preferredName":"Cynarine","primaryCompletionDate":"","productId":405,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://sombiotech.com/category/news/","https://www.pharmaceutical-technology.com/news/som-biotech-covid-19-candidates/"],"sponsors":[{"sponsorId":"a10386ee1438edc352e3ecdce639f4e60b04794a","sponsorName":"Som Biotech SL"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"prexasertib","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Spain"],"countryCodes":["ESP"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"SOM Biotech used artificial intelligence (called SOMAIPRO) to find molecules that could act as inihibitors of 3CL which could potentially treat COVID-19. They are waiting on an IND before proceeding with Phase 1 Clinical Trials.","numSites":"","otherPartners":"Ewha Woman's University","phase":"","preferredName":"prexasertib","primaryCompletionDate":"","productId":406,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.drugbank.ca/drugs/DB12008","https://www.medchemexpress.com/LY2606368.html","https://sombiotech.com/new-therapies-for-covid-19/"],"sponsors":[{"sponsorId":"a10386ee1438edc352e3ecdce639f4e60b04794a","sponsorName":"Som Biotech SL"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"","brandName":"Xerava","chemicalName":"eravacycline","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Spain"],"countryCodes":["ESP"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Sun, 02 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Small molecule","notes":"SOM Biotech used artificial intelligence (called SOMAIPRO) to find molecules that could act as inihibitors of 3CL which could potentially treat COVID-19. They are waiting on an IND before proceeding with Phase 1 Clinical Trials.","numSites":"","otherPartners":"Ewha Woman's University","phase":"","preferredName":"eravacycline","primaryCompletionDate":"","productId":407,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.drugbank.ca/drugs/DB12329","https://sombiotech.com/new-therapies-for-covid-19/","https://chemrxiv.org/articles/Fast_Identification_of_Possible_Drug_Treatment_of_Coronavirus_Disease_-19_COVID-19_Through_Computational_Drug_Repurposing_Study/11875446","https://www.pharmaceutical-technology.com/news/som-biotech-covid-19-candidates/"],"sponsors":[{"sponsorId":"a10386ee1438edc352e3ecdce639f4e60b04794a","sponsorName":"Som Biotech SL"},{"sponsorId":"83cfc31290e69df07985c4197a3d92ab4c6b2d1c","sponsorName":"Tetraphase Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antibiotics and antiparasitics","trialId":""},{"acceptsHealthySubjects":"","brandName":"Llama-derived antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"Sysvax Inc. is investigating several different COVID-19 vaccine approaches.","numSites":"","otherPartners":"Quacell Biotechnology Co. LTD","phase":"","preferredName":"Llama-derived antibodies","primaryCompletionDate":"","productId":408,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches"],"sponsors":[{"sponsorId":"94b9fb08c2b9a96fe640774a647230d6d7a7b34c","sponsorName":"Sysvax Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"PPP-003","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Pre-Clinical Testing","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"","notes":"Tetra BioPharma aims to have completed pre-clinical stuudies by fall of 2020 and begin human clinical trials in Montreal.","numSites":"","otherPartners":"","phase":"","preferredName":"PPP-003","primaryCompletionDate":"","productId":409,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2020/Tetra-Bio-Pharma-Provides-PPP003-Inflammatory-Cytokine-Reduction-Drug-Program/default.aspx","https://stockdaymedia.com/tetra-bio-pharma-discusses-development-of-ppp003-drug-for-cytokine-reduction-with-the-stock-day-podcast-tbpmf-may-7-2020/","https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2020/Tetra-Bio-Pharma-Announces-Drug-Candidate-as-Potential-Therapy-for-Managing-Cytokine-Release-Syndrome/default.aspx"],"sponsors":[{"sponsorId":"d64052c9fc506bd796cd3404142772d1197adf54","sponsorName":"Tetra BioPharma Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Allorx stem cells","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Cell therapies","notes":"Vitro Biopharma has submitted an IND application and is waiting on results before beginning Phase I human clinical trials.","numSites":"","otherPartners":"","phase":"","preferredName":"Allorx stem cells","primaryCompletionDate":"","productId":410,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://vitrobiopharma.com/vitro-biopharma-submits-ind-application-to-fda-for-allorx-stem-cellr-therapy-of-covid-19/","https://vitrobiopharma.com/vitro-biopharma-2019-ceo-shareholder-letter-record-revenues-leading-to-further-growth-into-2020/","https://vitrobiopharma.com/contact/"],"sponsors":[{"sponsorId":"2a124d615112a39893fb8a499cdb57c08486b0e4","sponsorName":"Vitro Diagnostics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"VBI-S","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"Other","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 01 Feb 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"VBI-S aims to lower blood pressure and oxygenation from septic shock,which is a common cause of death in COVID patients","numSites":"","otherPartners":"Ascendia Pharmaceuticals","phase":"","preferredName":"VBI-S","primaryCompletionDate":"","productId":411,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.prnewswire.com/news-releases/vivacelle-bio-announces-compassionate-use-for-covid-19-patients-with-its-sepsis-treatment-vbi-s-301044045.html","https://clinicaltrials.gov/ct2/show/NCT04257136","https://clinicaltrials.gov/ct2/show/NCT04257136?lead=Vivacelle+Bio&draw=2&rank=1","https://www.businesswire.com/news/home/20190708005192/en/Vivacelle-Bio-Announces-FDA-Clearance-Enroll-Patients","https://clinicaltrials.gov/ct2/show/study/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1","https://clinicaltrials.gov/ct2/show/study/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1#contacts","https://clinicaltrials.gov/ct2/show/record/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1&view=record"],"sponsors":[{"sponsorId":"96b4ec30be2b8b138d6a097ca033241b0479fed5","sponsorName":"Vivacelle Bio Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Vyripharm Biopharmaceuticals LLC therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Unknown","notes":"The drug will combine anti-viral and anti-CB1 antagonist analogues for nuclear medicine imaging applications","numSites":"","otherPartners":"","phase":"","preferredName":"Vyripharm Biopharmaceuticals LLC therapeutic","primaryCompletionDate":"","productId":412,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.biospace.com/article/releases/vyripharm-biopharmaceuticals-is-in-the-development-stage-of-a-novel-integrated-theranostic-approach-for-the-treatment-of-viral-infections-such-as-covid-19/","https://www.bioworld.com/COVID19products","https://www.pharmaceuticaldaily.com/vyripharm-biopharmaceuticals-is-in-the-development-stage-of-a-novel-integrated-theranostic-approach-for-the-treatment-of-viral-infections-such-as-covid-19/"],"sponsors":[{"sponsorId":"078da56adc71e2a029154078183324f8f351e10a","sponsorName":"Vyripharm Biopharmaceuticals LLC"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Mesencure","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Israel"],"countryCodes":["ISR"],"currentStage":"Pre-Clinical Testing","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Sun, 19 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"","numSites":"","otherPartners":"BONUS BioGroup","phase":"","preferredName":"Mesencure","primaryCompletionDate":"","productId":413,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","http://www.bonusbiogroup.com/index.php/news-media/press-releases/item/32-bonus-biogroup-has-initiated-a-preclinical-study-of-a-unique-drug-developed-for-the-treatment-of-life-threatening-respiratory-distress-in-corona-covid-19-patients-and-pneumonia","https://www.bonusbiogroup.com/"],"sponsors":[{"sponsorId":"21fffcbea9a29011a432f5076a9bf80e04b86566","sponsorName":"Wize Pharma Inc"},{"sponsorId":"33a0699dc37b7638ed3184d943514267306a6b62","sponsorName":"Bonus Biogroup Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"MAPS vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"Astellas Pharma Inc.","phase":"","preferredName":"MAPS vaccine","primaryCompletionDate":"","productId":414,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://affinivax.com/maps-platform/","https://affinivax.com/vaccine-pipeline/","https://www.bioworld.com/articles/434616-affinivax-raises-120m-series-b-to-advance-maps-vaccines-and-immunotherapies","https://labcentral.org/resident-companies/affinivax","https://affinivax.com/about/","https://www.clinicaltrials.gov/ct2/show/study/NCT03803202?term=ASP3772","https://www.clinicaltrials.gov/ct2/show/record/NCT03803202?term=ASP3772","https://www.clinicaltrials.gov/ct2/show/study/NCT03803202?term=ASP3772#contacts"],"sponsors":[{"sponsorId":"d4c4eaf123ba9a0ed44f528ea27f445b3ebffc82","sponsorName":"Affinivax Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Chimigen vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"Akshaya's Chimigen vaccine platform is being reappropriated for COVID-19 in combination with Cytovance's GMP insect cell microbial manufacturing platform","numSites":"","otherPartners":"Cytovance Biologics","phase":"","preferredName":"Chimigen vaccine","primaryCompletionDate":"","productId":415,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.globenewswire.com/news-release/2020/04/23/2020621/0/en/Cytovance-Biologics-and-Akshaya-Bio-Announce-Collaboration-Agreement-of-Therapeutics-for-Treatment-of-Coronavirus-and-Hepatitis-B-Virus-Infections.html","http://www.akshayabio.com/technology.html","http://www.akshayabio.com/pdf/Akshaya_Overview.pdf","https://www.cytovance.com/news-articles/cytovance-biologics-and-akshaya-bio-announce-collaboration-agreement-of-therapeutics-for-treatment-of-coronavirus-and-hepatitis-b-virus-infections"],"sponsors":[{"sponsorId":"8f43d7087cc0c2a8d9687603029d4f8c7c3e6446","sponsorName":"Akshaya Bio Inc"},{"sponsorId":"66f07a8584ac1fa31540d4786854faf6c4aa3957","sponsorName":"Cytovance Biologics"},{"sponsorId":"979bfa8ba62f21bb1e1f2b82b0e6aeb823504607","sponsorName":"Shenzhen Hepalink Pharmaceutical Group Co Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Brilacidin","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Sun, 01 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"A defense Protein (HDP)/Defensin-Mimetic drug candidate previously being investigated for inflammatory bowel disease and oral mucositis and Acute Bacterial Skin and Skin Structure Infection,Has antiviral and immunomodulatory/anti-inflammatory and antimicrobial properties,Phase 2 trial completed for other indications","numSites":"","otherPartners":"","phase":"","preferredName":"Brilacidin","primaryCompletionDate":"","productId":416,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://static1.squarespace.com/static/5715352e20c647639137f992/t/5e9cebd48660e44c2754fa00/1587342453349/Brilacidin+for+COVID-19+Overview+-+MOA%2C+PreClinical+Data%2C+Academic+Literature+-+4.20.20.pdf","http://www.ipharminc.com/stages-of-development"],"sponsors":[{"sponsorId":"1d734ed76d96923533eb179ad68641d15e10b3a1","sponsorName":"Innovation Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"PDS02023","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Unknown","notes":"Leveraging existing Versamune\u00ae platform","numSites":"","otherPartners":"","phase":"","preferredName":"PDS02023","primaryCompletionDate":"","productId":417,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.pdsbiotech.com/pipeline/overview","https://www.bioworld.com/COVID19products","https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/56-2020-news/377-iotechnologynitiatesovelaccineevelopmentrogr20200416"],"sponsors":[{"sponsorId":"e3a55329a850b005a641bf3bda030265211c6969","sponsorName":"PDS Biotechnology Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Adenoviral vector vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Italy"],"countryCodes":["ITA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Unknown","notes":"Vaccine candidate expected to target the spike protein of SARS-CoV-2,Vaccine technology is based on a novel ReiThera-proprietary simian adenoviral vector with strong immunological potency and low pre-existing immunity in humans","numSites":"","otherPartners":"Leukocare AG,Univercells SA","phase":"","preferredName":"Adenoviral vector vaccine","primaryCompletionDate":"","productId":418,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.univercells.com/newsroom/reithera-leukocare-and-univercells-announce-fast-track-development-of-a-covid-19-vaccine/","https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"9b79c8bf08e2131d6f17af795021cda7e20aa3f7","sponsorName":"Reithera Srl"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"DNA Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Unknown","notes":"Candidate to target the SARS-CoV-2 nucleocapsid (N) protein and the key receptor-binding domain of the spike (S) protein to generate both T cell responses and virus neutralizing antibodies","numSites":"","otherPartners":"","phase":"","preferredName":"DNA Vaccine","primaryCompletionDate":"","productId":419,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.scancell.co.uk/product-pipeline","https://www.bioworld.com/COVID19products","https://www.scancell.co.uk/Data/Sites/1/media/publications/news/covid-19-vaccine-programme.pdf"],"sponsors":[{"sponsorId":"092bd155058a125cab87c808b5adaf8207b382dd","sponsorName":"Scancell Holdings plc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Pathogen-specific aAPC","chemicalName":"","conditionOrDisease":"COVID 19","contact":[{"email":"c@szgimi.org","name":null,"notes":"","phone":"For China: +86(755)8672 5195","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"Covid-19/aAPC vaccine is prepared by applying lentivirus modification including immune modulatory genes and the viral minigenes to the artificial antigen presenting cells","numSites":"1","otherPartners":"Shenzhen Third People's Hospital,Shenzhen Second People's Hospital","phase":"1","preferredName":"Pathogen-specific aAPC","primaryCompletionDate":"Mon, 31 Jul 2023 00:00:00 GMT","productId":420,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04299724","repurposed":"","siteLocations":[{"city":"Shenzhen","country":"CHN","lat":22.543096,"lng":114.057865,"locationId":"5f746025122eb40db8643963e518b2fd4407e627","name":"Shenzhen","state":"Guangdong Province"}],"sources":["https://www.nature.com/articles/d41573-020-00073-5","https://clinicaltrials.gov/ct2/show/NCT04299724"],"sponsors":[{"sponsorId":"36892fb1d881bf4eb83d3e08c9a4f8319cf53660","sponsorName":"Shenzhen GenoImmune Medical Institute"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Sat, 15 Feb 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"OraPro-COVID-19","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"It is a viral vectored adenovirus 5 containing the spike protein DNA from SARS-CoV-2,As of 04/30/2020 they announced successful completion of initial animal safety trials. Website says they'll soon be raising funds for clinical trials and manufacturing. Clinical trials are expected to start in June","numSites":"","otherPartners":"","phase":"","preferredName":"OraPro-COVID-19","primaryCompletionDate":"","productId":421,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://invest.stabilitech.com/","https://www.stabilitech.com/","https://www.stabilitech.com/orapro-covid-19/; https://invest.stabilitech.com/; https://www.stabilitech.com/news/","https://www.stabilitech.com/orapro-covid-19/"],"sponsors":[{"sponsorId":"d3558ec7487260af8eeda161f466322bb598e734","sponsorName":"Stabilitech Biopharma Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Vivagel,SPL-7013","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Australia"],"countryCodes":["AUS"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"","notes":"Uses dendrimers--not sure how to classify the molecule type,Repurposing the active ingredient (SPL7013) but would come up with new products/formulations for COVID-19 application","numSites":"","otherPartners":"","phase":"","preferredName":"Vivagel,SPL-7013","primaryCompletionDate":"","productId":422,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://starpharma.com/news/473","https://starpharma.com/about_us"],"sponsors":[{"sponsorId":"8d39bbb89598527ce93987da7ed5e69cefec828b","sponsorName":"Starpharma Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"VLP Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Company is developing recombinant protein vaccine (detailed in this row) as well as a nanobody therapeutic and working to increase the half-life of COVID treatments,CEO says he expects vaccine will be IND-ready in the end of 2020 or early 2021","numSites":"","otherPartners":"Quacell Biotechnology Co. Ltd.","phase":"","preferredName":"VLP Vaccine","primaryCompletionDate":"","productId":423,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches"],"sponsors":[{"sponsorId":"94b9fb08c2b9a96fe640774a647230d6d7a7b34c","sponsorName":"Sysvax Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Baculovirus Expression Vector System vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Japan"],"countryCodes":["JPN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Sun, 01 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Japan Agency for Medical Research and Development (AMED)","phase":"","preferredName":"Baculovirus Expression Vector System vaccine","primaryCompletionDate":"","productId":424,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.shionogi.com/shionogi-accelerates-development-of-potential-covid-19-treatments-and-vaccine/","https://www.umnpharma.com/en/aboutus/"],"sponsors":[{"sponsorId":"85a7bc9d8e40313776bed1f5693ea229f6014f09","sponsorName":"UMN Pharma Inc"},{"sponsorId":"49af49978e8b9f02c1384c21ddd1c7526817f753","sponsorName":"Shionogi  Co Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Ixiaro","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Whole-pathogen vaccines","notes":"I don't think they would be using Ixiaro --at least not as-is-- as a COVID vaccine -- change Product Name? Also why I left the New/Repurposed column blank","numSites":"","otherPartners":"","phase":"","preferredName":"Ixiaro","primaryCompletionDate":"","productId":425,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://valneva.com/press-release/valneva-and-dynavax-announce-collaboration-to-advance-vaccine-development-for-covid-19/"],"sponsors":[{"sponsorId":"059f2a3d5a1e49d84849751adc693a806e10964c","sponsorName":"Valneva SE"},{"sponsorId":"8e7b2da49f08d6b67425d83fea0307211169ec91","sponsorName":"Dynavax Technologies Corp"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Pepticrad vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Finland"],"countryCodes":["FIN"],"currentStage":"Pre-Clinical Testing","indication":"Other","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Wed, 22 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Subunit Vaccines","notes":"It seems to be focused on tumor immunity rather virus immunity","numSites":"","otherPartners":"Valo Therapeutics","phase":"","preferredName":"Pepticrad vaccine","primaryCompletionDate":"","productId":426,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.valotx.com/what-pepticrad","https://cordis.europa.eu/project/id/681219/reporting","https://www.targovax.com/en/targovax-and-valo-therapeutics-enter-collaboration-to-develop-ras-neoantigen-coating-of-oncos-viruses-using-pepticrad-technology/ ; https://www.bioworld.com/COVID19products","https://cordis.europa.eu/project/rcn/204117/reporting/en?rcn=4155","https://www.prnewswire.com/news-releases/targovax-and-valo-therapeutics-enter-collaboration-to-develop-ras-neoantigen-coating-of-oncos-viruses-using-pepticrad-technology-301044964.html"],"sponsors":[{"sponsorId":"647f2087ef04f50197602c4a93c8cd00e43f1216","sponsorName":"Valo Therapeutics Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Combination","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Opdivo","chemicalName":"nivolumab","conditionOrDisease":"COVID-19","contact":[{"email":"gggjerry@gmail.com","name":null,"notes":"","phone":"","website":""}],"countries":["Hong Kong"],"countryCodes":["HKG"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 22 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"nivolumab","primaryCompletionDate":"Tue, 30 Jun 2020 00:00:00 GMT","productId":457,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04356508","repurposed":"Repurposed-Approved","siteLocations":[{"city":null,"country":"HKG","lat":22.2829989,"lng":114.1370848,"locationId":"ac87fadd052eec710d16a77c56e5c88d0ebbf2ae","name":"The University Of Hong Kong","state":"Hong Kong Island"}],"sources":["https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#","https://clinicaltrials.gov/ct2/show/NCT04356508","https://www.drugbank.ca/drugs/DB09035","https://clinicaltrials.gov/ct2/show/NCT04356508#contacts"],"sponsors":[{"sponsorId":"6b014b07406a291e8e325b2a212ac65562a16644","sponsorName":"University of Hong Kong"},{"sponsorId":"45cb448ccda5ba5bd7b24c304ad43117f0f1545f","sponsorName":"BMS"}],"status":"Ongoing","studyCompletionDate":"Tue, 31 Aug 2021 00:00:00 GMT","studyStartDate":"Wed, 22 Apr 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Vaxipatch vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Fri, 01 May 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"ESTIMATED"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Subunit Vaccines","notes":"The product is a combination of a new COVID-19 vaccine and new delivery system","numSites":"","otherPartners":"Verndari Inc.","phase":"","preferredName":"Vaxipatch vaccine","primaryCompletionDate":"","productId":427,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.verndariinc.com/news/4","https://www.businesswire.com/news/home/20200429005243/en/Verndari-Begins-Preclinical-Testing-COVID-19-Vaccine-University","https://www.ucdavis.edu/coronavirus/news/covid-19-vaccine-patch-delivery-technology-enters-preclinical-testing-uc-davis/","https://www.verndariinc.com/"],"sponsors":[{"sponsorId":"d55c14eadb5f58261f7259e0d7eeaa8926742a23","sponsorName":"Verndari Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Viravaxx Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Austria"],"countryCodes":["AUT"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"Viravaxx - Medical University of Vienna","phase":"","preferredName":"Viravaxx Vaccine","primaryCompletionDate":"","productId":428,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.genomeweb.com/immunoassays/viravaxx-medical-university-vienna-partnering-covid-19-dx-vaccine-work#.XsAfSGhKg2w","https://www.pharmiweb.com/press-release/2020-04-22/viravaxx-ag-and-the-medical-university-of-vienna-have-launched-a-project-for-an-integrated-platform-for-immune-diagnosis-and-vaccination-for-covid-19","https://www.lisavienna.at/news/viravaxx-ag-and-the-medical-university-of-vienna-have-launched-a-project-for-an-integrated-platform/","http://www.viravaxx.eu/company/covid-19/"],"sponsors":[{"sponsorId":"b49bbd5f20c2dcea7a6b4e32bbe73978f88a8fce","sponsorName":"Viravaxx AG"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Masitinib","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"DL_MEDICALWRITERS@ab-science.com","name":null,"notes":"","phone":"","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 04 May 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"1","otherPartners":"AB Science SA","phase":"2","preferredName":"Masitinib","primaryCompletionDate":"","productId":429,"registryLink":"https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001635-27/FR","repurposed":"New","siteLocations":[{"city":"Paris","country":"FRA","lat":48.86537389999999,"lng":2.3010134,"locationId":"7278beeaa06519f1fa18ea1dc852ba32a77e890f","name":"Ab Science","state":"IDF"}],"sources":["https://www.bioworld.com/COVID19products","https://www.reuters.com/article/brief-ab-science-initiates-phase-2-study/brief-ab-science-initiates-phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-for-treatment-of-covid-19-idUSASN0006G7","http://www.ab-science.com/pipeline/masitinib","https://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001635-27-FR","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001635-27/FR"],"sponsors":[{"sponsorId":"789e5231b8f9ca65a7723cb16dd32889a34ed5bc","sponsorName":"AB Science SA"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 04 May 2020 00:00:00 GMT","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"No","brandName":"MRx-4DP0004","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"clinicaltrials@4dpharmaplc.com","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 01 May 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"4D pharma plc","phase":"2","preferredName":"MRx-4DP0004","primaryCompletionDate":"Sat, 01 Aug 2020 00:00:00 GMT","productId":430,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04363372","repurposed":"New","siteLocations":[{"city":null,"country":"GBR","lat":53.806631,"lng":-1.7966408,"locationId":"553a6af47c746e1f54899a38a97e44ee2adb0c2c","name":"Bradford Royal Infirmary","state":"England"}],"sources":["https://www.bioworld.com/COVID19products","https://www.4dpharmaplc.com/en/developing-science/pipeline","https://clinicaltrials.gov/ct2/show/NCT04363372","https://clinicaltrials.gov/ct2/show/NCT04363372#contacts","https://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT04363372"],"sponsors":[{"sponsorId":"cc2e5994616b4b7838fad454261c03059f72adda","sponsorName":"4D Pharma plc"}],"status":"Ongoing","studyCompletionDate":"Tue, 01 Sep 2020 00:00:00 GMT","studyStartDate":"Fri, 01 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"ATYR-1923","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Tue, 21 Apr 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"aTyr Pharma Inc.","phase":"","preferredName":"ATYR-1923","primaryCompletionDate":"","productId":431,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-phase-2-study-atyr1923-covid-19-patients","https://www.globenewswire.com/news-release/2020/04/21/2019306/0/en/aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application.html","https://pipelinereview.com/index.php/2020042274397/Antibodies/aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application.html"],"sponsors":[{"sponsorId":"9fe0e590c2f59e3993488b50e1454cf4b33f89cc","sponsorName":"Atyr Pharma Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"PH-94B","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"Other","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"VistaGen Therapeutics","phase":"","preferredName":"PH-94B","primaryCompletionDate":"","productId":432,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.vistagen.com/news-media/press-releases/detail/138/vistagen-expands-ph94b-clinical-development-to-include","https://www.vistagen.com/"],"sponsors":[{"sponsorId":"ed125bf42550b194df6aae1e7e4306bf089a81c5","sponsorName":"Vistagen Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Cymerus","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Australia"],"countryCodes":["AUS"],"currentStage":"Phase 1","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Fri, 08 May 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"","numSites":"","otherPartners":"Cynata Therapeutics","phase":"","preferredName":"Cymerus","primaryCompletionDate":"","productId":433,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.clinicaltrialsarena.com/news/cynata-therapeutics-covid-19-trial/","https://www.cynata.com/about-cymerus","https://www.cynata.com/","https://www.atsjournals.org/doi/abs/10.1164/rccm.201911-2143OC"],"sponsors":[{"sponsorId":"e0209d6491b3ecdcf4e0f1ab73af91ca49a735f9","sponsorName":"Cynata Therapeutics Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"7HP-349","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"Other","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Tue, 14 Apr 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"7 Hills Pharma","phase":"","preferredName":"7HP-349","primaryCompletionDate":"","productId":434,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://drug-dev.com/7-hills-pharma-announces-covid-19-vaccine-program-targeting-at-risk-elderly/","https://www.bio.org/events/bio-digital/sessions/677987","http://www.7hillspharma.com/","https://www.globenewswire.com/news-release/2020/04/14/2015589/0/en/7-Hills-Pharma-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-7HP349-a-First-in-Class-Immune-Stimulant.html/","https://www.globenewswire.com/news-release/2020/04/14/2015589/0/en/7-Hills-Pharma-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-7HP349-a-First-in-Class-Immune-Stimulant.html"],"sponsors":[{"sponsorId":"a3b71c8e66306bb94d3f940d89f1664a0561c909","sponsorName":"7 Hills Pharma"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Combination","trialId":""},{"acceptsHealthySubjects":"","brandName":"Plasma therapy","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"ESTIMATED"}],"moleculeType":"Cell therapies","notes":"","numSites":"","otherPartners":"CoVIg-19 Plasma Alliance","phase":"","preferredName":"Plasma therapy","primaryCompletionDate":"","productId":435,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.pharmashots.com/32740/covig-19-plasma-alliance-to-initiate-clinical-study-evaluating-hyperimmune-therapy-for-covid-19-by-summer-2020/","https://www.covig-19plasmaalliance.org/en-us#recruitment","https://www.gatesfoundation.org/TheOptimist/Articles/coronavirus-interview-toni-hoover-covig-alliance"],"sponsors":[{"sponsorId":"4fb6f98d06346dfb8480801ffdeb277e7bf9a142","sponsorName":"Adma Biologics Inc"},{"sponsorId":"d57dd60076a98933462c35466d4808237238cb98","sponsorName":"Biopharma Plasma LLC"},{"sponsorId":"fb88543fd60aa16c3c184e6208739bc678ea7909","sponsorName":"GC Pharma"},{"sponsorId":"fdcec5fc0acc497097b5595f555306625de122b3","sponsorName":"Sanquin"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antibiotics and antiparasitics","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Ampligen","chemicalName":"rintatolimod","conditionOrDisease":"SARS Coronavirus 2 Infection,Malignant Neoplasm","contact":[{"email":"brahm.segal@roswellpark.org","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"ESTIMATED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"1","otherPartners":"","phase":"1","preferredName":"rintatolimod","primaryCompletionDate":"Sat, 04 Sep 2021 00:00:00 GMT","productId":436,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04379518","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Buffalo","country":"USA","lat":42.8987016,"lng":-78.86554819999999,"locationId":"21acb3e43a9f56844407b57f3fa9c0fefc4bba72","name":"Roswell Park Cancer Institute","state":"NY"}],"sources":["https://www.bioworld.com/COVID19products","https://adisinsight.springer.com/drugs/800001203","https://aidsinfo.nih.gov/drugs/530/rintatolimod/0/professional","https://www.clinicaltrials.gov/ct2/show/NCT04379518?term=rintatolimod&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1","https://www.clinicaltrials.gov/ct2/show/NCT04379518?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Rintatolimod&draw=2&rank=1#contacts"],"sponsors":[{"sponsorId":"a5d57560d2358d025ed56eb6ac56526d88680140","sponsorName":"Aim Immunotech Inc"},{"sponsorId":"2e24540b50be00a931dccd241b0636b9266f04e9","sponsorName":"GP Pharma SA"}],"status":"Ongoing","studyCompletionDate":"Sat, 04 Sep 2021 00:00:00 GMT","studyStartDate":"Fri, 04 Sep 2020 00:00:00 GMT","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"NK1R,MSC","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"Therapeutic","milestones":[],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"NK1R,MSC","primaryCompletionDate":"","productId":437,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"c9db829f16ef51a61f3cd081ad98c89a77816915","sponsorName":"Biocardia Inc"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"","brandName":"CB-5064","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Tue, 05 May 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"CB-5064","primaryCompletionDate":"","productId":438,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://ir.cohbar.com/press-releases/detail/106/cohbar-to-target-covid-19-associated-acute-respiratory","https://www.biospace.com/article/releases/cohbar-to-target-covid-19-associated-acute-respiratory-distress-syndrome-ards-with-its-apelin-receptor-agonist-peptidespreclinical-testing-of-cb5064-analogs-initiated-in-ards/"],"sponsors":[{"sponsorId":"afe0ce46a6b36052788fe265d4169a7e91f11c15","sponsorName":"Cohbar Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"DW-2008","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"ESTIMATED"}],"moleculeType":"Other","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"DW-2008","primaryCompletionDate":"","productId":439,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.businesswire.com/news/home/20200506005403/en/DongWha-Pharm%E2%80%99s-DW2008-Shows-Excellent-Antiviral-Activity"],"sponsors":[{"sponsorId":"0ea71c946179e2be0e9be90836aebd96833546ef","sponsorName":"Dongwha Pharmaceutical Co Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"DNA Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"DNA Vaccine","primaryCompletionDate":"","productId":495,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://uwaterloo.ca/stories/news/university-waterloo-developing-dna-based-covid-19-vaccine"],"sponsors":[{"sponsorId":"a07da6c1efe123b7fa3c2ce439820c1646f72988","sponsorName":"University of Waterloo"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"EDP-1815","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 26 Aug 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"EDP-1815","primaryCompletionDate":"","productId":440,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://evelobio.com/portfolio/","https://clinicaltrials.gov/ct2/show/NCT04488575","https://clinicaltrials.gov/ct2/show/NCT04488576","https://clinicaltrials.gov/ct2/show/NCT04488577","https://clinicaltrials.gov/ct2/show/NCT04488578","https://clinicaltrials.gov/ct2/show/NCT04488579","https://clinicaltrials.gov/ct2/show/NCT04488580","https://clinicaltrials.gov/ct2/show/NCT04488581","https://clinicaltrials.gov/ct2/show/NCT04488582","https://clinicaltrials.gov/ct2/show/NCT04488583"],"sponsors":[{"sponsorId":"f550d0dbaee63bc003995e8c7af74aca187e11a2","sponsorName":"Evelo Biosciences Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Nucleic Acid Therapy","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Nucleic Acid Therapy","primaryCompletionDate":"","productId":441,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.globenewswire.com/news-release/2020/04/15/2016577/0/en/Aligos-Therapeutics-Expands-Licensing-Agreement-with-Luxna-Biotech-in-Oligonucleotide-Technology-to-Include-Novel-Coronavirus-Targets.html"],"sponsors":[{"sponsorId":"330a20d0af980a475ef093d65b4d4ea3e054756b","sponsorName":"Aligos Therapeutics Inc"},{"sponsorId":"a23d124d39198914a13ff22112de76a68eaed76e","sponsorName":"Luxna Biotech Co Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Antibodies","primaryCompletionDate":"","productId":442,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.amgen.com/media/news-releases/2020/04/amgen-and-adaptive-biotechnologies-announce-strategic-partnership-to-develop-a-therapeutic-to-prevent-or-treat-covid-19/"],"sponsors":[{"sponsorId":"acd14e0eb640e0edd21f95856232fcef09bac5ff","sponsorName":"Amgen Inc"},{"sponsorId":"41e5fc673f8854b964c241d3e222a9d61b432222","sponsorName":"Adaptive Biotechnologies Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antiviral","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Mon, 20 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Antiviral","primaryCompletionDate":"","productId":443,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://ir.anixa.com/press-releases/detail/949/anixa-biosciences-and-ontochem-announce-discovery-of-first","https://ir.anixa.com/press-releases/detail/947/anixa-biosciences-and-ontochem-announce-collaboration-to"],"sponsors":[{"sponsorId":"360810fb2f49838a5afb9da083af7b2c1effa9be","sponsorName":"Anixa Bioscience Inc"},{"sponsorId":"a4ef2f5ab85094f28d88aa3073d73426d3009319","sponsorName":"Ontochem GmbH"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Knockdown Coronavirus","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 06 May 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Knockdown Coronavirus","primaryCompletionDate":"","productId":444,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.newswire.ca/news-releases/aum-lifetech-and-aum-biotech-launch-knockdown-coronavirus-research-program-879512340.html","https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"cd1a1a7e1700bd67f76dbb0979cfb550367890c2","sponsorName":"Aum Lifetech Inc"},{"sponsorId":"2f3a07259231f646a8c98cf47cd635cd2837ff4e","sponsorName":"Aum Biotech LLC"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"bacTRL-Spike","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"bd@symvivo.com","name":null,"notes":"","phone":"(604) 428-7474 ; 604-428-7474","website":"https://www.symvivo.com/"}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 01 Jul 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"1","otherPartners":"","phase":"1","preferredName":"bacTRL-Spike","primaryCompletionDate":"Tue, 08 Feb 2022 00:00:00 GMT","productId":445,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04334980","repurposed":"New","siteLocations":[{"city":"Melbourne","country":"AUS","lat":-37.8136276,"lng":144.9630576,"locationId":"6ce1202e7e777404ea6883227f983e0c200bcf62","name":"Melbourne","state":"VIC"}],"sources":["https://www.bioworld.com/COVID19products","https://www.symvivo.com/covid-19","https://www.clinicaltrials.gov/ct2/show/NCT04334980?term=symvivo&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1"],"sponsors":[{"sponsorId":"e67cd6e6e2d90ce2d60b99c1798176c943a02d7e","sponsorName":"Symvivo Corp"}],"status":"Ongoing","studyCompletionDate":"Mon, 28 Feb 2022 00:00:00 GMT","studyStartDate":"Mon, 02 Nov 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Recombinant vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Mexico"],"countryCodes":["MEX"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Laboratorios Liomont","phase":"","preferredName":"Recombinant vaccine","primaryCompletionDate":"","productId":446,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.bioworld.com/articles/435076-mexican-university-basing-covid-19-vaccine-on-zika-dengue"],"sponsors":[{"sponsorId":"ae65368e5dda7ac06191005363e4844d4740b0c1","sponsorName":"Autonomous University of Mexico"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Queretero Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Mexico"],"countryCodes":["MEX"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"National Council of Science and Technology","phase":"","preferredName":"Queretero Vaccine","primaryCompletionDate":"","productId":447,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.bioworld.com/articles/434931-mexican-team-lead-by-vets-racing-to-develop-covid-19-vaccine"],"sponsors":[{"sponsorId":"0bbca0d5754c5267ed051d9e9e225d44a2afcb2d","sponsorName":"Autonomous University of Queretero"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"CpG 1018","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"jszfc@vip.sina.com","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 16 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":"Thu, 16 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Combination","notes":"","numSites":"1","otherPartners":"Dynavax,Sinovac Biotech Ltd.","phase":"1","preferredName":"CpG 1018","primaryCompletionDate":"Thu, 13 Aug 2020 00:00:00 GMT","productId":448,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04352608","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Xuzhou","country":"CHN","lat":33.912597,"lng":117.941563,"locationId":"0d1809b9a96909600d50a5fefe0aee2562aba833","name":"Suining County Center For Disease Control And Prevention","state":"Jiangsu"}],"sources":["https://www.bioworld.com/COVID19products","http://investors.dynavax.com/news-releases/news-release-details/dynavax-and-sinovac-announce-collaboration-develop-coronavirus","https://www.dynavax.com/science/cpg-1018/","https://www.dynavax.com/","https://www.fiercebiotech.com/biotech/dynavax-sinovac-latest-to-ally-a-covid-19-vaccine","https://www.fdanews.com/articles/196715-sinovac-begins-phase-1-trial-of-its-covid-19-vaccine-candidate","https://clinicaltrials.gov/ct2/show/NCT04352608"],"sponsors":[{"sponsorId":"8e7b2da49f08d6b67425d83fea0307211169ec91","sponsorName":"Dynavax Technologies Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Thu, 16 Apr 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"mRNA Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Japan"],"countryCodes":["JPN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"","otherPartners":"Daiichi Sankyo,University of Tokyo","phase":"","preferredName":"mRNA Vaccine","primaryCompletionDate":"","productId":449,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.daiichisankyo.com/about_us/responsibility/csr/support/index.html","https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1","https://www.daiichisankyo.com/"],"sponsors":[{"sponsorId":"0bd3e0565493c03d25691fe59c64e75df50c6269","sponsorName":"Daiichi Sankyo"},{"sponsorId":"ab1e8ad3d379bcd134e4e3f47f828591f21bca7b","sponsorName":"University of Tokyo"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Viral Vector Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Germany"],"countryCodes":["DEU"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"ESTIMATED"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"German Center for Infection Research","phase":"","preferredName":"Viral Vector Vaccine","primaryCompletionDate":"","productId":450,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.dzif.de/en/sars-cov-2-dzif-scientists-and-development-vaccines","https://www.dzif.de/en/dzif-focuses-sars-cov-2-research"],"sponsors":[{"sponsorId":"43c5ca205d979b4627d9786a10dbcc7a28efe620","sponsorName":"German Center for Infection Research"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Combination","trialId":""},{"acceptsHealthySubjects":"","brandName":"TerraCoV2","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"Oragenics Inc.","phase":"","preferredName":"TerraCoV2","primaryCompletionDate":"","productId":451,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.businesswire.com/news/home/20200504005255/en/Oragenics-Acquires-Noachis-Terra-Develop-TerraCoV2-NIH-Generated"],"sponsors":[{"sponsorId":"525e613a8f2932fe3f0c17345916ceb457584531","sponsorName":"Noachis Terra Inc"},{"sponsorId":"37d795f226c583b0923370765712cfb305ea7951","sponsorName":"Oragenics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"CORVax12","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"OncoSec","phase":"","preferredName":"CORVax12","primaryCompletionDate":"","productId":452,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.cancernetwork.com/news/researchers-plan-evaluate-corvax12-vaccine-phase-i-clinical-trial-covid-19","https://idataresearch.com/oncosec-and-inovio-pursuing-phase-1-clinical-trials/"],"sponsors":[{"sponsorId":"870027d79725ce8aba9d63e3e3e414b41ab3e6a9","sponsorName":"Oncosec Medical Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Combination","trialId":""},{"acceptsHealthySubjects":"","brandName":"Ose Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Tue, 05 May 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"OSE Immunotherapeutics","phase":"","preferredName":"Ose Vaccine","primaryCompletionDate":"","productId":453,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://ose-immuno.com/wp-content/uploads/2020/05/EN_200505_COVID_VF.pdf","https://ose-immuno.com/en/"],"sponsors":[{"sponsorId":"b0c93e38a17b3b588585e151d3fc7aad0ba591b1","sponsorName":"Ose Immunotherapeutics SA"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Lineage Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Tue, 05 May 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Cell therapies","notes":"","numSites":"","otherPartners":"California Institute for Regenerative Medicine","phase":"","preferredName":"Lineage Vaccine","primaryCompletionDate":"","productId":454,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.businesswire.com/news/home/20200505005296/en/Lineage-Cell-Therapeutics-Apply-Allogeneic-Dendritic-Cell","https://lineagecell.com/","http://www.pharmaceuticaldaily.com/lineage-cell-therapeutics-to-apply-allogeneic-dendritic-cell-therapy-program-to-covid-19-vaccine-development-2/"],"sponsors":[{"sponsorId":"af5704392ebc92bfa0587cb489a242a1ecec053a","sponsorName":"Lineage Cell Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Zyus Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Thu, 07 May 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"ZYUS Life Sciences Inc.,VIDO-InterVac","phase":"","preferredName":"Zyus Vaccine","primaryCompletionDate":"","productId":455,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.zyus.com/news-and-events/news/news-details/2020/ZYUS-Collaborates-with-USasks-VIDO-InterVac-to-Develop-a-Plant-Based-Vaccine-for-COVID-19/default.aspx","https://www.vido.org/","https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/zyus-collaborates-with-usasks-vido-intervac-to-develop-a-plant-based-vaccine-for-covid-19"],"sponsors":[{"sponsorId":"f0c03914ca02d3e8f2291af133d7cfda224953cd","sponsorName":"Zyus Life Sciences Inc"},{"sponsorId":"7b2a555245dac6b0ae7cb9dd0f33a50d08853697","sponsorName":"VIDOIntervac"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"COVID-19 Immunoglobulin","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"COVID-19 Immunoglobulin","primaryCompletionDate":"","productId":456,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.csl.com/news/2020/20200506-csl-behring-australia-commences-development-of-treatment-for-serious-cases-of-covid-19"],"sponsors":[{"sponsorId":"086ded7bc6410c1971ea41cc7b102bd61b78be5d","sponsorName":"CSL Behring Australia"},{"sponsorId":"c51b564ec05a307bbc3b22a4b89f9c032a847dca","sponsorName":"CSL Limited"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"AiRuiKa","chemicalName":"camrelizumab","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Mon, 10 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"2","preferredName":"camrelizumab","primaryCompletionDate":"Thu, 30 Apr 2020 00:00:00 GMT","productId":458,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04268537","repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.hrs.com.cn/hren/products_pipeline_oncology.html","https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#","https://www.drugbank.ca/drugs/DB14776","https://clinicaltrials.gov/ct2/show/NCT04268537"],"sponsors":[{"sponsorId":"0c5c1dfd859ef4ba55b56530a5b4f12cf700ccc4","sponsorName":"Wuhan Jinyintan Hospital"},{"sponsorId":"67daca15db7dda94d46b570fc990f1a5b1d276a7","sponsorName":"Jiangsu HengRui Medicine Co"}],"status":"Ongoing","studyCompletionDate":"Sat, 31 Oct 2020 00:00:00 GMT","studyStartDate":"Mon, 10 Feb 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"United Kindom  Government","phase":"","preferredName":"Antibodies","primaryCompletionDate":"","productId":459,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.gov.uk/government/news/vaccine-trials-among-recipients-of-20-million-coronavirus-research-investment","https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-8-20-KR%5B1%5D.pdf"],"sponsors":[{"sponsorId":"9b2652ee65b8f7ac2fbc009851b6ef7d2faac03a","sponsorName":"Chelsea and Westminster Hospital"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Antibodies","primaryCompletionDate":"","productId":460,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.businesswire.com/news/home/20200519005826/en/Prellis-Biologics-Generates-300-Human-Antibodies-Bind","https://www.prellisbio.com/covid"],"sponsors":[{"sponsorId":"090447dc6c4ec30f0734d643a191fd594b173d68","sponsorName":"Prellis Biologics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Antibodies","primaryCompletionDate":"","productId":461,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.businesswire.com/news/home/20200406005284/en/Ligand-Corporate-Update-Announces-6th-Date-Quarter","https://investor.ligand.com/press-releases/detail/403/ligands-technologies-support-and-enable-potential"],"sponsors":[{"sponsorId":"84ed689e0ab14d5e34784cc4f76cde94a060206f","sponsorName":"Ligand Pharmaceuticals"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Costa Rica"],"countryCodes":["CRI"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Antibodies","primaryCompletionDate":"","productId":462,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#","https://www.presidencia.go.cr/comunicados/2020/04/costa-rica-to-develop-its-own-covid-19-detection-tests/"],"sponsors":[{"sponsorId":"956cde5aa334fee5ea41b8ef8bfcd942e83008fc","sponsorName":"Costa Rican Social Security Fund"},{"sponsorId":"b079ef3c1beae82abe8140f4ec81a68a9474e117","sponsorName":"University of Cost Rica"},{"sponsorId":"23956132e25e7933f285e2c95f701acdc8fa75b3","sponsorName":"Clodomiro Picado Institute"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"MEDI3506","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 28 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"MEDI3506","primaryCompletionDate":"","productId":463,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html","https://adisinsight.springer.com/drugs/800049222"],"sponsors":[{"sponsorId":"bb9ed07e215d6bebb274790c7ee0711a0da9f41e","sponsorName":"AstraZeneca"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"BTK inhibitor","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"BTK inhibitor","primaryCompletionDate":"","productId":464,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html","https://www.drugbank.ca/drugs/DB11703"],"sponsors":[{"sponsorId":"bb9ed07e215d6bebb274790c7ee0711a0da9f41e","sponsorName":"AstraZeneca"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Octagam","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"ctgov@clinicalresearchmgt.com","name":null,"notes":"","phone":"8663371868","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"11","otherPartners":"","phase":"3","preferredName":"Octagam","primaryCompletionDate":"","productId":465,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04400058","repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.businesswire.com/news/home/20200416005144/en/New-COVID-19-Clinical-Trial-Supported-Octapharma-USA","https://www.drugbank.ca/drugs/DB00028","https://clinicaltrials.gov/ct2/show/NCT04400058?term=octagam&cond=covid&draw=2&rank=1","https://clinicaltrials.gov/ct2/show/NCT04400058?term=octagam&cond=covid&draw=2&rank=1#contacts"],"sponsors":[{"sponsorId":"01f8847bee12adc194325c04b865f80d3f338fed","sponsorName":"Octapharma USA"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 01 Jun 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Immunoglobulin from Immunized Sheep","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Immunoglobulin from Immunized Sheep","primaryCompletionDate":"","productId":466,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://pink.pharmaintelligence.informa.com/-/media/supporting-documents/pink-sheet/2020/04/uk-covid19--april-2020.pdf?la=en&hash=63468870BA4F02331409F42AC9061BD6182C7710"],"sponsors":[{"sponsorId":"f9a892adb6624b2c054ff75c09fe66c94b05ec8a","sponsorName":"Public Health England"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Antibodies","primaryCompletionDate":"","productId":467,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.prnewswire.com/news-releases/ablexis-alivamab-discovery-services-and-berkeley-lights-collaborate-to-identify-a-diverse-panel-of-anti-sars-cov-2-human-antibodies-301045039.html","https://www.ablexis.com/ablexis-alivamab-discovery-services-and-berkeley-lights-collaborate-to-identify-a-diverse-panel-of-anti-sars-cov-2-human-antibodies/"],"sponsors":[{"sponsorId":"3cf57c67576a69c157365187bca4fa4cae4548a6","sponsorName":"Ablexis"},{"sponsorId":"6d78600d48c5ae40de6b7121b4357fa753958e26","sponsorName":"AlivaMab Discovery Services"},{"sponsorId":"a3fae7815b10a27a8b4c46a4e980cc12bef7bc77","sponsorName":"Berkeley Lights Collaborative"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"monoclonal antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"monoclonal antibodies","primaryCompletionDate":"","productId":468,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.businesswire.com/news/home/20200518005113/en/Abcore-Announces-Panel-Patent-Pending-Functional-Single"],"sponsors":[{"sponsorId":"1753a313e0d479ef0ea4b9cb41d499dc5703aee5","sponsorName":"Abcore"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Prezista","chemicalName":"darunavir","conditionOrDisease":"COVID-19","contact":[{"email":"luhongzhou@fudan.edu.cn","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"3","preferredName":"darunavir","primaryCompletionDate":"Mon, 31 Aug 2020 00:00:00 GMT","productId":469,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04252274","repurposed":"Repurposed-Approved","siteLocations":[{"city":null,"country":"CHN","lat":30.791749,"lng":121.341627,"locationId":"953ea76a8241ea2371b3d14e936ecbe1b8fa2853","name":"Shanghai Public Health Clinical Center","state":"Shanghai Shi"}],"sources":["https://medcitynews.com/2020/04/jj-hiv-drug-already-in-covid-19-clinical-trials-flunks-in-vitro-study/","https://www.drugbank.ca/drugs/DB01264","https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1","https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1#contacts"],"sponsors":[{"sponsorId":"79c2245b2e99e2ee02f6cc48aaefe048e67e29e0","sponsorName":"Johnson  Johnson"},{"sponsorId":"667987d4de01dd23efc5563684db4e2117b5d910","sponsorName":"Janssen"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Thu, 30 Jan 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Levovir","chemicalName":"clevudine","conditionOrDisease":"COVID-19","contact":[{"email":"bk.E106@bukwang.co.kr","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 14 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"clevudine","primaryCompletionDate":"Wed, 30 Sep 2020 00:00:00 GMT","productId":470,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04347915","repurposed":"Repurposed-Approved","siteLocations":[{"city":null,"country":"KOR","lat":37.4922173,"lng":126.8849478,"locationId":"8df561b5896da39a6f7b0e1a9d66d4c851187751","name":"Korea University Guro Hospital","state":"Seoul"}],"sources":["http://www.koreabiomed.com/news/articleView.html?idxno=8010","https://en.yna.co.kr/view/AEN20200414006700320","https://www.drugbank.ca/drugs/DB06683","https://clinicaltrials.gov/ct2/show/NCT04347915?term=clevudine&cond=Covid&draw=2&rank=1"],"sponsors":[{"sponsorId":"9560701a2c38713238ec1009dbb4dcf6fdf36153","sponsorName":"Bukwang Pharm"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Wed, 06 May 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"BTL-tml","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"BTL-tml","primaryCompletionDate":"","productId":471,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.beechtreelabs.com/","https://www.clinicaltrialsarena.com/contractors/contract_research/ncra/pressreleases/press7-5/","https://www.news10.com/news/local-news/president-ceo-of-beech-tree-labs-seeks-fda-approval-for-tml-covid-19-treatment/"],"sponsors":[{"sponsorId":"726053ab8e4d96ab800e4589733fc5b6baaf03e3","sponsorName":"Beech Tree Labs"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"emetine hydrochloride","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"emetine hydrochloride","primaryCompletionDate":"","productId":472,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.acertx.com/2020/05/11/acer-therapeutics-to-develop-emetine-as-potential-covid-19-treatment-in-collaboration-with-national-center-for-advancing-translational-sciences-one-of-the-national-institutes-of-health/"],"sponsors":[{"sponsorId":"5ad93754d0bd669c3270518802ff29ac3e9c49f5","sponsorName":"Acer Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"No","brandName":"AT-527","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"AteaClinicalTrials@ateapharma.com","name":null,"notes":"","phone":"888-481-1607","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Wed, 20 May 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"10","otherPartners":"","phase":"2","preferredName":"AT-527","primaryCompletionDate":"","productId":473,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04396106","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Sacramento","country":"USA","lat":38.5815719,"lng":-121.4943996,"locationId":"01f9a1d2071e5f045fcead8e032695104cca028b","name":"Sacramento","state":"CA"},{"city":"San Diego","country":"USA","lat":32.715738,"lng":-117.1610838,"locationId":"9df1e52f3f65ee3847887c6ca42279bd5ca7b5a4","name":"San Diego","state":"CA"},{"city":"Chicago","country":"USA","lat":41.8781136,"lng":-87.6297982,"locationId":"293ff0472767f902833a86ef16ffbe495cab768b","name":"Chicago","state":"IL"},{"city":"Baltimore","country":"USA","lat":39.2903848,"lng":-76.6121893,"locationId":"511ae4339ab4870f1541c8ad0dc84d8780276dad","name":"Baltimore","state":"MD"},{"city":"Boston","country":"USA","lat":42.3600825,"lng":-71.0588801,"locationId":"b0f89825d88c02c708edb8f9e1fa16917f7fc2ba","name":"Boston","state":"MA"},{"city":"St. Louis","country":"USA","lat":38.6270025,"lng":-90.19940419999999,"locationId":"06ecc0701b131b3efe48be1f7782c6de9e9d7d26","name":"Saint Louis","state":"MO"},{"city":"Cincinnati","country":"USA","lat":39.1031182,"lng":-84.5120196,"locationId":"5e5be39375c6ec6a1a2077e566ee764cfe7d8489","name":"Cincinnati","state":"OH"},{"city":"Cleveland","country":"USA","lat":41.49932,"lng":-81.6943605,"locationId":"e6fe3a87b0d1377e80cfbdbe1148d2eb439eef8e","name":"Cleveland","state":"OH"},{"city":"Columbus","country":"USA","lat":39.9611755,"lng":-82.99879419999999,"locationId":"218ca28a78a83780ff1261a775efea4c19f47614","name":"Columbus","state":"OH"},{"city":"Charleston","country":"USA","lat":32.7764749,"lng":-79.93105120000001,"locationId":"6b74f5b2dfd86964f01c1520fbe72c67e107ff32","name":"Charleston","state":"SC"}],"sources":["https://www.ateapharma.com/news/atea-pharmaceuticals-announces-ind-clearance-of-at-527-for-covid-19.html","https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1","https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1#contacts"],"sponsors":[{"sponsorId":"1af131cb41f699e8e340d1a93623b584af0336e5","sponsorName":"Atea Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"Sun, 10 Jan 2021 00:00:00 GMT","studyStartDate":"Sun, 10 May 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Astrotem-V","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 1","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Fri, 17 Apr 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Astrotem-V","primaryCompletionDate":"","productId":474,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["http://www.theasian.asia/archives/107878","http://en.kabar.kg/news/stem-cell-treatment-to-become-legal-in-south-korea/"],"sponsors":[{"sponsorId":"684afe67ec273a6d3fa849859049d84db2437fbe","sponsorName":"Naturecell"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Duke-NUS Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Singapore"],"countryCodes":["SGP"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Duke-NUS Therapeutic","primaryCompletionDate":"","productId":475,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.duke-nus.edu.sg/allnews/using-own-immune-cells-to-target-infectious-diseases-including-covid-19"],"sponsors":[{"sponsorId":"341b155328dbb89ef8d5f50acdfff58dffee22a5","sponsorName":"DukeNUS Medical School"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"Dexamethasone","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Dexamethasone","primaryCompletionDate":"","productId":476,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.recoverytrial.net/","https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9","https://www.drugbank.ca/drugs/DB01234"],"sponsors":[{"sponsorId":"38652628acf1b84b92cad2bea1a82015a920b0c3","sponsorName":"University of Oxford"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Alvesco","chemicalName":"ciclesonide","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"3","preferredName":"ciclesonide","primaryCompletionDate":"Tue, 01 Sep 2020 00:00:00 GMT","productId":477,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04377711","repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.prnewswire.com/news-releases/covis-pharma-bv-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19-301061105.html","https://www.drugbank.ca/drugs/DB01410","https://www.biospace.com/article/releases/covis-pharma-b-v-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19/","https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2"],"sponsors":[{"sponsorId":"531c7eed34b2778b17fc1ab00a5e3e9417e11f4e","sponsorName":"Covis Pharma BV"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Tue, 26 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"PegiHep","chemicalName":"Pegylated Interferon alpha-2b","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["India"],"countryCodes":["IND"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Pegylated Interferon alpha-2b","primaryCompletionDate":"","productId":478,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://zyduscadila.com/public/pdf/pressrelease/Zydus-announces-treatment-with-Interferon-alpha%20.pdf"],"sponsors":[{"sponsorId":"9e1c8045b7fdc2fe2d635960c9b93dbbdd1a14a7","sponsorName":"Zydus Cadila"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Novaferon,Nova","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"gongguozhong@csu.edu.cn","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 4","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"2","otherPartners":"","phase":"4","preferredName":"Novaferon,Nova","primaryCompletionDate":"","productId":479,"registryLink":"http://www.chictr.org.cn/showprojen.aspx?proj=48809","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Changsha Shi","country":"CHN","lat":28.204404,"lng":112.982622,"locationId":"7392bfb0f1595a3b32261f4f12c03678e83f415c","name":"The First Hospital Of Changsha","state":"Hunan Sheng"},{"city":"Changsha Shi","country":"CHN","lat":28.187002,"lng":112.993998,"locationId":"d8e9722d5e18a05dc1b9ca5365b112ff75982936","name":"The Second Xiangya Hospital Of Cental South University","state":"Hunan Sheng"}],"sources":["https://www.medrxiv.org/content/10.1101/2020.04.24.20077735v1","https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.f7ta2pb1z0as","http://www.chictr.org.cn/showprojen.aspx?proj=48809"],"sponsors":[{"sponsorId":"dfbc81449bec6db056d375ff6145db5fecbe6806","sponsorName":"First Affiliated Hosptial of Zhejiang University Medical School"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 03 Feb 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Rebif","chemicalName":"interferon beta-1a","conditionOrDisease":"COVID-19","contact":[{"email":"florence.ader@chu-lyon.fr; helene.esperou@inserm.fr","name":null,"notes":"","phone":"","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"34","otherPartners":"","phase":"3","preferredName":"interferon beta-1a","primaryCompletionDate":"Fri, 10 Mar 2023 00:00:00 GMT","productId":480,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04315948","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Amiens","country":"FRA","lat":49.8724804,"lng":2.2536562,"locationId":"2bcbdc73488bb3b737d7d999f9f526efbf70c26b","name":"Centre Hospitalier Universitaire Amiens","state":"Hauts-de-France"},{"city":"Ars-Laquenexy","country":"FRA","lat":49.0830952,"lng":6.242574299999999,"locationId":"7e0f9b871fc98771b603d71ee23203e0afa884c6","name":"Centre Hospitalier Regional Metz","state":"Grand Est"},{"city":"Besan\u00e7on","country":"FRA","lat":47.22530889999999,"lng":5.962617799999999,"locationId":"51849d42127675734573997170e84595d4592554","name":"Centre Hospitalier R\u00e9gional Universitaire De Besan\u00e7on","state":"Bourgogne-Franche-Comt\u00e9"},{"city":"Bordeaux","country":"FRA","lat":44.829016,"lng":-0.6061928,"locationId":"d325975225dd5476422dcbcb98c7280c93b41114","name":"Centre Hospitalier Universitaire De Bordeaux","state":"Nouvelle-Aquitaine"},{"city":"Cr\u00e9teil","country":"FRA","lat":48.7980441,"lng":2.4517989,"locationId":"b7b25e9cb5061bfd8221fcb07ed62f396fe2760d","name":"Aphp","state":"IDF"},{"city":"Dijon","country":"FRA","lat":47.3193867,"lng":5.0732821,"locationId":"ed9740037071b0f3ebe6ffe93bfd7385ea1f012f","name":"Centre Hospitalier Universitaire Dijon","state":"Bourgogne-Franche-Comt\u00e9"},{"city":"Fort-de-France","country":"MTQ","lat":14.6339646,"lng":-61.0380384,"locationId":"3916026d646e374a7e5a421610a0f9777ae71ec6","name":"Centre Hospitalier Universitaire De Martinique","state":"Fort-de-France"},{"city":"La Tronche","country":"FRA","lat":45.1978495,"lng":5.7460667,"locationId":"1b974c14a57b3930a7adee5d0b6b3bde241c570e","name":"Centre Hospitalo","state":"Auvergne-Rh\u00f4ne-Alpes"},{"city":"Lille","country":"FRA","lat":50.6108999,"lng":3.0347031,"locationId":"9ed62c33e2d53008a40eccb30025e41a28532fbe","name":"Centre Hospitalier R\u00e9gional Universitaire De Lille","state":"Hauts-de-France"},{"city":"Lyon","country":"FRA","lat":45.7608649,"lng":4.8315594,"locationId":"0da22abaedecf3048658ab7a2b9762c608a74779","name":"Hospices Civils De Lyon","state":"Auvergne-Rh\u00f4ne-Alpes"},{"city":"Montpellier","country":"FRA","lat":43.6315886,"lng":3.8504425,"locationId":"b12a670678a2a3036a96942a0e3bad5b08755c53","name":"Centre Hospitalier Universitaire De Montpellier","state":"Occitanie"},{"city":"Mulhouse","country":"FRA","lat":47.7387331,"lng":7.341206199999999,"locationId":"bd5d8aff3d2ff4cdbd14518800ca00150656c883","name":"Groupe Hospitalier De La R\u00e9gion De Mulhouse Sud Alsace","state":"Grand Est"},{"city":"Nancy","country":"FRA","lat":48.6852009,"lng":6.192022,"locationId":"d2d5fe1faa6b4da6602e3af22c78005c91f2ec11","name":"Centre Hospitalier R\u00e9gional Et Universitaire De Nancy","state":"Grand Est"},{"city":"Nantes","country":"FRA","lat":47.2456712,"lng":-1.5760826,"locationId":"625f52447c912aa82c11914abdc7f50eecc239b7","name":"Centre Hospitalier Universitaire De Nantes","state":"Pays de la Loire"},{"city":"Nice","country":"FRA","lat":43.7243743,"lng":7.282272600000001,"locationId":"3a4956fb40987398941c9a2355751bc6690f4866","name":"Centre Hospitalo","state":"Provence-Alpes-C\u00f4te d'Azur"},{"city":"Paris","country":"FRA","lat":48.8488116,"lng":2.3827263,"locationId":"efb1c6d74f469191842a9eda03a4e398d62741ac","name":"Aphp","state":"IDF"},{"city":"Paris","country":"FRA","lat":48.8370792,"lng":2.3650429,"locationId":"1fdaab4927b21cce958da4cef90874c5dd37a9f6","name":"Aphp","state":"IDF"},{"city":"Paris","country":"FRA","lat":48.8368937,"lng":2.3402667,"locationId":"4b7d60ec4256cb3833028110794183e15772d111","name":"Aphp","state":"IDF"},{"city":"Paris","country":"FRA","lat":48.829771,"lng":2.3103313,"locationId":"78a2d3fdd58d058b25e8ec6e514030075b3d6eb6","name":"H\u00f4pital Paris Saint","state":"IDF"},{"city":"Paris","country":"FRA","lat":48.83857889999999,"lng":2.2739604,"locationId":"3bc9ec960d077beaa48b09a8355f492cabb3607e","name":"Aphp","state":"IDF"},{"city":"Paris","country":"FRA","lat":48.8988811,"lng":2.3318771,"locationId":"3ca99017452f77d7ed9755b1e9f15884bd649b64","name":"Aphp","state":"IDF"},{"city":"Rennes","country":"FRA","lat":48.1200389,"lng":-1.6950594,"locationId":"c48020815ab374d67d60821f69c92c43717adfb6","name":"Centre Hospitalier Universitaire De Rennes","state":"Bretagne"},{"city":"Saint-Denis","country":"FRA","lat":48.9335315,"lng":2.3711375,"locationId":"44a688caff2832c10b2143b16b71c0ee5b0693a1","name":"Hopital Delafontaine","state":"IDF"},{"city":"Saint-Mand\u00e9","country":"FRA","lat":48.843381,"lng":2.4253137,"locationId":"442f77fca4acf45553a26195e06e59a9858c650e","name":"H\u00f4pital D'instruction Des Arm\u00e9es Begin","state":"IDF"},{"city":"Saint-Priest-en-Jarez","country":"FRA","lat":45.4819945,"lng":4.362985399999999,"locationId":"f924f95035e651a2fa6d35d2e7e6402fc0384225","name":"Centre Hospitalier Universitaire De Saint Etienne","state":"Auvergne-Rh\u00f4ne-Alpes"},{"city":"Strasbourg","country":"FRA","lat":48.5933098,"lng":7.707158000000001,"locationId":"e0092883f72a4454230d6455af04fa4dd09a82b5","name":"Centre Hospitalier R\u00e9gional Universitaire De Strasbourg","state":"Grand Est"},{"city":"Toulouse","country":"FRA","lat":43.5995462,"lng":1.4369245,"locationId":"22e5e130f41ca7e403497222bdda9a6430d366d3","name":"Centre Hospitalier Universitaire De Toulouse","state":"Occitanie"},{"city":"Tourcoing","country":"FRA","lat":50.743301,"lng":3.1812134,"locationId":"c9870bed0ed817adb50d65b809f03d701abd60c8","name":"Centre Hospitalier De Tourcoing","state":"Hauts-de-France"},{"city":"Epagny Metz-Tessy","country":"FRA","lat":45.9338394,"lng":6.1175557,"locationId":"81a6b0c411607926fbe968990fb7a433fda9eaeb","name":"Centre Hospitalier Annecy Genevois","state":"Auvergne-Rh\u00f4ne-Alpes"}],"sources":["https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html","https://clinicaltrials.gov/ct2/show/NCT04315948?term=Rebif&cond=covid&draw=2&rank=6#contacts"],"sponsors":[{"sponsorId":"23e976410b2cf3003eb62c734eb8e73702df9f66","sponsorName":"Merck kGaA"},{"sponsorId":"501208e53cef559b699e97764991aad6e3fe9e17","sponsorName":"French Institut National de la Sante et de la Recherche Medicale"},{"sponsorId":"0e1ea407af0902261db76719a57a5c127ea53bfe","sponsorName":"INSERM"}],"status":"Ongoing","studyCompletionDate":"Fri, 10 Mar 2023 00:00:00 GMT","studyStartDate":"Sun, 22 Mar 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Micardis","chemicalName":"telmisartan","conditionOrDisease":"COVID-19","contact":[{"email":"shikuma@hawaii.edu; ogataara@hawaii.edu","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"telmisartan","primaryCompletionDate":"Wed, 30 Jun 2021 00:00:00 GMT","productId":481,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04360551","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Honolulu","country":"USA","lat":21.296939,"lng":-157.8171118,"locationId":"9b408308ee74781fe17f895ed378b67b196eac56","name":"University Of Hawaii","state":"HI"}],"sources":["https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.a49g7p85hz36","https://clinicaltrials.gov/ct2/show/NCT04360551?term=Micardis&cond=covid&draw=2&rank=2","https://www.drugbank.ca/drugs/DB00966"],"sponsors":[{"sponsorId":"fddf7abcdfe84560834e2538e757cf92b17c723e","sponsorName":"Boehringer Ingelheim"},{"sponsorId":"2754aaae83566135ed0f7567cbcbf97a4c92f738","sponsorName":"University of Hawaii"}],"status":"Ongoing","studyCompletionDate":"Wed, 30 Jun 2021 00:00:00 GMT","studyStartDate":"Wed, 01 Jul 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Heparin","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Heparin","primaryCompletionDate":"","productId":482,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.a49g7p85hz36","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103696/","https://www.drugbank.ca/drugs/DB01109","https://onlinelibrary.wiley.com/doi/10.1111/jth.14817"],"sponsors":[{"sponsorId":"c271659ad5abc7b45c3da45b2f6d7536dd667619","sponsorName":"Union Hospital"},{"sponsorId":"f857eb83d5547b637ff03a9a03a62ecae804b9ef","sponsorName":"Tongji Medical College"},{"sponsorId":"206ac05e9d2f53359faa2f484ba97fb9947ad488","sponsorName":"Huazhong University of Science and Technology"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"ST-001,nanoFenretinide","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"ST-001,nanoFenretinide","primaryCompletionDate":"","productId":483,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.scitechdevelopment.com/covid-19","https://www.scitechdevelopment.com/"],"sponsors":[{"sponsorId":"300768e32f497d80e46fc738e6eb076afe1278b6","sponsorName":"SciTech Development"},{"sponsorId":"f9ea624f8683db34fe27d8b66556e1c68a0bbff7","sponsorName":"LLC"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Ruconest","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Netherlands"],"countryCodes":["NLD"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Ruconest","primaryCompletionDate":"","productId":484,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf","https://www.fdanews.com/articles/196751-pharming-reports-positive-results-from-compassionate-use-of-ruconest-in-covid-19-patients"],"sponsors":[{"sponsorId":"201d1167355ba363a989f5f3c28beafd43c63d43","sponsorName":"Pharming"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"DIBI","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"DIBI","primaryCompletionDate":"","productId":485,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.chelationpartners.com/novel-covid-19-therapeutic"],"sponsors":[{"sponsorId":"6a6bd2de0eb5947c17ac3a602d9acff5ad7670aa","sponsorName":"Chelation Partners"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"GP-1681","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"NIH\u2019s National Institute of Allergy and Infectious Diseases","phase":"","preferredName":"GP-1681","primaryCompletionDate":"","productId":486,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.businesswire.com/news/home/20200428005176/en/Quotient-Sciences-CytoAgents-Accelerate-Potential-Treatment-COVID-19","https://www.businesswire.com/news/home/20200513005097/en/CytoAgents-Receives-NIH-Funding-Accelerate-Treatment-Cytokine","https://www.cytoagents.com","https://www.pharmaceutical-technology.com/news/cytoagents-nih-funding/"],"sponsors":[{"sponsorId":"0be22b6b259f83f59ccbd5be89ac8e0889ac4303","sponsorName":"Quotient Sciences"},{"sponsorId":"b70cb7686ccf395a7b83bebb5de6068269194a5a","sponsorName":"CytoAgents Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"nebulized alkaline","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"nebulized alkaline","primaryCompletionDate":"","productId":487,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.phbarrier.com/","https://www.phbarrier.com/media/4143/ph-barrier-process-overview-brief-v19.pdf","https://www.allrecipes.com/recipe/19247/soft-oatmeal-cookies/"],"sponsors":[{"sponsorId":"96ddec31a0c1ab283619baa3878b527fb94d020f","sponsorName":"pHbarrier"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Coronzot","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Israel"],"countryCodes":["ISR"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 22 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Other","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Coronzot","primaryCompletionDate":"","productId":488,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.silkim.com/covid-19","https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/edit#gid=2075421071"],"sponsors":[{"sponsorId":"bd527ac2a1926e920092457295a6316ab04959d2","sponsorName":"Silkim Pharma"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Lysteda,Cyklokapron","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"tness@uabmc.edu","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"Lysteda,Cyklokapron","primaryCompletionDate":"","productId":489,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04338126","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Birmingham","country":"USA","lat":33.5019893,"lng":-86.8064433,"locationId":"c966e421152f43eb6046d6ba6f8d75762284a6dc","name":"University Of Alabama At Birmingham","state":"AL"}],"sources":["https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.ifp099y9gyv","https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1","https://www.drugbank.ca/drugs/DB00302"],"sponsors":[{"sponsorId":"554e9b0524bfdbca43acc75ad124f0ba00fa67b6","sponsorName":"University of Alabama at Birmingham"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Wed, 30 Sep 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"senicapoc","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Denmark"],"countryCodes":["DNK"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"senicapoc","primaryCompletionDate":"","productId":490,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["http://www.pharmafile.com/news/548588/researchers-denmark-testing-if-senicapoc-drug-can-reduce-lung-damage-covid-19-patients","https://www.drugbank.ca/drugs/DB06280"],"sponsors":[{"sponsorId":"72e1254f1f77af47e0f6f7da408cde214f876377","sponsorName":"Aarhus University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Luvox","chemicalName":"fluvoxamine","conditionOrDisease":"COVID-19","contact":[{"email":"stevens.a@wustl.edu; marissa@wustl.edu","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"2","otherPartners":"","phase":"2","preferredName":"fluvoxamine","primaryCompletionDate":"Thu, 20 Aug 2020 00:00:00 GMT","productId":491,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04342663","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Belleville","country":"USA","lat":38.5505222,"lng":-90.0221803,"locationId":"1c97d38f66205d9fdd2bcf5f0c4d1105fd381521","name":"Bjc","state":"IL"},{"city":"St. Louis","country":"USA","lat":38.6351441,"lng":-90.26292889999999,"locationId":"bff9891345e51117353cb63751019968daa3c705","name":"Washington University School Of Medicine","state":"MO"}],"sources":["https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#","https://medicine.wustl.edu/news/study-to-evaluate-antidepressant-as-potential-covid-19-treatment/","https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1","https://www.drugbank.ca/drugs/DB00176"],"sponsors":[{"sponsorId":"088525c7f9eadc1d83414786054e0737521e7139","sponsorName":"Washington University School of Medicine in St Louis"}],"status":"Ongoing","studyCompletionDate":"Thu, 01 Oct 2020 00:00:00 GMT","studyStartDate":"Fri, 10 Apr 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Gleevac","chemicalName":"imatinib","conditionOrDisease":"COVID-19","contact":[{"email":"aemadi@umm.edu","name":null,"notes":"","phone":"","website":""}],"countries":["Ireland"],"countryCodes":["IRL"],"currentStage":"Phase 3","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"3","preferredName":"imatinib","primaryCompletionDate":"Wed, 01 Jun 2022 00:00:00 GMT","productId":492,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04394416","repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.imi.europa.eu/news-events/press-releases/imi-announces-covid-projects-boosts-funding-pot-eur-72-million","https://www.drugbank.ca/drugs/DB00619","https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1"],"sponsors":[{"sponsorId":"d64dcdacea903a1d726c93fb9c27abff2ac03d67","sponsorName":"Exvastat Ltd"}],"status":"Ongoing","studyCompletionDate":"Thu, 01 Jun 2023 00:00:00 GMT","studyStartDate":"Wed, 20 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"ABX464","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"paul.gineste@abivax.com","name":null,"notes":"","phone":"","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"ABX464","primaryCompletionDate":"","productId":493,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04393038","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Nice","country":"FRA","lat":43.7243743,"lng":7.282272600000001,"locationId":"101730c1fb149c880c733117544a49027f2b05eb","name":"Centre Hospitalier Universitaire De Nice","state":"Provence-Alpes-C\u00f4te d'Azur"}],"sources":["https://abivax.gcs-web.com/news-releases/news-release-details/abx464-inhibits-replication-sars-cov-2-covid-19-reconstituted","https://www.drugbank.ca/drugs/DB14828","https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1"],"sponsors":[{"sponsorId":"c6da54a03f32dd41b8400b76dcd51eb01ec5cb77","sponsorName":"Abivax"}],"status":"Ongoing","studyCompletionDate":"Fri, 30 Apr 2021 00:00:00 GMT","studyStartDate":"Fri, 01 May 2020 00:00:00 GMT","therapeuticApproach":"Combination","trialId":""},{"acceptsHealthySubjects":"","brandName":"sPIF","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"sPIF","primaryCompletionDate":"","productId":494,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://bioincept.com/","https://bioincept.com"],"sponsors":[{"sponsorId":"a0388d32f7374fcd8165cab8a9c23eeb7f9c5b4a","sponsorName":"BioIncept"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"Inactivated Vaccine","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"liqihan@imbcams.com","name":null,"notes":"","phone":"For China: 86-0871-68335905; For Brazil:  +55(11) 49304243; For Malaysia: +6013-4528200 ","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 15 May 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 20 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Whole-pathogen vaccines","notes":"","numSites":"3","otherPartners":"","phase":"2","preferredName":"Inactivated Vaccine","primaryCompletionDate":"Sun, 01 Nov 2020 00:00:00 GMT","productId":496,"registryLink":["https://clinicaltrials.gov/ct2/show/NCT04412538","https://clinicaltrials.gov/ct2/show/NCT04470609","https://www.clinicaltrials.gov/ct2/show/NCT04659239?term=Inactivated+SARS-CoV-2+Vaccine+AND+Chinese+Academy+of+Medical+Sciences&draw=2&rank=3"],"repurposed":"New","siteLocations":[{"city":"Chengdu Shi","country":"CHN","lat":30.585759,"lng":104.14846,"locationId":"72927040bdf08890a25a81f3a7def2a2ddc421ce","name":"West China Second University Hospital","state":"Sichuan Sheng"},{"city":"S\u00e3o Paulo","country":"BRA","lat":-23.5505199,"lng":-46.63330939999999,"locationId":"f0347a607a40d7f2d078b03c57609fd57582ace1","name":"S\u00e3o Paulo","state":"SP"},{"city":null,"country":"MYS","lat":3.0738379,"lng":101.5183469,"locationId":"855c91d6bcba4dcbcd8c4ce703dae80ca496071f","name":"Selangor","state":"Selangor"}],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-198cf6037313a140ce89905bdd05b50332.pdf?sfvrsn=c457438f_2&download=true"],"sponsors":[{"sponsorId":"bf5e7b2bebc0928fcae433d07b46f1bb4fc5c3ba","sponsorName":"Chinese Academy of Medical Sciences"},{"sponsorId":"112dadb966996e2ab8f5db397f1a2361410582fc","sponsorName":"Institute of Medical Biology"}],"status":"Ongoing","studyCompletionDate":"Mon, 01 Nov 2021 00:00:00 GMT","studyStartDate":"Fri, 10 Jul 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Inactivated + CpG 1018 Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 16 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 16 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Whole-pathogen vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Inactivated + CpG 1018 Vaccine","primaryCompletionDate":"","productId":497,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.genengnews.com/covid-19-candidates/sinovac-biotech-and-dynavax/","https://clinicaltrials.gov/ct2/show/NCT04352608#contacts"],"sponsors":[{"sponsorId":"93bef25f8dc322ecb56eae9b00dfed2b3169a709","sponsorName":"Sinovac"},{"sponsorId":"8b4d210c885dc58c6711e526b8b4bd37c6acfd55","sponsorName":"Dynavax"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Inactivated Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Japan"],"countryCodes":["JPN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Thu, 19 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Whole-pathogen vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Inactivated Vaccine","primaryCompletionDate":"","productId":498,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf","https://pj.jiho.jp/article/241725"],"sponsors":[{"sponsorId":"51adf29b45adb2321acc929eef1a1764661b4261","sponsorName":"Osaka University"},{"sponsorId":"b82c2c21ac862400b11d6f29c7cae746450bbde7","sponsorName":"BIKEN"},{"sponsorId":"780f15c43efde8ab3fb2054bfabbd4431f961fb1","sponsorName":"NIBIOHN"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"VLP-recombinant protein + Adjuvant Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Japan"],"countryCodes":["JPN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"VLP-recombinant protein + Adjuvant Vaccine","primaryCompletionDate":"","productId":499,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf"],"sponsors":[{"sponsorId":"51adf29b45adb2321acc929eef1a1764661b4261","sponsorName":"Osaka University"},{"sponsorId":"b82c2c21ac862400b11d6f29c7cae746450bbde7","sponsorName":"BIKEN"},{"sponsorId":"17cbf856bb10416eb209f893f15592c5b0c5cf20","sponsorName":"National Institutes of Biomedical Innovation"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Inactivated Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Kazakhstan"],"countryCodes":["KAZ"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Fri, 15 May 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Whole-pathogen vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Inactivated Vaccine","primaryCompletionDate":"","productId":500,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://astanatimes.com/2020/05/who-approves-kazakh-covid-19-vaccine-for-preclinical-trials/"],"sponsors":[{"sponsorId":"491e7541c9106c54795c4fab54aeb1e6140c1faf","sponsorName":"Research Institute for Biological Safety Problems"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Codon deoptimized live attenuated virus","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Australia"],"countryCodes":["AUS"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Thu, 23 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Whole-pathogen vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Codon deoptimized live attenuated virus","primaryCompletionDate":"","productId":501,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://news.griffith.edu.au/2020/04/23/griffith-university-researchers-on-the-road-to-covid-19-vaccine/"],"sponsors":[{"sponsorId":"b5cb9e1deb926ecff4779f7d91e9cb95f8813c17","sponsorName":"Indian Immunologicals Ltd"},{"sponsorId":"4c0a544a8c18a6d3d126ac58097808c42561d093","sponsorName":"Griffith University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Non-replicating viral vector MVA expressing structural proteins","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Spain"],"countryCodes":["ESP"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Whole-pathogen vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Non-replicating viral vector MVA expressing structural proteins","primaryCompletionDate":"","productId":502,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines"],"sponsors":[{"sponsorId":"880c99550c8a42deeaff83ad0902af0b020c8848","sponsorName":"Centro Nacional Biotecnologia"},{"sponsorId":"ff7e4fdfaae0a64a50db02f60295658c622d7b87","sponsorName":"CNBCSIC"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Non-replicating viral vector vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Other","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Non-replicating viral vector vaccine","primaryCompletionDate":"","productId":503,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines"],"sponsors":[{"sponsorId":"459eec13328a1d43f3fa5a6bd1f187b1c2e6ea3d","sponsorName":"University of Manitoba"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"BBV152","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"kmohan@bharatbiotech.com  ","name":null,"notes":"","phone":"For India: 04023480567","website":""}],"countries":["India"],"countryCodes":["IND"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 13 Jul 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 13 Jul 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 25 Nov 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Whole-pathogen vaccines","notes":"","numSites":"12","otherPartners":"Thomas Jefferson University","phase":"3","preferredName":"BBV152","primaryCompletionDate":"Wed, 30 Jun 2021 00:00:00 GMT","productId":504,"registryLink":["http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152","https://clinicaltrials.gov/ct2/show/NCT04471519?term=BBV152&draw=2&rank=1","https://clinicaltrials.gov/ct2/show/NCT04641481?term=BBV152&draw=2&rank=2"],"repurposed":"New","siteLocations":[{"city":"Rohtak","country":"IND","lat":28.8955152,"lng":76.606611,"locationId":"cdbe4ff3f6dde1432bbfd2651122e2bbcffb57c9","name":"Rohtak","state":"HR"},{"city":"Visakhapatnam","country":"IND","lat":17.6868159,"lng":83.2184815,"locationId":"ff8447bb00869ac5e49a893b87ce69e1cc801e55","name":"Visakhapatnam","state":"AP"},{"city":"Patna","country":"IND","lat":25.5940947,"lng":85.1375645,"locationId":"d48694a450dd0763d8a1eefa7d5000aa942438bc","name":"Patna","state":"BR"},{"city":"Belgaum","country":"IND","lat":15.8496953,"lng":74.4976741,"locationId":"67d84aa6bc73aa859f6f5aefc726b0020dbb5bb4","name":"Belgaum","state":"KA"},{"city":"Nagpur","country":"IND","lat":21.1458004,"lng":79.0881546,"locationId":"383b78e79ee66404a301f45d6d49ea2b7032c835","name":"Nagpur","state":"MH"},{"city":"New Delhi","country":"IND","lat":28.6139391,"lng":77.2090212,"locationId":"070a7ff8aeaa1e7e1c7769dbf78ad070c492025b","name":"Delhi","state":"DL"},{"city":"Bhubaneswar","country":"IND","lat":20.2960587,"lng":85.8245398,"locationId":"0daaa877dd152a314aacb826056dfd3b99946ce6","name":"Bhubaneswar","state":"OD"},{"city":"Chennai","country":"IND","lat":13.0826802,"lng":80.2707184,"locationId":"eba6321f367e2796a3b51ac0bc73920b94a776cc","name":"Chennai","state":"TN"},{"city":"Hyderabad","country":"IND","lat":17.385044,"lng":78.486671,"locationId":"78d796f1da7a57eb848f1713ed434cde766d9322","name":"Hyderabad","state":"Telangana"},{"city":"Gorakhpur","country":"IND","lat":26.7605545,"lng":83.3731675,"locationId":"c569482fb8279059e71daaedf2f4ded98d848364","name":"Gorakhpur","state":"UP"},{"city":"Kanpur","country":"IND","lat":26.449923,"lng":80.3318736,"locationId":"23342d30db96fe192445f17d14144777da8f5dae","name":"Kanpur","state":"UP"},{"city":null,"country":"IND","lat":15.2993265,"lng":74.12399599999999,"locationId":"ceefec3395f5851df3ac8aeb910acab02c38a9f1","name":"Goa","state":"GA"}],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152"],"sponsors":[{"sponsorId":"9d4dee599ac3bb32cc6f8f46985c93c9410e5262","sponsorName":"Bharat Biotech"}],"status":"Ongoing","studyCompletionDate":"Tue, 01 Mar 2022 00:00:00 GMT","studyStartDate":"Mon, 13 Jul 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Protein subunit S Protein + adjuvant","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Japan"],"countryCodes":["JPN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Wed, 04 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"National Institute of Infectious Disease-Japan","phase":"","preferredName":"Protein subunit S Protein + adjuvant","primaryCompletionDate":"","productId":505,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://vpmthane.org/web2/assets/files/Dr.-SandeepKahandal-ArticleonCovid-19.pdf","https://www.genengnews.com/a-lists/vanquishing-the-virus-160-covid-19-drug-and-vaccine-candidates-in-development/4/","https://covidvax.org/covid19-vaccine/NIIDJapan/S-protein-National-Institute-of-Infectious-Disease-Japan"],"sponsors":[{"sponsorId":"e070ac198c1403ee83ff4b95b61c5b221dd1fe67","sponsorName":"National Institute of Infectious Disease"},{"sponsorId":"fcf29f6cad3232704b33e962ef5194fad3b6817b","sponsorName":"Japan"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"PittCoVacc","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Thu, 02 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"ESTIMATED"},{"category":"pre-clinical","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"University of Pittsburgh School of Medicine","phase":"","preferredName":"PittCoVacc","primaryCompletionDate":"","productId":506,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.eurekalert.org/pub_releases/2020-04/uop-cvc033120.php","https://www.id-hub.com/2020/04/02/covid-19-vaccine-candidate-shows-promise-preclinical-trial/","https://covidvax.org/covid19-vaccine/PittsburghUni/PittCoVacc-400-tiny-needles-array-skin-patch-University-of-Pittsburgh"],"sponsors":[{"sponsorId":"0c65a74d63b7a88d66a6d28b2f99159bd2923517","sponsorName":"University of Pittsburgh"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Peptide Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Russian Federation"],"countryCodes":["RUS"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Rospotrebnadzor,FBRI SRC VB VECTOR","phase":"","preferredName":"Peptide Vaccine","primaryCompletionDate":"","productId":507,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1","http://www.istc.int/en/institute/10150"],"sponsors":[{"sponsorId":"ecfe160f6421e8373446c4cf127484c21d580da4","sponsorName":"FBRI SRC VB VECTOR"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Subunit Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Russian Federation"],"countryCodes":["RUS"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"Rospotrebnadzor,FBRI SRC VB VECTOR","phase":"","preferredName":"Subunit Vaccine","primaryCompletionDate":"","productId":508,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1"],"sponsors":[{"sponsorId":"ecfe160f6421e8373446c4cf127484c21d580da4","sponsorName":"FBRI SRC VB VECTOR"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Protein Subunit Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Wed, 18 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"LakePharma Inc.","phase":"","preferredName":"Protein Subunit Vaccine","primaryCompletionDate":"","productId":509,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1","https://lakepharma.com/integrated-solutions/covid-19-activities/overview","https://covidvax.org/covid19-vaccine/LakePharma/Nanoparticle-vaccine-LakePharma"],"sponsors":[{"sponsorId":"716eefa2065d7dc4e322e6d5e2d9319014688bc3","sponsorName":"LakePharma"},{"sponsorId":"72a5f6c42a6c39ea891ecb24d22128fd281d0e18","sponsorName":"Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Protein Subunit Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Thu, 26 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"Canadian Institutes of Health Research,Alberta Innovates","phase":"","preferredName":"Protein Subunit Vaccine","primaryCompletionDate":"","productId":510,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1","https://www.ualberta.ca/medicine/news/2020/april/university-of-alberta-researchers-in-race-against-time-to-create-covid-19-vaccine"],"sponsors":[{"sponsorId":"12c3dd5f9333a0c4d0ae98732f48bf25cad78edd","sponsorName":"University of Alberta"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Protein Subunit Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Tue, 17 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"AnyGo Technology","phase":"","preferredName":"Protein Subunit Vaccine","primaryCompletionDate":"","productId":511,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1","http://anygo.sell.everychina.com/aboutus.html","https://covidvax.org/covid19-vaccine/AnyGoTech/S1---Fc-fusion-protein-AnyGo-Technology"],"sponsors":[{"sponsorId":"077fdd2e748f24405b69a367b3773ec90b94b59d","sponsorName":"AnyGo Technology"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Protein Subunit Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Sun, 08 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Yisheng Biopharma","phase":"","preferredName":"Protein Subunit Vaccine","primaryCompletionDate":"","productId":512,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1","https://covidvax.org/covid19-vaccine/YishengBiopharma/Recombinant-protein-Yisheng-Biopharma"],"sponsors":[{"sponsorId":"ba53ce7d125486beb154102a37b226621b7f1fc7","sponsorName":"Yisheng Biopharma"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Protein Subunit Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Sun, 26 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Vabiotech,Bristol University","phase":"","preferredName":"Protein Subunit Vaccine","primaryCompletionDate":"","productId":513,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1","https://e.vnexpress.net/news/news/vietnam-tests-covid-19-vaccine-on-mice-4093317.html","https://vietnamnews.vn/society/716407/mice-administered-with-vietnamese-covid-19-vaccine-remain-healthy.html","https://www.trialsitenews.com/vietnams-state-owned-vabiotech-pursues-a-vaccine-now-in-mice-testing-so-far-so-good/"],"sponsors":[{"sponsorId":"d66666a3c071393a24620b24d358e69ba3509e16","sponsorName":"Vabiotech"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Protein Subunit Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Mon, 20 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"National Science Foundation","phase":"","preferredName":"Protein Subunit Vaccine","primaryCompletionDate":"","productId":514,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://ucsdnews.ucsd.edu/pressrelease/marrying-molecular-farming-and-advanced-manufacturing-to-develop-a-covid-19-vaccine","https://covidvax.org/covid19-vaccine/SanDiegoCaliUni/Plant-virus-nanotechnology-University-of-California-San-Diego"],"sponsors":[{"sponsorId":"486a33cf556d4a11ca1a393e8f93ddeee90e3aa8","sponsorName":"University of California"},{"sponsorId":"acb342916471ac6bed5f3a6a13ca8e3ecdc48429","sponsorName":"San Diego"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"OMV-based Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Wed, 06 May 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"Quadram Institute","phase":"","preferredName":"OMV-based Vaccine","primaryCompletionDate":"","productId":515,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://quadram.ac.uk/quadram-researchers-working-on-covid-19-vaccine-join-who-expert-groups/","https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"],"sponsors":[{"sponsorId":"442afaf6e99f2d9c98f45ff216cd938e8a81ddf1","sponsorName":"Quadram Institute Biosciences"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"OMV-based Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Italy"],"countryCodes":["ITA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Tue, 28 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"BiOMViS Srl,University of Trento","phase":"","preferredName":"OMV-based Vaccine","primaryCompletionDate":"","productId":516,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.toscanalifesciences.org/it/2020/04/covid-19-piattaforma-di-biomvis-si-dimostra-efficace-nella-ricerca-di-un-possibile-vaccino-2/"],"sponsors":[{"sponsorId":"6d27be324405fd25505d58549d5f688eb822d1a3","sponsorName":"BiOMVis SR"},{"sponsorId":"593791b280e8c3c839e73ca9110644e71cb76369","sponsorName":"University of Trento"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Subunit Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"Applied Biotechnology Institute Inc.","phase":"","preferredName":"Subunit Vaccine","primaryCompletionDate":"","productId":517,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"],"sponsors":[{"sponsorId":"b7d9d4824d0196b796657e8d6d9728d256d6104b","sponsorName":"Applied Biotechnology Institute Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"Adjucanted recombinant protein","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"646022285@qq.com; dingfan@zhifeishengwu.com        ","name":null,"notes":"","phone":"13574109585","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 22 Jun 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 12 Jul 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"3","otherPartners":"Anhui Zhifei Longcom Biopharmaceutical,Institute of Microbiology Chinese Academy of Sciences","phase":"2","preferredName":"Adjucanted recombinant protein","primaryCompletionDate":"Wed, 15 Sep 2021 00:00:00 GMT","productId":518,"registryLink":["https://clinicaltrials.gov/ct2/show/NCT04466085","https://clinicaltrials.gov/ct2/show/NCT04445194","https://clinicaltrials.gov/ct2/show/NCT04550351"],"repurposed":"New","siteLocations":[{"city":"Changsha","country":"CHN","lat":28.2059324,"lng":112.9854218,"locationId":"4c41629d8e57f58a8ba859c7af11f092b82ec8fa","name":"Hunan Provincial Center For Disease Control And Prevention","state":"Hunan"},{"city":null,"country":"CHN","lat":29.5598412,"lng":106.5745894,"locationId":"10f79f22ab6cb5f47d81d9c7ac56a1f7f8231513","name":"The Second Affiliated Hospital Of Chongqing Medical University","state":"Chongqing"},{"city":"Xiangtan","country":"CHN","lat":27.829795,"lng":112.944026,"locationId":"9702260bed9cb6c2262a8efb2028030245ba9fb2","name":"Xiangtan","state":"Hunan"}],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines","https://clinicaltrials.gov/ct2/show/NCT04466085","https://clinicaltrials.gov/ct2/show/NCT04445194"],"sponsors":[{"sponsorId":"7b065d405ef1284ec1cbfd5ce6fb3719c2d87f0e","sponsorName":"Anhui Zhifei Longcom Biopharmaceutical"},{"sponsorId":"63cba1aff0183a31e1f1c916b451513c8733fdf4","sponsorName":"Institute of Microbiology"},{"sponsorId":"bc4227127320dc16e7fb7686767c7506d2a670a6","sponsorName":"Chinese Academy of Sciences"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Sun, 12 Jul 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"RBD-based","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Wed, 13 May 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"Tel Aviv University,Neovii","phase":"","preferredName":"RBD-based","primaryCompletionDate":"","productId":519,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.prnewswire.com/news-releases/neovii-to-develop-a-novel-vaccine-for-covid-19-in-an-exclusive-partnership-with-tel-aviv-university-301057606.html"],"sponsors":[{"sponsorId":"4dc81db10d5b875528cfc231d9c3e0179fdff8a1","sponsorName":"Neovii"},{"sponsorId":"c70d6300461b60aa0d62ede7a42516869f6aeada","sponsorName":"Tel Aviv University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Replicating Viral Vector,YF17D Vector","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Belgium"],"countryCodes":["BEL"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Thu, 26 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"KU Leuven,UZ Leuven","phase":"","preferredName":"Replicating Viral Vector,YF17D Vector","primaryCompletionDate":"","productId":520,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines","https://www.leuvenmindgate.be/news/support-our-leuven-researchers-in-finding-a-cure-against-corona"],"sponsors":[{"sponsorId":"32ce15bbd44eb2c4a104acc7af8fe4766751c699","sponsorName":"KU Leuven"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Measles Vector Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["India"],"countryCodes":["IND"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Mon, 17 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"Zydus Cadila","phase":"","preferredName":"Measles Vector Vaccine","primaryCompletionDate":"","productId":521,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf","https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines","https://www.pharmatutor.org/pharma-news/2020/zydus-cadila-accelerates-covid-19-vaccine-research"],"sponsors":[{"sponsorId":"9e1c8045b7fdc2fe2d635960c9b93dbbdd1a14a7","sponsorName":"Zydus Cadila"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Measles Vector Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Russian Federation"],"countryCodes":["RUS"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"FBRI SRC VB VECTOR,Rospotrebnadzor","phase":"","preferredName":"Measles Vector Vaccine","primaryCompletionDate":"","productId":522,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"],"sponsors":[{"sponsorId":"ecfe160f6421e8373446c4cf127484c21d580da4","sponsorName":"FBRI SRC VB VECTOR"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Recombinant Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Russian Federation"],"countryCodes":["RUS"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"FBRI SRC VB VECTOR,Rospotrebnadzor","phase":"","preferredName":"Recombinant Vaccine","primaryCompletionDate":"","productId":523,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"],"sponsors":[{"sponsorId":"ecfe160f6421e8373446c4cf127484c21d580da4","sponsorName":"FBRI SRC VB VECTOR"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"VSV Vector Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Russian Federation"],"countryCodes":["RUS"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"FBRI SRC VB VECTOR,Rospotrebnadzor","phase":"","preferredName":"VSV Vector Vaccine","primaryCompletionDate":"","productId":524,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"],"sponsors":[{"sponsorId":"ecfe160f6421e8373446c4cf127484c21d580da4","sponsorName":"FBRI SRC VB VECTOR"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"mRNA Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Russian Federation"],"countryCodes":["RUS"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"FBRI SRC VB VECTOR,Rospotrebnadzor","phase":"","preferredName":"mRNA Vaccine","primaryCompletionDate":"","productId":525,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines"],"sponsors":[{"sponsorId":"ecfe160f6421e8373446c4cf127484c21d580da4","sponsorName":"FBRI SRC VB VECTOR"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"VSV-S Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":"Thu, 19 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Combination","notes":"","numSites":"","otherPartners":"Canadian Institutes of Health Research","phase":"","preferredName":"VSV-S Vaccine","primaryCompletionDate":"","productId":526,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://covidvax.org/covid19-vaccine/WesternOntarioUni/VSV---S-University-of-Western-Ontario"],"sponsors":[{"sponsorId":"64b8159213f0e0f1b682d64dcd70edf9ca69799b","sponsorName":"University of Western Ontario"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Newcastle Disease Virus Vector Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Netherlands"],"countryCodes":["NLD"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Thu, 14 May 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"WBVR,Intravacc,Utrecht","phase":"","preferredName":"Newcastle Disease Virus Vector Vaccine","primaryCompletionDate":"","productId":527,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.wur.nl/en/Research-Results/Research-Institutes/Bioveterinary-Research/show-bvr/Development-of-an-intranasal-vaccine-against-COVID-19.htm","https://www.wur.nl/en/Research-Results/Research-Institutes/Bioveterinary-Research/About-us.htm","https://www.hollandbio.nl/nieuws/intravacc-to-develop-emergency-and-conventional-covid-19-vaccines/"],"sponsors":[{"sponsorId":"2fac1a221a15fc083eae5305d2594c769015b137","sponsorName":"Intravacc"},{"sponsorId":"ce48076f605d7364d1dba7c47a51996d843222db","sponsorName":"Wageningen Bioveterinary Research"},{"sponsorId":"b80905e2bb739693e1253446c2e0849e97ab16dd","sponsorName":"Utrecht University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"LNP-encapsulated mRNA cocktail encoding RBD","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Thu, 07 May 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Fudan University,Shanghai JiaoTong University,RNACure Biopharma","phase":"","preferredName":"LNP-encapsulated mRNA cocktail encoding RBD","primaryCompletionDate":"","productId":529,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.fudan.edu.cn/en/2020/0307/c344a104281/page.htm","https://covidvax.org/covid19-vaccine/FudanUniRBD/LNP-encapsulated-mRNA-cocktail-encoding-RBD-Fudan-University-Shangai-JiaoTong-University-RNACure-Bio"],"sponsors":[{"sponsorId":"4567098e44fc907783878b149c6d70d1f14aec40","sponsorName":"Fudan University"},{"sponsorId":"aa6799f660cd49b264d3e155560878bb15e8b804","sponsorName":"Shanghai JiatTong University"},{"sponsorId":"f8f4d45187fd48b7b35c26e73dc0b1c09938f8e0","sponsorName":"RNACure Biopharma"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Replicating Defective SARS-CoV-2 derived RNAs Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Spain"],"countryCodes":["ESP"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Fri, 01 May 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Centro Nacional Biotecnolog\u00eda","phase":"","preferredName":"Replicating Defective SARS-CoV-2 derived RNAs Vaccine","primaryCompletionDate":"","productId":530,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://covidvax.org/covid19-vaccine/CNB-RNA/RNA-defective-SARS-CoV-2-derived-RNAs-Centro-Nacional-Biotecnologia-CNB-CSIC-"],"sponsors":[{"sponsorId":"c1eb0322cb877870cc4fe7c42c87c0a02c5d0674","sponsorName":"Centro Nacional biotecnologia"},{"sponsorId":"ff7e4fdfaae0a64a50db02f60295658c622d7b87","sponsorName":"CNBCSIC"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"mRNA Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"RNAimmune Inc","phase":"","preferredName":"mRNA Vaccine","primaryCompletionDate":"","productId":531,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines"],"sponsors":[{"sponsorId":"96c9c4abf003991d12896ec5fc930b3875d2aa18","sponsorName":"RNAImmune Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"mRNA Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Tue, 17 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Inovio Pharmaceuticals","phase":"","preferredName":"mRNA Vaccine","primaryCompletionDate":"","productId":532,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.houstonmethodist.org/research/covid19/geneone/","https://www.chron.com/neighborhood/woodlands/health/article/Behind-the-scenes-Houston-doctor-preps-for-new-15192520.php"],"sponsors":[{"sponsorId":"a16b70b82bdd9b5e61c50e750862a8851ee80507","sponsorName":"GeneOne Life Science"},{"sponsorId":"0276ff1989d288ace3c36f410d4c8c1aa98a6910","sponsorName":"Houston Methodist"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"mRNA Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Tue, 12 May 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Greenlight Biosciences","phase":"","preferredName":"mRNA Vaccine","primaryCompletionDate":"","productId":533,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://bioprocessintl.com/bioprocess-insider/upstream-downstream-processing/greenlight-raises-17m-for-mrna-vaccine-capacity-hike-citing-covid-19-target/"],"sponsors":[{"sponsorId":"9bc71603d5f1ceefbc96ff17289d5ada42219959","sponsorName":"Greenligh Biosciences"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"VLP Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"OSIVAX","phase":"","preferredName":"VLP Vaccine","primaryCompletionDate":"","productId":534,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines"],"sponsors":[{"sponsorId":"dbc7ace17cd35ff8f85b54d21988dfa7824dcf8a","sponsorName":"OSIVAX"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"VLP Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Germany"],"countryCodes":["DEU"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Mon, 27 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"ARTES Biotechnology","phase":"","preferredName":"VLP Vaccine","primaryCompletionDate":"","productId":535,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://pharma-industry-review.com/artes-joins-fight-against-covid-19-vlp-vaccine-platforms","https://www.contractpharma.com/content-microsite/covid-19/2020-04-27/artes-biotech-to-develop-vlp-sars-cov-2-vax-candidates"],"sponsors":[{"sponsorId":"07a812ba1b31cfbef19b397a145bcc9d34fc20a1","sponsorName":"ARTES Biotechnology"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"VLP,Whole Virus Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Brazil"],"countryCodes":["BRA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"University of Sao Paulo","phase":"","preferredName":"VLP,Whole Virus Vaccine","primaryCompletionDate":"","productId":536,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.efe.com/efe/english/portada/brazil-scientists-using-new-approach-in-search-for-covid-19-vaccine/50000260-4199376"],"sponsors":[{"sponsorId":"65766da43898183e2da98c6704a2abbfa7aa4632","sponsorName":"Univeristy of Sao Paulo"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"SK Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Tue, 24 Mar 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 01 Sep 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"SK Biosciences,SK Group","phase":"","preferredName":"SK Vaccine","primaryCompletionDate":"","productId":537,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.upi.com/Health_News/2020/03/24/Korean-company-starts-animal-trial-of-coronavirus-vaccine/9671585056981/?sl=11","http://www.koreabiomed.com/news/articleView.html?idxno=7798","https://covidvax.org/covid19-vaccine/SK/SK-vaccine-SK-Bioscience"],"sponsors":[{"sponsorId":"478b6fcffcd9bf799b6789693a95c51d1d06af57","sponsorName":"SK Biosciences"},{"sponsorId":"b1e925b723690d4fd21dcf9ec6c1f26f2eb70ca5","sponsorName":"SK Group"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Tue, 10 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"Precision Vaccines Program,Boston Children's Hospital","phase":"","preferredName":"Vaccine","primaryCompletionDate":"","productId":538,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.scientificamerican.com/article/coronavirus-vaccines-may-not-work-for-the-elderly-and-this-lab-aims-to-change-that/","https://discoveries.childrenshospital.org/coronavirus-vaccine/"],"sponsors":[{"sponsorId":"1fed0b53fb22b1b1719e57613378cadb6bf64f66","sponsorName":"Precision Vaccines Program"},{"sponsorId":"30710cd9a14eb8e8b8fa545333e304e084ebcfc4","sponsorName":"Boston Childrens Hospital"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"Vaccine","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"guzmano@rjrt.com","name":null,"notes":"","phone":"336-741-5043","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 20 Jul 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"2","otherPartners":"Kentucky BioProcessing","phase":"2","preferredName":"Vaccine","primaryCompletionDate":"Thu, 06 May 2021 00:00:00 GMT","productId":539,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04473690","repurposed":"New","siteLocations":[{"city":"Wilmington","country":"USA","lat":34.2085533,"lng":-77.92795559999999,"locationId":"5a5e7e72026173136cebabc4dfb5fbd57208df07","name":"Pmg Research Of Wilmington","state":"NC"},{"city":"San Antonio","country":"USA","lat":29.5139583,"lng":-98.47002189999999,"locationId":"95e402c2fc239a649c0c8333fdbc32a568e639c8","name":"Icon Early Phase Studies","state":"TX"}],"sources":["https://www.bat.com/group/sites/UK__9D9KCY.nsf/vwPagesWebLive/DOBN8QNL","https://clinicaltrials.gov/ct2/show/NCT04473690","https://www.owensborotimes.com/news/2020/04/kbp-begins-testing-covid-19-vaccine-candidate-on-animals/"],"sponsors":[{"sponsorId":"c166c578447a7c9ab34935edb79ae58af5c26833","sponsorName":"Kentucky BioProcessing"},{"sponsorId":"04f6cb5885013bae64d2b1cecf249bb94735046b","sponsorName":"BAT"}],"status":"Ongoing","studyCompletionDate":"Wed, 23 Mar 2022 00:00:00 GMT","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Fri, 06 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"Canadian Institutes of Health Research","phase":"","preferredName":"Vaccine","primaryCompletionDate":"","productId":540,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.ulaval.ca/en/about-us/media-centre/press-releases/press-releases-2020/21-million-better-understand-and-combat-covid-19"],"sponsors":[{"sponsorId":"68fc3905a9dd7aa4f14be93f6f536bd303d16bab","sponsorName":"University of Laval"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Chile"],"countryCodes":["CHL"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Fri, 13 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Scientists will use respiratory syncytial virus (RSV) and human metapneumovirus (MPVh) vaccine developments and apply them to COVID-19 research.","numSites":"","otherPartners":"","phase":"","preferredName":"Vaccine","primaryCompletionDate":"","productId":541,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://translate.google.com/translate?hl=en&sl=es&tl=en&u=http%3A%2F%2Fwww.imii.cl%2Fcientificos-chilenos-trabajan-desarrollo-vacuna-coronavirus-preparacion-la-pandemia%2F","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635448/"],"sponsors":[{"sponsorId":"aaa32a3979ac5c274f389b02e07a20f54af034c7","sponsorName":"Universidad Catolica Instituto Milenio de Inmunologia e Inmunoterapia"},{"sponsorId":"3ecea3e5816f686ca7b07b073600326888093983","sponsorName":"Consorcio Technologica en Biomedicina Clinico Molecular"},{"sponsorId":"cfa06ba512db41f4402457107b0efb25017d088e","sponsorName":"IMMII"},{"sponsorId":"cbfa70574d8abd0d988aca0261d66abecf7cdebb","sponsorName":"BMRC"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"","brandName":"Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Scientists are developing a T-cell-inducing vaccine that produces a strong T cell immune response to help target and kill infected cells. It works by using peptides to stimulate T-cells.","numSites":"","otherPartners":"","phase":"","preferredName":"Vaccine","primaryCompletionDate":"","productId":542,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["http://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/","http://emergexvaccines.com/wp-content/uploads/2020/04/31-March-2020-White-Paper-Scientific-Rationale-for-the-Use-of-T-Cell-Priming-to-Reduce-R0-to-Limit-Spread-of-COVID-19-During-Active-Pandemic-FINAL.pdf","https://asia.nikkei.com/Business/Startups/Coronavirus-vaccine-set-for-testing-says-startup-backed-by-Singapore-VC"],"sponsors":[{"sponsorId":"edc8416948cc1ae11508ef4ae0b416a22c12ad4e","sponsorName":"Emergex Vaccines Holding Limited"},{"sponsorId":"592426722c1b68f6ce3b0cb2833cd378cea35d20","sponsorName":"George Mason Universitys National Center for Biodefense and Infectious Diseases"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"AVI-205","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"AVI-205","primaryCompletionDate":"","productId":543,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.biospace.com/article/first-in-class-active-targeting-vaccine-candidate-for-covid-19/","http://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/","http://abvisioninc.com/2020/05/03/abvision-announced-a-first-in-class-active-targeting-vaccine-candidate-for-covid-19/"],"sponsors":[{"sponsorId":"a25563e72a99e3dab077dcbd5a35f0b05e1a851b","sponsorName":"AbVision Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Recombinant LVS Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Scientists are attempting to develop a single vector platform vaccine that would protect against many emerging pathogens as well as \"Tier 1 Select Agents.\"","numSites":"","otherPartners":"","phase":"","preferredName":"Recombinant LVS Vaccine","primaryCompletionDate":"","productId":544,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["http://ucla.technologypublisher.com/techcase/20-0322","https://www.uclahealth.org/infectious-diseases/Workfiles/infectious-diseases/Marcus-Horwitz-profile-page2.pdf","http://ucla.technologypublisher.com/techcase/18-1241"],"sponsors":[{"sponsorId":"68a801de11b20a5784e2f9993135e416ea6d5ccc","sponsorName":"University of California Los Angeles"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"","brandName":"Attenuated Vaccine","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Brazil"],"countryCodes":["BRA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Whole-pathogen vaccines","notes":"","numSites":"","otherPartners":"LabWare","phase":"","preferredName":"Attenuated Vaccine","primaryCompletionDate":"","productId":546,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines","https://www.thepharmaletter.com/article/etherna-launches-consortium-and-starts-development-of-cov-2-mrna-vaccine","https://www.labware.com/en/p/About-Us/COVID19/Instituto-Butantan","http://www.butantan.gov.br/"],"sponsors":[{"sponsorId":"a428a9d798bc8d58f26fe00c022c9f48b3f79576","sponsorName":"Fundacao Oswaldo Cruz"},{"sponsorId":"e23ad6b02eceefb9094a74410045931a10079a06","sponsorName":"Instituto Butantan"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Organicell Flow","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"clinicaltrials@organicell.com","name":null,"notes":"","phone":"1-888-963-7881","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Mon, 11 May 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 12 May 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"2","otherPartners":"","phase":"1","preferredName":"Organicell Flow","primaryCompletionDate":"Sat, 31 Oct 2020 00:00:00 GMT","productId":547,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04384445","repurposed":"New","siteLocations":[{"city":"Naples","country":"USA","lat":26.2699775,"lng":-81.7891267,"locationId":"eebe419b17c5c5a5ae897dc79d0e34166e8e7b06","name":"Landmark Hospital","state":"FL"},{"city":"Athens","country":"USA","lat":33.9663705,"lng":-83.4115674,"locationId":"0a7f0fc1aab8885a01bbd5004e0d487426dcc596","name":"Landmark Hospital","state":"GA"}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04384445?term=Organicell&draw=2&rank=1","https://organicell.com/organicell-flow/","https://organicell.com/clinical-trials/","https://organicell.com/fda-approves-two-emergency-inds-to-administer-organicell-flow-for-covid-19/"],"sponsors":[{"sponsorId":"fd115f17ad17409455bb40c8d7b56ec40407be62","sponsorName":"Organicell Regenerative Medicine"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Tue, 08 Sep 2020 00:00:00 GMT","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"No","brandName":"KB-109","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 14 May 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Scientists are studying outpatients in 2 non-IND clinical studies","numSites":"1","otherPartners":"","phase":"2","preferredName":"KB-109","primaryCompletionDate":"","productId":548,"registryLink":null,"repurposed":"New","siteLocations":[{"city":"Worcester","country":"USA","lat":42.2777464,"lng":-71.76325419999999,"locationId":"8de58bf891b1400cb57e173601daed65757661df","name":"University Of Massachusetts Medical School","state":"MA"}],"sources":["https://www.bioworld.com/COVID19products","https://www.globenewswire.com/news-release/2020/05/14/2033339/0/en/Kaleido-Biosciences-Initiates-Controlled-Clinical-Study-of-Microbiome-Metabolic-Therapy-KB109-in-Outpatients-with-Mild-to-Moderate-COVID-19.html","https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/","https://kaleido.com/our-pipeline/"],"sponsors":[{"sponsorId":"b7a8a2d712ee76890113aebcca4616bf1019b420","sponsorName":"Kaleido Biosciences Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Thu, 14 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Estradiol patch","chemicalName":"","conditionOrDisease":"COIVD-19","contact":[{"email":"PatchStudy@stonybrookmedicine.edu","name":null,"notes":"","phone":"631-371-3309","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 24 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Scientists theorize that estrogen may effect angiotensin-converting enzyme 2 (ACE2) proteins which have receptors on cells that are used by COVID-19 as entry-points to the cell. Estrogen has also been shown to improve immune response,espeically in viral infections.","numSites":"1","otherPartners":"","phase":"2","preferredName":"Estradiol patch","primaryCompletionDate":"Sun, 15 Nov 2020 00:00:00 GMT","productId":549,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04359329","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Stony Brook","country":"USA","lat":40.9088246,"lng":-73.1147874,"locationId":"e5fa0f2863e2258a4b5865de1fefc67b21ef01f3","name":"Stony Brook University Hospital","state":"NY"}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04359329","https://www.drugbank.ca/drugs/DB00783","https://www.nytimes.com/2020/04/27/health/coronavirus-estrogen-men.html","https://www.healio.com/news/endocrinology/20200501/study-investigates-estrogen-patch-use-to-lessen-covid19-complications","https://clinicaltrials.gov/ct2/show/record/NCT04359329","https://clinicaltrials.gov/ct2/show/study/NCT04359329"],"sponsors":[{"sponsorId":"a7721518ad3f33d0aa3b8af76ef0c1880324607a","sponsorName":"Stony Brook University Hospital"}],"status":"Ongoing","studyCompletionDate":"Sun, 15 Nov 2020 00:00:00 GMT","studyStartDate":"Fri, 24 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Anticovir","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Drug will be dispensed via Metered Dose Inhaler (MDI).","numSites":"","otherPartners":"Altum Pharmaceuticals Inc.","phase":"","preferredName":"Anticovir","primaryCompletionDate":"","productId":550,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.biospace.com/article/releases/betterlife-pharma-enters-into-a-licensing-agreement/","https://www.altumpharma.com/pipeline/ap-003/","https://www.thepharmaletter.com/article/betterlife-pharma-inks-licensing-deal-for-anticovir"],"sponsors":[{"sponsorId":"80e96db9c9f78a58f5b44d2793c88c981132970f","sponsorName":"Betterlife Pharma Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Apograft-treated stem cells","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Israel"],"countryCodes":["ISR"],"currentStage":"Pre-Clinical Testing","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Cell therapies","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Apograft-treated stem cells","primaryCompletionDate":"","productId":551,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.prnewswire.com/news-releases/cellect-biotechnologys-apograft-to-empower-cellular-treatment-of-covid-19-related-pulmonary-diseases-301060683.html","https://www.cellect.co/solutions","https://www.cellect.co/"],"sponsors":[{"sponsorId":"3677197cebff0cf7947d2809124f96acf1cf3201","sponsorName":"Cellect Biotechnology Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Mesenchymal Stem Cells","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Mon, 27 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"","numSites":"","otherPartners":"Citius Pharmaceuticals Inc.","phase":"","preferredName":"Mesenchymal Stem Cells","primaryCompletionDate":"","productId":552,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://ir.citiuspharma.com/press-releases/detail/95/citius-signs-exclusive-option-with-novellus-to-license","https://ir.citiuspharma.com/press-releases/detail/98/citius-announces-data-on-novecite-mesenchymal-stem-cells","https://ir.citiuspharma.com/press-releases/detail/96/citius-announces-pre-ind-submission-to-fda-under-the"],"sponsors":[{"sponsorId":"ea3716c6b0205d251944d5e3a61cc9f1ba3744d4","sponsorName":"Citius Pharmaceuticals Inc"},{"sponsorId":"c48abd193caba28112832045ebaea95c6c5a0faf","sponsorName":"Novellus Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"CAL-02","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Switzerland"],"countryCodes":["CHE"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"CAL-02","primaryCompletionDate":"","productId":553,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.combioxin.com/pipeline/","https://www.mdpi.com/2079-6382/9/2/94","https://www.combioxin.com/news/","http://www.lascco.com/documents/200504PR-Combioxin-PositivefeedbackfromFDAonPINDforCAL02inCOVID-19patients.pdf"],"sponsors":[{"sponsorId":"01da66d9faf1279ac5cdf58ec85f96945d297558","sponsorName":"Combioxin SA"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"e-Therapeutics Therapeutic","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"Network-driven Drug Discovery works to determine host mechanisms that are critical for virus replication and spread","numSites":"","otherPartners":"","phase":"","preferredName":"e-Therapeutics Therapeutic","primaryCompletionDate":"","productId":554,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.etherapeutics.co.uk/media/1237/covid-19_ndd_overview.pdf","https://www.etherapeutics.co.uk/what-we-do/covid-19/"],"sponsors":[{"sponsorId":"fa4ddbe589e7b8b772f35f4f16d787866b9f4ae9","sponsorName":"eTherapeutics plc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"KAND-567","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Sweden"],"countryCodes":["SWE"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Kancera has applied to begin Phase II studies","numSites":"","otherPartners":"","phase":"","preferredName":"KAND-567","primaryCompletionDate":"","productId":555,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","http://kancera.com/en/researchportfolio/","http://kancera.com/en/press/press-releases/#"],"sponsors":[{"sponsorId":"fe4146d58f781a4971c5ec8a946b4fe02036a3cb","sponsorName":"Kancera AB"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Capton product","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Capton product","primaryCompletionDate":"","productId":556,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://mercaptor.com/mercaptor-discoveries-uses-its-proprietary-neurotherapeutic-platform-to-develop-treatment-for-covid-19/"],"sponsors":[{"sponsorId":"5b62e5f42bf6b8790b1f5d3d525aa8d615ab1ac0","sponsorName":"Mercaptor Discoveries Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"TR-C 19","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Germany"],"countryCodes":["DEU"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"TR-C 19","primaryCompletionDate":"","productId":557,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.vsybiotechnology.com/a-new-drug-to-treat-covid-19-tr-c-19-at-human-testing-phase/","https://www.vsybiotechnology.com/about-us/"],"sponsors":[{"sponsorId":"daeec1530e0e8919a34fb5c99ed5ddc5cd2e8f43","sponsorName":"Vsy Biotechnology GmbH"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibody","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Belgium"],"countryCodes":["BEL"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Antibody","primaryCompletionDate":"","productId":558,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","http://www.vib.be/en/news/Pages/Towards-antibodies-against-COVID-19.aspx"],"sponsors":[{"sponsorId":"0174fd8a066ed49f55c03cae0c00a6e53d1f1356","sponsorName":"Xavier Saelens"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Antibodies","primaryCompletionDate":"","productId":559,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.proteogenix.science/contact/"],"sponsors":[{"sponsorId":"dfe8fccd9d4a4ca4e46009e309f1281be6f25f78","sponsorName":"Proteogenix SA"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Germany"],"countryCodes":["DEU"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Thu, 07 May 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Antibodies","primaryCompletionDate":"","productId":560,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.yumab.com/wp-content/uploads/2020/05/2020.05.08_PR_SARS-CoV-2_ENG_final.pdf"],"sponsors":[{"sponsorId":"cc02b125f93be2b049360a4f49ab7a0c97bdfcf5","sponsorName":"Yumab GmbH"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"TY027","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"justin@tychanltd.com        ","name":null,"notes":"","phone":"","website":""}],"countries":["Singapore"],"countryCodes":["SGP"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"1","otherPartners":"","phase":"1","preferredName":"TY027","primaryCompletionDate":"Sun, 01 Nov 2020 00:00:00 GMT","productId":561,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1","repurposed":"New","siteLocations":[{"city":"Singapore","country":"SGP","lat":1.2809842,"lng":103.8388793,"locationId":"7a60dcd7638939bedba4871b750e6ee7cedaa0fd","name":"Singhealth Investigational Medicine Unit","state":null}],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1","https://www.genengnews.com/covid-19-candidates/tychan-ty027/"],"sponsors":[{"sponsorId":"336eecbaf567ac949aa38caead2ef8159f332f1d","sponsorName":"Tychan"}],"status":"Ongoing","studyCompletionDate":"Mon, 01 Feb 2021 00:00:00 GMT","studyStartDate":"Tue, 09 Jun 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Small Mobile Stem cells","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Cell therapies","notes":"treatment that could repair critically damaged tissues by the coronavirus","numSites":"","otherPartners":"","phase":"","preferredName":"Small Mobile Stem cells","primaryCompletionDate":"","productId":564,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.smsbiotech.com/covid19_treatment_proposal/"],"sponsors":[{"sponsorId":"038bb1d2f34b750da43d8976c099f0e9c2384161","sponsorName":"SMSbiotech"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Diovan","chemicalName":"valsartan","conditionOrDisease":"COVID-19","contact":[{"email":"Roland.vanKimmenade@radboudumc.nl","name":null,"notes":"","phone":"","website":""}],"countries":["Netherlands"],"countryCodes":["NLD"],"currentStage":"Phase 4","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"7","otherPartners":"","phase":"4","preferredName":"valsartan","primaryCompletionDate":"","productId":565,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1","repurposed":"Repurposed-Approved","siteLocations":[{"city":"'s-Hertogenbosch","country":"NLD","lat":51.6850355,"lng":5.277171,"locationId":"80f0d63f27eaa1bca1b8f89d52170cd5d319ca4a","name":"Jeroen Bosch Ziekenhuis","state":"NB"},{"city":"Arnhem","country":"NLD","lat":52.00081669999999,"lng":5.909809999999999,"locationId":"831d9d07ea75f6f3cfca588d6eb635e589da322d","name":"Rijnstate","state":"GE"},{"city":"Nijmegen","country":"NLD","lat":51.8235728,"lng":5.8611812,"locationId":"a08bdec61b064c899fad93770f65c55828c79b52","name":"Radboudumc","state":"GE"},{"city":"Roermond","country":"NLD","lat":51.1923918,"lng":6.0005231,"locationId":"458a6b008c29b96dd0fb713ae714a45fc74d6494","name":"Laurentius Ziekenhuis","state":"LI"},{"city":"Rotterdam","country":"NLD","lat":51.9108848,"lng":4.467854099999999,"locationId":"016c7b43fc4ac0815ace17dbbddf219403529f1e","name":"Erasmus Mc","state":"ZH"},{"city":"Rotterdam","country":"NLD","lat":51.94185,"lng":4.462831,"locationId":"2809ca2ab81011f510a9fedc3c17d077423f7b99","name":"Franciscus Gasthuis","state":"ZH"},{"city":"Rotterdam","country":"NLD","lat":51.886169,"lng":4.4939073,"locationId":"edebe6f3937e04abb6af3d8b4dd021f0ac2db7fa","name":"Ikazia Ziekenhuis","state":"ZH"}],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1","https://www.drugbank.ca/drugs/DB00177"],"sponsors":[{"sponsorId":"432bfc8336b289f3977566e16cf048972aa74569","sponsorName":"Radbound Univeristy"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Fri, 17 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Pepcid","chemicalName":"famotidine","conditionOrDisease":"COVID-19","contact":[{"email":"jdigregori@northwell.edu\t","name":null,"notes":"","phone":"(516) 493-7950","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"5","otherPartners":"","phase":"3","preferredName":"famotidine","primaryCompletionDate":"Mon, 07 Sep 2020 00:00:00 GMT","productId":566,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Bay Shore","country":"USA","lat":40.7257333,"lng":-73.2413591,"locationId":"6a90b2a358f1dbccf95de2622ce26339988f1759","name":"Southside Hospital","state":"NY"},{"city":"Manhasset","country":"USA","lat":40.7752276,"lng":-73.7013309,"locationId":"3706710a8593090af4a2a21ff1d6982c4b892907","name":"North Shore University Hospital","state":"NY"},{"city":"Mt Kisco","country":"USA","lat":41.1965451,"lng":-73.7255419,"locationId":"ed460c71415dbc3cd5e4fe24ec1b29a04e828ff7","name":"Northern Westchester Hospital","state":"NY"},{"city":"New York","country":"USA","lat":40.7739303,"lng":-73.9608921,"locationId":"6aac147008e3c9fd9ffc0c65a2db6e787e55c2fe","name":"Lenox Hill Hospital","state":"NY"},{"city":null,"country":"USA","lat":40.7541187,"lng":-73.7083079,"locationId":"a25b462959b17b5a69ddd70fde0a2169b26cb16a","name":"Long Island Jewish Medical Center","state":"NY"}],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2","https://www.drugbank.ca/drugs/DB00927"],"sponsors":[{"sponsorId":"a4e79c4da197e20df061d83c37e4e3717861e721","sponsorName":"Feinstein Institutes for Medical Research"},{"sponsorId":"239c019da219eac0cd5b03db2e1ae81decc90034","sponsorName":"Northwell Health"},{"sponsorId":"fc16463de92affc9e97a314e701dcd0678083433","sponsorName":"Alchem"}],"status":"Ongoing","studyCompletionDate":"Wed, 07 Apr 2021 00:00:00 GMT","studyStartDate":"Tue, 07 Apr 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Vascepa","chemicalName":"icosapent ethyl","conditionOrDisease":"COVID-19","contact":[{"email":"subodh.verma@unityhealth.to","name":null,"notes":"","phone":"1-416-864-5997","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"icosapent ethyl","primaryCompletionDate":"","productId":567,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Toronto","country":"CAN","lat":43.7524337,"lng":-79.457152,"locationId":"ad67064232a1acd4a39d67a4f166bafc1a29de91","name":"North York Diagnostic And Cardiology Clinic","state":"ON"}],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1","https://www.drugbank.ca/drugs/DB08887"],"sponsors":[{"sponsorId":"9daa331fe5b9e8dfada9be8fac934d427b5f3955","sponsorName":"Amarin Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 01 Jun 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"OP-101","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"cleland@orpheris.com","name":null,"notes":"","phone":"1 650 241 1697","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 28 May 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Other","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"OP-101","primaryCompletionDate":"Sat, 10 Oct 2020 00:00:00 GMT","productId":568,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1","repurposed":"Repurposed-Approved","siteLocations":[{"city":"San Diego","country":"USA","lat":32.715738,"lng":-117.1610838,"locationId":"01d4f1bd83d03c5239e2db04849242b2a2f8fa08","name":"San Diego","state":"CA"}],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1","https://www.fiercebiotech.com/biotech/after-passing-safety-hurdle-orpheris-kickstarts-covid-19-cytokine-storm-efficacy-test","https://www.businesswire.com/news/home/20200528005275/en/Ashvattha-Therapeutics-Subsidiary-Orpheris-Announces-FDA-Agreement"],"sponsors":[{"sponsorId":"3ce1e9abeb85d87e23025b0e1a8632687a2195b9","sponsorName":"Orpheris"},{"sponsorId":"269c37157681ff90864988b2d4948a61632db3ba","sponsorName":"Ashvattha Therapeutics"}],"status":"Ongoing","studyCompletionDate":"Tue, 10 Nov 2020 00:00:00 GMT","studyStartDate":"Wed, 01 Jul 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Flarin","chemicalName":"lipid ibupfofen","conditionOrDisease":"COVID-19","contact":[{"email":"ndaba.mazibuko@nhs.net","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Phase 4","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"4","preferredName":"lipid ibupfofen","primaryCompletionDate":"Fri, 25 Sep 2020 00:00:00 GMT","productId":569,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1","repurposed":"Repurposed-Approved","siteLocations":[{"city":null,"country":"GBR","lat":51.5046788,"lng":-0.08852929999999999,"locationId":"2eaef39539bf4f7ec2727811a278a586ac2e8287","name":"Guy's And St Thomas' Nhs Foundation Trust","state":"England"}],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1"],"sponsors":[{"sponsorId":"041e7ac45c1c3b265ad83dc490a67c30317c318e","sponsorName":"Kings College London"}],"status":"Ongoing","studyCompletionDate":"Tue, 25 May 2021 00:00:00 GMT","studyStartDate":"Tue, 26 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"almitrine","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"almitrine","primaryCompletionDate":"","productId":570,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.ox.ac.uk/news/2020-05-29-covid-19-drug-trial-could-lead-enhanced-respiratory-care-patients","https://www.pulmonologyadvisor.com/home/topics/lung-infection/hypoxemia-related-to-covid-19-may-benefit-from-almitrine-treatment/","https://covid-19tracker.milkeninstitute.org/"],"sponsors":[{"sponsorId":"38652628acf1b84b92cad2bea1a82015a920b0c3","sponsorName":"University of Oxford"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"VP01","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"mimi.flensburg@vicorepharma.com","name":null,"notes":"COVID-19 requiring hospitalization but not ventilation; only London location is recruiting","phone":"45 2210 9950","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 30 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Small molecule designed to target AT2R to reduce inflammation and treat pulmonary fibrosis,MHRA granted VP01 approval to commence phase 2 to investigate whether it reduced inflammation in COVID-19 patients","numSites":"3","otherPartners":"LifeArc,University College London","phase":"2","preferredName":"VP01","primaryCompletionDate":"Thu, 10 Sep 2020 00:00:00 GMT","productId":571,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04452435","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Ahmedabad","country":"IND","lat":23.0524508,"lng":72.6028567,"locationId":"80d9d58ca2bc4cc6d7f960c3ab9d325bb3272c4a","name":"Department Of Medicine","state":"GJ"},{"city":"Pune","country":"IND","lat":18.5035602,"lng":73.9273812,"locationId":"b76a0b36c5fdfac543a31132b04e7c4059028614","name":"Department Of Medicine","state":"MH"},{"city":null,"country":"GBR","lat":51.5251538,"lng":-0.1361126,"locationId":"f0d4e2158153ccca356f7c0d254003260b0c0736","name":"Respiratory Medicine","state":"England"}],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.lifearc.org/funding/covid-19-funding/attract/","https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1","https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1#contacts"],"sponsors":[{"sponsorId":"c2ea57bc39b23f4008b3b798267383fbd2c27571","sponsorName":"Vicore Pharma"}],"status":"Ongoing","studyCompletionDate":"Fri, 10 Sep 2021 00:00:00 GMT","studyStartDate":"Tue, 30 Jun 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"AQCH","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["India"],"countryCodes":["IND"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 08 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Plant derived treatment initially intended for treating dengue but broad-spectrum anti-viral activity shows promise for COVID-19,no detailed entry on clinicaltrials","numSites":"12","otherPartners":"","phase":"2","preferredName":"AQCH","primaryCompletionDate":"Sat, 10 Oct 2020 00:00:00 GMT","productId":572,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[{"city":null,"country":"IND","lat":20.593684,"lng":78.96288,"locationId":"f9b931ebabc7cd17a88bf4fa4cb4122e5578733c","name":"India","state":null}],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.clinicaltrialsarena.com/news/sun-pharma-covid-19-trial/"],"sponsors":[{"sponsorId":"ca23b6a4a7a874f5a61c26ea21f0112b4d78dbf0","sponsorName":"Sun Pharmaceutical Industries Ltd"}],"status":"Ongoing","studyCompletionDate":"Sat, 10 Oct 2020 00:00:00 GMT","studyStartDate":"Mon, 08 Jun 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"CIGB-258","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"TRIAL COMPLETED","phone":"","website":""}],"countries":["Cuba"],"countryCodes":["CUB"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Mon, 30 Mar 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 31 Mar 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Immunoregulatory peptide,clinical trial did not have a traditional phase but description appears to indicate phase 2 and was completed in 05/30/2020 and published results on 6/30/2020 https://www.medrxiv.org/content/10.1101/2020.05.27.20110601v1","numSites":"","otherPartners":"Ministry of Public Health - Cuba","phase":"","preferredName":"CIGB-258","primaryCompletionDate":"","productId":573,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://rpcec.sld.cu/en/trials/RPCEC00000313-En","https://rpcec.sld.cu/en/trials/RPCEC00000313-En https://www.medrxiv.org/content/10.1101/2020.05.27.20110601v1"],"sponsors":[{"sponsorId":"599b442f75a35f3a72fc558bc0202e8d0747618f","sponsorName":"Genetic Engineering and Biotechnology Center"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"FSD-201","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"TRIAL COMPLETED","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Drug is ultramicronized palmitoylethanolamide intended to reduce COVID-19 inflammation,currently is planning a phase 2a trial after receiving FDA approval,phase 1 results will be published soon","numSites":"","otherPartners":"","phase":"","preferredName":"FSD-201","primaryCompletionDate":"","productId":574,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://fsdpharma.com/about-us/","https://www.businesswire.com/news/home/20200602005990/en/FSD-Pharma-Receives-U.S.-FDA-Approval-Design","https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase"],"sponsors":[{"sponsorId":"b2bbb974a00d8c7f0df2c6ef240c54f29e4dc8c3","sponsorName":"FSD Pharma"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"PB-1046","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"Clinicaltrials@phasebio.com","name":null,"notes":"Male or Female aged 18-85; hospitalized for COVID-19; written or verbal consent; receiving O2 by face mask or nasal cannula and/or elevated markers of cardiac injury or dysfunction","phone":"888 521 2805","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Wed, 27 May 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 26 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Vasoactive intestinal peptide recptor agonist that targets VPAC receptors to have anti-inflammatory effects among others,also in trials for Pulmonary Arterial Hypertension","numSites":"","otherPartners":"","phase":"2","preferredName":"PB-1046","primaryCompletionDate":"","productId":575,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04433546","repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.businesswire.com/news/home/20200527005882/en/PhaseBio-Launches-Clinical-Trial-Evaluate-PB1046-Treatment","https://clinicaltrials.gov/ct2/show/NCT04433546","https://clinicaltrials.gov/ct2/show/NCT04433546#contacts"],"sponsors":[{"sponsorId":"843438e9026597e688588c1e3b1ffd5e9a5e31a0","sponsorName":"PhaseBio"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Fri, 26 Jun 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"pamrevlumab","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 21 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Anti-connective growth factor monoclonal antibody","numSites":"","otherPartners":"Fibrogen Inc","phase":"2","preferredName":"pamrevlumab","primaryCompletionDate":"","productId":606,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-first-patient-enrolled-pamrevlumab-clinical-0"],"sponsors":[{"sponsorId":"6f85ebbf6fab446350dc544d486ac541b13ce031","sponsorName":"Fibrogen Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"PTC299","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"medinfo@ptcbio.com","name":null,"notes":"Not yet recruiting; 18 or older with signed and dated informed consent; hospitalized for confirmed COVID19","phone":"866 562 4620","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 30 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 30 Jun 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Currently in evaluation for AML besides COVID19,small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) that reduces SARS-CoV-2 viral replication and selectively modulates immune response","numSites":"5","otherPartners":"","phase":"2","preferredName":"PTC299","primaryCompletionDate":"Sat, 30 Jan 2021 00:00:00 GMT","productId":576,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04439071","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Augusta","country":"USA","lat":33.4709094,"lng":-81.9898848,"locationId":"50f9b48265952b82fd81a17c529d6fb61d54dec1","name":"Augusta University","state":"GA"},{"city":"Baltimore","country":"USA","lat":39.2967385,"lng":-76.59273619999999,"locationId":"c8feb71d86b7350a0cca4799df4c46cc2143b67e","name":"Johns Hopkins Hospital","state":"MD"},{"city":"Barcelona","country":"ESP","lat":41.38389069999999,"lng":2.1941912,"locationId":"50836faa4e595ded114529b8cb069c08bb5d74fe","name":"Hospital Del Mar","state":"CT"},{"city":"Madrid","country":"ESP","lat":40.3864149,"lng":-3.6178463,"locationId":"e4627eb9070a8660c8f76d5dd552be663629aa60","name":"Hospital Universitario Infanta Leonor","state":"Comunidad de Madrid"},{"city":"Madrid","country":"ESP","lat":40.3760381,"lng":-3.6990068,"locationId":"00a88976c01426a61ecd80ceeb48e5098d0e3f17","name":"Hospital 12 De Octubre","state":"Comunidad de Madrid"}],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.ptcbio.com/about/contact-us/","https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-the-initiation-of-a-phase-23-clinical-trial-to-evaluate-ptc299-for-the-treatment-of-covid-19-301078337.html","https://clinicaltrials.gov/ct2/show/NCT04439071?intr=ptc299&draw=2&rank=4"],"sponsors":[{"sponsorId":"85ebe6b2e2259437754addc4fb2e9365153c49ae","sponsorName":"PTC Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"Sat, 30 Jan 2021 00:00:00 GMT","studyStartDate":"Tue, 30 Jun 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"Evista","chemicalName":"raloxifene","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Italy"],"countryCodes":["ITA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Currently on market for treatment of osteoporosis as raloxifene,currently in discussions with the EMA,drug intended to be used in clinical trials to observe efficacy against COVID-19","numSites":"","otherPartners":"","phase":"","preferredName":"raloxifene","primaryCompletionDate":"","productId":577,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.dompe.com/en/media/press-releases/eu-supported-private-public-consortium-exscalate4cov-raloxifene-proposed-for-clinical-trials-after-tests-show-it-inhibits-sars-cov-2"],"sponsors":[{"sponsorId":"f56dc548d8bfe74984064c59095b7bfd19c6ae3f","sponsorName":"Dompe farmaceutici"},{"sponsorId":"3290324bf4e652fd05bffce6079d5ebbe370538a","sponsorName":"Exscalate4CoV"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"losmapimod","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Wed, 24 Jun 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 24 Jun 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Oral p38 MAPK inhibitor,phase 3 to begin soon - conducted on 400 patients and aims to have topline data by Q1 2020","numSites":"","otherPartners":"","phase":"","preferredName":"losmapimod","primaryCompletionDate":"","productId":578,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.fulcrumtx.com/contact/","https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-initiation-multi-center-phase-3"],"sponsors":[{"sponsorId":"754a6a32f07e76bc8bc858dd075c286dfea0349b","sponsorName":"Fulcrum Therapeutics"}],"status":"Ongoing","studyCompletionDate":"Wed, 10 Feb 2021 00:00:00 GMT","studyStartDate":"Wed, 24 Jun 2020 00:00:00 GMT","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"No","brandName":"AndroCoV","chemicalName":"dutasteride","conditionOrDisease":"COVID-19","contact":[{"email":"f.cadegiani@gmail.com","name":null,"notes":"Not yet recruiting; male; 50 years or older; SARS Cov 2 positive but not hospitalized; informed consent","phone":"5561996506111","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 26 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"AndroCoV is an experimental trial utilizing 3 drugs - dutasteride-ivermectin-azithromycine,dutasteride is FDA approved to treat enlarged prostate,no specific trial phase announced but description resembles phase 2","numSites":"1","otherPartners":"","phase":"2","preferredName":"dutasteride","primaryCompletionDate":"","productId":579,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04446429","repurposed":"Repurposed-Approved","siteLocations":[{"city":null,"country":"BRA","lat":-15.8226564,"lng":-47.92831349999999,"locationId":"8850c28b51940f79e0c3da075a7f50c82bede846","name":"Corpometria Institute","state":"DF"}],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.businesswire.com/news/home/20200624005871/en/Applied-Biology-Collaboration-Brown-University-Researchers-Corpometria","https://clinicaltrials.gov/ct2/show/NCT04446429"],"sponsors":[{"sponsorId":"30a0bfe60f04ff11e51d1901a52fbea2c76f2b5d","sponsorName":"Applied Biology Inc"}],"status":"Ongoing","studyCompletionDate":"Sun, 31 Jan 2021 00:00:00 GMT","studyStartDate":"Fri, 26 Jun 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Eritoran","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"","interventionType":"Therapeutic","milestones":[],"moleculeType":"","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Eritoran","primaryCompletionDate":"","productId":580,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"],"sponsors":[{"sponsorId":"9014154541489159d60a164cdba2053774a7660f","sponsorName":"Eisai"}],"status":"","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"GX-19","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"yoonjeong.choi@genexine.com","name":null,"notes":"","phone":"82-31-628-3233","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 17 Jun 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"1","otherPartners":"","phase":"1","preferredName":"GX-19","primaryCompletionDate":"Wed, 17 Mar 2021 00:00:00 GMT","productId":581,"registryLink":"https://www.clinicaltrials.gov/ct2/show/NCT04445389","repurposed":"New","siteLocations":[{"city":null,"country":"KOR","lat":37.5623371,"lng":126.9408692,"locationId":"abe8bd817bf89c78a93b9933d0250a2fc1d0d352","name":"Severance Hospital","state":"Seoul"}],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.clinicaltrials.gov/ct2/show/NCT04445389","https://www.genengnews.com/covid-19-candidates/genexine-gx-19/"],"sponsors":[{"sponsorId":"5d9f7ffbf60a4d4017b42d8cdf7353cf0a4fe9e1","sponsorName":"Genexine Consortium"},{"sponsorId":"92ea2b8d0437f2a5d21b14d54802dcf2c2104c66","sponsorName":"GenNBio"},{"sponsorId":"ff047f0d6e9a5c4ac743aa16ce68aa6bcc915b64","sponsorName":"International Vaccine Institute"},{"sponsorId":"53374e83cc0c8a0628e5295c9c2adac4bcf36d58","sponsorName":"KAIST"},{"sponsorId":"9c5e4f465201422aa36c55b75e18717ad929bda9","sponsorName":"POSTECH"},{"sponsorId":"c3990da1fa59778f19060e57f09b0c9d42a018e5","sponsorName":"Binex"}],"status":"Ongoing","studyCompletionDate":"Fri, 17 Jun 2022 00:00:00 GMT","studyStartDate":"Wed, 17 Jun 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"DNA with electroporation","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Thailand"],"countryCodes":["THA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Tue, 26 May 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"Human trials planned for October.","numSites":"","otherPartners":"","phase":"","preferredName":"DNA with electroporation","primaryCompletionDate":"","productId":582,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.chula.ac.th/en/clipping/31103/"],"sponsors":[{"sponsorId":"e21faaa59cbe02fdff806f375f68495cc6e16e25","sponsorName":"Chula Vaccine Research Center"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"DNA plasmid vaccine S,S1,S2,RBD & N","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Egypt"],"countryCodes":["EGY"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"DNA plasmid vaccine S,S1,S2,RBD & N","primaryCompletionDate":"","productId":583,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"],"sponsors":[{"sponsorId":"1212b57ee9ead30a43480c416ee4aea43b78bf38","sponsorName":"National Research Centre"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"MV-014-210","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Tue, 30 Jun 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":"Tue, 30 Jun 2020 00:00:00 GMT","milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":"Tue, 30 Jun 2020 00:00:00 GMT","milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Tue, 30 Jun 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Whole-pathogen vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"MV-014-210","primaryCompletionDate":"","productId":584,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.meissavaccines.com/blog/meissa-vaccines-provides-a-pipeline-update-on-vaccine-candidatesfor-covid-19-and-rsv"],"sponsors":[{"sponsorId":"e1f0e57b91f2b40d3988d49377f0952d32b1bef2","sponsorName":"Meissa Vaccines"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"MVA-S","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Spain"],"countryCodes":["ESP"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"","otherPartners":"GeoVax/BravoVax","phase":"","preferredName":"MVA-S","primaryCompletionDate":"","productId":585,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.geovax.com/news/geovax-provides-update-on-coronavirus-covid-19-vaccine-development-program"],"sponsors":[{"sponsorId":"f46b68e943e93a62cdc8c93a4106f50eed6e636e","sponsorName":"IDIBAPS Hospital Clinic"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"AAVCOVID","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Thu, 14 May 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"AAVCOVID","primaryCompletionDate":"","productId":586,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.aao.org/eye-health/news/coronavirus-covid-vaccine-gene-therapy-luxturna"],"sponsors":[{"sponsorId":"724865bfbd0f66eb957dfad8bf5f581e6fa9602e","sponsorName":"Grousbeck Gene Therapy"},{"sponsorId":"5793c63ebb6b37c9aa97b85cc7021dfdca0d829c","sponsorName":"AveXis"},{"sponsorId":"913ccc1e99bd5cc53f8d0a15d443dc8f56dda47a","sponsorName":"Viralgen"},{"sponsorId":"42794122ad2e94771c0a0338770ff57f42a60112","sponsorName":"Aldevron"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Gam-COVID-Vac Lyo","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"COMPLETED","phone":"","website":""}],"countries":["Russian Federation"],"countryCodes":["RUS"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 17 Jun 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 17 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Gam-COVID-Vac Lyo","primaryCompletionDate":"","productId":587,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://clinicaltrials.gov/ct2/show/NCT04437875","https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://clinicaltrials.gov/ct2/show/NCT04436471"],"sponsors":[{"sponsorId":"8f805fbe6d3cf20118840cac06573229c25e36f4","sponsorName":"Gamaleya Research Institute"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Influenza A H1N1 vector","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Egypt"],"countryCodes":["EGY"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Whole-pathogen vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Influenza A H1N1 vector","primaryCompletionDate":"","productId":588,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z"],"sponsors":[{"sponsorId":"1212b57ee9ead30a43480c416ee4aea43b78bf38","sponsorName":"National Research Centre"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Structurally modified spherical particles of the tobacco mosaic virus (TMV)","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Russian Federation"],"countryCodes":["RUS"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Structurally modified spherical particles of the tobacco mosaic virus (TMV)","primaryCompletionDate":"","productId":589,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"],"sponsors":[{"sponsorId":"172ecd90dfdb7af014ad7f2054b1fbef2c9c5302","sponsorName":"Lomonosov Moscow State University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"RBD protein fused with Fc of IgG + Adjuvant","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Thailand"],"countryCodes":["THA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"RBD protein fused with Fc of IgG + Adjuvant","primaryCompletionDate":"","productId":590,"registryLink":null,"repurposed":"","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"],"sponsors":[{"sponsorId":"a16c5b03cf3aca5c2f20169b4caa909d5c2f07ad","sponsorName":"Chulalongkorn University"},{"sponsorId":"3d073bdf33aac8137319358450ceb3f373467fed","sponsorName":"GPO"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Targeted (Langerhans cell specific) protein subunit","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Germany"],"countryCodes":["DEU"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Vaccine-delivery technique using Langerhans cells","numSites":"","otherPartners":"KHAN-I","phase":"","preferredName":"Targeted (Langerhans cell specific) protein subunit","primaryCompletionDate":"","productId":591,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.mpg.de/14807464/0511-mpin-116799-corona-vaccination-via-the-skin","https://www.mpg.de/en"],"sponsors":[{"sponsorId":"ca87c56cfc7bc3d6a4ca4eee62fa5d404dae1d8e","sponsorName":"MaxPlanck Institute of Colloids and Interfaces"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"NA-831","chemicalName":"atazanavir,dexamethasone","conditionOrDisease":"COVID-19","contact":[{"email":"BTran@neuroactiva.com; FKennedy@neuroactiva.com","name":null,"notes":"","phone":"14159413133; 14159413133","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 15 Aug 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Combination","notes":"Anti-retroviral and anti-inflammatory combination therapy","numSites":"31","otherPartners":"NeuroActiva Inc.","phase":"2","preferredName":"atazanavir,dexamethasone","primaryCompletionDate":"","productId":607,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04452565","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Los Angeles","country":"USA","lat":34.070264,"lng":-118.4440562,"locationId":"4a73ed233003f12bb70ff9cf39b08320543d5931","name":"Coronavirus Research Institute","state":"CA"},{"city":"Orange","country":"USA","lat":33.787596,"lng":-117.863124,"locationId":"dd1535be5da5e75c0a5ef9f7e63f907cf3cbe774","name":"Coronavirus Research Institute","state":"CA"},{"city":"Palo Alto","country":"USA","lat":37.3813444,"lng":-122.1802812,"locationId":"eeae690eefe87560fe24c2788dcb78d8bb9d95dc","name":"Coronavirus Research Institute","state":"CA"},{"city":"Sacramento","country":"USA","lat":38.5500434,"lng":-121.4599012,"locationId":"f52f71fecc496d8f44a0abf47562976955c5f171","name":"Coronavirus Research Institute","state":"CA"},{"city":"San Diego","country":"USA","lat":32.715738,"lng":-117.1610838,"locationId":"fcdf7f1a7632a03b6662fd3d16464d1c7bb7f7e4","name":"Coronavirus Research Institute","state":"CA"},{"city":"SF","country":"USA","lat":37.7485824,"lng":-122.4184108,"locationId":"2efea7cdd5c7492c2b6f4203a906aaed71290daa","name":"Coronavirus Research Testing Site","state":"CA"},{"city":"Sunnyvale","country":"USA","lat":37.371859,"lng":-122.0212337,"locationId":"a1fc0bf720ff43331958c2cc622ea9a2a78faf4a","name":"Coronavirus Research Institute","state":"CA"},{"city":"Washington","country":"USA","lat":38.9156487,"lng":-77.0737149,"locationId":"9d86278601953addc80c4f1f5feb92d9122bf91a","name":"Coronavirus Research Institute","state":"DC"},{"city":"Washington","country":"USA","lat":38.9339046,"lng":-77.03053899999999,"locationId":"c50546839c8340fb5a57df9a804409e92a33f9f0","name":"Coronavirus Research Institute","state":"DC"},{"city":"LAUD BY SEA","country":"USA","lat":26.1897731,"lng":-80.1037721,"locationId":"7c77b7e4a511eb1fbf664886061dafd516536de6","name":"Coronavirus Research Institute","state":"FL"},{"city":"Tampa","country":"USA","lat":28.0634666,"lng":-82.4129729,"locationId":"2360fb399e57cee2df3e990d369f29e61c7a2d1b","name":"Coronavirus Research Institute","state":"FL"},{"city":"Chicago","country":"USA","lat":41.8816606,"lng":-87.6926257,"locationId":"3a7e17dd22537b5f89a4fc9c238336521a2a8ff9","name":"Coronavirus Research Institute","state":"IL"},{"city":"Naperville","country":"USA","lat":41.7606321,"lng":-88.1437782,"locationId":"4db628998f4498d4689b1cabbf39e1a894aeae6e","name":"Coronavirus Research Institute","state":"IL"},{"city":"Baltimore","country":"USA","lat":39.2962372,"lng":-76.5928888,"locationId":"7be5f43674ca42821b5ab3fd1e4941dda01e7cf7","name":"Coronavirus Research Institute","state":"MD"},{"city":"Bethesda","country":"USA","lat":39.0023604,"lng":-77.097455,"locationId":"a11d98b9ef3c103729ce9128248a5020b08cae1c","name":"Coronavirus Research Institute","state":"MD"},{"city":"Boston","country":"USA","lat":42.3652917,"lng":-71.0646337,"locationId":"89ec17703ab34b1c10298627d35f4763ef3cb100","name":"Coronavirus Research Institute","state":"MA"},{"city":"Worcester","country":"USA","lat":42.27174429999999,"lng":-71.7588217,"locationId":"101593168dae76772416f59c02789d40f9c4ecec","name":"Coronavirus Research Institute","state":"MA"},{"city":"Ann Arbor","country":"USA","lat":42.2985182,"lng":-83.7019401,"locationId":"20be968064f2451e2e95d28c7a79caac6fa9e5ce","name":"Coronavirus Research Institute","state":"MI"},{"city":"Detroit","country":"USA","lat":42.3664506,"lng":-83.0737195,"locationId":"b83aaa31a927ce2244eedba591f6ca484a5269a1","name":"Coronavirus Research Institute","state":"MI"},{"city":"Newark","country":"USA","lat":40.7350747,"lng":-74.17390569999999,"locationId":"826916c58504be12a31e4f2bb80408b2b1524bf1","name":"Coronavirus Research Institute","state":"NJ"},{"city":null,"country":"USA","lat":40.8723987,"lng":-73.8713099,"locationId":"120920144d67f0efbb8c2f76927e2d777b057f1f","name":"Coronavirus Research Institute","state":"NY"},{"city":"New York","country":"USA","lat":40.74727,"lng":-73.9800645,"locationId":"e45a33a8fe467705bef8e2a0951e14cd3fe8dfc1","name":"Coronavirus Research Institute","state":"NY"},{"city":"Rochester","country":"USA","lat":43.12247660000001,"lng":-77.62425739999999,"locationId":"d250c9321b815010b2b2902d835b3f6f7422c1b5","name":"Coronavirus Research Institute","state":"NY"},{"city":"Durham","country":"USA","lat":36.0323222,"lng":-78.8269385,"locationId":"4b205a8b43d4ba598dec3eb9583125273b58dbb6","name":"Coronavirus Research Institute","state":"NC"},{"city":"Philadelphia","country":"USA","lat":39.9583587,"lng":-75.1953934,"locationId":"f52fc5fe17f534da8d1210eda8716647ac757303","name":"Coronavirus Research Institute","state":"PA"},{"city":"San Antonio","country":"USA","lat":29.4569597,"lng":-98.4458421,"locationId":"2edadeaf6bcfd07805ccfb2ad5b282f02385cbad","name":"Coronavirus Research Institute","state":"TX"},{"city":"Galveston","country":"USA","lat":29.3106102,"lng":-94.77724930000001,"locationId":"b7e0a2e2356026c6d03d99854a194315e69d3ae5","name":"Coronavirus Research Institute","state":"TX"},{"city":"Houston","country":"USA","lat":29.7050857,"lng":-95.40180869999999,"locationId":"bd3a621fdef13f991576eb6666ae407c80e072e4","name":"Coronavirus Research Institute","state":"TX"},{"city":"Kirkland","country":"USA","lat":47.71481259999999,"lng":-122.2031264,"locationId":"29e9cab2c89070c4b1f409197547f48e59ab767d","name":"Coronavirus Research Institute","state":"WA"},{"city":"Seattle","country":"USA","lat":47.6015566,"lng":-122.3323351,"locationId":"a2300ae8a36635b62564f608c4255ccfd881fee7","name":"Coronavirus Research Institute","state":"WA"},{"city":"MADIGAN HOSP","country":"USA","lat":47.11040999999999,"lng":-122.5512299,"locationId":"f56ad859244c885c0b04bee1e6314f869b9472f1","name":"Coronavirus Research Institute","state":"WA"}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04452565"],"sponsors":[{"sponsorId":"322b1011c1d5b362545e86fc92bc54bfd5be2aa9","sponsorName":"Neuroactiva Inc"}],"status":"Ongoing","studyCompletionDate":"Sat, 15 Feb 2020 00:00:00 GMT","studyStartDate":"Sat, 15 Aug 2020 00:00:00 GMT","therapeuticApproach":"Combination","trialId":""},{"acceptsHealthySubjects":"","brandName":"Plant-based subunit (RBD-Fc + Adjuvant)","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Thailand"],"countryCodes":["THA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Plant-based subunit (RBD-Fc + Adjuvant)","primaryCompletionDate":"","productId":592,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines","https://baiyaphytopharm.com/wp-content/uploads/2020/07/RBD-Data-sheet-.pdf"],"sponsors":[{"sponsorId":"5514dab962f84d4adc4e93787ec5d00d3be66545","sponsorName":"Baiya Phytopharm"},{"sponsorId":"e21faaa59cbe02fdff806f375f68495cc6e16e25","sponsorName":"Chula Vaccine Research Center"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Subunit","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Nigeria"],"countryCodes":["NGA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Subunit","primaryCompletionDate":"","productId":593,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.today.ng/news/nigeria/nigerian-universities-scientists-vaccine-coronavirus-prevention-302420","https://www.von.gov.ng/covid-19-nigerian-scientists-develop-vaccines/"],"sponsors":[{"sponsorId":"63bb1c3d46177bd2f5b93e35800302face1bfb45","sponsorName":"Helix Biogen Consult"},{"sponsorId":"2e23b3149c032f51b36fccefbfba3b69bf7d08e8","sponsorName":"Ogbomoso  Trinity Immonoefficient Laboratory"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"","brandName":"VSV-S","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Israel"],"countryCodes":["ISR"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Other","notes":"VSV virus is a virus that doesn't cause diseases in humans,will be used to form antibodies against COVID","numSites":"","otherPartners":"","phase":"","preferredName":"VSV-S","primaryCompletionDate":"","productId":594,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://nocamels.com/2020/06/israeli-covid-19-vaccine-effective-animal-trial/","https://www.biorxiv.org/content/10.1101/2020.06.18.160655v1.full","https://www.jpost.com/health-science/iibr-coronavirus-vaccine-found-to-work-in-hamsters-632179","https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"],"sponsors":[{"sponsorId":"7b216642104c590a170581ca3077e7e78905d4b1","sponsorName":"Israel Institute for Biological Research"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"mRNA","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Spain"],"countryCodes":["ESP"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"mRNA","primaryCompletionDate":"","productId":595,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.thisistherealspain.com/en/latest-news/spain-10-covid-19-vaccine-projects/"],"sponsors":[{"sponsorId":"f46b68e943e93a62cdc8c93a4106f50eed6e636e","sponsorName":"IDIBAPS Hospital Clinic"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"mRNA in targeted LPNs (Langerhans cell specific)","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Germany"],"countryCodes":["DEU"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"KHAN-I","phase":"","preferredName":"mRNA in targeted LPNs (Langerhans cell specific)","primaryCompletionDate":"","productId":596,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.mpikg.mpg.de/6306915/news_publication_14807464_transferred?c=132305"],"sponsors":[{"sponsorId":"6a5c9de97b0c649b78e8f2e5bc3e4bf47383b2af","sponsorName":"Max Planck Institute of Colloids and Interfaces"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"Virus-like particles,lentivirus,and baculovirus vehicles","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Spain"],"countryCodes":["ESP"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Virus-like particles,lentivirus,and baculovirus vehicles","primaryCompletionDate":"","productId":597,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines","https://www.navarrabiomed.es/en/navarrabiomed/conocenos"],"sponsors":[{"sponsorId":"cb0fbb316dd2dcb8ed548d5effd8fe9692992576","sponsorName":"Navarrabiomed"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"expected to undergo human trials in summer 2020","numSites":"","otherPartners":"","phase":"","preferredName":"Multitope Peptide-based Vaccine","primaryCompletionDate":"","productId":598,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z","https://www.covaxx.com/","https://www.covaxx.com/vaccine"],"sponsors":[{"sponsorId":"be8691003b7f44ea5a31017727a29311b9804c9e","sponsorName":"Covaxx"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"DMX-200","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Pre-Clinical Testing","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"DMX-200","primaryCompletionDate":"","productId":599,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.bioworld.com/articles/435569-dimerixs-lead-candidate-to-enter-global-remap-cap-trial-to-treat-covid-19-ards","https://adisinsight.springer.com/drugs/800041842","https://www.mdmag.com/medical-news/update-dmx200-treatment-focal-segmental-sclerosis#:~:text=Packham%3A%20DMX%2D200%20is%20a","chemokine%20receptor%20blocker%20(CCR2).","https://dimerix.com/products/"],"sponsors":[{"sponsorId":"9009c03f5ebbf1b6351bfcff0f15b20c3d063ea4","sponsorName":"Dimerix Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Combination","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Bivalirudin","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"mlance@hamad.qa","name":null,"notes":"","phone":"00974 ext 33530292","website":""}],"countries":["Qatar"],"countryCodes":["QAT"],"currentStage":"Phase 4","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"type of anticoagulant","numSites":"1","otherPartners":"","phase":"4","preferredName":"Bivalirudin","primaryCompletionDate":"Mon, 28 Sep 2020 00:00:00 GMT","productId":600,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04445935","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Doha","country":"QAT","lat":25.2851562,"lng":51.5417265,"locationId":"344a6d06d1276d6fd2fc7829026e390875ae2100","name":"Hamad Medical Corporation","state":"Doha"}],"sources":["https://www.bioworld.com/COVID19products","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315936/","https://www.marketwatch.com/press-release/impact-analysis-of-covid-19-on-bivalirudin-and-desmopressin-market-future-forecast-2017-2024-by-global-key-players-size-share-trends-revenue-analysis-and-future-growth-analysis-2020-05-18?tesla=y","https://www.facs.org/-/media/files/covid19/umiami_study_uses_of_coagulopathy.ashx","https://www.hamad.qa/EN/Pages/default.aspx","https://clinicaltrials.gov/ct2/show/NCT04445935"],"sponsors":[{"sponsorId":"c541605ff178d2aa4073412dd96a05c336a1d99e","sponsorName":"Hamad Medical Corp"}],"status":"Ongoing","studyCompletionDate":"Sun, 28 Mar 2021 00:00:00 GMT","studyStartDate":"Sun, 28 Jun 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Tacrolimus","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"xsolanich@bellvitgehospital.cat","name":null,"notes":"","phone":"0034 932607500 ext 8946","website":""}],"countries":["Spain"],"countryCodes":["ESP"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"3","preferredName":"Tacrolimus","primaryCompletionDate":"Mon, 01 Jun 2020 00:00:00 GMT","productId":601,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04341038","repurposed":"Repurposed-Approved","siteLocations":[{"city":"L'Hospitalet de Llobregat","country":"ESP","lat":41.3448959,"lng":2.1042573,"locationId":"51cd51eed924a87c9ace1636dec15d16f473ec05","name":"Hospital Universitari De Bellvitge","state":"CT"}],"sources":["https://www.bioworld.com/COVID19products","https://laegemiddelstyrelsen.dk/da/nyheder/temaer/ny-coronavirus-covid-19/~/media/5B83D25935DF43A38FF823E24604AC36.ashx","https://www.drugbank.ca/drugs/DB00864","https://clinicaltrials.gov/ct2/show/NCT04341038"],"sponsors":[{"sponsorId":"6645ceaca15d1553ce17cc0dc6274a85ed816b86","sponsorName":"Hospital Universitari de Bellvitge"}],"status":"Ongoing","studyCompletionDate":"Wed, 01 Jul 2020 00:00:00 GMT","studyStartDate":"Wed, 01 Apr 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"BACTEK-R (MV130)","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"gangeles@gmail.com;mcasanovas@inmunotek.com","name":null,"notes":"","phone":"18299472222","website":""}],"countries":["Spain"],"countryCodes":["ESP"],"currentStage":"Phase 3","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome","numSites":"1","otherPartners":"","phase":"3","preferredName":"BACTEK-R (MV130)","primaryCompletionDate":"Thu, 01 Jul 2021 00:00:00 GMT","productId":602,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04363814","repurposed":"","siteLocations":[{"city":"Stgo","country":"DOM","lat":19.4361409,"lng":-70.6610997,"locationId":"71e98b83b8749f9f67767163f1e17a0bbed575db","name":"Hospital Metropolitano Santiago","state":"Santiago"}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04363814","https://www.inmunotek.com/en/022011-bactek-study/"],"sponsors":[{"sponsorId":"a079e72ac22bb802b456578240fd4b30b55b76bd","sponsorName":"Inmunotek SL"},{"sponsorId":"ba2f1de3e34ade67f95b6cbe61851e8b40a2b841","sponsorName":"Bioclever 2005 SL"}],"status":"Ongoing","studyCompletionDate":"Sat, 31 Jul 2021 00:00:00 GMT","studyStartDate":"Wed, 10 Jun 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Doxycycline","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"eve.maubec@aphp.fr; fabrice.bonnet@chu-bordeaux.fr; dompmartin-a@chu-caen.fr; lionel.piroth@chu-dijon.fr; mtleccia@chu-grenoble.fr; brigitte.dreno@atlanmed.fr; amir.khammari@chu-nantes.fr","name":null,"notes":"Not yet recruiting","phone":"1 48 95 70 90 ext 0033;  5 56 79 58 23 ext 0033; 2 31 27 25 10 ext 0033; 3 30 29 33 05 ext 0033; 476769320 ext 0033; 2 40 08 31 18 ext 0033","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"6","otherPartners":"","phase":"3","preferredName":"Doxycycline","primaryCompletionDate":"","productId":603,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04371952","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Bobigny","country":"FRA","lat":48.91461940000001,"lng":2.4239471,"locationId":"6255bf85824f769866d34c5b20946afa9ecc6964","name":"Chu Avicenne","state":"IDF"},{"city":"Bordeaux","country":"FRA","lat":44.8274249,"lng":-0.6043875,"locationId":"c792b648fcb66911a129d167bc31d446af227111","name":"Chu Bordeaux","state":"Nouvelle-Aquitaine"},{"city":"Caen","country":"FRA","lat":49.19005019999999,"lng":-0.3443813000000001,"locationId":"3b641ee8dec663869b8dd913f52f18b3296251b1","name":"Chu Caen","state":"Normandie"},{"city":"Dijon","country":"FRA","lat":47.3213803,"lng":5.069147099999999,"locationId":"3c3e1988063ef01f88caa5b694da53393827cb82","name":"Chu Dijon","state":"Bourgogne-Franche-Comt\u00e9"},{"city":"\u00c9chirolles","country":"FRA","lat":45.148338,"lng":5.732526399999999,"locationId":"4d713039d5cf9e9c73bec991823ee30a83cbb5b6","name":"Chu Grenoble","state":"Auvergne-Rh\u00f4ne-Alpes"},{"city":"Nantes","country":"FRA","lat":47.2120313,"lng":-1.5543918,"locationId":"f3bbd0a62cc596dca68b04e4d1184f18fc0c3296","name":"Chu Nantes","state":"Pays de la Loire"}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04371952","https://www.drugbank.ca/drugs/DB00864"],"sponsors":[{"sponsorId":"e0899b75679b87aa721de05cfe789eaf7a84d54a","sponsorName":"Nantes University Hospital"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 01 Jun 2020 00:00:00 GMT","therapeuticApproach":"Antibiotics and antiparasitics","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Sarconeos (BIO-101)","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"sam.agus@biophytis.com","name":null,"notes":"","phone":"16176424891","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Thu, 02 Jul 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Potential treatment for respiratory failure associated with Covid-19.","numSites":"1","otherPartners":"Biophytis SA","phase":"2","preferredName":"Sarconeos (BIO-101)","primaryCompletionDate":"Thu, 01 Jul 2021 00:00:00 GMT","productId":604,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Mechelen","country":"BEL","lat":51.0514471,"lng":4.475779699999999,"locationId":"d58ff03e5574102e64b5e3f245e3fcb18cba8c93","name":"Az","state":"Vlaanderen"}],"sources":["https://www.bioworld.com/COVID19products","https://www.biophytis.com/wp-content/uploads/2020/04/Biophytis-COVA-Launch-EN-PR.pdf","https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1","https://www.biospace.com/article/releases/biophytis-receives-fda-ind-clearance-for-cova-a-phase-2-3-clinical-trial-with-sarconeos-bio101-for-the-treatment-of-patients-with-covid-19-related-respiratory-failure/"],"sponsors":[{"sponsorId":"b7349cea33d3083bc02d13c4b387b855d6b808c1","sponsorName":"Biophytis SA"}],"status":"Ongoing","studyCompletionDate":"Wed, 01 Sep 2021 00:00:00 GMT","studyStartDate":"Tue, 16 Jun 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"","chemicalName":"sofosbuvir,daclatasvir,hydroxychloroquine","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"Not yet recruiting","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Combination","notes":"","numSites":"","otherPartners":"Sovaldi - Gilead Sciences,Daklinza - Bristol-Myers Squibb,Plaquenil - Sanofi Pharmaceuticals","phase":"2","preferredName":"sofosbuvir,daclatasvir,hydroxychloroquine","primaryCompletionDate":"Sat, 10 Oct 2020 00:00:00 GMT","productId":605,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04443725","repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.healio.com/news/infectious-disease/20200709/hcv-drugs-sofosbuvir-daclatasvir-show-promise-as-potential-covid19-treatment","https://www.medscape.com/viewarticle/933822","https://clinicaltrials.gov/ct2/show/NCT04443725"],"sponsors":[{"sponsorId":"a0e9f9902283ff153eeb6aeece1a1ac40ecb7c10","sponsorName":"Cairo University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Fri, 10 Jul 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Epoprostenol (Ventoprost)","chemicalName":"epoprostenol","conditionOrDisease":"COVID-19","contact":[{"email":"judydoto@aerogenpharma.com","name":null,"notes":"Not yet Recruiting","phone":"4847165438","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation.","numSites":"1","otherPartners":"","phase":"2","preferredName":"epoprostenol","primaryCompletionDate":"","productId":608,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Columbus","country":"USA","lat":39.9994009,"lng":-83.01264669999999,"locationId":"85ee6bc58d83f023ad55ebbd8bc52b22e49de795","name":"Ohio State University","state":"OH"}],"sources":["https://www.bioworld.com/COVID19products","https://www.acc.org/latest-in-cardiology/articles/2020/05/13/08/55/inpatient-use-of-inhaled-pulmonary-vasodilator-therapy-in-patients-infected-with-covid-19","https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1"],"sponsors":[{"sponsorId":"bc9e5eca997a144be366f4d6e88ea283e30a3403","sponsorName":"Aerogen Pharma Ltd"}],"status":"Ongoing","studyCompletionDate":"Mon, 01 Feb 2021 00:00:00 GMT","studyStartDate":"Fri, 31 Jul 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"razuprotafib","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"Razuprotafib blocks vascular endothelial protein tyrosine phosphatase,or VE-PTP,that depresses production of Tie2 receptor proteins. Tie2 proteins are receptors on the surface of cells that bind to angiopoietins,which are protein growth factors needed to form blood vessels; Thus,razuprotafib activates Tie2 receptor proteins,allowing for stable blood vessel formation in affected tissue in the eyes and kidneys,which the company is testing in mid-stage clinical trials. Aerpio says it has preclinical evidence showing the drug\u2019s beneficial effects extend to a number of disease states including ARDS resulting from Covid-19 infections.","numSites":"","otherPartners":"Aerpio Pharmaceuticals Inc,Quantum Leap","phase":"","preferredName":"razuprotafib","primaryCompletionDate":"","productId":609,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://sciencebusiness.technewslit.com/?p=39191","https://www.globenewswire.com/news-release/2020/05/27/2039771/0/en/Aerpio-Pharmaceuticals-Inc-and-Quantum-Leap-Healthcare-Collaborative-Announce-the-Selection-of-Razuprotafib-for-Evaluation-in-the-I-SPY-COVID-Trial-for-the-Treatment-of-Acute-Respi.html"],"sponsors":[{"sponsorId":"47c603698fd74b018b030979d7596f25a7f9a102","sponsorName":"Aerpio Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"LAM-002A","chemicalName":"apilimod","conditionOrDisease":"COVID-19","contact":[{"email":"pyoung@ai-thera.com","name":null,"notes":"","phone":"4158608370","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 15 Jul 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"AI Therapeutics Inc.","phase":"2","preferredName":"apilimod","primaryCompletionDate":"","productId":610,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04446377","repurposed":"Repurposed-Approved","siteLocations":[{"city":"New Haven","country":"USA","lat":41.3163244,"lng":-72.92234309999999,"locationId":"c2f99eea5e89c81eddf9db10569557f91536dbc6","name":"Yale University","state":"CT"}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04446377#contacts","https://adisinsight.springer.com/drugs/800043703"],"sponsors":[{"sponsorId":"eec7529f9327cfeb8fa0e547aa52d04796843327","sponsorName":"AI Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"Sun, 31 Jan 2021 00:00:00 GMT","studyStartDate":"Wed, 15 Jul 2020 00:00:00 GMT","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"No","brandName":"DUR-928","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"deborah.scott@durect.com ; julie.fergus@durect.com        ","name":null,"notes":"","phone":"4087771417","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"3","otherPartners":"","phase":"2","preferredName":"DUR-928","primaryCompletionDate":"Wed, 01 Sep 2021 00:00:00 GMT","productId":611,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04447404","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Chicago","country":"USA","lat":41.8781136,"lng":-87.6297982,"locationId":"63dd9231ec6c667699b64f5bb2d671f5f026d59f","name":"Chicago","state":"IL"},{"city":"Detroit","country":"USA","lat":42.331427,"lng":-83.0457538,"locationId":"ca8bd7a6ad38488dc3aa49896ef7786ba6df1ebc","name":"Detroit","state":"MI"},{"city":"Newark","country":"USA","lat":40.735657,"lng":-74.1723667,"locationId":"c1342fa58e6aa5860d159c6d987a718ab419d598","name":"Newark","state":"NJ"}],"sources":["https://www.bioworld.com/COVID19products","http://www.durect.com/dur-928/overview/","https://www.biospace.com/article/releases/durect-corporation-announces-initiation-of-patient-recruitment-in-phase-2-safety-and-efficacy-study-of-dur-928-in-covid-19-patients-with-acute-liver-or-kidney-injury/","https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4","https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=5","https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=6","https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=7","https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=8","https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=9","https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=10"],"sponsors":[{"sponsorId":"16d4dbeba3798fe50eefb54803d0a296bb9520ed","sponsorName":"Durect Corp"}],"status":"Ongoing","studyCompletionDate":"Fri, 01 Oct 2021 00:00:00 GMT","studyStartDate":"Mon, 21 Sep 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Tecfarin","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Currently in phase 3 for treating patients with End Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib)","numSites":"","otherPartners":"","phase":"","preferredName":"Tecfarin","primaryCompletionDate":"","productId":612,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://esperobio.com/espero-biopharma-inc-expands-collaboration-effort-for-tecarfarin/","https://esperobio.com/"],"sponsors":[{"sponsorId":"3a9d2099cfa8e9dee05c02576fe34151aa3a054d","sponsorName":"Espero Biopharma Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Interleukin-2","chemicalName":"ILT101","conditionOrDisease":"COVID-19","contact":[{"email":"Jean-michel.constantin@aphp.fr","name":null,"notes":"","phone":"3301421600","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"1","otherPartners":"Assistance Publique - H\u00f4pitaux de Paris","phase":"2","preferredName":"ILT101","primaryCompletionDate":"Wed, 01 Jul 2020 00:00:00 GMT","productId":613,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04357444","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Paris","country":"FRA","lat":48.856614,"lng":2.3522219,"locationId":"9e72777cb00052979f052c055c136aada5384aa9","name":"Paris","state":"IDF"}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04357444#contacts"],"sponsors":[{"sponsorId":"ccb2d316b0239e5a9b916549c4ebc0cc32112aa4","sponsorName":"ILTOO Pharma"}],"status":"Ongoing","studyCompletionDate":"Sat, 01 Aug 2020 00:00:00 GMT","studyStartDate":"Mon, 01 Jun 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Nangibotide","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"covtrem@inotrem.com","name":null,"notes":"","phone":"","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"Nangibotide","primaryCompletionDate":"Mon, 01 Mar 2021 00:00:00 GMT","productId":614,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04429334","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Nancy","country":"FRA","lat":48.68406419999999,"lng":6.1893877,"locationId":"a5ddf67735380520cf0923cd710cc7c8f4a5502a","name":"R\u00e9animation M\u00e9dicale H\u00f4pital Central","state":"Grand Est"}],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"704022b5f19f6408d4c855cfdc7fd3bb952dc2bf","sponsorName":"Inotrem"}],"status":"Ongoing","studyCompletionDate":"Mon, 01 Mar 2021 00:00:00 GMT","studyStartDate":"Tue, 01 Jun 2021 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"Inhibitor of Neutrophil Elastase,Isotretinoin","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"\tmahmoudramadan2051@yahoo.com","name":null,"notes":"","phone":"","website":""}],"countries":["Egypt"],"countryCodes":["EGY"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Combination","notes":"","numSites":"","otherPartners":"Damietta University","phase":"2","preferredName":"Inhibitor of Neutrophil Elastase,Isotretinoin","primaryCompletionDate":"Thu, 01 Oct 2020 00:00:00 GMT","productId":615,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04396067","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":null,"country":"EGY","lat":26.820553,"lng":30.802498,"locationId":"494e6d7f907b024e7cf387d70957d1687d32e5f5","name":"Egypt","state":null}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04396067#contacts"],"sponsors":[{"sponsorId":"fd151515ae478f71dd5fdce169d883577fa21257","sponsorName":"Kafrelsheikh University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Thu, 01 Oct 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Secukinumab","chemicalName":"Cosentyx","conditionOrDisease":"COVID-19","contact":[{"email":"begrambekova@ossn.ru ; yaorlova@mc.msu.ru","name":null,"notes":"","phone":"79854679273 ; 791651663002","website":""}],"countries":["Russian Federation"],"countryCodes":["RUS"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 08 May 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Combination","notes":"Study compares COLchicine Versus Ruxolitinib and Secukinumab","numSites":"1","otherPartners":"","phase":"2","preferredName":"Cosentyx","primaryCompletionDate":"","productId":616,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04403243","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Moscow","country":"RUS","lat":55.755826,"lng":37.6172999,"locationId":"6793e9e3f395ab79b62d8ac69f94f0e1a2280f58","name":"Moscow","state":null}],"sources":["https://www.cosentyx.com/","https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04403243#contacts"],"sponsors":[{"sponsorId":"0dbbfcca49ab1d748bc20572875508a44075ee0a","sponsorName":"Lomonosov Moscow State University Medical Research and Education Center"}],"status":"Ongoing","studyCompletionDate":"Sun, 23 Aug 2020 00:00:00 GMT","studyStartDate":"Fri, 08 May 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Rayaldee","chemicalName":"calcifediol","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Despite information that a phase 2 trial is happening,no information on clinical trials.com","numSites":"","otherPartners":"","phase":"2","preferredName":"calcifediol","primaryCompletionDate":"","productId":617,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.opko.com/news-media/press-releases/detail/394/fda-authorizes-opko-health-clinical-trial-evaluating","https://www.drugbank.ca/drugs/DB00146","https://www.drugbank.ca/drugs/DB00147","https://www.biospace.com/article/releases/fda-authorizes-opko-health-clinical-trial-evaluating-rayaldee-in-covid-19-patients/"],"sponsors":[{"sponsorId":"88c1753face32faae228509118d1afebd9cb9e06","sponsorName":"Opko Health Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"AMY-101","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 01 Jul 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"is a C3 inhibitor","numSites":"","otherPartners":"","phase":"2","preferredName":"AMY-101","primaryCompletionDate":"Fri, 01 Jan 2021 00:00:00 GMT","productId":618,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04395456","repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04395456#contacts","https://www.amyndas.com/contact/"],"sponsors":[{"sponsorId":"d8f6c93fd473eeeae66b037e34bdbf47207f50f6","sponsorName":"Amyndas Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"Mon, 01 Mar 2021 00:00:00 GMT","studyStartDate":"Wed, 01 Jul 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"RBT-9","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"covid19trials@renibus.com; sruiz@renibus.com\t","name":null,"notes":"","phone":"\t6822851733","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 30 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Unknown","notes":"","numSites":"1","otherPartners":"Frontier Scientific","phase":"2","preferredName":"RBT-9","primaryCompletionDate":"Tue, 30 Jun 2020 00:00:00 GMT","productId":619,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04364763","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Fort Worth","country":"USA","lat":32.7554883,"lng":-97.3307658,"locationId":"214c4140df0875942211b2f806e80fc4396aa146","name":"Fort Worth","state":"TX"}],"sources":["https://www.bioworld.com/COVID19products","https://www.biospace.com/article/releases/frontier-scientific-develops-and-provides-process-to-produce-active-pharmaceutical-ingredient-for-clinical-trial-of-covid-19-therapeutic-investigational-drug-rbt-9/","https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts"],"sponsors":[{"sponsorId":"e5bd469344b4fe42c4f9a766c3ad7c046e92843d","sponsorName":"Renibus Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Tue, 30 Jun 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Axatilimab","chemicalName":"SNDX-6352","conditionOrDisease":"COVID-19","contact":[{"email":"sfischer@syndax.com\t","name":null,"notes":"","phone":"7817959419","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 30 May 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"2","otherPartners":"","phase":"2","preferredName":"SNDX-6352","primaryCompletionDate":"Sun, 15 Nov 2020 00:00:00 GMT","productId":620,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04415073","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Scottsdale","country":"USA","lat":33.4941704,"lng":-111.9260519,"locationId":"fda138baea7468c8a96e06ab21289872f0aa259c","name":"Scottsdale","state":"AZ"},{"city":null,"country":"USA","lat":40.8447819,"lng":-73.8648268,"locationId":"8f5f880b744801a7075d53335c50e4a11e19e48f","name":"Bronx","state":"NY"}],"sources":["https://www.syndax.com/pipeline/","https://clinicaltrials.gov/ct2/show/NCT04415073?recrs=a&type=Intr&cond=COVID-19&draw=14&rank=606","https://www.bioworld.com/COVID19products","http://www.syndax.com/pipeline/sndx-6352-cgvhd/?gclid=Cj0KCQjw0rr4BRCtARIsAB0_48NDijYDEjJo1YwUfBkKSxB1uqVGIBraLLcRHE2jiv5TmqFxWz6djYUaAgWyEALw_wcB","https://clinicaltrials.gov/ct2/show/NCT04415073","https://clinicaltrials.gov/ct2/show/NCT04415073#contacts"],"sponsors":[{"sponsorId":"95ca711e2f6e8ea27c70dff5cddb64337335931c","sponsorName":"Syndax Pharmaceuticals"}],"status":"Ongoing","studyCompletionDate":"Sun, 15 Nov 2020 00:00:00 GMT","studyStartDate":"Sat, 30 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Zilucoplan","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"anja.delporte@uzgent.be; bart.lambrecht@ugent.be","name":null,"notes":"","phone":"003293320228","website":""}],"countries":["Belgium"],"countryCodes":["BEL"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 22 May 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"9","otherPartners":"University Hospital,Ghent","phase":"2","preferredName":"Zilucoplan","primaryCompletionDate":"Mon, 10 May 2021 00:00:00 GMT","productId":621,"registryLink":"https://www.clinicaltrials.gov/ct2/show/NCT04382755","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Aalst","country":"BEL","lat":50.9378101,"lng":4.0409517,"locationId":"59be98bfe153c50dd2467df45f4563da2c73a399","name":"Aalst","state":"Flanders"},{"city":"Bruges","country":"BEL","lat":51.209348,"lng":3.2246995,"locationId":"874100af636f66055e279ee6d2cee1d6ecc5de9c","name":"Brugge","state":"Flanders"},{"city":"Brussels","country":"BEL","lat":50.8503396,"lng":4.3517103,"locationId":"7c8845f2466610628151d1d4197564d483afdf6d","name":"Brussels","state":"Brussels"},{"city":"Ghent","country":"BEL","lat":51.0543422,"lng":3.7174243,"locationId":"6c2c5419fe32d12ed2aa8125a894f742d30008ac","name":"Gent","state":"Flanders"},{"city":"Ypres","country":"BEL","lat":50.8492265,"lng":2.8779388,"locationId":"bed9acecae478354b1f6fe82e30ad98322eaa55d","name":"Leper","state":"Flanders"},{"city":"Li\u00e8ge","country":"BEL","lat":50.6325574,"lng":5.5796662,"locationId":"caea36f27ae4a595d3f94ebb713378873274aa6b","name":"Li\u00e8ge","state":"Wallonia"},{"city":"Roeselare","country":"BEL","lat":50.94990869999999,"lng":3.1294471,"locationId":"92c79ea5ac20eeb7135d314bd81da6842601648c","name":"Roeselare","state":"Flanders"},{"city":"Tongeren","country":"BEL","lat":50.78419,"lng":5.474489999999999,"locationId":"ae14af42ae34740ad4a9db69b29953beca7a2fdb","name":"Tongeren","state":"Flanders"}],"sources":["https://www.bioworld.com/COVID19products","https://www.clinicaltrials.gov/ct2/show/NCT04382755","https://www.drugbank.ca/drugs/DB15636","https://myastheniagravisnews.com/zilucoplan/","https://www.ucb.com/our-science/pipeline"],"sponsors":[{"sponsorId":"c7e43505cffbcf9841685fe24b4c5bb8df416c6f","sponsorName":"UCB Pharma"}],"status":"Ongoing","studyCompletionDate":"Fri, 10 Sep 2021 00:00:00 GMT","studyStartDate":"Fri, 22 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Brequinar","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"clinical@clearcreekbio.com","name":null,"notes":"","phone":"(617) 765-2252","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 25 Jun 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"3","otherPartners":"","phase":"1","preferredName":"Brequinar","primaryCompletionDate":"Wed, 10 Mar 2021 00:00:00 GMT","productId":622,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04425252","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Hartford","country":"USA","lat":41.7545616,"lng":-72.6792339,"locationId":"fdb4548a09fef4291e1c6c149685d28e88ff35f1","name":"Hartford Hospital","state":"CT"},{"city":"Tampa","country":"USA","lat":27.9370769,"lng":-82.4590757,"locationId":"ce8ac3b9b2f828d866f8d00dd1715adaa889d900","name":"University Of South Florida/tampa General","state":"FL"},{"city":"Philadelphia","country":"USA","lat":39.9805942,"lng":-75.1557376,"locationId":"c9ada46fc98e987d9cb9e8b6534e3eb10e5ed0c7","name":"Temple University","state":"PA"}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04425252","https://www.clearcreekbio.com/"],"sponsors":[{"sponsorId":"f5c984948f7e8d0795dcb6accb0b2bd27f1d75ca","sponsorName":"Clear Creek Bio Inc"}],"status":"Ongoing","studyCompletionDate":"Sat, 10 Apr 2021 00:00:00 GMT","studyStartDate":"Thu, 25 Jun 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Lanadelumab","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"roger.bruggemann@radboudumc.nl","name":null,"notes":"","phone":"0031243611111","website":""}],"countries":["Netherlands"],"countryCodes":["NLD"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"ESTIMATED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"10","otherPartners":"","phase":"1","preferredName":"Lanadelumab","primaryCompletionDate":"Tue, 03 Aug 2021 00:00:00 GMT","productId":623,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04422509","repurposed":"Repurposed-Approved","siteLocations":[{"city":"'s-Hertogenbosch","country":"NLD","lat":51.6978162,"lng":5.3036748,"locationId":"f019c046d7b527f3d8c70699495920f4f7911527","name":null,"state":"NB"},{"city":"Amsterdam","country":"NLD","lat":52.3675734,"lng":4.9041389,"locationId":"5449fcd97967719b577917124ec53623e96c082b","name":"Amsterdam","state":"NH"},{"city":"Arnhem","country":"NLD","lat":51.9851034,"lng":5.898729599999999,"locationId":"0db9172158df7ec6b19507625ab79430a4d40af9","name":"Arnhem","state":"GE"},{"city":"Blaricum","country":"NLD","lat":52.2726695,"lng":5.248079499999999,"locationId":"af90ec73e61d189d4f3455dc4f00b357f1fda230","name":"Blaricum","state":"NH"},{"city":"Breda","country":"NLD","lat":51.5719149,"lng":4.768323,"locationId":"53a302d892455abf2097b7c0217ca0a40b10001f","name":"Breda","state":"NB"},{"city":"The Hague","country":"NLD","lat":52.0704978,"lng":4.3006999,"locationId":"2a51be738e27fbcfdfb191604168e37cbac37adc","name":"Den Haag","state":"ZH"},{"city":"Nijmegen","country":"NLD","lat":51.8448837,"lng":5.842828099999999,"locationId":"9a9982cf07e5795effd61b64390ee412cd28e036","name":"Nijmegen","state":"GE"},{"city":"Tilburg","country":"NLD","lat":51.560596,"lng":5.0919143,"locationId":"73f4ee4d54a656b1c0a9b42c6ca8e7aaf73a3d67","name":"Tilburg","state":"NB"},{"city":"Utrecht","country":"NLD","lat":52.09073739999999,"lng":5.1214201,"locationId":"a80c626a9d0b3178a114d76f5db1009a8711185f","name":"Utrecht","state":"UT"},{"city":"Zwolle","country":"NLD","lat":52.5167747,"lng":6.083021899999999,"locationId":"829628db2651e4bfeca65079681b963ef818382a","name":"Zwolle","state":"OV"}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04422509","https://www.takhzyro.com/","https://www.ru.nl/english/"],"sponsors":[{"sponsorId":"2535b4b541b25cc95cbd404bcf7c61d44c2d92d0","sponsorName":"Radbout Univercity"},{"sponsorId":"31759effba9dd9037b4a5b2a4e1bf87cb0e4042b","sponsorName":"Takeda"}],"status":"Ongoing","studyCompletionDate":"Tue, 03 Aug 2021 00:00:00 GMT","studyStartDate":"Sat, 03 Oct 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Pentoxifylline","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"mahmoud.samy@gop.usc.edu.eg","name":null,"notes":"","phone":"00201063340887","website":""}],"countries":["Egypt"],"countryCodes":["EGY"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"ESTIMATED"}],"moleculeType":"Other","notes":"","numSites":"1","otherPartners":"","phase":"1","preferredName":"Pentoxifylline","primaryCompletionDate":"","productId":624,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04433988","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Shebeen El-Kom","country":"EGY","lat":30.550334,"lng":31.0106341,"locationId":"106b402a089fe46c1ffc23a57877dcf7b0120865","name":"Shib\u012bn Al Kawn","state":"Menofia Governorate"}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04433988","https://onlinelibrary.wiley.com/doi/full/10.1111/dth.13733?af=R"],"sponsors":[{"sponsorId":"a16bac5a1c4bf6f4e33b72f12986c8d936f2d5f2","sponsorName":"Sadat City University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Thu, 13 Aug 2020 00:00:00 GMT","therapeuticApproach":"Combination","trialId":""},{"acceptsHealthySubjects":"No","brandName":"SBI-101","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"brian.miller@sentienbiotech.com","name":null,"notes":"","phone":"781-361-9031","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"ESTIMATED"}],"moleculeType":"Cell therapies","notes":"","numSites":"","otherPartners":"","phase":"1","preferredName":"SBI-101","primaryCompletionDate":"Wed, 10 Feb 2021 00:00:00 GMT","productId":625,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04445220","repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04445220","https://sentienbiotech.com/product/","https://sentienbiotech.com/"],"sponsors":[{"sponsorId":"da566f6dde9d880ea1d69769d90f4af25c5dadc0","sponsorName":"Sentien Biotechnologies Inc"}],"status":"Ongoing","studyCompletionDate":"Sat, 10 Jul 2021 00:00:00 GMT","studyStartDate":"Mon, 10 Aug 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"TL-895","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"jmei@teliospharma.com","name":null,"notes":"","phone":"650-542-0136","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"ESTIMATED"}],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"1","preferredName":"TL-895","primaryCompletionDate":"Sat, 10 Jul 2021 00:00:00 GMT","productId":626,"registryLink":"https://www.clinicaltrials.gov/ct2/show/NCT04419623","repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.clinicaltrials.gov/ct2/show/NCT04419623"],"sponsors":[{"sponsorId":"41bd7b0473a053c2df18cd85925146dcaf9ff2f7","sponsorName":"Telios Pharma Inc"}],"status":"Ongoing","studyCompletionDate":"Sat, 10 Jul 2021 00:00:00 GMT","studyStartDate":"Wed, 10 Jun 2020 00:00:00 GMT","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"","brandName":"Agent-797","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Tue, 02 Jun 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Agent-797","primaryCompletionDate":"","productId":627,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://agenusbio.com/pipeline/","https://investor.agenusbio.com/2020-06-02-FDA-Clears-IND-for-iNKT-Cells-to-Treat-COVID-19-Patients","https://agenusbio.com/inkt-allogeneic-cell-therapy/"],"sponsors":[{"sponsorId":"70aae622d49d503de9e5605f93675daf07bb0646","sponsorName":"Agenus Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Combination","trialId":""},{"acceptsHealthySubjects":"No","brandName":"APL-9","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"clinicaltrials@apellis.com","name":null,"notes":"","phone":"833-284-6361","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 26 May 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"4","otherPartners":"","phase":"1","preferredName":"APL-9","primaryCompletionDate":"Tue, 10 Nov 2020 00:00:00 GMT","productId":628,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04402060","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Miami","country":"USA","lat":25.747314,"lng":-80.31765469999999,"locationId":"ff1d674c2ac15f8eb420b273da2c5e1c9a30cf9b","name":"Westchester General Hospital","state":"FL"},{"city":"Louisville","country":"USA","lat":38.2354572,"lng":-85.63263889999999,"locationId":"5a001fcbfeb6b9d056d4fe8fde17f9efb42664f1","name":"Norton Women's And Children's Hospital","state":"KY"},{"city":"Louisville","country":"USA","lat":38.2153895,"lng":-85.7226919,"locationId":"dc705291f660196a95f31e262bc727be01734cbe","name":"Audobon Hospital","state":"KY"},{"city":"Buffalo","country":"USA","lat":43.0008093,"lng":-78.7889697,"locationId":"bcff69866a6d24439f561cb1c758963786bdd205","name":"University At Buffalo","state":"NY"}],"sources":["https://www.bioworld.com/COVID19products","https://investors.apellis.com/news-releases/news-release-details/apellis-initiates-phase-12-study-apl-9-patients-severe-covid-19","https://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-will-commence-apl-9-program-control","http://apellis.com/our-science/our-pipeline","https://apellis.com/contact-us/","https://clinicaltrials.gov/ct2/show/NCT04402060"],"sponsors":[{"sponsorId":"19a5ec9e2f0b0179e97fd0d2eed9c23d8bc9ff25","sponsorName":"Apellis Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"Tue, 10 Nov 2020 00:00:00 GMT","studyStartDate":"Tue, 26 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"BX-U001","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"baylx@baylxinc.com","name":null,"notes":"","phone":"949-308-1952","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Thu, 04 Jun 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"ONGOING"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"ESTIMATED"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"","numSites":"","otherPartners":"","phase":"1","preferredName":"BX-U001","primaryCompletionDate":"Fri, 30 Apr 2021 00:00:00 GMT","productId":629,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2","repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.baylxinc.com/post/baylx-inc-received-us-fda-clearance-of-ind-application-for-its-cord-tissue-mesenchymal-stem-cells","https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2","https://www.baylxinc.com/post/baylx-inc-received-us-fda-clearance-of-ind-application-for-its-cord-tissue-mesenchymal-stem-cells#:~:text=Irvine%2C%20CA%2C%20USA%2C%20June%2004%2C%202020%20--%20Baylx%2C","%28hUC-MSC%29%20product%20in%20patients%20with%20Rheumatoid%20Arthritis%20%28RA%29."],"sponsors":[{"sponsorId":"12e021f990b58f0c1d10bb15e82b486a26f92aa6","sponsorName":"Baylx Inc"}],"status":"On Hold","studyCompletionDate":"Wed, 30 Jun 2021 00:00:00 GMT","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"BAT-2020","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"ESTIMATED"}],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"","phase":"1","preferredName":"BAT-2020","primaryCompletionDate":"Wed, 20 Jan 2021 00:00:00 GMT","productId":630,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04432766","repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04432766","https://www.biothera.com/"],"sponsors":[{"sponsorId":"0ef1b6b8ccaf5de67fd274fb3286592880884373","sponsorName":"BioThera Solutions"}],"status":"Ongoing","studyCompletionDate":"Wed, 18 Aug 2021 00:00:00 GMT","studyStartDate":"Tue, 20 Oct 2020 00:00:00 GMT","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"","brandName":"FSD-201","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 21 Feb 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Phase 1 demonstrated no serious adverse side effects and company plans to advance into a Phase 2a trail for COVID-19 treatment without mention of a start date","numSites":"","otherPartners":"","phase":"","preferredName":"FSD-201","primaryCompletionDate":"","productId":631,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase","https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379084&isReview=true"],"sponsors":[{"sponsorId":"594be65a8371a5afc8037dcf3baf8df5ce31f8ea","sponsorName":"FSD Pharma Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"TAK-981","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"globaloncologymedinfo@takeda.com","name":null,"notes":"","phone":"1-844-662-8532","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 22 May 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Intended for studying in subset of cancer patients with COVID-19","numSites":"8","otherPartners":"","phase":"1","preferredName":"TAK-981","primaryCompletionDate":"Tue, 16 Feb 2021 00:00:00 GMT","productId":632,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT03648372?term=TAK-981&draw=2&rank=3","repurposed":"New","siteLocations":[{"city":"San Diego","country":"USA","lat":32.8786467,"lng":-117.2230577,"locationId":"6dcd7e73cafb0b66ce844104167faee51d781fb9","name":"University Of California San Diego Moores Cancer Center","state":"CA"},{"city":"Boston","country":"USA","lat":42.3626109,"lng":-71.067566,"locationId":"312b9fdbe5f2c44704ddad2ced3828fd99bf7f5a","name":"Massachusetts General Hospital","state":"MA"},{"city":"Detroit","country":"USA","lat":42.3520878,"lng":-83.0574925,"locationId":"90760b407741cf46b967d2fd25953618d4187203","name":"Barbara Ann Karmanos Cancer Institute","state":"MI"},{"city":"St Paul","country":"USA","lat":44.955735,"lng":-93.09477299999999,"locationId":"0ec934ef5b181d8f173260a552638fef720c4012","name":"Healthpartners Cancer Care Center Regions Hospital","state":"MN"},{"city":"Cleveland","country":"USA","lat":41.5069941,"lng":-81.6056084,"locationId":"f04a2a843b10762ba844a1802b499fc0184f5dc8","name":"University Hospitals Seidman Cancer Center","state":"OH"},{"city":"Philadelphia","country":"USA","lat":40.0716804,"lng":-75.0912008,"locationId":"f646d134dae60157c8b50c3e6445ae17435cd911","name":"Fox Chase Cancer Center","state":"PA"},{"city":"Houston","country":"USA","lat":29.7068146,"lng":-95.3971547,"locationId":"69752caca00e783ebf228e1f049147ee381ee3bf","name":"The University Of Texas Md Anderson Cancer Center","state":"TX"},{"city":"Milwaukee","country":"USA","lat":43.0412506,"lng":-88.0246804,"locationId":"e827a2f12d77e9c89ed91a50c739f88ec18d81c6","name":"Froedtert And The Medical College Of Wisconsin","state":"WI"}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT03648372?term=TAK-981&draw=2&rank=3","https://cancerres.aacrjournals.org/content/79/13_Supplement/3252","https://www.fool.com/earnings/call-transcripts/2020/05/15/takeda-pharmaceutical-tak-q4-2019-earnings-call-tr.aspx"],"sponsors":[{"sponsorId":"31759effba9dd9037b4a5b2a4e1bf87cb0e4042b","sponsorName":"Takeda"},{"sponsorId":"045e824a5da5f72babae368754662beedb102779","sponsorName":"Millenium Pharmaceuticals Inc"}],"status":"Ongoing","studyCompletionDate":"Wed, 06 Oct 2021 00:00:00 GMT","studyStartDate":"Mon, 01 Oct 2018 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"PL-8177","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Postive results in demonstrated in multiple preclinical inflammatory disease models and a lung injury model. IND is planned to be submitted in third quarter of 2020 and a Phase 2 clinical trial initiation in the fourth quarter of 2020.","numSites":"","otherPartners":"","phase":"","preferredName":"PL-8177","primaryCompletionDate":"","productId":633,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.prnewswire.com/news-releases/palatin-technologies-to-develop-pl8177-as-a-potential-treatment-for-covid-19-and-associated-lung-complications-301081588.html","https://www.palatin.com/research-focus/inflammatory-disease/"],"sponsors":[{"sponsorId":"b8857618611ee134961436d104fe230a1c93eb18","sponsorName":"Palatin Technologies Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"LYT-100","chemicalName":"deupirfenidone","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Sun, 01 Mar 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"A deuterated analogue of pirfenidone -an approved drug for treatment of idiopathic pulmonary fibrosis. Currently in a Phase 1 trial to determine safety in healthy volunteers and patients with breast cancer-related upper limb secondary lumphoedema. There are plans to initiate a trail in third quarter of 2020 for treating non-critical patients with COVID-19","numSites":"","otherPartners":"","phase":"","preferredName":"deupirfenidone","primaryCompletionDate":"","productId":634,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.puretechhealth.com/news/23-press-releases/1218-puretech-advances-lyt-100-deupirfenidone-for-treatment-of-serious-respiratory-complications-that-persist-following-resolution-of-covid-19-infection","https://clinicaltrials.gov/ct2/show/NCT04243837?term=LYT-100&draw=2&rank=1"],"sponsors":[{"sponsorId":"aa35972c3b3ff6b8976683f566db2d26a808a36f","sponsorName":"Puretech Health plc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"TY-027","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"justin@tychanltd.com ; anjalib@tychanltd.com","name":null,"notes":"","phone":"65 9002 5606 ; 65 9420 4576","website":""}],"countries":["Singapore"],"countryCodes":["SGP"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 09 Jun 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"TY-027 showed full clearance of the virus in lab studies and demonstrated safety in preclincal studies,Currently in a Phase 1 trial with efficacy data expected to be available in the third quarter.","numSites":"1","otherPartners":"","phase":"1","preferredName":"TY-027","primaryCompletionDate":"Tue, 10 Nov 2020 00:00:00 GMT","productId":635,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1","repurposed":"New","siteLocations":[{"city":"Singapore","country":"SGP","lat":1.2809842,"lng":103.8388793,"locationId":"d83bfef6b996e231aefe2573f5cf4d4ec8b548dd","name":"Singhealth Investigational Medicine Unit","state":null}],"sources":["https://www.bioworld.com/COVID19products","https://www.genengnews.com/covid-19-candidates/tychan-ty027/","https://www.tychan.com/","https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1"],"sponsors":[{"sponsorId":"496163600d3ce1d2d068fd9e415b870246a0fb39","sponsorName":"Tichan Pte Ltd"}],"status":"Ongoing","studyCompletionDate":"Mon, 01 Feb 2021 00:00:00 GMT","studyStartDate":"Tue, 09 Jun 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Decidual stromal cells","chemicalName":"","conditionOrDisease":"COVID-19 ","contact":[{"email":"john.granton@uhn.ca ; jonas.mattsson@uhn.ca","name":null,"notes":"","phone":"416-340-4485; 416-946-4501","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 1","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 30 Jun 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Cell therapies","notes":"","numSites":"1","otherPartners":"","phase":"1","preferredName":"Decidual stromal cells","primaryCompletionDate":"Wed, 24 Feb 2021 00:00:00 GMT","productId":636,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04451291#contacts","repurposed":"New","siteLocations":[{"city":"Toronto","country":"CAN","lat":43.6590384,"lng":-79.38835859999999,"locationId":"2a458a5a47739b70d0fef229c1e61f1c3ab265a4","name":"Toronto General Hospital","state":"ON"}],"sources":["https://www.bioworld.com/COVID19products","https://clinicaltrials.gov/ct2/show/NCT04451291","https://clinicaltrials.gov/ct2/show/NCT04451291#contacts"],"sponsors":[{"sponsorId":"6c811bcaeb424eb454f36bda3cfbde712bb26ffd","sponsorName":"University Health Network Toronto"},{"sponsorId":"acd37c2538b99b0058043071302b210fc68796ec","sponsorName":"Oslo University Hospital"}],"status":"Ongoing","studyCompletionDate":"Wed, 24 Feb 2021 00:00:00 GMT","studyStartDate":"Mon, 24 Aug 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"SARS-CoV-2 main protease inhibitors","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["India"],"countryCodes":["IND"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"The molecules were designed computationally using AI and preclinical optimization will lead to selection of lead candidates","numSites":"","otherPartners":"","phase":"","preferredName":"SARS-CoV-2 main protease inhibitors","primaryCompletionDate":"","productId":637,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"b2ef8bfd7ad33ad39c53f8cb90230b22f114c545","sponsorName":"A2A Pharmaceuticals Inc"},{"sponsorId":"1fcffdacd8cdad3268381d1ba4404852f44e7fea","sponsorName":"Laxai Life Sciences Pvt Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"","brandName":"Human monoclonal antibodies (mAbCo19)","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Italy"],"countryCodes":["ITA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"The EU Malaria Fund announced funding for the development of the antibodies on 06/03/2020","numSites":"","otherPartners":"EU Malaria Fund","phase":"","preferredName":"Human monoclonal antibodies (mAbCo19)","primaryCompletionDate":"","productId":638,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.covidx.eu/mabco19","https://www.businesswire.com/news/home/20200619005083/en/Italy-Beneficiary-EU-Malaria-Fund-Siena-Based-Achilles"],"sponsors":[{"sponsorId":"9d5a1c4e0733cb70aab96efa202d8ccfbe4dd694","sponsorName":"Achilles Vaccines srl"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Tempol","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Adamis is planning to apply for funding and work with the FDA to expedite testing.  Clinical trial material is curently available since Tempol is being tested in other clinical trials for other purposes.","numSites":"","otherPartners":"","phase":"","preferredName":"Tempol","primaryCompletionDate":"","productId":639,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","http://ir.adamispharmaceuticals.com/news-releases/news-release-details/adamis-pharmaceuticals-announces-license-commercialize-tempol","https://www.drugbank.ca/drugs/DB12449"],"sponsors":[{"sponsorId":"88ad5addd85ff89d03e845d226fc5d550df79484","sponsorName":"Adamis Pharmaceuticals Corp"},{"sponsorId":"d2795e3ee88c4be3d3d8cdb8d22d17048f6d25f0","sponsorName":"Matrix Biomed Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"AB-201 (rNAPc2)","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"Other","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"AB-201 is being developed as a potential treatment for COVID-related coagulopathy. It has undergone clinical testing through Phase 2 for anticoagulation. ARCA plans to file an IND application for COVID-19 in the third quarter of 2020 estimating late-stage clinical testing in the second half of 2020. A Phase 2B/3 clinical trial protocol is being developed for COVID-19 patients with elevated D-dimer levels.","numSites":"","otherPartners":"","phase":"","preferredName":"AB-201 (rNAPc2)","primaryCompletionDate":"","productId":640,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.globenewswire.com/news-release/2020/05/28/2040150/0/en/ARCA-biopharma-Announces-AB201-Development-Program-for-Treatment-of-COVID-19-Associated-Coagulopathy.html","https://www.drugbank.ca/drugs/DB06552"],"sponsors":[{"sponsorId":"9c13d33bd13132700e827beb6d905e4fd7881289","sponsorName":"Arca Biopharm Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Xospata","chemicalName":"gilteritinib","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Japan"],"countryCodes":["JPN"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"tyrosine kinase inhibitor","numSites":"","otherPartners":"","phase":"","preferredName":"gilteritinib","primaryCompletionDate":"","productId":641,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.drugbank.ca/drugs/DB12141","https://www.astellas.com/en/contact-us"],"sponsors":[{"sponsorId":"cb663fed483955b3dab4743f07b486955fed6169","sponsorName":"Astellas Pharma Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"","brandName":"ATR-002","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Germany"],"countryCodes":["DEU"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"MEK inhibitor","numSites":"","otherPartners":"","phase":"2","preferredName":"ATR-002","primaryCompletionDate":"","productId":642,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.genengnews.com/covid-19-candidates/atriva-therapeutics-atr-002/","https://www.clinicaltrialsarena.com/news/atriva-therapeutics-covid-19-trial/","https://www.globenewswire.com/news-release/2020/05/28/2039939/0/en/Atriva-Therapeutics-to-Develop-ATR-002-for-Treatment-of-Patients-with-COVID-19-in-Phase-II-Study.html","https://www.atriva-therapeutics.com/14-news/96-news-phase2-2020"],"sponsors":[{"sponsorId":"54e05d7f41524d6ae257f44e12f0540c0f86ca19","sponsorName":"Atriva Therapeutics GmbH"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-antiretrovirals","trialId":""},{"acceptsHealthySubjects":"","brandName":"TP-508","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"helps against blood clotting and other cardiovascular problems faced by COVID-19 patients","numSites":"","otherPartners":"","phase":"1","preferredName":"TP-508","primaryCompletionDate":"","productId":643,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://chrysbio.com/chrysalis-biotherapeutics-receives-funding-from-the-national-institutes-of-health-for-covid-19-therapeutic-development/","https://www.drugbank.ca/drugs/DB05309","https://www.galvnews.com/news/free/article_31c2f715-0467-5348-89ef-fdd3a45b304d.html"],"sponsors":[{"sponsorId":"079bc9b8c0c5b6efd67db7b7b9937c5c6eddb309","sponsorName":"Chrysalis Biotherapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Austria"],"countryCodes":["AUT"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"digital drug discovery platform","numSites":"","otherPartners":"","phase":"","preferredName":"Delta_4_GmbH-644","primaryCompletionDate":"","productId":644,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://delta4.ai/press-release-june-2020/"],"sponsors":[{"sponsorId":"eaf144f7405b7c0fb9d8bc5a52c5be73bf8db412","sponsorName":"Delta 4 GmbH"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"egg immunoglobulins","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Germany"],"countryCodes":["DEU"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"customized immunoglobulins to inhibit infection","numSites":"","otherPartners":"","phase":"","preferredName":"egg immunoglobulins","primaryCompletionDate":"","productId":645,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.prnewswire.com/in/news-releases/ignova-files-patent-application-on-antibody-against-covid-19-837978500.html","https://ignova.com/ignova-files-patent-application-on-antibody-against-covid-19/"],"sponsors":[{"sponsorId":"37e907f965e94c82c42432b138426dfa41608075","sponsorName":"Ignova GmbH"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"Antibodies","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"plans to isolate antibodies from blood that can used to treat COVID-19 patients","numSites":"","otherPartners":"","phase":"","preferredName":"Antibodies","primaryCompletionDate":"","productId":646,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.hospimedica.com/covid-19/articles/294783005/thermogenesis-announces-publishing-of-results-of-immunecytes-licensed-neutralizing-antibody-therapeutics-for-covid-19.html","https://www.biospace.com/article/releases/thermogenesis-and-immunecyte-joint-venture-developing-several-convalescent-plasma-and-antibody-therapeutic-approaches-against-covid-19-featured-on-fox40-and-other-local-news-outlets/"],"sponsors":[{"sponsorId":"912ea5a364bc1ef18e2b2eccce53de667656b271","sponsorName":"Immuncetye Life Sciences Inc"},{"sponsorId":"2d735c3d9d663fcc08e98c3576299ec02b7f8090","sponsorName":"Thermogenesis Holdings Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"IMS-001","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Cell therapies","notes":"stem cell therapy,also being used to treat ARDS and pneumonia for COVID-19 patients","numSites":"","otherPartners":"","phase":"","preferredName":"IMS-001","primaryCompletionDate":"","productId":647,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.pharmaceutical-business-review.com/news/agex-therapeutics-imstem-biotechnology-sign-non-binding-letter-of-intent-regarding-investigational-msc-candidate-ims001-for-covid-19/","https://www.bioworld.com/articles/435490-other-news-to-note-for-june-2-2020"],"sponsors":[{"sponsorId":"fdae0c19faa2abbdaba4890b2003312afa5ebbf5","sponsorName":"Imstem Biotechnology Inc"},{"sponsorId":"2af2b4cfdc7a01f1b1b30b7ed7d086ee3559a3f0","sponsorName":"Agex Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"R-107","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"also being used to treat ARDS","numSites":"","otherPartners":"","phase":"","preferredName":"R-107","primaryCompletionDate":"","productId":648,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://kalytera.co/news/kalytera-announces-data-demonstrating-that-r-107-preserves-organ-function-in-a-murine-study-mimicking-covid-19-lung-disease/"],"sponsors":[{"sponsorId":"d16b517fd34d1c88b285851f141f1f513dcd7559","sponsorName":"Kalytera Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"AlloStim","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"axellaresearch@gmail.com;  thu@immunovative.com","name":null,"notes":"","phone":"1-732-630-9059; 1-619-227-4872","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"Other","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 06 Jul 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Whole-pathogen vaccines","notes":"Protects against any type of viral infection and is designed for the elderly","numSites":"1","otherPartners":"Immunovative Therapies and Mirror Biologics","phase":"1","preferredName":"AlloStim","primaryCompletionDate":"","productId":665,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04441047","repurposed":"New","siteLocations":[{"city":"New York","country":"USA","lat":40.7127753,"lng":-74.0059728,"locationId":"982c6d2cd7d5a2596604af02a2962673eb275399","name":"New York","state":"NY"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04441047","https://www.prnewswire.com/il/news-releases/immunovative-therapies-and-mirror-biologics-announce-us-fda-clearance-of-a-universal-anti-viral-vaccine-phase-iii-clinical-trial-for-healthy-elderly-adults-301081793.html"],"sponsors":[{"sponsorId":"9ca3fdec10a2d19a058d21154ece1f6809409f21","sponsorName":"Immunovative Therapies Ltd"},{"sponsorId":"85d779a6ca464033b3af98c970d768ab80229774","sponsorName":"Mirror Biologics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 06 Jul 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"carragelose inhalation therapy","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Austria"],"countryCodes":["AUT"],"currentStage":"Phase 1","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"sulfated polymer that comes from red seaweed,interacts with virus particles","numSites":"","otherPartners":"","phase":"1","preferredName":"carragelose inhalation therapy","primaryCompletionDate":"","productId":649,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.oindpnews.com/2020/04/marinomed-gets-funding-for-development-of-carragelose-inhalation-solution-for-the-treatment-of-covid-19-pneumonia/","https://www.carragelose.com/en/mode-of-action","https://www.pharmiweb.com/press-release/2020-04-28/marinomed-receives-ffg-funding-to-research-sars-cov-2-therapy-based-on-carragelose-1","https://www.marinomed.com/en/news/marinomed-receives-ffg-funding-to-research-sars-cov-2-therapy-based-on-carragelose","https://www.expresspharma.in/covid19-updates/marinomed-receives-ffg-funding-to-research-sars-cov-2-therapy-based-on-carragelose/"],"sponsors":[{"sponsorId":"a5ce72622018f447da2a5877aa50c4c0ba0596df","sponsorName":"Marinomed Biotech Ag"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"Dinaciclib","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"little information about this -- repurposed drug","numSites":"","otherPartners":"","phase":"","preferredName":"Dinaciclib","primaryCompletionDate":"","productId":650,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296007/","https://qbi.ucsf.edu/"],"sponsors":[{"sponsorId":"35759a3021a327096a19d14e71986dd34642bd1c","sponsorName":"Merck Sharp  Dohme Corp"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"","brandName":"MNPR-101,Radioimmunotherapeutics","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"MNPR-101,Radioimmunotherapeutics","primaryCompletionDate":"","productId":651,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.monopartx.com/pipeline/mnpr-101","https://www.monopartx.com/contact-us","https://www.monopartx.com/"],"sponsors":[{"sponsorId":"87c57aa242a30221bb81157f5b54edf03f2f98e0","sponsorName":"Monopar Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"","brandName":"OBP-AI-005","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Unknown","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"OBP-AI-005","primaryCompletionDate":"","productId":652,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://ssl4.eir-parts.net/doc/4588/tdnet/1850514/00.pdf","https://www.oncolys.com/en/contact/"],"sponsors":[{"sponsorId":"cd89286aaff544849e5b727d1488b979ee9334a1","sponsorName":"Oncolys Biopharma Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"","brandName":"Ranpirnase","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Ranpirnase","primaryCompletionDate":"","productId":653,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://ir.orgenesis.com/press-releases/detail/159/orgenesis-and-leidos-collaborate-on-potential-treatment-for","https://www.thepharmaletter.com/article/orgenesis-falls-as-it-says-it-will-acquire-tamir-biotechnology-assets"],"sponsors":[{"sponsorId":"5681cd5b349d3daab2eea51e5cc5ac1aef63b7a6","sponsorName":"Orgenesis Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"ORP-100S","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"ORP-100S","primaryCompletionDate":"","productId":654,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.orprotherapeutics.com/covid-19/","https://www.orprotherapeutics.com/technology/orp-100s-for-inhalation/","https://www.orprotherapeutics.com/2020/05/28/347/"],"sponsors":[{"sponsorId":"ceff146133490de22f886f48d17ff6a3a56b4909","sponsorName":"Orpro Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"Neutrophil Extracellular Trap Inhibitor","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"Neutrophil Extracellular Trap Inhibitor","primaryCompletionDate":"","productId":655,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.prnewswire.com/news-releases/peel-therapeutics-announces-possible-new-treatment-for-covid-19-301085175.html","https://www.peeltx.com/science"],"sponsors":[{"sponsorId":"b05b4b8ae97bbb19557f4e8cc0ef97728495eec7","sponsorName":"Peel Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"97 frequently prescribed drugs being re-purposed to treat COVID-19","numSites":"","otherPartners":"","phase":"","preferredName":"Pharnext_SA-656","primaryCompletionDate":"","productId":656,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.pharnext.com/images/PDF/press_releases/2020.03.23_COVID19_EN.pdf","https://www.pharnext.com/fr/societe/profil-de-l-entreprise"],"sponsors":[{"sponsorId":"8ef7261cae683e2f3ccfe5dbf762a36c5ef48adb","sponsorName":"Pharnext SA"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"PTI-129","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"reduces level of misfolded proteins","numSites":"","otherPartners":"","phase":"","preferredName":"PTI-129","primaryCompletionDate":"","productId":657,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-announces-vitro-data-pti-129-potential","http://www.proteostasis.com/contact-us/"],"sponsors":[{"sponsorId":"725f7a6352f55d2607a2fb6023f1ab491ab75bf1","sponsorName":"Proteostasis Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"","brandName":"AS-1411","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"DNA aptamer designed to target and bind with nucleolin,a human protein utilized by some viruses to enter a cell.","numSites":"","otherPartners":"","phase":"","preferredName":"AS-1411","primaryCompletionDate":"","productId":658,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.genengnews.com/covid-19-candidates/qualigen-therapeutics-as1411/","https://www.qualigeninc.com/about-us/contact-qualigen/"],"sponsors":[{"sponsorId":"76359c6fac90eaaa53a84ee2d17a1e99bb0c3dee","sponsorName":"Qualigen Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Antiviral drugs-broad spectrum","trialId":""},{"acceptsHealthySubjects":"","brandName":"MAPK13-IN-1","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"MAPK13-IN-1","primaryCompletionDate":"","productId":659,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.bloomberg.com/press-releases/2020-06-28/ucsf-quantitative-biosciences-institute-cell-publication-elucidates-how-sars-cov-2-dramatically-rewires-important-cell-program","https://www.medchemexpress.com/MAPK13-IN-1.html","http://qbi.ucsf.edu/aboutus"],"sponsors":[{"sponsorId":"06f23ad22f5f3f44778ea99cb2275d05e92ecac9","sponsorName":"Quantitative Biosceinces Institute UCSF"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"","brandName":"SB203580","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"SB203580","primaryCompletionDate":"","productId":660,"registryLink":null,"repurposed":"Repurposed-Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products"],"sponsors":[{"sponsorId":"06f23ad22f5f3f44778ea99cb2275d05e92ecac9","sponsorName":"Quantitative Biosceinces Institute UCSF"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"","brandName":"Silmitasertib","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Discovery","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Tue, 31 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Small molecule","notes":"Curbes RNA from proliferating,CK2 inhibitor","numSites":"","otherPartners":"Taiwan headquartered Senhwa Biosciences Inc,The University of California San Francisco\u2019s Quantitative Biosciences Institute","phase":"","preferredName":"Silmitasertib","primaryCompletionDate":"","productId":661,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.biospace.com/article/releases/senhwa-biosciences-silmitasertib-named-as-potential-covid-19-therapy/","https://www.biospectrumasia.com/news/34/15848/senhwa-biosciences-nih-to-co-develop-covid-19-drug.html","https://www.drugbank.ca/drugs/DB15408"],"sponsors":[{"sponsorId":"1e9bcf520896b6caf986e652691d3a2891fa50d4","sponsorName":"Senhwa Biosciences Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"","brandName":"SFA-005","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"","indication":"ARDS","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"Preventing cytokine release syndrome,currently being evaluated in animal model of ARDS","numSites":"","otherPartners":"Ben Franklin","phase":"","preferredName":"SFA-005","primaryCompletionDate":"","productId":662,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.businesswire.com/news/home/20200624005197/en/Melior-Discovery-Announces-Partnership-SFA-Grant-Directed","https://www.sep.benfranklin.org/2020/06/18/ben-franklin-backs-founders-fighting-covid-19-and-its-effects/","https://sfatherapeutics.com/","https://www.sep.benfranklin.org/2020/06/18/ben-franklin-backs-founders-fighting-covid-19-and-its-effects/; https://www.businesswire.com/news/home/20200624005197/en/Melior-Discovery-Announces-Partnership-SFA-Grant-Directed"],"sponsors":[{"sponsorId":"de3cdcce6919716bc3c5263ab68dcafb702af417","sponsorName":"SFA Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"Immunotherapy,StemVacs","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"Based on activating universal donor immune systems so that upon injection they reprogram the bodies natural killer while also supressing lung inflammation","numSites":"","otherPartners":"Therapeutic Solutions Intl","phase":"","preferredName":"Immunotherapy,StemVacs","primaryCompletionDate":"","productId":663,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.biospace.com/article/releases/therapeutic-solutions-international-submits-publication-on-stemvacs-preclinical-data-supporting-covid-19-indication/"],"sponsors":[{"sponsorId":"b81dc519e12bb381185e293c3896855351179880","sponsorName":"Therapeutic Solutions International Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"","brandName":"VAL-201","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":["Ukraine"],"countryCodes":["UKR"],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Other","notes":"Treatment for hyperimmune response","numSites":"","otherPartners":"Collaboration with Oncolytika and Black Cat Bio","phase":"","preferredName":"VAL-201","primaryCompletionDate":"","productId":664,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.bioworld.com/COVID19products","https://www.sharesmagazine.co.uk/news/market/6944114/ValiRx-enters-collaboration-to-develop-SARS-CoV2-treatment","https://www.share-talk.com/valirx-plc-val-l-collaboration-agreement-signed/#gs.ae31u3"],"sponsors":[{"sponsorId":"7a299b49f65120e5661f5ab2ae1784384d2d9225","sponsorName":"Valirx plc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Oral Polio Vaccine (OPV)","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"a.fisker@bandim.org","name":null,"notes":"Enrolling by invitation only","phone":"245 966625316 ; 45 50570593","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 4","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Whole-pathogen vaccines","notes":"","numSites":"1","otherPartners":"Global Virus Network","phase":"4","preferredName":"Oral Polio Vaccine (OPV)","primaryCompletionDate":"Thu, 10 Jun 2021 00:00:00 GMT","productId":666,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04445428","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Bissau","country":"GNB","lat":11.8632196,"lng":-15.5843227,"locationId":"b4e4664b725e6db7782e1e491c15c980161834c1","name":"Bissau","state":"Bissau"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6&rank=46","https://biorender.com/covid-vaccine-tracker/details/v-CV15/-34","https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6"],"sponsors":[{"sponsorId":"57eec57daff4d3bbed859cb4ef877900baafee38","sponsorName":"Bandim Health Project"}],"status":"Ongoing","studyCompletionDate":"Thu, 10 Jun 2021 00:00:00 GMT","studyStartDate":"Fri, 10 Jul 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"No","brandName":"IMM-101","chemicalName":"","conditionOrDisease":"COVID-19 ","contact":[{"email":"cocallaghan@ctg.queensu.ca","name":null,"notes":"","phone":"613-533-6430","website":""}],"countries":["Canada"],"countryCodes":["CAN"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 01 Aug 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Other","notes":"Focused on strenghtening the immune system of cancer patients","numSites":"5","otherPartners":"Canadian Cancer Society - BioCanRx - the Ontario Institute for Cancer Research - The Ottawa Hospital Foundation - The Ottawa Hospital Academic Medical Organization - ATGen Canada/NKMax - and Immodulon Therapeutics","phase":"3","preferredName":"IMM-101","primaryCompletionDate":"","productId":667,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04442048","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Hamilton","country":"CAN","lat":43.2557206,"lng":-79.8711024,"locationId":"c83e2c967968363053d0701aafb2c8a82a0ef7ec","name":"Hamilton","state":"ON"},{"city":"London","country":"CAN","lat":42.9849233,"lng":-81.2452768,"locationId":"a120f0d9b6fee18d33eccfdc2379947cc51ba404","name":"London","state":"ON"},{"city":"Ottawa","country":"CAN","lat":45.4215296,"lng":-75.69719309999999,"locationId":"96c8afc020bb72a04f4865910e9c07c84804011c","name":"Ottawa","state":"ON"},{"city":"Toronto","country":"CAN","lat":43.653226,"lng":-79.3831843,"locationId":"521c355acf9f8108cd66041045ac2a60dd29ee06","name":"Toronto","state":"ON"},{"city":"Montreal","country":"CAN","lat":45.5016889,"lng":-73.567256,"locationId":"2b3d53b78757fbcdd5bc070c97cb11191fdf6a6a","name":"Montreal","state":"QC"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5&rank=40","https://ichgcp.net/clinical-trials-registry/NCT04442048","https://medicalxpress.com/news/2020-07-cancer-patients-covid-world-first-trial.html","https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5"],"sponsors":[{"sponsorId":"a8af43f60f0e421a43b632c90690329859938af5","sponsorName":"Canadian Cancer Trials Group"},{"sponsorId":"9685c58f38205dfadb5310c4b73cf1f96b1475d5","sponsorName":"Immodulon Therapeutics Ltd"},{"sponsorId":"430e04786b4eaafbfc9542951d4a766de2ab0e53","sponsorName":"BioCan Rx"},{"sponsorId":"3f075ee81f66154e4daa236b5d862aaeefd3e70f","sponsorName":"CCSRI"},{"sponsorId":"27fad021ac840435ee6b3db8a0d2315dbe481d1b","sponsorName":"AtGen Canada Inc"},{"sponsorId":"1248fe2b31b83483e8d6a9ee3d24d336359d0669","sponsorName":"ARCC"},{"sponsorId":"2d35d8fb47ee89b281e77116cdcc8d953016a76e","sponsorName":"Ontario Institute for Cancer Research"}],"status":"Ongoing","studyCompletionDate":"Wed, 31 Mar 2021 00:00:00 GMT","studyStartDate":"Wed, 01 Jul 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"RUTI Vaccine","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"pjcardona@igtp.cat","name":null,"notes":"","phone":"34 93 033 0527 ext 6400","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[],"moleculeType":"Whole-pathogen vaccines","notes":"A therapeutic vaccine for tuberculosis indications","numSites":"1","otherPartners":"Collaboration with  University Institute for Primary Health Care Research Jordi Gol,clinical triai financed by The General Directorate of Research and Innovation in Health of the Government of Catalonia","phase":"","preferredName":"RUTI Vaccine","primaryCompletionDate":"","productId":668,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04453488","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Barcelona","country":"ESP","lat":41.3850639,"lng":2.1734035,"locationId":"988672abb8e8138ee6cb118006ea9f5f924f4a82","name":"Barcelona","state":"CT"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3&rank=17","http://biotech-spain.com/en/articles/archivel-s-ruti-vaccine-begins-clinical-trial-to-increase-the-immunity-of-healthcare-professionals-exposed-to-covid-19/","https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3"],"sponsors":[{"sponsorId":"b0962c2b93dc6086519ac8714873a08bdec5dcb8","sponsorName":"Fundacio Institut Germans Trias i Pujol"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Thu, 30 Jul 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":"Tue, 10 Mar 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Other","notes":"Using personalized vaccine technology previously created to fight cancer,work centered around manipulating mRNA to deliver a message to make parts of the coronavirus visible to the immune system,approach may provide protection against all future corona viruses","numSites":"","otherPartners":"Investment from Sam Altman","phase":"","preferredName":"Helix_Nanotechnologies_Inc-669","primaryCompletionDate":"","productId":669,"registryLink":null,"repurposed":"Repurposed-Not Approved","siteLocations":[],"sources":["https://www.helixnano.com/","https://www.cnbc.com/2020/04/24/what-it-is-like-to-invent-a-covid-19-vaccine-during-pandemic.html","https://www.genengnews.com/covid-19-candidates/helix-nanotechnologies/","https://www.genengnews.com/covid-19-candidates/helix-nanotechnologies/; https://www.cnbc.com/2020/04/24/what-it-is-like-to-invent-a-covid-19-vaccine-during-pandemic.html"],"sponsors":[{"sponsorId":"01ef7c5fd722bab5aa40806e22631d3b6f7a7563","sponsorName":"Helix Nanotechnologies Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Infliximab","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"clawlor3@tuftsmedicalcenter.org","name":null,"notes":"","phone":"617-636-5000 ext 8897","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"TNF\u03b1 inhibitor therapy","numSites":"1","otherPartners":"Tufts Medical Center,NIH","phase":"2","preferredName":"Infliximab","primaryCompletionDate":"Tue, 01 Sep 2020 00:00:00 GMT","productId":670,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04425538","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Boston","country":"USA","lat":42.3600825,"lng":-71.0588801,"locationId":"82c296f0eeef8d7478f457becf59ad17d3a7f132","name":"Boston","state":"MA"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04425538","https://www.drugbank.ca/drugs/DB00065","https://biorender.com/covid-vaccine-tracker/details/d-0080/ryoncil-remestemcel-l-allogenic-mesenchymal-stem-cells"],"sponsors":[{"sponsorId":"806a8c2baa770636fe9a0bc6b58144d55ee4ae04","sponsorName":"Tufts Medical Center"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 01 Jun 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Infliximab","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"clawlor3@tuftsmedicalcenter.org","name":null,"notes":"","phone":"617-636-5000 ext 8897","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"TNF\u03b1 inhibitor therapy","numSites":"1","otherPartners":"Tufts Medical Center,NIH","phase":"2","preferredName":"Infliximab","primaryCompletionDate":"Tue, 01 Sep 2020 00:00:00 GMT","productId":671,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04425538","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Boston","country":"USA","lat":42.3600825,"lng":-71.0588801,"locationId":"2c7ad3381735780ea5577bb1ec3762b92d34e5cd","name":"Boston","state":"MA"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04425538","https://www.drugbank.ca/drugs/DB00065","https://biorender.com/covid-vaccine-tracker/details/d-0080/ryoncil-remestemcel-l-allogenic-mesenchymal-stem-cells"],"sponsors":[{"sponsorId":"806a8c2baa770636fe9a0bc6b58144d55ee4ae04","sponsorName":"Tufts Medical Center"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 01 Jun 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Deferoxamine","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"alirezaghaffariyeh@hotmail.com","name":null,"notes":"","phone":"16086987334","website":""}],"countries":["Iran","Islamic Republic of"],"countryCodes":["IRN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Acts as a chelating agent that eliminates iron and aluminum in the bloodstream.","numSites":"1","otherPartners":"Kermanshah University of Medical Sciences","phase":"2","preferredName":"Deferoxamine","primaryCompletionDate":"Tue, 01 Sep 2020 00:00:00 GMT","productId":672,"registryLink":"https://clinicaltrials.gov/ct2/show/record/NCT04333550","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Los Angeles","country":"USA","lat":34.067448,"lng":-118.441302,"locationId":"e7ea1a11897dcf49bc87b8f41b9c46680faf14f5","name":"Regenerative Medicine Research Center","state":"CA"},{"city":"Kermanshah","country":"IRN","lat":34.3443375,"lng":47.0985578,"locationId":"e85ea11b85ec8e5a2b43d1136d6dd996b89c8c12","name":"Kermanshah University Of Medical Sciences","state":"Kermanshah Province"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04333550","https://www.drugbank.ca/drugs/DB00746","http://gsia.kums.ac.ir/en","https://clinicaltrials.gov/ct2/show/study/NCT04333550","https://clinicaltrials.gov/ct2/show/record/NCT04333550","https://clinicaltrials.gov/ct2/show/study/NCT04333550#contacts"],"sponsors":[{"sponsorId":"c2754816106ca523c8d8464e63cc543e9a0d2213","sponsorName":"Kermanshah University of Medical Sciences"}],"status":"Ongoing","studyCompletionDate":"Mon, 01 Mar 2021 00:00:00 GMT","studyStartDate":"Mon, 01 Jun 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Puylmozyme","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"ercument.ovali@acibadem.com","name":null,"notes":"","phone":"905325729174","website":""}],"countries":["Turkey"],"countryCodes":["TUR"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 25 May 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"1","otherPartners":"The Scientific and Technological Research Council of Turkey","phase":"2","preferredName":"Puylmozyme","primaryCompletionDate":"Tue, 25 Aug 2020 00:00:00 GMT","productId":673,"registryLink":"https://clinicaltrials.gov/ct2/show/study/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2#contacts","repurposed":"Repurposed-Approved","siteLocations":[{"city":"\u0130stanbul","country":"TUR","lat":41.0082376,"lng":28.9783589,"locationId":"ba5e3cd2e691b1e0e6db17f697197e60085ee441","name":"Istanbul","state":"\u0130stanbul"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2&rank=4","https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2","https://www.drugbank.ca/drugs/DB00003","https://clinicaltrials.gov/ct2/show/record/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2","https://clinicaltrials.gov/ct2/show/study/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2#contacts"],"sponsors":[{"sponsorId":"1dbdb628b7360e9e7fbdf8f15440a46587de4524","sponsorName":"Acibadem University"}],"status":"Ongoing","studyCompletionDate":"Fri, 25 Sep 2020 00:00:00 GMT","studyStartDate":"Mon, 25 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Aspirin,clopidogrel,rivaroxaban,atorvastatin,omeprazole","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"alena.marynina@nhs.net","name":null,"notes":"","phone":"07776 224520","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Thu, 27 Feb 2020 00:00:00 GMT","milestoneId":11,"name":"discovery","status":"ONGOING"}],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"","preferredName":"Aspirin,clopidogrel,rivaroxaban,atorvastatin,omeprazole","primaryCompletionDate":"Tue, 30 Mar 2021 00:00:00 GMT","productId":674,"registryLink":"https://clinicaltrials.gov/ct2/show/study/NCT04333407#contacts","repurposed":"Repurposed-Approved","siteLocations":[{"city":"London","country":"GBR","lat":51.5073509,"lng":-0.1277583,"locationId":"d5c1d8998ba2e643982796cba34ad8457da1e701","name":"London","state":"England"}],"sources":["https://clinicaltrials.gov/ct2/show/study/NCT04333407","https://www.drugbank.ca/drugs/DB00945","https://docs.google.com/spreadsheets/d/1IUDoUXsEdk_d6FDgXTMVwuSHU_myagwVCEeMf81Tsjg/edit#gid=1988095192","https://pubmed.ncbi.nlm.nih.gov/32113509/","https://clinicaltrials.gov/ct2/show/study/NCT04333407#contacts"],"sponsors":[{"sponsorId":"1a693dd5acf9f3ae07a65241da0b2f2102ed1377","sponsorName":"Imperial College London"}],"status":"Ongoing","studyCompletionDate":"Tue, 30 Mar 2021 00:00:00 GMT","studyStartDate":"Fri, 03 Apr 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Prazosin","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"cbetteg1@jhmi.edu","name":null,"notes":"","phone":"4109558620","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Thu, 30 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 13 May 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"Prazosin","primaryCompletionDate":"","productId":675,"registryLink":"https://clinicaltrials.gov/ct2/show/study/NCT04365257#contacts","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Baltimore","country":"USA","lat":39.2903848,"lng":-76.6121893,"locationId":"7c19a7413bca48b8b8525e8ee245dacde0911934","name":"Baltimore","state":"MD"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04365257","https://www.drugbank.ca/drugs/DB00457","https://www.hopkinsmedicine.org/news/newsroom/news-releases/researchers-urge-clinical-trial-of-blood-pressure-drug-to-prevent-lethal-complication-of-covid-19","https://clinicaltrials.gov/ct2/show/study/NCT04365257","https://clinicaltrials.gov/ct2/show/study/NCT04365257#contacts"],"sponsors":[{"sponsorId":"a2061ed614e1cea96e01bbacea1c8e43eaf1c020","sponsorName":"John Hopkins University"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Wed, 13 May 2020 00:00:00 GMT","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Etoposide","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"mark.sloan@bmc.org","name":null,"notes":"","phone":"6176387002","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Fri, 01 May 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 08 May 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"Etoposide","primaryCompletionDate":"","productId":676,"registryLink":"https://clinicaltrials.gov/ct2/show/study/NCT04356690#contacts","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Boston","country":"USA","lat":42.3600825,"lng":-71.0588801,"locationId":"d4959c296b882013444aa0c45492551cdfec5d3b","name":"Boston","state":"MA"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04356690","https://www.drugbank.ca/drugs/DB00773","https://www.bmc.org/healthcity/research/etoposide-and-other-clinical-trials-covid-19-inflammation","https://clinicaltrials.gov/ct2/show/study/NCT04356690#contacts"],"sponsors":[{"sponsorId":"dd3995c1711a08d5f44869863581a63f4af7803b","sponsorName":"Boston Medical Center"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Fri, 08 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Cyclosporine","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"jgilmore@pennmedicine.upenn.edu","name":null,"notes":"","phone":"2157468902","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 22 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 22 Jun 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"1","preferredName":"Cyclosporine","primaryCompletionDate":"Tue, 01 Sep 2020 00:00:00 GMT","productId":677,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04412785#contacts","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Philadelphia","country":"USA","lat":39.9525839,"lng":-75.1652215,"locationId":"9182dd8745e32c7688e82477cc1323e9e6b9e1c1","name":"Philadelphia","state":"PA"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04412785","https://www.drugbank.ca/drugs/DB00091","https://www.thedp.com/article/2020/04/coronavirus-medicine-drug-therapy-treatment","https://clinicaltrials.gov/ct2/show/NCT04412785#contacts"],"sponsors":[{"sponsorId":"20ef76f96c3905ce188bfac7757864ea5931ce71","sponsorName":"University of Pennsylvania"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 22 Jun 2020 00:00:00 GMT","therapeuticApproach":"Other antiviral drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Sirolimus","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"guptans@ucmail.uc.edu","name":null,"notes":"","phone":"5135584831","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Wed, 15 Apr 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 24 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"2","otherPartners":"","phase":"2","preferredName":"Sirolimus","primaryCompletionDate":"Wed, 01 Jul 2020 00:00:00 GMT","productId":678,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04341675#contacts","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Chicago","country":"USA","lat":41.8781136,"lng":-87.6297982,"locationId":"aaba5345659866052c10b4187aed841aa1cff06c","name":"Chicago","state":"IL"},{"city":"Cincinnati","country":"USA","lat":39.1031182,"lng":-84.5120196,"locationId":"b289a5c12575606797b0c74f381434863cf661e5","name":"Cincinnati","state":"OH"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04341675","https://clinicaltrials.gov/ct2/show/NCT04412785#contacts","https://clinicaltrials.gov/ct2/show/NCT04341675#eligibility","https://www.uc.edu/news/articles/2020/05/n20912629.html","https://www.uc.edu/news/articles/2020/04/n20906921.html","https://clinicaltrials.gov/ct2/show/NCT04341675#contacts"],"sponsors":[{"sponsorId":"9853a7e1f0cfc0e6d46583970b6858d7e3b7ad12","sponsorName":"University of Cincinnati"},{"sponsorId":"1b9164e80e6eebf015de1a8aa6d9744d383d94d4","sponsorName":"Thomas Jefferson University"}],"status":"Ongoing","studyCompletionDate":"Tue, 01 Sep 2020 00:00:00 GMT","studyStartDate":"Fri, 24 Apr 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Povidone-Iodine","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"drnurul@usim.edu.my","name":null,"notes":"","phone":"","website":""}],"countries":["Malaysia"],"countryCodes":["MYS"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 22 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"complete","preferredName":"Povidone-Iodine","primaryCompletionDate":"Mon, 29 Jun 2020 00:00:00 GMT","productId":679,"registryLink":"https://clinicaltrials.gov/ct2/show/record/NCT04410159","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Kuala Lumpur","country":"MYS","lat":3.091953,"lng":101.7210971,"locationId":"42b948d9e3ea036a02ed5d77bab74f09a8d8b6cf","name":"Bandar Tun Razak","state":"Federal Territory of Kuala Lumpur"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04410159","https://www.drugbank.ca/drugs/DB06812","https://clinicaltrials.gov/ct2/show/record/NCT04410159","https://clinicaltrials.gov/ct2/show/study/NCT04410159"],"sponsors":[{"sponsorId":"0347591bd41b20ca07b8da471b5ad2e0e1e4dbd4","sponsorName":"Universiti Kebangsaan Malaysia Medical Centre"}],"status":"On Hold","studyCompletionDate":"Mon, 06 Jul 2020 00:00:00 GMT","studyStartDate":"Mon, 22 Jun 2020 00:00:00 GMT","therapeuticApproach":"Antibiotics and antiparasitics","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Zanubrutinib","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"clinicaltrials@beigene.com","name":null,"notes":"","phone":"18778285568","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Fri, 08 May 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"9","otherPartners":"","phase":"2","preferredName":"Zanubrutinib","primaryCompletionDate":"Thu, 01 Apr 2021 00:00:00 GMT","productId":680,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04382586#contacts","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Washington","country":"USA","lat":38.9071923,"lng":-77.0368707,"locationId":"93d339fbed1883798f9bbbe6d6bb650e05d90883","name":"District Of Columbia","state":"DC"},{"city":"Maywood","country":"USA","lat":41.8791979,"lng":-87.8431155,"locationId":"1a9283be212caa08c0350b892a0922390cfd1336","name":"Maywood","state":"IL"},{"city":"Boston","country":"USA","lat":42.3600825,"lng":-71.0588801,"locationId":"9315c83948709a902424882a27d3b6004c3fa65b","name":"Boston","state":"MA"},{"city":"Morristown","country":"USA","lat":40.79676670000001,"lng":-74.4815438,"locationId":"a44c57db33c2cb8dbd578b79782d6dc6b008640a","name":"Morristown","state":"NJ"},{"city":"Newark","country":"USA","lat":40.735657,"lng":-74.1723667,"locationId":"e58152170ca3ea9582156e33097da9ee77d5f121","name":"Newark","state":"NJ"},{"city":"Summit","country":"USA","lat":40.7146376,"lng":-74.3646122,"locationId":"b93f7217c85db05c8c5c928ef91a9800818ffc52","name":"Summit","state":"NJ"},{"city":"Lubbock","country":"USA","lat":33.5778631,"lng":-101.8551665,"locationId":"d5c657998792bb74800cd7ad0fc31fafca2375d8","name":"Lubbock","state":"TX"},{"city":"Milwaukee","country":"USA","lat":43.0389025,"lng":-87.9064736,"locationId":"b3ea14aed31bad1bb0ae0bcc3c1735c8b706dd0a","name":"Milwaukee","state":"WI"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04382586","https://www.drugbank.ca/drugs/DB15035","https://clinicaltrials.gov/ct2/show/NCT04382586#contacts","https://www.beigene.com/covid-response"],"sponsors":[{"sponsorId":"434ef2663aa327627ef0d2335c816613b5646c4f","sponsorName":"BeiGene"}],"status":"Ongoing","studyCompletionDate":"Thu, 01 Apr 2021 00:00:00 GMT","studyStartDate":"Mon, 01 Jun 2020 00:00:00 GMT","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Azithromycin","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"atomic2@ndorms.ox.ac.uk","name":null,"notes":"","phone":"01865227374","website":""}],"countries":["United Kingdom"],"countryCodes":["GBR"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Fri, 29 May 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"5","otherPartners":"Pfizer","phase":"3","preferredName":"Azithromycin","primaryCompletionDate":"Sun, 13 Sep 2020 00:00:00 GMT","productId":681,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04381962","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Banbury","country":"GBR","lat":52.0629009,"lng":-1.339775,"locationId":"7d33e527571b9d61c933ebfb70957b6cf0c90444","name":"Banbury","state":"England"},{"city":"Oxford","country":"GBR","lat":51.7520209,"lng":-1.2577263,"locationId":"687c3c7d4beed3334b5113342f79b970adde5fd7","name":"Oxford","state":"England"},{"city":"Dundee","country":"GBR","lat":56.462018,"lng":-2.970721,"locationId":"7375b9423a1ea5153dff66cba620faafe18deb28","name":"Dundee","state":"Scotland"},{"city":"Birmingham","country":"GBR","lat":52.48624299999999,"lng":-1.890401,"locationId":"3ed0f51b9c016533739feb32f95ba7162e60d6e7","name":"Birmingham","state":"England"},{"city":"West Bromwich","country":"GBR","lat":52.517664,"lng":-1.995159,"locationId":"52ae3ba8cb07a05d758b6351280d0ef0e2e0b5ae","name":"West Bromwich","state":"England"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04381962","https://www.drugbank.ca/drugs/DB00207"],"sponsors":[{"sponsorId":"38652628acf1b84b92cad2bea1a82015a920b0c3","sponsorName":"University of Oxford"},{"sponsorId":"531d5b28f1f18f219741627c0f2a1e09d355e46a","sponsorName":"Pfizer"}],"status":"Ongoing","studyCompletionDate":"Tue, 13 Oct 2020 00:00:00 GMT","studyStartDate":"Fri, 29 May 2020 00:00:00 GMT","therapeuticApproach":"Antibiotics and antiparasitics","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Levamisole,formoterol,budesonide","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"Dr.afazeli@gmail.com ; farjam.md@gmail.com","name":null,"notes":"","phone":"989121392982 ; 989177104789","website":""}],"countries":["Iran","Islamic Republic of"],"countryCodes":["IRN"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 04 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"This combined drug therapy is aimed at treating the ARDS associated with COVID-19 as well as the virus itself","numSites":"1","otherPartners":"","phase":"2","preferredName":"Levamisole,formoterol,budesonide","primaryCompletionDate":"Mon, 20 Apr 2020 00:00:00 GMT","productId":682,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04331470","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Tehran","country":"IRN","lat":35.7098012,"lng":51.3816297,"locationId":"4987c03038b0538e64e2b563c2d335929e355b51","name":"Vali","state":null}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04331470","https://www.drugbank.ca/drugs/DB00848 ; https://www.drugbank.ca/drugs/DB00983 ; https://www.drugbank.ca/drugs/DB01222"],"sponsors":[{"sponsorId":"169fcfe8011dadfe7b87f08c9ab8e63c8f10f1b0","sponsorName":"Fasa University of Medical Sciences"}],"status":"Ongoing","studyCompletionDate":"Wed, 20 May 2020 00:00:00 GMT","studyStartDate":"Sat, 04 Apr 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"MSTT1041A","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"global-roche-genentech-trials@gene.com","name":null,"notes":"","phone":"888-662-6728","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 02 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"Mechanism of Action is inhibition of interleukin-33","numSites":"24","otherPartners":"","phase":"2","preferredName":"MSTT1041A","primaryCompletionDate":"Fri, 29 Jan 2021 00:00:00 GMT","productId":683,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04386616","repurposed":"New","siteLocations":[{"city":"Chula Vista","country":"USA","lat":32.6172649,"lng":-117.024154,"locationId":"496ac27d333790aba3a67647d580cbb53c957483","name":"Estudysite","state":"CA"},{"city":"La Mesa","country":"USA","lat":32.7804422,"lng":-117.0094774,"locationId":"7c2d5a7e54e7e29ece96ee4b44b5bbba931be3a8","name":"Estudy Site","state":"CA"},{"city":"Torrance","country":"USA","lat":33.8118946,"lng":-118.3435467,"locationId":"213fe5a1789e9a8495cda7a294963d149ef42be2","name":"Torrance Memorial Medical Center","state":"CA"},{"city":"Hialeah","country":"USA","lat":25.868812,"lng":-80.312269,"locationId":"401691a6cd7f0ffbb496e493e230cda227a2e08a","name":"Larkin Community Hospital Palm Psring Campus","state":"FL"},{"city":"Tomball","country":"USA","lat":30.0849793,"lng":-95.6235351,"locationId":"fece3e2007b9483a686d4149ab5fb3cdbfc5497b","name":"Dm Clinical Research","state":"TX"},{"city":"Metairie","country":"USA","lat":30.01050529999999,"lng":-90.18101709999999,"locationId":"c6656030b980e7e99056468897e9edf94f413972","name":"Medpharmics","state":"LA"},{"city":"New Orleans","country":"USA","lat":29.9630768,"lng":-90.0846579,"locationId":"3383762725b65a991b90b28086edde3e73e08a38","name":"Southeast Lousiana Veterans Health Care System (navref)","state":"LA"},{"city":"Detroit","country":"USA","lat":42.3635633,"lng":-83.0750856,"locationId":"13570d400290d9141841bb3803145675d8baafaf","name":"Henry Ford Health System","state":"MI"},{"city":"Paterson","country":"USA","lat":40.9028953,"lng":-74.1653704,"locationId":"66603bf42feaf0a9fdb0867feff062195529fe47","name":"St.joseph's Regional Medical Center","state":"NJ"},{"city":"Albany","country":"USA","lat":42.6536483,"lng":-73.7771411,"locationId":"74e5f2cdd535722f10fcb925b6ea686940075e6e","name":"Albany Medical Center","state":"NY"},{"city":null,"country":"USA","lat":40.8160855,"lng":-73.9247762,"locationId":"21ae62e7b42a68e9d48bdfb457b88d36858d50a2","name":"Lincoln Medical Mental Health Center","state":"NY"},{"city":null,"country":"USA","lat":40.8556769,"lng":-73.8462363,"locationId":"72754bcd32231a1174e72cf615c3d63bd25a05b4","name":"Jacobi Medical Center Lewis M. Fraad Department Of Pediatrics","state":"NY"},{"city":null,"country":"USA","lat":40.5839485,"lng":-74.0876847,"locationId":"37e490777090185c47ea5708665c51e4ab0a1eea","name":"Staten Island University Hospital Department Of Pharmacy","state":"NY"},{"city":"Fayetteville","country":"USA","lat":35.0320636,"lng":-78.9345501,"locationId":"30d65415b607d5f8f5f9ab6076911d34ca82bc5a","name":"Cape Fear Valley Health System","state":"NC"},{"city":"Toledo","country":"USA","lat":41.6680317,"lng":-83.5427929,"locationId":"ce183c0618695fe465c0e3cbb22cd138f07cccee","name":"Mercy St. Vincent Medical Center","state":"OH"},{"city":"Portland","country":"USA","lat":45.5276578,"lng":-122.6125753,"locationId":"a4e35ed5985087ffd110b8a74957a748c944a9cc","name":"Providence Portland Medical Center Investigational Drug Service/ Regional Research","state":"OR"},{"city":"Allentown","country":"USA","lat":40.5667553,"lng":-75.5241629,"locationId":"c49326e4dd266b915c58350d2c2d4a99bbb79507","name":"Lehigh Valley Health Network","state":"PA"},{"city":"Philadelphia","country":"USA","lat":40.0058469,"lng":-75.1508915,"locationId":"84bc17861d37f12a17de714a4d78263b25e429fa","name":"Temple Uni Medical Center Pulmonary & Critical Care Medicine","state":"PA"},{"city":"Dallas","country":"USA","lat":32.8106256,"lng":-96.83830979999999,"locationId":"25d71421e2ec133d968d04df7d1376ff1a8234de","name":"Parkland Health & Hospital System","state":"TX"},{"city":"Dallas","country":"USA","lat":32.8143702,"lng":-96.84105029999999,"locationId":"68d2e401f6ff186ff4fc467b85fa3270b7473094","name":"University Of Texas Southwestern Medical Center","state":"TX"},{"city":"Richmond","country":"USA","lat":37.5483122,"lng":-77.4526805,"locationId":"357df415356d1c942ec5e2a34d70f8cb58e09a80","name":"Virginia Commonwealth University","state":"VA"},{"city":"Seattle","country":"USA","lat":47.6099974,"lng":-122.3277093,"locationId":"8f8522dd964bf620ac98b1f3aaa2eaaf520cc516","name":"Virginia Mason Medical Center","state":"WA"},{"city":"Tacoma","country":"USA","lat":47.259656,"lng":-122.4544832,"locationId":"a9932fa58c8a13c06f3c5dfb209fe17c9a25f086","name":"Multicare Institute For Research And Innovation Clinic/outpatient Facility","state":"WA"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04386616","https://adisinsight.springer.com/drugs/800038653","https://www.gene.com/contact-us/visit-us"],"sponsors":[{"sponsorId":"1cc9d3179b66670e4a36a366afbbe7179bae5329","sponsorName":"Genentech Inc"}],"status":"Ongoing","studyCompletionDate":"Wed, 03 Mar 2021 00:00:00 GMT","studyStartDate":"Tue, 02 Jun 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"UTTR1147A","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"global-roche-genentech-trials@gene.com","name":null,"notes":"","phone":"888-662-6728","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 02 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Mechanism of Action is activating IL-22R signaling","numSites":"24","otherPartners":"","phase":"2","preferredName":"UTTR1147A","primaryCompletionDate":"Fri, 29 Jan 2021 00:00:00 GMT","productId":684,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04386616","repurposed":"New","siteLocations":[{"city":"Chula Vista","country":"USA","lat":32.6172649,"lng":-117.024154,"locationId":"5cbce03d0907fec61c72b49ee24342b3dac17fe8","name":"Estudysite","state":"CA"},{"city":"La Mesa","country":"USA","lat":32.7804422,"lng":-117.0094774,"locationId":"d80e3a867dbdb33fb50be8c19cad973510d83bfd","name":"Estudy Site","state":"CA"},{"city":"Torrance","country":"USA","lat":33.8118946,"lng":-118.3435467,"locationId":"c0943b836f85a00569b9e57bc03ed5dda44ede97","name":"Torrance Memorial Medical Center","state":"CA"},{"city":"Hialeah","country":"USA","lat":25.868812,"lng":-80.312269,"locationId":"9bf0002b2cb1e953ee1caf4d4cdb16967503fb7f","name":"Larkin Community Hospital Palm Psring Campus","state":"FL"},{"city":"Tomball","country":"USA","lat":30.0849793,"lng":-95.6235351,"locationId":"25cbbee8f76d42bf743174bf8e08205a3311f451","name":"Dm Clinical Research","state":"TX"},{"city":"Metairie","country":"USA","lat":30.01050529999999,"lng":-90.18101709999999,"locationId":"d9a8cbcdfe6fc611a715ed1469bfd8295d82bab6","name":"Medpharmics","state":"LA"},{"city":"New Orleans","country":"USA","lat":29.9630768,"lng":-90.0846579,"locationId":"ff0ded3096367d51bf0531ed1e6278db5ad85246","name":"Southeast Lousiana Veterans Health Care System (navref)","state":"LA"},{"city":"Detroit","country":"USA","lat":42.3635633,"lng":-83.0750856,"locationId":"09b1e8ea5d6e4012e449b950056d571ac3a7f089","name":"Henry Ford Health System","state":"MI"},{"city":"Paterson","country":"USA","lat":40.9028953,"lng":-74.1653704,"locationId":"86315432fa118bda677bbdb722844412801979d3","name":"St.joseph's Regional Medical Center","state":"NJ"},{"city":"Albany","country":"USA","lat":42.6536483,"lng":-73.7771411,"locationId":"69b27f7acadf6f239585171022be881f22b15fda","name":"Albany Medical Center","state":"NY"},{"city":null,"country":"USA","lat":40.8160855,"lng":-73.9247762,"locationId":"8f8cabf85382ee42db0c7bc3271533d8fa04a05c","name":"Lincoln Medical Mental Health Center","state":"NY"},{"city":null,"country":"USA","lat":40.8556769,"lng":-73.8462363,"locationId":"7603f9837fb274ae6f195e10afcb92adfd5513f2","name":"Jacobi Medical Center Lewis M. Fraad Department Of Pediatrics","state":"NY"},{"city":null,"country":"USA","lat":40.5839485,"lng":-74.0876847,"locationId":"4b63bd4e2b03cf8b33d489059d7248aca038b030","name":"Staten Island University Hospital Department Of Pharmacy","state":"NY"},{"city":"Fayetteville","country":"USA","lat":35.0320636,"lng":-78.9345501,"locationId":"c6cfe9b6d87465e255f662bee1c24327746d8c3b","name":"Cape Fear Valley Health System","state":"NC"},{"city":"Toledo","country":"USA","lat":41.6680317,"lng":-83.5427929,"locationId":"1c073b40983bdfd072a8ee0caecd2ef764071caf","name":"Mercy St. Vincent Medical Center","state":"OH"},{"city":"Portland","country":"USA","lat":45.5276578,"lng":-122.6125753,"locationId":"21d289efcbc505ba9c31f5d8a9bf8cd48d17b14a","name":"Providence Portland Medical Center Investigational Drug Service/ Regional Research","state":"OR"},{"city":"Allentown","country":"USA","lat":40.5667553,"lng":-75.5241629,"locationId":"530aed29b008e3becafa8e8acbfd9690a1e561ce","name":"Lehigh Valley Health Network","state":"PA"},{"city":"Philadelphia","country":"USA","lat":40.0058469,"lng":-75.1508915,"locationId":"84a62fc2daaed4c8503b13820f634829f94f2058","name":"Temple Uni Medical Center Pulmonary & Critical Care Medicine","state":"PA"},{"city":"Dallas","country":"USA","lat":32.8106256,"lng":-96.83830979999999,"locationId":"71050ae7152437fcf089078e0db2d5aeede2a017","name":"Parkland Health & Hospital System","state":"TX"},{"city":"Dallas","country":"USA","lat":32.8143702,"lng":-96.84105029999999,"locationId":"3c074b1cc39b3ce723a87f962af0f31ddd035c6f","name":"University Of Texas Southwestern Medical Center","state":"TX"},{"city":"Richmond","country":"USA","lat":37.5483122,"lng":-77.4526805,"locationId":"671eb0cf9921b70d98621a1151d250ba02b514b9","name":"Virginia Commonwealth University","state":"VA"},{"city":"Seattle","country":"USA","lat":47.6099974,"lng":-122.3277093,"locationId":"2646681a3d677d8390cc9f72ff856abce8dd2dc6","name":"Virginia Mason Medical Center","state":"WA"},{"city":"Tacoma","country":"USA","lat":47.259656,"lng":-122.4544832,"locationId":"ddf5ceb7c56413bd764ecbe4a15f7b16aec533f8","name":"Multicare Institute For Research And Innovation Clinic/outpatient Facility","state":"WA"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04386616","https://www.gene.com/medical-professionals/pipeline","https://www.gene.com/contact-us/visit-us"],"sponsors":[{"sponsorId":"1cc9d3179b66670e4a36a366afbbe7179bae5329","sponsorName":"Genentech Inc"}],"status":"Ongoing","studyCompletionDate":"Wed, 03 Mar 2021 00:00:00 GMT","studyStartDate":"Tue, 02 Jun 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"metenkefalin,tridecactide","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"Jasna.Dzananovic@Bosnalijek.com","name":null,"notes":"","phone":"38733560603","website":""}],"countries":["Bosnia and Herzegovina"],"countryCodes":["BIH"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"This combined drug treatment is a immunomodulatory therapy to prevent as much tissue damage associated with COVID-19","numSites":"1","otherPartners":"","phase":"2","preferredName":"metenkefalin,tridecactide","primaryCompletionDate":"Sat, 31 Oct 2020 00:00:00 GMT","productId":685,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Sarajevo","country":"BIH","lat":43.8691644,"lng":18.4156868,"locationId":"a04195a5f6eeb4b23004eb0596c4ddf0bd8e8148","name":"Clinical Center University Of Sarajevo","state":"Federacija Bosne i Hercegovine"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04374032","https://www.drugbank.ca/drugs/DB12668 ; https://www.drugbank.ca/drugs/DB15687","http://www.bosnalijek.com/","https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2"],"sponsors":[{"sponsorId":"3e0a4169cedbfca56363d1777ac5493edf56ed33","sponsorName":"Bosnalijek DD"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Fri, 01 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Melatonin","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"sadegh.bagheri@gmail.com","name":null,"notes":"","phone":"0098 9356319204","website":""}],"countries":["Iran","Islamic Republic of"],"countryCodes":["IRN"],"currentStage":"","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Melatonin is being investigated for its potential anti-inflammatory effects in treatment of COVID-19","numSites":"1","otherPartners":"","phase":"","preferredName":"Melatonin","primaryCompletionDate":"Fri, 05 Jun 2020 00:00:00 GMT","productId":686,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04409522","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Tehran","country":"IRN","lat":35.6891975,"lng":51.3889736,"locationId":"3c91505d0fe92132503201831df43894f8ae6183","name":"Mohammad Sadegh Bagheri Baghdast","state":"Tehran Province"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04409522","https://www.drugbank.ca/drugs/DB01065"],"sponsors":[{"sponsorId":"00b2d29bf7b45cc1c59c38b5a33f94d0f62c2818","sponsorName":"Baqiyatallah Medical Sciences University"}],"status":"Ongoing","studyCompletionDate":"Fri, 25 Sep 2020 00:00:00 GMT","studyStartDate":"Tue, 12 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Iloprost","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"Per.johansson@regionh.dk ; Anders.Perner@regionh.dk","name":null,"notes":"","phone":"45 3545 2030 ; 45 3545 8333","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 15 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"This drug is being investigated for restoring vascular integrity in COVID-19 patients from respiratory failure.","numSites":"5","otherPartners":"","phase":"2","preferredName":"Iloprost","primaryCompletionDate":"Mon, 31 May 2021 00:00:00 GMT","productId":687,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04420741","repurposed":"Repurposed-Approved","siteLocations":[{"city":"K\u00f8benhavn","country":"CNK","lat":55.7140142,"lng":12.5401313,"locationId":"956f360d89b2f3a2ea8ed3cb29b7502e4b24711f","name":"Bispebjerg Hospital (dept. Of Anaethesia And Intensive Care)","state":null},{"city":"K\u00f8benhavn","country":"CNK","lat":55.6960841,"lng":12.5667877,"locationId":"85a723ada4e5d6f7b67ffcaaeef9a78ae7109a21","name":"Rigshopitalet (dept. Of Intensive Care)","state":null},{"city":"Herlev","country":"CNK","lat":55.7312255,"lng":12.44334,"locationId":"56383864e4aa5f2475e9ec0b671c8c7cd9089e34","name":"Copenhagen University Hospital Herlev (dept. Of Intensive Care)","state":null},{"city":"Hiller\u00f8d","country":"CNK","lat":55.930868,"lng":12.326221,"locationId":"3e7cc86f471514498f2e9904ec481dc6ea443c7a","name":"Nordsjaelands Hospital(dept. Of Anaesthesia And Intensive Care)","state":null},{"city":"Hvidovre","country":"CNK","lat":55.648779,"lng":12.470292,"locationId":"b5f2f03dc1a37f36abe54be74156c60e4662090d","name":"Hvidovre Hospital (dept. Anaesthesia And Intensive Care)","state":null}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04420741","https://www.drugbank.ca/drugs/DB01088"],"sponsors":[{"sponsorId":"3e34a11c6c1d9a73c04130f5f4a376615cbe7117","sponsorName":"Rigshospitalet"},{"sponsorId":"3f2cf252bd7183f751952ba8b138339621c9fbdc","sponsorName":"Hamad Medical Corporation"}],"status":"Ongoing","studyCompletionDate":"Mon, 31 May 2021 00:00:00 GMT","studyStartDate":"Mon, 15 Jun 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Progesterone","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"Vanessa.Vasco@csmns.org","name":null,"notes":"","phone":"3109677451","website":""}],"countries":["Switzerland"],"countryCodes":["CHE"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 27 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"This drug is being investigated in men with COVID-19 as an anti-inflammatory drug","numSites":"1","otherPartners":"","phase":"1","preferredName":"Progesterone","primaryCompletionDate":"Tue, 01 Sep 2020 00:00:00 GMT","productId":688,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04365127","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Los Angeles","country":"USA","lat":34.075232,"lng":-118.3801756,"locationId":"97c7941986522999488606bd9dbadb086b3dd952","name":"Cedars Sinai Medical Center","state":"CA"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04365127","https://www.drugbank.ca/drugs/DB00396","https://www.ibsagroup.com/ibsa-group/ibsa-headquarter.html","https://www.healio.com/news/endocrinology/20200507/study-examines-progesterone-to-reduce-inflammation-in-covid19"],"sponsors":[{"sponsorId":"810a11cfef19294172551c5c929f93ca1fbf010f","sponsorName":"IBSA Institut Biochimique SA"}],"status":"Ongoing","studyCompletionDate":"Sat, 17 Apr 2021 00:00:00 GMT","studyStartDate":"Mon, 27 Apr 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"Bacille Calmette-Gu\u00e9rin (BCG)","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"nigel.curtis@rch.org.au ; kaya.gardiner@mcri.edu.au","name":null,"notes":"","phone":"613 93456366 ; 613 99366461","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 30 Mar 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"6","otherPartners":"","phase":"3","preferredName":"Bacille Calmette-Gu\u00e9rin (BCG)","primaryCompletionDate":"Fri, 30 Oct 2020 00:00:00 GMT","productId":689,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04327206","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Sydney","country":"AUS","lat":-33.8688197,"lng":151.2092955,"locationId":"48650e4ea3cb7ac41a992f6fee0589916a19ca49","name":"Sydney","state":"NSW"},{"city":"Breda","country":"NLD","lat":51.5719149,"lng":4.768323,"locationId":"55fee514d3f247e0abcd4a35ede0e74024503675","name":"Breda","state":"NB"},{"city":"Nieuwegein","country":"NLD","lat":52.02482080000001,"lng":5.0918192,"locationId":"8f1a5e05caaa5db69e8f524a1c24b12bcb298089","name":"Nieuwegein","state":"UT"},{"city":"Barcelona","country":"ESP","lat":41.3850639,"lng":2.1734035,"locationId":"0150bf2b19030f935fca9dc12342f2bfe4f1bf19","name":"Barcelona","state":"CT"},{"city":"Seville","country":"ESP","lat":37.3890924,"lng":-5.9844589,"locationId":"ac79b2d6972cadafeb591c404acc684060ec0035","name":"Sevilla","state":"AL"},{"city":null,"country":"GBR","lat":50.7186385,"lng":-3.5212291,"locationId":"b309a31a3bd1a3f5cb36797b22701600a0548484","name":"St Leonards","state":"England"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04327206","https://www.cdc.gov/tb/publications/factsheets/prevention/bcg.htm"],"sponsors":[{"sponsorId":"25c88e3eb4d93b08b56cb1cb400c834d542cbee4","sponsorName":"Murdoch Childrens Research Institute"},{"sponsorId":"370728988e10a6f311c1f384a3cb85477753b1a2","sponsorName":"TASK Applied Science"},{"sponsorId":"1a862ddc71a8eb4c93961805a869c775316c9c3a","sponsorName":"Texas AM University"},{"sponsorId":"2dd4e69fcd3ebe36b954676861c245a30a347d30","sponsorName":"UMC Utrecth"},{"sponsorId":"15efcaf1de08b9cb2b76f392d4957714c2609c4c","sponsorName":"Radboud University"}],"status":"Ongoing","studyCompletionDate":"Wed, 30 Mar 2022 00:00:00 GMT","studyStartDate":"Mon, 30 Mar 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Tigerase","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"evzuev@generium.ru ; oamarkova@generium.ru","name":null,"notes":"","phone":"79466419698 ; 7 9854418959","website":""}],"countries":["Russian Federation"],"countryCodes":["RUS"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 01 Jun 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"This drug is currently approved in Russia for treatment of cystic fibrosis","numSites":"6","otherPartners":"","phase":"3","preferredName":"Tigerase","primaryCompletionDate":"Mon, 20 Jul 2020 00:00:00 GMT","productId":690,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04459325","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"\u041c\u043e\u0441\u043a\u0432\u0430","country":"RUS","lat":55.6184196,"lng":37.6541907,"locationId":"737417a243793b575c6c1fa7c59cf95e95a8a78f","name":"City Clinical Hospital #15","state":null},{"city":"Moskva","country":"RUS","lat":55.7301734,"lng":37.56690330000001,"locationId":"87974c51adf6057e0605dd087d602bc709e1bb6c","name":"I.m. Sechenov First Moscow State Medical University (sechenov University)","state":null},{"city":"\u041c\u043e\u0441\u043a\u0432\u0430","country":"RUS","lat":55.6184196,"lng":37.6541907,"locationId":"f0f431183846de790239a3bfbaeab875ce802da4","name":"City Clinical Hospital #51","state":null},{"city":"\u041c\u043e\u0441\u043a\u0432\u0430","country":"RUS","lat":55.6184196,"lng":37.6541907,"locationId":"4f8c24b8573030676c3ccd0e0eedb624c40b2bdd","name":"City Clinical Hospital #52","state":null},{"city":"Tomsk","country":"RUS","lat":56.4728589,"lng":84.9491219,"locationId":"40d44c6a84a464e1656f0ec6fab16ebf5ddf1f1a","name":"Siberian State Medical University (sibmed)","state":"Tomskaya oblast'"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04459325"],"sponsors":[{"sponsorId":"99634b02a898f433bdd576736a09577778a6144d","sponsorName":"AO GENERIUM"}],"status":"Ongoing","studyCompletionDate":"Mon, 20 Jul 2020 00:00:00 GMT","studyStartDate":"Mon, 01 Jun 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"N-acetylcysteine","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"vardhans@mskcc.org","name":null,"notes":"","phone":"646-888-3285","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"N-acetylcysteine","primaryCompletionDate":"Sat, 01 May 2021 00:00:00 GMT","productId":691,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04374461","repurposed":"Repurposed-Approved","siteLocations":[{"city":"New York","country":"USA","lat":40.7641925,"lng":-73.95624029999999,"locationId":"b4743430e3c891064978d2f199bee1b8ef7b9aff","name":"Memorial Sloan Kettering Cancer Center","state":"NY"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04374461","https://www.drugbank.ca/drugs/DB06151","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261085/"],"sponsors":[{"sponsorId":"c576f01fc28e684ff10c286a469e1a66ad86244c","sponsorName":"Memorial Sloan Kettering Cancer Center"}],"status":"Ongoing","studyCompletionDate":"Sat, 01 May 2021 00:00:00 GMT","studyStartDate":"Fri, 01 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Melphalan","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"kirillaz@inbox.ru\t","name":null,"notes":"","phone":"","website":""}],"countries":["Russian Federation"],"countryCodes":["RUS"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Chemotherapeutic","numSites":"1","otherPartners":"","phase":"2","preferredName":"Melphalan","primaryCompletionDate":"Fri, 30 Oct 2020 00:00:00 GMT","productId":692,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04380376","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Moscow","country":"RUS","lat":55.8544746,"lng":37.3660566,"locationId":"3aa11feb39c4bedb04f17496acc7ba91a6131983","name":"Moscow","state":null}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04380376","https://www.drugbank.ca/drugs/DB01042"],"sponsors":[{"sponsorId":"de240dedbb333ee63330c2e0ea844b8d8eab0384","sponsorName":"Federal State Budgetary Institution  Pulmonology Scientific Research Institute"}],"status":"Ongoing","studyCompletionDate":"Fri, 30 Oct 2020 00:00:00 GMT","studyStartDate":"Thu, 30 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"DFV890","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"novartis.email@novartis.com        ","name":null,"notes":"","phone":"","website":""}],"countries":["Denmark"],"countryCodes":["DNK"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Inhibitor of NLRP3","numSites":"10","otherPartners":"","phase":"2","preferredName":"DFV890","primaryCompletionDate":"","productId":693,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04382053","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Copenhagen","country":"CNK","lat":55.714619,"lng":12.5287293,"locationId":"ddcb30b084945a6819179d12d1be0c77c5189d44","name":"Copenhagen","state":null},{"city":"Hvidovre","country":"CNK","lat":55.6240369,"lng":12.4771974,"locationId":"121bb0743d7af54c19d2cc7584a4677b1ece4d91","name":"Hvidovre","state":null},{"city":"Heidelberg","country":"DEU","lat":49.3693394,"lng":8.693508099999999,"locationId":"2265be7f720bf6c15469c4538844924d2d4687c3","name":"Heidelberg","state":"BW"},{"city":"Regensburg","country":"DEU","lat":49.0134297,"lng":12.1016236,"locationId":"2f0f41fc3615e9fb987bd4e15432e64a00f769df","name":"Regensburg","state":"BY"},{"city":"BN","country":"DEU","lat":50.73743,"lng":7.0982068,"locationId":"77eb491f16a3d147715a18018238465a643564a6","name":"Bonn","state":"NRW"},{"city":"Hanover","country":"DEU","lat":52.3763832,"lng":9.8026933,"locationId":"e33613ef91736d53f739e736cadb2bbb3852ae5b","name":"Hannover","state":"NDS"},{"city":"W\u00dc","country":"DEU","lat":49.79130439999999,"lng":9.9533548,"locationId":"eadc783818cbac92f9802e8d295226628850d868","name":"Wuerzburg","state":"BY"},{"city":"Budapest","country":"HUN","lat":47.497912,"lng":19.040235,"locationId":"e18c8b7800aad0c12b0f28f7b58554fabba45600","name":"Budapest","state":null},{"city":"Budapest","country":"HUN","lat":47.4540768,"lng":19.0943343,"locationId":"afcddc1d6dbb70e333c97977cb8d9a2ecc41216f","name":"Budapest","state":null},{"city":"Harderwijk","country":"NLD","lat":52.3422025,"lng":5.6367423,"locationId":"d36a0670c29501e7ef62a88e730a82b38a875bd6","name":"Harderwijk","state":"GE"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04382053","https://medwatch.dk/Top_picks_in_english/article12214057.ece"],"sponsors":[{"sponsorId":"958604794b99b1af30fcaaf34a66324bbc90348d","sponsorName":"Novartis Pharmaceuticals"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Wed, 27 May 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"Fluoxetine","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"cheryl.mccullumsmith@utoledo.edu        ","name":null,"notes":"","phone":"4193835651","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 4","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Small molecule","notes":"Antidepressant","numSites":"1","otherPartners":"","phase":"4","preferredName":"Fluoxetine","primaryCompletionDate":"Tue, 20 Apr 2021 00:00:00 GMT","productId":694,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04377308","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Toledo","country":"USA","lat":41.6578804,"lng":-83.6142374,"locationId":"c541bcd806918761f1c3d6cf44043cc3b8572dc4","name":"University Of Toledo","state":"OH"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04377308","https://www.drugbank.ca/drugs/DB00472","https://medicine.wustl.edu/news/study-to-evaluate-antidepressant-as-potential-covid-19-treatment/"],"sponsors":[{"sponsorId":"9326f44d8c17be59503fdab91614bc83c4cd631b","sponsorName":"University of Toledo Health Science Campus"}],"status":"Ongoing","studyCompletionDate":"Wed, 20 Oct 2021 00:00:00 GMT","studyStartDate":"Fri, 01 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Clazakizumab","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"noriko.ammerman@cshs.org\t","name":null,"notes":"","phone":"310-248-8186","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"Clazakizumab","primaryCompletionDate":"","productId":695,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04348500","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Los Angeles","country":"USA","lat":34.075232,"lng":-118.3801756,"locationId":"fd1b5a0a2765317c82e7746c427943667b56a5a5","name":"Cedars","state":"CA"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04348500","https://www.drugbank.ca/drugs/DB12849"],"sponsors":[{"sponsorId":"e5b332c4009ba58797ec42566d7cf563aabdc215","sponsorName":"CedarsSinai Medical Center"},{"sponsorId":"491682d08f8b84eaabfc2121e730b32aa0da34d4","sponsorName":"Johns Hopkins University"}],"status":"Ongoing","studyCompletionDate":"Tue, 31 Mar 2020 00:00:00 GMT","studyStartDate":"Fri, 24 Apr 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Defibrotide","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"jmoraled@um.es        ","name":null,"notes":"","phone":"","website":""}],"countries":["Spain"],"countryCodes":["ESP"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Nucleic acid based therapies/vaccines","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"Defibrotide","primaryCompletionDate":"Fri, 15 Jan 2021 00:00:00 GMT","productId":696,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04348383","repurposed":"Repurposed-Approved","siteLocations":[{"city":"El Palmar","country":"ESP","lat":37.9326574,"lng":-1.162527,"locationId":"47ff701e9efa64a4efa6330ab0f8b6c6e593e893","name":"Virgen De La Arrixaca University Clinical Hospital","state":"Regi\u00f3n de Murcia"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04348383","https://www.drugbank.ca/drugs/DB04932"],"sponsors":[{"sponsorId":"7a22957f1b52dec631aa77a48e9b62a663c72aea","sponsorName":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia"}],"status":"Ongoing","studyCompletionDate":"Fri, 15 Jan 2021 00:00:00 GMT","studyStartDate":"Wed, 08 Apr 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"JS016","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"13816357098@163.com","name":null,"notes":"","phone":"","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"1","otherPartners":"","phase":"1","preferredName":"JS016","primaryCompletionDate":"","productId":697,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04441918","repurposed":"Repurposed-Approved","siteLocations":[{"city":null,"country":"CHN","lat":31.216624,"lng":121.443046,"locationId":"849a20133d360a294acefdb0399f989678d7bc7b","name":"Huashan Hospital Affiliated To Fudan University","state":"Shanghai Shi"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04441918","https://www.pharmaceutical-business-review.com/news/eli-lilly-junshi-covid-19-trial/"],"sponsors":[{"sponsorId":"d069f9390b3d2a799efdba5329c0b415dd610a4b","sponsorName":"Shanghai Junshi Bioscience Co Ltd"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Fri, 05 Jun 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"GLS-1200","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"jmaslow@geneonels-us.com","name":null,"notes":"","phone":"610-707-5671","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Wed, 06 May 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Other","notes":"Stimulates NO production which reduces coronavirus efficacy","numSites":"2","otherPartners":"","phase":"2","preferredName":"GLS-1200","primaryCompletionDate":"Mon, 01 Feb 2021 00:00:00 GMT","productId":698,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04408183","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Philadelphia","country":"USA","lat":39.9522188,"lng":-75.1932137,"locationId":"4fd9a19c5406a17dbadb925ed55367b8194d20a5","name":"University Of Pennsylvania","state":"PA"},{"city":"Baton Rouge","country":"USA","lat":30.4514677,"lng":-91.18714659999999,"locationId":"ca752c0ee50bfc08221cfa748a80c637c6c60b61","name":"Baton Rouge","state":"LA"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04408183","https://www.oindpnews.com/2020/05/fda-approves-ind-for-phase-2-study-of-geneone-life-science-nasal-spray-for-the-prevention-of-covid-19/"],"sponsors":[{"sponsorId":"a16b70b82bdd9b5e61c50e750862a8851ee80507","sponsorName":"GeneOne Life Science"},{"sponsorId":"72a5f6c42a6c39ea891ecb24d22128fd281d0e18","sponsorName":"Inc"}],"status":"Ongoing","studyCompletionDate":"Mon, 01 Mar 2021 00:00:00 GMT","studyStartDate":"Mon, 01 Jun 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Garadacimab","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"clinicaltrials@cslbehring.com        ","name":null,"notes":"","phone":"","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"Garadacimab","primaryCompletionDate":"","productId":699,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04409509","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Vineland","country":"USA","lat":39.4792442,"lng":-75.0119934,"locationId":"5ca8712a43d516b0cb4ec076d55637780a8403c6","name":"Inspira Health Center Vineland","state":"NJ"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04409509"],"sponsors":[{"sponsorId":"55f0aa800f25c9093f14e24ae7f37b8f48615a59","sponsorName":"CSL Behring"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Wed, 01 Jul 2020 00:00:00 GMT","therapeuticApproach":"Monoclonal antibodies","trialId":""},{"acceptsHealthySubjects":"No","brandName":"ArtemiC","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"nadyal@galilee-cbr.com","name":null,"notes":"","phone":"972529573063","website":""}],"countries":["Israel"],"countryCodes":["ISR"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 05 May 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"3","otherPartners":"","phase":"2","preferredName":"ArtemiC","primaryCompletionDate":"Sun, 01 Nov 2020 00:00:00 GMT","productId":700,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04382040","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Hadera","country":"ISR","lat":32.451313,"lng":34.895778,"locationId":"5dd8774fd148fb3821fe9e1ca929cb278dd5d536","name":"Hillel Yaffe Medical Center","state":"Haifa District"},{"city":"Nazareth","country":"ISR","lat":32.702209,"lng":35.2921401,"locationId":"09b2129cd56a370f69fcc40a1659b904b3973eb8","name":"Nazareth Hospital Emms","state":"North District"},{"city":"Haifa","country":"ISR","lat":32.8329875,"lng":34.9857066,"locationId":"6e71aa6503aea7af3cf3d7dc65cd20e6b17efea1","name":"Rambam Health Care Campus","state":"Haifa District"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04382040","https://www.clinicaltrialsarena.com/news/mgc-phase-ii-artemic-covid-19/"],"sponsors":[{"sponsorId":"fb1a448d595002a76acc688e10e55f9b1bc11137","sponsorName":"MGC Pharmaceuticals doo"}],"status":"Ongoing","studyCompletionDate":"Fri, 01 Jan 2021 00:00:00 GMT","studyStartDate":"Fri, 08 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"CERC-002","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"jwilkins@cerecor.com","name":null,"notes":"","phone":"6104575095","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Sun, 28 Jun 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Tue, 02 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"2","otherPartners":"","phase":"2","preferredName":"CERC-002","primaryCompletionDate":"Thu, 01 Oct 2020 00:00:00 GMT","productId":701,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04412057","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Fayetteville","country":"USA","lat":35.0317827,"lng":-78.93507029999999,"locationId":"4123b01821e516dc9fa07edee5ed0c6de84fe574","name":"Cape Fear Valley Medical Center","state":"NC"},{"city":"Fayetteville","country":"USA","lat":35.0423538,"lng":-78.9230338,"locationId":"8c7f0edae9f88293ae9534ac2aab3baa6fc1b3a8","name":"Carolina Institute For Clinical Research Llc","state":"NC"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04412057","https://ir.cerecor.com/press-releases/detail/94/cerecor-announces-fda-clearance-of-ind-for-cerc-002-in","https://clinicaltrials.gov/ct2/show/study/NCT04412057","https://www.cerecor.com/resources/related-publications/cerc-002-publications","https://www.cerecor.com/pipeline"],"sponsors":[{"sponsorId":"52b90346e93819a6411f86d06609490e4214e09b","sponsorName":"Aevi Genomic Medicine LLC"},{"sponsorId":"494058da7e8f7b7a41aee4e24ceb5ea1567e8aee","sponsorName":"Cerecor"}],"status":"Ongoing","studyCompletionDate":"Sun, 01 Nov 2020 00:00:00 GMT","studyStartDate":"Tue, 02 Jun 2020 00:00:00 GMT","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"No","brandName":"BMS-986253","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"cancerclinicaltrials@cumc.columbia.edu","name":null,"notes":"","phone":"2123425162","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 15 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Drug indication for solid tumor,COVID-19,and hematological malignancy","numSites":"1","otherPartners":"Bristol-Myers Squibb","phase":"2","preferredName":"BMS-986253","primaryCompletionDate":"Wed, 01 Sep 2021 00:00:00 GMT","productId":702,"registryLink":"https://clinicaltrials.gov/ct2/show/record/NCT04347226","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"New York","country":"USA","lat":40.8412426,"lng":-73.9409706,"locationId":"75b4448b96753a73f0c94cf914cee01f02fc06e9","name":"Columbia University Irving Medical Center","state":"NY"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04347226","https://clinicaltrials.gov/ct2/show/record/NCT04347226","https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-il-8-monoclonal-antibody-humax-il8","https://clinicaltrials.gov/ct2/show/study/NCT04347226"],"sponsors":[{"sponsorId":"930d83a6a56629a85b56e48193bd300b9cb6c258","sponsorName":"BristolMyers Squibb"}],"status":"Ongoing","studyCompletionDate":"Thu, 01 Sep 2022 00:00:00 GMT","studyStartDate":"Wed, 15 Apr 2020 00:00:00 GMT","therapeuticApproach":"Kinase inhibitors","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Anluohuaxian","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"john131212@sina.com","name":null,"notes":"","phone":"13911405123","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 1","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 01 Apr 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Unknown","notes":"","numSites":"9","otherPartners":"","phase":"1","preferredName":"Anluohuaxian","primaryCompletionDate":"Mon, 01 Jun 2020 00:00:00 GMT","productId":703,"registryLink":"https://clinicaltrials.gov/ct2/show/record/NCT04334265","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Fuyang Shi","country":"CHN","lat":33.164296,"lng":115.628262,"locationId":"d39c6b7c55fd8887ad21eccd18252454a6889103","name":"The Second People's Hospital Of Fuyang","state":"Anhui Sheng"},{"city":"Ezhou Shi","country":"CHN","lat":30.3987825,"lng":114.8819099,"locationId":"6e16eedd024f70077e8fce97b623710f6d5ece03","name":"Ezhou Central Hospital","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.6668794,"lng":114.2868443,"locationId":"7f2e029c499e2e1714611bcb305c8a54e3a84e09","name":"Huoshenshan Hospital Of Wuhan","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.6668794,"lng":114.2868443,"locationId":"dd6ef27ac9d15d1449476eb2e0d74ae2ccc8d136","name":"Jinyinyan Hospital Of Wuhan","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.5130043,"lng":114.4202756,"locationId":"56e644c9cd3eb819be59b1a7fcc8c7d8387c2716","name":"Tongji Hospital Of Huazhong University Of Science And Technology","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.4917469,"lng":114.1732702,"locationId":"a709f20515a0d4ae4e52ae260afcbfa98cefb5bf","name":"West Hospital Union Hospital Huazhong University Of Science And Technology","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.552985,"lng":114.353743,"locationId":"d72643837b408430f3332aa5b4055163a6557f9a","name":"Wuhan Pulmonary Hospital","state":"Hubei Sheng"},{"city":"Wuhan Shi","country":"CHN","lat":30.552985,"lng":114.353743,"locationId":"5eaf3bd2a8d206bb01bce167e0c0aeaf723f112d","name":"Zhongnan Hospital Of Wuhan University","state":"Hubei Sheng"},{"city":"Wenzhou","country":"CHN","lat":27.939761,"lng":120.695887,"locationId":"6edd28603f96a126890368afbca9f2772ae148ae","name":"Wenzhou Medical University Affiliated First Hospital","state":null}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04334265","https://clinicaltrials.gov/ct2/show/record/NCT04334265","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276971/","https://clinicaltrials.gov/ct2/show/study/NCT04334265","https://clinicaltrials.gov/ct2/show/study/NCT04334265#contacts"],"sponsors":[{"sponsorId":"e3b26f3f63704a702040cad0b3d5f4ff56f7360a","sponsorName":"Peking University First Hospital"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Wed, 01 Apr 2020 00:00:00 GMT","therapeuticApproach":"Unknown","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Polyoxidonium","chemicalName":"azoximer bromide","conditionOrDisease":"COVID-19","contact":[{"email":"dodonovns@petrovax.ru","name":null,"notes":"","phone":"7 (495)7307545 ext 125","website":""}],"countries":["Russian Federation"],"countryCodes":["RUS"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 29 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 29 Apr 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"Azoximer bromide acts as an immune adjuvent.","numSites":"12","otherPartners":"","phase":"2","preferredName":"azoximer bromide","primaryCompletionDate":"Thu, 01 Apr 2021 00:00:00 GMT","productId":704,"registryLink":"https://clinicaltrials.gov/ct2/show/record/NCT04381377","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Barnaul","country":"RUS","lat":53.3497499,"lng":83.78357369999999,"locationId":"3d80296a6b514b52392c82a53db493cd0d694f2c","name":"City Hospital No. 5 Of Barnaul","state":"Altai Krai"},{"city":"Moscow","country":"RUS","lat":55.755826,"lng":37.6172999,"locationId":"8d2cba7b87cd1c54268eb6fac1cb05bd0f34f0a6","name":"Central Research Institute Of Epidemiology Of Rospotrebnadzor","state":null},{"city":"Moscow","country":"RUS","lat":55.755826,"lng":37.6172999,"locationId":"e3d0e26069cb8051616bf07a1376850e24e4eb92","name":"City Clinical Hospital No. 15 Named After Om Filatov","state":null},{"city":"Moscow","country":"RUS","lat":55.755826,"lng":37.6172999,"locationId":"2f44c14ffe4a1e22f71b1c3c882042c450984515","name":"Infectious Clinical Hospital No. 1 Of The Moscow Department Of Healthcare","state":null},{"city":"Moskva","country":"RUS","lat":55.7497603,"lng":37.3897148,"locationId":"a19f7f009dfbe5f3a076e3232b8a945a3067533e","name":"City Clinical Hospital No. 24 Of The Moscow Department Of Healthcare","state":null},{"city":"Moskva","country":"RUS","lat":55.6471984,"lng":37.4904372,"locationId":"a4b9ecb88103e3e2a2fe989d613d56c54c93a96c","name":"Research Institute Of Emergency Care Named After N.v. Sklifosovsky In Department Of Health Of The City Of Moscow","state":null},{"city":"Moscow","country":"RUS","lat":55.755826,"lng":37.6172999,"locationId":"17e72a3959dde8b92d9b402565d58aafb6b9c509","name":"City Clinical Hospital No. 40 Of The Moscow Department Of Healthcare","state":null},{"city":"Nizhny Novgorod","country":"RUS","lat":56.3268684,"lng":44.0058793,"locationId":"569172f5cb7329ca5725a397efe51ede6592c9d5","name":"Infectious Clinical Hospital No. 2 Of Nizhny Novgorod","state":"Nizhny Novgorod Oblast"},{"city":"Orenburg","country":"RUS","lat":51.7562809,"lng":55.105858,"locationId":"819b52e020cd04b8c055b165892d868781916a19","name":"Orenburg State Medical University","state":"Orenburgskaya oblast'"},{"city":"\u0421\u041f\u0411","country":"RUS","lat":59.9645655,"lng":30.3206798,"locationId":"a01adaea068e0fdf3e29acb845b0b5d2a62e8cdb","name":"First St. Petersburg State Medical University Named After Academician I.p. Pavlov","state":null},{"city":"Vladimir","country":"RUS","lat":56.1428026,"lng":40.3895795,"locationId":"d4750f7ebfe73756de1fe1ea17ebd893da5e1a9c","name":"Regional Clinical Hospital","state":"Vladimir Oblast"},{"city":"Yaroslavl'","country":"RUS","lat":57.6244343,"lng":39.89681849999999,"locationId":"49f4c66876ddf2d2511a34fcc41f1cf33e069f74","name":"Yaroslavl State Medical University Of Ministry Of Health Of The Russian Federation","state":"Yaroslavskaya oblast'"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04381377","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276971/","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892947/","http://www.freepatentsonline.com/EP0789586.html","https://clinicaltrials.gov/ct2/show/record/NCT04381377"],"sponsors":[{"sponsorId":"c5dc6c359bcfbbbf78636c3fcd382827683e015e","sponsorName":"NPO Petrovax"}],"status":"Ongoing","studyCompletionDate":"Thu, 01 Apr 2021 00:00:00 GMT","studyStartDate":"Wed, 29 Apr 2020 00:00:00 GMT","therapeuticApproach":"Other","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Sevoflurane","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"martin.schlaepfer@usz.ch","name":null,"notes":"","phone":"41442554690 ext 41442554690","website":""}],"countries":["Switzerland"],"countryCodes":["CHE"],"currentStage":"Phase 3","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 23 Apr 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"","numSites":"1","otherPartners":"","phase":"3","preferredName":"Sevoflurane","primaryCompletionDate":"Wed, 31 Mar 2021 00:00:00 GMT","productId":705,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04355962","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Z\u00fcrich","country":"CHE","lat":47.377029,"lng":8.5507597,"locationId":"79b1051efa249100b6a53b99ddf61c2713e29706","name":"University Hospital Zurch","state":"ZH"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04355962","https://www.drugbank.ca/drugs/DB01236"],"sponsors":[{"sponsorId":"ae69a5c6de79a7259c3019a496c3a8f6b2b42a8e","sponsorName":"University of Zurich"}],"status":"Ongoing","studyCompletionDate":"Wed, 31 Mar 2021 00:00:00 GMT","studyStartDate":"Thu, 23 Apr 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Budesonide","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"mdaval@for.paris","name":null,"notes":"","phone":"0148036870","website":""}],"countries":["France"],"countryCodes":["FRA"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Fri, 15 May 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 18 Jun 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"This study specifically investigates treatments for olfaction disorders which may be caused or related to COVID-19.","numSites":"1","otherPartners":"","phase":"3","preferredName":"Budesonide","primaryCompletionDate":"Tue, 18 May 2021 00:00:00 GMT","productId":706,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04361474","repurposed":"Repurposed-Approved","siteLocations":[{"city":"Paris","country":"FRA","lat":48.8824675,"lng":2.3528824,"locationId":"50e3aa26e3ae2330b6e38cde0a64556a971f5ee2","name":"Hopital Lariboisi\u00e8re","state":"IDF"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04361474","https://www.drugbank.ca/drugs/DB01222","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001667-85/FR"],"sponsors":[{"sponsorId":"09a311388d29aefc82ca5a5df8f232b0444f9d85","sponsorName":"Fondation Ophtalmologique Adolphe de Rothschild"}],"status":"Ongoing","studyCompletionDate":"Tue, 25 May 2021 00:00:00 GMT","studyStartDate":"Mon, 18 May 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Abidol hydrochloride","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"qning@vip.sina.com","name":null,"notes":"","phone":"8613971521450","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 4","indication":"Pneumonia","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Sat, 01 Feb 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"1","otherPartners":"","phase":"4","preferredName":"Abidol hydrochloride","primaryCompletionDate":"Mon, 01 Jun 2020 00:00:00 GMT","productId":707,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04254874","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Wuhan","country":"CHN","lat":30.592849,"lng":114.305539,"locationId":"d71f775ed41bc697af7d220a6c04d81e9a348257","name":"Department And Institute Of Infectious Disease","state":"Hubei"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04254874","https://www.drugs.com/international/abidol.html","https://clinicaltrials.gov/ct2/show/study/NCT04254874","https://www.medrxiv.org/content/10.1101/2020.03.16.20034934v1.full.pdf"],"sponsors":[{"sponsorId":"5b5b8fac5162ad1d88a07970c29180291cab2655","sponsorName":"Tongji Hospital"}],"status":"Ongoing","studyCompletionDate":"Wed, 01 Jul 2020 00:00:00 GMT","studyStartDate":"Sat, 01 Feb 2020 00:00:00 GMT","therapeuticApproach":"Antiviral drugs-not specified","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Veru-111","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"gbarnette@verupharma.com","name":null,"notes":"","phone":"9194263611","website":""}],"countries":["United States"],"countryCodes":["USA"],"currentStage":"Phase 2","indication":"ARDS","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Tue, 18 Feb 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Fri, 12 Jun 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 18 Jun 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Small molecule","notes":"The therapeautic approach of this drug is both antivial and anti-inflammatory","numSites":"5","otherPartners":"","phase":"2","preferredName":"Veru-111","primaryCompletionDate":"Mon, 30 Nov 2020 00:00:00 GMT","productId":708,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04388826","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Scottsdale","country":"USA","lat":33.5808894,"lng":-111.885349,"locationId":"186c09be72ce43c4a767f2a3459189f5f2b3bb2b","name":"Honorhealth","state":"AZ"},{"city":"St Louis Park","country":"USA","lat":44.9300754,"lng":-93.3619384,"locationId":"408152ce784d6fce09e596ad74d0cec9fd9693af","name":"Methodist Hospital","state":"MN"},{"city":"St Paul","country":"USA","lat":44.9562032,"lng":-93.0943145,"locationId":"0837c714f6400f44df7b0db6c42222c80c4fd3a7","name":"Regions Hospital","state":"MN"},{"city":"North Las Vegas","country":"USA","lat":36.1951782,"lng":-115.1228081,"locationId":"0d9744089ccd6e5b174f6a1075853e4961430538","name":"Wc","state":"NV"},{"city":"Vineland","country":"USA","lat":39.4454545,"lng":-75.05814889999999,"locationId":"4f45e2ce88ff1830142de65c20047e52c3eb5553","name":"Inspira Medical Center","state":"NJ"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04388826","https://www.globenewswire.com/news-release/2020/05/05/2027535/0/en/Veru-Reports-Positive-Clinical-Results-from-VERU-111-Phase-1b-2-Trial-in-Men-with-Metastatic-Castration-Resistant-Prostate-Cancer-Advancing-to-Pivotal-Phase-3-Clinical-Program.html#:~:text=VERU%2D111%20is%20an%20oral","agents%20(abiraterone%20or%20enzalutamide).","https://verupharma.com/pipeline/veru-111-for-covid-19/"],"sponsors":[{"sponsorId":"222246536520b7e6a444b51878b5703278765b2c","sponsorName":"Venu Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Thu, 18 Jun 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"No","brandName":"Escin","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"gallelli@unicz.it","name":null,"notes":"","phone":"3339245656 ext 3339245656","website":""}],"countries":["Italy"],"countryCodes":["ITA"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Therapeutic","milestones":[{"category":"pre-clinical","date":"Mon, 06 Jan 2020 00:00:00 GMT","milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 23 Mar 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 23 Mar 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"1","otherPartners":"","phase":"2","preferredName":"Escin","primaryCompletionDate":"Tue, 30 Jun 2020 00:00:00 GMT","productId":709,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04322344","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Catanzaro","country":"ITA","lat":38.8686453,"lng":16.5788521,"locationId":"22ab4fbaff5310c332028a614c304e9b2679a887","name":"University Of Catanzaro","state":"Calabria"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04322344","https://www.drugbank.ca/drugs/DB13195","https://web.unicz.it/it/news/85621/il-prof-luca-gallelli-in-collaborazione-con-il-gruppo-cinese-di-farmacologia-di-yantai-university-ha-pubblicato-la-review-severe-acute-lung-injury-related-to-covid-19-infection-a-review-and-the-possible-role-for-escin-su-j-of-clinical-pharmacolog","https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts"],"sponsors":[{"sponsorId":"030d3cf98fce31a3c73af6370ea8080c49752897","sponsorName":"University of Catanzaro"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 23 Mar 2020 00:00:00 GMT","therapeuticApproach":"Nonspecific anti-inflammatory and immunosuppressive drugs","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"VPM1002,Bacillus Calmette-Gu\u00e9rin (BCG)","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"grode@vakzine-manager.de","name":null,"notes":"","phone":"49 (0)511 169908-14","website":""}],"countries":["Germany"],"countryCodes":["DEU"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":"Fri, 17 Apr 2020 00:00:00 GMT","milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Thu, 18 Jun 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Protein-based (including monoclonal antibodies)","notes":"","numSites":"5","otherPartners":"","phase":"3","preferredName":"VPM1002,Bacillus Calmette-Gu\u00e9rin (BCG)","primaryCompletionDate":"Mon, 31 May 2021 00:00:00 GMT","productId":710,"registryLink":"https://clinicaltrials.gov/ct2/show/NCT04435379","repurposed":"Repurposed-Not Approved","siteLocations":[{"city":"Hannover","country":"DEU","lat":52.383675,"lng":9.804955399999999,"locationId":"99ce14e03715263acb91dbab11230255310fc7cd","name":"Medizinische Hochschule Hannover","state":"NDS"},{"city":"EF","country":"DEU","lat":50.9750233,"lng":11.0195683,"locationId":"6a5e453716cc79ddfc80ea04275aae3c6852c490","name":"Socratec R&d Gmbh","state":"TH"},{"city":"Berlin","country":"DEU","lat":52.5023604,"lng":13.307609,"locationId":"b91515fe21626b0db3e08c24580ccabc53ac5076","name":"Emovis Gmbh","state":"Berlin"},{"city":"Berlin","country":"DEU","lat":52.5033061,"lng":13.3429489,"locationId":"853e1998da132df4f9dee3d630509210c1763b1d","name":"Klinische Forschung Berlin Gbr","state":"Berlin"},{"city":"Hamburg","country":"DEU","lat":53.57982,"lng":9.975249999999999,"locationId":"349c4b77bb07218b3d0274f07881dccb6b4c93e3","name":"Klinische Forschung Hamburg Gmbh","state":"HH"}],"sources":["https://clinicaltrials.gov/ct2/show/NCT04435379","https://clinicaltrials.gov/ct2/show/record/NCT04435379","https://www.drugbank.ca/drugs/DB05089","https://www.precisionvaccinations.com/vaccines/vpm1002-tuberculosis-vaccine","https://clinicaltrials.gov/ct2/show/study/NCT04435379","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001675-33/DE","https://clinicaltrials.gov/ct2/show/study/NCT04435379#contacts","https://clinicaltrials.gov/ct2/show/NCT04435379#contacts"],"sponsors":[{"sponsorId":"711c49a1ef9689688c2b88527c81dc01498bf2c8","sponsorName":"Vakzine Projekt Management GmbH"}],"status":"Ongoing","studyCompletionDate":"Mon, 31 May 2021 00:00:00 GMT","studyStartDate":"Thu, 18 Jun 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"Beijing Institute Innactivated Vaccine,BBIBP-CorV","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"investigaciones.clinicas@huesped.org.ar","name":null,"notes":"","phone":"For Argentina: +54 11 49817777","website":""}],"countries":["China"],"countryCodes":["CHN"],"currentStage":"Phase 3","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":null,"milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 29 Apr 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"COMPLETED"},{"category":"clinical_development","date":"Wed, 15 Jul 2020 00:00:00 GMT","milestoneId":43,"name":"phase_3","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Whole-pathogen vaccines","notes":"","numSites":"6","otherPartners":"","phase":"3","preferredName":"Beijing Institute Innactivated Vaccine,BBIBP-CorV","primaryCompletionDate":"","productId":711,"registryLink":["https://clinicaltrials.gov/ct2/show/NCT04560881?term=NCT04560881&draw=2&rank=1","http://www.chictr.org.cn/showproj.aspx?proj=53003"],"repurposed":"New","siteLocations":[{"city":"Abu Dhabi","country":"ARE","lat":24.4690012,"lng":54.33757689999999,"locationId":"a05e75d7c38af3521fe17537260bb621ba15b6fc","name":"Abu Dhabi Health Services","state":"Abu Dhabi"},{"city":"Al Ain","country":"ARE","lat":24.2211084,"lng":55.7139272,"locationId":"9a1132274173dc2599619625557e87f61b64abb9","name":"Abu Dhabi Health Services","state":"Abu Dhabi"},{"city":"CABA","country":"ARG","lat":-34.6104952,"lng":-58.4219106,"locationId":"97f150eef33f1673f7ad4297d7bd1f641f925378","name":"Fundaci\u00f3n Hu\u00e9sped","state":"Provincia de Buenos Aires"},{"city":"FVD","country":"ARG","lat":-34.6411785,"lng":-58.52620899999999,"locationId":"80419bd37e45e43daf28eec068cb96c3cf31c790","name":"Vacunar Liniers","state":"CABA"},{"city":"BOF","country":"ARG","lat":-34.569535,"lng":-58.43621299999999,"locationId":"c23eb74e3628e63fd46f54505826c3edffca1736","name":"Vacunar Ca\u00f1itas","state":"CABA"},{"city":"CABA","country":"ARG","lat":-34.56435,"lng":-58.46987799999999,"locationId":"20406d99a0d973c5b0b8c7193ef65a3049f32534","name":"Vacunar Coghlan","state":"Provincia de Buenos Aires"}],"sources":["https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving","http://www.chictr.org.cn/showproj.aspx?proj=53003"],"sponsors":[{"sponsorId":"3bd129a36a22b99edf40b395c2fad7b78193bda9","sponsorName":"Sinopharm"},{"sponsorId":"e1992462e6978a6ef1bdee8a86f7d513222c1ad6","sponsorName":"Beijing Institute of Biological Products"},{"sponsorId":"d8671bd89373ad829344fa7eb484819909f5301a","sponsorName":"China National Biotec Group"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Sun, 06 Sep 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"","brandName":"T-VIVA-19","chemicalName":"","conditionOrDisease":"","contact":[{"email":"","name":null,"notes":"","phone":"","website":""}],"countries":[""],"countryCodes":[""],"currentStage":"Pre-Clinical Testing","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":"Wed, 01 Jul 2020 00:00:00 GMT","milestoneId":13,"name":"lead_selection","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"","phase":"","preferredName":"T-VIVA-19","primaryCompletionDate":"","productId":712,"registryLink":null,"repurposed":"New","siteLocations":[],"sources":["https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-selection-t-viva-19tm-targeted-protein"],"sponsors":[{"sponsorId":"5fc64f72797f9967b8f89cf58d0d24a43168cffc","sponsorName":"Sorrento Therapeutics Inc"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"","therapeuticApproach":"Vaccine","trialId":""},{"acceptsHealthySubjects":"Yes","brandName":"Soberana 1","chemicalName":"","conditionOrDisease":"COVID-19","contact":[{"email":"bparedes@finlay.edu.cu","name":null,"notes":"","phone":"(+53) 72718331","website":""}],"countries":["Cuba"],"countryCodes":["CUB"],"currentStage":"Phase 2","indication":"COVID-19","interventionType":"Vaccine - Prophylactic","milestones":[{"category":"pre-clinical","date":null,"milestoneId":12,"name":"pre_clinical_studies","status":"COMPLETED"},{"category":"pre-clinical","date":null,"milestoneId":13,"name":"lead_selection","status":"COMPLETED"},{"category":"manufacturing","date":null,"milestoneId":21,"name":"clinical_batch","status":"COMPLETED"},{"category":"regulatory","date":null,"milestoneId":31,"name":"ind","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 24 Aug 2020 00:00:00 GMT","milestoneId":41,"name":"phase_1","status":"COMPLETED"},{"category":"clinical_development","date":"Mon, 24 Aug 2020 00:00:00 GMT","milestoneId":42,"name":"phase_2","status":"ONGOING"},{"category":"pre-clinical","date":null,"milestoneId":11,"name":"discovery","status":"COMPLETED"}],"moleculeType":"Subunit Vaccines","notes":"","numSites":"","otherPartners":"","phase":"1/2","preferredName":"Soberana 1","primaryCompletionDate":"","productId":713,"registryLink":"https://rpcec.sld.cu/ensayos/RPCEC00000332-Sp","repurposed":"New","siteLocations":[],"sources":["https://rpcec.sld.cu/ensayos/RPCEC00000332-Sp","https://www.dw.com/en/cuba-joins-the-race-for-vaccine-against-the-coronavirus/a-54615364"],"sponsors":[{"sponsorId":"9d310a76bf98268b51fc271f363478961f56049a","sponsorName":"Instituto Finlay de Vacunas"}],"status":"Ongoing","studyCompletionDate":"","studyStartDate":"Mon, 24 Aug 2020 00:00:00 GMT","therapeuticApproach":"Vaccine","trialId":""}]
